(lp0
(dp1
S'line'
p2
VIn this study, we investigated the expression of EG-VEGF in colorectal cancer, the relationship between its expression and clinicopathological factors, and the in vitro activity of EG-VEGF transfectants.
p3
sS'genes'
p4
(lp5
(dp6
S'index'
p7
I49
sS'uniprot'
p8
VP58294
p9
sS'lengthInChars'
p10
I7
sS'name'
p11
VEG-VEGF
p12
sS'lengthInWords'
p13
I1
sa(dp14
g7
I49
sg8
VP58294
p15
sg10
I7
sg11
VEG-VEGF
p16
sg13
I1
sasS'diseases'
p17
(lp18
(dp19
g7
I60
sS'cui'
p20
VC1527249
p21
sg10
I17
sg11
Vcolorectal cancer
p22
sg13
I2
sasa(dp23
g2
VWe determined expression levels of EG-VEGF in 113 advanced colorectal cancers resected in our hospital by quantitative PCR, and compared the expression levels and clinicopathological findings by multivariate analyses.
p24
sg4
(lp25
(dp26
g7
I35
sg8
VP58294
p27
sg10
I7
sg11
VEG-VEGF
p28
sg13
I1
sasg17
(lp29
(dp30
g7
I59
sg20
VC1527249
p31
sg10
I18
sg11
Vcolorectal cancers
p32
sg13
I2
sasa(dp33
g2
VWe speculate that, in colorectal cancers, the EG-VEGF gene functions as an important factor in angiogenesis in primary and metastatic lesions, and consider that it is useful as a novel prognostic factor.
p34
sg4
(lp35
(dp36
g7
I46
sg8
VP58294
p37
sg10
I12
sg11
VEG-VEGF gene
p38
sg13
I2
sasg17
(lp39
(dp40
g7
I22
sg20
VC1527249
p41
sg10
I18
sg11
Vcolorectal cancers
p42
sg13
I2
sasa(dp43
g2
VThe aim of the present study was to detect the correlation between the expression of vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang2), ephrinB2 and endocrine gland-derived vascular endothelial growth factor (EG-VEGF) and carcinogenesis or portal vein tumor thrombus (PVTT) formation in human hepatocellular carcinoma (HCC).
p44
sg4
(lp45
(dp46
g7
I128
sg8
S''
p47
sg10
I14
sg11
Vangiopoietin 2
p48
sg13
I2
sa(dp49
g7
I85
sg8
g47
sg10
I34
sg11
Vvascular endothelial growth factor
p50
sg13
I4
sa(dp51
g7
I151
sg8
VP52799
p52
sg10
I8
sg11
VephrinB2
p53
sg13
I1
sa(dp54
g7
I224
sg8
VP58294
p55
sg10
I7
sg11
VEG-VEGF
p56
sg13
I1
sa(dp57
g7
I164
sg8
VP58294
p58
sg10
I58
sg11
Vendocrine gland-derived vascular endothelial growth factor
p59
sg13
I6
sa(dp60
g7
I144
sg8
g47
sg10
I4
sg11
VAng2
p61
sg13
I1
sa(dp62
g7
I121
sg8
g47
sg10
I4
sg11
VVEGF
p63
sg13
I1
sasg17
(lp64
(dp65
g7
I334
sg20
VC2239176
p66
sg10
I3
sg11
VHCC
p67
sg13
I1
sa(dp68
g7
I237
sg20
VC0596263
p69
sg10
I14
sg11
Vcarcinogenesis
p70
sg13
I1
sa(dp71
g7
I267
sg20
VC3163918
p72
sg10
I14
sg11
Vtumor thrombus
p73
sg13
I2
sa(dp74
g7
I308
sg20
VC2239176
p75
sg10
I24
sg11
Vhepatocellular carcinoma
p76
sg13
I2
sasa(dp77
g2
VA recent genome-wide association study (GWA) reported a significant association between single nucleotide polymorphisms (SNPs) at the PCDH11X gene and late-onset Alzheimer's disease (LOAD).
p78
sg4
(lp79
sg17
(lp80
(dp81
g7
I162
sg20
VC1521724
p82
sg10
I19
sg11
VAlzheimer's disease
p83
sg13
I2
sasa(dp84
g2
VProtocadherin 11X (Pcdh11X) has been suspected to be associated with Alzheimer's disease through participating in the metabolism of PP1Alfa and Beta-catenin or by altering the synaptic functions.
p85
sg4
(lp86
(dp87
g7
I144
sg8
VP35222
p88
sg10
I12
sg11
VBeta-catenin
p89
sg13
I1
sa(dp90
g7
I0
sg8
g47
sg10
I17
sg11
VProtocadherin 11X
p91
sg13
I2
sa(dp92
g7
I19
sg8
g47
sg10
I7
sg11
VPcdh11X
p93
sg13
I1
sasg17
(lp94
(dp95
g7
I69
sg20
VC1521724
p96
sg10
I19
sg11
VAlzheimer's disease
p97
sg13
I2
sasa(dp98
g2
VA recent genome-wide association study reported that a common single nucleotide polymorphism (SNP, rs5984894) in the gene encoding Pcdh11X was associated with susceptibility to late-onset Alzheimer's disease (LOAD) in Caucasians.
p99
sg4
(lp100
sg17
(lp101
(dp102
g7
I188
sg20
VC1521724
p103
sg10
I19
sg11
VAlzheimer's disease
p104
sg13
I2
sasa(dp105
g2
VA recent genome-wide study on late-onset Alzheimer's disease identified a SNP (rs5984894) on Xq21.3 in the PCDH11X gene strongly associated with LOAD individuals of European descent from the United States.
p106
sg4
(lp107
sg17
(lp108
(dp109
g7
I41
sg20
VC1521724
p110
sg10
I19
sg11
VAlzheimer's disease
p111
sg13
I2
sasa(dp112
g2
VBy analyzing late-onset Alzheimer's disease (LOAD) in a genome-wide association study (313,504 SNPs, three series, 844 cases and 1,255 controls) and evaluating the 25 SNPs with the most significant allelic association in four additional series (1,547 cases and 1,209 controls), we identified a SNP (rs5984894) on Xq21.3 in PCDH11X that is strongly associated with LOAD in individuals of European descent from the United States.
p113
sg4
(lp114
sg17
(lp115
(dp116
g7
I45
sg20
VC1521724
p117
sg10
I4
sg11
VLOAD
p118
sg13
I1
sa(dp119
g7
I13
sg20
VC1521724
p120
sg10
I30
sg11
Vlate-onset Alzheimer's disease
p121
sg13
I3
sa(dp122
g7
I45
sg20
VC1521724
p123
sg10
I4
sg11
VLOAD
p124
sg13
I1
sasa(dp125
g2
VIn this study, we investigated the effect of Bim-1 siRNA on cell proliferation, cell cycle, cell apoptosis and migration of human esophageal carcinoma EC9706 cells, and explored its potential mechanisms.
p126
sg4
(lp127
sg17
(lp128
(dp129
g7
I65
sg20
VC0334094
p130
sg10
I13
sg11
Vproliferation
p131
sg13
I1
sa(dp132
g7
I130
sg20
VC0152018
p133
sg10
I20
sg11
Vesophageal carcinoma
p134
sg13
I2
sasa(dp135
g2
VIn the present study, 4-mm samples of BIM (n=31) and CIM (n=9) were selected from esophagectomy specimens that had been resected for esophageal cancer.
p136
sg4
(lp137
(dp138
g7
I53
sg8
g47
sg10
I3
sg11
VCIM
p139
sg13
I1
sasg17
(lp140
(dp141
g7
I133
sg20
VC0014859
p142
sg10
I17
sg11
Vesophageal cancer
p143
sg13
I2
sasa(dp144
g2
VMechanistically, HCMV upregulated two specific cellular antiapoptotic proteins, myeloid leukemia sequence 1 (Mcl-1) and heat shock protein 27 (HSP27), to block the two proteolytic cleavages necessary for the formation of fully active caspase 3 and the subsequent initiation of apoptosis.
p145
sg4
(lp146
(dp147
g7
I120
sg8
VP34931
p148
sg10
I21
sg11
Vheat shock protein 27
p149
sg13
I4
sa(dp150
g7
I109
sg8
VP07954
p151
sg10
I5
sg11
VMcl-1
p152
sg13
I1
sa(dp153
g7
I234
sg8
VP42574
p154
sg10
I9
sg11
Vcaspase 3
p155
sg13
I2
sa(dp156
g7
I143
sg8
g47
sg10
I5
sg11
VHSP27
p157
sg13
I1
sasg17
(lp158
(dp159
g7
I109
sg20
VC1708350
p160
sg10
I3
sg11
VMcl
p161
sg13
I1
sa(dp162
g7
I80
sg20
VC0023470
p163
sg10
I16
sg11
Vmyeloid leukemia
p164
sg13
I2
sasa(dp165
g2
VHeat shock protein 27 (HSP27) has been reported to promote the development of leukemia by protecting tumor cells from apoptosis through various mechanisms.
p166
sg4
(lp167
(dp168
g7
I0
sg8
VP34931
p169
sg10
I21
sg11
VHeat shock protein 27
p170
sg13
I4
sa(dp171
g7
I23
sg8
g47
sg10
I5
sg11
VHSP27
p172
sg13
I1
sasg17
(lp173
(dp174
g7
I101
sg20
VC0027651
p175
sg10
I5
sg11
Vtumor
p176
sg13
I1
sa(dp177
g7
I78
sg20
VC0023418
p178
sg10
I8
sg11
Vleukemia
p179
sg13
I1
sasa(dp180
g2
VThe present study investigated the effects of small hairpin (sh)RNA-mediated HSP27 knockdown on the anti-cancer effects of quercetin in U937 human leukemia cells.
p181
sg4
(lp182
(dp183
g7
I77
sg8
g47
sg10
I5
sg11
VHSP27
p184
sg13
I1
sasg17
(lp185
(dp186
g7
I105
sg20
VC0006826
p187
sg10
I6
sg11
Vcancer
p188
sg13
I1
sa(dp189
g7
I147
sg20
VC0023418
p190
sg10
I8
sg11
Vleukemia
p191
sg13
I1
sasa(dp192
g2
VTherefore, these findings collectively suggested that suppression of HSP27 expression amplified the anti-cancer effects of quercetin in U937 human leukemia cells, and that quercetin in combination with shHSP27 represents a promising therapeutic strategy for human leukemia.
p193
sg4
(lp194
(dp195
g7
I69
sg8
g47
sg10
I5
sg11
VHSP27
p196
sg13
I1
sasg17
(lp197
(dp198
g7
I105
sg20
VC0006826
p199
sg10
I6
sg11
Vcancer
p200
sg13
I1
sa(dp201
g7
I147
sg20
VC0023418
p202
sg10
I8
sg11
Vleukemia
p203
sg13
I1
sa(dp204
g7
I54
sg20
VC0221103
p205
sg10
I11
sg11
Vsuppression
p206
sg13
I1
sa(dp207
g7
I147
sg20
VC0023418
p208
sg10
I8
sg11
Vleukemia
p209
sg13
I1
sasa(dp210
g2
VAmong these proteins, enolase, aldolase, HSP70 and sorcin were up-regulated in doxorubicin-resistant myelogenous leukemia cell line, whereas HSP27 was down-regulated.
p211
sg4
(lp212
(dp213
g7
I22
sg8
VP13929
p214
sg10
I7
sg11
Venolase
p215
sg13
I1
sa(dp216
g7
I31
sg8
VP05062
p217
sg10
I8
sg11
Valdolase
p218
sg13
I1
sa(dp219
g7
I41
sg8
VP34932
p220
sg10
I5
sg11
VHSP70
p221
sg13
I1
sa(dp222
g7
I141
sg8
g47
sg10
I5
sg11
VHSP27
p223
sg13
I1
sa(dp224
g7
I51
sg8
VP30626
p225
sg10
I6
sg11
Vsorcin
p226
sg13
I1
sasg17
(lp227
(dp228
g7
I101
sg20
VC0023470
p229
sg10
I20
sg11
Vmyelogenous leukemia
p230
sg13
I2
sasa(dp231
g2
VHowever, the role of Hsp27 in the pathogenesis of pediatric acute             leukemia (AL) remains unknown.
p232
sg4
(lp233
(dp234
g7
I21
sg8
g47
sg10
I5
sg11
VHsp27
p235
sg13
I1
sasg17
(lp236
(dp237
g7
I78
sg20
VC0023418
p238
sg10
I8
sg11
Vleukemia
p239
sg13
I1
sa(dp240
g7
I34
sg20
VC0699748
p241
sg10
I12
sg11
Vpathogenesis
p242
sg13
I1
sasa(dp243
g2
VIn this study, we evaluated the expression levels             of Hsp27 in bone marrow samples from 94 children with newly diagnosed acute lymphoblastic             leukemia (ALL), acute myeloid leukemia (AML) and 5 leukemia cell lines.
p244
sg4
(lp245
(dp246
g7
I65
sg8
g47
sg10
I5
sg11
VHsp27
p247
sg13
I1
sasg17
(lp248
(dp249
g7
I164
sg20
VC0023418
p250
sg10
I8
sg11
Vleukemia
p251
sg13
I1
sa(dp252
g7
I164
sg20
VC0023418
p253
sg10
I8
sg11
Vleukemia
p254
sg13
I1
sa(dp255
g7
I180
sg20
VC0023467
p256
sg10
I22
sg11
Vacute myeloid leukemia
p257
sg13
I3
sa(dp258
g7
I204
sg20
VC0023467
p259
sg10
I3
sg11
VAML
p260
sg13
I1
sasa(dp261
g2
VAdditionally,             we transfected a target-specific siRNA duplex against Hsp27 into leukemia cells,             and examined the chemosensitivity and cell apoptosis in the response to antitumor             drugs.
p262
sg4
(lp263
(dp264
g7
I80
sg8
g47
sg10
I5
sg11
VHsp27
p265
sg13
I1
sasg17
(lp266
(dp267
g7
I91
sg20
VC0023418
p268
sg10
I8
sg11
Vleukemia
p269
sg13
I1
sasa(dp270
g2
VHsp27 was abundantly expressed in newly diagnosed AML-M4/M5 bone marrow             mononuclear cells (BMMCs) and THP-1, OCI/AML-3 leukemia cell lines.
p271
sg4
(lp272
(dp273
g7
I50
sg8
VP41212
p274
sg10
I3
sg11
VAML
p275
sg13
I1
sa(dp276
g7
I0
sg8
g47
sg10
I5
sg11
VHsp27
p277
sg13
I1
sasg17
(lp278
(dp279
g7
I131
sg20
VC0023418
p280
sg10
I8
sg11
Vleukemia
p281
sg13
I1
sa(dp282
g7
I50
sg20
VC0023467
p283
sg10
I3
sg11
VAML
p284
sg13
I1
sa(dp285
g7
I50
sg20
VC0023467
p286
sg10
I3
sg11
VAML
p287
sg13
I1
sasa(dp288
g2
VKnockdown of Hsp27 expression increased the chemosensitivity of             leukemia cells and the anticancer drug-induced apoptosis.
p289
sg4
(lp290
(dp291
g7
I13
sg8
g47
sg10
I5
sg11
VHsp27
p292
sg13
I1
sasg17
(lp293
(dp294
g7
I76
sg20
VC0023418
p295
sg10
I8
sg11
Vleukemia
p296
sg13
I1
sasa(dp297
g2
VTherefore, Hsp27 may be exploited as a new target for enhancing the             efficacy of chemotherapeutic drugs against leukemia.
p298
sg4
(lp299
(dp300
g7
I11
sg8
g47
sg10
I5
sg11
VHsp27
p301
sg13
I1
sasg17
(lp302
(dp303
g7
I123
sg20
VC0023418
p304
sg10
I8
sg11
Vleukemia
p305
sg13
I1
sasa(dp306
g2
VIt was: xS-D-D-K-K-A-K-A-A-T-S-S-V-L-T-K-F-T-Q-N-Q-I-Q-E-M-K-E-A-F-T-M-I-D-Q-N-R -D-G-L- I-D-V-S-D-L-K-E-M-Y-S-N-L-G-T-A-P-Q-D-S-V-L-Q-A-M-V-K-E-A-P-Q-M-N-F-T-G- F-L-S-L- F-S-E-K-M-S-G-T-D-P-E-E-T-L-R-N-A-F-Q-M-F-D-S-D-N-T-G-Y-I-P-E-E-Y-M-K-D- L- L-E-N-M-G-D-N-F-S-K-D-E-V-R-Q-T-W-K-E-A-P-I-A-G-G-K-V-D-Y-N-A-F-V-S-K-I- K- G-K-E-Q-D-D-A.
p307
sg4
(lp308
(dp309
g7
I8
sg8
g47
sg10
I246
sg11
VxS-D-D-K-K-A-K-A-A-T-S-S-V-L-T-K-F-T-Q-N-Q-I-Q-E-M-K-E-A-F-T-M-I-D-Q-N-R -D-G-L- I-D-V-S-D-L-K-E-M-Y-S-N-L-G-T-A-P-Q-D-S-V-L-Q-A-M-V-K-E-A-P-Q-M-N-F-T-G- F-L-S-L- F-S-E-K-M-S-G-T-D-P-E-E-T-L-R-N-A-F-Q-M-F-D-S-D-N-T-G-Y-I-P-E-E-Y-M-K-D- L- L-E-N-M
p310
sg13
I7
sasg17
(lp311
sa(dp312
g2
VIntegrin alpha 8 (ITGA8) encodes the alpha 8 subunit of the integrin alpha8beta1 protein and has recently been suggested as a new candidate gene for Parkinson's disease, an age related neurodegenerative disease with unknown etiology.
p313
sg4
(lp314
(dp315
g7
I18
sg8
VP53708
p316
sg10
I5
sg11
VITGA8
p317
sg13
I1
sa(dp318
g7
I0
sg8
VP53708
p319
sg10
I16
sg11
VIntegrin alpha 8
p320
sg13
I3
sasg17
(lp321
(dp322
g7
I149
sg20
VC0030567
p323
sg10
I19
sg11
VParkinson's disease
p324
sg13
I2
sa(dp325
g7
I185
sg20
VC0524851
p326
sg10
I25
sg11
Vneurodegenerative disease
p327
sg13
I2
sasa(dp328
g2
VScreen a Swedish case control material for rs7077361, a genetic variant in ITGA8, in order to investigate its possible implication in Parkinson's disease in Sweden.
p329
sg4
(lp330
(dp331
g7
I75
sg8
VP53708
p332
sg10
I5
sg11
VITGA8
p333
sg13
I1
sasg17
(lp334
(dp335
g7
I134
sg20
VC0030567
p336
sg10
I19
sg11
VParkinson's disease
p337
sg13
I2
sasa(dp338
g2
VOur results do not support the hypothesis of ITGA8 as a candidate gene for Parkinson's disease in Sweden.
p339
sg4
(lp340
(dp341
g7
I45
sg8
VP53708
p342
sg10
I5
sg11
VITGA8
p343
sg13
I1
sasg17
(lp344
(dp345
g7
I75
sg20
VC0030567
p346
sg10
I19
sg11
VParkinson's disease
p347
sg13
I2
sasa(dp348
g2
VCYFIP1 maps to the interval between proximal breakpoint 1 (BP1) and breakpoint 2 (BP2) of chromosomal 15q11-q13 deletions that are implicated in the Angelman (AS) and Prader-Willi syndrome (PWS).
p349
sg4
(lp350
(dp351
g7
I82
sg8
VP18065
p352
sg10
I3
sg11
VBP2
p353
sg13
I1
sa(dp354
g7
I45
sg8
g47
sg10
I35
sg11
Vbreakpoint 1 (BP1) and breakpoint 2
p355
sg13
I6
sa(dp356
g7
I0
sg8
g47
sg10
I6
sg11
VCYFIP1
p357
sg13
I1
sasg17
(lp358
(dp359
g7
I167
sg20
VC0032897
p360
sg10
I21
sg11
VPrader-Willi syndrome
p361
sg13
I2
sa(dp362
g7
I190
sg20
VC0032897
p363
sg10
I3
sg11
VPWS
p364
sg13
I1
sasa(dp365
g2
VWe found copy number variants in PDE10A (phosphodiesterase 10A), CYFIP1 [cytoplasmic FMR1 (Fragile X mental retardation 1)-interacting protein 1], K(+) channel genes KCNE1 and KCNE2, the Down's syndrome critical region 1 gene RCAN1 (regulator of calcineurin 1), cell-recognition protein CHL1 (cell adhesion molecule with homology with L1CAM), the transcription factor SP4 (specificity protein 4) and histone deacetylase HDAC9, among others (see http://www.genes2cognition.org/SCZ-CNV).
p366
sg4
(lp367
(dp368
g7
I335
sg8
VP32004
p369
sg10
I5
sg11
VL1CAM
p370
sg13
I1
sa(dp371
g7
I33
sg8
g47
sg10
I6
sg11
VPDE10A
p372
sg13
I1
sa(dp373
g7
I166
sg8
VP15382
p374
sg10
I5
sg11
VKCNE1
p375
sg13
I1
sa(dp376
g7
I176
sg8
g47
sg10
I5
sg11
VKCNE2
p377
sg13
I1
sa(dp378
g7
I41
sg8
g47
sg10
I21
sg11
Vphosphodiesterase 10A
p379
sg13
I2
sa(dp380
g7
I400
sg8
g47
sg10
I25
sg11
Vhistone deacetylase HDAC9
p381
sg13
I3
sa(dp382
g7
I287
sg8
g47
sg10
I28
sg11
VCHL1 (cell adhesion molecule
p383
sg13
I4
sasg17
(lp384
(dp385
g7
I298
sg20
VC0001511
p386
sg10
I8
sg11
Vadhesion
p387
sg13
I1
sa(dp388
g7
I187
sg20
VC0013080
p389
sg10
I15
sg11
VDown's syndrome
p390
sg13
I2
sa(dp391
g7
I101
sg20
VC0025362
p392
sg10
I18
sg11
Vmental retardation
p393
sg13
I2
sasa(dp394
g2
VWe describe nine cases with a microdeletion at 15q11.2 between BP1-BP2, thus having a haploinsufficiency for TUBGCP5, NIPA1, NIPA2, and CYFIP1 without Prader-Willi/Angelman syndrome.
p395
sg4
(lp396
(dp397
g7
I63
sg8
g47
sg10
I7
sg11
VBP1-BP2
p398
sg13
I1
sa(dp399
g7
I118
sg8
g47
sg10
I5
sg11
VNIPA1
p400
sg13
I1
sa(dp401
g7
I109
sg8
g47
sg10
I7
sg11
VTUBGCP5
p402
sg13
I1
sa(dp403
g7
I136
sg8
g47
sg10
I6
sg11
VCYFIP1
p404
sg13
I1
sa(dp405
g7
I125
sg8
g47
sg10
I5
sg11
VNIPA2
p406
sg13
I1
sasg17
(lp407
(dp408
g7
I164
sg20
VC0162635
p409
sg10
I17
sg11
VAngelman syndrome
p410
sg13
I2
sasa(dp411
g2
VAltered expression of CYFIP1 is seen in other developmental disabilities, including 15q disorders, and haploinsufficiency of CYFIP1 in Type I PWS cases may be associated with age-related phenotypic effects.
p412
sg4
(lp413
(dp414
g7
I22
sg8
g47
sg10
I6
sg11
VCYFIP1
p415
sg13
I1
sa(dp416
g7
I22
sg8
g47
sg10
I6
sg11
VCYFIP1
p417
sg13
I1
sasg17
(lp418
(dp419
g7
I142
sg20
VC0032897
p420
sg10
I3
sg11
VPWS
p421
sg13
I1
sa(dp422
g7
I46
sg20
VC0008073
p423
sg10
I26
sg11
Vdevelopmental disabilities
p424
sg13
I2
sasa(dp425
g2
VExpression analysis of cultured human cells and brain tissues from PWS patients indicates that CYFIP1 and NIPA2 are biallelically expressed.
p426
sg4
(lp427
(dp428
g7
I95
sg8
g47
sg10
I6
sg11
VCYFIP1
p429
sg13
I1
sa(dp430
g7
I106
sg8
g47
sg10
I5
sg11
VNIPA2
p431
sg13
I1
sasg17
(lp432
(dp433
g7
I67
sg20
VC0032897
p434
sg10
I3
sg11
VPWS
p435
sg13
I1
sasa(dp436
g2
VFour genes (NIPA1, NIPA2, CYFIP1, and GCP5) have been identified in the chromosomal region between breakpoints 1 and 2 and are implicated in compulsive behavior and lower intellectual ability observed in individuals with Prader-Willi syndrome with TI versus TII deletions.
p437
sg4
(lp438
(dp439
g7
I38
sg8
g47
sg10
I4
sg11
VGCP5
p440
sg13
I1
sa(dp441
g7
I19
sg8
g47
sg10
I5
sg11
VNIPA2
p442
sg13
I1
sa(dp443
g7
I26
sg8
g47
sg10
I6
sg11
VCYFIP1
p444
sg13
I1
sa(dp445
g7
I12
sg8
g47
sg10
I5
sg11
VNIPA1
p446
sg13
I1
sasg17
(lp447
(dp448
g7
I141
sg20
VC0600104
p449
sg10
I19
sg11
Vcompulsive behavior
p450
sg13
I2
sa(dp451
g7
I221
sg20
VC0032897
p452
sg10
I21
sg11
VPrader-Willi syndrome
p453
sg13
I2
sasa(dp454
g2
VMessenger RNA from NIPA1, NIPA2, CYFIP1, and GCP5 was reduced but detectable in the subjects with Prader-Willi syndrome with the TI deletion, supporting biallelic expression.
p455
sg4
(lp456
(dp457
g7
I26
sg8
g47
sg10
I5
sg11
VNIPA2
p458
sg13
I1
sa(dp459
g7
I45
sg8
g47
sg10
I4
sg11
VGCP5
p460
sg13
I1
sa(dp461
g7
I33
sg8
g47
sg10
I6
sg11
VCYFIP1
p462
sg13
I1
sa(dp463
g7
I19
sg8
g47
sg10
I5
sg11
VNIPA1
p464
sg13
I1
sasg17
(lp465
(dp466
g7
I98
sg20
VC0032897
p467
sg10
I21
sg11
VPrader-Willi syndrome
p468
sg13
I2
sasa(dp469
g2
VTherefore, we recruited 50 untreated house dust mite-sensitive allergic rhinitis patients and 29 non-atopic healthy individuals and performed comprehensive simultaneous flow cytometric analysis of mutual correlations between levels of CD14, CD16, CD163, CD206, CD124 (IL-4R), CD210 (IL-10R) and CD25, CD124, CD127 (IL-7R), CD210, ICOS expression on monocytes and CD4+ T cells, respectively.
p470
sg4
(lp471
(dp472
g7
I254
sg8
VP22897
p473
sg10
I5
sg11
VCD206
p474
sg13
I1
sa(dp475
g7
I363
sg8
VP01730
p476
sg10
I4
sg11
VCD4+
p477
sg13
I1
sa(dp478
g7
I295
sg8
VP01589
p479
sg10
I4
sg11
VCD25
p480
sg13
I1
sa(dp481
g7
I283
sg8
g47
sg10
I6
sg11
VIL-10R
p482
sg13
I1
sa(dp483
g7
I247
sg8
g47
sg10
I5
sg11
VCD163
p484
sg13
I1
sa(dp485
g7
I235
sg8
VP08571
p486
sg10
I4
sg11
VCD14
p487
sg13
I1
sa(dp488
g7
I241
sg8
VP08637
p489
sg10
I4
sg11
VCD16
p490
sg13
I1
sasg17
(lp491
(dp492
g7
I63
sg20
VC2607914
p493
sg10
I17
sg11
Vallergic rhinitis
p494
sg13
I2
sa(dp495
g7
I101
sg20
VC0392707
p496
sg10
I6
sg11
Vatopic
p497
sg13
I1
sasa(dp498
g2
VWe did not observe any statistically significant differences between healthy and diabetic children in mRNA expression for FoxP3, IL-7R (CD127), IL-8RA, IL-10RA, IL-12A, IL-2RA (CD25), IL-21, STAT1, STAT3, SOCS2, SOCS3, TGF-beta1-R1, TGF-beta-R2 and TBX-21 genes.
p499
sg4
(lp500
(dp501
g7
I191
sg8
VP42224
p502
sg10
I5
sg11
VSTAT1
p503
sg13
I1
sa(dp504
g7
I198
sg8
VP40763
p505
sg10
I5
sg11
VSTAT3
p506
sg13
I1
sa(dp507
g7
I184
sg8
g47
sg10
I5
sg11
VIL-21
p508
sg13
I1
sa(dp509
g7
I122
sg8
g47
sg10
I5
sg11
VFoxP3
p510
sg13
I1
sa(dp511
g7
I177
sg8
VP01589
p512
sg10
I4
sg11
VCD25
p513
sg13
I1
sa(dp514
g7
I205
sg8
g47
sg10
I5
sg11
VSOCS2
p515
sg13
I1
sa(dp516
g7
I161
sg8
VP29459
p517
sg10
I6
sg11
VIL-12A
p518
sg13
I1
sa(dp519
g7
I233
sg8
VP18075
p520
sg10
I11
sg11
VTGF-beta-R2
p521
sg13
I1
sa(dp522
g7
I212
sg8
g47
sg10
I5
sg11
VSOCS3
p523
sg13
I1
sa(dp524
g7
I219
sg8
VP01137
p525
sg10
I12
sg11
VTGF-beta1-R1
p526
sg13
I1
sasg17
(lp527
sa(dp528
g2
VExpression of the Growth Hormone (GH)-stimulated gene Socs2 (Suppressor of Cytokine Signaling 2) is mediated by the transcription activator STAT5 (Signal Transducer and Activator of Transcription 5) and the transcription repressor BCL6 (B-Cell Lymphoma 6).
p529
sg4
(lp530
(dp531
g7
I18
sg8
VP01242
p532
sg10
I14
sg11
VGrowth Hormone
p533
sg13
I2
sa(dp534
g7
I140
sg8
VP42229
p535
sg10
I5
sg11
VSTAT5
p536
sg13
I1
sa(dp537
g7
I34
sg8
VP01242
p538
sg10
I2
sg11
VGH
p539
sg13
I1
sa(dp540
g7
I54
sg8
g47
sg10
I5
sg11
VSocs2
p541
sg13
I1
sa(dp542
g7
I61
sg8
g47
sg10
I34
sg11
VSuppressor of Cytokine Signaling 2
p543
sg13
I5
sa(dp544
g7
I231
sg8
VP41182
p545
sg10
I4
sg11
VBCL6
p546
sg13
I1
sa(dp547
g7
I147
sg8
VP42229
p548
sg10
I50
sg11
VSignal Transducer and Activator of Transcription 5
p549
sg13
I7
sa(dp550
g7
I237
sg8
VP41182
p551
sg10
I17
sg11
VB-Cell Lymphoma 6
p552
sg13
I3
sasg17
(lp553
(dp554
g7
I237
sg20
VC0079731
p555
sg10
I15
sg11
VB-Cell Lymphoma
p556
sg13
I2
sasa(dp557
g2
VGene expression analysis revealed increased expression of MAPK1, AKT1, PRKCE, IL4R and DROSHA and decreased expression of CDKN1A/p21, SOCS2, CHEK1, RAD51, KLF4, BLIMP1 and IRF4 in follicular lymphoma.
p558
sg4
(lp559
(dp560
g7
I141
sg8
g47
sg10
I5
sg11
VCHEK1
p561
sg13
I1
sa(dp562
g7
I129
sg8
VP42857
p563
sg10
I3
sg11
Vp21
p564
sg13
I1
sa(dp565
g7
I161
sg8
g47
sg10
I6
sg11
VBLIMP1
p566
sg13
I1
sa(dp567
g7
I155
sg8
g47
sg10
I4
sg11
VKLF4
p568
sg13
I1
sa(dp569
g7
I172
sg8
g47
sg10
I4
sg11
VIRF4
p570
sg13
I1
sa(dp571
g7
I87
sg8
g47
sg10
I6
sg11
VDROSHA
p572
sg13
I1
sa(dp573
g7
I122
sg8
VP38936
p574
sg10
I6
sg11
VCDKN1A
p575
sg13
I1
sa(dp576
g7
I148
sg8
g47
sg10
I5
sg11
VRAD51
p577
sg13
I1
sa(dp578
g7
I134
sg8
g47
sg10
I5
sg11
VSOCS2
p579
sg13
I1
sa(dp580
g7
I65
sg8
VP31749
p581
sg10
I4
sg11
VAKT1
p582
sg13
I1
sa(dp583
g7
I58
sg8
VP28482
p584
sg10
I5
sg11
VMAPK1
p585
sg13
I1
sa(dp586
g7
I71
sg8
g47
sg10
I5
sg11
VPRKCE
p587
sg13
I1
sasg17
(lp588
(dp589
g7
I180
sg20
VC0024301
p590
sg10
I19
sg11
Vfollicular lymphoma
p591
sg13
I2
sasa(dp592
g2
VmiR-20a/b and miR-194 target CDKN1A and SOCS2 in follicular lymphoma, potentially contributing to tumor cell proliferation and survival.
p593
sg4
(lp594
(dp595
g7
I40
sg8
g47
sg10
I5
sg11
VSOCS2
p596
sg13
I1
sa(dp597
g7
I0
sg8
g47
sg10
I9
sg11
VmiR-20a/b
p598
sg13
I1
sa(dp599
g7
I29
sg8
VP38936
p600
sg10
I6
sg11
VCDKN1A
p601
sg13
I1
sa(dp602
g7
I14
sg8
g47
sg10
I7
sg11
VmiR-194
p603
sg13
I1
sasg17
(lp604
(dp605
g7
I98
sg20
VC0027651
p606
sg10
I5
sg11
Vtumor
p607
sg13
I1
sa(dp608
g7
I49
sg20
VC0024301
p609
sg10
I19
sg11
Vfollicular lymphoma
p610
sg13
I2
sa(dp611
g7
I109
sg20
VC0334094
p612
sg10
I13
sg11
Vproliferation
p613
sg13
I1
sasa(dp614
g2
VNuclear factors such as pregnane X receptor (PXR) and constitutive androstane receptor (CAR), as well as transporters and conjugation enzymes involved in the detoxification of lithocholic acid (LCA), also showed higher expression in SPF mice.
p615
sg4
(lp616
(dp617
g7
I24
sg8
g47
sg10
I19
sg11
Vpregnane X receptor
p618
sg13
I3
sa(dp619
g7
I45
sg8
g47
sg10
I3
sg11
VPXR
p620
sg13
I1
sasg17
(lp621
(dp622
g7
I54
sg20
VC2607929
p623
sg10
I32
sg11
Vconstitutive androstane receptor
p624
sg13
I3
sa(dp625
g7
I88
sg20
VC2607929
p626
sg10
I3
sg11
VCAR
p627
sg13
I1
sa(dp628
g7
I176
sg20
VC0339527
p629
sg10
I16
sg11
Vlithocholic acid
p630
sg13
I2
sa(dp631
g7
I194
sg20
VC0339527
p632
sg10
I3
sg11
VLCA
p633
sg13
I1
sasa(dp634
g2
VIn this study, using transgenic mice bearing conditional expression of the activated constitutive androstane receptor (CAR), we demonstrate that activation of CAR is both necessary and sufficient to confer resistance to the hepatotoxicity of lithocholic acid (LCA).
p635
sg4
(lp636
sg17
(lp637
(dp638
g7
I119
sg20
VC2607929
p639
sg10
I3
sg11
VCAR
p640
sg13
I1
sa(dp641
g7
I260
sg20
VC0339527
p642
sg10
I3
sg11
VLCA
p643
sg13
I1
sa(dp644
g7
I119
sg20
VC2607929
p645
sg10
I3
sg11
VCAR
p646
sg13
I1
sa(dp647
g7
I85
sg20
VC2607929
p648
sg10
I32
sg11
Vconstitutive androstane receptor
p649
sg13
I3
sa(dp650
g7
I242
sg20
VC0339527
p651
sg10
I16
sg11
Vlithocholic acid
p652
sg13
I2
sasa(dp653
g2
VThese results support the conclusion that dental caries is highly affected by the activity of CA VI in saliva as well as by the salivary flow rate.
p654
sg4
(lp655
(dp656
g7
I94
sg8
VP23280
p657
sg10
I5
sg11
VCA VI
p658
sg13
I2
sasg17
(lp659
(dp660
g7
I42
sg20
VC0333519
p661
sg10
I13
sg11
Vdental caries
p662
sg13
I2
sasa(dp663
g2
VEleven articles found a consistent association between salivary protein polymorphisms and risk of dental caries, for proteins related to antimicrobial activity (beta defensin 1 and lysozyme-like protein), pH control (carbonic anhydrase VI), and bacterial colonization/adhesion (lactotransferrin, mucin, and proline-rich protein Db).
p664
sg4
(lp665
(dp666
g7
I217
sg8
VP23280
p667
sg10
I21
sg11
Vcarbonic anhydrase VI
p668
sg13
I3
sa(dp669
g7
I161
sg8
VP60022
p670
sg10
I41
sg11
Vbeta defensin 1 and lysozyme-like protein
p671
sg13
I6
sa(dp672
g7
I296
sg8
g47
sg10
I5
sg11
Vmucin
p673
sg13
I1
sasg17
(lp674
(dp675
g7
I268
sg20
VC0001511
p676
sg10
I8
sg11
Vadhesion
p677
sg13
I1
sa(dp678
g7
I98
sg20
VC0333519
p679
sg10
I13
sg11
Vdental caries
p680
sg13
I2
sasa(dp681
g2
VThe rs17032907 genetic variant and the haplotype (ACA) of CA VI may be associated with dental caries susceptibility.
p682
sg4
(lp683
(dp684
g7
I58
sg8
VP23280
p685
sg10
I5
sg11
VCA VI
p686
sg13
I2
sasg17
(lp687
(dp688
g7
I87
sg20
VC0333519
p689
sg10
I13
sg11
Vdental caries
p690
sg13
I2
sasa(dp691
g2
VThe oral pathogenic bacterium involved in human dental caries formation Streptococcus mutans, encodes for two carbonic anhydrase (CA, EC 4.2.1.1) one belonging to the Alfa- and the other one to the Beta-class.
p692
sg4
(lp693
(dp694
g7
I110
sg8
VP35218
p695
sg10
I18
sg11
Vcarbonic anhydrase
p696
sg13
I2
sa(dp697
g7
I130
sg8
VP35218
p698
sg10
I2
sg11
VCA
p699
sg13
I1
sasg17
(lp700
(dp701
g7
I48
sg20
VC0333519
p702
sg10
I13
sg11
Vdental caries
p703
sg13
I2
sasa(dp704
g2
VStreptococcus mutans, the oral pathogenic bacterium provoking dental caries formation, encodes for a Beta-class carbonic anhydrase (CA, EC 4.2.1.1), SmuCA.
p705
sg4
(lp706
(dp707
g7
I101
sg8
VP35218
p708
sg10
I29
sg11
VBeta-class carbonic anhydrase
p709
sg13
I3
sasg17
(lp710
(dp711
g7
I62
sg20
VC0333519
p712
sg10
I13
sg11
Vdental caries
p713
sg13
I2
sasa(dp714
g2
VWe used mice lacking the CNTNAP2 gene, which has been implicated in autism, and achieved a temporally precise reduction in E:I balance in the medial prefrontal cortex (mPFC) either by optogenetically increasing the excitability of inhibitory parvalbumin (PV) neurons or decreasing the excitability of excitatory pyramidal neurons.
p715
sg4
(lp716
(dp717
g7
I255
sg8
VP20472
p718
sg10
I2
sg11
VPV
p719
sg13
I1
sa(dp720
g7
I242
sg8
VP20472
p721
sg10
I11
sg11
Vparvalbumin
p722
sg13
I1
sa(dp723
g7
I25
sg8
g47
sg10
I12
sg11
VCNTNAP2 gene
p724
sg13
I2
sasg17
(lp725
(dp726
g7
I215
sg20
VC0235169
p727
sg10
I12
sg11
Vexcitability
p728
sg13
I1
sa(dp729
g7
I68
sg20
VC0004352
p730
sg10
I6
sg11
Vautism
p731
sg13
I1
sa(dp732
g7
I215
sg20
VC0235169
p733
sg10
I12
sg11
Vexcitability
p734
sg13
I1
sasa(dp735
g2
VPost-mortem analyses have demonstrated a selective reduction in the expression of parvalbumin (PV) in GABAergic interneurons in the frontal rather than the sensory cortex of patients with neuropsychiatric disorders such as schizophrenia, autism spectrum disorders, and bipolar disorders.
p736
sg4
(lp737
(dp738
g7
I82
sg8
VP20472
p739
sg10
I11
sg11
Vparvalbumin
p740
sg13
I1
sa(dp741
g7
I95
sg8
VP20472
p742
sg10
I2
sg11
VPV
p743
sg13
I1
sasg17
(lp744
(dp745
g7
I223
sg20
VC0036341
p746
sg10
I13
sg11
Vschizophrenia
p747
sg13
I1
sa(dp748
g7
I269
sg20
VC0005586
p749
sg10
I17
sg11
Vbipolar disorders
p750
sg13
I2
sa(dp751
g7
I238
sg20
VC1510586
p752
sg10
I25
sg11
Vautism spectrum disorders
p753
sg13
I3
sasa(dp754
g2
VRecent neuropathology studies in human brains indicate that several areas of the prefrontal cortex have decreased numbers of parvalbumin interneurons or decreased parvalbumin expression in Autism Spectrum disorders (ASD) [Hashemi, Ariza, Rogers, Noctor, &amp; Martinez-Cerdeno, 2017; Zikopoulos &amp; Barbas, ].
p755
sg4
(lp756
(dp757
g7
I125
sg8
VP20472
p758
sg10
I11
sg11
Vparvalbumin
p759
sg13
I1
sa(dp760
g7
I125
sg8
VP20472
p761
sg10
I11
sg11
Vparvalbumin
p762
sg13
I1
sasg17
(lp763
(dp764
g7
I189
sg20
VC1510586
p765
sg10
I25
sg11
VAutism Spectrum disorders
p766
sg13
I3
sa(dp767
g7
I216
sg20
VC1510586
p768
sg10
I3
sg11
VASD
p769
sg13
I1
sa(dp770
g7
I7
sg20
VC1540677
p771
sg10
I14
sg11
Vneuropathology
p772
sg13
I1
sasa(dp773
g2
VIn view of the documented association between parvalbumin-expressing neurons and autism, the objective of the present study was to determine if parvalbumin gene expression is also altered in Purkinje neurons of the cerebellum.
p774
sg4
(lp775
(dp776
g7
I46
sg8
VP20472
p777
sg10
I11
sg11
Vparvalbumin
p778
sg13
I1
sa(dp779
g7
I144
sg8
VP20472
p780
sg10
I16
sg11
Vparvalbumin gene
p781
sg13
I2
sasg17
(lp782
(dp783
g7
I81
sg20
VC0004352
p784
sg10
I6
sg11
Vautism
p785
sg13
I1
sasa(dp786
g2
VOur hypothesis is that parvalbumin, a molecule that controls and coordinate many cellular brain functions, contributes to the excitatory/inhibitory imbalance in Autism.
p787
sg4
(lp788
(dp789
g7
I23
sg8
VP20472
p790
sg10
I11
sg11
Vparvalbumin
p791
sg13
I1
sasg17
(lp792
(dp793
g7
I148
sg20
VC1397014
p794
sg10
I9
sg11
Vimbalance
p795
sg13
I1
sa(dp796
g7
I161
sg20
VC0004352
p797
sg10
I6
sg11
VAutism
p798
sg13
I1
sasa(dp799
g2
VWe report that parvalbumin expression is depressed in Purkinje cells of the cerebellum in autism.
p800
sg4
(lp801
(dp802
g7
I15
sg8
VP20472
p803
sg10
I11
sg11
Vparvalbumin
p804
sg13
I1
sasg17
(lp805
(dp806
g7
I90
sg20
VC0004352
p807
sg10
I6
sg11
Vautism
p808
sg13
I1
sasa(dp809
g2
VFor children less than 32 weeks, FVL homozygosity may be associated with an increase in the risk of developing quadriplegia (OR 9.12, 95% CI 0.86-53.71).
p810
sg4
(lp811
sg17
(lp812
(dp813
g7
I111
sg20
VC0034372
p814
sg10
I12
sg11
Vquadriplegia
p815
sg13
I1
sasa(dp816
g2
VIn the myocardium activation of NFATc3 down-regulates the expression of voltage-gated K(+) (Kv) channels after myocardial infarction (MI).
p817
sg4
(lp818
(dp819
g7
I32
sg8
g47
sg10
I6
sg11
VNFATc3
p820
sg13
I1
sasg17
(lp821
(dp822
g7
I134
sg20
VC0027051
p823
sg10
I2
sg11
VMI
p824
sg13
I1
sa(dp825
g7
I111
sg20
VC0027051
p826
sg10
I21
sg11
Vmyocardial infarction
p827
sg13
I2
sasa(dp828
g2
VKnockdown of NFAT4 suppresses mitochondrial fission and protects cardiomyocyte from apoptosis and myocardial infarction.
p829
sg4
(lp830
(dp831
g7
I13
sg8
g47
sg10
I5
sg11
VNFAT4
p832
sg13
I1
sasg17
(lp833
(dp834
g7
I98
sg20
VC0027051
p835
sg10
I21
sg11
Vmyocardial infarction
p836
sg13
I2
sasa(dp837
g2
VThe expression pattern of WNT3A is consistent with BRG1 in colon cancer tissues and WNT3A expression was inhibited in BRG1 knockdown cells.
p838
sg4
(lp839
(dp840
g7
I51
sg8
VP51532
p841
sg10
I4
sg11
VBRG1
p842
sg13
I1
sa(dp843
g7
I26
sg8
VP56704
p844
sg10
I5
sg11
VWNT3A
p845
sg13
I1
sa(dp846
g7
I51
sg8
VP51532
p847
sg10
I28
sg11
VBRG1 in colon cancer tissues
p848
sg13
I5
sa(dp849
g7
I26
sg8
VP56704
p850
sg10
I5
sg11
VWNT3A
p851
sg13
I1
sasg17
(lp852
(dp853
g7
I59
sg20
VC0699790
p854
sg10
I12
sg11
Vcolon cancer
p855
sg13
I2
sasa(dp856
g2
VIn this study, we demonstrate that BRG1 may contribute to colon cancer progression through upregulating WNT3A expression.
p857
sg4
(lp858
(dp859
g7
I104
sg8
VP56704
p860
sg10
I5
sg11
VWNT3A
p861
sg13
I1
sa(dp862
g7
I35
sg8
VP51532
p863
sg10
I4
sg11
VBRG1
p864
sg13
I1
sasg17
(lp865
(dp866
g7
I64
sg20
VC0178874
p867
sg10
I18
sg11
Vcancer progression
p868
sg13
I2
sasa(dp869
g2
VVM-positive colon cancer samples showed increased Wnt3a expression (p &lt; 0.001) and Beta-catenin nuclear expression (p &lt; 0.001) compared with the VM-negative samples.
p870
sg4
(lp871
(dp872
g7
I50
sg8
VP56704
p873
sg10
I5
sg11
VWnt3a
p874
sg13
I1
sa(dp875
g7
I86
sg8
VP35222
p876
sg10
I12
sg11
VBeta-catenin
p877
sg13
I1
sasg17
(lp878
(dp879
g7
I12
sg20
VC0699790
p880
sg10
I12
sg11
Vcolon cancer
p881
sg13
I2
sasa(dp882
g2
VIn vitro, over-regulated Wnt3a expression in HT29 colon cancer cells promoted the capacity to form tube-like structures in the three-dimensional (3-D) culture together with increased expression of endothelial phenotype-associated proteins such as VEGFR2 and VE-cadherin.
p883
sg4
(lp884
(dp885
g7
I258
sg8
VP33151
p886
sg10
I11
sg11
VVE-cadherin
p887
sg13
I1
sa(dp888
g7
I247
sg8
VP35968
p889
sg10
I6
sg11
VVEGFR2
p890
sg13
I1
sa(dp891
g7
I25
sg8
VP56704
p892
sg10
I5
sg11
VWnt3a
p893
sg13
I1
sasg17
(lp894
(dp895
g7
I50
sg20
VC0699790
p896
sg10
I12
sg11
Vcolon cancer
p897
sg13
I2
sasa(dp898
g2
VHowever, the roles of Wnt3a, the representative canonical Wnt ligand, in EMT and colon cancer progression have not yet been fully explored.
p899
sg4
(lp900
(dp901
g7
I58
sg8
g47
sg10
I10
sg11
VWnt ligand
p902
sg13
I2
sa(dp903
g7
I22
sg8
VP56704
p904
sg10
I5
sg11
VWnt3a
p905
sg13
I1
sa(dp906
g7
I73
sg8
g47
sg10
I3
sg11
VEMT
p907
sg13
I1
sasg17
(lp908
(dp909
g7
I87
sg20
VC0178874
p910
sg10
I18
sg11
Vcancer progression
p911
sg13
I2
sasa(dp912
g2
VThe expression levels of Wnt3a and EMT-associated proteins (E-cadherin, vimentin, and Beta-catenin) were assessed by immunohistochemistry in human colon cancer tissues to evaluate the clinicopathological significance of Wnt3a, as well as the correlation between Wnt3a and EMT.
p913
sg4
(lp914
(dp915
g7
I25
sg8
VP56704
p916
sg10
I5
sg11
VWnt3a
p917
sg13
I1
sa(dp918
g7
I35
sg8
g47
sg10
I23
sg11
VEMT-associated proteins
p919
sg13
I2
sa(dp920
g7
I60
sg8
VP12830
p921
sg10
I10
sg11
VE-cadherin
p922
sg13
I1
sa(dp923
g7
I86
sg8
VP35222
p924
sg10
I12
sg11
VBeta-catenin
p925
sg13
I1
sa(dp926
g7
I35
sg8
g47
sg10
I3
sg11
VEMT
p927
sg13
I1
sa(dp928
g7
I25
sg8
VP56704
p929
sg10
I5
sg11
VWnt3a
p930
sg13
I1
sa(dp931
g7
I25
sg8
VP56704
p932
sg10
I5
sg11
VWnt3a
p933
sg13
I1
sasg17
(lp934
(dp935
g7
I147
sg20
VC0699790
p936
sg10
I12
sg11
Vcolon cancer
p937
sg13
I2
sasa(dp938
g2
VWe then upregulated Wnt3a expression in HCT116 colon cancer cells, established a nude mouse xenograft model, detected the expression of EMT and Wnt/Beta-catenin signaling-associated proteins, and observed invasion and clone-initiating abilities.
p939
sg4
(lp940
(dp941
g7
I20
sg8
VP56704
p942
sg10
I5
sg11
VWnt3a
p943
sg13
I1
sa(dp944
g7
I136
sg8
g47
sg10
I3
sg11
VEMT
p945
sg13
I1
sa(dp946
g7
I148
sg8
VP35222
p947
sg10
I12
sg11
VBeta-catenin
p948
sg13
I1
sasg17
(lp949
(dp950
g7
I47
sg20
VC0699790
p951
sg10
I12
sg11
Vcolon cancer
p952
sg13
I2
sa(dp953
g7
I205
sg20
VC2699153
p954
sg10
I8
sg11
Vinvasion
p955
sg13
I1
sasa(dp956
g2
VIn 203 human colon cancer tissue samples, Wnt3a protein overexpression was related to colon cancer histological differentiation (P = 0.004), clinical stage (P = 0.008), presence of metastasis and recurrence (P = 0.036), and survival time (P = 0.007) of colon cancer patients.
p957
sg4
(lp958
(dp959
g7
I42
sg8
VP56704
p960
sg10
I5
sg11
VWnt3a
p961
sg13
I1
sasg17
(lp962
(dp963
g7
I181
sg20
VC0027627
p964
sg10
I10
sg11
Vmetastasis
p965
sg13
I1
sa(dp966
g7
I13
sg20
VC0699790
p967
sg10
I12
sg11
Vcolon cancer
p968
sg13
I2
sa(dp969
g7
I13
sg20
VC0699790
p970
sg10
I12
sg11
Vcolon cancer
p971
sg13
I2
sa(dp972
g7
I13
sg20
VC0699790
p973
sg10
I12
sg11
Vcolon cancer
p974
sg13
I2
sa(dp975
g7
I196
sg20
VC1458156
p976
sg10
I10
sg11
Vrecurrence
p977
sg13
I1
sasa(dp978
g2
VWnt3a expression was associated with EMT and promoted colon cancer progression.
p979
sg4
(lp980
(dp981
g7
I37
sg8
g47
sg10
I3
sg11
VEMT
p982
sg13
I1
sa(dp983
g7
I0
sg8
VP56704
p984
sg10
I5
sg11
VWnt3a
p985
sg13
I1
sasg17
(lp986
(dp987
g7
I60
sg20
VC0178874
p988
sg10
I18
sg11
Vcancer progression
p989
sg13
I2
sasa(dp990
g2
VDisruption of 11-cis-RDHs causes a slowly developing cone dystrophy caused by inefficient cone pigment regeneration.
p991
sg4
(lp992
(dp993
g7
I14
sg8
g47
sg10
I11
sg11
V11-cis-RDHs
p994
sg13
I1
sasg17
(lp995
(dp996
g7
I53
sg20
VC0730290
p997
sg10
I14
sg11
Vcone dystrophy
p998
sg13
I2
sa(dp999
g7
I17
sg20
VC0007099
p1000
sg10
I3
sg11
Vcis
p1001
sg13
I1
sasa(dp1002
g2
VTo evaluate the GH-releasing hormone (GH-RH)-induced response of GH in patients affected by hypothalamic amenorrhea.
p1003
sg4
(lp1004
(dp1005
g7
I38
sg8
VP01286
p1006
sg10
I5
sg11
VGH-RH
p1007
sg13
I1
sa(dp1008
g7
I16
sg8
VP01286
p1009
sg10
I20
sg11
VGH-releasing hormone
p1010
sg13
I2
sasg17
(lp1011
(dp1012
g7
I92
sg20
VC0341862
p1013
sg10
I23
sg11
Vhypothalamic amenorrhea
p1014
sg13
I2
sasa(dp1015
g2
VThe amenorrheic condition associated with reduced BMI changes the GH-RH--induced GH response in hypothalamic amenorrhea, supporting a GH and a IGF-I disregulation in weight-loss--related amenorrhea.
p1016
sg4
(lp1017
(dp1018
g7
I143
sg8
VP01343
p1019
sg10
I5
sg11
VIGF-I
p1020
sg13
I1
sasg17
(lp1021
(dp1022
g7
I109
sg20
VC0002453
p1023
sg10
I10
sg11
Vamenorrhea
p1024
sg13
I1
sa(dp1025
g7
I96
sg20
VC0341862
p1026
sg10
I23
sg11
Vhypothalamic amenorrhea
p1027
sg13
I2
sa(dp1028
g7
I16
sg20
VC0012634
p1029
sg10
I9
sg11
Vcondition
p1030
sg13
I1
sasa(dp1031
g2
VWe report the case of a 17-year-old girl presenting short stature (height 149 cm, below the 3rd percentile), obesity (weight 83.5 kg, body mass index 37 kg/m2) and secondary amenorrhea, in whom endocrinological evaluation disclosed an absolute lack of GH responsiveness to both suprapituitary challenges and repetitive growth hormone releasing hormone administration together with failure of plasma gonadotropins and PRL, low under basal conditions, to rise in response to GnRH and insulin-hypoglycemia, respectively.
p1032
sg4
(lp1033
(dp1034
g7
I319
sg8
VP01242
p1035
sg10
I14
sg11
Vgrowth hormone
p1036
sg13
I2
sa(dp1037
g7
I482
sg8
VP01308
p1038
sg10
I7
sg11
Vinsulin
p1039
sg13
I1
sa(dp1040
g7
I417
sg8
VP01236
p1041
sg10
I3
sg11
VPRL
p1042
sg13
I1
sa(dp1043
g7
I473
sg8
VP01148
p1044
sg10
I4
sg11
VGnRH
p1045
sg13
I1
sasg17
(lp1046
(dp1047
g7
I164
sg20
VC0232940
p1048
sg10
I20
sg11
Vsecondary amenorrhea
p1049
sg13
I2
sa(dp1050
g7
I109
sg20
VC0028754
p1051
sg10
I7
sg11
Vobesity
p1052
sg13
I1
sa(dp1053
g7
I490
sg20
VC0020615
p1054
sg10
I12
sg11
Vhypoglycemia
p1055
sg13
I1
sa(dp1056
g7
I52
sg20
VC0013336
p1057
sg10
I13
sg11
Vshort stature
p1058
sg13
I2
sasa(dp1059
g2
VCommon genes include Jagged 1 (Jag1), Tetraspanin 2 (Tspan2), neuroblastoma, suppression of tumourigenicity 1 (Nbl1) and N-myc downstream regulated gene 2 (Ndrg2).
p1060
sg4
(lp1061
(dp1062
g7
I21
sg8
VP78504
p1063
sg10
I8
sg11
VJagged 1
p1064
sg13
I2
sa(dp1065
g7
I121
sg8
VP04198
p1066
sg10
I5
sg11
VN-myc
p1067
sg13
I1
sa(dp1068
g7
I38
sg8
g47
sg10
I13
sg11
VTetraspanin 2
p1069
sg13
I2
sa(dp1070
g7
I31
sg8
VP78504
p1071
sg10
I4
sg11
VJag1
p1072
sg13
I1
sa(dp1073
g7
I53
sg8
g47
sg10
I6
sg11
VTspan2
p1074
sg13
I1
sasg17
(lp1075
(dp1076
g7
I62
sg20
VC0027819
p1077
sg10
I13
sg11
Vneuroblastoma
p1078
sg13
I1
sa(dp1079
g7
I77
sg20
VC0221103
p1080
sg10
I11
sg11
Vsuppression
p1081
sg13
I1
sasa(dp1082
g2
VWhile vincristine was effective against 1 out 4 neuroblastoma xenografts, TS-N-2, with 58.1% maximum inhibition rate, etoposide was assessed ineffective as a single agent in all of the 3 xenografts used.
p1083
sg4
(lp1084
sg17
(lp1085
(dp1086
g7
I48
sg20
VC0027819
p1087
sg10
I13
sg11
Vneuroblastoma
p1088
sg13
I1
sasa(dp1089
g2
VThe purpose of this study was to evaluate the correlation of somatostatin receptor-2 (SSTR2) expression with 68Ga-DOTA-TATE uptake and 177Lu-DOTA-TATE therapy in neuroblastoma (NB) xenograft models.
p1090
sg4
(lp1091
(dp1092
g7
I86
sg8
VP30874
p1093
sg10
I5
sg11
VSSTR2
p1094
sg13
I1
sa(dp1095
g7
I61
sg8
VP61278
p1096
sg10
I23
sg11
Vsomatostatin receptor-2
p1097
sg13
I2
sasg17
(lp1098
(dp1099
g7
I177
sg20
VC0027819
p1100
sg10
I2
sg11
VNB
p1101
sg13
I1
sa(dp1102
g7
I162
sg20
VC0027819
p1103
sg10
I13
sg11
Vneuroblastoma
p1104
sg13
I1
sasa(dp1105
g2
VNeuroblastoma may be treated with molecular radiotherapy, 131I meta-Iodobenzylguanidine and 177Lu Lutetium DOTATATE, directed at distinct molecular targets: Noradrenaline Transporter Molecule (NAT) and Somatostatin Receptor (SSTR2), respectively.
p1106
sg4
(lp1107
(dp1108
g7
I225
sg8
VP30874
p1109
sg10
I5
sg11
VSSTR2
p1110
sg13
I1
sa(dp1111
g7
I202
sg8
VP61278
p1112
sg10
I21
sg11
VSomatostatin Receptor
p1113
sg13
I2
sasg17
(lp1114
(dp1115
g7
I0
sg20
VC0027819
p1116
sg10
I13
sg11
VNeuroblastoma
p1117
sg13
I1
sasa(dp1118
g2
VTissue bank samples of formalin fixed paraffin embedded neuroblastoma tissue from patients for whom clinical outcome data were available were sectioned and stained with haematoxylin and eosin, and monoclonal antibodies directed against NAT and SSTR2.
p1119
sg4
(lp1120
(dp1121
g7
I244
sg8
VP30874
p1122
sg10
I5
sg11
VSSTR2
p1123
sg13
I1
sa(dp1124
g7
I236
sg8
VP18440
p1125
sg10
I3
sg11
VNAT
p1126
sg13
I1
sasg17
(lp1127
(dp1128
g7
I56
sg20
VC0027819
p1129
sg10
I13
sg11
Vneuroblastoma
p1130
sg13
I1
sasa(dp1131
g2
V68Ga-DOTATATE PET/CT enables detection of meningioma tissue based on somatostatin receptor 2 expression.
p1132
sg4
(lp1133
(dp1134
g7
I69
sg8
VP61278
p1135
sg10
I23
sg11
Vsomatostatin receptor 2
p1136
sg13
I3
sasg17
(lp1137
(dp1138
g7
I42
sg20
VC0025286
p1139
sg10
I10
sg11
Vmeningioma
p1140
sg13
I1
sasa(dp1141
g2
VImmunohistochemistry for the meningioma markers EMA and SSTR2A raised the possibility of intraosseous meningioma, as all 3 lesions were convincingly positive for epithelial membrane antigen (EMA) and 1 lesion was convincingly positive for the somatostatin receptor subtype 2A (SSTR2A); weak, questionable positivity for SSTR2 was present in the remaining 2 cases.
p1142
sg4
(lp1143
(dp1144
g7
I56
sg8
VP61278
p1145
sg10
I6
sg11
VSSTR2A
p1146
sg13
I1
sa(dp1147
g7
I162
sg8
VP12830
p1148
sg10
I27
sg11
Vepithelial membrane antigen
p1149
sg13
I3
sa(dp1150
g7
I48
sg8
VP13804
p1151
sg10
I3
sg11
VEMA
p1152
sg13
I1
sa(dp1153
g7
I56
sg8
VP30874
p1154
sg10
I5
sg11
VSSTR2
p1155
sg13
I1
sa(dp1156
g7
I56
sg8
VP61278
p1157
sg10
I6
sg11
VSSTR2A
p1158
sg13
I1
sa(dp1159
g7
I243
sg8
VP61278
p1160
sg10
I32
sg11
Vsomatostatin receptor subtype 2A
p1161
sg13
I4
sa(dp1162
g7
I48
sg8
VP12830
p1163
sg10
I3
sg11
VEMA
p1164
sg13
I1
sasg17
(lp1165
(dp1166
g7
I29
sg20
VC0025286
p1167
sg10
I10
sg11
Vmeningioma
p1168
sg13
I1
sa(dp1169
g7
I48
sg20
VC0268596
p1170
sg10
I3
sg11
VEMA
p1171
sg13
I1
sa(dp1172
g7
I29
sg20
VC0025286
p1173
sg10
I10
sg11
Vmeningioma
p1174
sg13
I1
sa(dp1175
g7
I48
sg20
VC0268596
p1176
sg10
I3
sg11
VEMA
p1177
sg13
I1
sa(dp1178
g7
I162
sg20
VC0268596
p1179
sg10
I27
sg11
Vepithelial membrane antigen
p1180
sg13
I3
sasa(dp1181
g2
VSomatostatine receptors subtype 2 (SSTR2) are regarded as a potential target in neuroblastoma (NB) for imaging and promising therapeutic approaches.
p1182
sg4
(lp1183
(dp1184
g7
I0
sg8
g47
sg10
I33
sg11
VSomatostatine receptors subtype 2
p1185
sg13
I4
sa(dp1186
g7
I35
sg8
VP30874
p1187
sg10
I5
sg11
VSSTR2
p1188
sg13
I1
sasg17
(lp1189
(dp1190
g7
I80
sg20
VC0027819
p1191
sg10
I13
sg11
Vneuroblastoma
p1192
sg13
I1
sa(dp1193
g7
I95
sg20
VC0027819
p1194
sg10
I2
sg11
VNB
p1195
sg13
I1
sasa(dp1196
g2
VGaTATE PET was positive in a high proportion of patients with refractory neuroblastoma, correlating with SSTR 2 on IHC, with additional disease identified compared with MIBG imaging.
p1197
sg4
(lp1198
(dp1199
g7
I105
sg8
VP31391
p1200
sg10
I6
sg11
VSSTR 2
p1201
sg13
I2
sasg17
(lp1202
(dp1203
g7
I73
sg20
VC0027819
p1204
sg10
I13
sg11
Vneuroblastoma
p1205
sg13
I1
sasa(dp1206
g2
VPET using the SSTR2 analog (68)Ga-DOTATATE has recently been introduced for imaging of meningiomas.
p1207
sg4
(lp1208
(dp1209
g7
I14
sg8
VP30874
p1210
sg10
I5
sg11
VSSTR2
p1211
sg13
I1
sasg17
(lp1212
(dp1213
g7
I87
sg20
VC0025286
p1214
sg10
I11
sg11
Vmeningiomas
p1215
sg13
I1
sasa(dp1216
g2
V(68)Ga-DOTATATE uptake correlates with SSTR2 expression and offers high diagnostic accuracy to delineate meningioma from tumor-free tissue even in recurrent tumors after previous therapy.
p1217
sg4
(lp1218
(dp1219
g7
I39
sg8
VP30874
p1220
sg10
I5
sg11
VSSTR2
p1221
sg13
I1
sasg17
(lp1222
(dp1223
g7
I105
sg20
VC0025286
p1224
sg10
I10
sg11
Vmeningioma
p1225
sg13
I1
sa(dp1226
g7
I121
sg20
VC0027651
p1227
sg10
I5
sg11
Vtumor
p1228
sg13
I1
sa(dp1229
g7
I157
sg20
VC0027651
p1230
sg10
I6
sg11
Vtumors
p1231
sg13
I1
sasa(dp1232
g2
VWe aimed to compare the frequency of perineurial marker expression in these two entities, and to determine whether somatostatin receptor 2 (SSTR2) and progesterone receptor (PR), both expressed frequently in meningiomas, are also expressed in perineuriomas.
p1233
sg4
(lp1234
(dp1235
g7
I115
sg8
VP61278
p1236
sg10
I23
sg11
Vsomatostatin receptor 2
p1237
sg13
I3
sa(dp1238
g7
I151
sg8
VP06401
p1239
sg10
I21
sg11
Vprogesterone receptor
p1240
sg13
I2
sa(dp1241
g7
I174
sg8
VP06401
p1242
sg10
I2
sg11
VPR
p1243
sg13
I1
sa(dp1244
g7
I140
sg8
VP30874
p1245
sg10
I5
sg11
VSSTR2
p1246
sg13
I1
sasg17
(lp1247
(dp1248
g7
I208
sg20
VC0025286
p1249
sg10
I11
sg11
Vmeningiomas
p1250
sg13
I1
sa(dp1251
g7
I243
sg20
VC0751691
p1252
sg10
I13
sg11
Vperineuriomas
p1253
sg13
I1
sasa(dp1254
g2
VAll tumours were stained using five antibodies against antigens that are known to be expressed in perineuriomas or meningiomas: epithelial membrane antigen (EMA), claudin-1, GLUT-1 (glucose transporter-1), SSTR2, and PR.
p1255
sg4
(lp1256
(dp1257
g7
I174
sg8
VP11166
p1258
sg10
I6
sg11
VGLUT-1
p1259
sg13
I1
sa(dp1260
g7
I128
sg8
VP12830
p1261
sg10
I27
sg11
Vepithelial membrane antigen
p1262
sg13
I3
sa(dp1263
g7
I182
sg8
VP11166
p1264
sg10
I21
sg11
Vglucose transporter-1
p1265
sg13
I2
sa(dp1266
g7
I206
sg8
VP30874
p1267
sg10
I5
sg11
VSSTR2
p1268
sg13
I1
sa(dp1269
g7
I157
sg8
VP13804
p1270
sg10
I3
sg11
VEMA
p1271
sg13
I1
sa(dp1272
g7
I163
sg8
g47
sg10
I9
sg11
Vclaudin-1
p1273
sg13
I1
sasg17
(lp1274
(dp1275
g7
I98
sg20
VC0751691
p1276
sg10
I13
sg11
Vperineuriomas
p1277
sg13
I1
sa(dp1278
g7
I115
sg20
VC0025286
p1279
sg10
I11
sg11
Vmeningiomas
p1280
sg13
I1
sa(dp1281
g7
I128
sg20
VC0268596
p1282
sg10
I27
sg11
Vepithelial membrane antigen
p1283
sg13
I3
sa(dp1284
g7
I4
sg20
VC0027651
p1285
sg10
I7
sg11
Vtumours
p1286
sg13
I1
sa(dp1287
g7
I157
sg20
VC0268596
p1288
sg10
I3
sg11
VEMA
p1289
sg13
I1
sasa(dp1290
g2
VOf the meningiomas, EMA was expressed in 59 of 61, claudin-1 in five of 63, GLUT-1 in 19 of 62, SSTR2 in 59 of 68, and PR in 44 of 62.
p1291
sg4
(lp1292
(dp1293
g7
I51
sg8
g47
sg10
I9
sg11
Vclaudin-1
p1294
sg13
I1
sasg17
(lp1295
(dp1296
g7
I7
sg20
VC0025286
p1297
sg10
I11
sg11
Vmeningiomas
p1298
sg13
I1
sa(dp1299
g7
I20
sg20
VC0268596
p1300
sg10
I3
sg11
VEMA
p1301
sg13
I1
sasa(dp1302
g2
VThe SSTR2-positive/PR-positive phenotype was detected in 42 of 60 meningiomas, but in none of 20 perineuriomas.
p1303
sg4
(lp1304
(dp1305
g7
I4
sg8
VP30874
p1306
sg10
I5
sg11
VSSTR2
p1307
sg13
I1
sasg17
(lp1308
(dp1309
g7
I66
sg20
VC0025286
p1310
sg10
I11
sg11
Vmeningiomas
p1311
sg13
I1
sa(dp1312
g7
I97
sg20
VC0751691
p1313
sg10
I13
sg11
Vperineuriomas
p1314
sg13
I1
sasa(dp1315
g2
VSSTR2 and PR are highly sensitive and, in this context, specific meningioma markers.
p1316
sg4
(lp1317
(dp1318
g7
I0
sg8
VP30874
p1319
sg10
I5
sg11
VSSTR2
p1320
sg13
I1
sasg17
(lp1321
(dp1322
g7
I65
sg20
VC0025286
p1323
sg10
I10
sg11
Vmeningioma
p1324
sg13
I1
sasa(dp1325
g2
VWe utilized inhibitors of cPLA2 alpha, COX-1/2 and 5-LO to determine the potential roles of these enzymes in development of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS).
p1326
sg4
(lp1327
(dp1328
g7
I39
sg8
VP00395
p1329
sg10
I7
sg11
VCOX-1/2
p1330
sg13
I1
sa(dp1331
g7
I26
sg8
VP47712
p1332
sg10
I11
sg11
VcPLA2 alpha
p1333
sg13
I2
sasg17
(lp1334
(dp1335
g7
I167
sg20
VC0014070
p1336
sg10
I3
sg11
VEAE
p1337
sg13
I1
sa(dp1338
g7
I212
sg20
VC0026769
p1339
sg10
I2
sg11
VMS
p1340
sg13
I1
sa(dp1341
g7
I148
sg20
VC0014070
p1342
sg10
I17
sg11
Vencephalomyelitis
p1343
sg13
I1
sa(dp1344
g7
I192
sg20
VC0026769
p1345
sg10
I18
sg11
Vmultiple sclerosis
p1346
sg13
I2
sa(dp1347
g7
I137
sg20
VC0443146
p1348
sg10
I10
sg11
Vautoimmune
p1349
sg13
I1
sasa(dp1350
g2
VThis study aimed to better understand the role of miR-200a-3p and its correlation with HBx in HBV-induced hepatocellular carcinoma (HCC).
p1351
sg4
(lp1352
(dp1353
g7
I87
sg8
VP24821
p1354
sg10
I3
sg11
VHBx
p1355
sg13
I1
sa(dp1356
g7
I50
sg8
g47
sg10
I11
sg11
VmiR-200a-3p
p1357
sg13
I1
sasg17
(lp1358
(dp1359
g7
I106
sg20
VC2239176
p1360
sg10
I24
sg11
Vhepatocellular carcinoma
p1361
sg13
I2
sa(dp1362
g7
I94
sg20
VC0019163
p1363
sg10
I3
sg11
VHBV
p1364
sg13
I1
sa(dp1365
g7
I132
sg20
VC2239176
p1366
sg10
I3
sg11
VHCC
p1367
sg13
I1
sasa(dp1368
g2
VFurther study suggested that lncRNA-PE downregulated miR-200a/b by repressing the primary transcript expression, enhanced ZEB1 expression, and promoted epithelial-mesenchymal transition of hepatocellular carcinoma cells.
p1369
sg4
(lp1370
(dp1371
g7
I53
sg8
g47
sg10
I10
sg11
VmiR-200a/b
p1372
sg13
I1
sa(dp1373
g7
I29
sg8
VP48147
p1374
sg10
I9
sg11
VlncRNA-PE
p1375
sg13
I1
sa(dp1376
g7
I122
sg8
VP37275
p1377
sg10
I4
sg11
VZEB1
p1378
sg13
I1
sasg17
(lp1379
(dp1380
g7
I175
sg20
VC0599156
p1381
sg10
I10
sg11
Vtransition
p1382
sg13
I1
sa(dp1383
g7
I189
sg20
VC1512411
p1384
sg10
I24
sg11
Vhepatocellular carcinoma
p1385
sg13
I2
sasa(dp1386
g2
VAll these data imply that lncRNA-PE might play an important role in hepatocellular carcinoma development via the miR-200a/b-ZEB1 pathway.
p1387
sg4
(lp1388
(dp1389
g7
I26
sg8
VP48147
p1390
sg10
I9
sg11
VlncRNA-PE
p1391
sg13
I1
sa(dp1392
g7
I124
sg8
VP37275
p1393
sg10
I4
sg11
VZEB1
p1394
sg13
I1
sa(dp1395
g7
I113
sg8
g47
sg10
I8
sg11
VmiR-200a
p1396
sg13
I1
sasg17
(lp1397
(dp1398
g7
I68
sg20
VC1512411
p1399
sg10
I24
sg11
Vhepatocellular carcinoma
p1400
sg13
I2
sasa(dp1401
g2
VHerein, we found that hepatocellular carcinoma cells shed more microvesicles than normal hepatocytes and miR-200a were shown to inhibit the release of microvesicles in hepatocellular carcinoma cells.
p1402
sg4
(lp1403
(dp1404
g7
I105
sg8
g47
sg10
I8
sg11
VmiR-200a
p1405
sg13
I1
sasg17
(lp1406
(dp1407
g7
I22
sg20
VC1512411
p1408
sg10
I24
sg11
Vhepatocellular carcinoma
p1409
sg13
I2
sa(dp1410
g7
I22
sg20
VC1512411
p1411
sg10
I24
sg11
Vhepatocellular carcinoma
p1412
sg13
I2
sasa(dp1413
g2
VCollectively, our findings indicate that miR-200a regulated the microvesicle biogenesis involved in the hepatocellular carcinoma progression.
p1414
sg4
(lp1415
(dp1416
g7
I41
sg8
g47
sg10
I8
sg11
VmiR-200a
p1417
sg13
I1
sasg17
(lp1418
(dp1419
g7
I104
sg20
VC1512411
p1420
sg10
I24
sg11
Vhepatocellular carcinoma
p1421
sg13
I2
sasa(dp1422
g2
VConclusions: These findings indicate that miR-200a regulates the proliferation, migration and invasion of HCC cells by targeting Foxa2, suggesting that miR-200a may function as a potential therapeutic molecular for the diagnosis and treatment of the liver cancer.
p1423
sg4
(lp1424
(dp1425
g7
I129
sg8
g47
sg10
I5
sg11
VFoxa2
p1426
sg13
I1
sa(dp1427
g7
I42
sg8
g47
sg10
I8
sg11
VmiR-200a
p1428
sg13
I1
sa(dp1429
g7
I42
sg8
g47
sg10
I8
sg11
VmiR-200a
p1430
sg13
I1
sasg17
(lp1431
(dp1432
g7
I65
sg20
VC0334094
p1433
sg10
I13
sg11
Vproliferation
p1434
sg13
I1
sa(dp1435
g7
I94
sg20
VC2699153
p1436
sg10
I8
sg11
Vinvasion
p1437
sg13
I1
sa(dp1438
g7
I250
sg20
VC0345904
p1439
sg10
I12
sg11
Vliver cancer
p1440
sg13
I2
sa(dp1441
g7
I106
sg20
VC2239176
p1442
sg10
I3
sg11
VHCC
p1443
sg13
I1
sasa(dp1444
g2
VLong noncoding RNAs (lncRNAs)-activated by transforming growth factor beta (lncRNA-ATB) is known to be involved in the invasion of hepatocellular carcinoma by regulating target genes of miR-200a.
p1445
sg4
(lp1446
(dp1447
g7
I186
sg8
g47
sg10
I8
sg11
VmiR-200a
p1448
sg13
I1
sa(dp1449
g7
I76
sg8
VP00325
p1450
sg10
I10
sg11
VlncRNA-ATB
p1451
sg13
I1
sa(dp1452
g7
I43
sg8
VP18075
p1453
sg10
I31
sg11
Vtransforming growth factor beta
p1454
sg13
I4
sasg17
(lp1455
(dp1456
g7
I119
sg20
VC2699153
p1457
sg10
I8
sg11
Vinvasion
p1458
sg13
I1
sa(dp1459
g7
I131
sg20
VC1512411
p1460
sg10
I24
sg11
Vhepatocellular carcinoma
p1461
sg13
I2
sasa(dp1462
g2
VIn this study, we determined that miR-200a was downregulated in hepatocellular carcinoma (HCC) tissues and cell lines, consistent with the results of our previous study.
p1463
sg4
(lp1464
(dp1465
g7
I34
sg8
g47
sg10
I8
sg11
VmiR-200a
p1466
sg13
I1
sasg17
(lp1467
(dp1468
g7
I90
sg20
VC2239176
p1469
sg10
I3
sg11
VHCC
p1470
sg13
I1
sa(dp1471
g7
I64
sg20
VC2239176
p1472
sg10
I24
sg11
Vhepatocellular carcinoma
p1473
sg13
I2
sasa(dp1474
g2
VOur data indicate that nine distinct genes associated with multiple sclerosis risk, Bach2, Il2ra, Irf8, Mertk, Odf3b, Plek, Rgs1, Slc30a7 and Thada, can be confirmed to be differentially regulated in pathogenic CD4(+) T cells.
p1475
sg4
(lp1476
(dp1477
g7
I111
sg8
g47
sg10
I5
sg11
VOdf3b
p1478
sg13
I1
sa(dp1479
g7
I98
sg8
g47
sg10
I4
sg11
VIrf8
p1480
sg13
I1
sa(dp1481
g7
I91
sg8
VP01589
p1482
sg10
I5
sg11
VIl2ra
p1483
sg13
I1
sa(dp1484
g7
I104
sg8
g47
sg10
I5
sg11
VMertk
p1485
sg13
I1
sa(dp1486
g7
I211
sg8
VP01730
p1487
sg10
I3
sg11
VCD4
p1488
sg13
I1
sa(dp1489
g7
I84
sg8
g47
sg10
I5
sg11
VBach2
p1490
sg13
I1
sa(dp1491
g7
I130
sg8
g47
sg10
I7
sg11
VSlc30a7
p1492
sg13
I1
sa(dp1493
g7
I124
sg8
g47
sg10
I4
sg11
VRgs1
p1494
sg13
I1
sa(dp1495
g7
I118
sg8
VP08567
p1496
sg10
I4
sg11
VPlek
p1497
sg13
I1
sasg17
(lp1498
(dp1499
g7
I59
sg20
VC0026769
p1500
sg10
I18
sg11
Vmultiple sclerosis
p1501
sg13
I2
sasa(dp1502
g2
VGenetic polymorphisms within a single locus encoding the transcription factor BACH2 are associated with numerous autoimmune and allergic diseases including asthma, Crohn's disease, coeliac disease, vitiligo, multiple sclerosis and type 1 diabetes.
p1503
sg4
(lp1504
(dp1505
g7
I57
sg8
VP35398
p1506
sg10
I26
sg11
Vtranscription factor BACH2
p1507
sg13
I3
sasg17
(lp1508
(dp1509
g7
I208
sg20
VC0026769
p1510
sg10
I18
sg11
Vmultiple sclerosis
p1511
sg13
I2
sa(dp1512
g7
I164
sg20
VC0010346
p1513
sg10
I15
sg11
VCrohn's disease
p1514
sg13
I2
sa(dp1515
g7
I113
sg20
VC0443146
p1516
sg10
I10
sg11
Vautoimmune
p1517
sg13
I1
sa(dp1518
g7
I181
sg20
VC0007570
p1519
sg10
I15
sg11
Vcoeliac disease
p1520
sg13
I2
sa(dp1521
g7
I231
sg20
VC0011854
p1522
sg10
I15
sg11
Vtype 1 diabetes
p1523
sg13
I3
sa(dp1524
g7
I198
sg20
VC0042900
p1525
sg10
I8
sg11
Vvitiligo
p1526
sg13
I1
sa(dp1527
g7
I156
sg20
VC0004096
p1528
sg10
I6
sg11
Vasthma
p1529
sg13
I1
sasa(dp1530
g2
VHowever, array-based copy number analysis and qPCR were used to detect a hemizygous deletion in the PACD linkage interval containing 4 genes encoding small leucine-rich proteoglycans (SLRPs): KERA, LUM, DCN, and EPYC.
p1531
sg4
(lp1532
(dp1533
g7
I192
sg8
g47
sg10
I4
sg11
VKERA
p1534
sg13
I1
sa(dp1535
g7
I212
sg8
g47
sg10
I4
sg11
VEPYC
p1536
sg13
I1
sa(dp1537
g7
I198
sg8
VP51884
p1538
sg10
I3
sg11
VLUM
p1539
sg13
I1
sa(dp1540
g7
I203
sg8
VP07585
p1541
sg10
I3
sg11
VDCN
p1542
sg13
I1
sa(dp1543
g7
I184
sg8
g47
sg10
I5
sg11
VSLRPs
p1544
sg13
I1
sa(dp1545
g7
I150
sg8
VP30740
p1546
sg10
I32
sg11
Vsmall leucine-rich proteoglycans
p1547
sg13
I3
sasg17
(lp1548
(dp1549
g7
I100
sg20
VC2748502
p1550
sg10
I4
sg11
VPACD
p1551
sg13
I1
sasa(dp1552
g2
VThe authors performed clinical evaluation of a previously unreported pedigree with PACD, light and electron microscopic examination of an excised corneal button, genomewide linkage analysis, fine mapping linkage and haplotype analysis, and screening of four candidate genes (KERA, LUM, DCN, and EPYC).
p1553
sg4
(lp1554
(dp1555
g7
I295
sg8
g47
sg10
I4
sg11
VEPYC
p1556
sg13
I1
sa(dp1557
g7
I286
sg8
VP07585
p1558
sg10
I3
sg11
VDCN
p1559
sg13
I1
sa(dp1560
g7
I275
sg8
g47
sg10
I4
sg11
VKERA
p1561
sg13
I1
sa(dp1562
g7
I281
sg8
VP51884
p1563
sg10
I3
sg11
VLUM
p1564
sg13
I1
sasg17
(lp1565
(dp1566
g7
I83
sg20
VC2748502
p1567
sg10
I4
sg11
VPACD
p1568
sg13
I1
sasa(dp1569
g2
VEmerging evidence indicates that elevated CD164 expression is associated with aggressive metastasis, advanced stages, and shorter overall survival in lung cancer.
p1570
sg4
(lp1571
(dp1572
g7
I42
sg8
g47
sg10
I5
sg11
VCD164
p1573
sg13
I1
sasg17
(lp1574
(dp1575
g7
I150
sg20
VC0684249
p1576
sg10
I11
sg11
Vlung cancer
p1577
sg13
I2
sa(dp1578
g7
I89
sg20
VC0027627
p1579
sg10
I10
sg11
Vmetastasis
p1580
sg13
I1
sa(dp1581
g7
I78
sg20
VC0001807
p1582
sg10
I10
sg11
Vaggressive
p1583
sg13
I1
sasa(dp1584
g2
VHowever, no data are available regarding the clinical significance of CD164 expression in lung cancer.
p1585
sg4
(lp1586
(dp1587
g7
I70
sg8
g47
sg10
I5
sg11
VCD164
p1588
sg13
I1
sasg17
(lp1589
(dp1590
g7
I90
sg20
VC0684249
p1591
sg10
I11
sg11
Vlung cancer
p1592
sg13
I2
sasa(dp1593
g2
VUsing tissue microarrays, we determine that CD164 expression is correlated with clinicopathological characteristics in human lung cancer.
p1594
sg4
(lp1595
(dp1596
g7
I44
sg8
g47
sg10
I5
sg11
VCD164
p1597
sg13
I1
sasg17
(lp1598
(dp1599
g7
I125
sg20
VC0684249
p1600
sg10
I11
sg11
Vlung cancer
p1601
sg13
I2
sasa(dp1602
g2
VTherefore, identification of CD164 as a cancer stem cell therapeutic marker may develop an effective therapy in patients with chemoresistant lung cancer.
p1603
sg4
(lp1604
(dp1605
g7
I29
sg8
g47
sg10
I5
sg11
VCD164
p1606
sg13
I1
sasg17
(lp1607
(dp1608
g7
I40
sg20
VC0006826
p1609
sg10
I6
sg11
Vcancer
p1610
sg13
I1
sa(dp1611
g7
I141
sg20
VC0684249
p1612
sg10
I11
sg11
Vlung cancer
p1613
sg13
I2
sasa(dp1614
g2
VCluster of differentiation 164 (CD164), a sialomucin, has been demonstrated to be involved in the regulation of proliferation, apoptosis, adhesion and differentiation in multiple cancers.
p1615
sg4
(lp1616
(dp1617
g7
I42
sg8
g47
sg10
I10
sg11
Vsialomucin
p1618
sg13
I1
sa(dp1619
g7
I0
sg8
g47
sg10
I30
sg11
VCluster of differentiation 164
p1620
sg13
I4
sa(dp1621
g7
I32
sg8
g47
sg10
I5
sg11
VCD164
p1622
sg13
I1
sasg17
(lp1623
(dp1624
g7
I138
sg20
VC0001511
p1625
sg10
I8
sg11
Vadhesion
p1626
sg13
I1
sa(dp1627
g7
I112
sg20
VC0334094
p1628
sg10
I13
sg11
Vproliferation
p1629
sg13
I1
sa(dp1630
g7
I179
sg20
VC0006826
p1631
sg10
I7
sg11
Vcancers
p1632
sg13
I1
sasa(dp1633
g2
VHowever, the involvement of CD164 in human glioma proliferation and apoptosis remains unknown.
p1634
sg4
(lp1635
(dp1636
g7
I28
sg8
g47
sg10
I5
sg11
VCD164
p1637
sg13
I1
sasg17
(lp1638
(dp1639
g7
I43
sg20
VC0017638
p1640
sg10
I6
sg11
Vglioma
p1641
sg13
I1
sa(dp1642
g7
I50
sg20
VC0334094
p1643
sg10
I13
sg11
Vproliferation
p1644
sg13
I1
sasa(dp1645
g2
VThe aim of the present study was to investigate the expression and oncogenic function of CD164 in normal human astrocytes (NHA) and glioma cells in vitro and in vivo.
p1646
sg4
(lp1647
(dp1648
g7
I89
sg8
g47
sg10
I5
sg11
VCD164
p1649
sg13
I1
sasg17
(lp1650
(dp1651
g7
I132
sg20
VC0017638
p1652
sg10
I6
sg11
Vglioma
p1653
sg13
I1
sasa(dp1654
g2
VThe results of the present study demonstrated that CD164 mRNA and protein levels were significantly increased in human glioma cell lines and tissue samples.
p1655
sg4
(lp1656
(dp1657
g7
I51
sg8
g47
sg10
I10
sg11
VCD164 mRNA
p1658
sg13
I2
sasg17
(lp1659
(dp1660
g7
I119
sg20
VC0017638
p1661
sg10
I6
sg11
Vglioma
p1662
sg13
I1
sasa(dp1663
g2
VKnockdown of CD164 inhibited cell proliferation and promoted apoptosis of the U87 human glioma cell line in vitro and in vivo.
p1664
sg4
(lp1665
(dp1666
g7
I13
sg8
g47
sg10
I5
sg11
VCD164
p1667
sg13
I1
sasg17
(lp1668
(dp1669
g7
I88
sg20
VC0017638
p1670
sg10
I6
sg11
Vglioma
p1671
sg13
I1
sa(dp1672
g7
I34
sg20
VC0334094
p1673
sg10
I13
sg11
Vproliferation
p1674
sg13
I1
sasa(dp1675
g2
VThe results suggest that CD164 expression may have affected the proliferation and apoptosis of human glioma cells via the PTEN/phosphoinositide 3-kinase/AKT pathway, and may therefore present a potential target for the diagnosis and treatment of glioma.
p1676
sg4
(lp1677
(dp1678
g7
I127
sg8
g47
sg10
I25
sg11
Vphosphoinositide 3-kinase
p1679
sg13
I2
sa(dp1680
g7
I122
sg8
VP60484
p1681
sg10
I4
sg11
VPTEN
p1682
sg13
I1
sa(dp1683
g7
I153
sg8
g47
sg10
I3
sg11
VAKT
p1684
sg13
I1
sa(dp1685
g7
I25
sg8
g47
sg10
I5
sg11
VCD164
p1686
sg13
I1
sasg17
(lp1687
(dp1688
g7
I64
sg20
VC0334094
p1689
sg10
I13
sg11
Vproliferation
p1690
sg13
I1
sa(dp1691
g7
I101
sg20
VC0017638
p1692
sg10
I6
sg11
Vglioma
p1693
sg13
I1
sa(dp1694
g7
I101
sg20
VC0017638
p1695
sg10
I6
sg11
Vglioma
p1696
sg13
I1
sasa(dp1697
g2
VWe recently demonstrated the high expression of CD164 on CD4+ T cells from Sezary syndrome patients with a wide range of circulating tumor burdens.
p1698
sg4
(lp1699
(dp1700
g7
I48
sg8
g47
sg10
I5
sg11
VCD164
p1701
sg13
I1
sa(dp1702
g7
I57
sg8
VP01730
p1703
sg10
I4
sg11
VCD4+
p1704
sg13
I1
sasg17
(lp1705
(dp1706
g7
I133
sg20
VC0027651
p1707
sg10
I5
sg11
Vtumor
p1708
sg13
I1
sa(dp1709
g7
I75
sg20
VC0036920
p1710
sg10
I15
sg11
VSezary syndrome
p1711
sg13
I2
sasa(dp1712
g2
VOur results suggest that miR-124 function as a tumor suppressor miRNA and suppress tumor proliferation and aggression by directly targeting oncogenic CD164 signaling pathway in NSCLC.
p1713
sg4
(lp1714
(dp1715
g7
I150
sg8
g47
sg10
I5
sg11
VCD164
p1716
sg13
I1
sasg17
(lp1717
(dp1718
g7
I47
sg20
VC0027651
p1719
sg10
I5
sg11
Vtumor
p1720
sg13
I1
sa(dp1721
g7
I47
sg20
VC0027651
p1722
sg10
I5
sg11
Vtumor
p1723
sg13
I1
sa(dp1724
g7
I177
sg20
VC0007131
p1725
sg10
I5
sg11
VNSCLC
p1726
sg13
I1
sa(dp1727
g7
I107
sg20
VC0001807
p1728
sg10
I10
sg11
Vaggression
p1729
sg13
I1
sa(dp1730
g7
I89
sg20
VC0334094
p1731
sg10
I13
sg11
Vproliferation
p1732
sg13
I1
sasa(dp1733
g2
VIn a cohort of patients with Sezary syndrome, CD164 expression on total CD4+ lymphocytes was significantly upregulated compared with healthy controls.
p1734
sg4
(lp1735
(dp1736
g7
I72
sg8
VP01730
p1737
sg10
I4
sg11
VCD4+
p1738
sg13
I1
sa(dp1739
g7
I46
sg8
g47
sg10
I5
sg11
VCD164
p1740
sg13
I1
sasg17
(lp1741
(dp1742
g7
I29
sg20
VC0036920
p1743
sg10
I15
sg11
VSezary syndrome
p1744
sg13
I2
sasa(dp1745
g2
VIncreased expression of CD164 may be a promising diagnostic parameter and a potential target for a CD164-linked therapeutic approach in Sezary syndrome.
p1746
sg4
(lp1747
(dp1748
g7
I24
sg8
g47
sg10
I5
sg11
VCD164
p1749
sg13
I1
sa(dp1750
g7
I24
sg8
g47
sg10
I5
sg11
VCD164
p1751
sg13
I1
sasg17
(lp1752
(dp1753
g7
I136
sg20
VC0036920
p1754
sg10
I15
sg11
VSezary syndrome
p1755
sg13
I2
sasa(dp1756
g2
VThese results indicate that miR-219 suppresses the proliferation, migration and invasion of medulloblastoma cells by targeting CD164.
p1757
sg4
(lp1758
(dp1759
g7
I127
sg8
g47
sg10
I5
sg11
VCD164
p1760
sg13
I1
sasg17
(lp1761
(dp1762
g7
I80
sg20
VC2699153
p1763
sg10
I8
sg11
Vinvasion
p1764
sg13
I1
sa(dp1765
g7
I51
sg20
VC0334094
p1766
sg10
I13
sg11
Vproliferation
p1767
sg13
I1
sa(dp1768
g7
I92
sg20
VC0025149
p1769
sg10
I15
sg11
Vmedulloblastoma
p1770
sg13
I1
sasa(dp1771
g2
VDespite the known engagement of the AFAP1-AS in several human diseases, its biological function in Hirschsprung disease (HSCR) remains elusive.
p1772
sg4
(lp1773
(dp1774
g7
I36
sg8
g47
sg10
I8
sg11
VAFAP1-AS
p1775
sg13
I1
sa(dp1776
g7
I121
sg8
VP14138
p1777
sg10
I4
sg11
VHSCR
p1778
sg13
I1
sa(dp1779
g7
I99
sg8
VP14138
p1780
sg10
I20
sg11
VHirschsprung disease
p1781
sg13
I2
sasg17
(lp1782
(dp1783
g7
I121
sg20
VC2931876
p1784
sg10
I4
sg11
VHSCR
p1785
sg13
I1
sa(dp1786
g7
I99
sg20
VC0019569
p1787
sg10
I20
sg11
VHirschsprung disease
p1788
sg13
I2
sasa(dp1789
g2
VThis prospective observational study included 47 patients (mean age 29 years, range 3-50) with different resistant generalized epilepsy syndromes: idiopathic generalized syndromes (IGE) 15 patients, (juvenile myoclonic epilepsy four, absence epilepsy four, myoclonic absence two, unclassified IGE five), progressive myoclonic epilepsy type 1 (PME1) four, severe myoclonic epilepsy of infancy (SMEI) three, borderline SMEI three, Lennox-Gastaut syndrome/secondary generalized epileptic encephalopties 23 patients.
p1790
sg4
(lp1791
(dp1792
g7
I304
sg8
g47
sg10
I37
sg11
Vprogressive myoclonic epilepsy type 1
p1793
sg13
I5
sa(dp1794
g7
I343
sg8
g47
sg10
I4
sg11
VPME1
p1795
sg13
I1
sasg17
(lp1796
(dp1797
g7
I115
sg20
VC0014548
p1798
sg10
I20
sg11
Vgeneralized epilepsy
p1799
sg13
I2
sa(dp1800
g7
I147
sg20
VC0270850
p1801
sg10
I32
sg11
Vidiopathic generalized syndromes
p1802
sg13
I3
sa(dp1803
g7
I393
sg20
VC0751122
p1804
sg10
I4
sg11
VSMEI
p1805
sg13
I1
sa(dp1806
g7
I304
sg20
VC0751778
p1807
sg10
I30
sg11
Vprogressive myoclonic epilepsy
p1808
sg13
I3
sa(dp1809
g7
I234
sg20
VC0014553
p1810
sg10
I16
sg11
Vabsence epilepsy
p1811
sg13
I2
sa(dp1812
g7
I393
sg20
VC0751122
p1813
sg10
I4
sg11
VSMEI
p1814
sg13
I1
sa(dp1815
g7
I355
sg20
VC0751122
p1816
sg10
I36
sg11
Vsevere myoclonic epilepsy of infancy
p1817
sg13
I5
sa(dp1818
g7
I181
sg20
VC0270850
p1819
sg10
I3
sg11
VIGE
p1820
sg13
I1
sa(dp1821
g7
I475
sg20
VC0014544
p1822
sg10
I9
sg11
Vepileptic
p1823
sg13
I1
sa(dp1824
g7
I200
sg20
VC0270853
p1825
sg10
I27
sg11
Vjuvenile myoclonic epilepsy
p1826
sg13
I3
sa(dp1827
g7
I429
sg20
VC0238111
p1828
sg10
I23
sg11
VLennox-Gastaut syndrome
p1829
sg13
I2
sa(dp1830
g7
I181
sg20
VC0270850
p1831
sg10
I3
sg11
VIGE
p1832
sg13
I1
sa(dp1833
g7
I136
sg20
VC0039082
p1834
sg10
I9
sg11
Vsyndromes
p1835
sg13
I1
sasa(dp1836
g2
VThe International League Against Epilepsy (ILAE) classification recognizes 2 forms of myoclonic epilepsy with a good prognosis: benign myoclonic epilepsy of infancy (BMEI) and juvenile myoclonic epilepsy (JME); recent studies confirm the efficacy of levetiracetam (LEV) in treating idiopathic generalized epilepsies (IGE) in patients with myoclonic seizures.
p1837
sg4
(lp1838
sg17
(lp1839
(dp1840
g7
I86
sg20
VC0014550
p1841
sg10
I18
sg11
Vmyoclonic epilepsy
p1842
sg13
I2
sa(dp1843
g7
I339
sg20
VC0014550
p1844
sg10
I18
sg11
Vmyoclonic seizures
p1845
sg13
I2
sa(dp1846
g7
I317
sg20
VC0270850
p1847
sg10
I3
sg11
VIGE
p1848
sg13
I1
sa(dp1849
g7
I86
sg20
VC0014550
p1850
sg10
I18
sg11
Vmyoclonic epilepsy
p1851
sg13
I2
sa(dp1852
g7
I205
sg20
VC0270853
p1853
sg10
I3
sg11
VJME
p1854
sg13
I1
sa(dp1855
g7
I33
sg20
VC0014544
p1856
sg10
I8
sg11
VEpilepsy
p1857
sg13
I1
sa(dp1858
g7
I176
sg20
VC0270853
p1859
sg10
I27
sg11
Vjuvenile myoclonic epilepsy
p1860
sg13
I3
sa(dp1861
g7
I282
sg20
VC0270850
p1862
sg10
I33
sg11
Vidiopathic generalized epilepsies
p1863
sg13
I3
sasa(dp1864
g2
VWe evaluated 35 patients (21 female, mean age 24.7 years) with different types of generalised epilepsies (juvenile myoclonic epilepsy (JME), severe myoclonic epilepsy of infancy (SMEI), Lennox-Gastaut syndrome (LGS), myoclonic-astatic epilepsy (MAE), myoclonic absences (MA), benign myoclonic epilepsy in infancy (BMEI) and 4 patients had unspecified epileptic syndromes).
p1865
sg4
(lp1866
sg17
(lp1867
(dp1868
g7
I211
sg20
VC0023003
p1869
sg10
I3
sg11
VLGS
p1870
sg13
I1
sa(dp1871
g7
I125
sg20
VC0014544
p1872
sg10
I8
sg11
Vepilepsy
p1873
sg13
I1
sa(dp1874
g7
I314
sg20
VC0751120
p1875
sg10
I4
sg11
VBMEI
p1876
sg13
I1
sa(dp1877
g7
I135
sg20
VC0270853
p1878
sg10
I3
sg11
VJME
p1879
sg13
I1
sa(dp1880
g7
I276
sg20
VC0751120
p1881
sg10
I36
sg11
Vbenign myoclonic epilepsy in infancy
p1882
sg13
I5
sa(dp1883
g7
I179
sg20
VC0751122
p1884
sg10
I4
sg11
VSMEI
p1885
sg13
I1
sa(dp1886
g7
I361
sg20
VC0039082
p1887
sg10
I9
sg11
Vsyndromes
p1888
sg13
I1
sa(dp1889
g7
I141
sg20
VC0751122
p1890
sg10
I36
sg11
Vsevere myoclonic epilepsy of infancy
p1891
sg13
I5
sa(dp1892
g7
I186
sg20
VC0238111
p1893
sg10
I23
sg11
VLennox-Gastaut syndrome
p1894
sg13
I2
sa(dp1895
g7
I106
sg20
VC0270853
p1896
sg10
I27
sg11
Vjuvenile myoclonic epilepsy
p1897
sg13
I3
sa(dp1898
g7
I351
sg20
VC0014544
p1899
sg10
I9
sg11
Vepileptic
p1900
sg13
I1
sa(dp1901
g7
I94
sg20
VC0014544
p1902
sg10
I10
sg11
Vepilepsies
p1903
sg13
I1
sasa(dp1904
g2
VThe electroclinical features suggested juvenile myoclonic epilepsy in 14 patients, progressive myoclonus epilepsy in three, progressive familial cerebellar ataxia with myoclonus in two, and severe myoclonic epilepsy of infancy in one.
p1905
sg4
(lp1906
sg17
(lp1907
(dp1908
g7
I83
sg20
VC0751778
p1909
sg10
I30
sg11
Vprogressive myoclonus epilepsy
p1910
sg13
I3
sa(dp1911
g7
I190
sg20
VC0751122
p1912
sg10
I36
sg11
Vsevere myoclonic epilepsy of infancy
p1913
sg13
I5
sa(dp1914
g7
I136
sg20
VC0270749
p1915
sg10
I26
sg11
Vfamilial cerebellar ataxia
p1916
sg13
I3
sa(dp1917
g7
I39
sg20
VC0270853
p1918
sg10
I27
sg11
Vjuvenile myoclonic epilepsy
p1919
sg13
I3
sa(dp1920
g7
I95
sg20
VC0027066
p1921
sg10
I9
sg11
Vmyoclonus
p1922
sg13
I1
sasa(dp1923
g2
VIn the idiopathic generalized epilepsies we consider the benign myoclonic epilepsy of infancy and its reflex variant, juvenile myoclonic epilepsy and palpebral myoclonias with absences.
p1924
sg4
(lp1925
sg17
(lp1926
(dp1927
g7
I118
sg20
VC0270853
p1928
sg10
I27
sg11
Vjuvenile myoclonic epilepsy
p1929
sg13
I3
sa(dp1930
g7
I18
sg20
VC0014548
p1931
sg10
I22
sg11
Vgeneralized epilepsies
p1932
sg13
I2
sa(dp1933
g7
I64
sg20
VC0014550
p1934
sg10
I18
sg11
Vmyoclonic epilepsy
p1935
sg13
I2
sasa(dp1936
g2
VGroup 5 comprises the true myoclonic epilepsies, differentiating syndromes recognized as idiopathic--such as "Benign myoclonic epilepsy of infancy" and "Juvenile myoclonic epilepsy"--from those which are cryptogenic and carry a more cautious prognosis--as "Cryptogenic myoclonic and myoclonoastatic epilepsies" and "Severe myoclonic epilepsy of infancy".
p1937
sg4
(lp1938
sg17
(lp1939
(dp1940
g7
I117
sg20
VC0014550
p1941
sg10
I18
sg11
Vmyoclonic epilepsy
p1942
sg13
I2
sa(dp1943
g7
I27
sg20
VC0014550
p1944
sg10
I20
sg11
Vmyoclonic epilepsies
p1945
sg13
I2
sa(dp1946
g7
I37
sg20
VC0014544
p1947
sg10
I10
sg11
Vepilepsies
p1948
sg13
I1
sa(dp1949
g7
I153
sg20
VC0270853
p1950
sg10
I27
sg11
VJuvenile myoclonic epilepsy
p1951
sg13
I3
sa(dp1952
g7
I316
sg20
VC0751122
p1953
sg10
I36
sg11
VSevere myoclonic epilepsy of infancy
p1954
sg13
I5
sa(dp1955
g7
I65
sg20
VC0039082
p1956
sg10
I9
sg11
Vsyndromes
p1957
sg13
I1
sasa(dp1958
g2
VInteraction studies also showed that CEP78 binds to FAM161A, another ciliary protein associated with retinal degeneration.
p1959
sg4
(lp1960
(dp1961
g7
I52
sg8
g47
sg10
I7
sg11
VFAM161A
p1962
sg13
I1
sa(dp1963
g7
I37
sg8
g47
sg10
I5
sg11
VCEP78
p1964
sg13
I1
sasg17
(lp1965
(dp1966
g7
I101
sg20
VC0035304
p1967
sg10
I20
sg11
Vretinal degeneration
p1968
sg13
I2
sasa(dp1969
g2
VAltogether, our data strongly suggest that mutations in CEP78 cause a previously undescribed clinical entity of a ciliary nature characterized by blindness and deafness but clearly distinct from Usher syndrome, a condition for which visual impairment is due to retinitis pigmentosa.
p1970
sg4
(lp1971
(dp1972
g7
I56
sg8
g47
sg10
I5
sg11
VCEP78
p1973
sg13
I1
sasg17
(lp1974
(dp1975
g7
I261
sg20
VC0035334
p1976
sg10
I20
sg11
Vretinitis pigmentosa
p1977
sg13
I2
sa(dp1978
g7
I195
sg20
VC0271097
p1979
sg10
I14
sg11
VUsher syndrome
p1980
sg13
I2
sa(dp1981
g7
I160
sg20
VC0011053
p1982
sg10
I8
sg11
Vdeafness
p1983
sg13
I1
sa(dp1984
g7
I233
sg20
VC3489703
p1985
sg10
I17
sg11
Vvisual impairment
p1986
sg13
I2
sa(dp1987
g7
I213
sg20
VC0012634
p1988
sg10
I9
sg11
Vcondition
p1989
sg13
I1
sa(dp1990
g7
I146
sg20
VC0456909
p1991
sg10
I9
sg11
Vblindness
p1992
sg13
I1
sasa(dp1993
g2
VMethods Eligible survivors had curable breast or colorectal cancer or melanoma, had completed treatment (not including endocrine therapy) 2 months to 5 years previously, were age &gt; 18 years, and had scores above the clinical cutoff on the FCR Inventory (FCRI) severity subscale at screening.
p1994
sg4
(lp1995
sg17
(lp1996
(dp1997
g7
I49
sg20
VC1527249
p1998
sg10
I17
sg11
Vcolorectal cancer
p1999
sg13
I2
sa(dp2000
g7
I70
sg20
VC0025202
p2001
sg10
I8
sg11
Vmelanoma
p2002
sg13
I1
sasa(dp2003
g2
VConquerFear participants had clinically and statistically greater improvements than control participants from T0 to T1 on FCRI total ( P &lt; .001) and severity subscale scores ( P = .001), which were maintained at T2 ( P = .017 and P = .023, respectively) and, for FCRI total only, at T3 ( P = .018), and from T0 to T1 on three FCRI subscales (coping, psychological distress, and triggers) as well as in general anxiety, cancer-specific distress (total), and mental quality of life and metacognitions (total).
p2004
sg4
(lp2005
(dp2006
g7
I122
sg8
VP12314
p2007
sg10
I4
sg11
VFCRI
p2008
sg13
I1
sa(dp2009
g7
I122
sg8
VP12314
p2010
sg10
I4
sg11
VFCRI
p2011
sg13
I1
sasg17
(lp2012
(dp2013
g7
I353
sg20
VC0815107
p2014
sg10
I22
sg11
Vpsychological distress
p2015
sg13
I2
sa(dp2016
g7
I422
sg20
VC0006826
p2017
sg10
I6
sg11
Vcancer
p2018
sg13
I1
sasa(dp2019
g2
VDifferences in FCRI psychological distress and cancer-specific distress (total) remained significantly different at T3.
p2020
sg4
(lp2021
sg17
(lp2022
(dp2023
g7
I20
sg20
VC0815107
p2024
sg10
I22
sg11
Vpsychological distress
p2025
sg13
I2
sa(dp2026
g7
I47
sg20
VC0006826
p2027
sg10
I6
sg11
Vcancer
p2028
sg13
I1
sasa(dp2029
g2
VGanoderic acid interacts and modulates the signaling network in IR, IGFR-1, IGFR-2, VEGFR-1, VEFGR-2, and EGFR in cancer signaling pathways.
p2030
sg4
(lp2031
(dp2032
g7
I68
sg8
VP08069
p2033
sg10
I6
sg11
VIGFR-1
p2034
sg13
I1
sa(dp2035
g7
I84
sg8
VP17948
p2036
sg10
I7
sg11
VVEGFR-1
p2037
sg13
I1
sa(dp2038
g7
I76
sg8
VP08069
p2039
sg10
I6
sg11
VIGFR-2
p2040
sg13
I1
sasg17
(lp2041
(dp2042
g7
I114
sg20
VC0006826
p2043
sg10
I6
sg11
Vcancer
p2044
sg13
I1
sasa(dp2045
g2
VSixty-four patients with hematological tumors were selected and divided into the group complicated with bacterial infection (infection group, 33 cases) and the non-infection group (31 cases), the flow cytometry was be used to detect the related peripheral blood markers CD64 and CD14, the nCD64 IND and CD14 IND were calculated, and the peripheral blood WBC count, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were determined at the same time.
p2046
sg4
(lp2047
(dp2048
g7
I406
sg8
VP02741
p2049
sg10
I18
sg11
VC-reactive protein
p2050
sg13
I2
sa(dp2051
g7
I279
sg8
VP08571
p2052
sg10
I4
sg11
VCD14
p2053
sg13
I1
sa(dp2054
g7
I426
sg8
VP02741
p2055
sg10
I3
sg11
VCRP
p2056
sg13
I1
sa(dp2057
g7
I270
sg8
VP12314
p2058
sg10
I4
sg11
VCD64
p2059
sg13
I1
sa(dp2060
g7
I303
sg8
VP08571
p2061
sg10
I8
sg11
VCD14 IND
p2062
sg13
I2
sasg17
(lp2063
(dp2064
g7
I25
sg20
VC0376545
p2065
sg10
I20
sg11
Vhematological tumors
p2066
sg13
I2
sa(dp2067
g7
I104
sg20
VC0004623
p2068
sg10
I19
sg11
Vbacterial infection
p2069
sg13
I2
sa(dp2070
g7
I114
sg20
VC0009450
p2071
sg10
I9
sg11
Vinfection
p2072
sg13
I1
sa(dp2073
g7
I114
sg20
VC0009450
p2074
sg10
I9
sg11
Vinfection
p2075
sg13
I1
sasa(dp2076
g2
VThe study objectives are to translate the FCRI in Dutch, and to explore the factor structure and the psychometric qualities of the Dutch translation of the Fear of Cancer Recurrence Inventory (FCRI-NL).
p2077
sg4
(lp2078
sg17
(lp2079
(dp2080
g7
I164
sg20
VC0920420
p2081
sg10
I17
sg11
VCancer Recurrence
p2082
sg13
I2
sa(dp2083
g7
I156
sg20
VC0233705
p2084
sg10
I14
sg11
VFear of Cancer
p2085
sg13
I3
sasa(dp2086
g2
VThe Severity subscale (FCRI-SF-NL) may be a valuable screening tool for fear of cancer recurrence severity in clinical care.
p2087
sg4
(lp2088
sg17
(lp2089
(dp2090
g7
I80
sg20
VC0920420
p2091
sg10
I17
sg11
Vcancer recurrence
p2092
sg13
I2
sa(dp2093
g7
I72
sg20
VC0233705
p2094
sg10
I14
sg11
Vfear of cancer
p2095
sg13
I3
sasa(dp2096
g2
VFCI features, with single-tube 8-color combination using CD45, CD34, HAL-DR, CD11b, CD13, CD33, and CD117 and CD64, were compared for the 30 consecutive APL and 30 non-APL acute myeloid leukemia (AML) cases which morphologically mimicked an APL.
p2097
sg4
(lp2098
(dp2099
g7
I100
sg8
VP10721
p2100
sg10
I5
sg11
VCD117
p2101
sg13
I1
sa(dp2102
g7
I57
sg8
VP08575
p2103
sg10
I4
sg11
VCD45
p2104
sg13
I1
sa(dp2105
g7
I90
sg8
VP20138
p2106
sg10
I4
sg11
VCD33
p2107
sg13
I1
sa(dp2108
g7
I84
sg8
VP15144
p2109
sg10
I4
sg11
VCD13
p2110
sg13
I1
sa(dp2111
g7
I77
sg8
VP11215
p2112
sg10
I5
sg11
VCD11b
p2113
sg13
I1
sa(dp2114
g7
I69
sg8
VP42357
p2115
sg10
I6
sg11
VHAL-DR
p2116
sg13
I1
sa(dp2117
g7
I110
sg8
VP12314
p2118
sg10
I4
sg11
VCD64
p2119
sg13
I1
sa(dp2120
g7
I63
sg8
VP28906
p2121
sg10
I4
sg11
VCD34
p2122
sg13
I1
sasg17
(lp2123
(dp2124
g7
I196
sg20
VC0023467
p2125
sg10
I3
sg11
VAML
p2126
sg13
I1
sa(dp2127
g7
I153
sg20
VC0023487
p2128
sg10
I3
sg11
VAPL
p2129
sg13
I1
sa(dp2130
g7
I172
sg20
VC0023467
p2131
sg10
I22
sg11
Vacute myeloid leukemia
p2132
sg13
I3
sa(dp2133
g7
I153
sg20
VC0023487
p2134
sg10
I3
sg11
VAPL
p2135
sg13
I1
sa(dp2136
g7
I153
sg20
VC0023487
p2137
sg10
I3
sg11
VAPL
p2138
sg13
I1
sasa(dp2139
g2
VThis study aimed to confirm the cultural equivalence, reliability, and validity of the Korean version of Fear of Cancer Recurrence Inventory (K-FCRI).
p2140
sg4
(lp2141
sg17
(lp2142
(dp2143
g7
I113
sg20
VC0920420
p2144
sg10
I17
sg11
VCancer Recurrence
p2145
sg13
I2
sa(dp2146
g7
I105
sg20
VC0233705
p2147
sg10
I14
sg11
VFear of Cancer
p2148
sg13
I3
sasa(dp2149
g2
VThe psychometric property of the K-FCRI was then validated in 444 survivors from cancers at various sites.
p2150
sg4
(lp2151
(dp2152
g7
I33
sg8
VP12314
p2153
sg10
I6
sg11
VK-FCRI
p2154
sg13
I1
sasg17
(lp2155
(dp2156
g7
I81
sg20
VC0006826
p2157
sg10
I7
sg11
Vcancers
p2158
sg13
I1
sasa(dp2159
g2
VThe K-FCRI had significant correlations with the Korean version of Fear of Progression Questionnaire, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Version 3.0, Hospital Anxiety and Depression Scale, and Fatigue Severity Score, supporting the good construct validity and psychometric properties of K-FCRI.
p2160
sg4
(lp2161
sg17
(lp2162
(dp2163
g7
I154
sg20
VC0006826
p2164
sg10
I6
sg11
VCancer
p2165
sg13
I1
sa(dp2166
g7
I247
sg20
VC0015672
p2167
sg10
I7
sg11
VFatigue
p2168
sg13
I1
sa(dp2169
g7
I225
sg20
VC0011581
p2170
sg10
I10
sg11
VDepression
p2171
sg13
I1
sasa(dp2172
g2
VThe K-FCRI was confirmed as a valid and reliable psychometric test for measuring FCR of Korean survivors from cancers at various sites.
p2173
sg4
(lp2174
(dp2175
g7
I4
sg8
VP12314
p2176
sg10
I6
sg11
VK-FCRI
p2177
sg13
I1
sasg17
(lp2178
(dp2179
g7
I110
sg20
VC0006826
p2180
sg10
I7
sg11
Vcancers
p2181
sg13
I1
sasa(dp2182
g2
VRecently, CLPB deficiency has been shown to cause a genetic syndrome with cataracts, neutropenia, and 3-methylglutaconic aciduria.
p2183
sg4
(lp2184
(dp2185
g7
I10
sg8
g47
sg10
I4
sg11
VCLPB
p2186
sg13
I1
sasg17
(lp2187
(dp2188
g7
I102
sg20
VC0342727
p2189
sg10
I27
sg11
V3-methylglutaconic aciduria
p2190
sg13
I2
sa(dp2191
g7
I52
sg20
VC0567439
p2192
sg10
I16
sg11
Vgenetic syndrome
p2193
sg13
I2
sa(dp2194
g7
I74
sg20
VC0521707
p2195
sg10
I9
sg11
Vcataracts
p2196
sg13
I1
sasa(dp2197
g2
VCLPB deficiency should be considered in neonates with absence of voluntary movements, respiratory insufficiency and swallowing problems, especially if associated with 3-methylglutaconic aciduria, neutropenia and cataracts.
p2198
sg4
(lp2199
sg17
(lp2200
(dp2201
g7
I167
sg20
VC0342727
p2202
sg10
I27
sg11
V3-methylglutaconic aciduria
p2203
sg13
I2
sa(dp2204
g7
I86
sg20
VC0035229
p2205
sg10
I25
sg11
Vrespiratory insufficiency
p2206
sg13
I2
sa(dp2207
g7
I212
sg20
VC0521707
p2208
sg10
I9
sg11
Vcataracts
p2209
sg13
I1
sa(dp2210
g7
I116
sg20
VC0392678
p2211
sg10
I19
sg11
Vswallowing problems
p2212
sg13
I2
sasa(dp2213
g2
VMutations in CLPB, SERAC1, TAZ genes were identified in neonates with 3-methylglutaconic aciduria (3-MGA) as a discriminative feature.
p2214
sg4
(lp2215
(dp2216
g7
I27
sg8
g47
sg10
I9
sg11
VTAZ genes
p2217
sg13
I2
sa(dp2218
g7
I19
sg8
g47
sg10
I6
sg11
VSERAC1
p2219
sg13
I1
sasg17
(lp2220
(dp2221
g7
I99
sg20
VC0342727
p2222
sg10
I5
sg11
V3-MGA
p2223
sg13
I1
sa(dp2224
g7
I70
sg20
VC0342727
p2225
sg10
I27
sg11
V3-methylglutaconic aciduria
p2226
sg13
I2
sasa(dp2227
g2
VAltogether, our study suggests that disruption of CLPB causes a novel form of neonatal encephalopathy associated with 3-methylglutaconic aciduria.
p2228
sg4
(lp2229
(dp2230
g7
I50
sg8
g47
sg10
I4
sg11
VCLPB
p2231
sg13
I1
sasg17
(lp2232
(dp2233
g7
I78
sg20
VC0235820
p2234
sg10
I23
sg11
Vneonatal encephalopathy
p2235
sg13
I2
sa(dp2236
g7
I118
sg20
VC0342727
p2237
sg10
I27
sg11
V3-methylglutaconic aciduria
p2238
sg13
I2
sasa(dp2239
g2
VTaken together, mutations in CLPB define a syndrome with intellectual disability, congenital neutropenia, progressive brain atrophy, movement disorder, cataracts, and 3-methylglutaconic aciduria.
p2240
sg4
(lp2241
sg17
(lp2242
(dp2243
g7
I152
sg20
VC0521707
p2244
sg10
I9
sg11
Vcataracts
p2245
sg13
I1
sa(dp2246
g7
I57
sg20
VC0025362
p2247
sg10
I23
sg11
Vintellectual disability
p2248
sg13
I2
sa(dp2249
g7
I167
sg20
VC0342727
p2250
sg10
I27
sg11
V3-methylglutaconic aciduria
p2251
sg13
I2
sa(dp2252
g7
I82
sg20
VC0340970
p2253
sg10
I22
sg11
Vcongenital neutropenia
p2254
sg13
I2
sa(dp2255
g7
I133
sg20
VC0026650
p2256
sg10
I17
sg11
Vmovement disorder
p2257
sg13
I2
sa(dp2258
g7
I43
sg20
VC0039082
p2259
sg10
I8
sg11
Vsyndrome
p2260
sg13
I1
sa(dp2261
g7
I118
sg20
VC0235946
p2262
sg10
I13
sg11
Vbrain atrophy
p2263
sg13
I2
sasa(dp2264
g2
VWe conclude that accumulation of protein aggregates underlies the development of cataracts and nephrocalcinosis in CLPB deficiency, which is a novel genetic cause of 3-methylglutaconic aciduria.
p2265
sg4
(lp2266
sg17
(lp2267
(dp2268
g7
I95
sg20
VC0027709
p2269
sg10
I16
sg11
Vnephrocalcinosis
p2270
sg13
I1
sa(dp2271
g7
I81
sg20
VC0521707
p2272
sg10
I9
sg11
Vcataracts
p2273
sg13
I1
sa(dp2274
g7
I166
sg20
VC0342727
p2275
sg10
I27
sg11
V3-methylglutaconic aciduria
p2276
sg13
I2
sasa(dp2277
g2
VWe now propose that perturbation of the mitochondrial membranes by abnormal protein aggregates leads to 3-methylglutaconic aciduria in CLPB deficiency.
p2278
sg4
(lp2279
sg17
(lp2280
(dp2281
g7
I104
sg20
VC0342727
p2282
sg10
I27
sg11
V3-methylglutaconic aciduria
p2283
sg13
I2
sasa(dp2284
g2
VHere, we present mechanistic details about the Hsp100 chaperone inhibition by GdmCl using the Hsp104 homolog ClpB from Thermus thermophilus.
p2285
sg4
(lp2286
(dp2287
g7
I94
sg8
g47
sg10
I19
sg11
VHsp104 homolog ClpB
p2288
sg13
I3
sasg17
(lp2289
sa(dp2290
g2
VWe present a crystal structure of ClpB NBD1 in complex with GdmCl and ADP, showing that the Gdm(+) ion binds specifically to the active site of NBD1.
p2291
sg4
(lp2292
(dp2293
g7
I34
sg8
g47
sg10
I9
sg11
VClpB NBD1
p2294
sg13
I2
sasg17
(lp2295
(dp2296
g7
I60
sg20
VC0085207
p2297
sg10
I3
sg11
VGdm
p2298
sg13
I1
sasa(dp2299
g2
VOne patient with nesidioblastosis had no response to secretin, indicating that the pathophysiology of this entity is distinct from that of other forms of islet hyperplasia.
p2300
sg4
(lp2301
(dp2302
g7
I53
sg8
VP09683
p2303
sg10
I8
sg11
Vsecretin
p2304
sg13
I1
sasg17
(lp2305
(dp2306
g7
I160
sg20
VC0020507
p2307
sg10
I11
sg11
Vhyperplasia
p2308
sg13
I1
sa(dp2309
g7
I17
sg20
VC0027773
p2310
sg10
I16
sg11
Vnesidioblastosis
p2311
sg13
I1
sasa(dp2312
g2
VIn addition, the ability to respond to secretin appears to be lost in patients with single insulinomas and nesidioblastosis, but not in those with multiple B-cell adenomas and hyperplasia.
p2313
sg4
(lp2314
(dp2315
g7
I39
sg8
VP09683
p2316
sg10
I8
sg11
Vsecretin
p2317
sg13
I1
sasg17
(lp2318
(dp2319
g7
I176
sg20
VC0020507
p2320
sg10
I11
sg11
Vhyperplasia
p2321
sg13
I1
sa(dp2322
g7
I91
sg20
VC0021670
p2323
sg10
I11
sg11
Vinsulinomas
p2324
sg13
I1
sa(dp2325
g7
I107
sg20
VC0027773
p2326
sg10
I16
sg11
Vnesidioblastosis
p2327
sg13
I1
sa(dp2328
g7
I163
sg20
VC0001430
p2329
sg10
I8
sg11
Vadenomas
p2330
sg13
I1
sasa(dp2331
g2
VIn addition, HLXB9 is recurrently rearranged in young children with acute myeloid leukemia characterized by a chromosomal translocation t(7;12)-HLXB9/TEL and concomitant high expression of the unrearranged, wild-type HLXB9 allele.
p2332
sg4
(lp2333
(dp2334
g7
I13
sg8
VP50219
p2335
sg10
I5
sg11
VHLXB9
p2336
sg13
I1
sa(dp2337
g7
I207
sg8
VP50219
p2338
sg10
I22
sg11
Vwild-type HLXB9 allele
p2339
sg13
I3
sa(dp2340
g7
I150
sg8
VP41212
p2341
sg10
I3
sg11
VTEL
p2342
sg13
I1
sa(dp2343
g7
I13
sg8
VP50219
p2344
sg10
I5
sg11
VHLXB9
p2345
sg13
I1
sasg17
(lp2346
(dp2347
g7
I110
sg20
VC0040715
p2348
sg10
I25
sg11
Vchromosomal translocation
p2349
sg13
I2
sa(dp2350
g7
I68
sg20
VC0023467
p2351
sg10
I22
sg11
Vacute myeloid leukemia
p2352
sg13
I3
sasa(dp2353
g2
VHerein, we report the clinical course of an 8-month-old patient with acute myeloid leukemia, M2 subtype and with a HLXB9/TEL rearrangement.
p2354
sg4
(lp2355
(dp2356
g7
I121
sg8
VP41212
p2357
sg10
I3
sg11
VTEL
p2358
sg13
I1
sa(dp2359
g7
I115
sg8
VP50219
p2360
sg10
I5
sg11
VHLXB9
p2361
sg13
I1
sasg17
(lp2362
(dp2363
g7
I69
sg20
VC0023467
p2364
sg10
I22
sg11
Vacute myeloid leukemia
p2365
sg13
I3
sasa(dp2366
g2
VUsing RT-PCR, we screened members of the EHG family of homeobox genes, comprising EN1 (at 2q14), GBX2 (at 2q36), and EN2, GBX1, and HLXB9 (at 7q36), for dysregulation in acute myeloid leukemia (AML) cell lines indicated by chromosomal breakpoints at these sites.
p2367
sg4
(lp2368
(dp2369
g7
I55
sg8
VP52954
p2370
sg10
I14
sg11
Vhomeobox genes
p2371
sg13
I2
sa(dp2372
g7
I97
sg8
VP52951
p2373
sg10
I4
sg11
VGBX2
p2374
sg13
I1
sa(dp2375
g7
I122
sg8
g47
sg10
I4
sg11
VGBX1
p2376
sg13
I1
sa(dp2377
g7
I132
sg8
VP50219
p2378
sg10
I5
sg11
VHLXB9
p2379
sg13
I1
sa(dp2380
g7
I117
sg8
VP41208
p2381
sg10
I3
sg11
VEN2
p2382
sg13
I1
sasg17
(lp2383
(dp2384
g7
I194
sg20
VC0023467
p2385
sg10
I3
sg11
VAML
p2386
sg13
I1
sa(dp2387
g7
I170
sg20
VC0023467
p2388
sg10
I22
sg11
Vacute myeloid leukemia
p2389
sg13
I3
sasa(dp2390
g2
VPreviously, we showed that KLF5 is a mediator of RAS/MAPK and WNT signaling pathways under homeostatic conditions and that it promotes their tumorigenic functions during the development and progression of intestinal adenomas.
p2391
sg4
(lp2392
(dp2393
g7
I27
sg8
g47
sg10
I4
sg11
VKLF5
p2394
sg13
I1
sa(dp2395
g7
I53
sg8
VP53779
p2396
sg10
I4
sg11
VMAPK
p2397
sg13
I1
sa(dp2398
g7
I49
sg8
VP01116
p2399
sg10
I3
sg11
VRAS
p2400
sg13
I1
sasg17
(lp2401
(dp2402
g7
I216
sg20
VC0001430
p2403
sg10
I8
sg11
Vadenomas
p2404
sg13
I1
sasa(dp2405
g2
VMoreover, production of lethal adenomas and carcinomas by specific expression of an oncogenic mutant of Beta-catenin in Lgr5(+) stem cells was suppressed completely by Klf5 deletion in the same cells.
p2406
sg4
(lp2407
(dp2408
g7
I168
sg8
g47
sg10
I13
sg11
VKlf5 deletion
p2409
sg13
I2
sa(dp2410
g7
I120
sg8
g47
sg10
I4
sg11
VLgr5
p2411
sg13
I1
sa(dp2412
g7
I104
sg8
VP35222
p2413
sg10
I12
sg11
VBeta-catenin
p2414
sg13
I1
sasg17
(lp2415
(dp2416
g7
I31
sg20
VC0001430
p2417
sg10
I8
sg11
Vadenomas
p2418
sg13
I1
sa(dp2419
g7
I44
sg20
VC0007097
p2420
sg10
I10
sg11
Vcarcinomas
p2421
sg13
I1
sa(dp2422
g7
I94
sg20
VC0596988
p2423
sg10
I6
sg11
Vmutant
p2424
sg13
I1
sasa(dp2425
g2
VElevated levels of two particular Fbxw7 substrates, Klf5 and Tgif1, were found in normal intestine and adenomas of R482Q/+, R482Q/R482Q and Fbxw7(-/-) mice, but not Fbxw7(+/-) animals.
p2426
sg4
(lp2427
(dp2428
g7
I52
sg8
g47
sg10
I4
sg11
VKlf5
p2429
sg13
I1
sa(dp2430
g7
I61
sg8
g47
sg10
I5
sg11
VTgif1
p2431
sg13
I1
sa(dp2432
g7
I34
sg8
g47
sg10
I5
sg11
VFbxw7
p2433
sg13
I1
sa(dp2434
g7
I34
sg8
g47
sg10
I5
sg11
VFbxw7
p2435
sg13
I1
sa(dp2436
g7
I34
sg8
g47
sg10
I5
sg11
VFbxw7
p2437
sg13
I1
sasg17
(lp2438
(dp2439
g7
I103
sg20
VC0001430
p2440
sg10
I8
sg11
Vadenomas
p2441
sg13
I1
sasa(dp2442
g2
VHere we investigated the in vivo effect of Klf5 heterozygosity on the propensity of ApcMin/KRASV12 double transgenic mice to develop intestinal tumors.
p2443
sg4
(lp2444
(dp2445
g7
I43
sg8
g47
sg10
I4
sg11
VKlf5
p2446
sg13
I1
sasg17
(lp2447
(dp2448
g7
I133
sg20
VC0021841
p2449
sg10
I17
sg11
Vintestinal tumors
p2450
sg13
I2
sasa(dp2451
g2
VTo determine whether KLF5 contributes to intestinal adenoma formation, we examined tumor burdens in Apc(Min/+) mice and Apc(Min/+)/Klf5(+/-) mice.
p2452
sg4
(lp2453
(dp2454
g7
I100
sg8
VP25054
p2455
sg10
I3
sg11
VApc
p2456
sg13
I1
sa(dp2457
g7
I100
sg8
VP25054
p2458
sg10
I3
sg11
VApc
p2459
sg13
I1
sa(dp2460
g7
I21
sg8
g47
sg10
I4
sg11
VKLF5
p2461
sg13
I1
sa(dp2462
g7
I131
sg8
g47
sg10
I4
sg11
VKlf5
p2463
sg13
I1
sasg17
(lp2464
(dp2465
g7
I41
sg20
VC1142339
p2466
sg10
I18
sg11
Vintestinal adenoma
p2467
sg13
I2
sa(dp2468
g7
I83
sg20
VC0027651
p2469
sg10
I5
sg11
Vtumor
p2470
sg13
I1
sa(dp2471
g7
I100
sg20
VC0033036
p2472
sg10
I3
sg11
VApc
p2473
sg13
I1
sa(dp2474
g7
I100
sg20
VC0033036
p2475
sg10
I3
sg11
VApc
p2476
sg13
I1
sasa(dp2477
g2
VCompared with Apc(Min/+) mice, Apc(Min/+)/Klf5(+/-) mice had a 96% reduction in the number of intestinal adenomas.
p2478
sg4
(lp2479
(dp2480
g7
I14
sg8
VP25054
p2481
sg10
I3
sg11
VApc
p2482
sg13
I1
sa(dp2483
g7
I42
sg8
g47
sg10
I4
sg11
VKlf5
p2484
sg13
I1
sa(dp2485
g7
I14
sg8
VP25054
p2486
sg10
I3
sg11
VApc
p2487
sg13
I1
sasg17
(lp2488
(dp2489
g7
I14
sg20
VC0033036
p2490
sg10
I3
sg11
VApc
p2491
sg13
I1
sa(dp2492
g7
I105
sg20
VC0001430
p2493
sg10
I8
sg11
Vadenomas
p2494
sg13
I1
sa(dp2495
g7
I14
sg20
VC0033036
p2496
sg10
I3
sg11
VApc
p2497
sg13
I1
sasa(dp2498
g2
VThus, KLF5 is necessary for the tumor-initiating activity of beta-catenin during intestinal adenoma formation in Apc(Min/+) mice, and reduced expression of KLF5 offsets the tumor-initiating activity of the Apc(Min) mutation by reducing the nuclear localization and activity of beta-catenin.
p2499
sg4
(lp2500
(dp2501
g7
I6
sg8
g47
sg10
I4
sg11
VKLF5
p2502
sg13
I1
sa(dp2503
g7
I61
sg8
VP35222
p2504
sg10
I12
sg11
Vbeta-catenin
p2505
sg13
I1
sa(dp2506
g7
I113
sg8
VP25054
p2507
sg10
I3
sg11
VApc
p2508
sg13
I1
sa(dp2509
g7
I6
sg8
g47
sg10
I4
sg11
VKLF5
p2510
sg13
I1
sa(dp2511
g7
I61
sg8
VP35222
p2512
sg10
I12
sg11
Vbeta-catenin
p2513
sg13
I1
sa(dp2514
g7
I113
sg8
VP25054
p2515
sg10
I3
sg11
VApc
p2516
sg13
I1
sasg17
(lp2517
(dp2518
g7
I113
sg20
VC0033036
p2519
sg10
I3
sg11
VApc
p2520
sg13
I1
sa(dp2521
g7
I81
sg20
VC1142339
p2522
sg10
I18
sg11
Vintestinal adenoma
p2523
sg13
I2
sa(dp2524
g7
I32
sg20
VC0027651
p2525
sg10
I5
sg11
Vtumor
p2526
sg13
I1
sa(dp2527
g7
I113
sg20
VC0033036
p2528
sg10
I3
sg11
VApc
p2529
sg13
I1
sa(dp2530
g7
I32
sg20
VC0027651
p2531
sg10
I5
sg11
Vtumor
p2532
sg13
I1
sasa(dp2533
g2
VKLF5 expression was examined in intestinal tumors derived from transgenic mice expressing KRAS(V12G) under villin promoter and in human colorectal cancers with mutated KRAS.
p2534
sg4
(lp2535
(dp2536
g7
I90
sg8
VP01116
p2537
sg10
I4
sg11
VKRAS
p2538
sg13
I1
sa(dp2539
g7
I107
sg8
VP09327
p2540
sg10
I15
sg11
Vvillin promoter
p2541
sg13
I2
sa(dp2542
g7
I0
sg8
g47
sg10
I4
sg11
VKLF5
p2543
sg13
I1
sa(dp2544
g7
I90
sg8
VP01116
p2545
sg10
I4
sg11
VKRAS
p2546
sg13
I1
sasg17
(lp2547
(dp2548
g7
I32
sg20
VC0021841
p2549
sg10
I17
sg11
Vintestinal tumors
p2550
sg13
I2
sa(dp2551
g7
I136
sg20
VC1527249
p2552
sg10
I18
sg11
Vcolorectal cancers
p2553
sg13
I2
sasa(dp2554
g2
VIn vivo, both intestinal tumors derived from mice transgenic for villin-KRAS(V12G) and human primary colorectal cancers with mutated KRAS contained high levels of KLF5 and increased staining of the proliferative marker Ki67.
p2555
sg4
(lp2556
(dp2557
g7
I65
sg8
VP09327
p2558
sg10
I6
sg11
Vvillin
p2559
sg13
I1
sa(dp2560
g7
I72
sg8
VP01116
p2561
sg10
I4
sg11
VKRAS
p2562
sg13
I1
sa(dp2563
g7
I72
sg8
VP01116
p2564
sg10
I4
sg11
VKRAS
p2565
sg13
I1
sa(dp2566
g7
I163
sg8
g47
sg10
I4
sg11
VKLF5
p2567
sg13
I1
sasg17
(lp2568
(dp2569
g7
I198
sg20
VC0334094
p2570
sg10
I13
sg11
Vproliferative
p2571
sg13
I1
sa(dp2572
g7
I14
sg20
VC0021841
p2573
sg10
I17
sg11
Vintestinal tumors
p2574
sg13
I2
sa(dp2575
g7
I101
sg20
VC1527249
p2576
sg10
I18
sg11
Vcolorectal cancers
p2577
sg13
I2
sasa(dp2578
g2
VElevated levels of KLF5 protein are strongly correlated with activating KRAS mutations in intestinal tumors in vitro and in vivo.
p2579
sg4
(lp2580
(dp2581
g7
I19
sg8
g47
sg10
I12
sg11
VKLF5 protein
p2582
sg13
I2
sa(dp2583
g7
I72
sg8
VP01116
p2584
sg10
I4
sg11
VKRAS
p2585
sg13
I1
sasg17
(lp2586
(dp2587
g7
I90
sg20
VC0021841
p2588
sg10
I17
sg11
Vintestinal tumors
p2589
sg13
I2
sasa(dp2590
g2
VRas-transformation also markedly down-regulated KLF5; further analysis indicated that reduced expression of KLF5 mRNA and destabilization of KLF5 protein occur in intestinal tumors.
p2591
sg4
(lp2592
(dp2593
g7
I141
sg8
g47
sg10
I12
sg11
VKLF5 protein
p2594
sg13
I2
sa(dp2595
g7
I108
sg8
g47
sg10
I9
sg11
VKLF5 mRNA
p2596
sg13
I2
sa(dp2597
g7
I48
sg8
g47
sg10
I4
sg11
VKLF5
p2598
sg13
I1
sa(dp2599
g7
I0
sg8
VP01116
p2600
sg10
I3
sg11
VRas
p2601
sg13
I1
sasg17
(lp2602
(dp2603
g7
I163
sg20
VC0021841
p2604
sg10
I17
sg11
Vintestinal tumors
p2605
sg13
I2
sa(dp2606
g7
I4
sg20
VC1510411
p2607
sg10
I14
sg11
Vtransformation
p2608
sg13
I1
sasa(dp2609
g2
VReduced levels of KLF5 mRNA were also detected in APC(min) mouse and human familial adenomatous polyposis adenomas compared with normal crypt epithelium, indicating that down-regulation of KLF5 is an early event in intestinal tumorigenesis in vivo.
p2610
sg4
(lp2611
(dp2612
g7
I18
sg8
g47
sg10
I4
sg11
VKLF5
p2613
sg13
I1
sa(dp2614
g7
I18
sg8
g47
sg10
I9
sg11
VKLF5 mRNA
p2615
sg13
I2
sasg17
(lp2616
(dp2617
g7
I75
sg20
VC0032580
p2618
sg10
I30
sg11
Vfamilial adenomatous polyposis
p2619
sg13
I3
sa(dp2620
g7
I106
sg20
VC0001430
p2621
sg10
I8
sg11
Vadenomas
p2622
sg13
I1
sa(dp2623
g7
I226
sg20
VC0007621
p2624
sg10
I13
sg11
Vtumorigenesis
p2625
sg13
I1
sa(dp2626
g7
I50
sg20
VC0033036
p2627
sg10
I3
sg11
VAPC
p2628
sg13
I1
sasa(dp2629
g2
VCollectively, these data indicate that intestinal tumor progression is associated with a change in the growth-related functions of KLF5 and that intestinal tumors down-regulate KLF5 expression by multiple mechanisms.
p2630
sg4
(lp2631
(dp2632
g7
I131
sg8
g47
sg10
I4
sg11
VKLF5
p2633
sg13
I1
sa(dp2634
g7
I131
sg8
g47
sg10
I4
sg11
VKLF5
p2635
sg13
I1
sasg17
(lp2636
(dp2637
g7
I145
sg20
VC0021841
p2638
sg10
I17
sg11
Vintestinal tumors
p2639
sg13
I2
sa(dp2640
g7
I50
sg20
VC0178874
p2641
sg10
I17
sg11
Vtumor progression
p2642
sg13
I2
sasa(dp2643
g2
VVariable major lipoprotein (Vmp) is a major tumor necrosis factor (TNF)-inducing component of Borrelia recurrentis, the agent of louse-borne relapsing fever.
p2644
sg4
(lp2645
(dp2646
g7
I44
sg8
VP01375
p2647
sg10
I21
sg11
Vtumor necrosis factor
p2648
sg13
I3
sa(dp2649
g7
I67
sg8
VP01375
p2650
sg10
I3
sg11
VTNF
p2651
sg13
I1
sasg17
(lp2652
(dp2653
g7
I94
sg20
VC0024198
p2654
sg10
I8
sg11
VBorrelia
p2655
sg13
I1
sa(dp2656
g7
I129
sg20
VC0152061
p2657
sg10
I27
sg11
Vlouse-borne relapsing fever
p2658
sg13
I3
sa(dp2659
g7
I44
sg20
VC0333516
p2660
sg10
I14
sg11
Vtumor necrosis
p2661
sg13
I2
sasa(dp2662
g2
VLouse-borne relapsing fever, caused by Borrelia recurrentis, provides one of the best documented examples of the causative role of tumor necrosis factor (TNF) in the pathology of severe infection in humans.
p2663
sg4
(lp2664
(dp2665
g7
I154
sg8
VP01375
p2666
sg10
I3
sg11
VTNF
p2667
sg13
I1
sa(dp2668
g7
I131
sg8
VP01375
p2669
sg10
I21
sg11
Vtumor necrosis factor
p2670
sg13
I3
sasg17
(lp2671
(dp2672
g7
I186
sg20
VC0009450
p2673
sg10
I9
sg11
Vinfection
p2674
sg13
I1
sa(dp2675
g7
I166
sg20
VC0677042
p2676
sg10
I9
sg11
Vpathology
p2677
sg13
I1
sa(dp2678
g7
I0
sg20
VC0152061
p2679
sg10
I27
sg11
VLouse-borne relapsing fever
p2680
sg13
I3
sa(dp2681
g7
I131
sg20
VC0333516
p2682
sg10
I14
sg11
Vtumor necrosis
p2683
sg13
I2
sa(dp2684
g7
I39
sg20
VC0024198
p2685
sg10
I8
sg11
VBorrelia
p2686
sg13
I1
sasa(dp2687
g2
VSevere Jarisch Herxheimer reaction (J-HR) precipitated by antibiotic treatment of louse-borne relapsing fever (LBRF) is associated with a transient, marked rise in circulating tumour necrosis factor alpha (TNF alpha), interleukin 6 (IL-6) and interleukin 8 (IL-8).
p2688
sg4
(lp2689
(dp2690
g7
I206
sg8
VP01375
p2691
sg10
I9
sg11
VTNF alpha
p2692
sg13
I2
sa(dp2693
g7
I258
sg8
VP60568
p2694
sg10
I4
sg11
VIL-8
p2695
sg13
I1
sa(dp2696
g7
I218
sg8
VP05231
p2697
sg10
I13
sg11
Vinterleukin 6
p2698
sg13
I2
sa(dp2699
g7
I233
sg8
VP05231
p2700
sg10
I4
sg11
VIL-6
p2701
sg13
I1
sa(dp2702
g7
I176
sg8
VP01375
p2703
sg10
I28
sg11
Vtumour necrosis factor alpha
p2704
sg13
I4
sa(dp2705
g7
I243
sg8
VP60568
p2706
sg10
I13
sg11
Vinterleukin 8
p2707
sg13
I2
sasg17
(lp2708
(dp2709
g7
I111
sg20
VC0152061
p2710
sg10
I4
sg11
VLBRF
p2711
sg13
I1
sa(dp2712
g7
I82
sg20
VC0152061
p2713
sg10
I27
sg11
Vlouse-borne relapsing fever
p2714
sg13
I3
sa(dp2715
g7
I176
sg20
VC0333516
p2716
sg10
I15
sg11
Vtumour necrosis
p2717
sg13
I2
sasa(dp2718
g2
VIn patients with louse-borne relapsing fever (Borrelia recurrentis infection), antimicrobial treatment is often followed by sudden fever, rigors, and persistent hypotension (Jarisch-Herxheimer reactions) that are associated with increases in plasma concentrations of tumor necrosis factor alpha (TNF-alpha), interleukin-6, and interleukin-8.
p2719
sg4
(lp2720
(dp2721
g7
I296
sg8
VP01375
p2722
sg10
I9
sg11
VTNF-alpha
p2723
sg13
I1
sa(dp2724
g7
I327
sg8
VP60568
p2725
sg10
I13
sg11
Vinterleukin-8
p2726
sg13
I1
sa(dp2727
g7
I308
sg8
VP05231
p2728
sg10
I13
sg11
Vinterleukin-6
p2729
sg13
I1
sa(dp2730
g7
I267
sg8
VP01375
p2731
sg10
I27
sg11
Vtumor necrosis factor alpha
p2732
sg13
I4
sasg17
(lp2733
(dp2734
g7
I267
sg20
VC0333516
p2735
sg10
I14
sg11
Vtumor necrosis
p2736
sg13
I2
sa(dp2737
g7
I17
sg20
VC0152061
p2738
sg10
I27
sg11
Vlouse-borne relapsing fever
p2739
sg13
I3
sa(dp2740
g7
I46
sg20
VC0857817
p2741
sg10
I30
sg11
VBorrelia recurrentis infection
p2742
sg13
I3
sa(dp2743
g7
I138
sg20
VC0424790
p2744
sg10
I6
sg11
Vrigors
p2745
sg13
I1
sasa(dp2746
g2
VPretreatment with sheep anti-TNF-alpha Fab suppresses Jarisch-Herxheimer reactions that occur after penicillin treatment for louse-borne relapsing fever, reduces the associated increases in plasma concentrations of interleukin-6 and interleukin-8, and may be useful in other forms of sepsis.
p2747
sg4
(lp2748
(dp2749
g7
I233
sg8
VP60568
p2750
sg10
I13
sg11
Vinterleukin-8
p2751
sg13
I1
sa(dp2752
g7
I215
sg8
VP05231
p2753
sg10
I13
sg11
Vinterleukin-6
p2754
sg13
I1
sa(dp2755
g7
I24
sg8
VP01375
p2756
sg10
I18
sg11
Vanti-TNF-alpha Fab
p2757
sg13
I2
sasg17
(lp2758
(dp2759
g7
I125
sg20
VC0152061
p2760
sg10
I27
sg11
Vlouse-borne relapsing fever
p2761
sg13
I3
sa(dp2762
g7
I284
sg20
VC0243026
p2763
sg10
I6
sg11
Vsepsis
p2764
sg13
I1
sasa(dp2765
g2
VA frail 84-year old lady with situs inversus totalis and symptomatic aortic stenosis underwent a successful transcatheter aortic valve implantation (TAVI) after extensive diagnostic work-up.
p2766
sg4
(lp2767
sg17
(lp2768
(dp2769
g7
I57
sg20
VC0741183
p2770
sg10
I27
sg11
Vsymptomatic aortic stenosis
p2771
sg13
I3
sa(dp2772
g7
I30
sg20
VC0037221
p2773
sg10
I14
sg11
Vsitus inversus
p2774
sg13
I2
sasa(dp2775
g2
VHere, we report the first known case of Marfan's syndrome, combined with situs inversus totalis with dextrocardia and discrete subaortic stenosis and aortic insufficiency in a 22-year-old woman.
p2776
sg4
(lp2777
sg17
(lp2778
(dp2779
g7
I101
sg20
VC0011813
p2780
sg10
I12
sg11
Vdextrocardia
p2781
sg13
I1
sa(dp2782
g7
I118
sg20
VC0012628
p2783
sg10
I27
sg11
Vdiscrete subaortic stenosis
p2784
sg13
I3
sa(dp2785
g7
I73
sg20
VC0037221
p2786
sg10
I14
sg11
Vsitus inversus
p2787
sg13
I2
sa(dp2788
g7
I40
sg20
VC0024796
p2789
sg10
I17
sg11
VMarfan's syndrome
p2790
sg13
I2
sa(dp2791
g7
I150
sg20
VC0003504
p2792
sg10
I20
sg11
Vaortic insufficiency
p2793
sg13
I2
sasa(dp2794
g2
VLow-frequency artifacts that plague traditional TIE methods can be suppressed without an excessive number of captured images.
p2795
sg4
(lp2796
sg17
(lp2797
(dp2798
g7
I29
sg20
VC0032064
p2799
sg10
I6
sg11
Vplague
p2800
sg13
I1
sasa(dp2801
g2
VThe FGF9 subfamily, including FGF9, FGF16, and FGF20, in addition to rhFGF16, rhFGF9, and rhFGF20, were shown to stimulate the proliferation and migration of HuH7 human hepatocellular carcinoma (HCC) cells.
p2802
sg4
(lp2803
(dp2804
g7
I4
sg8
VP31371
p2805
sg10
I14
sg11
VFGF9 subfamily
p2806
sg13
I2
sa(dp2807
g7
I4
sg8
VP31371
p2808
sg10
I4
sg11
VFGF9
p2809
sg13
I1
sa(dp2810
g7
I36
sg8
g47
sg10
I5
sg11
VFGF16
p2811
sg13
I1
sa(dp2812
g7
I47
sg8
g47
sg10
I5
sg11
VFGF20
p2813
sg13
I1
sasg17
(lp2814
(dp2815
g7
I169
sg20
VC2239176
p2816
sg10
I24
sg11
Vhepatocellular carcinoma
p2817
sg13
I2
sa(dp2818
g7
I195
sg20
VC2239176
p2819
sg10
I3
sg11
VHCC
p2820
sg13
I1
sa(dp2821
g7
I127
sg20
VC0334094
p2822
sg10
I13
sg11
Vproliferation
p2823
sg13
I1
sasa(dp2824
g2
VFGF16 promoted proliferation and invasion behavior of SKOV-3 ovarian cancer cells, whose function may be similar in lung cancer.
p2825
sg4
(lp2826
(dp2827
g7
I0
sg8
g47
sg10
I5
sg11
VFGF16
p2828
sg13
I1
sasg17
(lp2829
(dp2830
g7
I61
sg20
VC1140680
p2831
sg10
I14
sg11
Vovarian cancer
p2832
sg13
I2
sa(dp2833
g7
I33
sg20
VC2699153
p2834
sg10
I8
sg11
Vinvasion
p2835
sg13
I1
sa(dp2836
g7
I116
sg20
VC0684249
p2837
sg10
I11
sg11
Vlung cancer
p2838
sg13
I2
sa(dp2839
g7
I15
sg20
VC0334094
p2840
sg10
I13
sg11
Vproliferation
p2841
sg13
I1
sasa(dp2842
g2
VThis finding indicated possible involvement of FGF16 in ovarian cancer progression.
p2843
sg4
(lp2844
(dp2845
g7
I47
sg8
g47
sg10
I5
sg11
VFGF16
p2846
sg13
I1
sasg17
(lp2847
(dp2848
g7
I64
sg20
VC0178874
p2849
sg10
I18
sg11
Vcancer progression
p2850
sg13
I2
sasa(dp2851
g2
VWe observed that FGF16 stimulates the proliferation of human ovarian adenocarcinoma cells, SKOV-3 and OAW-42.
p2852
sg4
(lp2853
(dp2854
g7
I17
sg8
g47
sg10
I5
sg11
VFGF16
p2855
sg13
I1
sasg17
(lp2856
(dp2857
g7
I61
sg20
VC0948216
p2858
sg10
I22
sg11
Vovarian adenocarcinoma
p2859
sg13
I2
sa(dp2860
g7
I38
sg20
VC0334094
p2861
sg10
I13
sg11
Vproliferation
p2862
sg13
I1
sasa(dp2863
g2
VTaken together, our findings indicate that FGF16 in conjunction with Wnt pathway contributes to the cancer phenotype of ovarian cells and suggests that modulation of its expression in ovarian cells might be a promising therapeutic strategy for the treatment of invasive ovarian cancers.
p2864
sg4
(lp2865
(dp2866
g7
I43
sg8
g47
sg10
I5
sg11
VFGF16
p2867
sg13
I1
sasg17
(lp2868
(dp2869
g7
I270
sg20
VC1140680
p2870
sg10
I15
sg11
Vovarian cancers
p2871
sg13
I2
sa(dp2872
g7
I100
sg20
VC0006826
p2873
sg10
I6
sg11
Vcancer
p2874
sg13
I1
sasa(dp2875
g2
VLoss-of-function mutations in the UBR1 gene cause Johanson-Blizzard syndrome, which involves pancreatic exocrine insufficiency.
p2876
sg4
(lp2877
(dp2878
g7
I34
sg8
g47
sg10
I9
sg11
VUBR1 gene
p2879
sg13
I2
sasg17
(lp2880
(dp2881
g7
I50
sg20
VC0175692
p2882
sg10
I26
sg11
VJohanson-Blizzard syndrome
p2883
sg13
I2
sasa(dp2884
g2
VJohanson-Blizzard syndrome (JBS) is considered as an infrequent, but clinically easily recognizable autosomal recessive entity by the pathognomonic combination of congenital exocrine pancreatic insufficiency and hypoplastic alae nasi, in addition to other distinctive findings such as scalp defects, hypothyroidism, and rectourogenital malformations.
p2885
sg4
(lp2886
sg17
(lp2887
(dp2888
g7
I336
sg20
VC0000768
p2889
sg10
I13
sg11
Vmalformations
p2890
sg13
I1
sa(dp2891
g7
I0
sg20
VC0175692
p2892
sg10
I26
sg11
VJohanson-Blizzard syndrome
p2893
sg13
I2
sa(dp2894
g7
I300
sg20
VC0020676
p2895
sg10
I14
sg11
Vhypothyroidism
p2896
sg13
I1
sa(dp2897
g7
I28
sg20
VC0175692
p2898
sg10
I3
sg11
VJBS
p2899
sg13
I1
sa(dp2900
g7
I174
sg20
VC0267963
p2901
sg10
I33
sg11
Vexocrine pancreatic insufficiency
p2902
sg13
I3
sasa(dp2903
g2
VThere are few reports of patients with JBS in association with facial clefting, referring all to types 2 to 6 of Tessier's classification that can be characterized properly as oblique facial clefts (OFCs).
p2904
sg4
(lp2905
sg17
(lp2906
(dp2907
g7
I199
sg20
VC1838348
p2908
sg10
I4
sg11
VOFCs
p2909
sg13
I1
sa(dp2910
g7
I176
sg20
VC1838348
p2911
sg10
I21
sg11
Voblique facial clefts
p2912
sg13
I3
sa(dp2913
g7
I39
sg20
VC0795841
p2914
sg10
I3
sg11
VJBS
p2915
sg13
I1
sasa(dp2916
g2
VWe describe the clinical aspects in four patients with JBS and extensive OFCs.
p2917
sg4
(lp2918
sg17
(lp2919
(dp2920
g7
I55
sg20
VC0795841
p2921
sg10
I3
sg11
VJBS
p2922
sg13
I1
sasa(dp2923
g2
VIn all of them, the diagnosis of JBS was confirmed by the demonstration of homozygous or compound-heterozygous mutations in the UBR1 gene.
p2924
sg4
(lp2925
(dp2926
g7
I128
sg8
g47
sg10
I9
sg11
VUBR1 gene
p2927
sg13
I2
sasg17
(lp2928
(dp2929
g7
I33
sg20
VC0795841
p2930
sg10
I3
sg11
VJBS
p2931
sg13
I1
sasa(dp2932
g2
VAdditionally, we review three previously reported cases of JBS with OFCs.
p2933
sg4
(lp2934
sg17
(lp2935
(dp2936
g7
I59
sg20
VC0795841
p2937
sg10
I3
sg11
VJBS
p2938
sg13
I1
sasa(dp2939
g2
VTaking into account a number of approximately 100 individuals affected by JBS that have been published in the literature we estimate that the frequency of OFCs in JBS is between 5% and 10%.
p2940
sg4
(lp2941
sg17
(lp2942
(dp2943
g7
I74
sg20
VC0795841
p2944
sg10
I3
sg11
VJBS
p2945
sg13
I1
sa(dp2946
g7
I74
sg20
VC0795841
p2947
sg10
I3
sg11
VJBS
p2948
sg13
I1
sasa(dp2949
g2
VThis report emphasizes that extensive OFCs may be the severe end of the spectrum of facial malformations occurring in JBS.
p2950
sg4
(lp2951
sg17
(lp2952
(dp2953
g7
I84
sg20
VC0266617
p2954
sg10
I20
sg11
Vfacial malformations
p2955
sg13
I2
sa(dp2956
g7
I118
sg20
VC0795841
p2957
sg10
I3
sg11
VJBS
p2958
sg13
I1
sasa(dp2959
g2
VJohanson-Blizzard Syndrome (JBS) (MIM #243800) is a rare autosomal recessive genetic disorder characterized by exocrine pancreatic insufficiency, abnormal facial appearance and varying degrees of mental retardation.
p2960
sg4
(lp2961
sg17
(lp2962
(dp2963
g7
I0
sg20
VC0175692
p2964
sg10
I26
sg11
VJohanson-Blizzard Syndrome
p2965
sg13
I2
sa(dp2966
g7
I77
sg20
VC0019247
p2967
sg10
I16
sg11
Vgenetic disorder
p2968
sg13
I2
sa(dp2969
g7
I28
sg20
VC0175692
p2970
sg10
I3
sg11
VJBS
p2971
sg13
I1
sa(dp2972
g7
I196
sg20
VC0025362
p2973
sg10
I18
sg11
Vmental retardation
p2974
sg13
I2
sa(dp2975
g7
I111
sg20
VC0267963
p2976
sg10
I33
sg11
Vexocrine pancreatic insufficiency
p2977
sg13
I3
sasa(dp2978
g2
VHere, we report a 3 year-old mentally normal JBS girl.
p2979
sg4
(lp2980
sg17
(lp2981
(dp2982
g7
I45
sg20
VC0795841
p2983
sg10
I3
sg11
VJBS
p2984
sg13
I1
sasa(dp2985
g2
VWith these findings, JBS diagnosis was established clinically.
p2986
sg4
(lp2987
sg17
(lp2988
(dp2989
g7
I21
sg20
VC0795841
p2990
sg10
I3
sg11
VJBS
p2991
sg13
I1
sasa(dp2992
g2
VJohanson-Blizzard syndrome (JBS) is a rare autosomal recessive syndrome characterized by dysmorphic nasal alae, ectodermal abnormalities, exocrine pancreatic insufficiency and early growth failure.
p2993
sg4
(lp2994
sg17
(lp2995
(dp2996
g7
I138
sg20
VC0267963
p2997
sg10
I33
sg11
Vexocrine pancreatic insufficiency
p2998
sg13
I3
sa(dp2999
g7
I0
sg20
VC0175692
p3000
sg10
I26
sg11
VJohanson-Blizzard syndrome
p3001
sg13
I2
sa(dp3002
g7
I28
sg20
VC0175692
p3003
sg10
I3
sg11
VJBS
p3004
sg13
I1
sa(dp3005
g7
I182
sg20
VC0878787
p3006
sg10
I14
sg11
Vgrowth failure
p3007
sg13
I2
sa(dp3008
g7
I18
sg20
VC0039082
p3009
sg10
I8
sg11
Vsyndrome
p3010
sg13
I1
sasa(dp3011
g2
VNonsense, frame shift and splice-site mutations of the ubiquitin ligase gene (UBR1) lead to early loss of acinar cells in individuals with JBS.
p3012
sg4
(lp3013
(dp3014
g7
I55
sg8
g47
sg10
I21
sg11
Vubiquitin ligase gene
p3015
sg13
I3
sa(dp3016
g7
I78
sg8
g47
sg10
I4
sg11
VUBR1
p3017
sg13
I1
sasg17
(lp3018
(dp3019
g7
I139
sg20
VC0795841
p3020
sg10
I3
sg11
VJBS
p3021
sg13
I1
sasa(dp3022
g2
VThis case illustrates that the phenotypic variability of pancreatic involvement in JBS may be subtle and may not manifest until the second decade of life.
p3023
sg4
(lp3024
(dp3025
g7
I83
sg8
g47
sg10
I3
sg11
VJBS
p3026
sg13
I1
sasg17
(lp3027
(dp3028
g7
I83
sg20
VC0795841
p3029
sg10
I3
sg11
VJBS
p3030
sg13
I1
sasa(dp3031
g2
VJohanson-Blizzard syndrome (JBS) is a rare autosomal recessive disorder resulting from loss-of-function mutations in the UBR1 gene.
p3032
sg4
(lp3033
(dp3034
g7
I121
sg8
g47
sg10
I9
sg11
VUBR1 gene
p3035
sg13
I2
sasg17
(lp3036
(dp3037
g7
I0
sg20
VC0175692
p3038
sg10
I26
sg11
VJohanson-Blizzard syndrome
p3039
sg13
I2
sa(dp3040
g7
I28
sg20
VC0175692
p3041
sg10
I3
sg11
VJBS
p3042
sg13
I1
sasa(dp3043
g2
VJBS can be easily recognized by its unique clinical presentation (including exocrine pancreatic insufficiency, hypoplasia/aplasia of the alae nasi, congenital scalp defects, sensorineural hearing loss, growth retardation, psychomotor retardation, and anal and genitourinary anomalies).
p3044
sg4
(lp3045
sg17
(lp3046
(dp3047
g7
I174
sg20
VC0018784
p3048
sg10
I26
sg11
Vsensorineural hearing loss
p3049
sg13
I3
sa(dp3050
g7
I76
sg20
VC0267963
p3051
sg10
I33
sg11
Vexocrine pancreatic insufficiency
p3052
sg13
I3
sa(dp3053
g7
I202
sg20
VC0151686
p3054
sg10
I18
sg11
Vgrowth retardation
p3055
sg13
I2
sa(dp3056
g7
I122
sg20
VC0243065
p3057
sg10
I7
sg11
Vaplasia
p3058
sg13
I1
sa(dp3059
g7
I0
sg20
VC0795841
p3060
sg10
I3
sg11
VJBS
p3061
sg13
I1
sa(dp3062
g7
I111
sg20
VC0243069
p3063
sg10
I10
sg11
Vhypoplasia
p3064
sg13
I1
sasa(dp3065
g2
VThe objective of this study is to report on the first familial case of gender-discordant twins presenting JBS and a novel mutation in the UBR1 gene.
p3066
sg4
(lp3067
(dp3068
g7
I138
sg8
g47
sg10
I9
sg11
VUBR1 gene
p3069
sg13
I2
sasg17
(lp3070
(dp3071
g7
I116
sg20
VC2985438
p3072
sg10
I14
sg11
Vnovel mutation
p3073
sg13
I2
sa(dp3074
g7
I106
sg20
VC0795841
p3075
sg10
I3
sg11
VJBS
p3076
sg13
I1
sasa(dp3077
g2
VWe also review literature describing molecularly confirmed cases of JBS.
p3078
sg4
(lp3079
sg17
(lp3080
(dp3081
g7
I68
sg20
VC0795841
p3082
sg10
I3
sg11
VJBS
p3083
sg13
I1
sasa(dp3084
g2
VBoth patients presented typical clinical features of JBS.
p3085
sg4
(lp3086
sg17
(lp3087
(dp3088
g7
I53
sg20
VC0795841
p3089
sg10
I3
sg11
VJBS
p3090
sg13
I1
sasa(dp3091
g2
VSevere presentation of JBS usually involves deleterious (nonsense, frameshift, or splice-site) mutations in the UBR1 gene that are thought to completely abolish the expression of a functional protein product, as in this familial case; however, milder presentation of JBS has occasionally been observed with missense mutations in at least 1 of the 2 copies of UBR1, in which there may be residual activity of the product of this gene.
p3092
sg4
(lp3093
(dp3094
g7
I112
sg8
g47
sg10
I9
sg11
VUBR1 gene
p3095
sg13
I2
sa(dp3096
g7
I112
sg8
g47
sg10
I4
sg11
VUBR1
p3097
sg13
I1
sasg17
(lp3098
(dp3099
g7
I23
sg20
VC0795841
p3100
sg10
I3
sg11
VJBS
p3101
sg13
I1
sa(dp3102
g7
I23
sg20
VC0795841
p3103
sg10
I3
sg11
VJBS
p3104
sg13
I1
sa(dp3105
g7
I67
sg20
VC0079380
p3106
sg10
I10
sg11
Vframeshift
p3107
sg13
I1
sasa(dp3108
g2
VJohanson-Blizzard syndrome (JBS) is a rare, autosomal recessive disorder characterized by exocrine pancreatic insufficiency, typical facial features, dental anomalies, hypothyroidism, sensorineural hearing loss, scalp defects, urogenital and anorectal anomalies, short stature, and cognitive impairment of variable degree.
p3109
sg4
(lp3110
sg17
(lp3111
(dp3112
g7
I168
sg20
VC0020676
p3113
sg10
I14
sg11
Vhypothyroidism
p3114
sg13
I1
sa(dp3115
g7
I28
sg20
VC0175692
p3116
sg10
I3
sg11
VJBS
p3117
sg13
I1
sa(dp3118
g7
I0
sg20
VC0175692
p3119
sg10
I26
sg11
VJohanson-Blizzard syndrome
p3120
sg13
I2
sa(dp3121
g7
I242
sg20
VC2974527
p3122
sg10
I19
sg11
Vanorectal anomalies
p3123
sg13
I2
sa(dp3124
g7
I282
sg20
VC0338656
p3125
sg10
I20
sg11
Vcognitive impairment
p3126
sg13
I2
sa(dp3127
g7
I90
sg20
VC0267963
p3128
sg10
I33
sg11
Vexocrine pancreatic insufficiency
p3129
sg13
I3
sa(dp3130
g7
I263
sg20
VC0013336
p3131
sg10
I13
sg11
Vshort stature
p3132
sg13
I2
sa(dp3133
g7
I184
sg20
VC0018784
p3134
sg10
I26
sg11
Vsensorineural hearing loss
p3135
sg13
I3
sasa(dp3136
g2
VMutation types include nonsense, frameshift, splice site, missense, and small in-frame deletions consistent with the hypothesis that loss of UBR1 protein function is the molecular basis of JBS.
p3137
sg4
(lp3138
(dp3139
g7
I141
sg8
g47
sg10
I12
sg11
VUBR1 protein
p3140
sg13
I2
sasg17
(lp3141
(dp3142
g7
I33
sg20
VC0079380
p3143
sg10
I10
sg11
Vframeshift
p3144
sg13
I1
sa(dp3145
g7
I189
sg20
VC0795841
p3146
sg10
I3
sg11
VJBS
p3147
sg13
I1
sasa(dp3148
g2
VThe review of clinical data of a large number of molecularly confirmed JBS cases allows us to define minimal clinical criteria for the diagnosis of JBS.
p3149
sg4
(lp3150
sg17
(lp3151
(dp3152
g7
I71
sg20
VC0795841
p3153
sg10
I3
sg11
VJBS
p3154
sg13
I1
sa(dp3155
g7
I71
sg20
VC0795841
p3156
sg10
I3
sg11
VJBS
p3157
sg13
I1
sasa(dp3158
g2
VJohanson-Blizzard syndrome (JBS) is a rare autosomal recessive disease characterized by exocrine pancreatic insufficiency, hypoplastic or aplastic nasal alae, cutis aplasia on the scalp, and other features including developmental delay, failure to thrive, hearing loss, mental retardation, hypothyroidism, dental abnormalities, and anomalies in cardiac and genitourinary systems.
p3159
sg4
(lp3160
sg17
(lp3161
(dp3162
g7
I159
sg20
VC0282160
p3163
sg10
I13
sg11
Vcutis aplasia
p3164
sg13
I2
sa(dp3165
g7
I256
sg20
VC0011053
p3166
sg10
I12
sg11
Vhearing loss
p3167
sg13
I2
sa(dp3168
g7
I88
sg20
VC0267963
p3169
sg10
I33
sg11
Vexocrine pancreatic insufficiency
p3170
sg13
I3
sa(dp3171
g7
I28
sg20
VC0175692
p3172
sg10
I3
sg11
VJBS
p3173
sg13
I1
sa(dp3174
g7
I0
sg20
VC0175692
p3175
sg10
I26
sg11
VJohanson-Blizzard syndrome
p3176
sg13
I2
sa(dp3177
g7
I216
sg20
VC0424605
p3178
sg10
I19
sg11
Vdevelopmental delay
p3179
sg13
I2
sa(dp3180
g7
I237
sg20
VC0015544
p3181
sg10
I17
sg11
Vfailure to thrive
p3182
sg13
I3
sa(dp3183
g7
I270
sg20
VC0025362
p3184
sg10
I18
sg11
Vmental retardation
p3185
sg13
I2
sa(dp3186
g7
I290
sg20
VC0020676
p3187
sg10
I14
sg11
Vhypothyroidism
p3188
sg13
I1
sasa(dp3189
g2
VWe describe the case of a male infant with typical symptoms of JBS.
p3190
sg4
(lp3191
sg17
(lp3192
(dp3193
g7
I63
sg20
VC0795841
p3194
sg10
I3
sg11
VJBS
p3195
sg13
I1
sasa(dp3196
g2
VJohanson-Blizzard syndrome (JBS; OMIM 243800) is an autosomal recessive disorder that includes congenital exocrine pancreatic insufficiency, facial dysmorphism with the characteristic nasal wing hypoplasia, multiple malformations, and frequent mental retardation.
p3197
sg4
(lp3198
sg17
(lp3199
(dp3200
g7
I216
sg20
VC0000768
p3201
sg10
I13
sg11
Vmalformations
p3202
sg13
I1
sa(dp3203
g7
I195
sg20
VC0243069
p3204
sg10
I10
sg11
Vhypoplasia
p3205
sg13
I1
sa(dp3206
g7
I28
sg20
VC0175692
p3207
sg10
I3
sg11
VJBS
p3208
sg13
I1
sa(dp3209
g7
I106
sg20
VC0267963
p3210
sg10
I33
sg11
Vexocrine pancreatic insufficiency
p3211
sg13
I3
sa(dp3212
g7
I244
sg20
VC0025362
p3213
sg10
I18
sg11
Vmental retardation
p3214
sg13
I2
sa(dp3215
g7
I0
sg20
VC0175692
p3216
sg10
I26
sg11
VJohanson-Blizzard syndrome
p3217
sg13
I2
sa(dp3218
g7
I141
sg20
VC0266617
p3219
sg10
I18
sg11
Vfacial dysmorphism
p3220
sg13
I2
sasa(dp3221
g2
VOur previous work has shown that JBS is caused by mutations in human UBR1, which encodes one of the E3 ubiquitin ligases of the N-end rule pathway.
p3222
sg4
(lp3223
(dp3224
g7
I63
sg8
g47
sg10
I10
sg11
Vhuman UBR1
p3225
sg13
I2
sa(dp3226
g7
I33
sg8
g47
sg10
I3
sg11
VJBS
p3227
sg13
I1
sa(dp3228
g7
I100
sg8
VP62979
p3229
sg10
I20
sg11
VE3 ubiquitin ligases
p3230
sg13
I3
sasg17
(lp3231
(dp3232
g7
I33
sg20
VC0795841
p3233
sg10
I3
sg11
VJBS
p3234
sg13
I1
sasa(dp3235
g2
VMost JBS-causing alterations of UBR1 are nonsense, frameshift or splice-site mutations that abolish UBR1 activity.
p3236
sg4
(lp3237
(dp3238
g7
I32
sg8
g47
sg10
I4
sg11
VUBR1
p3239
sg13
I1
sa(dp3240
g7
I32
sg8
g47
sg10
I4
sg11
VUBR1
p3241
sg13
I1
sasg17
(lp3242
(dp3243
g7
I51
sg20
VC0079380
p3244
sg10
I10
sg11
Vframeshift
p3245
sg13
I1
sa(dp3246
g7
I5
sg20
VC0795841
p3247
sg10
I3
sg11
VJBS
p3248
sg13
I1
sasa(dp3249
g2
VWe report here missense mutations of human UBR1 in patients with milder variants of JBS.
p3250
sg4
(lp3251
(dp3252
g7
I37
sg8
g47
sg10
I10
sg11
Vhuman UBR1
p3253
sg13
I2
sasg17
(lp3254
(dp3255
g7
I84
sg20
VC0795841
p3256
sg10
I3
sg11
VJBS
p3257
sg13
I1
sasa(dp3258
g2
VTaking advantage of this conservation, we constructed alleles of the yeast Saccharomyces cerevisiae UBR1 that were counterparts of missense JBS-UBR1 alleles.
p3259
sg4
(lp3260
(dp3261
g7
I140
sg8
g47
sg10
I3
sg11
VJBS
p3262
sg13
I1
sa(dp3263
g7
I69
sg8
g47
sg10
I35
sg11
Vyeast Saccharomyces cerevisiae UBR1
p3264
sg13
I4
sa(dp3265
g7
I100
sg8
g47
sg10
I4
sg11
VUBR1
p3266
sg13
I1
sasg17
(lp3267
(dp3268
g7
I140
sg20
VC0795841
p3269
sg10
I3
sg11
VJBS
p3270
sg13
I1
sasa(dp3271
g2
VAmong these yeast Ubr1 mutants, one of them (H160R) was inactive in yeast-based activity assays, the other one (Q1224E) had a detectable but weak activity, and the third one (V146L) exhibited a decreased but significant activity, in agreement with manifestations of JBS in the corresponding JBS patients.
p3272
sg4
(lp3273
(dp3274
g7
I18
sg8
g47
sg10
I12
sg11
VUbr1 mutants
p3275
sg13
I2
sasg17
(lp3276
(dp3277
g7
I266
sg20
VC0795841
p3278
sg10
I3
sg11
VJBS
p3279
sg13
I1
sa(dp3280
g7
I266
sg20
VC0795841
p3281
sg10
I3
sg11
VJBS
p3282
sg13
I1
sasa(dp3283
g2
VThese results, made possible by modeling defects of a human ubiquitin ligase in its yeast counterpart, verified and confirmed the relevance of specific missense UBR1 alleles to JBS, and suggested that a residual activity of a missense allele is causally associated with milder variants of JBS.
p3284
sg4
(lp3285
(dp3286
g7
I54
sg8
g47
sg10
I22
sg11
Vhuman ubiquitin ligase
p3287
sg13
I3
sa(dp3288
g7
I161
sg8
g47
sg10
I12
sg11
VUBR1 alleles
p3289
sg13
I2
sasg17
(lp3290
(dp3291
g7
I177
sg20
VC0795841
p3292
sg10
I3
sg11
VJBS
p3293
sg13
I1
sa(dp3294
g7
I177
sg20
VC0795841
p3295
sg10
I3
sg11
VJBS
p3296
sg13
I1
sasa(dp3297
g2
VWe report on a triplet pregnancy of consanguineous parents with one fetus being affected by recurrent Johanson-Blizzard syndrome (JBS).
p3298
sg4
(lp3299
sg17
(lp3300
(dp3301
g7
I130
sg20
VC0175692
p3302
sg10
I3
sg11
VJBS
p3303
sg13
I1
sa(dp3304
g7
I15
sg20
VC0152151
p3305
sg10
I17
sg11
Vtriplet pregnancy
p3306
sg13
I2
sa(dp3307
g7
I102
sg20
VC0175692
p3308
sg10
I26
sg11
VJohanson-Blizzard syndrome
p3309
sg13
I2
sasa(dp3310
g2
VIn addition to the lack of exocrine acini as the characteristic feature of JBS, the pancreas revealed a resorptive inflammatory reaction with infiltration by eosinophilic granulocytes that focally dispersed onto islets of Langerhans, thus favoring a progressive destructive rather than primary dysplastic process and possibly explaining the occurrence of diabetes mellitus in later life.
p3311
sg4
(lp3312
sg17
(lp3313
(dp3314
g7
I142
sg20
VC0332448
p3315
sg10
I12
sg11
Vinfiltration
p3316
sg13
I1
sa(dp3317
g7
I355
sg20
VC0011849
p3318
sg10
I17
sg11
Vdiabetes mellitus
p3319
sg13
I2
sa(dp3320
g7
I115
sg20
VC0021368
p3321
sg10
I21
sg11
Vinflammatory reaction
p3322
sg13
I2
sa(dp3323
g7
I294
sg20
VC0334044
p3324
sg10
I10
sg11
Vdysplastic
p3325
sg13
I1
sa(dp3326
g7
I75
sg20
VC0795841
p3327
sg10
I3
sg11
VJBS
p3328
sg13
I1
sasa(dp3329
g2
VJBS maps to chromosome 15q15-q21.1 and is associated with mutations in the UBR1 gene.
p3330
sg4
(lp3331
(dp3332
g7
I0
sg8
g47
sg10
I3
sg11
VJBS
p3333
sg13
I1
sa(dp3334
g7
I75
sg8
g47
sg10
I9
sg11
VUBR1 gene
p3335
sg13
I2
sasg17
(lp3336
(dp3337
g7
I0
sg20
VC0795841
p3338
sg10
I3
sg11
VJBS
p3339
sg13
I1
sasa(dp3340
g2
VJohanson-Blizzard syndrome is a rare autosomal recessive multisystem disorder, it is characterized by the association of congenital exocrine pancreatic insufficiency and hypoplasia or aplasia of the nasal wings, and can be diagnosed by clinical characteristics and UBR1 gene analysis.
p3341
sg4
(lp3342
(dp3343
g7
I265
sg8
g47
sg10
I9
sg11
VUBR1 gene
p3344
sg13
I2
sasg17
(lp3345
(dp3346
g7
I0
sg20
VC0175692
p3347
sg10
I26
sg11
VJohanson-Blizzard syndrome
p3348
sg13
I2
sa(dp3349
g7
I57
sg20
VC0559758
p3350
sg10
I20
sg11
Vmultisystem disorder
p3351
sg13
I2
sa(dp3352
g7
I184
sg20
VC0243065
p3353
sg10
I7
sg11
Vaplasia
p3354
sg13
I1
sa(dp3355
g7
I170
sg20
VC0243069
p3356
sg10
I10
sg11
Vhypoplasia
p3357
sg13
I1
sa(dp3358
g7
I132
sg20
VC0267963
p3359
sg10
I33
sg11
Vexocrine pancreatic insufficiency
p3360
sg13
I3
sasa(dp3361
g2
V* Sixteen distinct haplotypes were detected from 258 individuals in the C. conica complex inferred from the cpDNA sequences of intergenic spacer (IGS) between atpB and rbcL, IGS between trnT and trnL, trnL intron, and IGS between trnL and trnF.
p3362
sg4
(lp3363
(dp3364
g7
I146
sg8
g47
sg10
I3
sg11
VIGS
p3365
sg13
I1
sa(dp3366
g7
I186
sg8
g47
sg10
I4
sg11
VtrnT
p3367
sg13
I1
sa(dp3368
g7
I201
sg8
VP49184
p3369
sg10
I11
sg11
VtrnL intron
p3370
sg13
I2
sa(dp3371
g7
I146
sg8
g47
sg10
I3
sg11
VIGS
p3372
sg13
I1
sa(dp3373
g7
I195
sg8
VP49184
p3374
sg10
I4
sg11
VtrnL
p3375
sg13
I1
sa(dp3376
g7
I159
sg8
VP05026
p3377
sg10
I4
sg11
VatpB
p3378
sg13
I1
sa(dp3379
g7
I195
sg8
VP49184
p3380
sg10
I4
sg11
VtrnL
p3381
sg13
I1
sasg17
(lp3382
(dp3383
g7
I146
sg20
VC1306856
p3384
sg10
I3
sg11
VIGS
p3385
sg13
I1
sa(dp3386
g7
I146
sg20
VC1306856
p3387
sg10
I3
sg11
VIGS
p3388
sg13
I1
sa(dp3389
g7
I146
sg20
VC1306856
p3390
sg10
I3
sg11
VIGS
p3391
sg13
I1
sasa(dp3392
g2
VMaximum parsimony and Bayesian inference analyses of DNA sequence data of the plastid (the trnT-L igs, the trnL intron, two parts of the trnK intron, and the psbA-trnH igs) and nuclear genome (ITS1, 5.8S, and ITS2) showed these markers to be suitable to assess the species composition of sect.
p3393
sg4
(lp3394
(dp3395
g7
I158
sg8
VP40306
p3396
sg10
I13
sg11
VpsbA-trnH igs
p3397
sg13
I2
sa(dp3398
g7
I107
sg8
VP49184
p3399
sg10
I11
sg11
VtrnL intron
p3400
sg13
I2
sa(dp3401
g7
I91
sg8
g47
sg10
I10
sg11
VtrnT-L igs
p3402
sg13
I2
sa(dp3403
g7
I137
sg8
g47
sg10
I11
sg11
VtrnK intron
p3404
sg13
I2
sasg17
(lp3405
(dp3406
g7
I98
sg20
VC1306856
p3407
sg10
I3
sg11
Vigs
p3408
sg13
I1
sa(dp3409
g7
I98
sg20
VC1306856
p3410
sg10
I3
sg11
Vigs
p3411
sg13
I1
sasa(dp3412
g2
VHowever, the primers for amplification of chloroplast trnD-trnT intron and rRNA IGS failed to amplify the respective region in Elymus species.
p3413
sg4
(lp3414
(dp3415
g7
I42
sg8
VP27708
p3416
sg10
I28
sg11
Vchloroplast trnD-trnT intron
p3417
sg13
I3
sasg17
(lp3418
(dp3419
g7
I25
sg20
VC1705759
p3420
sg10
I13
sg11
Vamplification
p3421
sg13
I1
sa(dp3422
g7
I80
sg20
VC1306856
p3423
sg10
I3
sg11
VIGS
p3424
sg13
I1
sasa(dp3425
g2
VNew primer pairs were designed and successfully amplified the cpDNA trnD-trnT intron and rRNA IGS region in Elymus species.
p3426
sg4
(lp3427
(dp3428
g7
I73
sg8
g47
sg10
I4
sg11
VtrnT
p3429
sg13
I1
sasg17
(lp3430
(dp3431
g7
I94
sg20
VC1306856
p3432
sg10
I3
sg11
VIGS
p3433
sg13
I1
sasa(dp3434
g2
VIn the present study, we investigated the effect of taspine derivative 12k on human colorectal cancer targeted at EphrinB2 and its PDZ.
p3435
sg4
(lp3436
(dp3437
g7
I114
sg8
VP52799
p3438
sg10
I8
sg11
VEphrinB2
p3439
sg13
I1
sasg17
(lp3440
(dp3441
g7
I84
sg20
VC1527249
p3442
sg10
I17
sg11
Vcolorectal cancer
p3443
sg13
I2
sasa(dp3444
g2
VIn this study, we investigated the mechanism of chemoresistance and epithelial-to-mesenchymal transition (EMT) in colorectal cancer involving the gain-of-function (GOF) mutant p53/ephrin-B2 signaling axis.
p3445
sg4
(lp3446
(dp3447
g7
I176
sg8
VP42771
p3448
sg10
I3
sg11
Vp53
p3449
sg13
I1
sasg17
(lp3450
(dp3451
g7
I169
sg20
VC0596988
p3452
sg10
I6
sg11
Vmutant
p3453
sg13
I1
sa(dp3454
g7
I94
sg20
VC0599156
p3455
sg10
I10
sg11
Vtransition
p3456
sg13
I1
sa(dp3457
g7
I114
sg20
VC1527249
p3458
sg10
I17
sg11
Vcolorectal cancer
p3459
sg13
I2
sasa(dp3460
g2
VTwenty proteins from different signaling pathways (epidermal growth factor receptor [EGFR], phosphorylated extracellular signal regulated kinase [pERK], receptor for hyalouronic acid mediated motility [RHAMM], Raf-1 kinase inhibitor protein [RKIP], Beta-catenin, E-cadherin, phosphorylated AK transforming [pAKT], p16, p21, Ki-67, B-cell Lymphoma-2 [BCL2], vascular endothelial growth factor, apoptosis protease activating factor 1 [APAF-1], mucin1 [MUC1], ephrin B2 receptor [EphB2], matrix metalloproteinase 7 [MMP7], phosphorylated mothers against decapentaplegic 2 [pSMAD2], caudal type homeobox transcription factor 2 [CDX2], Laminin5Gamma2, and mammalian sterile 20-like kinase 1 [MST1]) involved in colorectal cancer progression were studied immunohistochemically on 220 well-characterized patients using a multiple-punch tissue microarray including 437 and 430 samples from the tumor center and the invasive front, respectively.
p3461
sg4
(lp3462
(dp3463
g7
I223
sg8
VP30086
p3464
sg10
I24
sg11
Vinhibitor protein [RKIP]
p3465
sg13
I3
sa(dp3466
g7
I210
sg8
VP04049
p3467
sg10
I12
sg11
VRaf-1 kinase
p3468
sg13
I2
sa(dp3469
g7
I51
sg8
VP01133
p3470
sg10
I32
sg11
Vepidermal growth factor receptor
p3471
sg13
I4
sa(dp3472
g7
I201
sg8
g47
sg10
I7
sg11
V[RHAMM]
p3473
sg13
I1
sa(dp3474
g7
I249
sg8
VP35222
p3475
sg10
I12
sg11
VBeta-catenin
p3476
sg13
I1
sa(dp3477
g7
I263
sg8
VP12830
p3478
sg10
I10
sg11
VE-cadherin
p3479
sg13
I1
sa(dp3480
g7
I579
sg8
g47
sg10
I50
sg11
Vcaudal type homeobox transcription factor 2 [CDX2]
p3481
sg13
I7
sa(dp3482
g7
I357
sg8
g47
sg10
I34
sg11
Vvascular endothelial growth factor
p3483
sg13
I4
sa(dp3484
g7
I314
sg8
VP42771
p3485
sg10
I3
sg11
Vp16
p3486
sg13
I1
sa(dp3487
g7
I393
sg8
VP63123
p3488
sg10
I38
sg11
Vapoptosis protease activating factor 1
p3489
sg13
I5
sa(dp3490
g7
I324
sg8
VP46013
p3491
sg10
I5
sg11
VKi-67
p3492
sg13
I1
sa(dp3493
g7
I319
sg8
VP42857
p3494
sg10
I3
sg11
Vp21
p3495
sg13
I1
sa(dp3496
g7
I669
sg8
VP27361
p3497
sg10
I16
sg11
V20-like kinase 1
p3498
sg13
I3
sa(dp3499
g7
I275
sg8
VP55263
p3500
sg10
I17
sg11
Vphosphorylated AK
p3501
sg13
I2
sa(dp3502
g7
I457
sg8
VP52799
p3503
sg10
I61
sg11
Vephrin B2 receptor [EphB2], matrix metalloproteinase 7 [MMP7]
p3504
sg13
I8
sa(dp3505
g7
I331
sg8
VP10415
p3506
sg10
I24
sg11
VB-cell Lymphoma-2 [BCL2]
p3507
sg13
I3
sa(dp3508
g7
I687
sg8
VP26927
p3509
sg10
I4
sg11
VMST1
p3510
sg13
I1
sa(dp3511
g7
I107
sg8
VP53778
p3512
sg10
I93
sg11
Vextracellular signal regulated kinase [pERK], receptor for hyalouronic acid mediated motility
p3513
sg13
I11
sasg17
(lp3514
(dp3515
g7
I717
sg20
VC0178874
p3516
sg10
I18
sg11
Vcancer progression
p3517
sg13
I2
sa(dp3518
g7
I886
sg20
VC0027651
p3519
sg10
I5
sg11
Vtumor
p3520
sg13
I1
sa(dp3521
g7
I661
sg20
VC0678108
p3522
sg10
I7
sg11
Vsterile
p3523
sg13
I1
sa(dp3524
g7
I331
sg20
VC0079731
p3525
sg10
I15
sg11
VB-cell Lymphoma
p3526
sg13
I2
sasa(dp3527
g2
VAbundant expression of IFN-Gamma-inducible protein 10 (IP-10) was observed on macrophages and in T cells in perimysial infiltrates of dermatomyositis (DM), and strong chemokine (C-X-C motif) receptor (CXCR)3 expression was observed on the majority of T cells in DM.
p3528
sg4
(lp3529
(dp3530
g7
I23
sg8
VP01579
p3531
sg10
I9
sg11
VIFN-Gamma
p3532
sg13
I1
sasg17
(lp3533
(dp3534
g7
I151
sg20
VC0221056
p3535
sg10
I2
sg11
VDM
p3536
sg13
I1
sa(dp3537
g7
I119
sg20
VC0332448
p3538
sg10
I11
sg11
Vinfiltrates
p3539
sg13
I1
sa(dp3540
g7
I134
sg20
VC0221056
p3541
sg10
I15
sg11
Vdermatomyositis
p3542
sg13
I1
sa(dp3543
g7
I151
sg20
VC0221056
p3544
sg10
I2
sg11
VDM
p3545
sg13
I1
sasa(dp3546
g2
VAbundant expression of IP-10 was observed on macrophages and T cells surrounding and invading non-necrotic muscle fibers in polymyositis and sporadic inclusion body myositis and in T cells in perimysial infiltrates of dermatomyositis.
p3547
sg4
(lp3548
sg17
(lp3549
(dp3550
g7
I141
sg20
VC0751713
p3551
sg10
I32
sg11
Vsporadic inclusion body myositis
p3552
sg13
I4
sa(dp3553
g7
I218
sg20
VC0221056
p3554
sg10
I15
sg11
Vdermatomyositis
p3555
sg13
I1
sa(dp3556
g7
I203
sg20
VC0332448
p3557
sg10
I11
sg11
Vinfiltrates
p3558
sg13
I1
sa(dp3559
g7
I124
sg20
VC0085655
p3560
sg10
I12
sg11
Vpolymyositis
p3561
sg13
I1
sasa(dp3562
g2
VDORs were colocalized in tissue slices and synaptosomes from the canine right atrium and SA node along with cholinergic and adrenergic markers, vesicular acetylcholine transporter (VAChT), and tyrosine hydroxylase (TH).
p3563
sg4
(lp3564
(dp3565
g7
I144
sg8
g47
sg10
I35
sg11
Vvesicular acetylcholine transporter
p3566
sg13
I3
sa(dp3567
g7
I181
sg8
g47
sg10
I5
sg11
VVAChT
p3568
sg13
I1
sa(dp3569
g7
I193
sg8
VP07101
p3570
sg10
I20
sg11
Vtyrosine hydroxylase
p3571
sg13
I2
sa(dp3572
g7
I215
sg8
VP07101
p3573
sg10
I2
sg11
VTH
p3574
sg13
I1
sasg17
(lp3575
sa(dp3576
g2
VFurthermore, the lack of interdigital programmed cell death and associated syndactyly was related to down-regulated gene expression of Bmp2, Bmp7, Msx1, and Msx2, which are known to promote apoptosis in the interdigital mesenchyme.
p3577
sg4
(lp3578
(dp3579
g7
I135
sg8
VP12643
p3580
sg10
I4
sg11
VBmp2
p3581
sg13
I1
sa(dp3582
g7
I147
sg8
VP28360
p3583
sg10
I4
sg11
VMsx1
p3584
sg13
I1
sa(dp3585
g7
I141
sg8
VP18075
p3586
sg10
I4
sg11
VBmp7
p3587
sg13
I1
sa(dp3588
g7
I157
sg8
VP35548
p3589
sg10
I4
sg11
VMsx2
p3590
sg13
I1
sasg17
(lp3591
(dp3592
g7
I75
sg20
VC0039075
p3593
sg10
I10
sg11
Vsyndactyly
p3594
sg13
I1
sasa(dp3595
g2
VIn this context, ERdj3 suppression may eliminate the toxic gain of function associated with polymerization of ZAAT, thus providing a potential new therapeutic approach to the treatment of AATD-related liver disease.
p3596
sg4
(lp3597
(dp3598
g7
I17
sg8
g47
sg10
I5
sg11
VERdj3
p3599
sg13
I1
sasg17
(lp3600
(dp3601
g7
I201
sg20
VC0023895
p3602
sg10
I13
sg11
Vliver disease
p3603
sg13
I2
sa(dp3604
g7
I23
sg20
VC0221103
p3605
sg10
I11
sg11
Vsuppression
p3606
sg13
I1
sa(dp3607
g7
I188
sg20
VC0221757
p3608
sg10
I4
sg11
VAATD
p3609
sg13
I1
sasa(dp3610
g2
VThe CPK, aldolase, GOT, GPT, and LDH concentrations in the serum and lumbar CSF of 80 patients with neuromuscular diseases and 20 controls were measured.
p3611
sg4
(lp3612
(dp3613
g7
I33
sg8
g47
sg10
I3
sg11
VLDH
p3614
sg13
I1
sa(dp3615
g7
I9
sg8
VP05062
p3616
sg10
I8
sg11
Valdolase
p3617
sg13
I1
sa(dp3618
g7
I69
sg8
VP04141
p3619
sg10
I10
sg11
Vlumbar CSF
p3620
sg13
I2
sa(dp3621
g7
I4
sg8
g47
sg10
I3
sg11
VCPK
p3622
sg13
I1
sa(dp3623
g7
I24
sg8
VP24298
p3624
sg10
I3
sg11
VGPT
p3625
sg13
I1
sasg17
(lp3626
(dp3627
g7
I100
sg20
VC0027868
p3628
sg10
I22
sg11
Vneuromuscular diseases
p3629
sg13
I2
sasa(dp3630
g2
VIn 60 cases of various neuromuscular diseases, serum CA-III, CPK and aldolase were measured.
p3631
sg4
(lp3632
(dp3633
g7
I53
sg8
VP07451
p3634
sg10
I6
sg11
VCA-III
p3635
sg13
I1
sa(dp3636
g7
I69
sg8
VP05062
p3637
sg10
I8
sg11
Valdolase
p3638
sg13
I1
sa(dp3639
g7
I61
sg8
g47
sg10
I3
sg11
VCPK
p3640
sg13
I1
sasg17
(lp3641
(dp3642
g7
I23
sg20
VC0027868
p3643
sg10
I22
sg11
Vneuromuscular diseases
p3644
sg13
I2
sasa(dp3645
g2
VTogether, our results show that P. gingivalis activates the ERK1/2-Ets1, p38/HSP27, and PAR2/NF-kB pathways to induce proMMP9 expression, after which the proenzyme is activated by gingipains to promote cellular invasion of OSCC cell lines.
p3646
sg4
(lp3647
(dp3648
g7
I88
sg8
VP55085
p3649
sg10
I4
sg11
VPAR2
p3650
sg13
I1
sa(dp3651
g7
I60
sg8
VP27361
p3652
sg10
I6
sg11
VERK1/2
p3653
sg13
I1
sa(dp3654
g7
I77
sg8
g47
sg10
I5
sg11
VHSP27
p3655
sg13
I1
sa(dp3656
g7
I73
sg8
VP46108
p3657
sg10
I3
sg11
Vp38
p3658
sg13
I1
sa(dp3659
g7
I67
sg8
VP14921
p3660
sg10
I4
sg11
VEts1
p3661
sg13
I1
sasg17
(lp3662
(dp3663
g7
I211
sg20
VC2699153
p3664
sg10
I8
sg11
Vinvasion
p3665
sg13
I1
sasa(dp3666
g2
VTissue sections ranging from normal mucosa to moderately-differentiated oral squamous cell carcinoma were studied using monoclonal antibodies against N-ras and ets-1 proteins.
p3667
sg4
(lp3668
(dp3669
g7
I152
sg8
VP01116
p3670
sg10
I3
sg11
Vras
p3671
sg13
I1
sa(dp3672
g7
I160
sg8
VP14921
p3673
sg10
I14
sg11
Vets-1 proteins
p3674
sg13
I2
sasg17
(lp3675
(dp3676
g7
I77
sg20
VC0007137
p3677
sg10
I23
sg11
Vsquamous cell carcinoma
p3678
sg13
I3
sasa(dp3679
g2
VIn a randomized controlled trial of patients with dyslipidemia assigned to either extended release niacin (ERN) alone, ERN combined with the selective prostaglandin D2 receptor subtype 1 inhibitor laropiprant (ERN-L) or placebo, niacin lowered serum phosphorus; however, it is not known if it lowers FGF23 concentrations.
p3680
sg4
(lp3681
(dp3682
g7
I300
sg8
g47
sg10
I5
sg11
VFGF23
p3683
sg13
I1
sasg17
(lp3684
(dp3685
g7
I50
sg20
VC0242339
p3686
sg10
I12
sg11
Vdyslipidemia
p3687
sg13
I1
sasa(dp3688
g2
VThe use of nicotinic acid to treat dyslipidemia is limited by induction of a "flushing" response, mediated in part by the interaction of prostaglandin D(2) (PGD(2)) with its G-protein coupled receptor, DP1 (Ptgdr).
p3689
sg4
(lp3690
(dp3691
g7
I174
sg8
VP32247
p3692
sg10
I26
sg11
VG-protein coupled receptor
p3693
sg13
I3
sa(dp3694
g7
I202
sg8
g47
sg10
I3
sg11
VDP1
p3695
sg13
I1
sa(dp3696
g7
I207
sg8
g47
sg10
I5
sg11
VPtgdr
p3697
sg13
I1
sasg17
(lp3698
(dp3699
g7
I78
sg20
VC0016382
p3700
sg10
I8
sg11
Vflushing
p3701
sg13
I1
sa(dp3702
g7
I35
sg20
VC0242339
p3703
sg10
I12
sg11
Vdyslipidemia
p3704
sg13
I1
sasa(dp3705
g2
VWe performed a post hoc data analysis of serum phosphorus concentrations that had been determined serially (at baseline and weeks 4, 8, 12, 18, and 24) among 1547 patients who had dyslipidemia and were randomly assigned in a 3:2:1 ratio to treatment with extended release niacin (ERN; 1 g/d for 4 weeks and dose advanced to 2 g/d for 20 weeks) combined with the selective prostaglandin D2 receptor subtype 1 inhibitor laropiprant (L; n = 761), ERN alone (n = 518), or placebo (n = 268).
p3706
sg4
(lp3707
sg17
(lp3708
(dp3709
g7
I180
sg20
VC0242339
p3710
sg10
I12
sg11
Vdyslipidemia
p3711
sg13
I1
sasa(dp3712
g2
VApart from primary aldosteronism, mineralocorticoid excess can be caused by congenital adrenal hyperplasia (CAH) due to mutations of the 11beta-hydroxylase and 17alpha-hydroxylase genes, by inactivating mutations of the glucocorticoid receptor gene (Chrousos syndrome), endogenous hypercortisolism (Cushing's syndrome), by mutations of the 11beta-hydroxysteroid dehydrogenase type 2 gene (apparent mineralocorticoid excess/AME) or licorice/carbenoxolone intake, mutations of the epithelial sodium channel genes (Liddle syndrome), mutations of the mineralocorticoid receptor gene (Geller syndrome), and by mutations in the WNK1, WNK4, KLHL3, CUL3 genes (pseudohypoaldosteronism type 2 or Gordon syndrome).
p3713
sg4
(lp3714
(dp3715
g7
I340
sg8
VP49366
p3716
sg10
I47
sg11
V11beta-hydroxysteroid dehydrogenase type 2 gene
p3717
sg13
I5
sa(dp3718
g7
I220
sg8
VP04150
p3719
sg10
I28
sg11
Vglucocorticoid receptor gene
p3720
sg13
I3
sa(dp3721
g7
I641
sg8
g47
sg10
I10
sg11
VCUL3 genes
p3722
sg13
I2
sa(dp3723
g7
I622
sg8
g47
sg10
I4
sg11
VWNK1
p3724
sg13
I1
sa(dp3725
g7
I160
sg8
VP01893
p3726
sg10
I25
sg11
V17alpha-hydroxylase genes
p3727
sg13
I2
sa(dp3728
g7
I547
sg8
VP08235
p3729
sg10
I31
sg11
Vmineralocorticoid receptor gene
p3730
sg13
I3
sa(dp3731
g7
I634
sg8
g47
sg10
I5
sg11
VKLHL3
p3732
sg13
I1
sa(dp3733
g7
I628
sg8
g47
sg10
I4
sg11
VWNK4
p3734
sg13
I1
sa(dp3735
g7
I479
sg8
VP12830
p3736
sg10
I31
sg11
Vepithelial sodium channel genes
p3737
sg13
I4
sasg17
(lp3738
(dp3739
g7
I11
sg20
VC1384514
p3740
sg10
I21
sg11
Vprimary aldosteronism
p3741
sg13
I2
sa(dp3742
g7
I259
sg20
VC0039082
p3743
sg10
I8
sg11
Vsyndrome
p3744
sg13
I1
sa(dp3745
g7
I281
sg20
VC0010481
p3746
sg10
I16
sg11
Vhypercortisolism
p3747
sg13
I1
sa(dp3748
g7
I259
sg20
VC0039082
p3749
sg10
I8
sg11
Vsyndrome
p3750
sg13
I1
sa(dp3751
g7
I76
sg20
VC0001627
p3752
sg10
I30
sg11
Vcongenital adrenal hyperplasia
p3753
sg13
I3
sa(dp3754
g7
I687
sg20
VC0220666
p3755
sg10
I15
sg11
VGordon syndrome
p3756
sg13
I2
sa(dp3757
g7
I299
sg20
VC0010481
p3758
sg10
I18
sg11
VCushing's syndrome
p3759
sg13
I2
sa(dp3760
g7
I108
sg20
VC0520463
p3761
sg10
I3
sg11
VCAH
p3762
sg13
I1
sa(dp3763
g7
I389
sg20
VC2936861
p3764
sg10
I33
sg11
Vapparent mineralocorticoid excess
p3765
sg13
I3
sa(dp3766
g7
I512
sg20
VC0221043
p3767
sg10
I15
sg11
VLiddle syndrome
p3768
sg13
I2
sa(dp3769
g7
I653
sg20
VC1449844
p3770
sg10
I30
sg11
Vpseudohypoaldosteronism type 2
p3771
sg13
I3
sasa(dp3772
g2
VWe provide an overview and diagnostic approach to apparent mineralocorticoid excess, glucocorticoid remediable aldosteronism, familial hyperaldosteronism type 2, Liddle's syndrome, Gordon's syndrome, activating mutations of the mineralocorticoid receptor, generalized glucocorticoid resistance and hypertensive forms of congenital adrenal hyperplasia.
p3773
sg4
(lp3774
sg17
(lp3775
(dp3776
g7
I181
sg20
VC0220666
p3777
sg10
I17
sg11
VGordon's syndrome
p3778
sg13
I2
sa(dp3779
g7
I162
sg20
VC0221043
p3780
sg10
I17
sg11
VLiddle's syndrome
p3781
sg13
I2
sa(dp3782
g7
I320
sg20
VC0001627
p3783
sg10
I30
sg11
Vcongenital adrenal hyperplasia
p3784
sg13
I3
sa(dp3785
g7
I135
sg20
VC0020428
p3786
sg10
I18
sg11
Vhyperaldosteronism
p3787
sg13
I1
sa(dp3788
g7
I268
sg20
VC1841971
p3789
sg10
I25
sg11
Vglucocorticoid resistance
p3790
sg13
I2
sa(dp3791
g7
I50
sg20
VC2936861
p3792
sg10
I33
sg11
Vapparent mineralocorticoid excess
p3793
sg13
I3
sa(dp3794
g7
I111
sg20
VC0020428
p3795
sg10
I13
sg11
Valdosteronism
p3796
sg13
I1
sasa(dp3797
g2
VAs chronic pancreatitis (CP) is characterized by tissue infiltration of inflammatory cells, fibrosis, pancreatic neuritis and severe pain, the roles of fractalkine and CX3CR1 were investigated in CP (n=61) and normal pancreas (NP, n=21) by QRT-PCR, western blot and immunohistochemistry analyses.
p3798
sg4
(lp3799
sg17
(lp3800
(dp3801
g7
I49
sg20
VC0332448
p3802
sg10
I19
sg11
Vtissue infiltration
p3803
sg13
I2
sa(dp3804
g7
I92
sg20
VC0016059
p3805
sg10
I8
sg11
Vfibrosis
p3806
sg13
I1
sa(dp3807
g7
I126
sg20
VC0278140
p3808
sg10
I11
sg11
Vsevere pain
p3809
sg13
I2
sa(dp3810
g7
I113
sg20
VC0027813
p3811
sg10
I8
sg11
Vneuritis
p3812
sg13
I1
sa(dp3813
g7
I3
sg20
VC0149521
p3814
sg10
I20
sg11
Vchronic pancreatitis
p3815
sg13
I2
sa(dp3816
g7
I25
sg20
VC0149521
p3817
sg10
I2
sg11
VCP
p3818
sg13
I1
sa(dp3819
g7
I25
sg20
VC0149521
p3820
sg10
I2
sg11
VCP
p3821
sg13
I1
sasa(dp3822
g2
VNeuro-immunoreactivity for fractalkine and CX3CR1 was strongest in patients suffering from severe pain and pancreatic neuritis.
p3823
sg4
(lp3824
(dp3825
g7
I43
sg8
VP78423
p3826
sg10
I6
sg11
VCX3CR1
p3827
sg13
I1
sasg17
(lp3828
(dp3829
g7
I76
sg20
VC0683278
p3830
sg10
I9
sg11
Vsuffering
p3831
sg13
I1
sa(dp3832
g7
I91
sg20
VC0278140
p3833
sg10
I11
sg11
Vsevere pain
p3834
sg13
I2
sa(dp3835
g7
I118
sg20
VC0027813
p3836
sg10
I8
sg11
Vneuritis
p3837
sg13
I1
sasa(dp3838
g2
VOur data suggest that CRISPR/Cas9-mediated NRL disruption in rods may be a promising treatment option for patients with retinitis pigmentosa.
p3839
sg4
(lp3840
sg17
(lp3841
(dp3842
g7
I120
sg20
VC0035334
p3843
sg10
I20
sg11
Vretinitis pigmentosa
p3844
sg13
I2
sasa(dp3845
g2
VThe index patients were homozygotes for both a dominant mutation of the PABPN1 gene, (GCN)13, and a recessive mutation of the NRL gene, p.R31X, on chromosome 14q11.1, leading to early-onset OPMD accompanied by night blindness and reduced visual acuity.
p3846
sg4
(lp3847
(dp3848
g7
I126
sg8
VP54845
p3849
sg10
I8
sg11
VNRL gene
p3850
sg13
I2
sa(dp3851
g7
I72
sg8
g47
sg10
I11
sg11
VPABPN1 gene
p3852
sg13
I2
sasg17
(lp3853
(dp3854
g7
I210
sg20
VC0028077
p3855
sg10
I15
sg11
Vnight blindness
p3856
sg13
I2
sa(dp3857
g7
I190
sg20
VC0270952
p3858
sg10
I4
sg11
VOPMD
p3859
sg13
I1
sasa(dp3860
g2
VHomozygosity for the recessive NRL mutation described here appears to be associated with a distinct retinal phenotype, demonstrating ERG characteristics similar to those of ESCS patients.
p3861
sg4
(lp3862
(dp3863
g7
I31
sg8
VP54845
p3864
sg10
I12
sg11
VNRL mutation
p3865
sg13
I2
sasg17
(lp3866
(dp3867
g7
I173
sg20
VC1849394
p3868
sg10
I4
sg11
VESCS
p3869
sg13
I1
sasa(dp3870
g2
VThis report expands the spectrum of NRL recessive mutations, as well as the genetic spectrum of ESCS, and indicates a new syndrome of OPMD with an ESCS-like phenotype.
p3871
sg4
(lp3872
(dp3873
g7
I96
sg8
g47
sg10
I4
sg11
VESCS
p3874
sg13
I1
sa(dp3875
g7
I36
sg8
VP54845
p3876
sg10
I3
sg11
VNRL
p3877
sg13
I1
sa(dp3878
g7
I147
sg8
g47
sg10
I9
sg11
VESCS-like
p3879
sg13
I1
sasg17
(lp3880
(dp3881
g7
I96
sg20
VC1849394
p3882
sg10
I4
sg11
VESCS
p3883
sg13
I1
sa(dp3884
g7
I122
sg20
VC0039082
p3885
sg10
I8
sg11
Vsyndrome
p3886
sg13
I1
sa(dp3887
g7
I96
sg20
VC1849394
p3888
sg10
I4
sg11
VESCS
p3889
sg13
I1
sa(dp3890
g7
I134
sg20
VC0270952
p3891
sg10
I4
sg11
VOPMD
p3892
sg13
I1
sasa(dp3893
g2
VBlue light exposure of the R91W;Nrl(-/-) mouse could therefore be used to study molecular events preceding edema formation in a cone-rich environment, and thus potentially help to develop treatment strategies for edema-based complications in macular degenerations.
p3894
sg4
(lp3895
(dp3896
g7
I32
sg8
VP54845
p3897
sg10
I8
sg11
VNrl(-/-)
p3898
sg13
I1
sasg17
(lp3899
(dp3900
g7
I107
sg20
VC0013604
p3901
sg10
I5
sg11
Vedema
p3902
sg13
I1
sa(dp3903
g7
I242
sg20
VC0242383
p3904
sg10
I21
sg11
Vmacular degenerations
p3905
sg13
I2
sa(dp3906
g7
I107
sg20
VC0013604
p3907
sg10
I5
sg11
Vedema
p3908
sg13
I1
sasa(dp3909
g2
VCXCL6 and CXCL2 enhanced angiogenesis by HUVECs when cultured with fibroblast cells and colon cancer cells (P &lt; 0.01).
p3910
sg4
(lp3911
(dp3912
g7
I0
sg8
VP80162
p3913
sg10
I5
sg11
VCXCL6
p3914
sg13
I1
sa(dp3915
g7
I10
sg8
VP19875
p3916
sg10
I5
sg11
VCXCL2
p3917
sg13
I1
sasg17
(lp3918
(dp3919
g7
I88
sg20
VC0699790
p3920
sg10
I12
sg11
Vcolon cancer
p3921
sg13
I2
sasa(dp3922
g2
VAfter quality and quantity measurements, gene expression analysis of a colorectal cancer-specific marker set with 11 genes (CA7, COL12A1, CXCL1, CXCL2, CHI3L1, GREM1, IL1B, IL1RN, IL8, MMP3, SLC5A7) was performed with array real-time PCR using Transcriptor First Strand cDNA Synthesis Kit (Roche) and RealTime ready assays on LightCycler480 System (Roche).
p3923
sg4
(lp3924
(dp3925
g7
I167
sg8
VP01584
p3926
sg10
I4
sg11
VIL1B
p3927
sg13
I1
sa(dp3928
g7
I173
sg8
VP18510
p3929
sg10
I5
sg11
VIL1RN
p3930
sg13
I1
sa(dp3931
g7
I152
sg8
VP36222
p3932
sg10
I6
sg11
VCHI3L1
p3933
sg13
I1
sa(dp3934
g7
I160
sg8
g47
sg10
I5
sg11
VGREM1
p3935
sg13
I1
sa(dp3936
g7
I124
sg8
VP43166
p3937
sg10
I3
sg11
VCA7
p3938
sg13
I1
sa(dp3939
g7
I138
sg8
VP09341
p3940
sg10
I5
sg11
VCXCL1
p3941
sg13
I1
sa(dp3942
g7
I185
sg8
VP08254
p3943
sg10
I4
sg11
VMMP3
p3944
sg13
I1
sa(dp3945
g7
I145
sg8
VP19875
p3946
sg10
I5
sg11
VCXCL2
p3947
sg13
I1
sa(dp3948
g7
I129
sg8
g47
sg10
I7
sg11
VCOL12A1
p3949
sg13
I1
sa(dp3950
g7
I191
sg8
g47
sg10
I6
sg11
VSLC5A7
p3951
sg13
I1
sasg17
(lp3952
(dp3953
g7
I71
sg20
VC1527249
p3954
sg10
I17
sg11
Vcolorectal cancer
p3955
sg13
I2
sasa(dp3956
g2
VThese observations indicate a crucial role for TANs in the initiation and progression of CAC and suggest that the CXCL2-CXCR2 axis might be useful in reducing the risk of UC-associated colon cancer.
p3957
sg4
(lp3958
(dp3959
g7
I120
sg8
VP25025
p3960
sg10
I5
sg11
VCXCR2
p3961
sg13
I1
sa(dp3962
g7
I114
sg8
VP19875
p3963
sg10
I5
sg11
VCXCL2
p3964
sg13
I1
sasg17
(lp3965
(dp3966
g7
I185
sg20
VC0699790
p3967
sg10
I12
sg11
Vcolon cancer
p3968
sg13
I2
sasa(dp3969
g2
VGene expression analysis of a colorectal cancer-specific marker set (with 7 genes: COL12A1, CXCL1, CXCL2, GREM1, IL1B, IL8, SLC7A5) was performed with array real-time PCR using Transcriptor First Strand cDNA Synthesis Kit (Roche) and RealTime ready assays on LightCycler(R) 480 System (Roche).
p3970
sg4
(lp3971
(dp3972
g7
I99
sg8
VP19875
p3973
sg10
I5
sg11
VCXCL2
p3974
sg13
I1
sa(dp3975
g7
I83
sg8
g47
sg10
I7
sg11
VCOL12A1
p3976
sg13
I1
sa(dp3977
g7
I124
sg8
g47
sg10
I6
sg11
VSLC7A5
p3978
sg13
I1
sa(dp3979
g7
I113
sg8
VP01584
p3980
sg10
I4
sg11
VIL1B
p3981
sg13
I1
sa(dp3982
g7
I92
sg8
VP09341
p3983
sg10
I5
sg11
VCXCL1
p3984
sg13
I1
sa(dp3985
g7
I106
sg8
g47
sg10
I5
sg11
VGREM1
p3986
sg13
I1
sasg17
(lp3987
(dp3988
g7
I30
sg20
VC1527249
p3989
sg10
I17
sg11
Vcolorectal cancer
p3990
sg13
I2
sasa(dp3991
g2
VIt is approved for use in all indications for which reference etanercept is approved, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis and paediatric plaque psoriasis.
p3992
sg4
(lp3993
sg17
(lp3994
(dp3995
g7
I211
sg20
VC3203547
p3996
sg10
I23
sg11
Vaxial spondyloarthritis
p3997
sg13
I2
sa(dp3998
g7
I236
sg20
VC0406317
p3999
sg10
I16
sg11
Vplaque psoriasis
p4000
sg13
I2
sa(dp4001
g7
I107
sg20
VC0003864
p4002
sg10
I9
sg11
Varthritis
p4003
sg13
I1
sa(dp4004
g7
I236
sg20
VC0406317
p4005
sg10
I16
sg11
Vplaque psoriasis
p4006
sg13
I2
sa(dp4007
g7
I107
sg20
VC0553662
p4008
sg10
I30
sg11
Varthritis, juvenile idiopathic
p4009
sg13
I3
sa(dp4010
g7
I138
sg20
VC0003872
p4011
sg10
I20
sg11
Varthritis, psoriatic
p4012
sg13
I2
sa(dp4013
g7
I170
sg20
VC0038013
p4014
sg10
I22
sg11
Vankylosing spondylitis
p4015
sg13
I2
sasa(dp4016
g2
VWe describe the case of a boy with a TUBA1A mutation presenting with microphthalmia and congenital cataracts in addition to microcephaly and severe brain malformation.
p4017
sg4
(lp4018
(dp4019
g7
I37
sg8
g47
sg10
I6
sg11
VTUBA1A
p4020
sg13
I1
sasg17
(lp4021
(dp4022
g7
I69
sg20
VC0026010
p4023
sg10
I14
sg11
Vmicrophthalmia
p4024
sg13
I1
sa(dp4025
g7
I148
sg20
VC0266449
p4026
sg10
I18
sg11
Vbrain malformation
p4027
sg13
I2
sa(dp4028
g7
I88
sg20
VC0009691
p4029
sg10
I20
sg11
Vcongenital cataracts
p4030
sg13
I2
sa(dp4031
g7
I124
sg20
VC0025958
p4032
sg10
I12
sg11
Vmicrocephaly
p4033
sg13
I1
sasa(dp4034
g2
VWe previously showed that Decorin--a leucine-rich proteoglycan inhibiting the progression of glomerulonephritis and glomerular sclerosis--can be degraded by the ubiquitin-proteasome pathway and deubiquitinated and stabilized by ubiquitin-specific processing protease 2-69(Usp2-69).
p4035
sg4
(lp4036
(dp4037
g7
I26
sg8
VP07585
p4038
sg10
I7
sg11
VDecorin
p4039
sg13
I1
sa(dp4040
g7
I161
sg8
VP62979
p4041
sg10
I9
sg11
Vubiquitin
p4042
sg13
I1
sa(dp4043
g7
I228
sg8
g47
sg10
I43
sg11
Vubiquitin-specific processing protease 2-69
p4044
sg13
I4
sa(dp4045
g7
I272
sg8
g47
sg10
I7
sg11
VUsp2-69
p4046
sg13
I1
sasg17
(lp4047
(dp4048
g7
I116
sg20
VC0178664
p4049
sg10
I20
sg11
Vglomerular sclerosis
p4050
sg13
I2
sa(dp4051
g7
I93
sg20
VC0017658
p4052
sg10
I18
sg11
Vglomerulonephritis
p4053
sg13
I1
sasa(dp4054
g2
VHere, we explored the effect of Usp2-69 on MC proliferation and ECM deposition by transfecting Usp2-69 plasmid into rat anti-Thy1.1 nephritis model and into cultured MCs, as well as detected Usp2-69 and Decorin in rat anti-Thy1.1 nephritis model by western blot.
p4055
sg4
(lp4056
(dp4057
g7
I32
sg8
g47
sg10
I7
sg11
VUsp2-69
p4058
sg13
I1
sa(dp4059
g7
I32
sg8
g47
sg10
I7
sg11
VUsp2-69
p4060
sg13
I1
sa(dp4061
g7
I116
sg8
VP04216
p4062
sg10
I13
sg11
Vrat anti-Thy1
p4063
sg13
I2
sa(dp4064
g7
I203
sg8
VP07585
p4065
sg10
I7
sg11
VDecorin
p4066
sg13
I1
sa(dp4067
g7
I32
sg8
g47
sg10
I7
sg11
VUsp2-69
p4068
sg13
I1
sasg17
(lp4069
(dp4070
g7
I166
sg20
VC0036221
p4071
sg10
I3
sg11
VMCs
p4072
sg13
I1
sa(dp4073
g7
I132
sg20
VC0027697
p4074
sg10
I9
sg11
Vnephritis
p4075
sg13
I1
sa(dp4076
g7
I46
sg20
VC0334094
p4077
sg10
I13
sg11
Vproliferation
p4078
sg13
I1
sa(dp4079
g7
I132
sg20
VC0027697
p4080
sg10
I9
sg11
Vnephritis
p4081
sg13
I1
sasa(dp4082
g2
VOverexpressing Usp2-69 at the early stage, but not advanced stage, of anti-Thy1.1 nephritis alleviated cell proliferation and ECM deposition, which was shown by decreased Ki-67, Collagen IV and Fibronectin detected by immunohistochemistry.
p4083
sg4
(lp4084
(dp4085
g7
I15
sg8
g47
sg10
I7
sg11
VUsp2-69
p4086
sg13
I1
sa(dp4087
g7
I171
sg8
VP46013
p4088
sg10
I5
sg11
VKi-67
p4089
sg13
I1
sa(dp4090
g7
I70
sg8
VP04216
p4091
sg10
I11
sg11
Vanti-Thy1.1
p4092
sg13
I1
sasg17
(lp4093
(dp4094
g7
I82
sg20
VC0027697
p4095
sg10
I9
sg11
Vnephritis
p4096
sg13
I1
sa(dp4097
g7
I108
sg20
VC0334094
p4098
sg10
I13
sg11
Vproliferation
p4099
sg13
I1
sasa(dp4100
g2
VIn conclusion, our findings suggest that Usp2-69 overexpression alleviates the progression of rat anti-Thy1.1 nephritis and, therefore, that exogenous plasmid injection via the renal artery enhanced by electrotransfer technology could be a promising avenue for glomerular disease research.
p4101
sg4
(lp4102
(dp4103
g7
I94
sg8
VP04216
p4104
sg10
I15
sg11
Vrat anti-Thy1.1
p4105
sg13
I2
sa(dp4106
g7
I41
sg8
g47
sg10
I7
sg11
VUsp2-69
p4107
sg13
I1
sasg17
(lp4108
(dp4109
g7
I261
sg20
VC0268731
p4110
sg10
I18
sg11
Vglomerular disease
p4111
sg13
I2
sa(dp4112
g7
I110
sg20
VC0027697
p4113
sg10
I9
sg11
Vnephritis
p4114
sg13
I1
sasa(dp4115
g2
VThe proportion of USP2-69 positive area in the glomeruli was 3.90% in normal kidney, 4.96% in minimal change disease, and 4.39% in membranous glomerulonephritides, while it was 14.84% in IgA nephropathy (IgAN) (mesangial proliferative type), 16.18% in lupus nephritis (LN; diffuse proliferative type) and 15.54% in acute proliferative glomerulonephritides (APGN); the difference of the percentages between IgAN, LN (IV subtype) and APGN and normal kidney were statistically significant (P &lt; 0.05).
p4116
sg4
(lp4117
(dp4118
g7
I187
sg8
VP11912
p4119
sg10
I15
sg11
VIgA nephropathy
p4120
sg13
I2
sa(dp4121
g7
I204
sg8
VP11912
p4122
sg10
I4
sg11
VIgAN
p4123
sg13
I1
sa(dp4124
g7
I18
sg8
g47
sg10
I7
sg11
VUSP2-69
p4125
sg13
I1
sa(dp4126
g7
I204
sg8
VP11912
p4127
sg10
I4
sg11
VIgAN
p4128
sg13
I1
sasg17
(lp4129
(dp4130
g7
I187
sg20
VC0017661
p4131
sg10
I15
sg11
VIgA nephropathy
p4132
sg13
I2
sa(dp4133
g7
I269
sg20
VC0024143
p4134
sg10
I2
sg11
VLN
p4135
sg13
I1
sa(dp4136
g7
I357
sg20
VC0017658
p4137
sg10
I4
sg11
VAPGN
p4138
sg13
I1
sa(dp4139
g7
I221
sg20
VC0334094
p4140
sg10
I13
sg11
Vproliferative
p4141
sg13
I1
sa(dp4142
g7
I269
sg20
VC0024143
p4143
sg10
I2
sg11
VLN
p4144
sg13
I1
sa(dp4145
g7
I131
sg20
VC0017665
p4146
sg10
I31
sg11
Vmembranous glomerulonephritides
p4147
sg13
I2
sa(dp4148
g7
I252
sg20
VC0024143
p4149
sg10
I15
sg11
Vlupus nephritis
p4150
sg13
I2
sa(dp4151
g7
I204
sg20
VC0017661
p4152
sg10
I4
sg11
VIgAN
p4153
sg13
I1
sa(dp4154
g7
I315
sg20
VC0017658
p4155
sg10
I40
sg11
Vacute proliferative glomerulonephritides
p4156
sg13
I3
sa(dp4157
g7
I357
sg20
VC0017658
p4158
sg10
I4
sg11
VAPGN
p4159
sg13
I1
sa(dp4160
g7
I221
sg20
VC0334094
p4161
sg10
I13
sg11
Vproliferative
p4162
sg13
I1
sa(dp4163
g7
I204
sg20
VC0017661
p4164
sg10
I4
sg11
VIgAN
p4165
sg13
I1
sa(dp4166
g7
I94
sg20
VC1704320
p4167
sg10
I22
sg11
Vminimal change disease
p4168
sg13
I3
sasa(dp4169
g2
VWe analysed surviving human SN DA neurons from patients with Parkinson's disease and from controls, and detected elevated messenger RNA levels of D2-autoreceptors and GIRK2 in Parkinson's disease.
p4170
sg4
(lp4171
(dp4172
g7
I167
sg8
VP48051
p4173
sg10
I5
sg11
VGIRK2
p4174
sg13
I1
sasg17
(lp4175
(dp4176
g7
I61
sg20
VC0030567
p4177
sg10
I19
sg11
VParkinson's disease
p4178
sg13
I2
sa(dp4179
g7
I61
sg20
VC0030567
p4180
sg10
I19
sg11
VParkinson's disease
p4181
sg13
I2
sasa(dp4182
g2
VThus, our findings provide a novel homeostatic functional link in SN DA neurons between Cav1.3- L-type-Ca(2+) channels and D2-autoreceptor activity, controlled by NCS-1, and indicate that this adaptive signalling network (Cav1.3/NCS-1/D2/GIRK2) is also active in human SN DA neurons, and contributes to Parkinson's disease pathology.
p4183
sg4
(lp4184
(dp4185
g7
I88
sg8
g47
sg10
I9
sg11
VCav1.3- L
p4186
sg13
I2
sa(dp4187
g7
I222
sg8
VP62166
p4188
sg10
I12
sg11
VCav1.3/NCS-1
p4189
sg13
I1
sa(dp4190
g7
I238
sg8
VP48051
p4191
sg10
I5
sg11
VGIRK2
p4192
sg13
I1
sasg17
(lp4193
(dp4194
g7
I323
sg20
VC0677042
p4195
sg10
I9
sg11
Vpathology
p4196
sg13
I1
sa(dp4197
g7
I303
sg20
VC0030567
p4198
sg10
I19
sg11
VParkinson's disease
p4199
sg13
I2
sasa(dp4200
g2
VIn conclusion, sera from AIH-1 patients reacted with the amino acids in the sequence 33-37 (PQDGS) of the N-terminal of UGT1A6.
p4201
sg4
(lp4202
(dp4203
g7
I120
sg8
VP35504
p4204
sg10
I6
sg11
VUGT1A6
p4205
sg13
I1
sasg17
(lp4206
sa(dp4207
g2
VSeveral proapoptotic genes (AKT1 and AKT2) were down-regulated and antiapoptotic genes (APAF1 and BCL2L1) were up-regulated in multiple myeloma, both symptomatic and asymptomatic, compared to monoclonal gammopathy of undetermined significance.
p4208
sg4
(lp4209
(dp4210
g7
I98
sg8
g47
sg10
I6
sg11
VBCL2L1
p4211
sg13
I1
sa(dp4212
g7
I37
sg8
VP31751
p4213
sg10
I4
sg11
VAKT2
p4214
sg13
I1
sa(dp4215
g7
I28
sg8
VP31749
p4216
sg10
I4
sg11
VAKT1
p4217
sg13
I1
sasg17
(lp4218
(dp4219
g7
I192
sg20
VC0026470
p4220
sg10
I50
sg11
Vmonoclonal gammopathy of undetermined significance
p4221
sg13
I5
sa(dp4222
g7
I127
sg20
VC0026764
p4223
sg10
I16
sg11
Vmultiple myeloma
p4224
sg13
I2
sasa(dp4225
g2
VTo study the role of gene promoter hypermethylation of the putative tumour suppressor genes involved in the death-associated protein (DAP) kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma (MM).
p4226
sg4
(lp4227
(dp4228
g7
I155
sg8
VP42771
p4229
sg10
I3
sg11
Vp53
p4230
sg13
I1
sa(dp4231
g7
I134
sg8
VP51397
p4232
sg10
I3
sg11
VDAP
p4233
sg13
I1
sa(dp4234
g7
I108
sg8
VP51397
p4235
sg10
I24
sg11
Vdeath-associated protein
p4236
sg13
I2
sa(dp4237
g7
I146
sg8
VP03971
p4238
sg10
I3
sg11
Vp14
p4239
sg13
I1
sasg17
(lp4240
(dp4241
g7
I187
sg20
VC0026764
p4242
sg10
I16
sg11
Vmultiple myeloma
p4243
sg13
I2
sa(dp4244
g7
I68
sg20
VC0027651
p4245
sg10
I6
sg11
Vtumour
p4246
sg13
I1
sasa(dp4247
g2
VThe other was a spermatocytic seminoma with focal primitive neuroectodermal differentiation: formation of Homer-Wright rosettes and perivascular pseudorosettes, with immunoreactivity for S-100 protein, neuron-specific enolase, synaptophysin, neurofilament-68 kDa, microtubule-associated protein 2, and vimentin.
p4248
sg4
(lp4249
(dp4250
g7
I264
sg8
VP11137
p4251
sg10
I32
sg11
Vmicrotubule-associated protein 2
p4252
sg13
I3
sa(dp4253
g7
I187
sg8
VP04271
p4254
sg10
I13
sg11
VS-100 protein
p4255
sg13
I2
sa(dp4256
g7
I202
sg8
VP09104
p4257
sg10
I23
sg11
Vneuron-specific enolase
p4258
sg13
I2
sa(dp4259
g7
I227
sg8
VP08247
p4260
sg10
I13
sg11
Vsynaptophysin
p4261
sg13
I1
sasg17
(lp4262
(dp4263
g7
I16
sg20
VC0334517
p4264
sg10
I22
sg11
Vspermatocytic seminoma
p4265
sg13
I2
sasa(dp4266
g2
VIn addition to Rett syndrome and breast/ovarian cancer observed in other studies, we report evidence for the first time, to our knowledge, that overexpression of ubiquinol-cytochrome c reductase core protein I might affect mitochondrial morphology and/or physiology and lead to development of obesity and related conditions.
p4267
sg4
(lp4268
(dp4269
g7
I162
sg8
VP99999
p4270
sg10
I47
sg11
Vubiquinol-cytochrome c reductase core protein I
p4271
sg13
I6
sasg17
(lp4272
(dp4273
g7
I293
sg20
VC0028754
p4274
sg10
I7
sg11
Vobesity
p4275
sg13
I1
sa(dp4276
g7
I15
sg20
VC0035372
p4277
sg10
I13
sg11
VRett syndrome
p4278
sg13
I2
sa(dp4279
g7
I40
sg20
VC1140680
p4280
sg10
I14
sg11
Vovarian cancer
p4281
sg13
I2
sasa(dp4282
g2
VFrom the therapeutic standpoint, colitis-associated cancers are associated with a lower prevalence of KRAS mutations than the sporadic variant.
p4283
sg4
(lp4284
(dp4285
g7
I102
sg8
VP01116
p4286
sg10
I4
sg11
VKRAS
p4287
sg13
I1
sasg17
(lp4288
(dp4289
g7
I33
sg20
VC0009319
p4290
sg10
I7
sg11
Vcolitis
p4291
sg13
I1
sa(dp4292
g7
I52
sg20
VC0006826
p4293
sg10
I7
sg11
Vcancers
p4294
sg13
I1
sasa(dp4295
g2
VIn a murine acute systemic candidiasis model, C albicans strongly stimulated hepcidin, accompanied by a major reduction in transferrin saturation.
p4296
sg4
(lp4297
(dp4298
g7
I123
sg8
VP02787
p4299
sg10
I11
sg11
Vtransferrin
p4300
sg13
I1
sasg17
(lp4301
(dp4302
g7
I18
sg20
VC0153252
p4303
sg10
I20
sg11
Vsystemic candidiasis
p4304
sg13
I2
sasa(dp4305
g2
VOn the other hand, iron overload (iron saturated transferrin) is a serious risk factor for candidiasis in newborn and in leukemic patients.
p4306
sg4
(lp4307
(dp4308
g7
I49
sg8
VP02787
p4309
sg10
I11
sg11
Vtransferrin
p4310
sg13
I1
sasg17
(lp4311
(dp4312
g7
I19
sg20
VC0282193
p4313
sg10
I13
sg11
Viron overload
p4314
sg13
I2
sa(dp4315
g7
I91
sg20
VC0006840
p4316
sg10
I11
sg11
Vcandidiasis
p4317
sg13
I1
sasa(dp4318
g2
VIt has been suggested that blockade of the Na+/H+ exchanger (NHE1) can prevent atrial fibrillation (AF)-induced electrical remodeling and the development of AF.
p4319
sg4
(lp4320
(dp4321
g7
I61
sg8
VP19634
p4322
sg10
I4
sg11
VNHE1
p4323
sg13
I1
sasg17
(lp4324
(dp4325
g7
I79
sg20
VC0004238
p4326
sg10
I19
sg11
Vatrial fibrillation
p4327
sg13
I2
sa(dp4328
g7
I100
sg20
VC0232197
p4329
sg10
I2
sg11
VAF
p4330
sg13
I1
sa(dp4331
g7
I100
sg20
VC0232197
p4332
sg10
I2
sg11
VAF
p4333
sg13
I1
sasa(dp4334
g2
VThe case of a 13-year-old boy is presented and the diagnostic process discussed especially the differentiation between trance states and epilepsy.
p4335
sg4
(lp4336
sg17
(lp4337
(dp4338
g7
I137
sg20
VC0014544
p4339
sg10
I8
sg11
Vepilepsy
p4340
sg13
I1
sa(dp4341
g7
I119
sg20
VC0855240
p4342
sg10
I6
sg11
Vtrance
p4343
sg13
I1
sasa(dp4344
g2
VThe phenotype is usually T-B+NK+ SCID with lymphopenia where the clinical findings may be mild (CD3Gamma) or severe (CD3Delta, Epsilon, Zeta) owing to the underlying molecular defect.
p4345
sg4
(lp4346
(dp4347
g7
I25
sg8
VP31785
p4348
sg10
I12
sg11
VT-B+NK+ SCID
p4349
sg13
I2
sasg17
(lp4350
(dp4351
g7
I43
sg20
VC0024312
p4352
sg10
I11
sg11
Vlymphopenia
p4353
sg13
I1
sa(dp4354
g7
I65
sg20
VC0037088
p4355
sg10
I17
sg11
Vclinical findings
p4356
sg13
I2
sa(dp4357
g7
I33
sg20
VC0085110
p4358
sg10
I4
sg11
VSCID
p4359
sg13
I1
sasa(dp4360
g2
VIn contrast, all reported human complete CD3delta (or CD3epsilon) deficiencies are in infants with life-threatening SCID and very severe alphabeta and gammadelta T lymphocytopenia.
p4361
sg4
(lp4362
sg17
(lp4363
(dp4364
g7
I116
sg20
VC0085110
p4365
sg10
I4
sg11
VSCID
p4366
sg13
I1
sa(dp4367
g7
I164
sg20
VC0024312
p4368
sg10
I15
sg11
Vlymphocytopenia
p4369
sg13
I1
sasa(dp4370
g2
VAlthough clozapine, olanzapine, and other atypical antipsychotic drugs (APDs) have fewer extrapyramidal side effects, they have serious metabolic side effects such as substantial weight gain, intra-abdominal obesity, and type 2 diabetes mellitus.
p4371
sg4
(lp4372
sg17
(lp4373
(dp4374
g7
I221
sg20
VC0011860
p4375
sg10
I24
sg11
Vtype 2 diabetes mellitus
p4376
sg13
I4
sa(dp4377
g7
I198
sg20
VC0311277
p4378
sg10
I17
sg11
Vabdominal obesity
p4379
sg13
I2
sasa(dp4380
g2
VGiven that most patients with mental disorders face chronic, even life-long, treatment with APDs, the risks of weight gain/obesity and other metabolic symptoms are major considerations for APD maintenance treatment.
p4381
sg4
(lp4382
sg17
(lp4383
(dp4384
g7
I141
sg20
VC0476237
p4385
sg10
I18
sg11
Vmetabolic symptoms
p4386
sg13
I2
sa(dp4387
g7
I47
sg20
VC3160739
p4388
sg10
I4
sg11
Vface
p4389
sg13
I1
sa(dp4390
g7
I30
sg20
VC0004936
p4391
sg10
I16
sg11
Vmental disorders
p4392
sg13
I2
sa(dp4393
g7
I123
sg20
VC0028754
p4394
sg10
I7
sg11
Vobesity
p4395
sg13
I1
sasa(dp4396
g2
VAlthough offering many benefits for several psychiatric disorders, antipsychotic drugs (APDs) as a class have a major liability in their tendency to promote adiposity, obesity, and metabolic dysregulation in an already metabolically vulnerable population.
p4397
sg4
(lp4398
sg17
(lp4399
(dp4400
g7
I168
sg20
VC0028754
p4401
sg10
I7
sg11
Vobesity
p4402
sg13
I1
sa(dp4403
g7
I44
sg20
VC0004936
p4404
sg10
I21
sg11
Vpsychiatric disorders
p4405
sg13
I2
sa(dp4406
g7
I157
sg20
VC0028754
p4407
sg10
I9
sg11
Vadiposity
p4408
sg13
I1
sasa(dp4409
g2
VTo describe the association between obesity and the use of antipsychotic drugs (APDs) in adult outpatients followed-up on in five Primary Care settings.
p4410
sg4
(lp4411
sg17
(lp4412
(dp4413
g7
I36
sg20
VC0028754
p4414
sg10
I7
sg11
Vobesity
p4415
sg13
I1
sasa(dp4416
g2
VObesity was associated with the use of APDs [OR = 1.5 (CI: 1.3-1.8)], hypertension [OR = 2.4 (CI: 2.2-2.5)], diabetes [OR = 1.4 (CI: 1.3-1.5)] and dyslipidemia [OR = 1.3 (CI: 1.2-1.4)], p &lt; 0.0001 in all cases.
p4417
sg4
(lp4418
sg17
(lp4419
(dp4420
g7
I0
sg20
VC0028754
p4421
sg10
I7
sg11
VObesity
p4422
sg13
I1
sa(dp4423
g7
I147
sg20
VC0242339
p4424
sg10
I12
sg11
Vdyslipidemia
p4425
sg13
I1
sa(dp4426
g7
I70
sg20
VC0020538
p4427
sg10
I12
sg11
Vhypertension
p4428
sg13
I1
sa(dp4429
g7
I109
sg20
VC0011849
p4430
sg10
I8
sg11
Vdiabetes
p4431
sg13
I1
sasa(dp4432
g2
VObesity was associated with the use of APDs, regardless of the type of drug, and with the presence of hypertension, diabetes and dyslipidemia.
p4433
sg4
(lp4434
sg17
(lp4435
(dp4436
g7
I0
sg20
VC0028754
p4437
sg10
I7
sg11
VObesity
p4438
sg13
I1
sa(dp4439
g7
I116
sg20
VC0011849
p4440
sg10
I8
sg11
Vdiabetes
p4441
sg13
I1
sa(dp4442
g7
I129
sg20
VC0242339
p4443
sg10
I12
sg11
Vdyslipidemia
p4444
sg13
I1
sa(dp4445
g7
I102
sg20
VC0020538
p4446
sg10
I12
sg11
Vhypertension
p4447
sg13
I1
sasa(dp4448
g2
VHigher DARs were associated with lower rates of moderate or severe paravalvular aortic regurgitation: DAR &lt;=10%, 17.6%; DAR 10% to 15%, 9.9%; DAR 15% to 20%, 6.3%; and DAR &gt;20%, 4.9%; P&lt;0.001.
p4449
sg4
(lp4450
(dp4451
g7
I7
sg8
VP14868
p4452
sg10
I4
sg11
VDARs
p4453
sg13
I1
sasg17
(lp4454
(dp4455
g7
I7
sg20
VC0022595
p4456
sg10
I3
sg11
VDAR
p4457
sg13
I1
sa(dp4458
g7
I7
sg20
VC0022595
p4459
sg10
I3
sg11
VDAR
p4460
sg13
I1
sa(dp4461
g7
I80
sg20
VC0003504
p4462
sg10
I20
sg11
Vaortic regurgitation
p4463
sg13
I2
sa(dp4464
g7
I7
sg20
VC0022595
p4465
sg10
I3
sg11
VDAR
p4466
sg13
I1
sa(dp4467
g7
I7
sg20
VC0022595
p4468
sg10
I3
sg11
VDAR
p4469
sg13
I1
sasa(dp4470
g2
VIn 1990, Hopkins and Ruiz-Riben stated that the target date o f the end o f 1995 for the eradication of dracunculiasis is unrealistic only if it is judged to be unimportant.
p4471
sg4
(lp4472
sg17
(lp4473
(dp4474
g7
I104
sg20
VC0013100
p4475
sg10
I14
sg11
Vdracunculiasis
p4476
sg13
I1
sasa(dp4477
g2
VDLL1 influence drug resistance of small cell lung cancer through activating transcription of downstream genes HES1 and HEY1.
p4478
sg4
(lp4479
(dp4480
g7
I119
sg8
g47
sg10
I4
sg11
VHEY1
p4481
sg13
I1
sa(dp4482
g7
I110
sg8
g47
sg10
I4
sg11
VHES1
p4483
sg13
I1
sa(dp4484
g7
I0
sg8
g47
sg10
I4
sg11
VDLL1
p4485
sg13
I1
sasg17
(lp4486
(dp4487
g7
I34
sg20
VC0149925
p4488
sg10
I22
sg11
Vsmall cell lung cancer
p4489
sg13
I4
sasa(dp4490
g2
VIn this study, we showed that a high percentage of lung cancer lines expressed Jagged1, Notch receptors, and their transcriptional target genes (HES1, Hey1), suggesting that the Notch pathway plays an important role in lung cancer biology.
p4491
sg4
(lp4492
(dp4493
g7
I145
sg8
g47
sg10
I4
sg11
VHES1
p4494
sg13
I1
sa(dp4495
g7
I79
sg8
VP78504
p4496
sg10
I7
sg11
VJagged1
p4497
sg13
I1
sa(dp4498
g7
I151
sg8
g47
sg10
I4
sg11
VHey1
p4499
sg13
I1
sa(dp4500
g7
I88
sg8
g47
sg10
I15
sg11
VNotch receptors
p4501
sg13
I2
sasg17
(lp4502
(dp4503
g7
I51
sg20
VC0684249
p4504
sg10
I11
sg11
Vlung cancer
p4505
sg13
I2
sa(dp4506
g7
I51
sg20
VC0684249
p4507
sg10
I11
sg11
Vlung cancer
p4508
sg13
I2
sasa(dp4509
g2
VALPs easily insert in the outer leaflet of the plasma membrane and cross the membrane via an ATP-dependent CDC50a-containing 'flippase' complex (in carcinoma cells), or are internalized by lipid raft-dependent endocytosis (in lymphoma/leukemic cells).
p4510
sg4
(lp4511
(dp4512
g7
I107
sg8
g47
sg10
I6
sg11
VCDC50a
p4513
sg13
I1
sa(dp4514
g7
I125
sg8
VP98196
p4515
sg10
I9
sg11
V'flippase
p4516
sg13
I1
sa(dp4517
g7
I0
sg8
VP03973
p4518
sg10
I4
sg11
VALPs
p4519
sg13
I1
sasg17
(lp4520
(dp4521
g7
I148
sg20
VC0007097
p4522
sg10
I9
sg11
Vcarcinoma
p4523
sg13
I1
sa(dp4524
g7
I226
sg20
VC0024299
p4525
sg10
I8
sg11
Vlymphoma
p4526
sg13
I1
sa(dp4527
g7
I0
sg20
VC1328840
p4528
sg10
I4
sg11
VALPs
p4529
sg13
I1
sasa(dp4530
g2
VLevels of 27 transcripts were investigated as potential novel markers for prostate cancer, including genes encoding plasma membrane proteins (ADAM2, ELOVL5, MARCKSL1, RAMP1, TMEM30A, and TMEM66); secreted proteins (SPON2, TMEM30A, TMEM66, and truncated TMEFF2 (called POP4)); intracellular proteins (CAMK2N1, DHCR24, GLO1, NGFRAP1, PGK1, PSMA7, SBDS, and YWHAQ); and noncoding transcripts (POP1 (100 kb) from mRNA AK000023), POP2 (4 kb from mRNA AL832227), POP3 (50 kb from EST CFI40309), POP5 (intron of NCAM2, accession DO668384), POP6 (intron of FHIT), POP7 (intron of TNFAIP8), POP8 (intron of EFNA5), POP9 (intron of DSTN), POP10 (intron of ADAM2, accession DO668396), POP11 (87kb from EST BG194644), and POP12 (intron of EST BQ226050)).
p4531
sg4
(lp4532
(dp4533
g7
I489
sg8
g47
sg10
I4
sg11
VPOP5
p4534
sg13
I1
sa(dp4535
g7
I149
sg8
g47
sg10
I6
sg11
VELOVL5
p4536
sg13
I1
sa(dp4537
g7
I332
sg8
VP00558
p4538
sg10
I4
sg11
VPGK1
p4539
sg13
I1
sa(dp4540
g7
I174
sg8
g47
sg10
I7
sg11
VTMEM30A
p4541
sg13
I1
sa(dp4542
g7
I582
sg8
VP52803
p4543
sg10
I22
sg11
VPOP8 (intron of EFNA5)
p4544
sg13
I4
sa(dp4545
g7
I157
sg8
VP49006
p4546
sg10
I8
sg11
VMARCKSL1
p4547
sg13
I1
sa(dp4548
g7
I142
sg8
g47
sg10
I5
sg11
VADAM2
p4549
sg13
I1
sa(dp4550
g7
I309
sg8
g47
sg10
I6
sg11
VDHCR24
p4551
sg13
I1
sa(dp4552
g7
I300
sg8
g47
sg10
I7
sg11
VCAMK2N1
p4553
sg13
I1
sa(dp4554
g7
I317
sg8
g47
sg10
I4
sg11
VGLO1
p4555
sg13
I1
sa(dp4556
g7
I142
sg8
g47
sg10
I5
sg11
VADAM2
p4557
sg13
I1
sa(dp4558
g7
I187
sg8
g47
sg10
I6
sg11
VTMEM66
p4559
sg13
I1
sa(dp4560
g7
I323
sg8
g47
sg10
I7
sg11
VNGFRAP1
p4561
sg13
I1
sa(dp4562
g7
I556
sg8
g47
sg10
I24
sg11
VPOP7 (intron of TNFAIP8)
p4563
sg13
I4
sa(dp4564
g7
I533
sg8
VP49789
p4565
sg10
I21
sg11
VPOP6 (intron of FHIT)
p4566
sg13
I4
sa(dp4567
g7
I505
sg8
g47
sg10
I5
sg11
VNCAM2
p4568
sg13
I1
sa(dp4569
g7
I167
sg8
g47
sg10
I5
sg11
VRAMP1
p4570
sg13
I1
sa(dp4571
g7
I268
sg8
g47
sg10
I4
sg11
VPOP4
p4572
sg13
I1
sa(dp4573
g7
I457
sg8
VP49888
p4574
sg10
I29
sg11
VPOP3 (50 kb from EST CFI40309
p4575
sg13
I6
sa(dp4576
g7
I174
sg8
g47
sg10
I7
sg11
VTMEM30A
p4577
sg13
I1
sa(dp4578
g7
I187
sg8
g47
sg10
I6
sg11
VTMEM66
p4579
sg13
I1
sa(dp4580
g7
I116
sg8
VP35968
p4581
sg10
I24
sg11
Vplasma membrane proteins
p4582
sg13
I3
sa(dp4583
g7
I338
sg8
g47
sg10
I5
sg11
VPSMA7
p4584
sg13
I1
sa(dp4585
g7
I215
sg8
g47
sg10
I5
sg11
VSPON2
p4586
sg13
I1
sa(dp4587
g7
I390
sg8
g47
sg10
I32
sg11
VPOP1 (100 kb) from mRNA AK000023
p4588
sg13
I6
sasg17
(lp4589
(dp4590
g7
I74
sg20
VC0600139
p4591
sg10
I15
sg11
Vprostate cancer
p4592
sg13
I2
sasa(dp4593
g2
VLevels of CAMK2N1, GLO1, SDBS, and TMEM30A transcripts tended to be increased in primary prostate cancer from patients who later had biochemical failure.
p4594
sg4
(lp4595
(dp4596
g7
I10
sg8
g47
sg10
I7
sg11
VCAMK2N1
p4597
sg13
I1
sa(dp4598
g7
I35
sg8
g47
sg10
I19
sg11
VTMEM30A transcripts
p4599
sg13
I2
sa(dp4600
g7
I19
sg8
g47
sg10
I4
sg11
VGLO1
p4601
sg13
I1
sasg17
(lp4602
(dp4603
g7
I89
sg20
VC0600139
p4604
sg10
I15
sg11
Vprostate cancer
p4605
sg13
I2
sasa(dp4606
g2
VHuman CDC50A mRNA was expressed in embryonic stem (ES) cells, placenta, brain and chondrosarcoma, while CDC50B mRNA was expressed in pancreatic islet, kidney, prostate as well as in lung carcinoid, parathyroid tumor, bladder tumor, meningioma and pancreatic cancer.
p4607
sg4
(lp4608
(dp4609
g7
I0
sg8
g47
sg10
I17
sg11
VHuman CDC50A mRNA
p4610
sg13
I3
sa(dp4611
g7
I104
sg8
g47
sg10
I11
sg11
VCDC50B mRNA
p4612
sg13
I2
sasg17
(lp4613
(dp4614
g7
I198
sg20
VC0030521
p4615
sg10
I17
sg11
Vparathyroid tumor
p4616
sg13
I2
sa(dp4617
g7
I247
sg20
VC0235974
p4618
sg10
I17
sg11
Vpancreatic cancer
p4619
sg13
I2
sa(dp4620
g7
I232
sg20
VC0025286
p4621
sg10
I10
sg11
Vmeningioma
p4622
sg13
I1
sa(dp4623
g7
I217
sg20
VC0005695
p4624
sg10
I13
sg11
Vbladder tumor
p4625
sg13
I2
sa(dp4626
g7
I82
sg20
VC0008479
p4627
sg10
I14
sg11
Vchondrosarcoma
p4628
sg13
I1
sa(dp4629
g7
I187
sg20
VC0007095
p4630
sg10
I9
sg11
Vcarcinoid
p4631
sg13
I1
sasa(dp4632
g2
VFinally, ephrin-B2/Fc promoted angiogenesis in vivo in corneal neovascularization and Matrigel plug assays in adult mice, whereas LY294002 reduced angiogenesis in Matrigel that was induced by ephrin-B2/Fc.
p4633
sg4
(lp4634
(dp4635
g7
I9
sg8
VP52799
p4636
sg10
I9
sg11
Vephrin-B2
p4637
sg13
I1
sasg17
(lp4638
(dp4639
g7
I55
sg20
VC0085109
p4640
sg10
I26
sg11
Vcorneal neovascularization
p4641
sg13
I2
sasa(dp4642
g2
VMutations of SYNGAP1 have been frequently linked to brain disorders including intellectual disability, autisms, and seizure.
p4643
sg4
(lp4644
(dp4645
g7
I13
sg8
g47
sg10
I7
sg11
VSYNGAP1
p4646
sg13
I1
sasg17
(lp4647
(dp4648
g7
I116
sg20
VC0036572
p4649
sg10
I7
sg11
Vseizure
p4650
sg13
I1
sa(dp4651
g7
I103
sg20
VC0004352
p4652
sg10
I7
sg11
Vautisms
p4653
sg13
I1
sa(dp4654
g7
I52
sg20
VC0006111
p4655
sg10
I15
sg11
Vbrain disorders
p4656
sg13
I2
sa(dp4657
g7
I78
sg20
VC0025362
p4658
sg10
I23
sg11
Vintellectual disability
p4659
sg13
I2
sasa(dp4660
g2
VFurthermore, the LTP-regulated phosphoproteins, which included the scaffold proteins Shank3, Syngap1, Dlgap1, and Dlg4, represented the "PSD risk" for schizophrenia and autism spectrum disorder, such that without these proteins in the analysis, the association with the PSD and these two psychiatric diseases was not present.
p4661
sg4
(lp4662
(dp4663
g7
I102
sg8
g47
sg10
I6
sg11
VDlgap1
p4664
sg13
I1
sa(dp4665
g7
I114
sg8
VP78352
p4666
sg10
I4
sg11
VDlg4
p4667
sg13
I1
sa(dp4668
g7
I137
sg8
g47
sg10
I3
sg11
VPSD
p4669
sg13
I1
sa(dp4670
g7
I85
sg8
g47
sg10
I6
sg11
VShank3
p4671
sg13
I1
sa(dp4672
g7
I93
sg8
g47
sg10
I7
sg11
VSyngap1
p4673
sg13
I1
sasg17
(lp4674
(dp4675
g7
I151
sg20
VC0036341
p4676
sg10
I13
sg11
Vschizophrenia
p4677
sg13
I1
sa(dp4678
g7
I169
sg20
VC1510586
p4679
sg10
I24
sg11
Vautism spectrum disorder
p4680
sg13
I3
sasa(dp4681
g2
VDevelopmental delay was the first manifestation of SYNGAP1-related encephalopathy; intellectual disability became progressively obvious and was associated with autistic behaviours in eight patients.
p4682
sg4
(lp4683
(dp4684
g7
I51
sg8
g47
sg10
I7
sg11
VSYNGAP1
p4685
sg13
I1
sasg17
(lp4686
(dp4687
g7
I0
sg20
VC0424605
p4688
sg10
I19
sg11
VDevelopmental delay
p4689
sg13
I2
sa(dp4690
g7
I83
sg20
VC0025362
p4691
sg10
I23
sg11
Vintellectual disability
p4692
sg13
I2
sa(dp4693
g7
I160
sg20
VC0004352
p4694
sg10
I8
sg11
Vautistic
p4695
sg13
I1
sa(dp4696
g7
I67
sg20
VC0085584
p4697
sg10
I14
sg11
Vencephalopathy
p4698
sg13
I1
sasa(dp4699
g2
VThe only two genes upregulated across all transcriptome-wide PE analyses to date (microarray, RNA-Seq and PAS-Seq) are NRIP1 (RIP140), a transcriptional co-regulator linked to metabolic syndromes associated with obesity, and Flt1.
p4700
sg4
(lp4701
(dp4702
g7
I126
sg8
VP48552
p4703
sg10
I6
sg11
VRIP140
p4704
sg13
I1
sa(dp4705
g7
I106
sg8
VP05165
p4706
sg10
I7
sg11
VPAS-Seq
p4707
sg13
I1
sa(dp4708
g7
I119
sg8
VP48552
p4709
sg10
I5
sg11
VNRIP1
p4710
sg13
I1
sa(dp4711
g7
I225
sg8
VP17948
p4712
sg10
I4
sg11
VFlt1
p4713
sg13
I1
sasg17
(lp4714
(dp4715
g7
I212
sg20
VC0028754
p4716
sg10
I7
sg11
Vobesity
p4717
sg13
I1
sa(dp4718
g7
I176
sg20
VC0524620
p4719
sg10
I19
sg11
Vmetabolic syndromes
p4720
sg13
I2
sasa(dp4721
g2
VFurthermore, endothelial Flt1 gene deletion enhanced the effect of VEGFB, activating the thermogenic program in subcutaneous adipose tissue, which increased the basal metabolic rate, thus preventing diet-induced obesity and related metabolic complications.
p4722
sg4
(lp4723
(dp4724
g7
I25
sg8
VP17948
p4725
sg10
I4
sg11
VFlt1
p4726
sg13
I1
sa(dp4727
g7
I67
sg8
VP49765
p4728
sg10
I5
sg11
VVEGFB
p4729
sg13
I1
sasg17
(lp4730
(dp4731
g7
I212
sg20
VC0028754
p4732
sg10
I7
sg11
Vobesity
p4733
sg13
I1
sa(dp4734
g7
I30
sg20
VC1442161
p4735
sg10
I13
sg11
Vgene deletion
p4736
sg13
I2
sasa(dp4737
g2
V(2016) demonstrate that VEGF-B, by displacing VEGF-A from VEGFR1 and activating VEGFR2, increases adipose tissue vascularity, improves insulin sensitivity, diminishes obesity, and alleviates metabolic syndrome.
p4738
sg4
(lp4739
(dp4740
g7
I135
sg8
VP01308
p4741
sg10
I7
sg11
Vinsulin
p4742
sg13
I1
sa(dp4743
g7
I58
sg8
VP17948
p4744
sg10
I6
sg11
VVEGFR1
p4745
sg13
I1
sa(dp4746
g7
I24
sg8
VP49765
p4747
sg10
I6
sg11
VVEGF-B
p4748
sg13
I1
sa(dp4749
g7
I69
sg8
VP35968
p4750
sg10
I17
sg11
Vactivating VEGFR2
p4751
sg13
I2
sasg17
(lp4752
(dp4753
g7
I135
sg20
VC0920563
p4754
sg10
I19
sg11
Vinsulin sensitivity
p4755
sg13
I2
sa(dp4756
g7
I191
sg20
VC0524620
p4757
sg10
I18
sg11
Vmetabolic syndrome
p4758
sg13
I2
sa(dp4759
g7
I167
sg20
VC0028754
p4760
sg10
I7
sg11
Vobesity
p4761
sg13
I1
sasa(dp4762
g2
VHere, we hypothesized that increased activity of PlGF/VEGFR-1 signaling mediates obesity-induced tumor progression by augmenting tumor angiogenesis and TAM recruitment/activity.
p4763
sg4
(lp4764
(dp4765
g7
I49
sg8
VP49763
p4766
sg10
I4
sg11
VPlGF
p4767
sg13
I1
sa(dp4768
g7
I54
sg8
VP17948
p4769
sg10
I7
sg11
VVEGFR-1
p4770
sg13
I1
sasg17
(lp4771
(dp4772
g7
I81
sg20
VC0028754
p4773
sg10
I7
sg11
Vobesity
p4774
sg13
I1
sa(dp4775
g7
I156
sg20
VC0271510
p4776
sg10
I11
sg11
Vrecruitment
p4777
sg13
I1
sa(dp4778
g7
I97
sg20
VC0178874
p4779
sg10
I17
sg11
Vtumor progression
p4780
sg13
I2
sa(dp4781
g7
I129
sg20
VC1519670
p4782
sg10
I18
sg11
Vtumor angiogenesis
p4783
sg13
I2
sa(dp4784
g7
I152
sg20
VC1834582
p4785
sg10
I3
sg11
VTAM
p4786
sg13
I1
sasa(dp4787
g2
VAblation of VEGFR-1 signaling prevented obesity-induced tumor progression and shifted the tumor immune environment toward an antitumor phenotype.
p4788
sg4
(lp4789
(dp4790
g7
I12
sg8
VP17948
p4791
sg10
I7
sg11
VVEGFR-1
p4792
sg13
I1
sasg17
(lp4793
(dp4794
g7
I56
sg20
VC0027651
p4795
sg10
I5
sg11
Vtumor
p4796
sg13
I1
sa(dp4797
g7
I56
sg20
VC0178874
p4798
sg10
I17
sg11
Vtumor progression
p4799
sg13
I2
sa(dp4800
g7
I40
sg20
VC0028754
p4801
sg10
I7
sg11
Vobesity
p4802
sg13
I1
sasa(dp4803
g2
VTargeting PlGF/VEGFR-1 signaling reprograms the tumor immune microenvironment and inhibits obesity-induced acceleration of tumor progression.
p4804
sg4
(lp4805
(dp4806
g7
I15
sg8
VP17948
p4807
sg10
I7
sg11
VVEGFR-1
p4808
sg13
I1
sa(dp4809
g7
I10
sg8
VP49763
p4810
sg10
I4
sg11
VPlGF
p4811
sg13
I1
sasg17
(lp4812
(dp4813
g7
I123
sg20
VC0178874
p4814
sg10
I17
sg11
Vtumor progression
p4815
sg13
I2
sa(dp4816
g7
I91
sg20
VC0028754
p4817
sg10
I7
sg11
Vobesity
p4818
sg13
I1
sa(dp4819
g7
I48
sg20
VC0027651
p4820
sg10
I5
sg11
Vtumor
p4821
sg13
I1
sasa(dp4822
g2
VIn a group of unmedicated patients with major depressive disorder matched for age with normal control group, we found a significant increase in 5-HT (100 microM)-induced accumulation of IP-1 (150 +/- 7% of basal for depressed patients, 132 +/- 3% for controls).
p4823
sg4
(lp4824
sg17
(lp4825
(dp4826
g7
I40
sg20
VC1269683
p4827
sg10
I25
sg11
Vmajor depressive disorder
p4828
sg13
I3
sasa(dp4829
g2
VIt is hoped that the same will happen in other MPN with specific genetic alterations: polycythemia vera (JAK2 V617F and other JAK2 mutations), essential thrombocythemia (JAK2V617F and MPL515 mutations), primary myelofibrosis (JAK2 V617F and MPL515 mutations), systemic mastocytosis (KITD816V and other KIT mutations) and stem cell leukaemia/lymphoma (ZNF198-FGFR1 and other FGFR1 fusion genes).
p4830
sg4
(lp4831
(dp4832
g7
I126
sg8
g47
sg10
I14
sg11
VJAK2 mutations
p4833
sg13
I2
sa(dp4834
g7
I302
sg8
VP10721
p4835
sg10
I13
sg11
VKIT mutations
p4836
sg13
I2
sa(dp4837
g7
I374
sg8
VP35637
p4838
sg10
I18
sg11
VFGFR1 fusion genes
p4839
sg13
I3
sa(dp4840
g7
I105
sg8
g47
sg10
I10
sg11
VJAK2 V617F
p4841
sg13
I2
sa(dp4842
g7
I105
sg8
g47
sg10
I10
sg11
VJAK2 V617F
p4843
sg13
I2
sa(dp4844
g7
I358
sg8
VP20930
p4845
sg10
I5
sg11
VFGFR1
p4846
sg13
I1
sasg17
(lp4847
(dp4848
g7
I321
sg20
VC1378511
p4849
sg10
I19
sg11
Vstem cell leukaemia
p4850
sg13
I3
sa(dp4851
g7
I203
sg20
VC0001815
p4852
sg10
I21
sg11
Vprimary myelofibrosis
p4853
sg13
I2
sa(dp4854
g7
I143
sg20
VC0040028
p4855
sg10
I25
sg11
Vessential thrombocythemia
p4856
sg13
I2
sa(dp4857
g7
I260
sg20
VC0221013
p4858
sg10
I21
sg11
Vsystemic mastocytosis
p4859
sg13
I2
sa(dp4860
g7
I86
sg20
VC0032463
p4861
sg10
I17
sg11
Vpolycythemia vera
p4862
sg13
I2
sa(dp4863
g7
I341
sg20
VC0024299
p4864
sg10
I8
sg11
Vlymphoma
p4865
sg13
I1
sasa(dp4866
g2
VWe show that stimulation of B-cells with the TLR9 ligands CpG-oligodeoxynucleotides (CpG-ODN) prevents spontaneous and irradiation-induced death of normal peripheral blood B-cells, and of B-cells from patients diagnosed with Common variable immunodeficiency (CVID).
p4867
sg4
(lp4868
(dp4869
g7
I45
sg8
g47
sg10
I4
sg11
VTLR9
p4870
sg13
I1
sasg17
(lp4871
(dp4872
g7
I259
sg20
VC0009447
p4873
sg10
I4
sg11
VCVID
p4874
sg13
I1
sa(dp4875
g7
I225
sg20
VC0009447
p4876
sg10
I32
sg11
VCommon variable immunodeficiency
p4877
sg13
I3
sasa(dp4878
g2
VDecreased IFN-Alfa secretion induced by TLR7/TLR8 activation was observed in CVID, which was recovered with TLR9 signaling.
p4879
sg4
(lp4880
(dp4881
g7
I45
sg8
g47
sg10
I4
sg11
VTLR8
p4882
sg13
I1
sa(dp4883
g7
I108
sg8
g47
sg10
I4
sg11
VTLR9
p4884
sg13
I1
sa(dp4885
g7
I40
sg8
g47
sg10
I4
sg11
VTLR7
p4886
sg13
I1
sa(dp4887
g7
I10
sg8
VP01562
p4888
sg10
I8
sg11
VIFN-Alfa
p4889
sg13
I1
sasg17
(lp4890
(dp4891
g7
I77
sg20
VC0009447
p4892
sg10
I4
sg11
VCVID
p4893
sg13
I1
sasa(dp4894
g2
VOur findings revealed that TLR9 activation has an adjuvant effect on the altered type I response in CVID.
p4895
sg4
(lp4896
(dp4897
g7
I27
sg8
g47
sg10
I4
sg11
VTLR9
p4898
sg13
I1
sasg17
(lp4899
(dp4900
g7
I100
sg20
VC0009447
p4901
sg10
I4
sg11
VCVID
p4902
sg13
I1
sasa(dp4903
g2
VWe activated purified CVID B-cells with surrogate T-dependent (anti-CD40), T-independent (TLR-9 ligand) stimuli or through B-cell receptor engagement (anti-IgM) with or without IL-21.
p4904
sg4
(lp4905
(dp4906
g7
I123
sg8
g47
sg10
I26
sg11
VB-cell receptor engagement
p4907
sg13
I3
sa(dp4908
g7
I151
sg8
VP29965
p4909
sg10
I8
sg11
Vanti-IgM
p4910
sg13
I1
sasg17
(lp4911
(dp4912
g7
I22
sg20
VC0009447
p4913
sg10
I4
sg11
VCVID
p4914
sg13
I1
sasa(dp4915
g2
VMoreover, studies at the single cell level showed that DCs from CVID patients and healthy controls produced similar amounts of interferon-Alfa or interleukin-12 and expressed similar levels of activation markers in response to human cytomegalovirus and ligands for TLR-7 and TLR-9.
p4916
sg4
(lp4917
(dp4918
g7
I127
sg8
VP01563
p4919
sg10
I15
sg11
Vinterferon-Alfa
p4920
sg13
I1
sa(dp4921
g7
I146
sg8
VP60568
p4922
sg10
I14
sg11
Vinterleukin-12
p4923
sg13
I1
sa(dp4924
g7
I265
sg8
g47
sg10
I5
sg11
VTLR-7
p4925
sg13
I1
sa(dp4926
g7
I275
sg8
g47
sg10
I5
sg11
VTLR-9
p4927
sg13
I1
sasg17
(lp4928
(dp4929
g7
I64
sg20
VC0009447
p4930
sg10
I4
sg11
VCVID
p4931
sg13
I1
sa(dp4932
g7
I55
sg20
VC0268238
p4933
sg10
I3
sg11
VDCs
p4934
sg13
I1
sasa(dp4935
g2
VIn conclusion, it seems unlikely that CVID is secondary to insufficient production of naturally occurring DCs or a defect in their signalling through TLR-7 or TLR-9.
p4936
sg4
(lp4937
(dp4938
g7
I150
sg8
g47
sg10
I5
sg11
VTLR-7
p4939
sg13
I1
sa(dp4940
g7
I159
sg8
g47
sg10
I5
sg11
VTLR-9
p4941
sg13
I1
sasg17
(lp4942
(dp4943
g7
I38
sg20
VC0009447
p4944
sg10
I4
sg11
VCVID
p4945
sg13
I1
sa(dp4946
g7
I106
sg20
VC0268238
p4947
sg10
I3
sg11
VDCs
p4948
sg13
I1
sasa(dp4949
g2
VGiven the established link between vitamin A deficiency and increased susceptibility to infections, we investigated the ability of the vitamin A metabolite all-trans retinoic acid (RA) to restore the defective immune responses in CVID-derived B cells activated through the TLRs TLR9 and RP105.
p4950
sg4
(lp4951
(dp4952
g7
I273
sg8
g47
sg10
I9
sg11
VTLRs TLR9
p4953
sg13
I2
sa(dp4954
g7
I287
sg8
g47
sg10
I5
sg11
VRP105
p4955
sg13
I1
sasg17
(lp4956
(dp4957
g7
I88
sg20
VC0021311
p4958
sg10
I10
sg11
Vinfections
p4959
sg13
I1
sa(dp4960
g7
I35
sg20
VC0042842
p4961
sg10
I20
sg11
Vvitamin A deficiency
p4962
sg13
I3
sa(dp4963
g7
I230
sg20
VC0009447
p4964
sg10
I4
sg11
VCVID
p4965
sg13
I1
sasa(dp4966
g2
VThis can be explained by impaired RA-mediated isotype switching in TLR9/RP105-stimulated CVID-derived B cells owing to reduced induction of activation-induced deaminase.
p4967
sg4
(lp4968
(dp4969
g7
I72
sg8
g47
sg10
I5
sg11
VRP105
p4970
sg13
I1
sa(dp4971
g7
I67
sg8
g47
sg10
I4
sg11
VTLR9
p4972
sg13
I1
sasg17
(lp4973
(dp4974
g7
I89
sg20
VC0009447
p4975
sg10
I4
sg11
VCVID
p4976
sg13
I1
sa(dp4977
g7
I25
sg20
VC0684336
p4978
sg10
I8
sg11
Vimpaired
p4979
sg13
I1
sasa(dp4980
g2
VThe ability of RA to improve critical immune parameters in CVID-derived B cells stimulated through TLR9 and RP105 support the possibility of combining RA with TLR stimulation for the treatment of CVID.
p4981
sg4
(lp4982
(dp4983
g7
I99
sg8
g47
sg10
I4
sg11
VTLR9
p4984
sg13
I1
sa(dp4985
g7
I108
sg8
g47
sg10
I5
sg11
VRP105
p4986
sg13
I1
sasg17
(lp4987
(dp4988
g7
I59
sg20
VC0009447
p4989
sg10
I4
sg11
VCVID
p4990
sg13
I1
sa(dp4991
g7
I59
sg20
VC0009447
p4992
sg10
I4
sg11
VCVID
p4993
sg13
I1
sasa(dp4994
g2
VThe CD21(low) V(H)1-69(+) B cells of MC patients, like those of CVID and HIV patients, are anergic to BCR and TLR9 stimulation and display deregulation of several anergy-related genes; proliferative anergy is also observed in CD21(high) MZ-like V(H)1-69(+) B cells, that over-express the antiproliferative transcriptional repressor Stra13.
p4995
sg4
(lp4996
(dp4997
g7
I4
sg8
VP20023
p4998
sg10
I18
sg11
VCD21(low) V(H)1-69
p4999
sg13
I2
sa(dp5000
g7
I226
sg8
VP20023
p5001
sg10
I27
sg11
VCD21(high) MZ-like V(H)1-69
p5002
sg13
I3
sa(dp5003
g7
I332
sg8
g47
sg10
I6
sg11
VStra13
p5004
sg13
I1
sa(dp5005
g7
I102
sg8
VP11274
p5006
sg10
I3
sg11
VBCR
p5007
sg13
I1
sa(dp5008
g7
I110
sg8
g47
sg10
I4
sg11
VTLR9
p5009
sg13
I1
sasg17
(lp5010
(dp5011
g7
I185
sg20
VC0334094
p5012
sg10
I13
sg11
Vproliferative
p5013
sg13
I1
sa(dp5014
g7
I64
sg20
VC0009447
p5015
sg10
I4
sg11
VCVID
p5016
sg13
I1
sa(dp5017
g7
I73
sg20
VC0019693
p5018
sg10
I3
sg11
VHIV
p5019
sg13
I1
sasa(dp5020
g2
VThe secretion of glucagon by islet Alfa cells is normally suppressed by high blood glucose, but this suppressibility is impaired in patients with diabetes or cystic fibrosis (CF), a disease caused by mutations in the gene encoding CF transmembrane conductance regulator (CFTR), a cyclic adenosine monophosphate-activated Cl- channel.
p5021
sg4
(lp5022
(dp5023
g7
I17
sg8
VP01275
p5024
sg10
I8
sg11
Vglucagon
p5025
sg13
I1
sa(dp5026
g7
I231
sg8
g47
sg10
I38
sg11
VCF transmembrane conductance regulator
p5027
sg13
I4
sa(dp5028
g7
I271
sg8
VP13569
p5029
sg10
I4
sg11
VCFTR
p5030
sg13
I1
sasg17
(lp5031
(dp5032
g7
I175
sg20
VC0016059
p5033
sg10
I2
sg11
VCF
p5034
sg13
I1
sa(dp5035
g7
I158
sg20
VC0010674
p5036
sg10
I15
sg11
Vcystic fibrosis
p5037
sg13
I2
sa(dp5038
g7
I146
sg20
VC0011849
p5039
sg10
I8
sg11
Vdiabetes
p5040
sg13
I1
sa(dp5041
g7
I120
sg20
VC0684336
p5042
sg10
I8
sg11
Vimpaired
p5043
sg13
I1
sa(dp5044
g7
I175
sg20
VC0016059
p5045
sg10
I2
sg11
VCF
p5046
sg13
I1
sasa(dp5047
g2
VThe results reveal that by potentiating KATP channels, CFTR acts as a glucose-sensing negative regulator of glucagon secretion in Alfa cells, a defect of which may contribute to glucose intolerance in CF and other types of diabetes.
p5048
sg4
(lp5049
(dp5050
g7
I55
sg8
VP13569
p5051
sg10
I4
sg11
VCFTR
p5052
sg13
I1
sa(dp5053
g7
I108
sg8
VP01275
p5054
sg10
I8
sg11
Vglucagon
p5055
sg13
I1
sasg17
(lp5056
(dp5057
g7
I178
sg20
VC0271650
p5058
sg10
I19
sg11
Vglucose intolerance
p5059
sg13
I2
sa(dp5060
g7
I223
sg20
VC0011849
p5061
sg10
I8
sg11
Vdiabetes
p5062
sg13
I1
sasa(dp5063
g2
VAlthough Beta-cell dysfunction in cystic fibrosis (CF) leads to diabetes, the mechanism by which the cystic fibrosis transmembrane conductance regulator (CFTR) channel influences islet insulin secretion remains debated.
p5064
sg4
(lp5065
(dp5066
g7
I101
sg8
VP13569
p5067
sg10
I51
sg11
Vcystic fibrosis transmembrane conductance regulator
p5068
sg13
I5
sa(dp5069
g7
I9
sg8
VP13569
p5070
sg10
I45
sg11
VBeta-cell dysfunction in cystic fibrosis (CF)
p5071
sg13
I6
sa(dp5072
g7
I185
sg8
VP01308
p5073
sg10
I7
sg11
Vinsulin
p5074
sg13
I1
sa(dp5075
g7
I154
sg8
VP13569
p5076
sg10
I4
sg11
VCFTR
p5077
sg13
I1
sasg17
(lp5078
(dp5079
g7
I64
sg20
VC0011849
p5080
sg10
I8
sg11
Vdiabetes
p5081
sg13
I1
sa(dp5082
g7
I34
sg20
VC0010674
p5083
sg10
I15
sg11
Vcystic fibrosis
p5084
sg13
I2
sa(dp5085
g7
I34
sg20
VC0010674
p5086
sg10
I15
sg11
Vcystic fibrosis
p5087
sg13
I2
sa(dp5088
g7
I51
sg20
VC0010674
p5089
sg10
I2
sg11
VCF
p5090
sg13
I1
sasa(dp5091
g2
VBaseline estimated cost in 2008 for a hypothetical underweight, homozygous F508del-CFTR 6-year-old female without chronic Pseudomonas aeruginosa/Staphylococcus aureus, CF-related diabetes (CFRD) or methicillin-resistant S. aureus (MRSA), and with a poor percent predicted forced expiratory volume in 1 s (ppFEV1) was Euro10,113, and was Euro21,082 in a 25-year-old with the same hypothetical profile.
p5092
sg4
(lp5093
(dp5094
g7
I75
sg8
VP13569
p5095
sg10
I14
sg11
VF508del-CFTR 6
p5096
sg13
I2
sasg17
(lp5097
(dp5098
g7
I179
sg20
VC0011849
p5099
sg10
I8
sg11
Vdiabetes
p5100
sg13
I1
sa(dp5101
g7
I231
sg20
VC0343401
p5102
sg10
I4
sg11
VMRSA
p5103
sg13
I1
sasa(dp5104
g2
VThe goal of this work was to evaluate renal function and the expression of megalin, cubilin, CFTR (cystic fibrosis transmembrane conductance regulator), and ClC-5 in the proximal tubule and renal cortex of rats with type 1 diabetes.
p5105
sg4
(lp5106
(dp5107
g7
I157
sg8
VP51795
p5108
sg10
I5
sg11
VClC-5
p5109
sg13
I1
sa(dp5110
g7
I84
sg8
g47
sg10
I7
sg11
Vcubilin
p5111
sg13
I1
sa(dp5112
g7
I75
sg8
VP54317
p5113
sg10
I7
sg11
Vmegalin
p5114
sg13
I1
sasg17
(lp5115
(dp5116
g7
I216
sg20
VC0011854
p5117
sg10
I15
sg11
Vtype 1 diabetes
p5118
sg13
I3
sa(dp5119
g7
I99
sg20
VC0010674
p5120
sg10
I15
sg11
Vcystic fibrosis
p5121
sg13
I2
sasa(dp5122
g2
VMean values in lichen ruber planus were Zn 784 micrograms/l, RBP 5.26 mg/dl and Vit A 656 ng/ml; in leukoplakia Zn 696 micrograms/l, RBP 5.30 mg/dl and Vit A 652 ng/ml; and in OSCC Zn 659 micrograms/l, RBP 5.00 mg/dl and Vit A 617 ng/ml.
p5123
sg4
(lp5124
sg17
(lp5125
(dp5126
g7
I100
sg20
VC0023531
p5127
sg10
I11
sg11
Vleukoplakia
p5128
sg13
I1
sa(dp5129
g7
I15
sg20
VC0023646
p5130
sg10
I19
sg11
Vlichen ruber planus
p5131
sg13
I3
sasa(dp5132
g2
VThese observations indicate that HYA and PIIINP mainly reflect expansive synovitis proliferation while galectin-3 is more closely linked to autoimmunity, smoking and joint destructive processes.
p5133
sg4
(lp5134
(dp5135
g7
I103
sg8
VP17931
p5136
sg10
I10
sg11
Vgalectin-3
p5137
sg13
I1
sasg17
(lp5138
(dp5139
g7
I73
sg20
VC0039103
p5140
sg10
I9
sg11
Vsynovitis
p5141
sg13
I1
sa(dp5142
g7
I83
sg20
VC0334094
p5143
sg10
I13
sg11
Vproliferation
p5144
sg13
I1
sa(dp5145
g7
I140
sg20
VC0004368
p5146
sg10
I12
sg11
Vautoimmunity
p5147
sg13
I1
sasa(dp5148
g2
VIn the entire UA cohort, galectin-3 correlated with the MRI bone marrow edema score, while PIIANP correlated with the MRI erosion score, and HYA with the synovitis and erosion scores.
p5149
sg4
(lp5150
(dp5151
g7
I25
sg8
VP17931
p5152
sg10
I10
sg11
Vgalectin-3
p5153
sg13
I1
sasg17
(lp5154
(dp5155
g7
I122
sg20
VC1959609
p5156
sg10
I7
sg11
Verosion
p5157
sg13
I1
sa(dp5158
g7
I154
sg20
VC0039103
p5159
sg10
I9
sg11
Vsynovitis
p5160
sg13
I1
sa(dp5161
g7
I60
sg20
VC0948162
p5162
sg10
I17
sg11
Vbone marrow edema
p5163
sg13
I3
sa(dp5164
g7
I122
sg20
VC1959609
p5165
sg10
I7
sg11
Verosion
p5166
sg13
I1
sasa(dp5167
g2
VPrevious studies have reported overexpression of Galectin-3 in RA synovitis and increased levels in synovial fluid and serum in long-standing RA compared with osteoarthritis and healthy controls.
p5168
sg4
(lp5169
(dp5170
g7
I49
sg8
VP17931
p5171
sg10
I10
sg11
VGalectin-3
p5172
sg13
I1
sasg17
(lp5173
(dp5174
g7
I159
sg20
VC0029408
p5175
sg10
I14
sg11
Vosteoarthritis
p5176
sg13
I1
sa(dp5177
g7
I66
sg20
VC0039103
p5178
sg10
I9
sg11
Vsynovitis
p5179
sg13
I1
sasa(dp5180
g2
VWe defined by immunohistology the infiltrating cells and examined the in situ expression of plausible protagonists in synovitis of FMF: myeloperoxidase, lysozyme, galectin 1, galectin 3, p65 (RelA)/nuclear factor KB, inducible nitric-oxide synthase, cyclooxygenase 2, and cleaved caspase 3.
p5181
sg4
(lp5182
(dp5183
g7
I192
sg8
g47
sg10
I4
sg11
VRelA
p5184
sg13
I1
sa(dp5185
g7
I187
sg8
VP21579
p5186
sg10
I3
sg11
Vp65
p5187
sg13
I1
sa(dp5188
g7
I131
sg8
g47
sg10
I3
sg11
VFMF
p5189
sg13
I1
sa(dp5190
g7
I153
sg8
VP61626
p5191
sg10
I8
sg11
Vlysozyme
p5192
sg13
I1
sa(dp5193
g7
I280
sg8
VP42574
p5194
sg10
I9
sg11
Vcaspase 3
p5195
sg13
I2
sa(dp5196
g7
I163
sg8
VP09382
p5197
sg10
I10
sg11
Vgalectin 1
p5198
sg13
I2
sa(dp5199
g7
I198
sg8
VP01160
p5200
sg10
I17
sg11
Vnuclear factor KB
p5201
sg13
I3
sa(dp5202
g7
I175
sg8
VP17931
p5203
sg10
I10
sg11
Vgalectin 3
p5204
sg13
I2
sa(dp5205
g7
I250
sg8
VP35354
p5206
sg10
I16
sg11
Vcyclooxygenase 2
p5207
sg13
I2
sa(dp5208
g7
I227
sg8
VP29475
p5209
sg10
I21
sg11
Vnitric-oxide synthase
p5210
sg13
I2
sa(dp5211
g7
I136
sg8
VP05164
p5212
sg10
I15
sg11
Vmyeloperoxidase
p5213
sg13
I1
sasg17
(lp5214
(dp5215
g7
I131
sg20
VC0031069
p5216
sg10
I3
sg11
VFMF
p5217
sg13
I1
sa(dp5218
g7
I34
sg20
VC0332448
p5219
sg10
I12
sg11
Vinfiltrating
p5220
sg13
I1
sa(dp5221
g7
I118
sg20
VC0039103
p5222
sg10
I9
sg11
Vsynovitis
p5223
sg13
I1
sasa(dp5224
g2
VOnly one of these, pFLJ2, was mobilized by the IncP plasmids RP4, pRK231 and R702, but not by plasmids pSa, R40a, R387, pN3 or R16.
p5225
sg4
(lp5226
sg17
(lp5227
(dp5228
g7
I103
sg20
VC1519176
p5229
sg10
I3
sg11
VpSa
p5230
sg13
I1
sa(dp5231
g7
I61
sg20
VC3151001
p5232
sg10
I3
sg11
VRP4
p5233
sg13
I1
sasa(dp5234
g2
VChanges in the frequencies of genotypes and mutant alleles of ACE, AGTR1, AGT, and ITGB3 genes were analyzed in patients with arterial hypertension coupled with metabolic syndrome (N=15) and compared with population data and corresponding parameters in patients with isolated hypertension (N=15).
p5235
sg4
(lp5236
(dp5237
g7
I67
sg8
VP30556
p5238
sg10
I5
sg11
VAGTR1
p5239
sg13
I1
sa(dp5240
g7
I62
sg8
VP12821
p5241
sg10
I3
sg11
VACE
p5242
sg13
I1
sa(dp5243
g7
I83
sg8
VP05106
p5244
sg10
I11
sg11
VITGB3 genes
p5245
sg13
I2
sa(dp5246
g7
I67
sg8
VP21549
p5247
sg10
I3
sg11
VAGT
p5248
sg13
I1
sasg17
(lp5249
(dp5250
g7
I126
sg20
VC0020538
p5251
sg10
I21
sg11
Varterial hypertension
p5252
sg13
I2
sa(dp5253
g7
I135
sg20
VC0020538
p5254
sg10
I12
sg11
Vhypertension
p5255
sg13
I1
sa(dp5256
g7
I44
sg20
VC0596988
p5257
sg10
I6
sg11
Vmutant
p5258
sg13
I1
sa(dp5259
g7
I161
sg20
VC0524620
p5260
sg10
I18
sg11
Vmetabolic syndrome
p5261
sg13
I2
sasa(dp5262
g2
VWe examined associations between 15 single nucleotide polymorphisms (SNPs) across ITGB3 and five CVD-related traits in the Hutterites: plasma levels of high density lipoprotein-cholesterol (HDL-c), triglycerides (TG), low density lipoprotein-cholesterol (LDL-c), and lipoprotein(a) [Lp(a)] and blood pressure or hypertension.
p5263
sg4
(lp5264
(dp5265
g7
I218
sg8
VP02652
p5266
sg10
I35
sg11
Vlow density lipoprotein-cholesterol
p5267
sg13
I3
sa(dp5268
g7
I255
sg8
VP02652
p5269
sg10
I5
sg11
VLDL-c
p5270
sg13
I1
sa(dp5271
g7
I152
sg8
VP28845
p5272
sg10
I36
sg11
Vhigh density lipoprotein-cholesterol
p5273
sg13
I3
sa(dp5274
g7
I267
sg8
VP02652
p5275
sg10
I14
sg11
Vlipoprotein(a)
p5276
sg13
I1
sa(dp5277
g7
I190
sg8
VP28845
p5278
sg10
I5
sg11
VHDL-c
p5279
sg13
I1
sasg17
(lp5280
(dp5281
g7
I97
sg20
VC0007222
p5282
sg10
I3
sg11
VCVD
p5283
sg13
I1
sa(dp5284
g7
I312
sg20
VC0020538
p5285
sg10
I12
sg11
Vhypertension
p5286
sg13
I1
sasa(dp5287
g2
VThe present study was performed to investigate the expressions of transforming growth factor Beta1 (TGF-Beta1) and matrix metalloproteinase-9 (MMP-9) in an experimental model of tympanosclerosis and their possible roles in the formation of this disorder.
p5288
sg4
(lp5289
(dp5290
g7
I66
sg8
VP01137
p5291
sg10
I32
sg11
Vtransforming growth factor Beta1
p5292
sg13
I4
sa(dp5293
g7
I100
sg8
VP01137
p5294
sg10
I9
sg11
VTGF-Beta1
p5295
sg13
I1
sa(dp5296
g7
I115
sg8
VP14780
p5297
sg10
I26
sg11
Vmatrix metalloproteinase-9
p5298
sg13
I2
sa(dp5299
g7
I143
sg8
VP14780
p5300
sg10
I5
sg11
VMMP-9
p5301
sg13
I1
sasg17
(lp5302
(dp5303
g7
I178
sg20
VC0395887
p5304
sg10
I16
sg11
Vtympanosclerosis
p5305
sg13
I1
sasa(dp5306
g2
VRT-PCR analysis showed that the overall transcriptional activity of the main HS biosynthesis-involved genes (EXT1, EXT2, NDST1, NDST2, GLCE, HS2ST1, HS3ST1, HS3ST2, HS6ST1, HS6ST2, SULF1, SULF2, HPSE) was decreased by 1.5-2-fold in Grade II-III glioma (p &lt; 0.01) and by 3-fold in Grade IV glioma (glioblastoma multiforme, GBM) (p &lt; 0.05), as compared with the para-tumourous tissue.
p5307
sg4
(lp5308
(dp5309
g7
I157
sg8
g47
sg10
I6
sg11
VHS3ST2
p5310
sg13
I1
sa(dp5311
g7
I115
sg8
g47
sg10
I4
sg11
VEXT2
p5312
sg13
I1
sa(dp5313
g7
I195
sg8
g47
sg10
I4
sg11
VHPSE
p5314
sg13
I1
sa(dp5315
g7
I181
sg8
g47
sg10
I5
sg11
VSULF1
p5316
sg13
I1
sa(dp5317
g7
I128
sg8
VP52849
p5318
sg10
I5
sg11
VNDST2
p5319
sg13
I1
sa(dp5320
g7
I141
sg8
g47
sg10
I6
sg11
VHS2ST1
p5321
sg13
I1
sa(dp5322
g7
I121
sg8
VP52848
p5323
sg10
I5
sg11
VNDST1
p5324
sg13
I1
sa(dp5325
g7
I135
sg8
g47
sg10
I4
sg11
VGLCE
p5326
sg13
I1
sa(dp5327
g7
I109
sg8
g47
sg10
I4
sg11
VEXT1
p5328
sg13
I1
sa(dp5329
g7
I149
sg8
g47
sg10
I6
sg11
VHS3ST1
p5330
sg13
I1
sa(dp5331
g7
I165
sg8
g47
sg10
I6
sg11
VHS6ST1
p5332
sg13
I1
sa(dp5333
g7
I188
sg8
g47
sg10
I5
sg11
VSULF2
p5334
sg13
I1
sasg17
(lp5335
(dp5336
g7
I115
sg20
VC1851413
p5337
sg10
I4
sg11
VEXT2
p5338
sg13
I1
sa(dp5339
g7
I245
sg20
VC0017638
p5340
sg10
I6
sg11
Vglioma
p5341
sg13
I1
sa(dp5342
g7
I245
sg20
VC0017638
p5343
sg10
I6
sg11
Vglioma
p5344
sg13
I1
sa(dp5345
g7
I300
sg20
VC1621958
p5346
sg10
I23
sg11
Vglioblastoma multiforme
p5347
sg13
I2
sa(dp5348
g7
I109
sg20
VC0015306
p5349
sg10
I4
sg11
VEXT1
p5350
sg13
I1
sa(dp5351
g7
I325
sg20
VC1621958
p5352
sg10
I3
sg11
VGBM
p5353
sg13
I1
sasa(dp5354
g2
VThis study aimed to analyze the expression and function of HS6ST3 in breast cancer.
p5355
sg4
(lp5356
(dp5357
g7
I59
sg8
g47
sg10
I6
sg11
VHS6ST3
p5358
sg13
I1
sasg17
(lp5359
(dp5360
g7
I69
sg20
VC0678222
p5361
sg10
I13
sg11
Vbreast cancer
p5362
sg13
I2
sasa(dp5363
g2
VHS6ST3 was found up-regulated in T47D, MCF7 and MDA-MB231 breast cancer cell lines.
p5364
sg4
(lp5365
(dp5366
g7
I0
sg8
g47
sg10
I6
sg11
VHS6ST3
p5367
sg13
I1
sasg17
(lp5368
(dp5369
g7
I58
sg20
VC0678222
p5370
sg10
I13
sg11
Vbreast cancer
p5371
sg13
I2
sasa(dp5372
g2
VSilencing HS6ST3 diminished tumor cell growth, migration and invasion, but enhanced cell adhesion and apoptosis in breast cancer.
p5373
sg4
(lp5374
sg17
(lp5375
(dp5376
g7
I28
sg20
VC0027651
p5377
sg10
I5
sg11
Vtumor
p5378
sg13
I1
sa(dp5379
g7
I115
sg20
VC0678222
p5380
sg10
I13
sg11
Vbreast cancer
p5381
sg13
I2
sa(dp5382
g7
I61
sg20
VC2699153
p5383
sg10
I8
sg11
Vinvasion
p5384
sg13
I1
sa(dp5385
g7
I89
sg20
VC0001511
p5386
sg10
I8
sg11
Vadhesion
p5387
sg13
I1
sasa(dp5388
g2
VGene microarray analysis revealed that silencing HS6ST3 significantly changed the expression of IGF1R and XAF1 in breast cancer cells.
p5389
sg4
(lp5390
(dp5391
g7
I96
sg8
VP08069
p5392
sg10
I5
sg11
VIGF1R
p5393
sg13
I1
sa(dp5394
g7
I49
sg8
g47
sg10
I6
sg11
VHS6ST3
p5395
sg13
I1
sa(dp5396
g7
I106
sg8
g47
sg10
I4
sg11
VXAF1
p5397
sg13
I1
sasg17
(lp5398
(dp5399
g7
I114
sg20
VC0678222
p5400
sg10
I13
sg11
Vbreast cancer
p5401
sg13
I2
sasa(dp5402
g2
VFurther functional studies showed that the cellular processes were mediated by IGF1R and XAF1 after silencing HS6ST3 in breast cancer cells.
p5403
sg4
(lp5404
(dp5405
g7
I89
sg8
g47
sg10
I4
sg11
VXAF1
p5406
sg13
I1
sa(dp5407
g7
I79
sg8
VP08069
p5408
sg10
I5
sg11
VIGF1R
p5409
sg13
I1
sa(dp5410
g7
I110
sg8
g47
sg10
I6
sg11
VHS6ST3
p5411
sg13
I1
sasg17
(lp5412
(dp5413
g7
I120
sg20
VC0678222
p5414
sg10
I13
sg11
Vbreast cancer
p5415
sg13
I2
sasa(dp5416
g2
VTogether these results indicate that HS6ST3 might be involved in the tumorigenesis of breast cancer and it could be a promising target in breast cancer therapy.
p5417
sg4
(lp5418
(dp5419
g7
I37
sg8
g47
sg10
I6
sg11
VHS6ST3
p5420
sg13
I1
sasg17
(lp5421
(dp5422
g7
I86
sg20
VC0678222
p5423
sg10
I13
sg11
Vbreast cancer
p5424
sg13
I2
sa(dp5425
g7
I69
sg20
VC0007621
p5426
sg10
I13
sg11
Vtumorigenesis
p5427
sg13
I1
sa(dp5428
g7
I86
sg20
VC0678222
p5429
sg10
I13
sg11
Vbreast cancer
p5430
sg13
I2
sasa(dp5431
g2
VWe aimed to examine the relationship between the preoperative GSA index [uptake ratio of the liver to the liver plus heart at 15 min (LHL15) to uptake ratio of the heart at 15 min to that at 3 min (HH15) ratio] calculated from 99mTc-labeled diethylene triamine pentaacetate-galactosyl human serum albumin (99mTc-GSA) scintigraphy and background liver fibrosis and to investigate whether the GSA index can be a useful predictor in hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) patients treated with surgical resection (SR).
p5432
sg4
(lp5433
(dp5434
g7
I285
sg8
g47
sg10
I19
sg11
Vhuman serum albumin
p5435
sg13
I3
sasg17
(lp5436
(dp5437
g7
I462
sg20
VC2239176
p5438
sg10
I24
sg11
Vhepatocellular carcinoma
p5439
sg13
I2
sa(dp5440
g7
I345
sg20
VC0239946
p5441
sg10
I14
sg11
Vliver fibrosis
p5442
sg13
I2
sa(dp5443
g7
I430
sg20
VC0019196
p5444
sg10
I11
sg11
Vhepatitis C
p5445
sg13
I2
sa(dp5446
g7
I488
sg20
VC2239176
p5447
sg10
I3
sg11
VHCC
p5448
sg13
I1
sasa(dp5449
g2
VHere we demonstrate that HS 6-O-sulfotransferases 1 and 2 (HS6ST-1 and HS6ST-2), which perform sulfation at 6-O position in glucosamine in HS, impact ovarian cancer angiogenesis through the HS-dependent HB-EGF/EGFR axis that subsequently modulates the expression of multiple angiogenic cytokines.
p5450
sg4
(lp5451
(dp5452
g7
I190
sg8
VP19525
p5453
sg10
I19
sg11
VHS-dependent HB-EGF
p5454
sg13
I2
sa(dp5455
g7
I59
sg8
g47
sg10
I7
sg11
VHS6ST-1
p5456
sg13
I1
sa(dp5457
g7
I25
sg8
g47
sg10
I32
sg11
VHS 6-O-sulfotransferases 1 and 2
p5458
sg13
I5
sa(dp5459
g7
I71
sg8
g47
sg10
I7
sg11
VHS6ST-2
p5460
sg13
I1
sasg17
(lp5461
(dp5462
g7
I158
sg20
VC1536999
p5463
sg10
I19
sg11
Vcancer angiogenesis
p5464
sg13
I2
sasa(dp5465
g2
VDown-regulation of HS6ST-1 or HS6ST-2 in human ovarian cancer cell lines results in 30-50% reduction in glucosamine 6-O-sulfate levels in HS, impairing HB-EGF-dependent EGFR signaling and diminishing FGF2, IL-6, and IL-8 mRNA and protein levels in cancer cells.
p5466
sg4
(lp5467
(dp5468
g7
I19
sg8
g47
sg10
I7
sg11
VHS6ST-1
p5469
sg13
I1
sa(dp5470
g7
I30
sg8
g47
sg10
I7
sg11
VHS6ST-2
p5471
sg13
I1
sa(dp5472
g7
I152
sg8
g47
sg10
I21
sg11
VHB-EGF-dependent EGFR
p5473
sg13
I2
sa(dp5474
g7
I206
sg8
VP05231
p5475
sg10
I4
sg11
VIL-6
p5476
sg13
I1
sa(dp5477
g7
I200
sg8
g47
sg10
I4
sg11
VFGF2
p5478
sg13
I1
sasg17
(lp5479
(dp5480
g7
I55
sg20
VC0006826
p5481
sg10
I6
sg11
Vcancer
p5482
sg13
I1
sa(dp5483
g7
I47
sg20
VC1140680
p5484
sg10
I14
sg11
Vovarian cancer
p5485
sg13
I2
sasa(dp5486
g2
VOur results show that in addition to the critical role that 6-O-sulfate moieties play in angiogenic cytokine activation, HS 6-O-sulfation level, determined by the expression of HS6ST isoforms in ovarian cancer cells, is a major regulator of angiogenic program in ovarian cancer cells impacting HB-EGF signaling and subsequent expression of angiogenic cytokines by cancer cells.
p5487
sg4
(lp5488
(dp5489
g7
I340
sg8
VP01374
p5490
sg10
I20
sg11
Vangiogenic cytokines
p5491
sg13
I2
sa(dp5492
g7
I297
sg8
VP01133
p5493
sg10
I3
sg11
VEGF
p5494
sg13
I1
sa(dp5495
g7
I177
sg8
g47
sg10
I14
sg11
VHS6ST isoforms
p5496
sg13
I2
sasg17
(lp5497
(dp5498
g7
I195
sg20
VC1140680
p5499
sg10
I14
sg11
Vovarian cancer
p5500
sg13
I2
sa(dp5501
g7
I203
sg20
VC0006826
p5502
sg10
I6
sg11
Vcancer
p5503
sg13
I1
sa(dp5504
g7
I195
sg20
VC1140680
p5505
sg10
I14
sg11
Vovarian cancer
p5506
sg13
I2
sasa(dp5507
g2
VWe have investigated whether the expression of HS6STs and SULFs changes during chondrosarcoma progression and have determined 6O-sulphation levels in two chondrosarcoma cell lines.
p5508
sg4
(lp5509
(dp5510
g7
I47
sg8
g47
sg10
I6
sg11
VHS6STs
p5511
sg13
I1
sasg17
(lp5512
(dp5513
g7
I79
sg20
VC0008479
p5514
sg10
I14
sg11
Vchondrosarcoma
p5515
sg13
I1
sa(dp5516
g7
I79
sg20
VC0008479
p5517
sg10
I14
sg11
Vchondrosarcoma
p5518
sg13
I1
sasa(dp5519
g2
VImmunohistochemistry on tissue microarrays of chondrosarcomas showed that HS6ST3 and SULF1 were highly expressed in most chondrosarcomas, whereas SULF2 expression was absent in most cases.
p5520
sg4
(lp5521
(dp5522
g7
I85
sg8
g47
sg10
I5
sg11
VSULF1
p5523
sg13
I1
sa(dp5524
g7
I74
sg8
g47
sg10
I6
sg11
VHS6ST3
p5525
sg13
I1
sa(dp5526
g7
I146
sg8
g47
sg10
I5
sg11
VSULF2
p5527
sg13
I1
sasg17
(lp5528
(dp5529
g7
I46
sg20
VC0008479
p5530
sg10
I15
sg11
Vchondrosarcomas
p5531
sg13
I1
sa(dp5532
g7
I46
sg20
VC0008479
p5533
sg10
I15
sg11
Vchondrosarcomas
p5534
sg13
I1
sasa(dp5535
g2
VHS6ST1 and HS6ST2 expression are significantly increased during chondrosarcoma progression, which suggest that 6O-sulphation is increased during progression.
p5536
sg4
(lp5537
(dp5538
g7
I0
sg8
g47
sg10
I6
sg11
VHS6ST1
p5539
sg13
I1
sasg17
(lp5540
(dp5541
g7
I64
sg20
VC0008479
p5542
sg10
I14
sg11
Vchondrosarcoma
p5543
sg13
I1
sasa(dp5544
g2
VIn conclusion, our results show increased HS6ST1 and HS6ST2 expression during chondrosarcoma progression and increased HS 6O-sulphation in vitro.
p5545
sg4
(lp5546
(dp5547
g7
I42
sg8
g47
sg10
I6
sg11
VHS6ST1
p5548
sg13
I1
sasg17
(lp5549
(dp5550
g7
I78
sg20
VC0008479
p5551
sg10
I14
sg11
Vchondrosarcoma
p5552
sg13
I1
sasa(dp5553
g2
VAs 6O-sulphation plays an important role in signal transduction, altered HS6ST expression might be associated with changes in signal transduction pathways in chondrosarcoma progression.
p5554
sg4
(lp5555
(dp5556
g7
I73
sg8
g47
sg10
I5
sg11
VHS6ST
p5557
sg13
I1
sasg17
(lp5558
(dp5559
g7
I158
sg20
VC0008479
p5560
sg10
I14
sg11
Vchondrosarcoma
p5561
sg13
I1
sasa(dp5562
g2
VThus, neutrophils and NK cells act as important disease-promoting immune cells in experimental osteoarthritis and their functional interaction is promoted by the CXCL10/CXCR3 axis.
p5563
sg4
(lp5564
(dp5565
g7
I162
sg8
VP02778
p5566
sg10
I6
sg11
VCXCL10
p5567
sg13
I1
sa(dp5568
g7
I169
sg8
VP49682
p5569
sg10
I5
sg11
VCXCR3
p5570
sg13
I1
sasg17
(lp5571
(dp5572
g7
I95
sg20
VC0029408
p5573
sg10
I14
sg11
Vosteoarthritis
p5574
sg13
I1
sasa(dp5575
g2
VOvarian cancer cell line OC316 was reverse transfected with a miR-223 mimic and relative expression levels of miR-223 and SMARCD1 were quantified by RT-PCR; protein expression of SMARCD1 was evaluated by Western Blot.
p5576
sg4
(lp5577
(dp5578
g7
I122
sg8
g47
sg10
I7
sg11
VSMARCD1
p5579
sg13
I1
sa(dp5580
g7
I122
sg8
g47
sg10
I7
sg11
VSMARCD1
p5581
sg13
I1
sa(dp5582
g7
I62
sg8
g47
sg10
I7
sg11
VmiR-223
p5583
sg13
I1
sasg17
(lp5584
(dp5585
g7
I0
sg20
VC1140680
p5586
sg10
I14
sg11
VOvarian cancer
p5587
sg13
I2
sasa(dp5588
g2
VmiR-223 expression was upregulated in high grade ovarian serous carcinoma samples (median RQ=4.8881, P=.0045), whilst SMARCD1 was down-regulated (median RQ=0.5107, P=.0492).
p5589
sg4
(lp5590
(dp5591
g7
I118
sg8
g47
sg10
I7
sg11
VSMARCD1
p5592
sg13
I1
sasg17
(lp5593
(dp5594
g7
I49
sg20
VC1335177
p5595
sg10
I24
sg11
Vovarian serous carcinoma
p5596
sg13
I3
sasa(dp5597
g2
VIt was indicated that SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily D, member 1, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily D, member 1, dihydropyrimidinase-like 2, RMND5A and ANGPTL1 were potential prognostic markers in breast cancer, and the cell cycle may be involved in the regulation of breast cancer.
p5598
sg4
(lp5599
(dp5600
g7
I186
sg8
g47
sg10
I60
sg11
Vchromatin, subfamily D, member 1, dihydropyrimidinase-like 2
p5601
sg13
I7
sa(dp5602
g7
I259
sg8
g47
sg10
I7
sg11
VANGPTL1
p5603
sg13
I1
sa(dp5604
g7
I248
sg8
g47
sg10
I6
sg11
VRMND5A
p5605
sg13
I1
sa(dp5606
g7
I22
sg8
VP28370
p5607
sg10
I3
sg11
VSWI
p5608
sg13
I1
sa(dp5609
g7
I26
sg8
g47
sg10
I3
sg11
VSNF
p5610
sg13
I1
sa(dp5611
g7
I26
sg8
g47
sg10
I3
sg11
VSNF
p5612
sg13
I1
sa(dp5613
g7
I87
sg8
g47
sg10
I32
sg11
Vchromatin, subfamily D, member 1
p5614
sg13
I5
sa(dp5615
g7
I22
sg8
VP28370
p5616
sg10
I3
sg11
VSWI
p5617
sg13
I1
sasg17
(lp5618
(dp5619
g7
I304
sg20
VC0678222
p5620
sg10
I13
sg11
Vbreast cancer
p5621
sg13
I2
sa(dp5622
g7
I304
sg20
VC0678222
p5623
sg10
I13
sg11
Vbreast cancer
p5624
sg13
I2
sasa(dp5625
g2
VMiR-490-3p plays a tumour suppressor role in epithelial ovarian cancer by targeting CDK1 regulation and influencing SMARCD1 and cyclin D1 (CCND1) expressions.
p5626
sg4
(lp5627
(dp5628
g7
I84
sg8
VP06493
p5629
sg10
I4
sg11
VCDK1
p5630
sg13
I1
sa(dp5631
g7
I139
sg8
VP24385
p5632
sg10
I5
sg11
VCCND1
p5633
sg13
I1
sa(dp5634
g7
I116
sg8
g47
sg10
I7
sg11
VSMARCD1
p5635
sg13
I1
sa(dp5636
g7
I0
sg8
g47
sg10
I10
sg11
VMiR-490-3p
p5637
sg13
I1
sa(dp5638
g7
I128
sg8
VP24385
p5639
sg10
I9
sg11
Vcyclin D1
p5640
sg13
I2
sasg17
(lp5641
(dp5642
g7
I19
sg20
VC0027651
p5643
sg10
I6
sg11
Vtumour
p5644
sg13
I1
sa(dp5645
g7
I45
sg20
VC0677886
p5646
sg10
I25
sg11
Vepithelial ovarian cancer
p5647
sg13
I3
sasa(dp5648
g2
VHepatocyte-specific inactivation of Baf60a reduced bile acid production and cholesterol absorption, and attenuated diet-induced hypercholesterolemia and atherosclerosis in mice.
p5649
sg4
(lp5650
(dp5651
g7
I36
sg8
g47
sg10
I6
sg11
VBaf60a
p5652
sg13
I1
sasg17
(lp5653
(dp5654
g7
I128
sg20
VC0020443
p5655
sg10
I20
sg11
Vhypercholesterolemia
p5656
sg13
I1
sa(dp5657
g7
I153
sg20
VC0004153
p5658
sg10
I15
sg11
Vatherosclerosis
p5659
sg13
I1
sa(dp5660
g7
I20
sg20
VC0544461
p5661
sg10
I12
sg11
Vinactivation
p5662
sg13
I1
sasa(dp5663
g2
VmiR-7 expression reduced SMARCD1 protein expression in lung cancer cell lines.
p5664
sg4
(lp5665
(dp5666
g7
I25
sg8
g47
sg10
I15
sg11
VSMARCD1 protein
p5667
sg13
I2
sa(dp5668
g7
I0
sg8
g47
sg10
I5
sg11
VmiR-7
p5669
sg13
I1
sasg17
(lp5670
(dp5671
g7
I55
sg20
VC0684249
p5672
sg10
I11
sg11
Vlung cancer
p5673
sg13
I2
sasa(dp5674
g2
VWe found that although SMARCD1 sensitized lung cancer cells to chemotherapy drug-induced apoptosis, miR-7 enhanced the drug resistance potential of lung cancer cells against chemotherapy drugs.
p5675
sg4
(lp5676
(dp5677
g7
I100
sg8
g47
sg10
I5
sg11
VmiR-7
p5678
sg13
I1
sa(dp5679
g7
I23
sg8
g47
sg10
I7
sg11
VSMARCD1
p5680
sg13
I1
sasg17
(lp5681
(dp5682
g7
I42
sg20
VC0684249
p5683
sg10
I11
sg11
Vlung cancer
p5684
sg13
I2
sa(dp5685
g7
I42
sg20
VC0684249
p5686
sg10
I11
sg11
Vlung cancer
p5687
sg13
I2
sasa(dp5688
g2
VSMARCD1 was down-regulated in patients with non-small cell lung cancer and lung adenocarcinoma cell lines, and SMARCD1 and miR-7 expression levels were negatively correlated in clinical samples.
p5689
sg4
(lp5690
(dp5691
g7
I0
sg8
g47
sg10
I7
sg11
VSMARCD1
p5692
sg13
I1
sa(dp5693
g7
I0
sg8
g47
sg10
I7
sg11
VSMARCD1
p5694
sg13
I1
sa(dp5695
g7
I123
sg8
g47
sg10
I5
sg11
VmiR-7
p5696
sg13
I1
sasg17
(lp5697
(dp5698
g7
I75
sg20
VC0152013
p5699
sg10
I19
sg11
Vlung adenocarcinoma
p5700
sg13
I2
sa(dp5701
g7
I44
sg20
VC0007131
p5702
sg10
I26
sg11
Vnon-small cell lung cancer
p5703
sg13
I4
sasa(dp5704
g2
VOur investigation into the involvement of the EGFR-regulated microRNA pathway in the SWI/SNF chromatin remodeling complex suggests that EGFR-mediated miR-7 suppresses the coupling of the chromatin remodeling factor SMARCD1 with p53, resulting in increased chemo-resistance of lung cancer cells.
p5705
sg4
(lp5706
(dp5707
g7
I187
sg8
g47
sg10
I27
sg11
Vchromatin remodeling factor
p5708
sg13
I3
sa(dp5709
g7
I85
sg8
VP28370
p5710
sg10
I3
sg11
VSWI
p5711
sg13
I1
sa(dp5712
g7
I89
sg8
g47
sg10
I3
sg11
VSNF
p5713
sg13
I1
sa(dp5714
g7
I150
sg8
g47
sg10
I5
sg11
VmiR-7
p5715
sg13
I1
sa(dp5716
g7
I215
sg8
g47
sg10
I7
sg11
VSMARCD1
p5717
sg13
I1
sa(dp5718
g7
I228
sg8
VP42771
p5719
sg10
I3
sg11
Vp53
p5720
sg13
I1
sasg17
(lp5721
(dp5722
g7
I276
sg20
VC0684249
p5723
sg10
I11
sg11
Vlung cancer
p5724
sg13
I2
sasa(dp5725
g2
VmiR-490-3p exerted growth- and metastasis-suppressive effects on gastric cancer cells through directly targeting SMARCD1, a SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeling complex subunit.
p5726
sg4
(lp5727
(dp5728
g7
I159
sg8
g47
sg10
I3
sg11
VSNF
p5729
sg13
I1
sa(dp5730
g7
I124
sg8
VP28370
p5731
sg10
I3
sg11
VSWI
p5732
sg13
I1
sa(dp5733
g7
I0
sg8
g47
sg10
I10
sg11
VmiR-490-3p
p5734
sg13
I1
sa(dp5735
g7
I113
sg8
g47
sg10
I7
sg11
VSMARCD1
p5736
sg13
I1
sasg17
(lp5737
(dp5738
g7
I65
sg20
VC0024623
p5739
sg10
I14
sg11
Vgastric cancer
p5740
sg13
I2
sa(dp5741
g7
I31
sg20
VC0027627
p5742
sg10
I10
sg11
Vmetastasis
p5743
sg13
I1
sasa(dp5744
g2
VKnockdown of SMARCD1 significantly attenuated the protumorigenic effects of miR-490-3p inhibitor, whereas enforced expression of SMARCD1 promoted in vitro and in vivo oncogenic phenotypes of gastric cancer cells.
p5745
sg4
(lp5746
(dp5747
g7
I13
sg8
g47
sg10
I7
sg11
VSMARCD1
p5748
sg13
I1
sa(dp5749
g7
I13
sg8
g47
sg10
I7
sg11
VSMARCD1
p5750
sg13
I1
sa(dp5751
g7
I76
sg8
g47
sg10
I10
sg11
VmiR-490-3p
p5752
sg13
I1
sasg17
(lp5753
(dp5754
g7
I191
sg20
VC0024623
p5755
sg10
I14
sg11
Vgastric cancer
p5756
sg13
I2
sasa(dp5757
g2
VSMARCD1 was markedly upregulated in gastric cancer in which its high expression was associated with shortened patients' survival independent of TNM staging.
p5758
sg4
(lp5759
(dp5760
g7
I144
sg8
g47
sg10
I3
sg11
VTNM
p5761
sg13
I1
sa(dp5762
g7
I0
sg8
g47
sg10
I7
sg11
VSMARCD1
p5763
sg13
I1
sasg17
(lp5764
(dp5765
g7
I36
sg20
VC0024623
p5766
sg10
I14
sg11
Vgastric cancer
p5767
sg13
I2
sasa(dp5768
g2
ViTD, nTD, and ECLNI were all significant independent adverse factors for RFS in rectal cancer, and were all associated with pT, pN, and LN ratio.
p5769
sg4
(lp5770
(dp5771
g7
I5
sg8
g47
sg10
I3
sg11
VnTD
p5772
sg13
I1
sasg17
(lp5773
(dp5774
g7
I73
sg20
VC0015624
p5775
sg10
I3
sg11
VRFS
p5776
sg13
I1
sa(dp5777
g7
I80
sg20
VC0007113
p5778
sg10
I13
sg11
Vrectal cancer
p5779
sg13
I2
sasa(dp5780
g2
VSilencing CCM3 by siRNA stimulated endothelial proliferation, migration and sprouting accompanied by significant downregulation of the core components of Notch signalling including DLL4, Notch4, HEY2 and HES1 and by activation of VEGF and Erk pathways.
p5781
sg4
(lp5782
(dp5783
g7
I204
sg8
g47
sg10
I4
sg11
VHES1
p5784
sg13
I1
sa(dp5785
g7
I195
sg8
g47
sg10
I4
sg11
VHEY2
p5786
sg13
I1
sa(dp5787
g7
I181
sg8
g47
sg10
I4
sg11
VDLL4
p5788
sg13
I1
sa(dp5789
g7
I10
sg8
g47
sg10
I4
sg11
VCCM3
p5790
sg13
I1
sa(dp5791
g7
I239
sg8
VP29323
p5792
sg10
I3
sg11
VErk
p5793
sg13
I1
sa(dp5794
g7
I187
sg8
g47
sg10
I6
sg11
VNotch4
p5795
sg13
I1
sasg17
(lp5796
(dp5797
g7
I10
sg20
VC1864040
p5798
sg10
I4
sg11
VCCM3
p5799
sg13
I1
sa(dp5800
g7
I47
sg20
VC0334094
p5801
sg10
I13
sg11
Vproliferation
p5802
sg13
I1
sasa(dp5803
g2
VThe aim was to assess the efficacy of glucomannan (GNN) as a sole treatment for functional constipation.
p5804
sg4
(lp5805
sg17
(lp5806
(dp5807
g7
I80
sg20
VC0401146
p5808
sg10
I23
sg11
Vfunctional constipation
p5809
sg13
I2
sasa(dp5810
g2
VChildren aged 3-16 years with functional constipation according to Rome III criteria were randomly assigned to receive GNN (2.52 g/d) or placebo for 4 weeks.
p5811
sg4
(lp5812
sg17
(lp5813
(dp5814
g7
I30
sg20
VC0401146
p5815
sg10
I23
sg11
Vfunctional constipation
p5816
sg13
I2
sasa(dp5817
g2
VInterestingly, using Affymetrix gene expression data of a cohort of 285 patients with acute myeloid leukemia (AML), we found that GNN/TU12B1-TY expression was specifically increased in two AML clusters.
p5818
sg4
(lp5819
(dp5820
g7
I130
sg8
g47
sg10
I3
sg11
VGNN
p5821
sg13
I1
sasg17
(lp5822
(dp5823
g7
I110
sg20
VC0023467
p5824
sg10
I3
sg11
VAML
p5825
sg13
I1
sa(dp5826
g7
I110
sg20
VC0023467
p5827
sg10
I3
sg11
VAML
p5828
sg13
I1
sa(dp5829
g7
I86
sg20
VC0023467
p5830
sg10
I22
sg11
Vacute myeloid leukemia
p5831
sg13
I3
sasa(dp5832
g2
VThe present results indicate that reduced function of TU12B1-TY may contribute to the development and/or progression of human pancreatic cancer.
p5833
sg4
(lp5834
(dp5835
g7
I54
sg8
g47
sg10
I9
sg11
VTU12B1-TY
p5836
sg13
I1
sasg17
(lp5837
(dp5838
g7
I126
sg20
VC0235974
p5839
sg10
I17
sg11
Vpancreatic cancer
p5840
sg13
I2
sasa(dp5841
g2
VTo characterize morphologic alterations in the retina of the visual mutant zebrafish gantenbein (gnn) and to examine whether these alterations correlate with those present in human hereditary eye diseases.
p5842
sg4
(lp5843
(dp5844
g7
I61
sg8
g47
sg10
I34
sg11
Vvisual mutant zebrafish gantenbein
p5845
sg13
I4
sa(dp5846
g7
I97
sg8
g47
sg10
I3
sg11
Vgnn
p5847
sg13
I1
sasg17
(lp5848
(dp5849
g7
I181
sg20
VC0015398
p5850
sg10
I23
sg11
Vhereditary eye diseases
p5851
sg13
I3
sa(dp5852
g7
I68
sg20
VC0596988
p5853
sg10
I6
sg11
Vmutant
p5854
sg13
I1
sasa(dp5855
g2
VThus, the early developmental morphology of gnn exhibits similarities to cone dystrophies most commonly seen in age-related macular degeneration (AMD) among humans, whereas the later stages of degeneration in gnn resemble RPE alterations in retinitis pigmentosa (RP) in humans.
p5856
sg4
(lp5857
(dp5858
g7
I44
sg8
g47
sg10
I3
sg11
Vgnn
p5859
sg13
I1
sasg17
(lp5860
(dp5861
g7
I78
sg20
VC0333606
p5862
sg10
I11
sg11
Vdystrophies
p5863
sg13
I1
sa(dp5864
g7
I132
sg20
VC0011164
p5865
sg10
I12
sg11
Vdegeneration
p5866
sg13
I1
sa(dp5867
g7
I222
sg20
VC0035334
p5868
sg10
I2
sg11
VRP
p5869
sg13
I1
sa(dp5870
g7
I112
sg20
VC0242383
p5871
sg10
I32
sg11
Vage-related macular degeneration
p5872
sg13
I3
sa(dp5873
g7
I241
sg20
VC0035334
p5874
sg10
I20
sg11
Vretinitis pigmentosa
p5875
sg13
I2
sa(dp5876
g7
I146
sg20
VC0242383
p5877
sg10
I3
sg11
VAMD
p5878
sg13
I1
sasa(dp5879
g2
VThe gnn zebrafish mutant may therefore be a useful model for examining the possible interplay and connection between cone dystrophy and RPE degeneration.
p5880
sg4
(lp5881
(dp5882
g7
I4
sg8
g47
sg10
I20
sg11
Vgnn zebrafish mutant
p5883
sg13
I3
sasg17
(lp5884
(dp5885
g7
I117
sg20
VC0730290
p5886
sg10
I14
sg11
Vcone dystrophy
p5887
sg13
I2
sa(dp5888
g7
I18
sg20
VC0596988
p5889
sg10
I6
sg11
Vmutant
p5890
sg13
I1
sa(dp5891
g7
I140
sg20
VC0011164
p5892
sg10
I12
sg11
Vdegeneration
p5893
sg13
I1
sasa(dp5894
g2
VOur goal was to assess the patterns of familial aggregation of three melanoma risk factors: great number of naevi (GNN), light phototype (LP) and high degree of sun exposure (HDSE).
p5895
sg4
(lp5896
(dp5897
g7
I69
sg8
VP19883
p5898
sg10
I21
sg11
Vmelanoma risk factors
p5899
sg13
I3
sasg17
(lp5900
(dp5901
g7
I69
sg20
VC0025202
p5902
sg10
I8
sg11
Vmelanoma
p5903
sg13
I1
sasa(dp5904
g2
VTwenty-five patients were divided into the following groups: (1) chronic glomerulonephritis with normal renal function (GNN) (2) chronic glomerulonephritis with moderate renal insufficiency (GNI) (3) severe chronic renal failure undergoing maintenance dialysis (CRF) (4) acute renal failure during oliguric phase (ARF) (5) normal control without renal suffering (NC).
p5905
sg4
(lp5906
sg17
(lp5907
(dp5908
g7
I65
sg20
VC0152451
p5909
sg10
I26
sg11
Vchronic glomerulonephritis
p5910
sg13
I2
sa(dp5911
g7
I170
sg20
VC0035078
p5912
sg10
I19
sg11
Vrenal insufficiency
p5913
sg13
I2
sa(dp5914
g7
I271
sg20
VC0022660
p5915
sg10
I41
sg11
Vacute renal failure during oliguric phase
p5916
sg13
I6
sa(dp5917
g7
I262
sg20
VC0022661
p5918
sg10
I3
sg11
VCRF
p5919
sg13
I1
sa(dp5920
g7
I314
sg20
VC0022660
p5921
sg10
I3
sg11
VARF
p5922
sg13
I1
sa(dp5923
g7
I352
sg20
VC0683278
p5924
sg10
I9
sg11
Vsuffering
p5925
sg13
I1
sa(dp5926
g7
I207
sg20
VC0022661
p5927
sg10
I53
sg11
Vchronic renal failure undergoing maintenance dialysis
p5928
sg13
I6
sa(dp5929
g7
I65
sg20
VC0152451
p5930
sg10
I26
sg11
Vchronic glomerulonephritis
p5931
sg13
I2
sasa(dp5932
g2
VThe levels of PTH/PTHrP receptor mRNA (corrected by beta-actin mRNA) in the kidney of GNN, GNI, CRF and ARF patients was markedly decreased by up to 35.7%, 68.5%, 77.9% and 92.2%, respectively.
p5933
sg4
(lp5934
(dp5935
g7
I86
sg8
g47
sg10
I3
sg11
VGNN
p5936
sg13
I1
sa(dp5937
g7
I96
sg8
VP06850
p5938
sg10
I3
sg11
VCRF
p5939
sg13
I1
sa(dp5940
g7
I14
sg8
VP01270
p5941
sg10
I3
sg11
VPTH
p5942
sg13
I1
sa(dp5943
g7
I18
sg8
VP12272
p5944
sg10
I19
sg11
VPTHrP receptor mRNA
p5945
sg13
I3
sa(dp5946
g7
I52
sg8
VP63261
p5947
sg10
I15
sg11
Vbeta-actin mRNA
p5948
sg13
I2
sa(dp5949
g7
I104
sg8
VP42771
p5950
sg10
I3
sg11
VARF
p5951
sg13
I1
sasg17
(lp5952
(dp5953
g7
I104
sg20
VC0264490
p5954
sg10
I3
sg11
VARF
p5955
sg13
I1
sa(dp5956
g7
I96
sg20
VC0022661
p5957
sg10
I3
sg11
VCRF
p5958
sg13
I1
sasa(dp5959
g2
VHere, we tested whether rhMG53 protein can improve membrane repair in a dysferlin-deficient mouse model of LGMD2B (B6.129-Dysftm1Kcam/J).
p5960
sg4
(lp5961
sg17
(lp5962
(dp5963
g7
I107
sg20
VC1850889
p5964
sg10
I6
sg11
VLGMD2B
p5965
sg13
I1
sasa(dp5966
g2
VThree interacting partners of dysferlin are also implicated in membrane resealing: caveolin-3 (in limb girdle muscular dystrophy type 1C), annexin A1, and the newly identified protein mitsugumin 53 (MG53).
p5967
sg4
(lp5968
(dp5969
g7
I139
sg8
VP04083
p5970
sg10
I10
sg11
Vannexin A1
p5971
sg13
I2
sa(dp5972
g7
I83
sg8
VP56539
p5973
sg10
I10
sg11
Vcaveolin-3
p5974
sg13
I1
sasg17
(lp5975
(dp5976
g7
I98
sg20
VC0686353
p5977
sg10
I30
sg11
Vlimb girdle muscular dystrophy
p5978
sg13
I4
sasa(dp5979
g2
VLatency and amplitude of the visual P300 and N270 were examined in patients with transient ischemic attack (TIA) and in age-matched healthy control subjects to investigate the feasibility of N270 as a clinical examination method to evaluate the cognitive status of patients with TIA.
p5980
sg4
(lp5981
sg17
(lp5982
(dp5983
g7
I81
sg20
VC0007787
p5984
sg10
I25
sg11
Vtransient ischemic attack
p5985
sg13
I3
sa(dp5986
g7
I108
sg20
VC0007787
p5987
sg10
I3
sg11
VTIA
p5988
sg13
I1
sa(dp5989
g7
I108
sg20
VC0007787
p5990
sg10
I3
sg11
VTIA
p5991
sg13
I1
sasa(dp5992
g2
VWe applied multichannel recording of P300 in 28 patients (68.3 +/- 8.1 years; 15 asymptomatic, 13 with a history of transient ischemic attack (TIA)) and compared them with an age- and sex-matched control group.
p5993
sg4
(lp5994
sg17
(lp5995
(dp5996
g7
I116
sg20
VC0007787
p5997
sg10
I25
sg11
Vtransient ischemic attack
p5998
sg13
I3
sa(dp5999
g7
I143
sg20
VC0007787
p6000
sg10
I3
sg11
VTIA
p6001
sg13
I1
sasa(dp6002
g2
VPrevious studies have implicated the roles of NT and NTR1 in the etiology or expression of schizophrenia.
p6003
sg4
(lp6004
(dp6005
g7
I53
sg8
g47
sg10
I4
sg11
VNTR1
p6006
sg13
I1
sasg17
(lp6007
(dp6008
g7
I91
sg20
VC0036341
p6009
sg10
I13
sg11
Vschizophrenia
p6010
sg13
I1
sasa(dp6011
g2
VThis case-control study examined the associations between schizophrenia and three NTR1 gene polymorphisms (rs6090453C/G, rs6011914C/G, and rs2427422A/G) previously linked to working memory performance in a Han Chinese population.
p6012
sg4
(lp6013
(dp6014
g7
I82
sg8
g47
sg10
I9
sg11
VNTR1 gene
p6015
sg13
I2
sasg17
(lp6016
(dp6017
g7
I58
sg20
VC0036341
p6018
sg10
I13
sg11
Vschizophrenia
p6019
sg13
I1
sasa(dp6020
g2
VThis suggested that nonpeptide agonist mimetics acting at the NTR1 might be helpful in the treatment of Parkinson's disease and schizophrenia.
p6021
sg4
(lp6022
(dp6023
g7
I62
sg8
g47
sg10
I4
sg11
VNTR1
p6024
sg13
I1
sasg17
(lp6025
(dp6026
g7
I104
sg20
VC0030567
p6027
sg10
I19
sg11
VParkinson's disease
p6028
sg13
I2
sa(dp6029
g7
I128
sg20
VC0036341
p6030
sg10
I13
sg11
Vschizophrenia
p6031
sg13
I1
sasa(dp6032
g2
VThe patients carrying either one or both of GCT and AGG alleles of SP-A2 and patients with A allele at position 1011 of MBL had markedly higher eosinophilia, total IgE antibodies and lower FEV1 (the clinical markers of ABPA).
p6033
sg4
(lp6034
(dp6035
g7
I164
sg8
VP01854
p6036
sg10
I3
sg11
VIgE
p6037
sg13
I1
sasg17
(lp6038
(dp6039
g7
I219
sg20
VC0004031
p6040
sg10
I4
sg11
VABPA
p6041
sg13
I1
sa(dp6042
g7
I144
sg20
VC0014457
p6043
sg10
I12
sg11
Veosinophilia
p6044
sg13
I1
sa(dp6045
g7
I164
sg20
VC0270850
p6046
sg10
I3
sg11
VIgE
p6047
sg13
I1
sasa(dp6048
g2
VThe patients carrying either one or both of GCT and AGG alleles of SP-A2 and patients with A allele at position 1011 of MBL had markedly higher eosinophilia, total IgE antibodies and lower FEV1 (the clinical markers of ABPA).
p6049
sg4
(lp6050
(dp6051
g7
I164
sg8
VP01854
p6052
sg10
I3
sg11
VIgE
p6053
sg13
I1
sasg17
(lp6054
(dp6055
g7
I219
sg20
VC0004031
p6056
sg10
I4
sg11
VABPA
p6057
sg13
I1
sa(dp6058
g7
I144
sg20
VC0014457
p6059
sg10
I12
sg11
Veosinophilia
p6060
sg13
I1
sa(dp6061
g7
I164
sg20
VC0270850
p6062
sg10
I3
sg11
VIgE
p6063
sg13
I1
sasa(dp6064
g2
Vsph1- and spa2-deleted cells possess defects in mating projection morphology and pseudohyphal growth.
p6065
sg4
(lp6066
(dp6067
g7
I0
sg8
VP16157
p6068
sg10
I4
sg11
Vsph1
p6069
sg13
I1
sa(dp6070
g7
I10
sg8
g47
sg10
I4
sg11
Vspa2
p6071
sg13
I1
sasg17
(lp6072
(dp6073
g7
I29
sg20
VC0850310
p6074
sg10
I7
sg11
Vpossess
p6075
sg13
I1
sa(dp6076
g7
I0
sg20
VC2674218
p6077
sg10
I4
sg11
Vsph1
p6078
sg13
I1
sasa(dp6079
g2
Vsph1(Delta) spa2(Delta) double mutants also exhibit a strong haploid invasive growth defect and an exacerbated mating projection defect relative to either sph1(Delta) or spa2(Delta) single mutants.
p6080
sg4
(lp6081
(dp6082
g7
I170
sg8
g47
sg10
I26
sg11
Vspa2(Delta) single mutants
p6083
sg13
I3
sa(dp6084
g7
I0
sg8
VP16157
p6085
sg10
I11
sg11
Vsph1(Delta)
p6086
sg13
I1
sa(dp6087
g7
I0
sg8
VP16157
p6088
sg10
I38
sg11
Vsph1(Delta) spa2(Delta) double mutants
p6089
sg13
I4
sasg17
(lp6090
(dp6091
g7
I0
sg20
VC2674218
p6092
sg10
I4
sg11
Vsph1
p6093
sg13
I1
sa(dp6094
g7
I0
sg20
VC2674218
p6095
sg10
I4
sg11
Vsph1
p6096
sg13
I1
sa(dp6097
g7
I69
sg20
VC1156244
p6098
sg10
I15
sg11
Vinvasive growth
p6099
sg13
I2
sasa(dp6100
g2
VSPH1, which is similar to SPA2, is required for bipolar budding and plays a role in shmoo formation.
p6101
sg4
(lp6102
(dp6103
g7
I0
sg8
VP16157
p6104
sg10
I4
sg11
VSPH1
p6105
sg13
I1
sa(dp6106
g7
I26
sg8
g47
sg10
I4
sg11
VSPA2
p6107
sg13
I1
sasg17
(lp6108
(dp6109
g7
I0
sg20
VC2674218
p6110
sg10
I4
sg11
VSPH1
p6111
sg13
I1
sasa(dp6112
g2
VOutcomes were best in patients with ovarian cancer (MS 15.9 months) and colorectal cancer (MS 14.3 months) and worst in patients with lung (MS 2.4 months) and pancreas (MS 1.9 months) cancers.
p6113
sg4
(lp6114
sg17
(lp6115
(dp6116
g7
I184
sg20
VC0006826
p6117
sg10
I7
sg11
Vcancers
p6118
sg13
I1
sa(dp6119
g7
I72
sg20
VC1527249
p6120
sg10
I17
sg11
Vcolorectal cancer
p6121
sg13
I2
sa(dp6122
g7
I36
sg20
VC1140680
p6123
sg10
I14
sg11
Vovarian cancer
p6124
sg13
I2
sasa(dp6125
g2
VThis study was undertaken to evaluate the effect of ADAM8 on the proliferation and apoptosis of hepatocytes and hepatoma carcinoma cells during hepatocellular carcinoma (HCC) progression.
p6126
sg4
(lp6127
(dp6128
g7
I52
sg8
VP78325
p6129
sg10
I5
sg11
VADAM8
p6130
sg13
I1
sasg17
(lp6131
(dp6132
g7
I170
sg20
VC2239176
p6133
sg10
I3
sg11
VHCC
p6134
sg13
I1
sa(dp6135
g7
I65
sg20
VC0334094
p6136
sg10
I13
sg11
Vproliferation
p6137
sg13
I1
sa(dp6138
g7
I121
sg20
VC0007097
p6139
sg10
I9
sg11
Vcarcinoma
p6140
sg13
I1
sa(dp6141
g7
I144
sg20
VC2239176
p6142
sg10
I24
sg11
Vhepatocellular carcinoma
p6143
sg13
I2
sa(dp6144
g7
I112
sg20
VC2239176
p6145
sg10
I8
sg11
Vhepatoma
p6146
sg13
I1
sasa(dp6147
g2
VIn conclusion, our study suggested that ADAM8 could promote the proliferation of normal hepatocytes and render hepatoma carcinoma cells more resistant to apoptosis to play important roles during the progression of HCC.
p6148
sg4
(lp6149
(dp6150
g7
I40
sg8
VP78325
p6151
sg10
I5
sg11
VADAM8
p6152
sg13
I1
sasg17
(lp6153
(dp6154
g7
I64
sg20
VC0334094
p6155
sg10
I13
sg11
Vproliferation
p6156
sg13
I1
sa(dp6157
g7
I111
sg20
VC2239176
p6158
sg10
I8
sg11
Vhepatoma
p6159
sg13
I1
sa(dp6160
g7
I120
sg20
VC0007097
p6161
sg10
I9
sg11
Vcarcinoma
p6162
sg13
I1
sa(dp6163
g7
I214
sg20
VC2239176
p6164
sg10
I3
sg11
VHCC
p6165
sg13
I1
sasa(dp6166
g2
VThus, our data integrate ADAM8 in pancreatic cancer signalling and validate ADAM8 as a target for PDAC therapy.
p6167
sg4
(lp6168
(dp6169
g7
I25
sg8
VP78325
p6170
sg10
I5
sg11
VADAM8
p6171
sg13
I1
sa(dp6172
g7
I25
sg8
VP78325
p6173
sg10
I5
sg11
VADAM8
p6174
sg13
I1
sasg17
(lp6175
(dp6176
g7
I34
sg20
VC0235974
p6177
sg10
I17
sg11
Vpancreatic cancer
p6178
sg13
I2
sasa(dp6179
g2
VThis study focuses on investigating the concrete role of a disintegrin and metalloproteinase 8 (ADAM8) in the progression of hepatocellular carcinoma (HCC).
p6180
sg4
(lp6181
(dp6182
g7
I59
sg8
VP78325
p6183
sg10
I43
sg11
Vdisintegrin and metalloproteinase 8 (ADAM8)
p6184
sg13
I5
sasg17
(lp6185
(dp6186
g7
I125
sg20
VC2239176
p6187
sg10
I24
sg11
Vhepatocellular carcinoma
p6188
sg13
I2
sa(dp6189
g7
I151
sg20
VC2239176
p6190
sg10
I3
sg11
VHCC
p6191
sg13
I1
sasa(dp6192
g2
VHowever, no studies have examined ADAM8 association in colorectal cancer (CRC).
p6193
sg4
(lp6194
(dp6195
g7
I34
sg8
VP78325
p6196
sg10
I44
sg11
VADAM8 association in colorectal cancer (CRC)
p6197
sg13
I6
sasg17
(lp6198
(dp6199
g7
I74
sg20
VC1527249
p6200
sg10
I3
sg11
VCRC
p6201
sg13
I1
sa(dp6202
g7
I55
sg20
VC1527249
p6203
sg10
I17
sg11
Vcolorectal cancer
p6204
sg13
I2
sasa(dp6205
g2
VSubgroup analysis showed that 5-year OS of colon cancer, T3-T4 stage and N0 stage was worse for patients with ADAM8-positive tumors than those with ADAM8-negative tumors (p &lt; 0.05).
p6206
sg4
(lp6207
(dp6208
g7
I110
sg8
VP78325
p6209
sg10
I5
sg11
VADAM8
p6210
sg13
I1
sasg17
(lp6211
(dp6212
g7
I125
sg20
VC0027651
p6213
sg10
I6
sg11
Vtumors
p6214
sg13
I1
sa(dp6215
g7
I43
sg20
VC0699790
p6216
sg10
I12
sg11
Vcolon cancer
p6217
sg13
I2
sa(dp6218
g7
I125
sg20
VC0027651
p6219
sg10
I6
sg11
Vtumors
p6220
sg13
I1
sasa(dp6221
g2
VThe 5-year DFS in colon cancer, T3-T4 stage, N0 stage, TNM stage II, adenocarcinoma, moderate differentiation and male patient subgroups was also worse for patients with ADAM8-positive tumors than those with ADAM8-negative tumors (p &lt; 0.05).
p6222
sg4
(lp6223
(dp6224
g7
I170
sg8
VP78325
p6225
sg10
I5
sg11
VADAM8
p6226
sg13
I1
sa(dp6227
g7
I55
sg8
g47
sg10
I12
sg11
VTNM stage II
p6228
sg13
I3
sasg17
(lp6229
(dp6230
g7
I69
sg20
VC0001418
p6231
sg10
I14
sg11
Vadenocarcinoma
p6232
sg13
I1
sa(dp6233
g7
I18
sg20
VC0699790
p6234
sg10
I12
sg11
Vcolon cancer
p6235
sg13
I2
sa(dp6236
g7
I185
sg20
VC0027651
p6237
sg10
I6
sg11
Vtumors
p6238
sg13
I1
sa(dp6239
g7
I185
sg20
VC0027651
p6240
sg10
I6
sg11
Vtumors
p6241
sg13
I1
sasa(dp6242
g2
VThe aim of this study was to examine the role of the inflammatory cells in the invasion of pancreatic cancer cells, focusing on the involvement of a disintegrin and metalloproteinase 8 (ADAM8) and matrix metalloproteinase 9 (MMP9) proteins.
p6243
sg4
(lp6244
(dp6245
g7
I197
sg8
VP14780
p6246
sg10
I42
sg11
Vmatrix metalloproteinase 9 (MMP9) proteins
p6247
sg13
I5
sa(dp6248
g7
I149
sg8
VP78325
p6249
sg10
I43
sg11
Vdisintegrin and metalloproteinase 8 (ADAM8)
p6250
sg13
I5
sasg17
(lp6251
(dp6252
g7
I91
sg20
VC0235974
p6253
sg10
I17
sg11
Vpancreatic cancer
p6254
sg13
I2
sa(dp6255
g7
I79
sg20
VC2699153
p6256
sg10
I8
sg11
Vinvasion
p6257
sg13
I1
sasa(dp6258
g2
VADAM8 expression is associated with worse survival of pancreatic cancer patients.
p6259
sg4
(lp6260
(dp6261
g7
I0
sg8
VP78325
p6262
sg10
I5
sg11
VADAM8
p6263
sg13
I1
sasg17
(lp6264
(dp6265
g7
I54
sg20
VC0235974
p6266
sg10
I17
sg11
Vpancreatic cancer
p6267
sg13
I2
sasa(dp6268
g2
VAnti-inflammatory macrophages increase pancreatic cancer cell migration rate in basement membrane matrix by inducing ADAM8 and MMP9 expression in cancer cells, thereby possibly enhancing the invasiveness of cancer.
p6269
sg4
(lp6270
(dp6271
g7
I127
sg8
VP14780
p6272
sg10
I4
sg11
VMMP9
p6273
sg13
I1
sa(dp6274
g7
I117
sg8
VP78325
p6275
sg10
I5
sg11
VADAM8
p6276
sg13
I1
sasg17
(lp6277
(dp6278
g7
I39
sg20
VC0235974
p6279
sg10
I17
sg11
Vpancreatic cancer
p6280
sg13
I2
sa(dp6281
g7
I50
sg20
VC0006826
p6282
sg10
I6
sg11
Vcancer
p6283
sg13
I1
sa(dp6284
g7
I50
sg20
VC0006826
p6285
sg10
I6
sg11
Vcancer
p6286
sg13
I1
sasa(dp6287
g2
VIn this study,we investigated the ADAM8 expression in hepatocellular carcinoma (HCC) and its correlation with clinicopathologic features,including the survival of patients with HCC.
p6288
sg4
(lp6289
(dp6290
g7
I34
sg8
VP78325
p6291
sg10
I5
sg11
VADAM8
p6292
sg13
I1
sasg17
(lp6293
(dp6294
g7
I54
sg20
VC2239176
p6295
sg10
I24
sg11
Vhepatocellular carcinoma
p6296
sg13
I2
sa(dp6297
g7
I80
sg20
VC2239176
p6298
sg10
I3
sg11
VHCC
p6299
sg13
I1
sa(dp6300
g7
I80
sg20
VC2239176
p6301
sg10
I3
sg11
VHCC
p6302
sg13
I1
sasa(dp6303
g2
VOther studies have demonstrated overexpression of some ADAM family proteins in a variety of human tumors, but no report is available on the actual expression of ADAM8 and the correlation between clinicopathologic features and prognosis of hepatocellular carcinoma (HCC) patients.
p6304
sg4
(lp6305
(dp6306
g7
I55
sg8
VP02649
p6307
sg10
I20
sg11
VADAM family proteins
p6308
sg13
I3
sa(dp6309
g7
I161
sg8
VP78325
p6310
sg10
I5
sg11
VADAM8
p6311
sg13
I1
sasg17
(lp6312
(dp6313
g7
I98
sg20
VC0027651
p6314
sg10
I6
sg11
Vtumors
p6315
sg13
I1
sa(dp6316
g7
I265
sg20
VC2239176
p6317
sg10
I3
sg11
VHCC
p6318
sg13
I1
sa(dp6319
g7
I239
sg20
VC2239176
p6320
sg10
I24
sg11
Vhepatocellular carcinoma
p6321
sg13
I2
sasa(dp6322
g2
VTo evaluate the association between ADAM8 tissue expression and patient prognosis in hepatocellular carcinoma (HCC).
p6323
sg4
(lp6324
(dp6325
g7
I36
sg8
VP78325
p6326
sg10
I5
sg11
VADAM8
p6327
sg13
I1
sasg17
(lp6328
(dp6329
g7
I111
sg20
VC2239176
p6330
sg10
I3
sg11
VHCC
p6331
sg13
I1
sa(dp6332
g7
I85
sg20
VC2239176
p6333
sg10
I24
sg11
Vhepatocellular carcinoma
p6334
sg13
I2
sasa(dp6335
g2
VSome of the previously reported gout associated loci (except ALDH16A1), including ABCG2, SLC2A9, GCKR, ALDH2 and CNIH2, were replicated.
p6336
sg4
(lp6337
(dp6338
g7
I113
sg8
g47
sg10
I5
sg11
VCNIH2
p6339
sg13
I1
sa(dp6340
g7
I89
sg8
g47
sg10
I6
sg11
VSLC2A9
p6341
sg13
I1
sa(dp6342
g7
I103
sg8
VP05091
p6343
sg10
I5
sg11
VALDH2
p6344
sg13
I1
sa(dp6345
g7
I61
sg8
g47
sg10
I8
sg11
VALDH16A1
p6346
sg13
I1
sa(dp6347
g7
I97
sg8
g47
sg10
I4
sg11
VGCKR
p6348
sg13
I1
sasg17
(lp6349
(dp6350
g7
I32
sg20
VC0018099
p6351
sg10
I4
sg11
Vgout
p6352
sg13
I1
sasa(dp6353
g2
VThe aim of this study was to examine the role of SLC2A9 and ABCG2 variants in tophaceous disease in people with gout.
p6354
sg4
(lp6355
(dp6356
g7
I49
sg8
g47
sg10
I6
sg11
VSLC2A9
p6357
sg13
I1
sa(dp6358
g7
I60
sg8
VP26640
p6359
sg10
I14
sg11
VABCG2 variants
p6360
sg13
I2
sasg17
(lp6361
(dp6362
g7
I112
sg20
VC0018099
p6363
sg10
I4
sg11
Vgout
p6364
sg13
I1
sasa(dp6365
g2
VThe main objective of this study is to elucidate the clinical significance of the SLC2A9/GLUT9 rs11722228 polymorphism among male gout patients.
p6366
sg4
(lp6367
(dp6368
g7
I89
sg8
g47
sg10
I5
sg11
VGLUT9
p6369
sg13
I1
sa(dp6370
g7
I82
sg8
g47
sg10
I6
sg11
VSLC2A9
p6371
sg13
I1
sasg17
(lp6372
(dp6373
g7
I130
sg20
VC0018099
p6374
sg10
I4
sg11
Vgout
p6375
sg13
I1
sasa(dp6376
g2
VThe genotypic frequencies of SLC2A9/GLUT9 rs1172228 did not differ significantly between the gout cases and the healthy controls.
p6377
sg4
(lp6378
(dp6379
g7
I29
sg8
g47
sg10
I6
sg11
VSLC2A9
p6380
sg13
I1
sa(dp6381
g7
I36
sg8
g47
sg10
I5
sg11
VGLUT9
p6382
sg13
I1
sasg17
(lp6383
(dp6384
g7
I93
sg20
VC0018099
p6385
sg10
I4
sg11
Vgout
p6386
sg13
I1
sasa(dp6387
g2
VThe genotypic distribution of SLC2A9/GLUT9 rs1172228 in male gout patients did not differ significantly from that of healthy male controls.
p6388
sg4
(lp6389
(dp6390
g7
I37
sg8
g47
sg10
I15
sg11
VGLUT9 rs1172228
p6391
sg13
I2
sa(dp6392
g7
I30
sg8
g47
sg10
I6
sg11
VSLC2A9
p6393
sg13
I1
sasg17
(lp6394
(dp6395
g7
I61
sg20
VC0018099
p6396
sg10
I4
sg11
Vgout
p6397
sg13
I1
sasa(dp6398
g2
VThe relationship between the SLC2A9 (solute carrier family 2, member 9) gene polymorphisms and gout was still inconsistent among the individual genetic association studies.
p6399
sg4
(lp6400
(dp6401
g7
I37
sg8
g47
sg10
I23
sg11
Vsolute carrier family 2
p6402
sg13
I4
sa(dp6403
g7
I29
sg8
g47
sg10
I6
sg11
VSLC2A9
p6404
sg13
I1
sasg17
(lp6405
(dp6406
g7
I95
sg20
VC0018099
p6407
sg10
I4
sg11
Vgout
p6408
sg13
I1
sasa(dp6409
g2
VTherefore, this present research was aimed to systematically evaluate the association between SLC2A9 gene polymorphisms and gout susceptibility.
p6410
sg4
(lp6411
(dp6412
g7
I94
sg8
g47
sg10
I11
sg11
VSLC2A9 gene
p6413
sg13
I2
sasg17
(lp6414
(dp6415
g7
I124
sg20
VC0018099
p6416
sg10
I4
sg11
Vgout
p6417
sg13
I1
sasa(dp6418
g2
VThis study demonstrated that the genetic susceptibility for gout is associated with the SLC2A9 gene polymorphisms.
p6419
sg4
(lp6420
(dp6421
g7
I88
sg8
g47
sg10
I11
sg11
VSLC2A9 gene
p6422
sg13
I2
sasg17
(lp6423
(dp6424
g7
I60
sg20
VC0018099
p6425
sg10
I4
sg11
Vgout
p6426
sg13
I1
sasa(dp6427
g2
VEight variants of ABCG2, SLC2A9, SLC22A12, SLC22A11 and SLC17A3 were genotyped in male individuals in a case-control study with 157 gout (33% tophi), 106 asymptomatic hyperuricaemia and 295 control subjects from Taiwan.
p6428
sg4
(lp6429
(dp6430
g7
I33
sg8
g47
sg10
I8
sg11
VSLC22A12
p6431
sg13
I1
sa(dp6432
g7
I43
sg8
g47
sg10
I8
sg11
VSLC22A11
p6433
sg13
I1
sa(dp6434
g7
I25
sg8
g47
sg10
I6
sg11
VSLC2A9
p6435
sg13
I1
sa(dp6436
g7
I56
sg8
g47
sg10
I7
sg11
VSLC17A3
p6437
sg13
I1
sasg17
(lp6438
(dp6439
g7
I142
sg20
VC0221248
p6440
sg10
I5
sg11
Vtophi
p6441
sg13
I1
sa(dp6442
g7
I132
sg20
VC0018099
p6443
sg10
I4
sg11
Vgout
p6444
sg13
I1
sa(dp6445
g7
I167
sg20
VC0740394
p6446
sg10
I14
sg11
Vhyperuricaemia
p6447
sg13
I1
sasa(dp6448
g2
VABCG2 Q141K (T), SLC2A9 rs1014290 (A) and SLC22A12 rs475688 (C) under an additive model and alcohol use independently predicted the risk of gout (respective odds ratio for each factor=2.48, 2.03, 1.95 and 2.48).
p6449
sg4
(lp6450
(dp6451
g7
I17
sg8
g47
sg10
I16
sg11
VSLC2A9 rs1014290
p6452
sg13
I2
sa(dp6453
g7
I42
sg8
g47
sg10
I8
sg11
VSLC22A12
p6454
sg13
I1
sasg17
(lp6455
(dp6456
g7
I140
sg20
VC0018099
p6457
sg10
I4
sg11
Vgout
p6458
sg13
I1
sasa(dp6459
g2
VThe aim of this study was to determine whether polymorphisms in solute carrier family 2 and facilitated glucose transporter member 9 (SLC2A9) are associated with susceptibility to gout.
p6460
sg4
(lp6461
(dp6462
g7
I134
sg8
g47
sg10
I6
sg11
VSLC2A9
p6463
sg13
I1
sa(dp6464
g7
I64
sg8
g47
sg10
I68
sg11
Vsolute carrier family 2 and facilitated glucose transporter member 9
p6465
sg13
I10
sasg17
(lp6466
(dp6467
g7
I180
sg20
VC0018099
p6468
sg10
I4
sg11
Vgout
p6469
sg13
I1
sasa(dp6470
g2
VA meta-analysis was conducted on associations between the rs12510549, rs16890979, and rs1014290 polymorphisms of SLC2A9 and gout susceptibility using fixed and random effects models.
p6471
sg4
(lp6472
(dp6473
g7
I113
sg8
g47
sg10
I6
sg11
VSLC2A9
p6474
sg13
I1
sasg17
(lp6475
(dp6476
g7
I124
sg20
VC0018099
p6477
sg10
I4
sg11
Vgout
p6478
sg13
I1
sasa(dp6479
g2
VThis meta-analysis shows that the rs12510549, rs16890979, and rs1014290 polymorphisms of SLC2A9 protect against the development of gout in Caucasians and/or Asians.
p6480
sg4
(lp6481
sg17
(lp6482
(dp6483
g7
I131
sg20
VC0018099
p6484
sg10
I4
sg11
Vgout
p6485
sg13
I1
sasa(dp6486
g2
VWe investigated the association of polymorphisms in the ABCG2 and SLC2A9 genes with gout in Korean patients and healthy individuals.
p6487
sg4
(lp6488
(dp6489
g7
I66
sg8
g47
sg10
I12
sg11
VSLC2A9 genes
p6490
sg13
I2
sasg17
(lp6491
(dp6492
g7
I84
sg20
VC0018099
p6493
sg10
I4
sg11
Vgout
p6494
sg13
I1
sasa(dp6495
g2
VWe demonstrated a significant association between rs2231142 in the ABCG2 gene and gout and identified novel SNPs, c.881A&gt;G and c.1002+78G&gt;A, in the SLC2A9 gene that may be associated with gout in a Korean population.
p6496
sg4
(lp6497
(dp6498
g7
I154
sg8
g47
sg10
I11
sg11
VSLC2A9 gene
p6499
sg13
I2
sasg17
(lp6500
(dp6501
g7
I82
sg20
VC0018099
p6502
sg10
I4
sg11
Vgout
p6503
sg13
I1
sa(dp6504
g7
I82
sg20
VC0018099
p6505
sg10
I4
sg11
Vgout
p6506
sg13
I1
sasa(dp6507
g2
VSLC2A9 and ZNF518B may play a role in gout progression in different populations, but no studies have focused on the Tibetan Chinese population.
p6508
sg4
(lp6509
(dp6510
g7
I11
sg8
g47
sg10
I7
sg11
VZNF518B
p6511
sg13
I1
sa(dp6512
g7
I0
sg8
g47
sg10
I6
sg11
VSLC2A9
p6513
sg13
I1
sasg17
(lp6514
(dp6515
g7
I38
sg20
VC0018099
p6516
sg10
I4
sg11
Vgout
p6517
sg13
I1
sasa(dp6518
g2
VWe detected 6 single nucleotide polymorphisms in SLC2A9 and ZNF518B in 319 Chinese Tibetan gout patients.
p6519
sg4
(lp6520
(dp6521
g7
I49
sg8
g47
sg10
I6
sg11
VSLC2A9
p6522
sg13
I1
sa(dp6523
g7
I60
sg8
g47
sg10
I7
sg11
VZNF518B
p6524
sg13
I1
sasg17
(lp6525
(dp6526
g7
I91
sg20
VC0018099
p6527
sg10
I4
sg11
Vgout
p6528
sg13
I1
sasa(dp6529
g2
VPolymorphisms in SLC2A9 and ZNF518B affected multiple risk factors related to gout development.
p6530
sg4
(lp6531
(dp6532
g7
I17
sg8
g47
sg10
I6
sg11
VSLC2A9
p6533
sg13
I1
sa(dp6534
g7
I28
sg8
g47
sg10
I7
sg11
VZNF518B
p6535
sg13
I1
sasg17
(lp6536
(dp6537
g7
I78
sg20
VC0018099
p6538
sg10
I4
sg11
Vgout
p6539
sg13
I1
sasa(dp6540
g2
VThis study is the first to investigate and identify positive correlations between SLC2A9 and ZNF518B gene polymorphisms and metabolic indices in Tibetan gout patients.
p6541
sg4
(lp6542
(dp6543
g7
I93
sg8
g47
sg10
I12
sg11
VZNF518B gene
p6544
sg13
I2
sa(dp6545
g7
I82
sg8
g47
sg10
I6
sg11
VSLC2A9
p6546
sg13
I1
sasg17
(lp6547
(dp6548
g7
I153
sg20
VC0018099
p6549
sg10
I4
sg11
Vgout
p6550
sg13
I1
sasa(dp6551
g2
VIn conclusion, two patients who developed hypercalcemia associated with bone metastasis after surgery for HCC were treated with alendronate and they experienced alleviation of the pain due to bone metastasis, improvement of their quality of life and a marked decrease in AFP levels with tumor regression.
p6552
sg4
(lp6553
sg17
(lp6554
(dp6555
g7
I42
sg20
VC0020437
p6556
sg10
I13
sg11
Vhypercalcemia
p6557
sg13
I1
sa(dp6558
g7
I72
sg20
VC0153690
p6559
sg10
I15
sg11
Vbone metastasis
p6560
sg13
I2
sa(dp6561
g7
I287
sg20
VC0027651
p6562
sg10
I5
sg11
Vtumor
p6563
sg13
I1
sa(dp6564
g7
I106
sg20
VC2239176
p6565
sg10
I3
sg11
VHCC
p6566
sg13
I1
sa(dp6567
g7
I72
sg20
VC0153690
p6568
sg10
I15
sg11
Vbone metastasis
p6569
sg13
I2
sasa(dp6570
g2
VColoboma-like optic discs might be an additional feature observed in patients with SPTAN1 mutations.
p6571
sg4
(lp6572
sg17
(lp6573
(dp6574
g7
I0
sg20
VC0009363
p6575
sg10
I8
sg11
VColoboma
p6576
sg13
I1
sasa(dp6577
g2
VA newly described autoantibody to alpha-fodrin found in other neurodegenerative diseases such as Alzheimer's, further implicate a role for autoimmunity and the neurodegenerative processes in glaucoma.
p6578
sg4
(lp6579
sg17
(lp6580
(dp6581
g7
I62
sg20
VC0524851
p6582
sg10
I26
sg11
Vneurodegenerative diseases
p6583
sg13
I2
sa(dp6584
g7
I191
sg20
VC0017601
p6585
sg10
I8
sg11
Vglaucoma
p6586
sg13
I1
sa(dp6587
g7
I139
sg20
VC0004368
p6588
sg10
I12
sg11
Vautoimmunity
p6589
sg13
I1
sasa(dp6590
g2
VIn a similar experiment, ocular hypertension was induced in four eyes pre-treated with an intravitreal injection of AAV-BIRC4 to assess alpha-fodrin cleavage.
p6591
sg4
(lp6592
sg17
(lp6593
(dp6594
g7
I25
sg20
VC0028840
p6595
sg10
I19
sg11
Vocular hypertension
p6596
sg13
I2
sasa(dp6597
g2
VComparison of the Zrs z-scores between the healthy children and the health groups found significant differences in children with asthma, current wheeze and respiratory symptoms, but not in children born preterm or with early-life wheeze.
p6598
sg4
(lp6599
sg17
(lp6600
(dp6601
g7
I156
sg20
VC0037090
p6602
sg10
I20
sg11
Vrespiratory symptoms
p6603
sg13
I2
sa(dp6604
g7
I145
sg20
VC0043144
p6605
sg10
I6
sg11
Vwheeze
p6606
sg13
I1
sa(dp6607
g7
I145
sg20
VC0043144
p6608
sg10
I6
sg11
Vwheeze
p6609
sg13
I1
sa(dp6610
g7
I129
sg20
VC0004096
p6611
sg10
I6
sg11
Vasthma
p6612
sg13
I1
sasa(dp6613
g2
VThe aim of this retrospective study was to assess responses to a bronchodilator by forced oscillation technique (FOT) and to relate the results of respiratory impedance (Zrs) to spirometric parameters in patients with chronic obstructive pulmonary disease (COPD).
p6614
sg4
(lp6615
sg17
(lp6616
(dp6617
g7
I218
sg20
VC0024117
p6618
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p6619
sg13
I4
sa(dp6620
g7
I257
sg20
VC0024117
p6621
sg10
I4
sg11
VCOPD
p6622
sg13
I1
sasa(dp6623
g2
VThe diagnostic efficiency of Zrs, R5 and X35 when diagnosis asthma, expressed by ROC curve parameters, was as follows: AUC (0.721, 0.710, 0.695), sensitivity (62%, 72%, 53%) and specificity (72%, 61%, 76%), respectively.
p6624
sg4
(lp6625
sg17
(lp6626
(dp6627
g7
I60
sg20
VC0004096
p6628
sg10
I6
sg11
Vasthma
p6629
sg13
I1
sasa(dp6630
g2
VAnd R5, X35 and Zrs may provide useful IOS parameters for asthma.
p6631
sg4
(lp6632
(dp6633
g7
I16
sg8
g47
sg10
I3
sg11
VZrs
p6634
sg13
I1
sasg17
(lp6635
(dp6636
g7
I58
sg20
VC0004096
p6637
sg10
I6
sg11
Vasthma
p6638
sg13
I1
sasa(dp6639
g2
VBirth weight less than 3,000 g was associated with larger exercise-induced changes in Zrs and Rrs at 5 Hz, and in reactance (Xrs) at 5 Hz, than those with birth weight more than 3,000 g. Preliminary evidence was found that obesity may be associated with airway obstruction, but not with bronchial hyper-reactivity.
p6640
sg4
(lp6641
sg17
(lp6642
(dp6643
g7
I223
sg20
VC0028754
p6644
sg10
I7
sg11
Vobesity
p6645
sg13
I1
sa(dp6646
g7
I94
sg20
VC1849334
p6647
sg10
I3
sg11
VRrs
p6648
sg13
I1
sa(dp6649
g7
I254
sg20
VC0001883
p6650
sg10
I18
sg11
Vairway obstruction
p6651
sg13
I2
sasa(dp6652
g2
VTo investigate the nature of mutations in exons 4 and 5 of the uromodulin (UM) gene, including in the area encoding the domain of 8 cysteines (D8C), in patients with multiple myeloma (MM) with the secretion of monoclonal light chains (LC) in cast nephropathy (CN) and without kidney injury.
p6653
sg4
(lp6654
(dp6655
g7
I63
sg8
VP07911
p6656
sg10
I20
sg11
Vuromodulin (UM) gene
p6657
sg13
I3
sasg17
(lp6658
(dp6659
g7
I247
sg20
VC0022658
p6660
sg10
I11
sg11
Vnephropathy
p6661
sg13
I1
sa(dp6662
g7
I166
sg20
VC0026764
p6663
sg10
I16
sg11
Vmultiple myeloma
p6664
sg13
I2
sasa(dp6665
g2
VThe aim of the study was to investigate the association of the uromodulin (UMOD) genotype with patient health status and with renal cell carcinoma (RCC) aggressiveness.
p6666
sg4
(lp6667
(dp6668
g7
I75
sg8
VP07911
p6669
sg10
I4
sg11
VUMOD
p6670
sg13
I1
sa(dp6671
g7
I63
sg8
VP07911
p6672
sg10
I10
sg11
Vuromodulin
p6673
sg13
I1
sasg17
(lp6674
(dp6675
g7
I148
sg20
VC0007134
p6676
sg10
I3
sg11
VRCC
p6677
sg13
I1
sa(dp6678
g7
I126
sg20
VC0007134
p6679
sg10
I20
sg11
Vrenal cell carcinoma
p6680
sg13
I3
sa(dp6681
g7
I153
sg20
VC0001807
p6682
sg10
I14
sg11
Vaggressiveness
p6683
sg13
I1
sasa(dp6684
g2
VIn patients diagnosed with renal cell carcinoma and treated with surgery, uromodulin homozygous genotype is associated with more aggressive renal cell carcinoma clinical and pathological characteristics.
p6685
sg4
(lp6686
(dp6687
g7
I74
sg8
VP07911
p6688
sg10
I10
sg11
Vuromodulin
p6689
sg13
I1
sasg17
(lp6690
(dp6691
g7
I129
sg20
VC0001807
p6692
sg10
I10
sg11
Vaggressive
p6693
sg13
I1
sa(dp6694
g7
I27
sg20
VC0007134
p6695
sg10
I20
sg11
Vrenal cell carcinoma
p6696
sg13
I3
sa(dp6697
g7
I27
sg20
VC0007134
p6698
sg10
I20
sg11
Vrenal cell carcinoma
p6699
sg13
I3
sasa(dp6700
g2
VCYP11B2 was sequenced if the aldosterone level was high (primary aldosteronism phenotype); SCNN1B, NEDD4L, GRK4, UMOD, and NPPA genes were sequenced if the aldosterone level was low (Liddle phenotype).
p6701
sg4
(lp6702
(dp6703
g7
I91
sg8
VP51168
p6704
sg10
I6
sg11
VSCNN1B
p6705
sg13
I1
sa(dp6706
g7
I0
sg8
VP19099
p6707
sg10
I7
sg11
VCYP11B2
p6708
sg13
I1
sa(dp6709
g7
I123
sg8
VP01160
p6710
sg10
I10
sg11
VNPPA genes
p6711
sg13
I2
sa(dp6712
g7
I113
sg8
VP07911
p6713
sg10
I4
sg11
VUMOD
p6714
sg13
I1
sasg17
(lp6715
(dp6716
g7
I57
sg20
VC1384514
p6717
sg10
I21
sg11
Vprimary aldosteronism
p6718
sg13
I2
sasa(dp6719
g2
VMT1F, MT1G, MT1X, and MT2A gene expression was significantly downregulated in colon cancer tissue (p&lt;0.05).
p6720
sg4
(lp6721
(dp6722
g7
I12
sg8
VP80297
p6723
sg10
I4
sg11
VMT1X
p6724
sg13
I1
sa(dp6725
g7
I6
sg8
VP04733
p6726
sg10
I4
sg11
VMT1G
p6727
sg13
I1
sa(dp6728
g7
I0
sg8
VP04733
p6729
sg10
I4
sg11
VMT1F
p6730
sg13
I1
sa(dp6731
g7
I22
sg8
VP02795
p6732
sg10
I9
sg11
VMT2A gene
p6733
sg13
I2
sasg17
(lp6734
(dp6735
g7
I78
sg20
VC0699790
p6736
sg10
I12
sg11
Vcolon cancer
p6737
sg13
I2
sasa(dp6738
g2
VHere, we describe the discovery of a new MSI marker for colorectal cancer located in the 3'-untranslated region (3'UTR, T20 mononucleotide repeat) of the metallothionein 1X gene (MT1XT20).
p6739
sg4
(lp6740
(dp6741
g7
I154
sg8
VP80297
p6742
sg10
I23
sg11
Vmetallothionein 1X gene
p6743
sg13
I3
sasg17
(lp6744
(dp6745
g7
I41
sg20
VC0920269
p6746
sg10
I3
sg11
VMSI
p6747
sg13
I1
sa(dp6748
g7
I56
sg20
VC1527249
p6749
sg10
I17
sg11
Vcolorectal cancer
p6750
sg13
I2
sasa(dp6751
g2
VIndeed, MT1XT20 instability was detected in 36 out of 37 cases (97.3%) of MSI-high colorectal cancers, whereas no MT1XT20 alterations were observed in 254 MSS or in 46 MSI-low cases.
p6752
sg4
(lp6753
sg17
(lp6754
(dp6755
g7
I74
sg20
VC0920269
p6756
sg10
I3
sg11
VMSI
p6757
sg13
I1
sa(dp6758
g7
I155
sg20
VC0024814
p6759
sg10
I3
sg11
VMSS
p6760
sg13
I1
sa(dp6761
g7
I74
sg20
VC0920269
p6762
sg10
I3
sg11
VMSI
p6763
sg13
I1
sa(dp6764
g7
I83
sg20
VC1527249
p6765
sg10
I18
sg11
Vcolorectal cancers
p6766
sg13
I2
sasa(dp6767
g2
VHNF-1Beta regulates tissue-specific gene expression in endometriosis, as well as the expression of several genes, including CD44v9, which binds several molecules, including hyaluronan, epidermal growth factor receptor (EGFR), leukemia-associated Rho-guanine nucleotide exchange factor (LARG), IQ motif containing GTPase activating protein 1 (IQGAP1), macrophage migration inhibitory factor (MIF), major histocompatibility complex, class II invariant chain (CD74), cystine transporter subunit (xCT), Fas and extracellular matrix (ECM) proteins.
p6768
sg4
(lp6769
(dp6770
g7
I342
sg8
VP46940
p6771
sg10
I6
sg11
VIQGAP1
p6772
sg13
I1
sa(dp6773
g7
I286
sg8
g47
sg10
I4
sg11
VLARG
p6774
sg13
I1
sa(dp6775
g7
I0
sg8
g47
sg10
I9
sg11
VHNF-1Beta
p6776
sg13
I1
sa(dp6777
g7
I507
sg8
g47
sg10
I35
sg11
Vextracellular matrix (ECM) proteins
p6778
sg13
I4
sa(dp6779
g7
I293
sg8
VP46940
p6780
sg10
I47
sg11
VIQ motif containing GTPase activating protein 1
p6781
sg13
I7
sa(dp6782
g7
I226
sg8
g47
sg10
I58
sg11
Vleukemia-associated Rho-guanine nucleotide exchange factor
p6783
sg13
I5
sa(dp6784
g7
I219
sg8
VP01133
p6785
sg10
I4
sg11
VEGFR
p6786
sg13
I1
sa(dp6787
g7
I499
sg8
VP48023
p6788
sg10
I3
sg11
VFas
p6789
sg13
I1
sa(dp6790
g7
I457
sg8
VP04233
p6791
sg10
I4
sg11
VCD74
p6792
sg13
I1
sa(dp6793
g7
I397
sg8
VP18464
p6794
sg10
I58
sg11
Vmajor histocompatibility complex, class II invariant chain
p6795
sg13
I7
sa(dp6796
g7
I464
sg8
g47
sg10
I27
sg11
Vcystine transporter subunit
p6797
sg13
I3
sa(dp6798
g7
I185
sg8
VP01133
p6799
sg10
I32
sg11
Vepidermal growth factor receptor
p6800
sg13
I4
sa(dp6801
g7
I493
sg8
g47
sg10
I3
sg11
VxCT
p6802
sg13
I1
sasg17
(lp6803
(dp6804
g7
I226
sg20
VC0023418
p6805
sg10
I8
sg11
Vleukemia
p6806
sg13
I1
sa(dp6807
g7
I55
sg20
VC0014175
p6808
sg10
I13
sg11
Vendometriosis
p6809
sg13
I1
sa(dp6810
g7
I499
sg20
VC0015923
p6811
sg10
I3
sg11
VFas
p6812
sg13
I1
sasa(dp6813
g2
VWe sought to determine whether oxidative stress or a relative deficit of l-arginine plays a role in reducing cutaneous vasodilation in response to local heating in chronic kidney disease (CKD).
p6814
sg4
(lp6815
sg17
(lp6816
(dp6817
g7
I62
sg20
VC0162429
p6818
sg10
I7
sg11
Vdeficit
p6819
sg13
I1
sa(dp6820
g7
I164
sg20
VC1561643
p6821
sg10
I22
sg11
Vchronic kidney disease
p6822
sg13
I3
sa(dp6823
g7
I188
sg20
VC1561643
p6824
sg10
I3
sg11
VCKD
p6825
sg13
I1
sa(dp6826
g7
I119
sg20
VC0595862
p6827
sg10
I12
sg11
Vvasodilation
p6828
sg13
I1
sa(dp6829
g7
I31
sg20
VC0242606
p6830
sg10
I16
sg11
Voxidative stress
p6831
sg13
I2
sasa(dp6832
g2
VEight patients with stage 3-4 CKD and eight age- and sex-matched healthy control (HC) subjects were instrumented with four microdialysis (MD) fibers for the local delivery of 1) Ringers solution (R), 2) 20 mM ascorbic acid (AA), 3) 10 mM l-arginine (l-Arg), and 4) 10 mM N(G)-nitro-l-arginine methyl ester (l-NAME).
p6833
sg4
(lp6834
sg17
(lp6835
sa(dp6836
g2
VThe plateau %CVC(max) in the CKD group was significantly greater at the AA and l-Arg sites compared with R (AA: 89 +/- 2; l-Arg: 90 +/- 1; R: 76 +/- 4; P &lt; 0.05) and did not differ from HC.
p6837
sg4
(lp6838
sg17
(lp6839
sa(dp6840
g2
VInitial peak %CVC(max) was also significantly attenuated at the R and l-Arg sites in CKD (P &lt; 0.05) but did not differ at the AA site.
p6841
sg4
(lp6842
sg17
(lp6843
sa(dp6844
g2
VThese results suggest that cutaneous microvascular function is impaired in stage 3-4 CKD and that oxidative stress and a deficit of l-arginine play a role in this impairment.
p6845
sg4
(lp6846
sg17
(lp6847
(dp6848
g7
I163
sg20
VC0684336
p6849
sg10
I10
sg11
Vimpairment
p6850
sg13
I1
sa(dp6851
g7
I63
sg20
VC0684336
p6852
sg10
I8
sg11
Vimpaired
p6853
sg13
I1
sa(dp6854
g7
I121
sg20
VC0162429
p6855
sg10
I7
sg11
Vdeficit
p6856
sg13
I1
sa(dp6857
g7
I98
sg20
VC0242606
p6858
sg10
I16
sg11
Voxidative stress
p6859
sg13
I2
sasa(dp6860
g2
VIf true, plasma L-arg should be severely reduced in chronic renal failure (CRF); however, plasma L-arg is frequently unchanged in CRF.
p6861
sg4
(lp6862
(dp6863
g7
I75
sg8
VP06850
p6864
sg10
I3
sg11
VCRF
p6865
sg13
I1
sa(dp6866
g7
I52
sg8
VP06850
p6867
sg10
I21
sg11
Vchronic renal failure
p6868
sg13
I3
sasg17
(lp6869
(dp6870
g7
I75
sg20
VC0022661
p6871
sg10
I3
sg11
VCRF
p6872
sg13
I1
sa(dp6873
g7
I52
sg20
VC0022661
p6874
sg10
I21
sg11
Vchronic renal failure
p6875
sg13
I3
sa(dp6876
g7
I75
sg20
VC0022661
p6877
sg10
I3
sg11
VCRF
p6878
sg13
I1
sasa(dp6879
g2
Vl-arg, by its cytoprotective effect, maintained the thiol status, thereby preserving the activities of the membrane bound ATPases and preventing proteinuria and subsequent weight loss in EG-treated rats.
p6880
sg4
(lp6881
(dp6882
g7
I122
sg8
VP05026
p6883
sg10
I7
sg11
VATPases
p6884
sg13
I1
sasg17
(lp6885
sa(dp6886
g2
VAs expected, a physiological analgesia is produced by administration of inhibitors, especially kelatorphan and analogues, demonstrating unambiguously the implication of enkephalinase and aminopeptidase M in enkephalin metabolism.
p6887
sg4
(lp6888
(dp6889
g7
I187
sg8
VP15144
p6890
sg10
I16
sg11
Vaminopeptidase M
p6891
sg13
I2
sa(dp6892
g7
I169
sg8
VP08473
p6893
sg10
I13
sg11
Venkephalinase
p6894
sg13
I1
sasg17
(lp6895
(dp6896
g7
I29
sg20
VC0344307
p6897
sg10
I9
sg11
Vanalgesia
p6898
sg13
I1
sasa(dp6899
g2
VAssociated with antigliadin and anti-HSP antibodies, children with autism and patients with autoimmune disease developed anti-dipeptidylpeptidase I (DPP I), anti-dipeptidylpeptidase IV (DPP IV [or CD26]) and anti-aminopeptidase N (CD13) autoantibodies.
p6900
sg4
(lp6901
(dp6902
g7
I32
sg8
g47
sg10
I19
sg11
Vanti-HSP antibodies
p6903
sg13
I2
sa(dp6904
g7
I149
sg8
g47
sg10
I5
sg11
VDPP I
p6905
sg13
I2
sa(dp6906
g7
I121
sg8
g47
sg10
I26
sg11
Vanti-dipeptidylpeptidase I
p6907
sg13
I2
sa(dp6908
g7
I208
sg8
VP15144
p6909
sg10
I21
sg11
Vanti-aminopeptidase N
p6910
sg13
I2
sa(dp6911
g7
I231
sg8
VP15144
p6912
sg10
I4
sg11
VCD13
p6913
sg13
I1
sa(dp6914
g7
I186
sg8
VP27487
p6915
sg10
I6
sg11
VDPP IV
p6916
sg13
I2
sa(dp6917
g7
I157
sg8
VP27487
p6918
sg10
I27
sg11
Vanti-dipeptidylpeptidase IV
p6919
sg13
I2
sasg17
(lp6920
(dp6921
g7
I92
sg20
VC0004364
p6922
sg10
I18
sg11
Vautoimmune disease
p6923
sg13
I2
sa(dp6924
g7
I37
sg20
VC0034152
p6925
sg10
I3
sg11
VHSP
p6926
sg13
I1
sa(dp6927
g7
I67
sg20
VC0004352
p6928
sg10
I6
sg11
Vautism
p6929
sg13
I1
sasa(dp6930
g2
VWe therefore investigated plasma ApN in anorexia nervosa (AN).
p6931
sg4
(lp6932
sg17
(lp6933
(dp6934
g7
I58
sg20
VC0003125
p6935
sg10
I2
sg11
VAN
p6936
sg13
I1
sa(dp6937
g7
I40
sg20
VC0003125
p6938
sg10
I16
sg11
Vanorexia nervosa
p6939
sg13
I2
sasa(dp6940
g2
VThe observed ocular comorbidities included nystagmus (36.7%, 18/49), vitreous opacity (28.6%, 14/49), foveal hypoplasia (20.4%, 10/49), ametropia (12.2%, 6/49), exotropia (12.2%, 6/49), congenital glaucoma (12.2%, 6/49), esotropia (4.1%, 2/49), congenital ptosis (4.1%, 2/49), lens ectopia (4.1%, 2/49), scleral staphyloma (2.0%, 1/49) and pigmentary degeneration of retina (2.0%, 1/49).
p6941
sg4
(lp6942
sg17
(lp6943
(dp6944
g7
I351
sg20
VC0035304
p6945
sg10
I22
sg11
Vdegeneration of retina
p6946
sg13
I3
sa(dp6947
g7
I186
sg20
VC0020302
p6948
sg10
I19
sg11
Vcongenital glaucoma
p6949
sg13
I2
sa(dp6950
g7
I340
sg20
VC0333446
p6951
sg10
I23
sg11
Vpigmentary degeneration
p6952
sg13
I2
sa(dp6953
g7
I245
sg20
VC0266573
p6954
sg10
I17
sg11
Vcongenital ptosis
p6955
sg13
I2
sa(dp6956
g7
I161
sg20
VC0015310
p6957
sg10
I9
sg11
Vexotropia
p6958
sg13
I1
sa(dp6959
g7
I109
sg20
VC0243069
p6960
sg10
I10
sg11
Vhypoplasia
p6961
sg13
I1
sa(dp6962
g7
I221
sg20
VC0014877
p6963
sg10
I9
sg11
Vesotropia
p6964
sg13
I1
sa(dp6965
g7
I136
sg20
VC1527310
p6966
sg10
I9
sg11
Vametropia
p6967
sg13
I1
sa(dp6968
g7
I43
sg20
VC0028738
p6969
sg10
I9
sg11
Vnystagmus
p6970
sg13
I1
sa(dp6971
g7
I78
sg20
VC1265876
p6972
sg10
I7
sg11
Vopacity
p6973
sg13
I1
sa(dp6974
g7
I304
sg20
VC0155359
p6975
sg10
I18
sg11
Vscleral staphyloma
p6976
sg13
I2
sa(dp6977
g7
I282
sg20
VC1562630
p6978
sg10
I7
sg11
Vectopia
p6979
sg13
I1
sasa(dp6980
g2
VThe common eye disorders for which genetic testing is commonly requested are briefly discussed - anophthalmia, microphthalmia, coloboma, anterior segment dysgenesis, corneal dystrophies, cataracts, optic atrophy, congenital glaucoma, congenital amaurosis, retinitis pigmentosa, color blindness, juvenile retinoshisis, retinoblastoma etc.
p6981
sg4
(lp6982
(dp6983
g7
I318
sg8
g47
sg10
I18
sg11
Vretinoblastoma etc
p6984
sg13
I2
sasg17
(lp6985
(dp6986
g7
I97
sg20
VC0003119
p6987
sg10
I12
sg11
Vanophthalmia
p6988
sg13
I1
sa(dp6989
g7
I318
sg20
VC0035335
p6990
sg10
I14
sg11
Vretinoblastoma
p6991
sg13
I1
sa(dp6992
g7
I256
sg20
VC0035334
p6993
sg10
I20
sg11
Vretinitis pigmentosa
p6994
sg13
I2
sa(dp6995
g7
I137
sg20
VC0266525
p6996
sg10
I27
sg11
Vanterior segment dysgenesis
p6997
sg13
I3
sa(dp6998
g7
I245
sg20
VC0376288
p6999
sg10
I9
sg11
Vamaurosis
p7000
sg13
I1
sa(dp7001
g7
I166
sg20
VC0010036
p7002
sg10
I19
sg11
Vcorneal dystrophies
p7003
sg13
I2
sa(dp7004
g7
I187
sg20
VC0521707
p7005
sg10
I9
sg11
Vcataracts
p7006
sg13
I1
sa(dp7007
g7
I198
sg20
VC0029124
p7008
sg10
I13
sg11
Voptic atrophy
p7009
sg13
I2
sa(dp7010
g7
I224
sg20
VC0020302
p7011
sg10
I20
sg11
Vglaucoma, congenital
p7012
sg13
I2
sa(dp7013
g7
I111
sg20
VC0026010
p7014
sg10
I14
sg11
Vmicrophthalmia
p7015
sg13
I1
sa(dp7016
g7
I278
sg20
VC0242225
p7017
sg10
I15
sg11
Vcolor blindness
p7018
sg13
I2
sa(dp7019
g7
I127
sg20
VC0009363
p7020
sg10
I8
sg11
Vcoloboma
p7021
sg13
I1
sa(dp7022
g7
I11
sg20
VC0015397
p7023
sg10
I13
sg11
Veye disorders
p7024
sg13
I2
sasa(dp7025
g2
VThe anatomical causes of blindness include optic nerve disorders in 75 (24.8%) cases, retinal disorders in 55 (18.2%), corneal disorders in 47 (15.6%), lens-related disorders in 39 (12.9%), congenital anomalies in 11 (3.6%), and congenital glaucoma in 20 (6.6%) cases.
p7026
sg4
(lp7027
sg17
(lp7028
(dp7029
g7
I86
sg20
VC0035309
p7030
sg10
I17
sg11
Vretinal disorders
p7031
sg13
I2
sa(dp7032
g7
I190
sg20
VC0000768
p7033
sg10
I20
sg11
Vcongenital anomalies
p7034
sg13
I2
sa(dp7035
g7
I119
sg20
VC0010034
p7036
sg10
I17
sg11
Vcorneal disorders
p7037
sg13
I2
sa(dp7038
g7
I229
sg20
VC0020302
p7039
sg10
I19
sg11
Vcongenital glaucoma
p7040
sg13
I2
sa(dp7041
g7
I25
sg20
VC0456909
p7042
sg10
I9
sg11
Vblindness
p7043
sg13
I1
sa(dp7044
g7
I43
sg20
VC0029132
p7045
sg10
I21
sg11
Voptic nerve disorders
p7046
sg13
I3
sasa(dp7047
g2
VAmong conditions causing blindness, optic atrophy seen in 73 (24.17%) cases was the most common, followed by retinal dystrophy in 44 (14.56%), corneal scarring in 35 (11.59%), cataract in 22 (7.28%), and congenital glaucoma in 20 (6.6%) cases.
p7048
sg4
(lp7049
sg17
(lp7050
(dp7051
g7
I36
sg20
VC0029124
p7052
sg10
I13
sg11
Voptic atrophy
p7053
sg13
I2
sa(dp7054
g7
I151
sg20
VC0008767
p7055
sg10
I8
sg11
Vscarring
p7056
sg13
I1
sa(dp7057
g7
I204
sg20
VC0020302
p7058
sg10
I19
sg11
Vcongenital glaucoma
p7059
sg13
I2
sa(dp7060
g7
I176
sg20
VC0086543
p7061
sg10
I8
sg11
Vcataract
p7062
sg13
I1
sa(dp7063
g7
I109
sg20
VC0854723
p7064
sg10
I17
sg11
Vretinal dystrophy
p7065
sg13
I2
sa(dp7066
g7
I25
sg20
VC0456909
p7067
sg10
I9
sg11
Vblindness
p7068
sg13
I1
sasa(dp7069
g2
VOther abnormalities included vitreous hemorrhage (n=1), congenital glaucoma (n=2), uveal coloboma (n=2), retinopathy mimicking retinopathy of prematurity (n=2), and cystic fovea (n=3).
p7070
sg4
(lp7071
sg17
(lp7072
(dp7073
g7
I29
sg20
VC0042909
p7074
sg10
I19
sg11
Vvitreous hemorrhage
p7075
sg13
I2
sa(dp7076
g7
I89
sg20
VC0009363
p7077
sg10
I8
sg11
Vcoloboma
p7078
sg13
I1
sa(dp7079
g7
I105
sg20
VC0035309
p7080
sg10
I11
sg11
Vretinopathy
p7081
sg13
I1
sa(dp7082
g7
I56
sg20
VC0020302
p7083
sg10
I19
sg11
Vcongenital glaucoma
p7084
sg13
I2
sa(dp7085
g7
I127
sg20
VC0035344
p7086
sg10
I26
sg11
Vretinopathy of prematurity
p7087
sg13
I3
sasa(dp7088
g2
VPrimary congenital glaucoma (PCG) is isolated, non-syndromic glaucoma that occurs in the first three years of life and is a major cause of childhood blindness.
p7089
sg4
(lp7090
sg17
(lp7091
(dp7092
g7
I19
sg20
VC0017601
p7093
sg10
I8
sg11
Vglaucoma
p7094
sg13
I1
sa(dp7095
g7
I149
sg20
VC0456909
p7096
sg10
I9
sg11
Vblindness
p7097
sg13
I1
sa(dp7098
g7
I0
sg20
VC1533041
p7099
sg10
I27
sg11
VPrimary congenital glaucoma
p7100
sg13
I3
sa(dp7101
g7
I29
sg20
VC1533041
p7102
sg10
I3
sg11
VPCG
p7103
sg13
I1
sasa(dp7104
g2
VThe purpose of the present study is to investigate the association between the polymorphisms in AXIN1 with susceptibility to clear cell renal cell carcinoma (ccRCC).
p7105
sg4
(lp7106
(dp7107
g7
I96
sg8
g47
sg10
I5
sg11
VAXIN1
p7108
sg13
I1
sasg17
(lp7109
(dp7110
g7
I158
sg20
VC0279702
p7111
sg10
I5
sg11
VccRCC
p7112
sg13
I1
sa(dp7113
g7
I125
sg20
VC0279702
p7114
sg10
I31
sg11
Vclear cell renal cell carcinoma
p7115
sg13
I5
sasa(dp7116
g2
VIn both cultured melanoma cell lines and in vivo in melanoma cell-derived tumor xenografts, 1-benzyl-I3C disrupted canonical Wnt/Beta-catenin signaling that resulted in the down regulation of Beta-catenin protein levels with a concomitant increase in levels of the Beta-catenin destruction complex components GSK3Beta and Axin.
p7117
sg4
(lp7118
(dp7119
g7
I192
sg8
VP35222
p7120
sg10
I20
sg11
VBeta-catenin protein
p7121
sg13
I2
sa(dp7122
g7
I129
sg8
VP35222
p7123
sg10
I12
sg11
VBeta-catenin
p7124
sg13
I1
sa(dp7125
g7
I322
sg8
g47
sg10
I4
sg11
VAxin
p7126
sg13
I1
sasg17
(lp7127
(dp7128
g7
I74
sg20
VC0027651
p7129
sg10
I5
sg11
Vtumor
p7130
sg13
I1
sa(dp7131
g7
I17
sg20
VC0025202
p7132
sg10
I8
sg11
Vmelanoma
p7133
sg13
I1
sa(dp7134
g7
I17
sg20
VC0025202
p7135
sg10
I8
sg11
Vmelanoma
p7136
sg13
I1
sasa(dp7137
g2
VHere, we showed that SKL2001, which has been identified as an activator for Wnt signaling by disrupting the Axin/Beta-Catenin complex, negatively regulates growth of colon cancer spheroids cultured in the 3D condition that simulates tumor microenvironment in vivo.
p7138
sg4
(lp7139
(dp7140
g7
I108
sg8
g47
sg10
I4
sg11
VAxin
p7141
sg13
I1
sasg17
(lp7142
(dp7143
g7
I233
sg20
VC0027651
p7144
sg10
I5
sg11
Vtumor
p7145
sg13
I1
sa(dp7146
g7
I166
sg20
VC0699790
p7147
sg10
I12
sg11
Vcolon cancer
p7148
sg13
I2
sa(dp7149
g7
I208
sg20
VC0012634
p7150
sg10
I9
sg11
Vcondition
p7151
sg13
I1
sasa(dp7152
g2
VDefective lysosomal function defines many neurodegenerative diseases, such as neuronal ceroid lipofuscinoses (NCL) and Niemann-Pick type C (NPC), and is implicated in Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD-TDP) with progranulin (PGRN) deficiency.
p7153
sg4
(lp7154
(dp7155
g7
I140
sg8
g47
sg10
I3
sg11
VNPC
p7156
sg13
I1
sa(dp7157
g7
I119
sg8
g47
sg10
I19
sg11
VNiemann-Pick type C
p7158
sg13
I3
sasg17
(lp7159
(dp7160
g7
I231
sg20
VC0751072
p7161
sg10
I4
sg11
VFTLD
p7162
sg13
I1
sa(dp7163
g7
I167
sg20
VC1521724
p7164
sg10
I19
sg11
VAlzheimer's disease
p7165
sg13
I2
sa(dp7166
g7
I110
sg20
VC0027877
p7167
sg10
I3
sg11
VNCL
p7168
sg13
I1
sa(dp7169
g7
I140
sg20
VC2931822
p7170
sg10
I3
sg11
VNPC
p7171
sg13
I1
sa(dp7172
g7
I188
sg20
VC1521724
p7173
sg10
I2
sg11
VAD
p7174
sg13
I1
sa(dp7175
g7
I196
sg20
VC0751072
p7176
sg10
I33
sg11
Vfrontotemporal lobar degeneration
p7177
sg13
I3
sa(dp7178
g7
I119
sg20
VC2931822
p7179
sg10
I19
sg11
VNiemann-Pick type C
p7180
sg13
I3
sa(dp7181
g7
I78
sg20
VC0027877
p7182
sg10
I30
sg11
Vneuronal ceroid lipofuscinoses
p7183
sg13
I3
sa(dp7184
g7
I42
sg20
VC0524851
p7185
sg10
I26
sg11
Vneurodegenerative diseases
p7186
sg13
I2
sasa(dp7187
g2
VMoreover, recent findings indicate that Grn mutations are associated with other neurodegenerative disorders with tau pathology, including Alzheimer's disease.
p7188
sg4
(lp7189
sg17
(lp7190
(dp7191
g7
I117
sg20
VC0677042
p7192
sg10
I9
sg11
Vpathology
p7193
sg13
I1
sa(dp7194
g7
I80
sg20
VC0524851
p7195
sg10
I27
sg11
Vneurodegenerative disorders
p7196
sg13
I2
sa(dp7197
g7
I138
sg20
VC1521724
p7198
sg10
I19
sg11
VAlzheimer's disease
p7199
sg13
I2
sasa(dp7200
g2
VTogether, these critical roles in the CNS suggest that PGRN has the potential to be an important therapeutic target for the treatment of various neurodegenerative disorders, particularly Alzheimer's disease (AD).
p7201
sg4
(lp7202
sg17
(lp7203
(dp7204
g7
I187
sg20
VC1521724
p7205
sg10
I19
sg11
VAlzheimer's disease
p7206
sg13
I2
sa(dp7207
g7
I145
sg20
VC0524851
p7208
sg10
I27
sg11
Vneurodegenerative disorders
p7209
sg13
I2
sa(dp7210
g7
I208
sg20
VC1521724
p7211
sg10
I2
sg11
VAD
p7212
sg13
I1
sasa(dp7213
g2
VPathological examination revealed Alzheimer's disease in three cases (all LPA), pathological PSP in two cases (one clinical PSP and one PNFA) and corticobasal degeneration in one case (PNFA).
p7214
sg4
(lp7215
sg17
(lp7216
(dp7217
g7
I93
sg20
VC0038868
p7218
sg10
I3
sg11
VPSP
p7219
sg13
I1
sa(dp7220
g7
I34
sg20
VC1521724
p7221
sg10
I19
sg11
VAlzheimer's disease
p7222
sg13
I2
sa(dp7223
g7
I146
sg20
VC0393570
p7224
sg10
I25
sg11
Vcorticobasal degeneration
p7225
sg13
I2
sa(dp7226
g7
I93
sg20
VC0038868
p7227
sg10
I3
sg11
VPSP
p7228
sg13
I1
sasa(dp7229
g2
VGranulin mutations were initially found in tau-negative patients, though recent findings indicate that these mutations are associated with other neurodegenerative disorders with tau pathology, including Alzheimer's disease and corticobasal degeneration.
p7230
sg4
(lp7231
sg17
(lp7232
(dp7233
g7
I182
sg20
VC0677042
p7234
sg10
I9
sg11
Vpathology
p7235
sg13
I1
sa(dp7236
g7
I227
sg20
VC0393570
p7237
sg10
I25
sg11
Vcorticobasal degeneration
p7238
sg13
I2
sa(dp7239
g7
I145
sg20
VC0524851
p7240
sg10
I27
sg11
Vneurodegenerative disorders
p7241
sg13
I2
sa(dp7242
g7
I203
sg20
VC1521724
p7243
sg10
I19
sg11
VAlzheimer's disease
p7244
sg13
I2
sasa(dp7245
g2
VInter-individual variation in CCAAT/enhancer binding protein gamma (CEBPG) transcript expression in normal human bronchial epithelial cells (NBEC) is associated with predisposition to lung cancer.
p7246
sg4
(lp7247
(dp7248
g7
I30
sg8
g47
sg10
I36
sg11
VCCAAT/enhancer binding protein gamma
p7249
sg13
I4
sa(dp7250
g7
I68
sg8
VP53567
p7251
sg10
I5
sg11
VCEBPG
p7252
sg13
I1
sasg17
(lp7253
(dp7254
g7
I184
sg20
VC0684249
p7255
sg10
I11
sg11
Vlung cancer
p7256
sg13
I2
sasa(dp7257
g2
VThese data support the hypothesis that genetic variation in linkage disequilibrium with rs2772 influences regulation of CEBPG transcript expression through a trans-effect downstream of RNA polymerase II transcription and confirm that cis-acting genetic variation contributes to inter-individual variation in CEBPG transcript expression in NBEC, which is associated with variation in lung cancer risk.
p7258
sg4
(lp7259
(dp7260
g7
I120
sg8
VP53567
p7261
sg10
I16
sg11
VCEBPG transcript
p7262
sg13
I2
sa(dp7263
g7
I120
sg8
VP53567
p7264
sg10
I16
sg11
VCEBPG transcript
p7265
sg13
I2
sa(dp7266
g7
I185
sg8
VP19388
p7267
sg10
I17
sg11
VRNA polymerase II
p7268
sg13
I3
sasg17
(lp7269
(dp7270
g7
I383
sg20
VC0684249
p7271
sg10
I11
sg11
Vlung cancer
p7272
sg13
I2
sa(dp7273
g7
I234
sg20
VC0007099
p7274
sg10
I3
sg11
Vcis
p7275
sg13
I1
sa(dp7276
g7
I68
sg20
VC0394006
p7277
sg10
I14
sg11
Vdisequilibrium
p7278
sg13
I1
sasa(dp7279
g2
VIn an effort to develop a biomarker for lung cancer risk, we evaluated the transcript expressions of 14 antioxidant, DNA repair, and transcription factor genes in normal bronchial epithelial cells (HUGO names CAT, CEBPG, E2F1, ERCC4, ERCC5, GPX1, GPX3, GSTM3, GSTP1, GSTT1, GSTZ1, MGST1, SOD1, and XRCC1).
p7280
sg4
(lp7281
(dp7282
g7
I227
sg8
g47
sg10
I5
sg11
VERCC4
p7283
sg13
I1
sa(dp7284
g7
I209
sg8
VP04040
p7285
sg10
I3
sg11
VCAT
p7286
sg13
I1
sa(dp7287
g7
I234
sg8
VP28715
p7288
sg10
I5
sg11
VERCC5
p7289
sg13
I1
sa(dp7290
g7
I274
sg8
g47
sg10
I5
sg11
VGSTZ1
p7291
sg13
I1
sa(dp7292
g7
I214
sg8
VP53567
p7293
sg10
I5
sg11
VCEBPG
p7294
sg13
I1
sa(dp7295
g7
I221
sg8
g47
sg10
I4
sg11
VE2F1
p7296
sg13
I1
sa(dp7297
g7
I267
sg8
VP30711
p7298
sg10
I5
sg11
VGSTT1
p7299
sg13
I1
sa(dp7300
g7
I260
sg8
VP09211
p7301
sg10
I5
sg11
VGSTP1
p7302
sg13
I1
sa(dp7303
g7
I288
sg8
VP00441
p7304
sg10
I4
sg11
VSOD1
p7305
sg13
I1
sa(dp7306
g7
I298
sg8
VP18887
p7307
sg10
I5
sg11
VXRCC1
p7308
sg13
I1
sa(dp7309
g7
I253
sg8
VP21266
p7310
sg10
I5
sg11
VGSTM3
p7311
sg13
I1
sa(dp7312
g7
I281
sg8
VP10620
p7313
sg10
I5
sg11
VMGST1
p7314
sg13
I1
sa(dp7315
g7
I247
sg8
VP22352
p7316
sg10
I4
sg11
VGPX3
p7317
sg13
I1
sa(dp7318
g7
I241
sg8
VP07203
p7319
sg10
I4
sg11
VGPX1
p7320
sg13
I1
sasg17
(lp7321
(dp7322
g7
I40
sg20
VC0684249
p7323
sg10
I11
sg11
Vlung cancer
p7324
sg13
I2
sasa(dp7325
g2
VWe sought to review English language research articles examining the presence, clinical significance, and/or pathophysiology of MM in Parkinson's disease (PD), corticobasal syndrome (CBS), essential tremor (ET), focal hand dystonia, Creutzfeldt-Jakob's disease (CJD), and Huntington's disease.
p7326
sg4
(lp7327
sg17
(lp7328
(dp7329
g7
I155
sg20
VC0030567
p7330
sg10
I2
sg11
VPD
p7331
sg13
I1
sa(dp7332
g7
I262
sg20
VC0022336
p7333
sg10
I3
sg11
VCJD
p7334
sg13
I1
sa(dp7335
g7
I207
sg20
VC0270736
p7336
sg10
I2
sg11
VET
p7337
sg13
I1
sa(dp7338
g7
I189
sg20
VC0270736
p7339
sg10
I16
sg11
Vessential tremor
p7340
sg13
I2
sa(dp7341
g7
I272
sg20
VC0020179
p7342
sg10
I20
sg11
VHuntington's disease
p7343
sg13
I2
sa(dp7344
g7
I173
sg20
VC0039082
p7345
sg10
I8
sg11
Vsyndrome
p7346
sg13
I1
sa(dp7347
g7
I212
sg20
VC3267192
p7348
sg10
I19
sg11
Vfocal hand dystonia
p7349
sg13
I3
sa(dp7350
g7
I134
sg20
VC0030567
p7351
sg10
I19
sg11
VParkinson's disease
p7352
sg13
I2
sa(dp7353
g7
I233
sg20
VC0022336
p7354
sg10
I27
sg11
VCreutzfeldt-Jakob's disease
p7355
sg13
I2
sasa(dp7356
g2
VWe report a patient that presented with the corticobasal syndrome (CBS), including progressive dementia, asymmetric parkinsonism associated with constructional and ideomotor apraxia, action myoclonus and focal hand dystonia.
p7357
sg4
(lp7358
sg17
(lp7359
(dp7360
g7
I83
sg20
VC0743039
p7361
sg10
I20
sg11
Vprogressive dementia
p7362
sg13
I2
sa(dp7363
g7
I204
sg20
VC3267192
p7364
sg10
I19
sg11
Vfocal hand dystonia
p7365
sg13
I3
sa(dp7366
g7
I116
sg20
VC0242422
p7367
sg10
I12
sg11
Vparkinsonism
p7368
sg13
I1
sa(dp7369
g7
I183
sg20
VC0751354
p7370
sg10
I16
sg11
Vaction myoclonus
p7371
sg13
I2
sa(dp7372
g7
I164
sg20
VC0234523
p7373
sg10
I17
sg11
Videomotor apraxia
p7374
sg13
I2
sa(dp7375
g7
I57
sg20
VC0039082
p7376
sg10
I8
sg11
Vsyndrome
p7377
sg13
I1
sasa(dp7378
g2
VFifteen rearrangements detected in Sezary syndrome patients and SeAx resulted in an expression of new fusion transcripts, nine of them were in frame (EHD1-CAPN12, TMEM66-BAIAP2, MBD4-PTPRC, PTPRC-CPN2, MYB-MBNL1, TFG-GPR128, MAP4K3-FIGLA, DCP1A-CCL27, MBNL1-KIAA2018) and five resulted in ectopic expression of fragments of genes not expressed in normal T-cells (BAIAP2, CPN2, GPR128, CAPN12, FIGLA).
p7379
sg4
(lp7380
(dp7381
g7
I150
sg8
g47
sg10
I4
sg11
VEHD1
p7382
sg13
I1
sa(dp7383
g7
I163
sg8
g47
sg10
I6
sg11
VTMEM66
p7384
sg13
I1
sa(dp7385
g7
I190
sg8
VP08575
p7386
sg10
I10
sg11
VPTPRC-CPN2
p7387
sg13
I1
sa(dp7388
g7
I232
sg8
g47
sg10
I5
sg11
VFIGLA
p7389
sg13
I1
sa(dp7390
g7
I217
sg8
g47
sg10
I6
sg11
VGPR128
p7391
sg13
I1
sa(dp7392
g7
I155
sg8
g47
sg10
I6
sg11
VCAPN12
p7393
sg13
I1
sa(dp7394
g7
I252
sg8
g47
sg10
I14
sg11
VMBNL1-KIAA2018
p7395
sg13
I1
sa(dp7396
g7
I217
sg8
g47
sg10
I6
sg11
VGPR128
p7397
sg13
I1
sa(dp7398
g7
I178
sg8
g47
sg10
I4
sg11
VMBD4
p7399
sg13
I1
sa(dp7400
g7
I232
sg8
g47
sg10
I5
sg11
VFIGLA
p7401
sg13
I1
sa(dp7402
g7
I155
sg8
g47
sg10
I6
sg11
VCAPN12
p7403
sg13
I1
sa(dp7404
g7
I225
sg8
g47
sg10
I6
sg11
VMAP4K3
p7405
sg13
I1
sa(dp7406
g7
I206
sg8
g47
sg10
I5
sg11
VMBNL1
p7407
sg13
I1
sa(dp7408
g7
I170
sg8
g47
sg10
I6
sg11
VBAIAP2
p7409
sg13
I1
sa(dp7410
g7
I213
sg8
g47
sg10
I3
sg11
VTFG
p7411
sg13
I1
sa(dp7412
g7
I170
sg8
g47
sg10
I6
sg11
VBAIAP2
p7413
sg13
I1
sa(dp7414
g7
I196
sg8
VP15538
p7415
sg10
I4
sg11
VCPN2
p7416
sg13
I1
sa(dp7417
g7
I202
sg8
VP10243
p7418
sg10
I3
sg11
VMYB
p7419
sg13
I1
sa(dp7420
g7
I239
sg8
g47
sg10
I5
sg11
VDCP1A
p7421
sg13
I1
sa(dp7422
g7
I245
sg8
g47
sg10
I5
sg11
VCCL27
p7423
sg13
I1
sa(dp7424
g7
I183
sg8
VP08575
p7425
sg10
I5
sg11
VPTPRC
p7426
sg13
I1
sasg17
(lp7427
(dp7428
g7
I35
sg20
VC0036920
p7429
sg10
I15
sg11
VSezary syndrome
p7430
sg13
I2
sasa(dp7431
g2
VIn addition, we found eleven potential cancer-related genes with mutations (EZH1, SPOP, NF1, TCF12, IGF2BP3, KMT2C, CNOT1, BRIP1, KDM5C, STAG2 and MAP4K3) that have not been reported in thyroid follicular tumors.
p7432
sg4
(lp7433
(dp7434
g7
I123
sg8
g47
sg10
I5
sg11
VBRIP1
p7435
sg13
I1
sa(dp7436
g7
I82
sg8
g47
sg10
I4
sg11
VSPOP
p7437
sg13
I1
sa(dp7438
g7
I137
sg8
g47
sg10
I5
sg11
VSTAG2
p7439
sg13
I1
sa(dp7440
g7
I109
sg8
g47
sg10
I5
sg11
VKMT2C
p7441
sg13
I1
sa(dp7442
g7
I130
sg8
VP41229
p7443
sg10
I5
sg11
VKDM5C
p7444
sg13
I1
sa(dp7445
g7
I88
sg8
VP21359
p7446
sg10
I3
sg11
VNF1
p7447
sg13
I1
sa(dp7448
g7
I93
sg8
g47
sg10
I5
sg11
VTCF12
p7449
sg13
I1
sa(dp7450
g7
I76
sg8
g47
sg10
I4
sg11
VEZH1
p7451
sg13
I1
sa(dp7452
g7
I147
sg8
g47
sg10
I6
sg11
VMAP4K3
p7453
sg13
I1
sa(dp7454
g7
I100
sg8
g47
sg10
I7
sg11
VIGF2BP3
p7455
sg13
I1
sasg17
(lp7456
(dp7457
g7
I194
sg20
VC0474808
p7458
sg10
I17
sg11
Vfollicular tumors
p7459
sg13
I2
sa(dp7460
g7
I39
sg20
VC0006826
p7461
sg10
I6
sg11
Vcancer
p7462
sg13
I1
sa(dp7463
g7
I88
sg20
VC0027831
p7464
sg10
I3
sg11
VNF1
p7465
sg13
I1
sasa(dp7466
g2
VSince GLK (also named MAP4K3) induces activation of NF-KB, which contributes to tumor progression, we investigated the role of GLK in NSCLC.
p7467
sg4
(lp7468
(dp7469
g7
I6
sg8
VP35557
p7470
sg10
I3
sg11
VGLK
p7471
sg13
I1
sa(dp7472
g7
I22
sg8
g47
sg10
I6
sg11
VMAP4K3
p7473
sg13
I1
sa(dp7474
g7
I6
sg8
VP35557
p7475
sg10
I3
sg11
VGLK
p7476
sg13
I1
sasg17
(lp7477
(dp7478
g7
I80
sg20
VC0178874
p7479
sg10
I17
sg11
Vtumor progression
p7480
sg13
I2
sa(dp7481
g7
I134
sg20
VC0007131
p7482
sg10
I5
sg11
VNSCLC
p7483
sg13
I1
sasa(dp7484
g2
VGLK protein levels of 190 samples from pulmonary tissue arrays and 58 pulmonary resection samples from stage I to stage III NSCLC patients were studied using immunohistochemistry or immunoblotting.
p7485
sg4
(lp7486
(dp7487
g7
I0
sg8
VP35557
p7488
sg10
I3
sg11
VGLK
p7489
sg13
I1
sasg17
(lp7490
(dp7491
g7
I114
sg20
VC0278506
p7492
sg10
I15
sg11
Vstage III NSCLC
p7493
sg13
I3
sasa(dp7494
g2
VHigh levels of GLK proteins were detected in pulmonary tissues from NSCLC patients.
p7495
sg4
(lp7496
(dp7497
g7
I15
sg8
VP35557
p7498
sg10
I12
sg11
VGLK proteins
p7499
sg13
I2
sasg17
(lp7500
(dp7501
g7
I68
sg20
VC0007131
p7502
sg10
I5
sg11
VNSCLC
p7503
sg13
I1
sasa(dp7504
g2
VElevated GLK protein levels were correlated with increased recurrence risks and poor recurrence-free survival rates in NSCLC patients after adjusting for pathologic stage, smoking status, alcohol status, and EGFR levels.
p7505
sg4
(lp7506
(dp7507
g7
I9
sg8
VP35557
p7508
sg10
I11
sg11
VGLK protein
p7509
sg13
I2
sasg17
(lp7510
(dp7511
g7
I59
sg20
VC1458156
p7512
sg10
I10
sg11
Vrecurrence
p7513
sg13
I1
sa(dp7514
g7
I59
sg20
VC1458156
p7515
sg10
I10
sg11
Vrecurrence
p7516
sg13
I1
sa(dp7517
g7
I119
sg20
VC0007131
p7518
sg10
I5
sg11
VNSCLC
p7519
sg13
I1
sasa(dp7520
g2
VThus, GLK is a novel prognostic biomarker for NSCLC recurrence.
p7521
sg4
(lp7522
(dp7523
g7
I6
sg8
VP35557
p7524
sg10
I3
sg11
VGLK
p7525
sg13
I1
sasg17
(lp7526
(dp7527
g7
I46
sg20
VC0007131
p7528
sg10
I5
sg11
VNSCLC
p7529
sg13
I1
sa(dp7530
g7
I52
sg20
VC1458156
p7531
sg10
I10
sg11
Vrecurrence
p7532
sg13
I1
sasa(dp7533
g2
VRNA fusion-based CISs were identified corresponding to both DNA-based CISs (Cdkn2a, Mycl1, Nf2, Pten, Sema6d, and Rere) and additional regions strongly associated with cancer that were not observed by LM-PCR (Myc, Akt1, Pth, Csf1r, Fgfr2, Wisp1, Map3k5, and Map4k3).
p7534
sg4
(lp7535
(dp7536
g7
I84
sg8
VP12524
p7537
sg10
I3
sg11
VMyc
p7538
sg13
I1
sa(dp7539
g7
I258
sg8
g47
sg10
I6
sg11
VMap4k3
p7540
sg13
I1
sa(dp7541
g7
I84
sg8
VP12524
p7542
sg10
I5
sg11
VMycl1
p7543
sg13
I1
sa(dp7544
g7
I96
sg8
VP60484
p7545
sg10
I4
sg11
VPten
p7546
sg13
I1
sa(dp7547
g7
I225
sg8
VP09619
p7548
sg10
I5
sg11
VCsf1r
p7549
sg13
I1
sa(dp7550
g7
I220
sg8
VP01270
p7551
sg10
I3
sg11
VPth
p7552
sg13
I1
sa(dp7553
g7
I76
sg8
VP42771
p7554
sg10
I6
sg11
VCdkn2a
p7555
sg13
I1
sa(dp7556
g7
I239
sg8
g47
sg10
I5
sg11
VWisp1
p7557
sg13
I1
sa(dp7558
g7
I17
sg8
g47
sg10
I4
sg11
VCISs
p7559
sg13
I1
sa(dp7560
g7
I214
sg8
VP31749
p7561
sg10
I4
sg11
VAkt1
p7562
sg13
I1
sa(dp7563
g7
I246
sg8
g47
sg10
I6
sg11
VMap3k5
p7564
sg13
I1
sasg17
(lp7565
(dp7566
g7
I168
sg20
VC0006826
p7567
sg10
I6
sg11
Vcancer
p7568
sg13
I1
sa(dp7569
g7
I91
sg20
VC0027832
p7570
sg10
I3
sg11
VNf2
p7571
sg13
I1
sasa(dp7572
g2
VComputationally, PTPRF, PRKAR2B, MAP4K3, and RICTOR were calculated as highly drug-targetable genes for breast cancer.
p7573
sg4
(lp7574
(dp7575
g7
I24
sg8
VP31323
p7576
sg10
I7
sg11
VPRKAR2B
p7577
sg13
I1
sa(dp7578
g7
I33
sg8
g47
sg10
I6
sg11
VMAP4K3
p7579
sg13
I1
sa(dp7580
g7
I17
sg8
VP10586
p7581
sg10
I5
sg11
VPTPRF
p7582
sg13
I1
sa(dp7583
g7
I45
sg8
g47
sg10
I6
sg11
VRICTOR
p7584
sg13
I1
sasg17
(lp7585
(dp7586
g7
I104
sg20
VC0678222
p7587
sg10
I13
sg11
Vbreast cancer
p7588
sg13
I2
sasa(dp7589
g2
VIn the GeparTrio FFPE training cohort, a significant linear correlation between TMSB15A expression and pCR was apparent in triple-negative breast cancer (TNBC) (n=61, P=0.040).
p7590
sg4
(lp7591
(dp7592
g7
I80
sg8
g47
sg10
I7
sg11
VTMSB15A
p7593
sg13
I1
sasg17
(lp7594
(dp7595
g7
I139
sg20
VC0678222
p7596
sg10
I13
sg11
Vbreast cancer
p7597
sg13
I2
sasa(dp7598
g2
VIn normal human prostate and prostate cancer tissues, TMSB15A was the predominant isoform expressed.
p7599
sg4
(lp7600
sg17
(lp7601
(dp7602
g7
I29
sg20
VC0600139
p7603
sg10
I15
sg11
Vprostate cancer
p7604
sg13
I2
sasa(dp7605
g2
VIn contrast, normal colon and colon cancer tissue expressed predominantly TMSB15B.
p7606
sg4
(lp7607
(dp7608
g7
I74
sg8
g47
sg10
I7
sg11
VTMSB15B
p7609
sg13
I1
sasg17
(lp7610
(dp7611
g7
I30
sg20
VC0699790
p7612
sg10
I12
sg11
Vcolon cancer
p7613
sg13
I2
sasa(dp7614
g2
VTreatment of MCF-7 breast cancer cells with transforming growth factor beta 1 repressed TMSB15A expression but had no effect on TMSB15B.
p7615
sg4
(lp7616
(dp7617
g7
I88
sg8
g47
sg10
I7
sg11
VTMSB15A
p7618
sg13
I1
sa(dp7619
g7
I128
sg8
g47
sg10
I7
sg11
VTMSB15B
p7620
sg13
I1
sa(dp7621
g7
I44
sg8
VP01137
p7622
sg10
I33
sg11
Vtransforming growth factor beta 1
p7623
sg13
I5
sasg17
(lp7624
(dp7625
g7
I19
sg20
VC0678222
p7626
sg10
I13
sg11
Vbreast cancer
p7627
sg13
I2
sasa(dp7628
g2
VsiRNA specific to the TMSB15B isoform suppressed cell migration of prostate cancer cells to epidermal growth factor, suggesting a functional role for this second isoform.
p7629
sg4
(lp7630
(dp7631
g7
I92
sg8
VP01133
p7632
sg10
I23
sg11
Vepidermal growth factor
p7633
sg13
I3
sasg17
(lp7634
(dp7635
g7
I67
sg20
VC0600139
p7636
sg10
I15
sg11
Vprostate cancer
p7637
sg13
I2
sasa(dp7638
g2
VWe showed earlier that human beta-thymosin 15 (Tb15) is up-regulated in prostate cancer, confirming studies from others that propagated Tb15 as a prostate cancer biomarker.
p7639
sg4
(lp7640
(dp7641
g7
I18
sg8
g47
sg10
I27
sg11
Vthat human beta-thymosin 15
p7642
sg13
I4
sa(dp7643
g7
I47
sg8
g47
sg10
I4
sg11
VTb15
p7644
sg13
I1
sa(dp7645
g7
I47
sg8
g47
sg10
I4
sg11
VTb15
p7646
sg13
I1
sasg17
(lp7647
(dp7648
g7
I72
sg20
VC0600139
p7649
sg10
I15
sg11
Vprostate cancer
p7650
sg13
I2
sa(dp7651
g7
I72
sg20
VC0600139
p7652
sg10
I15
sg11
Vprostate cancer
p7653
sg13
I2
sasa(dp7654
g2
VTb15r is present also in mouse prostate cancer cell lines.
p7655
sg4
(lp7656
sg17
(lp7657
(dp7658
g7
I31
sg20
VC0600139
p7659
sg10
I15
sg11
Vprostate cancer
p7660
sg13
I2
sasa(dp7661
g2
VIn those patients with isolated adenopathy the following diagnoses were reached; sarcoidosis 23, TB 15, lymphoma 4, carcinoma 4, no diagnosis 1.
p7662
sg4
(lp7663
sg17
(lp7664
(dp7665
g7
I81
sg20
VC0036202
p7666
sg10
I11
sg11
Vsarcoidosis
p7667
sg13
I1
sa(dp7668
g7
I116
sg20
VC0007097
p7669
sg10
I9
sg11
Vcarcinoma
p7670
sg13
I1
sa(dp7671
g7
I104
sg20
VC0024299
p7672
sg10
I8
sg11
Vlymphoma
p7673
sg13
I1
sasa(dp7674
g2
VHowever, in this report we provide evidence that TbNB, initially identified in human neuroblastoma, is the only Tb isoform upregulated in human prostate cancer and that the Tb15 sequence is not present herein.
p7675
sg4
(lp7676
(dp7677
g7
I49
sg8
g47
sg10
I4
sg11
VTbNB
p7678
sg13
I1
sa(dp7679
g7
I173
sg8
g47
sg10
I13
sg11
VTb15 sequence
p7680
sg13
I2
sasg17
(lp7681
(dp7682
g7
I144
sg20
VC0600139
p7683
sg10
I15
sg11
Vprostate cancer
p7684
sg13
I2
sa(dp7685
g7
I85
sg20
VC0027819
p7686
sg10
I13
sg11
Vneuroblastoma
p7687
sg13
I1
sasa(dp7688
g2
VHuman NB thymosin beta is a beta-thymosin originally found in neuroblastoma.
p7689
sg4
(lp7690
(dp7691
g7
I0
sg8
VP20962
p7692
sg10
I22
sg11
VHuman NB thymosin beta
p7693
sg13
I4
sa(dp7694
g7
I28
sg8
VP20962
p7695
sg10
I13
sg11
Vbeta-thymosin
p7696
sg13
I1
sasg17
(lp7697
(dp7698
g7
I62
sg20
VC0027819
p7699
sg10
I13
sg11
Vneuroblastoma
p7700
sg13
I1
sasa(dp7701
g2
VOur studies provide the first evidence that Upk1b is directly associated with the development of congenital anomalies of the urinary tract (CAKUT), spontaneous age-dependent hydronephrosis, and dysplastic urothelia.
p7702
sg4
(lp7703
(dp7704
g7
I44
sg8
g47
sg10
I5
sg11
VUpk1b
p7705
sg13
I1
sasg17
(lp7706
(dp7707
g7
I97
sg20
VC0000768
p7708
sg10
I20
sg11
Vcongenital anomalies
p7709
sg13
I2
sa(dp7710
g7
I140
sg20
VC1968949
p7711
sg10
I5
sg11
VCAKUT
p7712
sg13
I1
sa(dp7713
g7
I194
sg20
VC0334044
p7714
sg10
I10
sg11
Vdysplastic
p7715
sg13
I1
sa(dp7716
g7
I174
sg20
VC0020295
p7717
sg10
I14
sg11
Vhydronephrosis
p7718
sg13
I1
sasa(dp7719
g2
VUpk1b(RFP/RFP) mice developed age-dependent progressive hydronephrosis.
p7720
sg4
(lp7721
(dp7722
g7
I0
sg8
g47
sg10
I5
sg11
VUpk1b
p7723
sg13
I1
sa(dp7724
g7
I6
sg8
VP25090
p7725
sg10
I3
sg11
VRFP
p7726
sg13
I1
sa(dp7727
g7
I6
sg8
VP25090
p7728
sg10
I3
sg11
VRFP
p7729
sg13
I1
sasg17
(lp7730
(dp7731
g7
I56
sg20
VC0020295
p7732
sg10
I14
sg11
Vhydronephrosis
p7733
sg13
I1
sasa(dp7734
g2
VThe aim of the present study was to investigate the role of serotonin (5-hydroxytryptamine) in the rostral ventromedial medulla (RVM) and spinal cord in pain sensory abnormalities in a 6-hydroxydopamine-treated rat model of Parkinson's disease.
p7735
sg4
(lp7736
sg17
(lp7737
(dp7738
g7
I145
sg20
VC0035334
p7739
sg10
I4
sg11
Vcord
p7740
sg13
I1
sa(dp7741
g7
I224
sg20
VC0030567
p7742
sg10
I19
sg11
VParkinson's disease
p7743
sg13
I2
sasa(dp7744
g2
VConclusions These results suggest that the decreased 5-hydroxytryptamine contents in the rostral ventromedial medulla and spinal dorsal horn may be involved in hyperalgesia in the 6-hydroxydopamine-induced rat model of Parkinson's disease.
p7745
sg4
(lp7746
sg17
(lp7747
(dp7748
g7
I219
sg20
VC0030567
p7749
sg10
I19
sg11
VParkinson's disease
p7750
sg13
I2
sa(dp7751
g7
I160
sg20
VC0020429
p7752
sg10
I12
sg11
Vhyperalgesia
p7753
sg13
I1
sasa(dp7754
g2
VThe role of serotonin7 (5-HT7) receptors in the regulation of depression is poorly understood, particularly in Parkinson's disease-associated depression.
p7755
sg4
(lp7756
(dp7757
g7
I12
sg8
VP34969
p7758
sg10
I28
sg11
Vserotonin7 (5-HT7) receptors
p7759
sg13
I3
sasg17
(lp7760
(dp7761
g7
I62
sg20
VC0011581
p7762
sg10
I10
sg11
Vdepression
p7763
sg13
I1
sa(dp7764
g7
I111
sg20
VC0030567
p7765
sg10
I19
sg11
VParkinson's disease
p7766
sg13
I2
sa(dp7767
g7
I62
sg20
VC0011581
p7768
sg10
I10
sg11
Vdepression
p7769
sg13
I1
sasa(dp7770
g2
VThe expression of 13 fibrosis-related microRNAs (miRNAs) (miR-20a, miR-21, miR-27a, miR-27b, miR-29a, miR-29c, miR-92a, miR-122, miR-146a, miR-155, miR-221, miR-222, and miR-224) was analyzed in 194 serums and 177 liver biopsies of patients with either CHB or CHC to develop models to diagnose advanced fibrosis and cirrhosis (Metavir F3-F4).
p7771
sg4
(lp7772
(dp7773
g7
I75
sg8
g47
sg10
I7
sg11
VmiR-27a
p7774
sg13
I1
sa(dp7775
g7
I148
sg8
g47
sg10
I7
sg11
VmiR-221
p7776
sg13
I1
sa(dp7777
g7
I67
sg8
g47
sg10
I6
sg11
VmiR-21
p7778
sg13
I1
sa(dp7779
g7
I58
sg8
g47
sg10
I7
sg11
VmiR-20a
p7780
sg13
I1
sa(dp7781
g7
I139
sg8
g47
sg10
I7
sg11
VmiR-155
p7782
sg13
I1
sa(dp7783
g7
I102
sg8
g47
sg10
I7
sg11
VmiR-29c
p7784
sg13
I1
sa(dp7785
g7
I93
sg8
g47
sg10
I7
sg11
VmiR-29a
p7786
sg13
I1
sa(dp7787
g7
I111
sg8
g47
sg10
I7
sg11
VmiR-92a
p7788
sg13
I1
sa(dp7789
g7
I157
sg8
g47
sg10
I7
sg11
VmiR-222
p7790
sg13
I1
sa(dp7791
g7
I129
sg8
g47
sg10
I8
sg11
VmiR-146a
p7792
sg13
I1
sa(dp7793
g7
I84
sg8
g47
sg10
I7
sg11
VmiR-27b
p7794
sg13
I1
sa(dp7795
g7
I120
sg8
g47
sg10
I7
sg11
VmiR-122
p7796
sg13
I1
sasg17
(lp7797
(dp7798
g7
I21
sg20
VC0016059
p7799
sg10
I8
sg11
Vfibrosis
p7800
sg13
I1
sa(dp7801
g7
I253
sg20
VC0151517
p7802
sg10
I3
sg11
VCHB
p7803
sg13
I1
sa(dp7804
g7
I21
sg20
VC0016059
p7805
sg10
I8
sg11
Vfibrosis
p7806
sg13
I1
sa(dp7807
g7
I316
sg20
VC0023890
p7808
sg10
I9
sg11
Vcirrhosis
p7809
sg13
I1
sasa(dp7810
g2
VFor this reason, the expression levels of 24 miRNA (let-7c, miR-92a-3p, 423-5p, 150-5p, 223-3p, 125b-5p, 342-3p, miR-206, 122-5p, 375, 223-5p, 10a-5p, 23b-5p, 99a-5p, 23a-5p, 10a-3p, 122-3p, 125b-1-3p, 23b-3p, 125b-2-3p, 23a-3p, 92a-1-5p, 92a-2-5p, 99a-3p) were analyzed in plasma of patients with chronic hepatitis B, HBV-positive cirrhosis and HBV-positive HCC and compared with control group samples.
p7811
sg4
(lp7812
(dp7813
g7
I60
sg8
g47
sg10
I10
sg11
VmiR-92a-3p
p7814
sg13
I1
sasg17
(lp7815
(dp7816
g7
I359
sg20
VC2239176
p7817
sg10
I3
sg11
VHCC
p7818
sg13
I1
sa(dp7819
g7
I319
sg20
VC0019163
p7820
sg10
I3
sg11
VHBV
p7821
sg13
I1
sa(dp7822
g7
I319
sg20
VC0019163
p7823
sg10
I3
sg11
VHBV
p7824
sg13
I1
sa(dp7825
g7
I298
sg20
VC0524909
p7826
sg10
I19
sg11
Vchronic hepatitis B
p7827
sg13
I3
sa(dp7828
g7
I332
sg20
VC0023890
p7829
sg10
I9
sg11
Vcirrhosis
p7830
sg13
I1
sasa(dp7831
g2
VConsistently, Bhlhb2 expression was significantly higher in PFC of ADHD model SHR than control.
p7832
sg4
(lp7833
(dp7834
g7
I67
sg8
g47
sg10
I14
sg11
VADHD model SHR
p7835
sg13
I3
sa(dp7836
g7
I14
sg8
g47
sg10
I6
sg11
VBhlhb2
p7837
sg13
I1
sa(dp7838
g7
I60
sg8
VP27918
p7839
sg10
I3
sg11
VPFC
p7840
sg13
I1
sasg17
(lp7841
(dp7842
g7
I67
sg20
VC1263846
p7843
sg10
I4
sg11
VADHD
p7844
sg13
I1
sasa(dp7845
g2
VWe examined ANG expression in WTs, human fetal kidney (FK) and childhood kidney (NK) samples and studied its relationship with microvascular density (MVD) and with three other hypoxia-induced angiogenic factors: lactate dehydrogenase A (LDHA), vascular endothelial growth factor (VEGFA) and BHLHE40 (basic helix-loop-helix transcription factor E40).
p7846
sg4
(lp7847
(dp7848
g7
I244
sg8
g47
sg10
I34
sg11
Vvascular endothelial growth factor
p7849
sg13
I4
sa(dp7850
g7
I291
sg8
g47
sg10
I7
sg11
VBHLHE40
p7851
sg13
I1
sa(dp7852
g7
I280
sg8
g47
sg10
I5
sg11
VVEGFA
p7853
sg13
I1
sa(dp7854
g7
I212
sg8
VP49366
p7855
sg10
I23
sg11
Vlactate dehydrogenase A
p7856
sg13
I3
sa(dp7857
g7
I237
sg8
VP00338
p7858
sg10
I4
sg11
VLDHA
p7859
sg13
I1
sa(dp7860
g7
I300
sg8
g47
sg10
I47
sg11
Vbasic helix-loop-helix transcription factor E40
p7861
sg13
I5
sasg17
(lp7862
(dp7863
g7
I176
sg20
VC0242184
p7864
sg10
I7
sg11
Vhypoxia
p7865
sg13
I1
sa(dp7866
g7
I30
sg20
VC1839736
p7867
sg10
I3
sg11
VWTs
p7868
sg13
I1
sasa(dp7869
g2
VANG, CD31, VEGFA and BHLHE40 mRNA levels were significantly lower in 15 WTs compared with matched-paired NKs.
p7870
sg4
(lp7871
(dp7872
g7
I0
sg8
VP03950
p7873
sg10
I3
sg11
VANG
p7874
sg13
I1
sa(dp7875
g7
I5
sg8
VP69905
p7876
sg10
I4
sg11
VCD31
p7877
sg13
I1
sa(dp7878
g7
I21
sg8
g47
sg10
I12
sg11
VBHLHE40 mRNA
p7879
sg13
I2
sasg17
(lp7880
(dp7881
g7
I72
sg20
VC1839736
p7882
sg10
I3
sg11
VWTs
p7883
sg13
I1
sasa(dp7884
g2
VMutations in the SLC5A5 gene encoding NIS that result in a non-functional protein lead to congenital hypothyroidism due to I- transport defect (ITD).
p7885
sg4
(lp7886
(dp7887
g7
I17
sg8
g47
sg10
I24
sg11
VSLC5A5 gene encoding NIS
p7888
sg13
I4
sasg17
(lp7889
(dp7890
g7
I90
sg20
VC0342200
p7891
sg10
I25
sg11
Vcongenital hypothyroidism
p7892
sg13
I2
sasa(dp7893
g2
VThyroid concentrates radioactive iodine by sodium-iodide symporter; this is used for treating hyperthyroidism and thyroid cancer.
p7894
sg4
(lp7895
sg17
(lp7896
(dp7897
g7
I94
sg20
VC0020550
p7898
sg10
I15
sg11
Vhyperthyroidism
p7899
sg13
I1
sa(dp7900
g7
I114
sg20
VC0007115
p7901
sg10
I14
sg11
Vthyroid cancer
p7902
sg13
I2
sasa(dp7903
g2
VIn this study, we investigated the relationship between iodine content and sodium iodide symporter (NIS) expression by using the clinical specimens from patients with nodular goiter and explored the pathogenesis triggered by iodine deficiency in nodular goiter.
p7904
sg4
(lp7905
(dp7906
g7
I100
sg8
g47
sg10
I3
sg11
VNIS
p7907
sg13
I1
sa(dp7908
g7
I75
sg8
g47
sg10
I23
sg11
Vsodium iodide symporter
p7909
sg13
I3
sasg17
(lp7910
(dp7911
g7
I167
sg20
VC1318500
p7912
sg10
I14
sg11
Vnodular goiter
p7913
sg13
I2
sa(dp7914
g7
I167
sg20
VC1318500
p7915
sg10
I14
sg11
Vnodular goiter
p7916
sg13
I2
sa(dp7917
g7
I225
sg20
VC0342199
p7918
sg10
I17
sg11
Viodine deficiency
p7919
sg13
I2
sa(dp7920
g7
I199
sg20
VC0699748
p7921
sg10
I12
sg11
Vpathogenesis
p7922
sg13
I1
sasa(dp7923
g2
VThe same technique was used for the assays of the hepatic levels of FGF-21, silent information regulator (SIRT1), malondialdehyde (MDA),IL-10, tumor necrosis factor-Alfa (TNF-Alfa) as well as the apoptotic markers; caspase-3 and B-cell lymphoma (Bcl-2).
p7924
sg4
(lp7925
(dp7926
g7
I68
sg8
g47
sg10
I6
sg11
VFGF-21
p7927
sg13
I1
sa(dp7928
g7
I171
sg8
VP01375
p7929
sg10
I8
sg11
VTNF-Alfa
p7930
sg13
I1
sa(dp7931
g7
I215
sg8
VP42574
p7932
sg10
I9
sg11
Vcaspase-3
p7933
sg13
I1
sa(dp7934
g7
I106
sg8
g47
sg10
I5
sg11
VSIRT1
p7935
sg13
I1
sa(dp7936
g7
I143
sg8
VP01375
p7937
sg10
I26
sg11
Vtumor necrosis factor-Alfa
p7938
sg13
I3
sasg17
(lp7939
(dp7940
g7
I229
sg20
VC0079731
p7941
sg10
I15
sg11
VB-cell lymphoma
p7942
sg13
I2
sa(dp7943
g7
I143
sg20
VC0333516
p7944
sg10
I14
sg11
Vtumor necrosis
p7945
sg13
I2
sasa(dp7946
g2
VWe report here the case of a 25-year-old woman with a bulbar onset ALS that progressed in less than 12 months to invasive ventilation due to respiratory failure; Genetic screening identified a new mutation in the FUS gene that lies within the last codon.
p7947
sg4
(lp7948
(dp7949
g7
I213
sg8
VP35637
p7950
sg10
I8
sg11
VFUS gene
p7951
sg13
I2
sasg17
(lp7952
(dp7953
g7
I141
sg20
VC1145670
p7954
sg10
I19
sg11
Vrespiratory failure
p7955
sg13
I2
sa(dp7956
g7
I193
sg20
VC2985439
p7957
sg10
I12
sg11
Vnew mutation
p7958
sg13
I2
sa(dp7959
g7
I67
sg20
VC0002736
p7960
sg10
I3
sg11
VALS
p7961
sg13
I1
sasa(dp7962
g2
VThe expression and biological function of Grb2-associated binding 2 (Gab2) in renal cell carcinoma (RCC) cells was tested here.
p7963
sg4
(lp7964
(dp7965
g7
I69
sg8
g47
sg10
I4
sg11
VGab2
p7966
sg13
I1
sa(dp7967
g7
I42
sg8
VP62993
p7968
sg10
I25
sg11
VGrb2-associated binding 2
p7969
sg13
I3
sasg17
(lp7970
(dp7971
g7
I78
sg20
VC0007134
p7972
sg10
I20
sg11
Vrenal cell carcinoma
p7973
sg13
I3
sa(dp7974
g7
I100
sg20
VC0007134
p7975
sg10
I3
sg11
VRCC
p7976
sg13
I1
sasa(dp7977
g2
VHowever, the significance of Grb2 and Sos proteins, which is related to EGF-triggered Ras activation, has not been elucidated in human bladder cancer.
p7978
sg4
(lp7979
(dp7980
g7
I72
sg8
VP01133
p7981
sg10
I3
sg11
VEGF
p7982
sg13
I1
sa(dp7983
g7
I29
sg8
VP62993
p7984
sg10
I4
sg11
VGrb2
p7985
sg13
I1
sa(dp7986
g7
I86
sg8
VP01116
p7987
sg10
I3
sg11
VRas
p7988
sg13
I1
sa(dp7989
g7
I38
sg8
g47
sg10
I12
sg11
VSos proteins
p7990
sg13
I2
sasg17
(lp7991
(dp7992
g7
I135
sg20
VC0699885
p7993
sg10
I14
sg11
Vbladder cancer
p7994
sg13
I2
sasa(dp7995
g2
VOn the other hand, expression of Grb2 and Sos proteins was substantially increased in all human bladder cancer cell lines examined in comparison with cultured normal urothelial cells, whether codon 12 of H-ras was mutated or not.
p7996
sg4
(lp7997
(dp7998
g7
I42
sg8
g47
sg10
I12
sg11
VSos proteins
p7999
sg13
I2
sa(dp8000
g7
I204
sg8
VP01112
p8001
sg10
I5
sg11
VH-ras
p8002
sg13
I1
sa(dp8003
g7
I33
sg8
VP62993
p8004
sg10
I4
sg11
VGrb2
p8005
sg13
I1
sasg17
(lp8006
(dp8007
g7
I96
sg20
VC0699885
p8008
sg10
I14
sg11
Vbladder cancer
p8009
sg13
I2
sasa(dp8010
g2
VThese results suggest that the amplification of both Grb2 and SOS proteins plays an important role in the carcinogenesis of human bladder cancer.
p8011
sg4
(lp8012
(dp8013
g7
I62
sg8
g47
sg10
I12
sg11
VSOS proteins
p8014
sg13
I2
sa(dp8015
g7
I53
sg8
VP62993
p8016
sg10
I4
sg11
VGrb2
p8017
sg13
I1
sasg17
(lp8018
(dp8019
g7
I31
sg20
VC1705759
p8020
sg10
I13
sg11
Vamplification
p8021
sg13
I1
sa(dp8022
g7
I130
sg20
VC0699885
p8023
sg10
I14
sg11
Vbladder cancer
p8024
sg13
I2
sa(dp8025
g7
I106
sg20
VC0596263
p8026
sg10
I14
sg11
Vcarcinogenesis
p8027
sg13
I1
sasa(dp8028
g2
VIn the 32 patients studied, bladder cancer was diagnosed as pTaG1-2 in 8 cases, pT1G2 in 6, pT1G3 in 7, pT2G2-3 in 7, pT3G2-3 in 3 and pT4 in 1 patient.
p8029
sg4
(lp8030
sg17
(lp8031
(dp8032
g7
I28
sg20
VC0699885
p8033
sg10
I14
sg11
Vbladder cancer
p8034
sg13
I2
sasa(dp8035
g2
VIn this study, we investigated whether silencing Wnt2B expression could inhibit the invasiveness of ovarian cancer cells and reduce drug resistance.
p8036
sg4
(lp8037
(dp8038
g7
I49
sg8
g47
sg10
I5
sg11
VWnt2B
p8039
sg13
I1
sasg17
(lp8040
(dp8041
g7
I100
sg20
VC1140680
p8042
sg10
I14
sg11
Vovarian cancer
p8043
sg13
I2
sasa(dp8044
g2
VThese data suggest that Wnt2B indeed plays an important role in ovarian cancer metastasis and drug resistance.
p8045
sg4
(lp8046
(dp8047
g7
I24
sg8
g47
sg10
I5
sg11
VWnt2B
p8048
sg13
I1
sasg17
(lp8049
(dp8050
g7
I64
sg20
VC1140680
p8051
sg10
I14
sg11
Vovarian cancer
p8052
sg13
I2
sa(dp8053
g7
I79
sg20
VC0027627
p8054
sg10
I10
sg11
Vmetastasis
p8055
sg13
I1
sasa(dp8056
g2
VWNT2B is expressed in several types of human cancer, such as basal cell carcinoma, gastric cancer, breast cancer, head/neck squamous cell carcinoma, cervical cancer and leukemia.
p8057
sg4
(lp8058
(dp8059
g7
I0
sg8
g47
sg10
I5
sg11
VWNT2B
p8060
sg13
I1
sasg17
(lp8061
(dp8062
g7
I45
sg20
VC0006826
p8063
sg10
I6
sg11
Vcancer
p8064
sg13
I1
sa(dp8065
g7
I149
sg20
VC0302592
p8066
sg10
I15
sg11
Vcervical cancer
p8067
sg13
I2
sa(dp8068
g7
I91
sg20
VC0006142
p8069
sg10
I14
sg11
Vcancer, breast
p8070
sg13
I2
sa(dp8071
g7
I124
sg20
VC0007137
p8072
sg10
I23
sg11
Vsquamous cell carcinoma
p8073
sg13
I3
sa(dp8074
g7
I45
sg20
VC0006826
p8075
sg10
I6
sg11
Vcancer
p8076
sg13
I1
sa(dp8077
g7
I61
sg20
VC0007117
p8078
sg10
I20
sg11
Vbasal cell carcinoma
p8079
sg13
I3
sa(dp8080
g7
I169
sg20
VC0023418
p8081
sg10
I8
sg11
Vleukemia
p8082
sg13
I1
sasa(dp8083
g2
VAmong various cancer cell lines, the Wnt-13 mRNA was detected in HeLa (cervical cancer), MKN28 and MKN74 (gastric cancer).
p8084
sg4
(lp8085
(dp8086
g7
I37
sg8
g47
sg10
I11
sg11
VWnt-13 mRNA
p8087
sg13
I2
sasg17
(lp8088
(dp8089
g7
I14
sg20
VC0006826
p8090
sg10
I6
sg11
Vcancer
p8091
sg13
I1
sa(dp8092
g7
I71
sg20
VC0302592
p8093
sg10
I15
sg11
Vcervical cancer
p8094
sg13
I2
sa(dp8095
g7
I106
sg20
VC0024623
p8096
sg10
I14
sg11
Vgastric cancer
p8097
sg13
I2
sasa(dp8098
g2
VThe receptor protein tyrosine phosphatase PTPRG has been genetically associated with psychiatric disorders and is a ligand for members of the contactin family, which are themselves linked to autism spectrum disorders.
p8099
sg4
(lp8100
(dp8101
g7
I142
sg8
g47
sg10
I16
sg11
Vcontactin family
p8102
sg13
I2
sa(dp8103
g7
I4
sg8
g47
sg10
I43
sg11
Vreceptor protein tyrosine phosphatase PTPRG
p8104
sg13
I5
sasg17
(lp8105
(dp8106
g7
I191
sg20
VC1510586
p8107
sg10
I25
sg11
Vautism spectrum disorders
p8108
sg13
I3
sa(dp8109
g7
I85
sg20
VC0004936
p8110
sg10
I21
sg11
Vpsychiatric disorders
p8111
sg13
I2
sasa(dp8112
g2
VBased on our finding of a phosphatase-null de novo mutation in PTPRG associated with a case of sporadic schizophrenia, we used PTPRG knockout (KO) mice to model the effect of a loss-of-function mutation.
p8113
sg4
(lp8114
(dp8115
g7
I63
sg8
VP23470
p8116
sg10
I5
sg11
VPTPRG
p8117
sg13
I1
sasg17
(lp8118
(dp8119
g7
I43
sg20
VC2985439
p8120
sg10
I16
sg11
Vde novo mutation
p8121
sg13
I3
sa(dp8122
g7
I104
sg20
VC0036341
p8123
sg10
I13
sg11
Vschizophrenia
p8124
sg13
I1
sasa(dp8125
g2
VThe most notable behavioral consequences of PTPRG gene inactivation were reduced immobilization in the forced swim test, suggestive of some negative symptoms of schizophrenia.
p8126
sg4
(lp8127
(dp8128
g7
I44
sg8
VP23470
p8129
sg10
I10
sg11
VPTPRG gene
p8130
sg13
I2
sasg17
(lp8131
(dp8132
g7
I161
sg20
VC0036341
p8133
sg10
I13
sg11
Vschizophrenia
p8134
sg13
I1
sa(dp8135
g7
I55
sg20
VC0544461
p8136
sg10
I12
sg11
Vinactivation
p8137
sg13
I1
sasa(dp8138
g2
VThe subgroups significantly differed in important features, including specific working memory deficits for PTPRG (n=5); severe negative symptoms, global cognitive deficits and poor educational attainment, suggesting a developmental disorder, for SLC39A13 (n=4); slow processing speed, childhood attention deficit disorder and milder symptoms for TGM5 (n=4); and global cognitive deficits with good educational attainment suggesting neurodegeneration for ARMS/KIDINS220 (n=5).
p8139
sg4
(lp8140
(dp8141
g7
I246
sg8
g47
sg10
I8
sg11
VSLC39A13
p8142
sg13
I1
sa(dp8143
g7
I346
sg8
g47
sg10
I4
sg11
VTGM5
p8144
sg13
I1
sa(dp8145
g7
I107
sg8
VP23470
p8146
sg10
I5
sg11
VPTPRG
p8147
sg13
I1
sa(dp8148
g7
I459
sg8
g47
sg10
I9
sg11
VKIDINS220
p8149
sg13
I1
sasg17
(lp8150
(dp8151
g7
I432
sg20
VC0027746
p8152
sg10
I17
sg11
Vneurodegeneration
p8153
sg13
I1
sa(dp8154
g7
I153
sg20
VC0679466
p8155
sg10
I18
sg11
Vcognitive deficits
p8156
sg13
I2
sa(dp8157
g7
I87
sg20
VC0233794
p8158
sg10
I15
sg11
Vmemory deficits
p8159
sg13
I2
sa(dp8160
g7
I295
sg20
VC0339002
p8161
sg10
I26
sg11
Vattention deficit disorder
p8162
sg13
I3
sa(dp8163
g7
I153
sg20
VC0679466
p8164
sg10
I18
sg11
Vcognitive deficits
p8165
sg13
I2
sa(dp8166
g7
I218
sg20
VC0008073
p8167
sg10
I22
sg11
Vdevelopmental disorder
p8168
sg13
I2
sa(dp8169
g7
I454
sg20
VC0206655
p8170
sg10
I4
sg11
VARMS
p8171
sg13
I1
sasa(dp8172
g2
VFirst, whole exome sequencing was conducted to identify disruptive de novo mutations in 14 complete parent-offspring trios with sporadic schizophrenia from Jerusalem, which identified 5 sporadic cases with de novo gene mutations in 5 different genes (PTPRG, TGM5, SLC39A13, BTK, CDKN3).
p8173
sg4
(lp8174
(dp8175
g7
I258
sg8
g47
sg10
I4
sg11
VTGM5
p8176
sg13
I1
sa(dp8177
g7
I264
sg8
g47
sg10
I8
sg11
VSLC39A13
p8178
sg13
I1
sa(dp8179
g7
I251
sg8
VP23470
p8180
sg10
I5
sg11
VPTPRG
p8181
sg13
I1
sa(dp8182
g7
I274
sg8
g47
sg10
I3
sg11
VBTK
p8183
sg13
I1
sasg17
(lp8184
(dp8185
g7
I137
sg20
VC0036341
p8186
sg10
I13
sg11
Vschizophrenia
p8187
sg13
I1
sasa(dp8188
g2
VNext, targeted exome capture of these genes was conducted in 48 well-characterized, unrelated, ethnically diverse schizophrenia cases, recruited and characterized by the same research team in New York (NY sample), which demonstrated extremely rare and potentially damaging variants in three of the five genes (MAF&lt;0.01) in 12/48 cases (25%); including PTPRG (5 cases), SCL39A13 (4 cases) and TGM5 (4 cases), a higher number than usually identified by whole exome sequencing.
p8189
sg4
(lp8190
sg17
(lp8191
(dp8192
g7
I114
sg20
VC0036341
p8193
sg10
I13
sg11
Vschizophrenia
p8194
sg13
I1
sasa(dp8195
g2
VActivated astrocytes were found to be strongly positive for RPTPGamma also in a mice model of Alzheimer's disease.
p8196
sg4
(lp8197
(dp8198
g7
I60
sg8
VP23470
p8199
sg10
I9
sg11
VRPTPGamma
p8200
sg13
I1
sasg17
(lp8201
(dp8202
g7
I94
sg20
VC1521724
p8203
sg10
I19
sg11
VAlzheimer's disease
p8204
sg13
I2
sasa(dp8205
g2
VAqueous humor (AH) samples from 14 patients with presumed tuberculous uveitis (PTU), and 30 control patients were assayed for the proinflammatory cytokines interleukin IL-4, IL-12, IL-15, IL-17, interferon (IFN)-Gamma, and tumor necrosis factor (TNF)-Alfa, the immunosuppressive cytokine IL-10, and the chemokines GRO-Alfa/CXCL1, IL-8/CXCL8, MIG/CXCL9, IP-10/CXCL10 and SDF-1/CXCL12 with the use of a multiplex assay.
p8206
sg4
(lp8207
(dp8208
g7
I342
sg8
g47
sg10
I3
sg11
VMIG
p8209
sg13
I1
sa(dp8210
g7
I353
sg8
VP02778
p8211
sg10
I5
sg11
VIP-10
p8212
sg13
I1
sa(dp8213
g7
I370
sg8
VP48061
p8214
sg10
I5
sg11
VSDF-1
p8215
sg13
I1
sa(dp8216
g7
I314
sg8
VP09341
p8217
sg10
I3
sg11
VGRO
p8218
sg13
I1
sa(dp8219
g7
I207
sg8
VP01562
p8220
sg10
I3
sg11
VIFN
p8221
sg13
I1
sa(dp8222
g7
I195
sg8
VP01563
p8223
sg10
I10
sg11
Vinterferon
p8224
sg13
I1
sa(dp8225
g7
I346
sg8
g47
sg10
I5
sg11
VCXCL9
p8226
sg13
I1
sa(dp8227
g7
I156
sg8
VP05112
p8228
sg10
I16
sg11
Vinterleukin IL-4
p8229
sg13
I2
sa(dp8230
g7
I223
sg8
VP01375
p8231
sg10
I32
sg11
Vtumor necrosis factor (TNF)-Alfa
p8232
sg13
I4
sa(dp8233
g7
I181
sg8
VP40933
p8234
sg10
I5
sg11
VIL-15
p8235
sg13
I1
sa(dp8236
g7
I359
sg8
VP02778
p8237
sg10
I6
sg11
VCXCL10
p8238
sg13
I1
sa(dp8239
g7
I323
sg8
VP09341
p8240
sg10
I5
sg11
VCXCL1
p8241
sg13
I1
sa(dp8242
g7
I376
sg8
VP48061
p8243
sg10
I6
sg11
VCXCL12
p8244
sg13
I1
sasg17
(lp8245
(dp8246
g7
I0
sg20
VC0595936
p8247
sg10
I13
sg11
VAqueous humor
p8248
sg13
I2
sa(dp8249
g7
I15
sg20
VC0595936
p8250
sg10
I2
sg11
VAH
p8251
sg13
I1
sa(dp8252
g7
I58
sg20
VC1281935
p8253
sg10
I19
sg11
Vtuberculous uveitis
p8254
sg13
I2
sa(dp8255
g7
I223
sg20
VC0333516
p8256
sg10
I14
sg11
Vtumor necrosis
p8257
sg13
I2
sasa(dp8258
g2
VAqueous humor (AH) samples from patients with Behcet's disease (BD) (n=29), Vogt-Koyanagi-Harada (VKH) disease (n=21), and HLA-B27-associated uveitis (n=8), and 42 control patients were assayed for the neutrophil chemoattractants CXCL1/GRO-Alfa and CXCL8/IL-8 and the lymphocyte chemoattractants CXCL9/MIG, CXCL10/IP-10 and CXCL12/SDF-1 with the use of a multiplex chemokine assay.
p8259
sg4
(lp8260
(dp8261
g7
I331
sg8
VP48061
p8262
sg10
I5
sg11
VSDF-1
p8263
sg13
I1
sa(dp8264
g7
I236
sg8
VP09341
p8265
sg10
I3
sg11
VGRO
p8266
sg13
I1
sa(dp8267
g7
I314
sg8
VP02778
p8268
sg10
I5
sg11
VIP-10
p8269
sg13
I1
sa(dp8270
g7
I296
sg8
g47
sg10
I5
sg11
VCXCL9
p8271
sg13
I1
sa(dp8272
g7
I324
sg8
VP48061
p8273
sg10
I6
sg11
VCXCL12
p8274
sg13
I1
sa(dp8275
g7
I123
sg8
VP30486
p8276
sg10
I7
sg11
VHLA-B27
p8277
sg13
I1
sa(dp8278
g7
I302
sg8
g47
sg10
I3
sg11
VMIG
p8279
sg13
I1
sa(dp8280
g7
I230
sg8
VP09341
p8281
sg10
I5
sg11
VCXCL1
p8282
sg13
I1
sa(dp8283
g7
I307
sg8
VP02778
p8284
sg10
I6
sg11
VCXCL10
p8285
sg13
I1
sasg17
(lp8286
(dp8287
g7
I0
sg20
VC0595936
p8288
sg10
I13
sg11
VAqueous humor
p8289
sg13
I2
sa(dp8290
g7
I15
sg20
VC0595936
p8291
sg10
I2
sg11
VAH
p8292
sg13
I1
sa(dp8293
g7
I46
sg20
VC0004943
p8294
sg10
I16
sg11
VBehcet's disease
p8295
sg13
I2
sa(dp8296
g7
I142
sg20
VC0042164
p8297
sg10
I7
sg11
Vuveitis
p8298
sg13
I1
sa(dp8299
g7
I64
sg20
VC0004943
p8300
sg10
I2
sg11
VBD
p8301
sg13
I1
sasa(dp8302
g2
VIn patients with the same disease activity, AH levels of GRO-Alfa and IP-10 were significantly higher in patients with BD than in patients with VKH disease and HLA-B27-associated uveitis (p=0.0474; p&lt;0.001, respectively).
p8303
sg4
(lp8304
(dp8305
g7
I160
sg8
VP30486
p8306
sg10
I7
sg11
VHLA-B27
p8307
sg13
I1
sa(dp8308
g7
I70
sg8
VP02778
p8309
sg10
I5
sg11
VIP-10
p8310
sg13
I1
sa(dp8311
g7
I57
sg8
VP09341
p8312
sg10
I8
sg11
VGRO-Alfa
p8313
sg13
I1
sasg17
(lp8314
(dp8315
g7
I179
sg20
VC0042164
p8316
sg10
I7
sg11
Vuveitis
p8317
sg13
I1
sasa(dp8318
g2
VThese data suggest that GRO-Alfa and IP-10 are the predominant CXC chemokines involved in neutrophil and activated T lymphocyte chemoattraction in endogenous uveitis, particularly in BD.
p8319
sg4
(lp8320
(dp8321
g7
I24
sg8
VP09341
p8322
sg10
I3
sg11
VGRO
p8323
sg13
I1
sa(dp8324
g7
I37
sg8
VP02778
p8325
sg10
I5
sg11
VIP-10
p8326
sg13
I1
sasg17
(lp8327
(dp8328
g7
I158
sg20
VC0042164
p8329
sg10
I7
sg11
Vuveitis
p8330
sg13
I1
sasa(dp8331
g2
VThe purpose of this study was to investigate the role and regulation of the CXC chemokine GRO and the interaction between GRO and IL-8 in LPS-induced uveitis in rabbits.
p8332
sg4
(lp8333
(dp8334
g7
I90
sg8
VP09341
p8335
sg10
I3
sg11
VGRO
p8336
sg13
I1
sasg17
(lp8337
(dp8338
g7
I138
sg20
VC0175697
p8339
sg10
I3
sg11
VLPS
p8340
sg13
I1
sa(dp8341
g7
I150
sg20
VC0042164
p8342
sg10
I7
sg11
Vuveitis
p8343
sg13
I1
sasa(dp8344
g2
VTaken together, our results suggest that GRO is an essential mediator for neutrophil infiltration in LPS-induced uveitis in rabbits.
p8345
sg4
(lp8346
(dp8347
g7
I41
sg8
VP09341
p8348
sg10
I3
sg11
VGRO
p8349
sg13
I1
sasg17
(lp8350
(dp8351
g7
I113
sg20
VC0042164
p8352
sg10
I7
sg11
Vuveitis
p8353
sg13
I1
sa(dp8354
g7
I101
sg20
VC0175697
p8355
sg10
I3
sg11
VLPS
p8356
sg13
I1
sa(dp8357
g7
I85
sg20
VC0332448
p8358
sg10
I12
sg11
Vinfiltration
p8359
sg13
I1
sasa(dp8360
g2
VNa(+)K(+)ATPase, NKCC1, and alpha-syntrophin were expressed within sensory epithelia and were unaltered in Meniere's disease specimens.
p8361
sg4
(lp8362
(dp8363
g7
I17
sg8
VP55011
p8364
sg10
I5
sg11
VNKCC1
p8365
sg13
I1
sa(dp8366
g7
I28
sg8
g47
sg10
I16
sg11
Valpha-syntrophin
p8367
sg13
I1
sa(dp8368
g7
I0
sg8
VP38606
p8369
sg10
I15
sg11
VNa(+)K(+)ATPase
p8370
sg13
I1
sasg17
(lp8371
(dp8372
g7
I107
sg20
VC0025281
p8373
sg10
I17
sg11
VMeniere's disease
p8374
sg13
I2
sasa(dp8375
g2
VAlthough an elevated hemoglobin A1c (HbAc1) level is an independent predictor of worse survival in patients with both digestive cancer and diabetes mellitus, its relationship to short-term prognosis in these patients has not been addressed.
p8376
sg4
(lp8377
(dp8378
g7
I37
sg8
VP40145
p8379
sg10
I5
sg11
VHbAc1
p8380
sg13
I1
sa(dp8381
g7
I21
sg8
g47
sg10
I14
sg11
Vhemoglobin A1c
p8382
sg13
I2
sasg17
(lp8383
(dp8384
g7
I139
sg20
VC0011849
p8385
sg10
I17
sg11
Vdiabetes mellitus
p8386
sg13
I2
sa(dp8387
g7
I118
sg20
VC0685938
p8388
sg10
I16
sg11
Vdigestive cancer
p8389
sg13
I2
sasa(dp8390
g2
VWe identified novel driver mutations that developed during adenoma and cancer evolution, particularly in OR1B1 (GPCR signaling pathway) for adenoma evolution, and LAMA1 (PI3K-Akt signaling pathway) and ADCY3 (FGFR signaling pathway) for CRC evolution.
p8391
sg4
(lp8392
(dp8393
g7
I163
sg8
VP25391
p8394
sg10
I5
sg11
VLAMA1
p8395
sg13
I1
sa(dp8396
g7
I175
sg8
g47
sg10
I3
sg11
VAkt
p8397
sg13
I1
sa(dp8398
g7
I112
sg8
g47
sg10
I4
sg11
VGPCR
p8399
sg13
I1
sa(dp8400
g7
I170
sg8
VP42336
p8401
sg10
I4
sg11
VPI3K
p8402
sg13
I1
sa(dp8403
g7
I105
sg8
g47
sg10
I5
sg11
VOR1B1
p8404
sg13
I1
sa(dp8405
g7
I237
sg8
VP31749
p8406
sg10
I3
sg11
VCRC
p8407
sg13
I1
sa(dp8408
g7
I202
sg8
VP40145
p8409
sg10
I5
sg11
VADCY3
p8410
sg13
I1
sasg17
(lp8411
(dp8412
g7
I59
sg20
VC0001430
p8413
sg10
I7
sg11
Vadenoma
p8414
sg13
I1
sa(dp8415
g7
I237
sg20
VC1527249
p8416
sg10
I3
sg11
VCRC
p8417
sg13
I1
sa(dp8418
g7
I59
sg20
VC0001430
p8419
sg10
I7
sg11
Vadenoma
p8420
sg13
I1
sa(dp8421
g7
I71
sg20
VC0006826
p8422
sg10
I6
sg11
Vcancer
p8423
sg13
I1
sasa(dp8424
g2
VRecently, we provided human validation for a cooperating oncogenic role for cAMP in brain tumorigenesis when we found that SNPs in ADCY8 were correlated with glioma (brain tumor) risk in individuals with Neurofibromatosis type 1 (NF1).
p8425
sg4
(lp8426
(dp8427
g7
I230
sg8
VP21359
p8428
sg10
I3
sg11
VNF1
p8429
sg13
I1
sa(dp8430
g7
I131
sg8
VP40145
p8431
sg10
I5
sg11
VADCY8
p8432
sg13
I1
sa(dp8433
g7
I204
sg8
VP21359
p8434
sg10
I24
sg11
VNeurofibromatosis type 1
p8435
sg13
I3
sasg17
(lp8436
(dp8437
g7
I230
sg20
VC0027831
p8438
sg10
I3
sg11
VNF1
p8439
sg13
I1
sa(dp8440
g7
I84
sg20
VC0006118
p8441
sg10
I11
sg11
Vbrain tumor
p8442
sg13
I2
sa(dp8443
g7
I204
sg20
VC0027831
p8444
sg10
I24
sg11
VNeurofibromatosis type 1
p8445
sg13
I3
sa(dp8446
g7
I84
sg20
VC0006118
p8447
sg10
I80
sg11
Vbrain tumorigenesis when we found that SNPs in ADCY8 were correlated with glioma
p8448
sg13
I13
sasa(dp8449
g2
VHowever, the cAMP pathway is well-known to be sexually dimorphic, and SNPs in ADCY8 affected glioma risk in a sex-specific fashion, elevating the risk for females while protecting males.
p8450
sg4
(lp8451
(dp8452
g7
I78
sg8
VP40145
p8453
sg10
I5
sg11
VADCY8
p8454
sg13
I1
sasg17
(lp8455
(dp8456
g7
I93
sg20
VC0017638
p8457
sg10
I6
sg11
Vglioma
p8458
sg13
I1
sasa(dp8459
g2
VHere, we report genetic polymorphisms in the human adenylate cyclase gene adenylate cyclase 8 (ADCY8) that correlate with glioma risk in NF1 in a sex-specific manner, elevating risk in females while reducing risk in males.
p8460
sg4
(lp8461
(dp8462
g7
I95
sg8
VP40145
p8463
sg10
I5
sg11
VADCY8
p8464
sg13
I1
sa(dp8465
g7
I45
sg8
g47
sg10
I48
sg11
Vhuman adenylate cyclase gene adenylate cyclase 8
p8466
sg13
I7
sa(dp8467
g7
I137
sg8
VP21359
p8468
sg10
I3
sg11
VNF1
p8469
sg13
I1
sasg17
(lp8470
(dp8471
g7
I122
sg20
VC0017638
p8472
sg10
I6
sg11
Vglioma
p8473
sg13
I1
sa(dp8474
g7
I137
sg20
VC0027831
p8475
sg10
I3
sg11
VNF1
p8476
sg13
I1
sasa(dp8477
g2
VOverall, our results establish a sex-specific role for cAMP regulation in human gliomagenesis, specifically identifying ADCY8 as a modifier of glioma risk in NF1.
p8478
sg4
(lp8479
(dp8480
g7
I158
sg8
VP21359
p8481
sg10
I3
sg11
VNF1
p8482
sg13
I1
sa(dp8483
g7
I120
sg8
VP40145
p8484
sg10
I5
sg11
VADCY8
p8485
sg13
I1
sasg17
(lp8486
(dp8487
g7
I158
sg20
VC0027831
p8488
sg10
I3
sg11
VNF1
p8489
sg13
I1
sa(dp8490
g7
I80
sg20
VC0017638
p8491
sg10
I6
sg11
Vglioma
p8492
sg13
I1
sasa(dp8493
g2
VThe effect of insulin on the oxidative desaturation of 1-14C palmitic acid to palmitoleic acid (delta 9 desaturase) 1-14C linoleic acid to alpha-linolenic acid (delta 6 desaturase) on rat liver microsomes and 1-14C eicosa-8,11,14-trienoic acid to arachidonic acid (delta 5 desaturase) on rat liver microsomes and hepatoma tissue culture (HTC) cells was studied.
p8494
sg4
(lp8495
(dp8496
g7
I265
sg8
VP28072
p8497
sg10
I18
sg11
Vdelta 5 desaturase
p8498
sg13
I3
sa(dp8499
g7
I161
sg8
VP28072
p8500
sg10
I18
sg11
Vdelta 6 desaturase
p8501
sg13
I3
sa(dp8502
g7
I14
sg8
VP01308
p8503
sg10
I7
sg11
Vinsulin
p8504
sg13
I1
sasg17
(lp8505
(dp8506
g7
I313
sg20
VC0023903
p8507
sg10
I8
sg11
Vhepatoma
p8508
sg13
I1
sasa(dp8509
g2
VMethylation of CALCA, CDH1, DAPK1, and EVX2 was more common in squamous cell carcinomas (SCC) compared to adenocarcinomas (ADC).
p8510
sg4
(lp8511
(dp8512
g7
I39
sg8
VP55085
p8513
sg10
I4
sg11
VEVX2
p8514
sg13
I1
sa(dp8515
g7
I22
sg8
VP12830
p8516
sg10
I4
sg11
VCDH1
p8517
sg13
I1
sa(dp8518
g7
I28
sg8
VP53355
p8519
sg10
I5
sg11
VDAPK1
p8520
sg13
I1
sasg17
(lp8521
(dp8522
g7
I89
sg20
VC0007137
p8523
sg10
I3
sg11
VSCC
p8524
sg13
I1
sa(dp8525
g7
I63
sg20
VC0007137
p8526
sg10
I24
sg11
Vsquamous cell carcinomas
p8527
sg13
I3
sa(dp8528
g7
I106
sg20
VC0001418
p8529
sg10
I15
sg11
Vadenocarcinomas
p8530
sg13
I1
sa(dp8531
g7
I123
sg20
VC0001418
p8532
sg10
I3
sg11
VADC
p8533
sg13
I1
sasa(dp8534
g2
VOverall, CALCA, DAPK, ESR1, TIMP3, APC and RAR-beta2 promoters were significantly more often hypermethylated in cancers than in controls, while adenocarcinomas were more often hypermethylated above the highest control ratio for APC, TIMP3 and RASSF1A promoters.
p8535
sg4
(lp8536
(dp8537
g7
I28
sg8
VP35625
p8538
sg10
I5
sg11
VTIMP3
p8539
sg13
I1
sa(dp8540
g7
I35
sg8
VP25054
p8541
sg10
I3
sg11
VAPC
p8542
sg13
I1
sa(dp8543
g7
I9
sg8
VP06881
p8544
sg10
I5
sg11
VCALCA
p8545
sg13
I1
sa(dp8546
g7
I16
sg8
VP53355
p8547
sg10
I4
sg11
VDAPK
p8548
sg13
I1
sa(dp8549
g7
I22
sg8
VP03372
p8550
sg10
I4
sg11
VESR1
p8551
sg13
I1
sa(dp8552
g7
I43
sg8
VP10276
p8553
sg10
I19
sg11
VRAR-beta2 promoters
p8554
sg13
I2
sa(dp8555
g7
I35
sg8
VP25054
p8556
sg10
I3
sg11
VAPC
p8557
sg13
I1
sa(dp8558
g7
I28
sg8
VP35625
p8559
sg10
I5
sg11
VTIMP3
p8560
sg13
I1
sasg17
(lp8561
(dp8562
g7
I112
sg20
VC0006826
p8563
sg10
I7
sg11
Vcancers
p8564
sg13
I1
sa(dp8565
g7
I144
sg20
VC0001418
p8566
sg10
I15
sg11
Vadenocarcinomas
p8567
sg13
I1
sa(dp8568
g7
I35
sg20
VC0033036
p8569
sg10
I3
sg11
VAPC
p8570
sg13
I1
sa(dp8571
g7
I35
sg20
VC0033036
p8572
sg10
I3
sg11
VAPC
p8573
sg13
I1
sasa(dp8574
g2
VCombining 4 genes (CALCA, DAPK, ESR1 and APC) yielded a sensitivity of 89% (with all adenocarcinomas identified), equal to cytomorphology (89%) and high-risk human papilloma virus (Hr-HPV; 90%).
p8575
sg4
(lp8576
(dp8577
g7
I26
sg8
VP53355
p8578
sg10
I4
sg11
VDAPK
p8579
sg13
I1
sa(dp8580
g7
I19
sg8
VP06881
p8581
sg10
I5
sg11
VCALCA
p8582
sg13
I1
sa(dp8583
g7
I0
sg8
VP01893
p8584
sg10
I17
sg11
VCombining 4 genes
p8585
sg13
I3
sa(dp8586
g7
I41
sg8
VP25054
p8587
sg10
I3
sg11
VAPC
p8588
sg13
I1
sa(dp8589
g7
I32
sg8
VP03372
p8590
sg10
I4
sg11
VESR1
p8591
sg13
I1
sasg17
(lp8592
(dp8593
g7
I41
sg20
VC0033036
p8594
sg10
I3
sg11
VAPC
p8595
sg13
I1
sa(dp8596
g7
I85
sg20
VC0001418
p8597
sg10
I15
sg11
Vadenocarcinomas
p8598
sg13
I1
sa(dp8599
g7
I164
sg20
VC0030354
p8600
sg10
I9
sg11
Vpapilloma
p8601
sg13
I1
sasa(dp8602
g2
VThe thyroid tumor was diagnosed as metastasis to the thyroid from lung adenocarcinoma, because it showed mucin production, positive immunoreactivity for carcinoembryonic antigen and negative immunoreactivities for thyroglobulin and calcitonin.
p8603
sg4
(lp8604
(dp8605
g7
I153
sg8
VP40198
p8606
sg10
I24
sg11
Vcarcinoembryonic antigen
p8607
sg13
I2
sa(dp8608
g7
I214
sg8
g47
sg10
I13
sg11
Vthyroglobulin
p8609
sg13
I1
sa(dp8610
g7
I105
sg8
g47
sg10
I5
sg11
Vmucin
p8611
sg13
I1
sa(dp8612
g7
I232
sg8
VP06881
p8613
sg10
I10
sg11
Vcalcitonin
p8614
sg13
I1
sasg17
(lp8615
(dp8616
g7
I66
sg20
VC0152013
p8617
sg10
I19
sg11
Vlung adenocarcinoma
p8618
sg13
I2
sa(dp8619
g7
I4
sg20
VC0040136
p8620
sg10
I13
sg11
Vthyroid tumor
p8621
sg13
I2
sa(dp8622
g7
I35
sg20
VC0347023
p8623
sg10
I25
sg11
Vmetastasis to the thyroid
p8624
sg13
I4
sasa(dp8625
g2
VWe searched Medline for clinical trials that assessed disease-modifying drugs for relapsing-remitting multiple sclerosis published from Sept 1, 2008, to Oct 31, 2012.
p8626
sg4
(lp8627
(dp8628
g7
I153
sg8
VP00480
p8629
sg10
I6
sg11
VOct 31
p8630
sg13
I2
sasg17
(lp8631
(dp8632
g7
I82
sg20
VC0751967
p8633
sg10
I38
sg11
Vrelapsing-remitting multiple sclerosis
p8634
sg13
I3
sasa(dp8635
g2
VSEPT1, SEPT4, and SEPT2 have been found in deposits known as neurofibrillary tangles and glial fibrils in Alzheimer's disease.
p8636
sg4
(lp8637
(dp8638
g7
I7
sg8
g47
sg10
I5
sg11
VSEPT4
p8639
sg13
I1
sa(dp8640
g7
I0
sg8
g47
sg10
I5
sg11
VSEPT1
p8641
sg13
I1
sa(dp8642
g7
I18
sg8
g47
sg10
I5
sg11
VSEPT2
p8643
sg13
I1
sasg17
(lp8644
(dp8645
g7
I61
sg20
VC0085400
p8646
sg10
I23
sg11
Vneurofibrillary tangles
p8647
sg13
I2
sa(dp8648
g7
I106
sg20
VC1521724
p8649
sg10
I19
sg11
VAlzheimer's disease
p8650
sg13
I2
sasa(dp8651
g2
VFinally, we evaluated the effect of the pro-arousal neuropeptides CRF and Hcrt-1/Ox-A in NPSR-deficient mice.
p8652
sg4
(lp8653
(dp8654
g7
I74
sg8
VP50336
p8655
sg10
I6
sg11
VHcrt-1
p8656
sg13
I1
sasg17
(lp8657
(dp8658
g7
I66
sg20
VC0022661
p8659
sg10
I3
sg11
VCRF
p8660
sg13
I1
sasa(dp8661
g2
VThe administration of CRF and Hcrt-1/Ox-A, two classic pro-arousal peptides, elicited the same effects in both NPSR(-/-) and wild type mice, ruling out the possibility that adaptive mechanisms occurring at the level of these two systems could have occurred during NPSR(-/-) development to compensate for the lack of NPSR receptors.
p8662
sg4
(lp8663
(dp8664
g7
I30
sg8
VP50336
p8665
sg10
I6
sg11
VHcrt-1
p8666
sg13
I1
sa(dp8667
g7
I316
sg8
g47
sg10
I14
sg11
VNPSR receptors
p8668
sg13
I2
sa(dp8669
g7
I22
sg8
VP06850
p8670
sg10
I3
sg11
VCRF
p8671
sg13
I1
sasg17
(lp8672
(dp8673
g7
I22
sg20
VC0022661
p8674
sg10
I3
sg11
VCRF
p8675
sg13
I1
sasa(dp8676
g2
VMoreover, we demonstrated that the deletion of NPSR did not lead to compensatory changes in the vigilance-promoting effects of the CRF and Hcrt-1/Ox-A systems.
p8677
sg4
(lp8678
(dp8679
g7
I131
sg8
VP06850
p8680
sg10
I3
sg11
VCRF
p8681
sg13
I1
sa(dp8682
g7
I139
sg8
VP50336
p8683
sg10
I6
sg11
VHcrt-1
p8684
sg13
I1
sasg17
(lp8685
(dp8686
g7
I131
sg20
VC0022661
p8687
sg10
I3
sg11
VCRF
p8688
sg13
I1
sasa(dp8689
g2
VWe included all RCTs of any calcimimetic agent, cinacalcet HCl (AMG-073, Sensipar), NPS R-467 or NPS R-568 administered to patients with CKD for the treatment of SHPT.
p8690
sg4
(lp8691
sg17
(lp8692
(dp8693
g7
I84
sg20
VC0027341
p8694
sg10
I3
sg11
VNPS
p8695
sg13
I1
sa(dp8696
g7
I84
sg20
VC0027341
p8697
sg10
I3
sg11
VNPS
p8698
sg13
I1
sasa(dp8699
g2
VRenal osteodystrophy (RO) due to secondary hyperparathyroidism (HPT) in chronic renal failure was an obvious target for studying the effects of NPS R-568.
p8700
sg4
(lp8701
sg17
(lp8702
(dp8703
g7
I33
sg20
VC0020503
p8704
sg10
I29
sg11
Vsecondary hyperparathyroidism
p8705
sg13
I2
sa(dp8706
g7
I22
sg20
VC0035086
p8707
sg10
I2
sg11
VRO
p8708
sg13
I1
sa(dp8709
g7
I144
sg20
VC0027341
p8710
sg10
I3
sg11
VNPS
p8711
sg13
I1
sa(dp8712
g7
I0
sg20
VC0035086
p8713
sg10
I20
sg11
VRenal osteodystrophy
p8714
sg13
I2
sa(dp8715
g7
I72
sg20
VC0022661
p8716
sg10
I21
sg11
Vchronic renal failure
p8717
sg13
I3
sasa(dp8718
g2
VChanges in BIS (bispectral index) VISTA bilateral monitoring system associated with intraoperative episodes of generalized and focal seizures, during total intravenous anesthesia for resection of a left frontal parasagittal meningioma, are herein described.
p8719
sg4
(lp8720
sg17
(lp8721
(dp8722
g7
I211
sg20
VC0751304
p8723
sg10
I23
sg11
Vparasagittal meningioma
p8724
sg13
I2
sa(dp8725
g7
I127
sg20
VC0751495
p8726
sg10
I14
sg11
Vfocal seizures
p8727
sg13
I2
sa(dp8728
g7
I168
sg20
VC0278134
p8729
sg10
I10
sg11
Vanesthesia
p8730
sg13
I1
sasa(dp8731
g2
VPrevious studies identified a variety of putative target genes from several pathways associated with DNA damage repair, chromatin remodeling complex, PI3K-AKT-mTOR signaling, Notch signaling, cell cycle checkpoint signaling, BRCA-associated complex and Fanconi's anemia susceptibility genes that could be used as biomarkers or therapeutic targets for PARP inhibition.
p8732
sg4
(lp8733
(dp8734
g7
I155
sg8
g47
sg10
I3
sg11
VAKT
p8735
sg13
I1
sa(dp8736
g7
I351
sg8
VP09874
p8737
sg10
I4
sg11
VPARP
p8738
sg13
I1
sa(dp8739
g7
I150
sg8
VP42336
p8740
sg10
I4
sg11
VPI3K
p8741
sg13
I1
sa(dp8742
g7
I159
sg8
VP42345
p8743
sg10
I4
sg11
VmTOR
p8744
sg13
I1
sasg17
(lp8745
(dp8746
g7
I101
sg20
VC0012860
p8747
sg10
I10
sg11
VDNA damage
p8748
sg13
I2
sa(dp8749
g7
I253
sg20
VC0015625
p8750
sg10
I16
sg11
VFanconi's anemia
p8751
sg13
I2
sasa(dp8752
g2
VHematologic toxicities, including neutropenia, thrombocytopenia, and anemia, are major adverse effects of PARP inhibitors (PARPis), but the incidence rate and overall risk has not been systematically studied.
p8753
sg4
(lp8754
(dp8755
g7
I106
sg8
VP09874
p8756
sg10
I4
sg11
VPARP
p8757
sg13
I1
sasg17
(lp8758
(dp8759
g7
I69
sg20
VC0002871
p8760
sg10
I6
sg11
Vanemia
p8761
sg13
I1
sa(dp8762
g7
I87
sg20
VC0879626
p8763
sg10
I15
sg11
Vadverse effects
p8764
sg13
I2
sasa(dp8765
g2
VA total of 2,479 patients from 12 RCTs revealed that the incidence of PARPi-associated severe hematologic toxicities was, respectively: neutropenia: 32.9% (95% CI, 20.5%-48.3%); thrombocytopenia: 15.9% (95% CI, 9.5%-25.4%), and anemia: 9.1% (95% CI, 5.1%-15.7%).
p8766
sg4
(lp8767
sg17
(lp8768
(dp8769
g7
I228
sg20
VC0002871
p8770
sg10
I6
sg11
Vanemia
p8771
sg13
I1
sasa(dp8772
g2
VExamples of endocrine syndromes are classical carcinoid syndrome caused by serotonin (measured in the urine as its metabolite 5-HIAA), insulinoma syndrome caused by insulin or proinsulin, Zollinger-Ellison syndrome resulting from gastrin secretion, glucagonoma syndrome caused by glucagon, WDHA syndrome caused by vasoactive intestinal peptide, or Cushing's syndrome resulting from ectopic production of adrenocorticotropic hormone or corticotropin-releasing hormone.
p8773
sg4
(lp8774
(dp8775
g7
I230
sg8
VP01350
p8776
sg10
I7
sg11
Vgastrin
p8777
sg13
I1
sa(dp8778
g7
I176
sg8
VP01308
p8779
sg10
I10
sg11
Vproinsulin
p8780
sg13
I1
sa(dp8781
g7
I435
sg8
VP06850
p8782
sg10
I31
sg11
Vcorticotropin-releasing hormone
p8783
sg13
I2
sa(dp8784
g7
I135
sg8
VP01308
p8785
sg10
I7
sg11
Vinsulin
p8786
sg13
I1
sa(dp8787
g7
I249
sg8
VP01275
p8788
sg10
I8
sg11
Vglucagon
p8789
sg13
I1
sa(dp8790
g7
I404
sg8
VP01189
p8791
sg10
I27
sg11
Vadrenocorticotropic hormone
p8792
sg13
I2
sasg17
(lp8793
(dp8794
g7
I135
sg20
VC0021670
p8795
sg10
I10
sg11
Vinsulinoma
p8796
sg13
I1
sa(dp8797
g7
I22
sg20
VC0039082
p8798
sg10
I8
sg11
Vsyndrome
p8799
sg13
I1
sa(dp8800
g7
I188
sg20
VC0043515
p8801
sg10
I26
sg11
VZollinger-Ellison syndrome
p8802
sg13
I2
sa(dp8803
g7
I22
sg20
VC0039082
p8804
sg10
I9
sg11
Vsyndromes
p8805
sg13
I1
sa(dp8806
g7
I46
sg20
VC0024586
p8807
sg10
I18
sg11
Vcarcinoid syndrome
p8808
sg13
I2
sa(dp8809
g7
I249
sg20
VC0017689
p8810
sg10
I20
sg11
Vglucagonoma syndrome
p8811
sg13
I2
sa(dp8812
g7
I290
sg20
VC0086768
p8813
sg10
I13
sg11
VWDHA syndrome
p8814
sg13
I2
sa(dp8815
g7
I348
sg20
VC0010481
p8816
sg10
I18
sg11
VCushing's syndrome
p8817
sg13
I2
sasa(dp8818
g2
VWe have previously reported and confirmed that vasoactive intestinal peptide (VIP) is a significant stimulator of ACTH and cortisol secretion in at least some patients with Cushing's disease.
p8819
sg4
(lp8820
(dp8821
g7
I78
sg8
VP01282
p8822
sg10
I3
sg11
VVIP
p8823
sg13
I1
sa(dp8824
g7
I114
sg8
VP01189
p8825
sg10
I4
sg11
VACTH
p8826
sg13
I1
sa(dp8827
g7
I47
sg8
VP01282
p8828
sg10
I29
sg11
Vvasoactive intestinal peptide
p8829
sg13
I3
sasg17
(lp8830
(dp8831
g7
I173
sg20
VC0221406
p8832
sg10
I17
sg11
VCushing's disease
p8833
sg13
I2
sasa(dp8834
g2
VWe have also found that the hormonal responses to corticotropin-releasing hormone (CRH) in VIP-responsive patients with Cushing's disease were higher than those in VIP non-responders, which suggested a linkage between the actions of CRH and VIP in this disorder.
p8835
sg4
(lp8836
(dp8837
g7
I83
sg8
VP06850
p8838
sg10
I3
sg11
VCRH
p8839
sg13
I1
sa(dp8840
g7
I50
sg8
VP06850
p8841
sg10
I31
sg11
Vcorticotropin-releasing hormone
p8842
sg13
I2
sa(dp8843
g7
I83
sg8
VP06850
p8844
sg10
I3
sg11
VCRH
p8845
sg13
I1
sa(dp8846
g7
I91
sg8
VP01282
p8847
sg10
I3
sg11
VVIP
p8848
sg13
I1
sasg17
(lp8849
(dp8850
g7
I120
sg20
VC0221406
p8851
sg10
I17
sg11
VCushing's disease
p8852
sg13
I2
sasa(dp8853
g2
VThis study is the first to demonstrate the parallel inhibition by DEX of ACTH and cortisol responses to CRH and VIP in Cushing's disease.
p8854
sg4
(lp8855
(dp8856
g7
I73
sg8
VP01189
p8857
sg10
I4
sg11
VACTH
p8858
sg13
I1
sa(dp8859
g7
I112
sg8
VP01282
p8860
sg10
I3
sg11
VVIP
p8861
sg13
I1
sa(dp8862
g7
I104
sg8
VP06850
p8863
sg10
I3
sg11
VCRH
p8864
sg13
I1
sasg17
(lp8865
(dp8866
g7
I119
sg20
VC0221406
p8867
sg10
I17
sg11
VCushing's disease
p8868
sg13
I2
sasa(dp8869
g2
VOf the patients with Cushing's disease, 9 (75%) were responsive to hCRH, 5 (42%) were to VIP, and 3 (25%) were to PHM, showing significant increases in both ACTH and cortisol.
p8870
sg4
(lp8871
(dp8872
g7
I89
sg8
VP01282
p8873
sg10
I3
sg11
VVIP
p8874
sg13
I1
sa(dp8875
g7
I157
sg8
VP01189
p8876
sg10
I4
sg11
VACTH
p8877
sg13
I1
sasg17
(lp8878
(dp8879
g7
I21
sg20
VC0221406
p8880
sg10
I17
sg11
VCushing's disease
p8881
sg13
I2
sasa(dp8882
g2
VIn addition, in the patients with Cushing's disease the coadministration of hCRH with PHM or VIP produced additive increases in both ACTH and cortisol.
p8883
sg4
(lp8884
(dp8885
g7
I93
sg8
VP01282
p8886
sg10
I3
sg11
VVIP
p8887
sg13
I1
sa(dp8888
g7
I133
sg8
VP01189
p8889
sg10
I4
sg11
VACTH
p8890
sg13
I1
sasg17
(lp8891
(dp8892
g7
I34
sg20
VC0221406
p8893
sg10
I17
sg11
VCushing's disease
p8894
sg13
I2
sasa(dp8895
g2
VAbnormalities in hypothalamic-pituitary adrenal axis function were demonstrated by measuring plasma adrenocorticotropin abnormal concentrations following Vasoactive Intestinal Peptide (VIP) and Corticotropin Releasing Hormone (CRH) administration during a phase of remission of Cushing's disease in a 45-year-old female patient.
p8896
sg4
(lp8897
(dp8898
g7
I194
sg8
VP06850
p8899
sg10
I31
sg11
VCorticotropin Releasing Hormone
p8900
sg13
I3
sa(dp8901
g7
I100
sg8
VP01189
p8902
sg10
I19
sg11
Vadrenocorticotropin
p8903
sg13
I1
sa(dp8904
g7
I185
sg8
VP01282
p8905
sg10
I3
sg11
VVIP
p8906
sg13
I1
sa(dp8907
g7
I154
sg8
VP01282
p8908
sg10
I29
sg11
VVasoactive Intestinal Peptide
p8909
sg13
I3
sa(dp8910
g7
I227
sg8
VP06850
p8911
sg10
I3
sg11
VCRH
p8912
sg13
I1
sasg17
(lp8913
(dp8914
g7
I278
sg20
VC0221406
p8915
sg10
I17
sg11
VCushing's disease
p8916
sg13
I2
sa(dp8917
g7
I265
sg20
VC0687702
p8918
sg10
I9
sg11
Vremission
p8919
sg13
I1
sasa(dp8920
g2
VWe conclude that the study of ACTH and cortisol response to VIP and CRH may be useful in revealing Cushing's disease even during a remission phase of the disorder.
p8921
sg4
(lp8922
(dp8923
g7
I68
sg8
VP06850
p8924
sg10
I3
sg11
VCRH
p8925
sg13
I1
sa(dp8926
g7
I30
sg8
VP01189
p8927
sg10
I4
sg11
VACTH
p8928
sg13
I1
sa(dp8929
g7
I60
sg8
VP01282
p8930
sg10
I3
sg11
VVIP
p8931
sg13
I1
sasg17
(lp8932
(dp8933
g7
I131
sg20
VC0687702
p8934
sg10
I9
sg11
Vremission
p8935
sg13
I1
sa(dp8936
g7
I99
sg20
VC0221406
p8937
sg10
I17
sg11
VCushing's disease
p8938
sg13
I2
sasa(dp8939
g2
VHere we introduce a cell culture model of EAD propagation consisting of monolayers of cultured neonatal rat ventricular myocytes treated with anthopleurin-A (AP-A).
p8940
sg4
(lp8941
(dp8942
g7
I142
sg8
g47
sg10
I14
sg11
Vanthopleurin-A
p8943
sg13
I1
sa(dp8944
g7
I158
sg8
g47
sg10
I4
sg11
VAP-A
p8945
sg13
I1
sasg17
(lp8946
(dp8947
g7
I42
sg20
VC1864233
p8948
sg10
I3
sg11
VEAD
p8949
sg13
I1
sasa(dp8950
g2
VThe present study provides evidence in support of the hypothesis that AP-A-induced ventricular tachyarrhythmias are due to bradycardia-dependent EAD and triggered activity.
p8951
sg4
(lp8952
(dp8953
g7
I70
sg8
g47
sg10
I4
sg11
VAP-A
p8954
sg13
I1
sasg17
(lp8955
(dp8956
g7
I145
sg20
VC1864233
p8957
sg10
I3
sg11
VEAD
p8958
sg13
I1
sa(dp8959
g7
I123
sg20
VC0428977
p8960
sg10
I11
sg11
Vbradycardia
p8961
sg13
I1
sasa(dp8962
g2
VTU alternans was investigated by MAP recordings in six normal dogs, following the administration of anthopleurin-A (AP-A), a drug shown to delay sodium inactivation and to induce bradycardia dependent long QTU, EADs, and TdP.
p8963
sg4
(lp8964
(dp8965
g7
I179
sg8
VP19525
p8966
sg10
I36
sg11
Vbradycardia dependent long QTU, EADs
p8967
sg13
I5
sa(dp8968
g7
I100
sg8
g47
sg10
I14
sg11
Vanthopleurin-A
p8969
sg13
I1
sa(dp8970
g7
I116
sg8
g47
sg10
I4
sg11
VAP-A
p8971
sg13
I1
sasg17
(lp8972
(dp8973
g7
I179
sg20
VC0428977
p8974
sg10
I11
sg11
Vbradycardia
p8975
sg13
I1
sa(dp8976
g7
I152
sg20
VC0544461
p8977
sg10
I12
sg11
Vinactivation
p8978
sg13
I1
sasa(dp8979
g2
VMoreover, a series of recent studies have genetically and functionally linked kalirin signaling to several disorders, including schizophrenia and Alzheimer's disease.
p8980
sg4
(lp8981
(dp8982
g7
I78
sg8
g47
sg10
I7
sg11
Vkalirin
p8983
sg13
I1
sasg17
(lp8984
(dp8985
g7
I128
sg20
VC0036341
p8986
sg10
I13
sg11
Vschizophrenia
p8987
sg13
I1
sa(dp8988
g7
I146
sg20
VC1521724
p8989
sg10
I19
sg11
VAlzheimer's disease
p8990
sg13
I2
sasa(dp8991
g2
VA series of recent studies has improved our understanding of spine dynamics by establishing kalirin-7 as an important regulator of dendritic spine development as well as structural and functional plasticity, providing a model for the molecular control of structural plasticity and implicating kalirin-7 in synaptic pathology in several disorders including schizophrenia and Alzheimer's disease.
p8992
sg4
(lp8993
(dp8994
g7
I92
sg8
g47
sg10
I9
sg11
Vkalirin-7
p8995
sg13
I1
sa(dp8996
g7
I92
sg8
g47
sg10
I9
sg11
Vkalirin-7
p8997
sg13
I1
sasg17
(lp8998
(dp8999
g7
I356
sg20
VC0036341
p9000
sg10
I13
sg11
Vschizophrenia
p9001
sg13
I1
sa(dp9002
g7
I374
sg20
VC1521724
p9003
sg10
I19
sg11
VAlzheimer's disease
p9004
sg13
I2
sa(dp9005
g7
I315
sg20
VC0677042
p9006
sg10
I9
sg11
Vpathology
p9007
sg13
I1
sasa(dp9008
g2
VHere, we report that inhibition of the cell cycle-dependent kinase 9 (Cdk9) by RNA interference, or the compound flavopiridol, blocked infections with HAdV-C2/5, EKC-causing HAdV-D8/37, and progeny formation in human corneal epithelial and cancer cells.
p9009
sg4
(lp9010
(dp9011
g7
I44
sg8
VP19525
p9012
sg10
I24
sg11
Vcycle-dependent kinase 9
p9013
sg13
I3
sa(dp9014
g7
I70
sg8
VP50750
p9015
sg10
I4
sg11
VCdk9
p9016
sg13
I1
sasg17
(lp9017
(dp9018
g7
I240
sg20
VC0006826
p9019
sg10
I6
sg11
Vcancer
p9020
sg13
I1
sa(dp9021
g7
I135
sg20
VC0021311
p9022
sg10
I10
sg11
Vinfections
p9023
sg13
I1
sa(dp9024
g7
I162
sg20
VC0014493
p9025
sg10
I3
sg11
VEKC
p9026
sg13
I1
sasa(dp9027
g2
VThe study identifies Cdk9 as a postexposure drug target against adenovirus infections in vitro and suggests that the clinically tested anticancer drug flavopiridol is a candidate for treating adenoviral EKC or adenovirus emergence upon immune suppression.
p9028
sg4
(lp9029
(dp9030
g7
I21
sg8
VP50750
p9031
sg10
I4
sg11
VCdk9
p9032
sg13
I1
sasg17
(lp9033
(dp9034
g7
I64
sg20
VC0001486
p9035
sg10
I21
sg11
Vadenovirus infections
p9036
sg13
I2
sa(dp9037
g7
I236
sg20
VC1840264
p9038
sg10
I18
sg11
Vimmune suppression
p9039
sg13
I2
sa(dp9040
g7
I203
sg20
VC0014493
p9041
sg10
I3
sg11
VEKC
p9042
sg13
I1
sa(dp9043
g7
I64
sg20
VC0001486
p9044
sg10
I10
sg11
Vadenovirus
p9045
sg13
I1
sasa(dp9046
g2
VWe conclude that: 1) synthetic non-thiazolidinediones can serve as ligands of PPARgamma and PPARdelta; 2) ligand-dependent activation of PPARdelta involves an apparent conformational change and association of the receptor ligand binding domain with CREB-binding protein; 3) PPARgamma activation (but not PPARdelta or PPARalpha activation) is sufficient to potentiate preadipocyte differentiation; 4) non-thiazolidinedione PPARgamma agonists improve hyperglycemia and hypertriglyceridemia in vivo; 5) although PPARalpha activation is sufficient to affect triglyceride metabolism, PPARdelta activation does not appear to modulate glucose or triglyceride levels.
p9047
sg4
(lp9048
(dp9049
g7
I92
sg8
g47
sg10
I9
sg11
VPPARdelta
p9050
sg13
I1
sa(dp9051
g7
I92
sg8
g47
sg10
I9
sg11
VPPARdelta
p9052
sg13
I1
sa(dp9053
g7
I92
sg8
g47
sg10
I9
sg11
VPPARdelta
p9054
sg13
I1
sa(dp9055
g7
I317
sg8
g47
sg10
I9
sg11
VPPARalpha
p9056
sg13
I1
sa(dp9057
g7
I249
sg8
g47
sg10
I20
sg11
VCREB-binding protein
p9058
sg13
I2
sa(dp9059
g7
I92
sg8
g47
sg10
I9
sg11
VPPARdelta
p9060
sg13
I1
sa(dp9061
g7
I317
sg8
g47
sg10
I9
sg11
VPPARalpha
p9062
sg13
I1
sa(dp9063
g7
I213
sg8
g47
sg10
I30
sg11
Vreceptor ligand binding domain
p9064
sg13
I4
sasg17
(lp9065
(dp9066
g7
I449
sg20
VC0020456
p9067
sg10
I13
sg11
Vhyperglycemia
p9068
sg13
I1
sasa(dp9069
g2
VAt present, four loci associated with non-syndromic auditory neuropathy have been mapped: Autosomal recessive deafness-9 [DFNB9; the otoferlin (OTOF) gene] and autosomal recessive deafness-59 [DFNB59; the pejvakin (PJVK) gene], associated with autosomal recessive inheritance; the autosomal dominant auditory neuropathy gene [AUNA1; the diaphanous-3 (DIAPH3) gene]; and AUNX1, linked to chromosome X.
p9070
sg4
(lp9071
(dp9072
g7
I122
sg8
g47
sg10
I5
sg11
VDFNB9
p9073
sg13
I1
sasg17
(lp9074
(dp9075
g7
I370
sg20
VC1845095
p9076
sg10
I5
sg11
VAUNX1
p9077
sg13
I1
sa(dp9078
g7
I110
sg20
VC0011053
p9079
sg10
I8
sg11
Vdeafness
p9080
sg13
I1
sa(dp9081
g7
I122
sg20
VC1832828
p9082
sg10
I5
sg11
VDFNB9
p9083
sg13
I1
sa(dp9084
g7
I110
sg20
VC0011053
p9085
sg10
I8
sg11
Vdeafness
p9086
sg13
I1
sa(dp9087
g7
I193
sg20
VC1857744
p9088
sg10
I6
sg11
VDFNB59
p9089
sg13
I1
sa(dp9090
g7
I326
sg20
VC1836743
p9091
sg10
I5
sg11
VAUNA1
p9092
sg13
I1
sa(dp9093
g7
I52
sg20
VC1852271
p9094
sg10
I19
sg11
Vauditory neuropathy
p9095
sg13
I2
sa(dp9096
g7
I52
sg20
VC1852271
p9097
sg10
I19
sg11
Vauditory neuropathy
p9098
sg13
I2
sasa(dp9099
g2
VPresence of antibodies to carbamylated fetal calf serum (CarP-FCS) and fibrinogen (CarP-Fib) was determined by inhouse ELISAs among RA cases in the Leiden Early Arthritis Clinic (n=846) and in the Swedish Epidemiological Investigation of Rheumatoid Arthritis (n=1985) cohorts.
p9100
sg4
(lp9101
(dp9102
g7
I57
sg8
VP35219
p9103
sg10
I8
sg11
VCarP-FCS
p9104
sg13
I1
sa(dp9105
g7
I71
sg8
VP22087
p9106
sg10
I10
sg11
Vfibrinogen
p9107
sg13
I1
sa(dp9108
g7
I83
sg8
VP35219
p9109
sg10
I8
sg11
VCarP-Fib
p9110
sg13
I1
sasg17
(lp9111
(dp9112
g7
I57
sg20
VC0263385
p9113
sg10
I4
sg11
VCarP
p9114
sg13
I1
sa(dp9115
g7
I238
sg20
VC0003873
p9116
sg10
I20
sg11
VRheumatoid Arthritis
p9117
sg13
I2
sa(dp9118
g7
I57
sg20
VC0263385
p9119
sg10
I4
sg11
VCarP
p9120
sg13
I1
sa(dp9121
g7
I161
sg20
VC0003864
p9122
sg10
I9
sg11
VArthritis
p9123
sg13
I1
sasa(dp9124
g2
VTo detect the antibodies against human fibrinogen (FIB) Beta67-77 peptide and citrullinated human FIB Beta67-77 peptide in rheumatoid arthritis (RA) and examine their diagnostic values in RA.
p9125
sg4
(lp9126
(dp9127
g7
I92
sg8
VP22087
p9128
sg10
I27
sg11
Vhuman FIB Beta67-77 peptide
p9129
sg13
I4
sa(dp9130
g7
I51
sg8
VP22087
p9131
sg10
I3
sg11
VFIB
p9132
sg13
I1
sa(dp9133
g7
I56
sg8
g47
sg10
I17
sg11
VBeta67-77 peptide
p9134
sg13
I2
sa(dp9135
g7
I33
sg8
VP22087
p9136
sg10
I16
sg11
Vhuman fibrinogen
p9137
sg13
I2
sasg17
(lp9138
(dp9139
g7
I123
sg20
VC0003873
p9140
sg10
I20
sg11
Vrheumatoid arthritis
p9141
sg13
I2
sa(dp9142
g7
I145
sg20
VC0003873
p9143
sg10
I2
sg11
VRA
p9144
sg13
I1
sa(dp9145
g7
I145
sg20
VC0003873
p9146
sg10
I2
sg11
VRA
p9147
sg13
I1
sasa(dp9148
g2
VPolymyositis/dermatomyositis, systemic lupus erythematosus and Addison's disease, three conditions regulated by the HLA-B8-DR3 haplotype, were most strongly associated with MG, especially early-onset disease.
p9149
sg4
(lp9150
(dp9151
g7
I116
sg8
VP30486
p9152
sg10
I20
sg11
VHLA-B8-DR3 haplotype
p9153
sg13
I2
sasg17
(lp9154
(dp9155
g7
I30
sg20
VC0024141
p9156
sg10
I28
sg11
Vsystemic lupus erythematosus
p9157
sg13
I3
sa(dp9158
g7
I63
sg20
VC0001403
p9159
sg10
I17
sg11
VAddison's disease
p9160
sg13
I2
sa(dp9161
g7
I0
sg20
VC0085655
p9162
sg10
I12
sg11
VPolymyositis
p9163
sg13
I1
sa(dp9164
g7
I13
sg20
VC0221056
p9165
sg10
I15
sg11
Vdermatomyositis
p9166
sg13
I1
sasa(dp9167
g2
VThe prevalence of sporadic inclusion body myositis (sIBM) was correlated with the frequency of HLA-DR3.
p9168
sg4
(lp9169
(dp9170
g7
I95
sg8
VP30486
p9171
sg10
I7
sg11
VHLA-DR3
p9172
sg13
I1
sasg17
(lp9173
(dp9174
g7
I18
sg20
VC0751713
p9175
sg10
I32
sg11
Vsporadic inclusion body myositis
p9176
sg13
I4
sa(dp9177
g7
I52
sg20
VC0751713
p9178
sg10
I4
sg11
VsIBM
p9179
sg13
I1
sasa(dp9180
g2
VThe B8-DR3 haplotype fragment conferred the strongest susceptibility (OR 2.9, 95% CI 1.8-4.6), and the B-DR region of other ancestral haplotypes was associated with myositis subgroups.
p9181
sg4
(lp9182
sg17
(lp9183
(dp9184
g7
I165
sg20
VC0027121
p9185
sg10
I8
sg11
Vmyositis
p9186
sg13
I1
sasa(dp9187
g2
VMost gastric IFPs were associated with chronic atrophic gastritis while only one ileal polyp was associated with Meckels diverticulum.
p9188
sg4
(lp9189
(dp9190
g7
I13
sg8
g47
sg10
I4
sg11
VIFPs
p9191
sg13
I1
sasg17
(lp9192
(dp9193
g7
I87
sg20
VC0032584
p9194
sg10
I5
sg11
Vpolyp
p9195
sg13
I1
sa(dp9196
g7
I113
sg20
VC0025037
p9197
sg10
I20
sg11
VMeckels diverticulum
p9198
sg13
I2
sa(dp9199
g7
I39
sg20
VC0017154
p9200
sg10
I26
sg11
Vchronic atrophic gastritis
p9201
sg13
I3
sasa(dp9202
g2
VCBR1, DYRK1A, HMGN1, ITSN1, RCAN1, SON, TMEM50B, and TTC3 were each up-regulated two-fold in Down syndrome samples compared to normal samples; of these, SON and TTC3 were newly reported.
p9203
sg4
(lp9204
(dp9205
g7
I21
sg8
g47
sg10
I5
sg11
VITSN1
p9206
sg13
I1
sa(dp9207
g7
I40
sg8
VP56557
p9208
sg10
I7
sg11
VTMEM50B
p9209
sg13
I1
sa(dp9210
g7
I0
sg8
VP16152
p9211
sg10
I4
sg11
VCBR1
p9212
sg13
I1
sa(dp9213
g7
I6
sg8
g47
sg10
I6
sg11
VDYRK1A
p9214
sg13
I1
sa(dp9215
g7
I14
sg8
VP05114
p9216
sg10
I5
sg11
VHMGN1
p9217
sg13
I1
sasg17
(lp9218
(dp9219
g7
I93
sg20
VC0013080
p9220
sg10
I13
sg11
VDown syndrome
p9221
sg13
I2
sasa(dp9222
g2
VIn this report we show that high levels of the TTC3 protein, encoded by one of the genes of the Down Syndrome Critical Region (DCR), prevent neurite extension and disrupt Golgi compactness in differentiating primary neurons.
p9223
sg4
(lp9224
sg17
(lp9225
(dp9226
g7
I96
sg20
VC1860787
p9227
sg10
I29
sg11
VDown Syndrome Critical Region
p9228
sg13
I4
sa(dp9229
g7
I127
sg20
VC1860787
p9230
sg10
I3
sg11
VDCR
p9231
sg13
I1
sasa(dp9232
g2
VTTC3 contains a canonical RING finger motif, a pair of tetratricopeptide motifs, a putative Akt phosphorylation site, and nuclear localization signals, and is encoded by a gene within the Down syndrome (DS) critical region on chromosome 21.
p9233
sg4
(lp9234
(dp9235
g7
I92
sg8
g47
sg10
I3
sg11
VAkt
p9236
sg13
I1
sasg17
(lp9237
(dp9238
g7
I203
sg20
VC0013080
p9239
sg10
I2
sg11
VDS
p9240
sg13
I1
sa(dp9241
g7
I188
sg20
VC0013080
p9242
sg10
I13
sg11
VDown syndrome
p9243
sg13
I2
sasa(dp9244
g2
VNonchimeric polytransgenic 152F7 mice encompassing four human chromosome 21 genes (DSCR3, DSCR5, TTC3, and DYRK1A) within the Down syndrome critical region present with learning and memory impairment.
p9245
sg4
(lp9246
(dp9247
g7
I90
sg8
VP57054
p9248
sg10
I5
sg11
VDSCR5
p9249
sg13
I1
sa(dp9250
g7
I107
sg8
g47
sg10
I6
sg11
VDYRK1A
p9251
sg13
I1
sa(dp9252
g7
I83
sg8
g47
sg10
I5
sg11
VDSCR3
p9253
sg13
I1
sasg17
(lp9254
(dp9255
g7
I126
sg20
VC1860787
p9256
sg10
I29
sg11
VDown syndrome critical region
p9257
sg13
I4
sa(dp9258
g7
I182
sg20
VC0233794
p9259
sg10
I17
sg11
Vmemory impairment
p9260
sg13
I2
sasa(dp9261
g2
VMultivariate regression analysis revealed that plasma VWF Ag level is an independent predictor of mortality in ARDS pediatric patients.
p9262
sg4
(lp9263
(dp9264
g7
I47
sg8
VP04275
p9265
sg10
I13
sg11
Vplasma VWF Ag
p9266
sg13
I3
sasg17
(lp9267
(dp9268
g7
I111
sg20
VC0035222
p9269
sg10
I4
sg11
VARDS
p9270
sg13
I1
sasa(dp9271
g2
VPlasma VWF Ag level is an excellent predictive marker for outcome in children with ALI/ARDS.
p9272
sg4
(lp9273
(dp9274
g7
I0
sg8
VP04275
p9275
sg10
I13
sg11
VPlasma VWF Ag
p9276
sg13
I3
sasg17
(lp9277
(dp9278
g7
I87
sg20
VC0035222
p9279
sg10
I4
sg11
VARDS
p9280
sg13
I1
sasa(dp9281
g2
VIn the multicenter study, patients with direct ARDS also had lower levels of von Willebrand factor antigen and IL-6 and IL-8, markers of endothelial injury and inflammation, respectively.
p9282
sg4
(lp9283
(dp9284
g7
I111
sg8
VP05231
p9285
sg10
I4
sg11
VIL-6
p9286
sg13
I1
sa(dp9287
g7
I77
sg8
VP04275
p9288
sg10
I29
sg11
Vvon Willebrand factor antigen
p9289
sg13
I4
sasg17
(lp9290
(dp9291
g7
I47
sg20
VC0035222
p9292
sg10
I4
sg11
VARDS
p9293
sg13
I1
sa(dp9294
g7
I160
sg20
VC0021368
p9295
sg10
I12
sg11
Vinflammation
p9296
sg13
I1
sasa(dp9297
g2
VTo investigate the role of endothelial cell mediators, E-selectin (ES), intercellular adhesion molecule-1 (ICAM-1), tissue factor (TF), and von Willebrand factor (vWF), in the early phase of severe acute pancreatitis (SAP) complicated with respiratory failure [pancreatitis-associated lung injury (PALI)].
p9298
sg4
(lp9299
(dp9300
g7
I72
sg8
VP05362
p9301
sg10
I33
sg11
Vintercellular adhesion molecule-1
p9302
sg13
I3
sa(dp9303
g7
I140
sg8
VP04275
p9304
sg10
I21
sg11
Vvon Willebrand factor
p9305
sg13
I3
sa(dp9306
g7
I163
sg8
VP04275
p9307
sg10
I3
sg11
VvWF
p9308
sg13
I1
sa(dp9309
g7
I107
sg8
VP05362
p9310
sg10
I6
sg11
VICAM-1
p9311
sg13
I1
sa(dp9312
g7
I27
sg8
VP16581
p9313
sg10
I38
sg11
Vendothelial cell mediators, E-selectin
p9314
sg13
I4
sasg17
(lp9315
(dp9316
g7
I86
sg20
VC0001511
p9317
sg10
I8
sg11
Vadhesion
p9318
sg13
I1
sa(dp9319
g7
I240
sg20
VC1145670
p9320
sg10
I19
sg11
Vrespiratory failure
p9321
sg13
I2
sa(dp9322
g7
I204
sg20
VC0030305
p9323
sg10
I12
sg11
Vpancreatitis
p9324
sg13
I1
sa(dp9325
g7
I198
sg20
VC0001339
p9326
sg10
I18
sg11
Vacute pancreatitis
p9327
sg13
I2
sasa(dp9328
g2
VThus, CLC-2 may be a promising and potential novel therapeutic strategy for combating primary open-angle glaucoma.
p9329
sg4
(lp9330
(dp9331
g7
I6
sg8
VP51788
p9332
sg10
I5
sg11
VCLC-2
p9333
sg13
I1
sasg17
(lp9334
(dp9335
g7
I86
sg20
VC0339573
p9336
sg10
I27
sg11
Vprimary open-angle glaucoma
p9337
sg13
I3
sasa(dp9338
g2
VIn type 2 diabetes mellitus (T2DM) patients, chronic kidney disease (CKD) progression may occur without detectable changes in urinary albumin excretion (UAE) rate.
p9339
sg4
(lp9340
(dp9341
g7
I134
sg8
VP00441
p9342
sg10
I7
sg11
Valbumin
p9343
sg13
I1
sasg17
(lp9344
(dp9345
g7
I45
sg20
VC1561643
p9346
sg10
I22
sg11
Vchronic kidney disease
p9347
sg13
I3
sa(dp9348
g7
I3
sg20
VC0011860
p9349
sg10
I24
sg11
Vtype 2 diabetes mellitus
p9350
sg13
I4
sa(dp9351
g7
I29
sg20
VC0011860
p9352
sg10
I4
sg11
VT2DM
p9353
sg13
I1
sa(dp9354
g7
I69
sg20
VC1561643
p9355
sg10
I3
sg11
VCKD
p9356
sg13
I1
sasa(dp9357
g2
VTo investigate, for the first time, the impact of systolic pulmonary arterial pressure (PASP) on maximal exercise capacity in adults with mild-to-moderate cystic fibrosis, without PH at rest.
p9358
sg4
(lp9359
sg17
(lp9360
(dp9361
g7
I155
sg20
VC0010674
p9362
sg10
I15
sg11
Vcystic fibrosis
p9363
sg13
I2
sasa(dp9364
g2
VAssays of carboxypeptidase B-like activity and C3 in serum from patients with cystic fibrosis and appropriate control subjects failed to demonstrate a deficiency of carboxypeptidase B-like activity or a consistent increase in C3, as was suggested by Conover and associates.
p9365
sg4
(lp9366
(dp9367
g7
I10
sg8
VP15086
p9368
sg10
I23
sg11
Vcarboxypeptidase B-like
p9369
sg13
I2
sa(dp9370
g7
I10
sg8
VP15086
p9371
sg10
I23
sg11
Vcarboxypeptidase B-like
p9372
sg13
I2
sasg17
(lp9373
(dp9374
g7
I78
sg20
VC0010674
p9375
sg10
I15
sg11
Vcystic fibrosis
p9376
sg13
I2
sa(dp9377
g7
I151
sg20
VC0398782
p9378
sg10
I32
sg11
Vdeficiency of carboxypeptidase B
p9379
sg13
I4
sasa(dp9380
g2
VDifferences between men and women with cystic fibrosis were apparent, in that women with cystic fibrosis had higher concentrations of both serum carboxypeptidase B-like activity and C3 than either men with cystic fibrosis or control subjects.
p9381
sg4
(lp9382
(dp9383
g7
I139
sg8
VP15086
p9384
sg10
I24
sg11
Vserum carboxypeptidase B
p9385
sg13
I3
sasg17
(lp9386
(dp9387
g7
I39
sg20
VC0010674
p9388
sg10
I15
sg11
Vcystic fibrosis
p9389
sg13
I2
sa(dp9390
g7
I39
sg20
VC0010674
p9391
sg10
I15
sg11
Vcystic fibrosis
p9392
sg13
I2
sa(dp9393
g7
I39
sg20
VC0010674
p9394
sg10
I15
sg11
Vcystic fibrosis
p9395
sg13
I2
sasa(dp9396
g2
VThe properties and lysosomal distribution of the enzyme indicated that it was a carboxypeptidase B. Substrate affinity, thermolability, pH stability, the fall and rise in activity with subculture, the cyclical pattern of activity through serial passage and the level of activity were similar for the control and cystic fibrosis enzyme.
p9397
sg4
(lp9398
(dp9399
g7
I80
sg8
VP15086
p9400
sg10
I18
sg11
Vcarboxypeptidase B
p9401
sg13
I2
sa(dp9402
g7
I312
sg8
VP13569
p9403
sg10
I22
sg11
Vcystic fibrosis enzyme
p9404
sg13
I3
sasg17
(lp9405
(dp9406
g7
I312
sg20
VC0010674
p9407
sg10
I15
sg11
Vcystic fibrosis
p9408
sg13
I2
sasa(dp9409
g2
VIn this review the roles identified for different selenoproteins in these steps and how they may promote or inhibit metastatic cancers is discussed.
p9410
sg4
(lp9411
sg17
(lp9412
(dp9413
g7
I127
sg20
VC0006826
p9414
sg10
I7
sg11
Vcancers
p9415
sg13
I1
sasa(dp9416
g2
VIndeed, many selenoproteins have antioxidant activity which can attenuate cancer development by minimizing oxidative insult and resultant DNA damage.
p9417
sg4
(lp9418
(dp9419
g7
I13
sg8
VP55073
p9420
sg10
I14
sg11
Vselenoproteins
p9421
sg13
I1
sasg17
(lp9422
(dp9423
g7
I138
sg20
VC0012860
p9424
sg10
I10
sg11
VDNA damage
p9425
sg13
I2
sa(dp9426
g7
I74
sg20
VC0006826
p9427
sg10
I6
sg11
Vcancer
p9428
sg13
I1
sasa(dp9429
g2
VIn this review, we discuss what is currently known about selenoproteins in tumorigenesis with a focus on their contextual roles in cancer development, growth, and progression.
p9430
sg4
(lp9431
(dp9432
g7
I57
sg8
VP55073
p9433
sg10
I14
sg11
Vselenoproteins
p9434
sg13
I1
sasg17
(lp9435
(dp9436
g7
I75
sg20
VC0007621
p9437
sg10
I13
sg11
Vtumorigenesis
p9438
sg13
I1
sa(dp9439
g7
I131
sg20
VC0006826
p9440
sg10
I6
sg11
Vcancer
p9441
sg13
I1
sasa(dp9442
g2
VNew aspects of Se actions in breast cancer have emerged such as the impact of genetic polymorphisms on Se metabolism and response, new functions of selenoproteins, epigenetic modulation of gene expression, and long-term influence of early-life exposure on disease risk.
p9443
sg4
(lp9444
(dp9445
g7
I148
sg8
VP55073
p9446
sg10
I14
sg11
Vselenoproteins
p9447
sg13
I1
sasg17
(lp9448
(dp9449
g7
I29
sg20
VC0678222
p9450
sg10
I13
sg11
Vbreast cancer
p9451
sg13
I2
sasa(dp9452
g2
VWe observed that both SelS and C99 were colocalized in the membrane fraction of mouse neuroblastoma Neuro2a (N2a) cells.
p9453
sg4
(lp9454
(dp9455
g7
I22
sg8
g47
sg10
I4
sg11
VSelS
p9456
sg13
I1
sasg17
(lp9457
(dp9458
g7
I80
sg20
VC1524043
p9459
sg10
I19
sg11
Vmouse neuroblastoma
p9460
sg13
I2
sasa(dp9461
g2
VThe results suggest that decreased NPY expression in the extended amygdala might be causally linked with the depression induced following type 2 diabetes and that the antidepressant action of imipramine in diabetic mice might be mediated by NPY-NPY Y1 receptor system.
p9462
sg4
(lp9463
(dp9464
g7
I35
sg8
VP25929
p9465
sg10
I3
sg11
VNPY
p9466
sg13
I1
sa(dp9467
g7
I241
sg8
VP25929
p9468
sg10
I19
sg11
VNPY-NPY Y1 receptor
p9469
sg13
I3
sasg17
(lp9470
(dp9471
g7
I138
sg20
VC0011860
p9472
sg10
I15
sg11
Vtype 2 diabetes
p9473
sg13
I3
sa(dp9474
g7
I109
sg20
VC0011581
p9475
sg10
I10
sg11
Vdepression
p9476
sg13
I1
sasa(dp9477
g2
VNumerous models of obesity and diabetes are characterized by increased central nervous system (CNS) neuropeptide Y (NPY); in fact, a single intracerebroventricular (icv) administration of NPY in lean fasted rats elevates hepatic VLDL-TG secretion and does so, in large part, via signaling through the CNS NPY Y1 receptor.
p9478
sg4
(lp9479
(dp9480
g7
I301
sg8
VP25929
p9481
sg10
I19
sg11
VCNS NPY Y1 receptor
p9482
sg13
I4
sa(dp9483
g7
I116
sg8
VP25929
p9484
sg10
I3
sg11
VNPY
p9485
sg13
I1
sa(dp9486
g7
I116
sg8
VP25929
p9487
sg10
I3
sg11
VNPY
p9488
sg13
I1
sa(dp9489
g7
I100
sg8
VP01303
p9490
sg10
I14
sg11
Vneuropeptide Y
p9491
sg13
I2
sasg17
(lp9492
(dp9493
g7
I31
sg20
VC0011849
p9494
sg10
I8
sg11
Vdiabetes
p9495
sg13
I1
sa(dp9496
g7
I19
sg20
VC0028754
p9497
sg10
I7
sg11
Vobesity
p9498
sg13
I1
sa(dp9499
g7
I79
sg20
VC0027769
p9500
sg10
I7
sg11
Vnervous
p9501
sg13
I1
sasa(dp9502
g2
VWe investigated whether annexin A8 (A-A8), a Ca-binding protein overexpressed in pancreatic cancer, plays a role in cell growth and migration and investigated its association with pancreatic cancer prognosis.
p9503
sg4
(lp9504
(dp9505
g7
I45
sg8
g47
sg10
I18
sg11
VCa-binding protein
p9506
sg13
I2
sasg17
(lp9507
(dp9508
g7
I81
sg20
VC0235974
p9509
sg10
I17
sg11
Vpancreatic cancer
p9510
sg13
I2
sa(dp9511
g7
I81
sg20
VC0235974
p9512
sg10
I17
sg11
Vpancreatic cancer
p9513
sg13
I2
sasa(dp9514
g2
VAlthough Annexin A8 (ANXA8), a member of a superfamily of calcium and phospholipid binding proteins, is physiologically expressed in a tissue-specific manner, recent microarray studies reported that ANXA8 was also ectopically expressed in pancreatic cancers.
p9515
sg4
(lp9516
(dp9517
g7
I21
sg8
VP13928
p9518
sg10
I5
sg11
VANXA8
p9519
sg13
I1
sa(dp9520
g7
I21
sg8
VP13928
p9521
sg10
I5
sg11
VANXA8
p9522
sg13
I1
sa(dp9523
g7
I9
sg8
VP13928
p9524
sg10
I10
sg11
VAnnexin A8
p9525
sg13
I2
sasg17
(lp9526
(dp9527
g7
I239
sg20
VC0346647
p9528
sg10
I18
sg11
Vpancreatic cancers
p9529
sg13
I2
sasa(dp9530
g2
VWe investigated the molecular mechanism of expression of ANXA8 in cancer cells and its functional role in pancreatic cancer cells.
p9531
sg4
(lp9532
(dp9533
g7
I57
sg8
VP13928
p9534
sg10
I5
sg11
VANXA8
p9535
sg13
I1
sasg17
(lp9536
(dp9537
g7
I66
sg20
VC0006826
p9538
sg10
I6
sg11
Vcancer
p9539
sg13
I1
sa(dp9540
g7
I106
sg20
VC0235974
p9541
sg10
I17
sg11
Vpancreatic cancer
p9542
sg13
I2
sasa(dp9543
g2
VTo investigate the utility of 26 immunohistochemical markers (CAM 5.2, CK [cytokeratin] 7, CK20, CK17, CK19, MUC1, MUC2, MUC4, MUC5AC, MUC6, p53, DPC4/SMAD4, CDX2, pVHL [von Hippel-Lindau tumor suppressor gene protein], S100P, IMP-3 [insulin-like growth factor 2 messenger RNA binding protein 3], maspin, mesothelin, claudin 4, claudin 18, annexin A8, fascin, PSCA [prostate stem cell antigen], MOC31, CEA [carcinoembryonic antigen], and CA19-9 [cancer antigen 19-9]) in the diagnosis of ductal adenocarcinoma of the pancreas.
p9544
sg4
(lp9545
(dp9546
g7
I135
sg8
g47
sg10
I4
sg11
VMUC6
p9547
sg13
I1
sa(dp9548
g7
I220
sg8
VP25815
p9549
sg10
I5
sg11
VS100P
p9550
sg13
I1
sa(dp9551
g7
I328
sg8
VP56856
p9552
sg10
I10
sg11
Vclaudin 18
p9553
sg13
I2
sa(dp9554
g7
I91
sg8
VP35900
p9555
sg10
I4
sg11
VCK20
p9556
sg13
I1
sa(dp9557
g7
I151
sg8
g47
sg10
I5
sg11
VSMAD4
p9558
sg13
I1
sa(dp9559
g7
I158
sg8
g47
sg10
I4
sg11
VCDX2
p9560
sg13
I1
sa(dp9561
g7
I317
sg8
g47
sg10
I9
sg11
Vclaudin 4
p9562
sg13
I2
sa(dp9563
g7
I227
sg8
g47
sg10
I5
sg11
VIMP-3
p9564
sg13
I1
sa(dp9565
g7
I115
sg8
g47
sg10
I4
sg11
VMUC2
p9566
sg13
I1
sa(dp9567
g7
I164
sg8
VP40337
p9568
sg10
I4
sg11
VpVHL
p9569
sg13
I1
sa(dp9570
g7
I402
sg8
VP40198
p9571
sg10
I3
sg11
VCEA
p9572
sg13
I1
sa(dp9573
g7
I352
sg8
g47
sg10
I6
sg11
Vfascin
p9574
sg13
I1
sa(dp9575
g7
I395
sg8
VP16422
p9576
sg10
I5
sg11
VMOC31
p9577
sg13
I1
sa(dp9578
g7
I340
sg8
VP13928
p9579
sg10
I10
sg11
Vannexin A8
p9580
sg13
I2
sa(dp9581
g7
I360
sg8
g47
sg10
I4
sg11
VPSCA
p9582
sg13
I1
sa(dp9583
g7
I62
sg8
VP01768
p9584
sg10
I7
sg11
VCAM 5.2
p9585
sg13
I2
sa(dp9586
g7
I297
sg8
VP36952
p9587
sg10
I6
sg11
Vmaspin
p9588
sg13
I1
sa(dp9589
g7
I141
sg8
VP42771
p9590
sg10
I3
sg11
Vp53
p9591
sg13
I1
sa(dp9592
g7
I234
sg8
VP01308
p9593
sg10
I60
sg11
Vinsulin-like growth factor 2 messenger RNA binding protein 3
p9594
sg13
I9
sa(dp9595
g7
I71
sg8
g47
sg10
I18
sg11
VCK [cytokeratin] 7
p9596
sg13
I3
sa(dp9597
g7
I146
sg8
g47
sg10
I4
sg11
VDPC4
p9598
sg13
I1
sasg17
(lp9599
(dp9600
g7
I446
sg20
VC0006826
p9601
sg10
I6
sg11
Vcancer
p9602
sg13
I1
sa(dp9603
g7
I62
sg20
VC1861821
p9604
sg10
I3
sg11
VCAM
p9605
sg13
I1
sa(dp9606
g7
I488
sg20
VC1335302
p9607
sg10
I37
sg11
Vductal adenocarcinoma of the pancreas
p9608
sg13
I5
sa(dp9609
g7
I188
sg20
VC0027651
p9610
sg10
I5
sg11
Vtumor
p9611
sg13
I1
sasa(dp9612
g2
VClaudin 18 and annexin A8 are frequently highly overexpressed in infiltrating ductal adenocarcinomas when compared with normal reactive ducts, suggesting a role for these molecules in pancreatic ductal adenocarcinomas.
p9613
sg4
(lp9614
(dp9615
g7
I15
sg8
VP13928
p9616
sg10
I10
sg11
Vannexin A8
p9617
sg13
I2
sa(dp9618
g7
I0
sg8
VP56856
p9619
sg10
I10
sg11
VClaudin 18
p9620
sg13
I2
sasg17
(lp9621
(dp9622
g7
I85
sg20
VC0001418
p9623
sg10
I15
sg11
Vadenocarcinomas
p9624
sg13
I1
sa(dp9625
g7
I85
sg20
VC0001418
p9626
sg10
I15
sg11
Vadenocarcinomas
p9627
sg13
I1
sa(dp9628
g7
I65
sg20
VC0332448
p9629
sg10
I12
sg11
Vinfiltrating
p9630
sg13
I1
sasa(dp9631
g2
VMultivariate analysis further confirmed that miR-340-low/ROCK1-high expression was an independent prognostic factor of unfavorable survival in pediatric osteosarcoma (for overall survival: p = 0.006, for progression-free survival: p = 0.008).
p9632
sg4
(lp9633
(dp9634
g7
I57
sg8
g47
sg10
I5
sg11
VROCK1
p9635
sg13
I1
sa(dp9636
g7
I45
sg8
g47
sg10
I11
sg11
VmiR-340-low
p9637
sg13
I1
sasg17
(lp9638
(dp9639
g7
I143
sg20
VC1332986
p9640
sg10
I22
sg11
Vpediatric osteosarcoma
p9641
sg13
I2
sasa(dp9642
g2
VOur data offer convincing evidence, for the first time, that the combined miR-340 downregulation and ROCK1 upregulation may be linked to tumor progression and adverse prognosis in pediatric osteosarcoma.
p9643
sg4
(lp9644
(dp9645
g7
I101
sg8
g47
sg10
I5
sg11
VROCK1
p9646
sg13
I1
sasg17
(lp9647
(dp9648
g7
I180
sg20
VC1332986
p9649
sg10
I22
sg11
Vpediatric osteosarcoma
p9650
sg13
I2
sa(dp9651
g7
I137
sg20
VC0178874
p9652
sg10
I17
sg11
Vtumor progression
p9653
sg13
I2
sasa(dp9654
g2
VWe analyzed the effects of 3 war components-combat exposure (CES), observation of abusive violence (OBS), and participation in abusive violence (PARTC)-and sense of coherence (SOC) on the development of both posttraumatic stress disorder (PTSD) and depression among a sample of war veterans.
p9655
sg4
(lp9656
sg17
(lp9657
(dp9658
g7
I61
sg20
VC0265493
p9659
sg10
I3
sg11
VCES
p9660
sg13
I1
sa(dp9661
g7
I90
sg20
VC0042693
p9662
sg10
I8
sg11
Vviolence
p9663
sg13
I1
sa(dp9664
g7
I208
sg20
VC0038436
p9665
sg10
I29
sg11
Vposttraumatic stress disorder
p9666
sg13
I3
sa(dp9667
g7
I249
sg20
VC0011581
p9668
sg10
I10
sg11
Vdepression
p9669
sg13
I1
sa(dp9670
g7
I90
sg20
VC0042693
p9671
sg10
I8
sg11
Vviolence
p9672
sg13
I1
sa(dp9673
g7
I239
sg20
VC0038436
p9674
sg10
I4
sg11
VPTSD
p9675
sg13
I1
sa(dp9676
g7
I33
sg20
VC0265493
p9677
sg10
I26
sg11
Vcomponents-combat exposure
p9678
sg13
I2
sasa(dp9679
g2
VThe expression levels of miR-155 in 38 pairs of cancer tissues and adjacent normal tissues from breast cancer patients were detected using quantitative real-time PCR.
p9680
sg4
(lp9681
sg17
(lp9682
(dp9683
g7
I48
sg20
VC0006826
p9684
sg10
I6
sg11
Vcancer
p9685
sg13
I1
sa(dp9686
g7
I96
sg20
VC0678222
p9687
sg10
I13
sg11
Vbreast cancer
p9688
sg13
I2
sasa(dp9689
g2
VSoft agar colony formation assay and tumor xenografts showed inhibition of miR-155 could significantly reduce proliferation of cancer cells in vivo and vitro, which confirmed that miR-155 is an effective therapeutic target of breast cancer.
p9690
sg4
(lp9691
(dp9692
g7
I75
sg8
g47
sg10
I7
sg11
VmiR-155
p9693
sg13
I1
sa(dp9694
g7
I75
sg8
g47
sg10
I7
sg11
VmiR-155
p9695
sg13
I1
sasg17
(lp9696
(dp9697
g7
I37
sg20
VC0027651
p9698
sg10
I5
sg11
Vtumor
p9699
sg13
I1
sa(dp9700
g7
I127
sg20
VC0006826
p9701
sg10
I6
sg11
Vcancer
p9702
sg13
I1
sa(dp9703
g7
I226
sg20
VC0678222
p9704
sg10
I13
sg11
Vbreast cancer
p9705
sg13
I2
sa(dp9706
g7
I110
sg20
VC0334094
p9707
sg10
I13
sg11
Vproliferation
p9708
sg13
I1
sasa(dp9709
g2
VOur results underscore the importance of miR-155 as a therapeutic target and combination of Doxorubicinol and miR-155-silencing would be a potential way to cure breast cancer.
p9710
sg4
(lp9711
sg17
(lp9712
(dp9713
g7
I161
sg20
VC0678222
p9714
sg10
I13
sg11
Vbreast cancer
p9715
sg13
I2
sasa(dp9716
g2
VWe have quantified expression of seven oncomiRs, namely miR-17/92 cluster (miR-17, miR-18a, miR-19a and miR-20a), miR-21, miR-27a and miR-155, in plasma of 137 breast cancer (BC) patients.
p9717
sg4
(lp9718
(dp9719
g7
I134
sg8
g47
sg10
I7
sg11
VmiR-155
p9720
sg13
I1
sa(dp9721
g7
I92
sg8
g47
sg10
I7
sg11
VmiR-19a
p9722
sg13
I1
sa(dp9723
g7
I56
sg8
g47
sg10
I6
sg11
VmiR-17
p9724
sg13
I1
sa(dp9725
g7
I83
sg8
g47
sg10
I7
sg11
VmiR-18a
p9726
sg13
I1
sa(dp9727
g7
I104
sg8
g47
sg10
I7
sg11
VmiR-20a
p9728
sg13
I1
sa(dp9729
g7
I122
sg8
g47
sg10
I7
sg11
VmiR-27a
p9730
sg13
I1
sa(dp9731
g7
I56
sg8
g47
sg10
I17
sg11
VmiR-17/92 cluster
p9732
sg13
I2
sasg17
(lp9733
(dp9734
g7
I175
sg20
VC0678222
p9735
sg10
I2
sg11
VBC
p9736
sg13
I1
sa(dp9737
g7
I160
sg20
VC0678222
p9738
sg10
I13
sg11
Vbreast cancer
p9739
sg13
I2
sasa(dp9740
g2
VOur results suggested that MIAT acted as a competing endogenous RNA (ceRNA) to regulate the expression of dual specificity phosphatase 7 (DUSP7) by taking up miR-155-5p in breast cancer.
p9741
sg4
(lp9742
(dp9743
g7
I158
sg8
g47
sg10
I10
sg11
VmiR-155-5p
p9744
sg13
I1
sa(dp9745
g7
I138
sg8
g47
sg10
I5
sg11
VDUSP7
p9746
sg13
I1
sa(dp9747
g7
I106
sg8
g47
sg10
I30
sg11
Vdual specificity phosphatase 7
p9748
sg13
I4
sasg17
(lp9749
(dp9750
g7
I172
sg20
VC0678222
p9751
sg10
I13
sg11
Vbreast cancer
p9752
sg13
I2
sasa(dp9753
g2
VWe conclude that MIAT promotes breast cancer progression and functions as ceRNA to regulate DUSP7 expression by sponging miR-155-5p in breast cancer.
p9754
sg4
(lp9755
(dp9756
g7
I92
sg8
g47
sg10
I5
sg11
VDUSP7
p9757
sg13
I1
sa(dp9758
g7
I121
sg8
g47
sg10
I10
sg11
VmiR-155-5p
p9759
sg13
I1
sasg17
(lp9760
(dp9761
g7
I31
sg20
VC0678222
p9762
sg10
I13
sg11
Vbreast cancer
p9763
sg13
I2
sa(dp9764
g7
I38
sg20
VC0178874
p9765
sg10
I18
sg11
Vcancer progression
p9766
sg13
I2
sasa(dp9767
g2
VFour oncogenic microRNAs (miR-155, miR-19a, miR-181b, and miR-24) and one tumor suppressor microRNA (let-7a) were shown to differentiate between high- and low-risk early breast cancer (EBC) and reflect the surgical tumor removal and adjuvant therapy.
p9768
sg4
(lp9769
(dp9770
g7
I35
sg8
g47
sg10
I7
sg11
VmiR-19a
p9771
sg13
I1
sa(dp9772
g7
I44
sg8
g47
sg10
I8
sg11
VmiR-181b
p9773
sg13
I1
sa(dp9774
g7
I58
sg8
g47
sg10
I6
sg11
VmiR-24
p9775
sg13
I1
sasg17
(lp9776
(dp9777
g7
I170
sg20
VC0678222
p9778
sg10
I13
sg11
Vbreast cancer
p9779
sg13
I2
sa(dp9780
g7
I74
sg20
VC0027651
p9781
sg10
I5
sg11
Vtumor
p9782
sg13
I1
sa(dp9783
g7
I74
sg20
VC0027651
p9784
sg10
I5
sg11
Vtumor
p9785
sg13
I1
sasa(dp9786
g2
VThe present study determined the role of postoperative wound fluids (WFs) from patients diagnosed with breast cancer subsequent to breast conserving surgery or breast conserving surgery followed by IORT on the expression of three microRNAs (miRNAs), consisting of miR-21, miR-155 and miR-221, in distinct breast cancer cell lines that represent the general subtypes of breast cancer.
p9787
sg4
(lp9788
sg17
(lp9789
(dp9790
g7
I103
sg20
VC0678222
p9791
sg10
I13
sg11
Vbreast cancer
p9792
sg13
I2
sa(dp9793
g7
I103
sg20
VC0678222
p9794
sg10
I13
sg11
Vbreast cancer
p9795
sg13
I2
sa(dp9796
g7
I55
sg20
VC0043207
p9797
sg10
I12
sg11
Vwound fluids
p9798
sg13
I2
sa(dp9799
g7
I103
sg20
VC0678222
p9800
sg10
I13
sg11
Vbreast cancer
p9801
sg13
I2
sa(dp9802
g7
I69
sg20
VC0043207
p9803
sg10
I3
sg11
VWFs
p9804
sg13
I1
sasa(dp9805
g2
VAdditionally, it was indicated that both WFs and RT-WF strongly downregulated the expression of miR-21, miR-155 and miR-221 in basal/epithelial and luminal subtypes of breast cancer.
p9806
sg4
(lp9807
(dp9808
g7
I41
sg8
g47
sg10
I3
sg11
VWFs
p9809
sg13
I1
sasg17
(lp9810
(dp9811
g7
I41
sg20
VC0043207
p9812
sg10
I3
sg11
VWFs
p9813
sg13
I1
sa(dp9814
g7
I168
sg20
VC0678222
p9815
sg10
I13
sg11
Vbreast cancer
p9816
sg13
I2
sasa(dp9817
g2
VThe expression of three different microRNAs (miR-9, miR-21, and miR-155) in 52 formalin-fixed paraffin-embedded (FFPE) primary cervical cancer tissue samples and 50 FFPE normal cervical tissue samples were evaluated.
p9818
sg4
(lp9819
sg17
(lp9820
(dp9821
g7
I127
sg20
VC0302592
p9822
sg10
I15
sg11
Vcervical cancer
p9823
sg13
I2
sasa(dp9824
g2
VMiR-9, miR-21, and miR-155 were significantly overexpressed in cervical cancer tissues compared to normal tissues (P &lt; 0.001).
p9825
sg4
(lp9826
(dp9827
g7
I0
sg8
g47
sg10
I5
sg11
VMiR-9
p9828
sg13
I1
sasg17
(lp9829
(dp9830
g7
I63
sg20
VC0302592
p9831
sg10
I15
sg11
Vcervical cancer
p9832
sg13
I2
sasa(dp9833
g2
VMiR-21 and miR-155 expression combined with the HPV E6/E7 mRNA assay in HPV E6/E7 negative cervical cancer showed increased AUC of 0.7267 and 0.7000, respectively (P = 0.01, P = 0.04), demonstrating their potential as diagnostic tools.
p9834
sg4
(lp9835
sg17
(lp9836
(dp9837
g7
I91
sg20
VC0302592
p9838
sg10
I15
sg11
Vcervical cancer
p9839
sg13
I2
sasa(dp9840
g2
VMoreover, miR-21 and miR-155 were predictors showing a 7 fold and 10.3 fold higher risk for HPV E6/E7 negative patients with cervical cancer (P = 0.024 and P = 0.017, respectively) while miR-155 was a predictor showing a 27.9 fold higher risk for HPV E6/E7 positive patients with cervical cancer (P &lt; 0.0001).
p9841
sg4
(lp9842
sg17
(lp9843
(dp9844
g7
I125
sg20
VC0302592
p9845
sg10
I15
sg11
Vcervical cancer
p9846
sg13
I2
sa(dp9847
g7
I125
sg20
VC0302592
p9848
sg10
I15
sg11
Vcervical cancer
p9849
sg13
I2
sasa(dp9850
g2
VMiR-21 and miR-155 may be helpful in the prediction of both HPV positive and HPV negative cases of cervical cancer.
p9851
sg4
(lp9852
(dp9853
g7
I0
sg8
g47
sg10
I6
sg11
VMiR-21
p9854
sg13
I1
sa(dp9855
g7
I11
sg8
g47
sg10
I7
sg11
VmiR-155
p9856
sg13
I1
sasg17
(lp9857
(dp9858
g7
I99
sg20
VC0302592
p9859
sg10
I15
sg11
Vcervical cancer
p9860
sg13
I2
sasa(dp9861
g2
VThe purpose of this study was to analyze the clinicopathologic significance of expression of EMT-related miRNAs, miR-9 and miR-155, in triple-negative breast cancers (TNBCs).
p9862
sg4
(lp9863
(dp9864
g7
I113
sg8
g47
sg10
I5
sg11
VmiR-9
p9865
sg13
I1
sa(dp9866
g7
I123
sg8
g47
sg10
I7
sg11
VmiR-155
p9867
sg13
I1
sa(dp9868
g7
I93
sg8
g47
sg10
I18
sg11
VEMT-related miRNAs
p9869
sg13
I2
sasg17
(lp9870
(dp9871
g7
I151
sg20
VC0006142
p9872
sg10
I14
sg11
Vbreast cancers
p9873
sg13
I2
sasa(dp9874
g2
VThen, based on the experimentally validated miRNA regulations to target genes, 4 candidate miRNAs (miR-24-3p, miR-192-5p, miR-139-5p and miR-155-5p) were identified to potentially contribute to ovarian cancer cell chemoresistance to CDDP through mediating OVCAR-8R cell CDDP resistance-related gene modules, which participated in functions that were closely related to "apoptosis", "cell cycle" and "adhesion".
p9875
sg4
(lp9876
(dp9877
g7
I137
sg8
g47
sg10
I10
sg11
VmiR-155-5p
p9878
sg13
I1
sa(dp9879
g7
I122
sg8
g47
sg10
I10
sg11
VmiR-139-5p
p9880
sg13
I1
sa(dp9881
g7
I99
sg8
g47
sg10
I9
sg11
VmiR-24-3p
p9882
sg13
I1
sa(dp9883
g7
I110
sg8
g47
sg10
I10
sg11
VmiR-192-5p
p9884
sg13
I1
sasg17
(lp9885
(dp9886
g7
I400
sg20
VC0001511
p9887
sg10
I8
sg11
Vadhesion
p9888
sg13
I1
sa(dp9889
g7
I194
sg20
VC1140680
p9890
sg10
I14
sg11
Vovarian cancer
p9891
sg13
I2
sasa(dp9892
g2
VThe renal involvement may present with symptoms arising from interstitial nephritis, mainly distal renal tubular acidosis.
p9893
sg4
(lp9894
sg17
(lp9895
(dp9896
g7
I92
sg20
VC1704380
p9897
sg10
I29
sg11
Vdistal renal tubular acidosis
p9898
sg13
I4
sa(dp9899
g7
I61
sg20
VC0027707
p9900
sg10
I22
sg11
Vinterstitial nephritis
p9901
sg13
I2
sasa(dp9902
g2
VIn a 29-year-old female patient, with bilateral nephrolithiasis, the diagnosis of primary Sjoegren's syndrome, tubulo-interstitial nephritis, distal renal tubular acidosis, and hypokalemia were established.
p9903
sg4
(lp9904
sg17
(lp9905
(dp9906
g7
I90
sg20
VC1527336
p9907
sg10
I19
sg11
VSjoegren's syndrome
p9908
sg13
I2
sa(dp9909
g7
I48
sg20
VC0392525
p9910
sg10
I15
sg11
Vnephrolithiasis
p9911
sg13
I1
sa(dp9912
g7
I111
sg20
VC0041349
p9913
sg10
I29
sg11
Vtubulo-interstitial nephritis
p9914
sg13
I2
sa(dp9915
g7
I142
sg20
VC1704380
p9916
sg10
I29
sg11
Vdistal renal tubular acidosis
p9917
sg13
I4
sasa(dp9918
g2
VTubulo-interstitial nephritis constitutes the most frequent renal lesion and distal tubular acidosis (Type 1) is the most important clinical manifestation of this tubular dysfunction, although the occurrence of chronic renal insufficiency is not an uncommon finding in the presence of distal renal tubular acidosis.
p9919
sg4
(lp9920
sg17
(lp9921
(dp9922
g7
I211
sg20
VC0022661
p9923
sg10
I27
sg11
Vchronic renal insufficiency
p9924
sg13
I3
sa(dp9925
g7
I0
sg20
VC0041349
p9926
sg10
I29
sg11
VTubulo-interstitial nephritis
p9927
sg13
I2
sa(dp9928
g7
I92
sg20
VC0001122
p9929
sg10
I8
sg11
Vacidosis
p9930
sg13
I1
sa(dp9931
g7
I285
sg20
VC1704380
p9932
sg10
I29
sg11
Vdistal renal tubular acidosis
p9933
sg13
I4
sasa(dp9934
g2
VRight atrial thrombosis is classified as two type: A (mobile, thin) and B (non mobile and attached to atrial wall) that they are probably of cardiac origin due to local pathology, indwelling catheter, atrial fibrillation, stasis, rheumatological or hematological disease like protein C or S deficiency.
p9935
sg4
(lp9936
(dp9937
g7
I276
sg8
VP02810
p9938
sg10
I9
sg11
Vprotein C
p9939
sg13
I2
sasg17
(lp9940
(dp9941
g7
I169
sg20
VC0677042
p9942
sg10
I9
sg11
Vpathology
p9943
sg13
I1
sa(dp9944
g7
I222
sg20
VC0333138
p9945
sg10
I6
sg11
Vstasis
p9946
sg13
I1
sa(dp9947
g7
I6
sg20
VC0340517
p9948
sg10
I17
sg11
Vatrial thrombosis
p9949
sg13
I2
sa(dp9950
g7
I201
sg20
VC0004238
p9951
sg10
I19
sg11
Vatrial fibrillation
p9952
sg13
I2
sa(dp9953
g7
I249
sg20
VC0018939
p9954
sg10
I21
sg11
Vhematological disease
p9955
sg13
I2
sasa(dp9956
g2
VVenous stasis (e.g., immobilization, congestive heart failure, acute myocardial infarction, obesity), hypercoagulability (e.g., malignancy, inflammatory bowel disease, hyperhomocysteinemia, protein C resistance, antithrombin III, protein C or S deficiency) and endothelial trauma (e.g., surgical trauma, venous trauma, in-dwelling venous instrumentation) are risk factors.
p9957
sg4
(lp9958
(dp9959
g7
I212
sg8
VP05546
p9960
sg10
I16
sg11
Vantithrombin III
p9961
sg13
I2
sa(dp9962
g7
I190
sg8
VP02810
p9963
sg10
I9
sg11
Vprotein C
p9964
sg13
I2
sasg17
(lp9965
(dp9966
g7
I0
sg20
VC0277919
p9967
sg10
I13
sg11
VVenous stasis
p9968
sg13
I2
sa(dp9969
g7
I140
sg20
VC0021390
p9970
sg10
I26
sg11
Vinflammatory bowel disease
p9971
sg13
I3
sa(dp9972
g7
I168
sg20
VC0598608
p9973
sg10
I20
sg11
Vhyperhomocysteinemia
p9974
sg13
I1
sa(dp9975
g7
I37
sg20
VC0018802
p9976
sg10
I24
sg11
Vcongestive heart failure
p9977
sg13
I3
sa(dp9978
g7
I92
sg20
VC0028754
p9979
sg10
I7
sg11
Vobesity
p9980
sg13
I1
sa(dp9981
g7
I63
sg20
VC0155626
p9982
sg10
I27
sg11
Vacute myocardial infarction
p9983
sg13
I3
sa(dp9984
g7
I128
sg20
VC0006826
p9985
sg10
I10
sg11
Vmalignancy
p9986
sg13
I1
sa(dp9987
g7
I102
sg20
VC0398623
p9988
sg10
I18
sg11
Vhypercoagulability
p9989
sg13
I1
sasa(dp9990
g2
VTo evaluate the use of selective vs. non-selective cyclo-oxygenase inhibitors (COXIs) for the treatment of chronic non-infectious, non-necrotizing scleritis and episcleritis.
p9991
sg4
(lp9992
(dp9993
g7
I51
sg8
VP23219
p9994
sg10
I15
sg11
Vcyclo-oxygenase
p9995
sg13
I1
sasg17
(lp9996
(dp9997
g7
I147
sg20
VC1971635
p9998
sg10
I26
sg11
Vscleritis and episcleritis
p9999
sg13
I3
sa(dp10000
g7
I119
sg20
VC0009450
p10001
sg10
I10
sg11
Vinfectious
p10002
sg13
I1
sasa(dp10003
g2
VSixty-nine patients with scleritis and episcleritis treated for &gt;=2 months with COXIs were included.
p10004
sg4
(lp10005
sg17
(lp10006
(dp10007
g7
I25
sg20
VC1971635
p10008
sg10
I26
sg11
Vscleritis and episcleritis
p10009
sg13
I3
sasa(dp10010
g2
VInitial inflammation control was achieved in 78-81% of scleritis patients and 73-80% episcleritis patients on COXIs (p &gt; .05).
p10011
sg4
(lp10012
sg17
(lp10013
(dp10014
g7
I8
sg20
VC0021368
p10015
sg10
I12
sg11
Vinflammation
p10016
sg13
I1
sa(dp10017
g7
I85
sg20
VC0014583
p10018
sg10
I12
sg11
Vepiscleritis
p10019
sg13
I1
sa(dp10020
g7
I55
sg20
VC0036416
p10021
sg10
I9
sg11
Vscleritis
p10022
sg13
I1
sasa(dp10023
g2
VSelective vs. non-selective COXIs were equally efficacious for the treatment of chronic non-infectious, non-necrotizing scleritis and episcleritis.
p10024
sg4
(lp10025
sg17
(lp10026
(dp10027
g7
I92
sg20
VC0009450
p10028
sg10
I10
sg11
Vinfectious
p10029
sg13
I1
sa(dp10030
g7
I120
sg20
VC1971635
p10031
sg10
I26
sg11
Vscleritis and episcleritis
p10032
sg13
I3
sasa(dp10033
g2
VHere we show that KIAA0793, containing substantial sequence homology with the catalytic Dbl homology domain of the faciogenital dysplasia gene product (FGD1), is a specific GEF for Cdc42.
p10034
sg4
(lp10035
(dp10036
g7
I181
sg8
VP60953
p10037
sg10
I5
sg11
VCdc42
p10038
sg13
I1
sa(dp10039
g7
I152
sg8
VP98174
p10040
sg10
I4
sg11
VFGD1
p10041
sg13
I1
sa(dp10042
g7
I173
sg8
VP10911
p10043
sg10
I3
sg11
VGEF
p10044
sg13
I1
sa(dp10045
g7
I78
sg8
g47
sg10
I29
sg11
Vcatalytic Dbl homology domain
p10046
sg13
I4
sasg17
(lp10047
(dp10048
g7
I152
sg20
VC1859974
p10049
sg10
I4
sg11
VFGD1
p10050
sg13
I1
sa(dp10051
g7
I115
sg20
VC0175701
p10052
sg10
I22
sg11
Vfaciogenital dysplasia
p10053
sg13
I2
sasa(dp10054
g2
VThe faciogenital dysplasia gene product, FGD1, is a Dbl family member that has recently been shown to function as a CDC42-specific GEF.
p10055
sg4
(lp10056
(dp10057
g7
I52
sg8
VP10911
p10058
sg10
I17
sg11
VDbl family member
p10059
sg13
I3
sa(dp10060
g7
I41
sg8
VP98174
p10061
sg10
I4
sg11
VFGD1
p10062
sg13
I1
sa(dp10063
g7
I116
sg8
VP60953
p10064
sg10
I18
sg11
VCDC42-specific GEF
p10065
sg13
I2
sasg17
(lp10066
(dp10067
g7
I41
sg20
VC1859974
p10068
sg10
I4
sg11
VFGD1
p10069
sg13
I1
sa(dp10070
g7
I4
sg20
VC0175701
p10071
sg10
I22
sg11
Vfaciogenital dysplasia
p10072
sg13
I2
sasa(dp10073
g2
VThe majority of proteins that contain a DH (Dbl homology) domain were isolated as oncogenes in transfection assays, but two members of the DH family, FGD1 (the product of the faciogenital dysplasia or Aarskog-Scott syndrome locus) and Vav, have been shown to be essential for normal embryonic development.
p10074
sg4
(lp10075
(dp10076
g7
I44
sg8
VP10911
p10077
sg10
I3
sg11
VDbl
p10078
sg13
I1
sa(dp10079
g7
I235
sg8
VP15498
p10080
sg10
I3
sg11
VVav
p10081
sg13
I1
sa(dp10082
g7
I150
sg8
VP98174
p10083
sg10
I4
sg11
VFGD1
p10084
sg13
I1
sasg17
(lp10085
(dp10086
g7
I201
sg20
VC0175701
p10087
sg10
I22
sg11
VAarskog-Scott syndrome
p10088
sg13
I2
sa(dp10089
g7
I175
sg20
VC0175701
p10090
sg10
I22
sg11
Vfaciogenital dysplasia
p10091
sg13
I2
sa(dp10092
g7
I150
sg20
VC1859974
p10093
sg10
I4
sg11
VFGD1
p10094
sg13
I1
sasa(dp10095
g2
VHere we have examined the role of a Dbl-like molecule, the faciogenital dysplasia gene product (FGD1), which when mutated in its Dbl homology domain, cosegregates with the developmental disease Aarskog-Scott syndrome.
p10096
sg4
(lp10097
(dp10098
g7
I129
sg8
VP10911
p10099
sg10
I19
sg11
VDbl homology domain
p10100
sg13
I3
sa(dp10101
g7
I36
sg8
VP10911
p10102
sg10
I17
sg11
VDbl-like molecule
p10103
sg13
I2
sa(dp10104
g7
I96
sg8
VP98174
p10105
sg10
I4
sg11
VFGD1
p10106
sg13
I1
sasg17
(lp10107
(dp10108
g7
I59
sg20
VC0175701
p10109
sg10
I22
sg11
Vfaciogenital dysplasia
p10110
sg13
I2
sa(dp10111
g7
I96
sg20
VC1859974
p10112
sg10
I4
sg11
VFGD1
p10113
sg13
I1
sa(dp10114
g7
I194
sg20
VC0175701
p10115
sg10
I22
sg11
VAarskog-Scott syndrome
p10116
sg13
I2
sasa(dp10117
g2
VNon-survivors (n=29) versus survivors (n=46) were: older (77+/-9.8 vs 68+/-14, p=0.006), had higher New York Heart Association (NYHA) class (2.7+/-0.8 vs 2.3+/-0.8, p=0.037), higher brain natriuretic peptide (1157+/-717 vs 427+/-502 pg/mL, p=0.024, n=18), more coronary artery disease (61% vs 35%, p=0.031), more frequent left ventricular ejection fraction &lt;50% (20.7% vs 4.3%, p=0.026), more functional MR (41% vs 22%, p=0.069), higher mitral E/E(') (12.7+/-4.6 vs 9.8+/-4, p=0.008), higher pulmonary artery systolic pressure (PASP; 52.6+/-18.7 vs 36.7+/-14, p &lt;0.001), more &gt;=3+ tricuspid regurgitation (28% vs 4%, p=0.005) and more right ventricular dysfunction (26% vs 6%, p=0.035).
p10118
sg4
(lp10119
sg17
(lp10120
(dp10121
g7
I261
sg20
VC1956346
p10122
sg10
I23
sg11
Vcoronary artery disease
p10123
sg13
I3
sa(dp10124
g7
I644
sg20
VC0242707
p10125
sg10
I29
sg11
Vright ventricular dysfunction
p10126
sg13
I3
sa(dp10127
g7
I590
sg20
VC0040961
p10128
sg10
I23
sg11
Vtricuspid regurgitation
p10129
sg13
I2
sasa(dp10130
g2
VThe presence of RBBB, IVCD, PASP &gt;= 40 mmHg, left atrium diameter and NYHA functional class were independent predictors of all-cause mortality in DCM patients.
p10131
sg4
(lp10132
sg17
(lp10133
(dp10134
g7
I16
sg20
VC0085615
p10135
sg10
I4
sg11
VRBBB
p10136
sg13
I1
sa(dp10137
g7
I22
sg20
VC1882112
p10138
sg10
I4
sg11
VIVCD
p10139
sg13
I1
sasa(dp10140
g2
VThe goals of therapy, which should be highlighted in follow-up imaging, include not only reduction of PASP, decrease in pulmonary vascular resistance, and improvements in right ventricular function, cardiac output, and tricuspid regurgitation.
p10141
sg4
(lp10142
sg17
(lp10143
(dp10144
g7
I219
sg20
VC0040961
p10145
sg10
I23
sg11
Vtricuspid regurgitation
p10146
sg13
I2
sasa(dp10147
g2
VThe objective of this study was to determine the prognostic significance of CD163(+) cells, interleukin-10 (IL-10), and interferon-gamma (IFN-Gamma) in oral lesions associated with oral squamous cell carcinoma (OSCC).
p10148
sg4
(lp10149
(dp10150
g7
I92
sg8
VP22301
p10151
sg10
I14
sg11
Vinterleukin-10
p10152
sg13
I1
sa(dp10153
g7
I120
sg8
VP01579
p10154
sg10
I16
sg11
Vinterferon-gamma
p10155
sg13
I1
sa(dp10156
g7
I76
sg8
g47
sg10
I5
sg11
VCD163
p10157
sg13
I1
sa(dp10158
g7
I138
sg8
VP01579
p10159
sg10
I9
sg11
VIFN-Gamma
p10160
sg13
I1
sa(dp10161
g7
I108
sg8
VP22301
p10162
sg10
I5
sg11
VIL-10
p10163
sg13
I1
sasg17
(lp10164
(dp10165
g7
I186
sg20
VC0007137
p10166
sg10
I23
sg11
Vsquamous cell carcinoma
p10167
sg13
I3
sasa(dp10168
g2
Vbeta-defensin expression was quantitatively assessed using real-time polymerase chain reactions in OSCC and control cell lines after exposure to interleukin-1beta, tumor necrosis factor-alpha, and interferon-gamma.
p10169
sg4
(lp10170
(dp10171
g7
I0
sg8
VP59861
p10172
sg10
I13
sg11
Vbeta-defensin
p10173
sg13
I1
sa(dp10174
g7
I145
sg8
VP01584
p10175
sg10
I17
sg11
Vinterleukin-1beta
p10176
sg13
I1
sa(dp10177
g7
I164
sg8
VP01375
p10178
sg10
I27
sg11
Vtumor necrosis factor-alpha
p10179
sg13
I3
sa(dp10180
g7
I197
sg8
VP01579
p10181
sg10
I16
sg11
Vinterferon-gamma
p10182
sg13
I1
sasg17
(lp10183
(dp10184
g7
I164
sg20
VC0333516
p10185
sg10
I14
sg11
Vtumor necrosis
p10186
sg13
I2
sasa(dp10187
g2
VWe investigated the utility of J chain and MEF2B in the diagnosis of CHL, NLPHL, PMBL, T-cell/histiocyte-rich large B-cell lymphoma (TCRLBL), and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and CHL (BCLU, DLBCL/CHL) compared to OCT-2 and BOB.1.
p10188
sg4
(lp10189
(dp10190
g7
I292
sg8
VP49685
p10191
sg10
I5
sg11
VBOB.1
p10192
sg13
I1
sa(dp10193
g7
I282
sg8
VP09086
p10194
sg10
I5
sg11
VOCT-2
p10195
sg13
I1
sasg17
(lp10196
(dp10197
g7
I87
sg20
VC1321547
p10198
sg10
I44
sg11
VT-cell/histiocyte-rich large B-cell lymphoma
p10199
sg13
I4
sa(dp10200
g7
I74
sg20
VC1334968
p10201
sg10
I5
sg11
VNLPHL
p10202
sg13
I1
sa(dp10203
g7
I116
sg20
VC0079731
p10204
sg10
I15
sg11
VB-cell lymphoma
p10205
sg13
I2
sa(dp10206
g7
I133
sg20
VC1321547
p10207
sg10
I6
sg11
VTCRLBL
p10208
sg13
I1
sa(dp10209
g7
I214
sg20
VC0079744
p10210
sg10
I29
sg11
Vdiffuse large B-cell lymphoma
p10211
sg13
I4
sasa(dp10212
g2
VJ chain and MEF2B are highly sensitive and specific markers of NLPHL versus CHL, are particularly useful in highlighting LP cells, and, with rare exception, are of greater utility than OCT-2 and BOB.1 in differentiating CHL from NLPHL and other large B-cell lymphomas.
p10213
sg4
(lp10214
(dp10215
g7
I12
sg8
g47
sg10
I5
sg11
VMEF2B
p10216
sg13
I1
sa(dp10217
g7
I195
sg8
VP49685
p10218
sg10
I5
sg11
VBOB.1
p10219
sg13
I1
sa(dp10220
g7
I185
sg8
VP09086
p10221
sg10
I5
sg11
VOCT-2
p10222
sg13
I1
sasg17
(lp10223
(dp10224
g7
I251
sg20
VC0079731
p10225
sg10
I16
sg11
VB-cell lymphomas
p10226
sg13
I2
sa(dp10227
g7
I63
sg20
VC1334968
p10228
sg10
I5
sg11
VNLPHL
p10229
sg13
I1
sa(dp10230
g7
I63
sg20
VC1334968
p10231
sg10
I5
sg11
VNLPHL
p10232
sg13
I1
sasa(dp10233
g2
VWe identified several consensus differentially expressed genes and these genes were further confirmed with literature mining; at last, two genes, that is, immunoglobulin J chain and C-X-C motif chemokine ligand 17, were screened as novel gastric cancer associated genes.
p10234
sg4
(lp10235
(dp10236
g7
I155
sg8
VP01591
p10237
sg10
I22
sg11
Vimmunoglobulin J chain
p10238
sg13
I3
sa(dp10239
g7
I182
sg8
VP55773
p10240
sg10
I31
sg11
VC-X-C motif chemokine ligand 17
p10241
sg13
I5
sasg17
(lp10242
(dp10243
g7
I238
sg20
VC0024623
p10244
sg10
I14
sg11
Vgastric cancer
p10245
sg13
I2
sasa(dp10246
g2
VA discovery/validation study on RR-MS responsive to glatiramer acetate identified 8 differentially expressed genes: ITGA2B, ITGB3, CD177, IGJ, IL5RA, MMP8, P2RY12, and S100Beta.
p10247
sg4
(lp10248
(dp10249
g7
I143
sg8
g47
sg10
I5
sg11
VIL5RA
p10250
sg13
I1
sa(dp10251
g7
I168
sg8
VP04271
p10252
sg10
I8
sg11
VS100Beta
p10253
sg13
I1
sa(dp10254
g7
I150
sg8
VP22894
p10255
sg10
I4
sg11
VMMP8
p10256
sg13
I1
sa(dp10257
g7
I138
sg8
VP01591
p10258
sg10
I3
sg11
VIGJ
p10259
sg13
I1
sa(dp10260
g7
I131
sg8
g47
sg10
I5
sg11
VCD177
p10261
sg13
I1
sa(dp10262
g7
I124
sg8
VP05106
p10263
sg10
I5
sg11
VITGB3
p10264
sg13
I1
sa(dp10265
g7
I116
sg8
VP08514
p10266
sg10
I6
sg11
VITGA2B
p10267
sg13
I1
sa(dp10268
g7
I156
sg8
g47
sg10
I6
sg11
VP2RY12
p10269
sg13
I1
sasg17
(lp10270
sa(dp10271
g2
VFor the transcriptome analysis, we found some genes related to Alzheimer's disease (LRP1), an insulin-like growth factor receptor (IGF2R), immunity genes (IGL family and IGJ), two genes related to inflammatory reaction (CXCL5 and CCL3), one gene related to maintenance of cellular morphology (NHS), one gene considered to be a strong apoptosis inductor (LGALS14), and several transcripts of the neuroblastoma breakpoint family (NBPF).
p10272
sg4
(lp10273
(dp10274
g7
I220
sg8
VP42830
p10275
sg10
I5
sg11
VCXCL5
p10276
sg13
I1
sa(dp10277
g7
I170
sg8
VP01591
p10278
sg10
I3
sg11
VIGJ
p10279
sg13
I1
sa(dp10280
g7
I230
sg8
VP10147
p10281
sg10
I4
sg11
VCCL3
p10282
sg13
I1
sa(dp10283
g7
I428
sg8
g47
sg10
I4
sg11
VNBPF
p10284
sg13
I1
sa(dp10285
g7
I395
sg8
g47
sg10
I31
sg11
Vneuroblastoma breakpoint family
p10286
sg13
I3
sa(dp10287
g7
I131
sg8
VP11717
p10288
sg10
I5
sg11
VIGF2R
p10289
sg13
I1
sa(dp10290
g7
I94
sg8
VP01308
p10291
sg10
I35
sg11
Vinsulin-like growth factor receptor
p10292
sg13
I4
sa(dp10293
g7
I84
sg8
g47
sg10
I4
sg11
VLRP1
p10294
sg13
I1
sa(dp10295
g7
I155
sg8
VP15814
p10296
sg10
I10
sg11
VIGL family
p10297
sg13
I2
sasg17
(lp10298
(dp10299
g7
I63
sg20
VC1521724
p10300
sg10
I19
sg11
VAlzheimer's disease
p10301
sg13
I2
sa(dp10302
g7
I197
sg20
VC0021368
p10303
sg10
I21
sg11
Vinflammatory reaction
p10304
sg13
I2
sa(dp10305
g7
I293
sg20
VC0796085
p10306
sg10
I3
sg11
VNHS
p10307
sg13
I1
sa(dp10308
g7
I395
sg20
VC0027819
p10309
sg10
I13
sg11
Vneuroblastoma
p10310
sg13
I1
sasa(dp10311
g2
VUsing principal components analysis, spots containing immunoglobulin J chain, apolipoprotein A-I, procollagen C-endopeptidase enhancer-1 and complement C4-A were associated with lymphoma development (P &lt; 0.0001).
p10312
sg4
(lp10313
(dp10314
g7
I54
sg8
VP01591
p10315
sg10
I22
sg11
Vimmunoglobulin J chain
p10316
sg13
I3
sa(dp10317
g7
I98
sg8
g47
sg10
I38
sg11
Vprocollagen C-endopeptidase enhancer-1
p10318
sg13
I3
sa(dp10319
g7
I141
sg8
g47
sg10
I15
sg11
Vcomplement C4-A
p10320
sg13
I2
sa(dp10321
g7
I78
sg8
VP02647
p10322
sg10
I18
sg11
Vapolipoprotein A-I
p10323
sg13
I2
sasg17
(lp10324
(dp10325
g7
I37
sg20
VC0015230
p10326
sg10
I5
sg11
Vspots
p10327
sg13
I1
sa(dp10328
g7
I178
sg20
VC0024299
p10329
sg10
I8
sg11
Vlymphoma
p10330
sg13
I1
sasa(dp10331
g2
VThe relationship between combined temperature factors showed a linear impact until reaching high temperatures limiting malaria incidence, with a lag 3.25 months.
p10332
sg4
(lp10333
sg17
(lp10334
(dp10335
g7
I119
sg20
VC0024530
p10336
sg10
I7
sg11
Vmalaria
p10337
sg13
I1
sasa(dp10338
g2
VExperimental models of malaria have shown that the regulatory molecules, cytotoxic T-lymphocyte attenuator-4 (CTLA-4), lymphocyte activation gene-3 (LAG-3), and programmed death-1 (PD-1) are involved in the functional impairment of T cells during infection.
p10339
sg4
(lp10340
(dp10341
g7
I119
sg8
VP05154
p10342
sg10
I28
sg11
Vlymphocyte activation gene-3
p10343
sg13
I3
sa(dp10344
g7
I110
sg8
VP16410
p10345
sg10
I6
sg11
VCTLA-4
p10346
sg13
I1
sa(dp10347
g7
I149
sg8
VP16949
p10348
sg10
I5
sg11
VLAG-3
p10349
sg13
I1
sa(dp10350
g7
I161
sg8
VP18621
p10351
sg10
I18
sg11
Vprogrammed death-1
p10352
sg13
I2
sa(dp10353
g7
I73
sg8
VP16410
p10354
sg10
I35
sg11
Vcytotoxic T-lymphocyte attenuator-4
p10355
sg13
I3
sa(dp10356
g7
I181
sg8
VP18621
p10357
sg10
I4
sg11
VPD-1
p10358
sg13
I1
sasg17
(lp10359
(dp10360
g7
I23
sg20
VC0024530
p10361
sg10
I7
sg11
Vmalaria
p10362
sg13
I1
sa(dp10363
g7
I218
sg20
VC0684336
p10364
sg10
I10
sg11
Vimpairment
p10365
sg13
I1
sa(dp10366
g7
I247
sg20
VC0009450
p10367
sg10
I9
sg11
Vinfection
p10368
sg13
I1
sasa(dp10369
g2
VWe evaluated the HLA-G 3' untranslated region (3'UTR) polymorphic sites (associated with mRNA stability and target for microRNA binding) and HLA-G tissue expression (heart, colon, and esophagus) in patients presenting Chagas disease, stratified according to the major clinical variants.
p10370
sg4
(lp10371
(dp10372
g7
I17
sg8
VP17693
p10373
sg10
I5
sg11
VHLA-G
p10374
sg13
I1
sasg17
(lp10375
(dp10376
g7
I218
sg20
VC0041234
p10377
sg10
I14
sg11
VChagas disease
p10378
sg13
I2
sasa(dp10379
g2
VChagas disease patients exhibited differential HLA-G 3'UTR susceptibility allele/genotype/haplotype patterns, according to the major clinical variant (digestive/cardiac/mixed/indeterminate).
p10380
sg4
(lp10381
(dp10382
g7
I47
sg8
VP17693
p10383
sg10
I26
sg11
VHLA-G 3'UTR susceptibility
p10384
sg13
I3
sasg17
(lp10385
(dp10386
g7
I0
sg20
VC0041234
p10387
sg10
I14
sg11
VChagas disease
p10388
sg13
I2
sasa(dp10389
g2
VWe studied the arthritis association and the spliceo-transcriptome of four different Ltab-Ncr3 haplotypes and showed that higher Ltb and Ncr3 expression, lower Lst1 expression, and the expression of a shorter splice variant of Lst1 correlate with reduced arthritis severity in rats.
p10390
sg4
(lp10391
(dp10392
g7
I160
sg8
g47
sg10
I4
sg11
VLst1
p10393
sg13
I1
sa(dp10394
g7
I129
sg8
g47
sg10
I3
sg11
VLtb
p10395
sg13
I1
sa(dp10396
g7
I160
sg8
g47
sg10
I4
sg11
VLst1
p10397
sg13
I1
sasg17
(lp10398
(dp10399
g7
I15
sg20
VC0003864
p10400
sg10
I9
sg11
Varthritis
p10401
sg13
I1
sa(dp10402
g7
I15
sg20
VC0003864
p10403
sg10
I9
sg11
Varthritis
p10404
sg13
I1
sasa(dp10405
g2
VThe C825T polymorphism (rs5443) of the Guanine Nucleotide-Binding protein subunit Beta3 (GNB3) gene has been associated with obesity, essential hypertension, atherosclerosis, coronary diseases, and cerebrovascular events, but with some sex-specific effects.
p10406
sg4
(lp10407
(dp10408
g7
I39
sg8
VP09471
p10409
sg10
I48
sg11
VGuanine Nucleotide-Binding protein subunit Beta3
p10410
sg13
I5
sa(dp10411
g7
I89
sg8
VP16520
p10412
sg10
I4
sg11
VGNB3
p10413
sg13
I1
sasg17
(lp10414
(dp10415
g7
I125
sg20
VC0028754
p10416
sg10
I7
sg11
Vobesity
p10417
sg13
I1
sa(dp10418
g7
I158
sg20
VC0010054
p10419
sg10
I25
sg11
Vatherosclerosis, coronary
p10420
sg13
I2
sa(dp10421
g7
I134
sg20
VC0085580
p10422
sg10
I22
sg11
Vessential hypertension
p10423
sg13
I2
sasa(dp10424
g2
VThe guanine nucleotide-binding protein beta polypeptide 3 (GNB3) 825T allele encodes a product that enhances the activation of heterotrimeric G proteins, which is associated with the occurrence of the splice variant GBeta3 s that could play a role in vascular reactivity and hyperproliferation of smooth muscle cells, that makes such proteins attractive candidate gene products for susceptibility to essential hypertension (EH).
p10425
sg4
(lp10426
(dp10427
g7
I201
sg8
VP26640
p10428
sg10
I23
sg11
Vsplice variant GBeta3 s
p10429
sg13
I4
sa(dp10430
g7
I4
sg8
VP09471
p10431
sg10
I53
sg11
Vguanine nucleotide-binding protein beta polypeptide 3
p10432
sg13
I6
sa(dp10433
g7
I127
sg8
g47
sg10
I25
sg11
Vheterotrimeric G proteins
p10434
sg13
I3
sa(dp10435
g7
I59
sg8
VP16520
p10436
sg10
I4
sg11
VGNB3
p10437
sg13
I1
sasg17
(lp10438
(dp10439
g7
I400
sg20
VC0085580
p10440
sg10
I22
sg11
Vessential hypertension
p10441
sg13
I2
sa(dp10442
g7
I424
sg20
VC0085580
p10443
sg10
I2
sg11
VEH
p10444
sg13
I1
sasa(dp10445
g2
VIn our investigation of how Ang II signals are converted by the AT1R from physiological to pathological outputs, we found that the purinergic P2Y6 receptor (P2Y6R), an inflammation-inducible G protein (heterotrimeric guanine nucleotide-binding protein)-coupled receptor (GPCR), promoted Ang II-induced hypertension in mice.
p10446
sg4
(lp10447
(dp10448
g7
I28
sg8
VP01019
p10449
sg10
I6
sg11
VAng II
p10450
sg13
I2
sa(dp10451
g7
I64
sg8
VP30556
p10452
sg10
I4
sg11
VAT1R
p10453
sg13
I1
sa(dp10454
g7
I271
sg8
g47
sg10
I4
sg11
VGPCR
p10455
sg13
I1
sa(dp10456
g7
I28
sg8
VP01019
p10457
sg10
I6
sg11
VAng II
p10458
sg13
I2
sa(dp10459
g7
I131
sg8
g47
sg10
I24
sg11
Vpurinergic P2Y6 receptor
p10460
sg13
I3
sa(dp10461
g7
I191
sg8
g47
sg10
I9
sg11
VG protein
p10462
sg13
I2
sasg17
(lp10463
(dp10464
g7
I302
sg20
VC0020538
p10465
sg10
I12
sg11
Vhypertension
p10466
sg13
I1
sa(dp10467
g7
I168
sg20
VC0021368
p10468
sg10
I12
sg11
Vinflammation
p10469
sg13
I1
sasa(dp10470
g2
VWe identified the role of regulator of G protein (heterotrimeric guanine nucleotide-binding protein) signaling 5 (RGS5) in blood pressure regulation during pregnancy and preeclampsia.
p10471
sg4
(lp10472
(dp10473
g7
I114
sg8
g47
sg10
I4
sg11
VRGS5
p10474
sg13
I1
sa(dp10475
g7
I39
sg8
g47
sg10
I9
sg11
VG protein
p10476
sg13
I2
sa(dp10477
g7
I50
sg8
VP09471
p10478
sg10
I49
sg11
Vheterotrimeric guanine nucleotide-binding protein
p10479
sg13
I4
sasg17
(lp10480
(dp10481
g7
I170
sg20
VC0032914
p10482
sg10
I12
sg11
Vpreeclampsia
p10483
sg13
I1
sasa(dp10484
g2
VHere, we investigated the expression and function of NR6A1 and its underlying mechanisms in prostate cancer (PCa) patients who underwent radical prostatectomy.
p10485
sg4
(lp10486
(dp10487
g7
I53
sg8
g47
sg10
I5
sg11
VNR6A1
p10488
sg13
I1
sasg17
(lp10489
(dp10490
g7
I92
sg20
VC0600139
p10491
sg10
I15
sg11
Vprostate cancer
p10492
sg13
I2
sa(dp10493
g7
I109
sg20
VC0268398
p10494
sg10
I3
sg11
VPCa
p10495
sg13
I1
sasa(dp10496
g2
VA total of 303 cases of prostate cancer after radical prostatectomy were analysed in a tissue microarray (TMA) for NR6A1 immunohistochemistry-based protein expression.
p10497
sg4
(lp10498
(dp10499
g7
I115
sg8
g47
sg10
I40
sg11
VNR6A1 immunohistochemistry-based protein
p10500
sg13
I3
sasg17
(lp10501
(dp10502
g7
I24
sg20
VC0600139
p10503
sg10
I15
sg11
Vprostate cancer
p10504
sg13
I2
sasa(dp10505
g2
VKnockdown of NR6A1 by small interfering RNA mediated gene silencing and overexpression of NR6A1 through lentivirus were utilized to investigate its potential role in prostate cancer cells.
p10506
sg4
(lp10507
(dp10508
g7
I13
sg8
g47
sg10
I5
sg11
VNR6A1
p10509
sg13
I1
sa(dp10510
g7
I13
sg8
g47
sg10
I5
sg11
VNR6A1
p10511
sg13
I1
sasg17
(lp10512
(dp10513
g7
I166
sg20
VC0600139
p10514
sg10
I15
sg11
Vprostate cancer
p10515
sg13
I2
sasa(dp10516
g2
VIn addition, gene silencing of NR6A1 resulted in G0/G1 phase cell cycle arrest, and decreased metastatic and invasive potential of prostate cancer cells DU145 and PC3.
p10517
sg4
(lp10518
(dp10519
g7
I31
sg8
g47
sg10
I5
sg11
VNR6A1
p10520
sg13
I1
sasg17
(lp10521
(dp10522
g7
I131
sg20
VC0600139
p10523
sg10
I15
sg11
Vprostate cancer
p10524
sg13
I2
sasa(dp10525
g2
VIn contrast, overexpression of NR6A1 reduced G0/G1 phase cell cycle arrest, and promoted metastatic and invasive potential of prostate cancer cells 22RV1.
p10526
sg4
(lp10527
(dp10528
g7
I31
sg8
g47
sg10
I5
sg11
VNR6A1
p10529
sg13
I1
sasg17
(lp10530
(dp10531
g7
I126
sg20
VC0600139
p10532
sg10
I15
sg11
Vprostate cancer
p10533
sg13
I2
sasa(dp10534
g2
VThe increasing age and number of RTR is likely to be paralleled by an increase of prostate cancer (PCa) incidence.
p10535
sg4
(lp10536
(dp10537
g7
I33
sg8
g47
sg10
I3
sg11
VRTR
p10538
sg13
I1
sasg17
(lp10539
(dp10540
g7
I82
sg20
VC0600139
p10541
sg10
I15
sg11
Vprostate cancer
p10542
sg13
I2
sa(dp10543
g7
I99
sg20
VC0268398
p10544
sg10
I3
sg11
VPCa
p10545
sg13
I1
sasa(dp10546
g2
VWe conducted a multicenter retrospective study and reviewed the charts and records of 20 RTRs who had undergone RRP for localized prostate cancer at four French renal transplant centers belonging to the Renal Transplantation Committee of the French Urological Association from April 1996 to April 2007.
p10547
sg4
(lp10548
(dp10549
g7
I112
sg8
g47
sg10
I3
sg11
VRRP
p10550
sg13
I1
sasg17
(lp10551
(dp10552
g7
I130
sg20
VC0600139
p10553
sg10
I15
sg11
Vprostate cancer
p10554
sg13
I2
sasa(dp10555
g2
VIn our study, RRP was a safe procedure to treat localized prostate cancer in RTRs.
p10556
sg4
(lp10557
sg17
(lp10558
(dp10559
g7
I58
sg20
VC0600139
p10560
sg10
I15
sg11
Vprostate cancer
p10561
sg13
I2
sasa(dp10562
g2
VIn this study, we examine the expression of RTR in murine placenta and several human placental choriocarcinoma cell lines.
p10563
sg4
(lp10564
(dp10565
g7
I44
sg8
g47
sg10
I3
sg11
VRTR
p10566
sg13
I1
sasg17
(lp10567
(dp10568
g7
I85
sg20
VC0855173
p10569
sg10
I25
sg11
Vplacental choriocarcinoma
p10570
sg13
I2
sasa(dp10571
g2
VRTR mRNA was also expressed in rat choriocarcinoma Rcho-1 cells and in the human placental choriocarcinoma cell lines BeWo, JAR, and JEG-3.
p10572
sg4
(lp10573
(dp10574
g7
I0
sg8
g47
sg10
I8
sg11
VRTR mRNA
p10575
sg13
I2
sasg17
(lp10576
(dp10577
g7
I31
sg20
VC1882624
p10578
sg10
I19
sg11
Vrat choriocarcinoma
p10579
sg13
I2
sa(dp10580
g7
I81
sg20
VC0855173
p10581
sg10
I25
sg11
Vplacental choriocarcinoma
p10582
sg13
I2
sasa(dp10583
g2
VTo evaluate the prognostic significance of PSA nadir (nPSA) and the time to nadir in disease free of recurrence (DFR) in localized carcinoma of prostate treated with radical radiotherapy (RTR).
p10584
sg4
(lp10585
(dp10586
g7
I43
sg8
VP55786
p10587
sg10
I9
sg11
VPSA nadir
p10588
sg13
I2
sasg17
(lp10589
(dp10590
g7
I101
sg20
VC1458156
p10591
sg10
I10
sg11
Vrecurrence
p10592
sg13
I1
sa(dp10593
g7
I131
sg20
VC0600139
p10594
sg10
I21
sg11
Vcarcinoma of prostate
p10595
sg13
I3
sa(dp10596
g7
I43
sg20
VC1519176
p10597
sg10
I3
sg11
VPSA
p10598
sg13
I1
sasa(dp10599
g2
VThe present study was aimed to determine the effect of steviol on PC1, CFTR, and Beta-catenin levels in renal epithelial cells with defective PC1 biogenesis and expression (Prkcsh-/- cell) and postnatal Pkd1 homozygous cell (Pkd1-/- cells).
p10600
sg4
(lp10601
(dp10602
g7
I71
sg8
VP13569
p10603
sg10
I4
sg11
VCFTR
p10604
sg13
I1
sa(dp10605
g7
I203
sg8
VP98161
p10606
sg10
I20
sg11
VPkd1 homozygous cell
p10607
sg13
I3
sa(dp10608
g7
I203
sg8
VP98161
p10609
sg10
I4
sg11
VPkd1
p10610
sg13
I1
sa(dp10611
g7
I81
sg8
VP35222
p10612
sg10
I12
sg11
VBeta-catenin
p10613
sg13
I1
sa(dp10614
g7
I66
sg8
VP98161
p10615
sg10
I3
sg11
VPC1
p10616
sg13
I1
sasg17
(lp10617
(dp10618
g7
I203
sg20
VC3149841
p10619
sg10
I4
sg11
VPkd1
p10620
sg13
I1
sa(dp10621
g7
I203
sg20
VC3149841
p10622
sg10
I4
sg11
VPkd1
p10623
sg13
I1
sa(dp10624
g7
I66
sg20
VC1706595
p10625
sg10
I3
sg11
VPC1
p10626
sg13
I1
sa(dp10627
g7
I66
sg20
VC1706595
p10628
sg10
I3
sg11
VPC1
p10629
sg13
I1
sasa(dp10630
g2
VUsing western blot analysis, it was found that steviol treatment at 100myM for 24-48h substantially enhanced and stabilized PC1 C-terminal expression, while decreasing CFTR and Beta-catenin protein expression in both Prkcsh-/- and Pkd1-/- cells.
p10631
sg4
(lp10632
(dp10633
g7
I231
sg8
VP98161
p10634
sg10
I4
sg11
VPkd1
p10635
sg13
I1
sa(dp10636
g7
I124
sg8
VP98161
p10637
sg10
I5
sg11
VPC1 C
p10638
sg13
I2
sa(dp10639
g7
I168
sg8
VP13569
p10640
sg10
I4
sg11
VCFTR
p10641
sg13
I1
sa(dp10642
g7
I177
sg8
VP35222
p10643
sg10
I20
sg11
VBeta-catenin protein
p10644
sg13
I2
sasg17
(lp10645
(dp10646
g7
I231
sg20
VC3149841
p10647
sg10
I4
sg11
VPkd1
p10648
sg13
I1
sa(dp10649
g7
I124
sg20
VC1706595
p10650
sg10
I3
sg11
VPC1
p10651
sg13
I1
sasa(dp10652
g2
VKPT-9274 can attenuate cellular proliferation and induce apoptosis associated with a decrease in active (phosphorylated) PAK4 and Beta-catenin in several Pkd1-null murine cell lines, with a less pronounced effect on the corresponding phenotypically normal cells.
p10653
sg4
(lp10654
(dp10655
g7
I130
sg8
VP35222
p10656
sg10
I12
sg11
VBeta-catenin
p10657
sg13
I1
sa(dp10658
g7
I121
sg8
g47
sg10
I4
sg11
VPAK4
p10659
sg13
I1
sa(dp10660
g7
I154
sg8
VP98161
p10661
sg10
I9
sg11
VPkd1-null
p10662
sg13
I1
sasg17
(lp10663
(dp10664
g7
I154
sg20
VC3149841
p10665
sg10
I4
sg11
VPkd1
p10666
sg13
I1
sa(dp10667
g7
I23
sg20
VC0020507
p10668
sg10
I22
sg11
Vcellular proliferation
p10669
sg13
I2
sasa(dp10670
g2
VGiven the fundamental role of Beta-catenin signaling in intestinal epithelial cell proliferation and the growth-promoting function of protein kinase D1 (PKD1) in these cells, we hypothesized that PKDs mediate cross talk with Beta-catenin signaling.
p10671
sg4
(lp10672
(dp10673
g7
I134
sg8
g47
sg10
I17
sg11
Vprotein kinase D1
p10674
sg13
I3
sa(dp10675
g7
I30
sg8
VP35222
p10676
sg10
I12
sg11
VBeta-catenin
p10677
sg13
I1
sa(dp10678
g7
I196
sg8
g47
sg10
I4
sg11
VPKDs
p10679
sg13
I1
sa(dp10680
g7
I30
sg8
VP35222
p10681
sg10
I12
sg11
VBeta-catenin
p10682
sg13
I1
sa(dp10683
g7
I153
sg8
VP98161
p10684
sg10
I4
sg11
VPKD1
p10685
sg13
I1
sasg17
(lp10686
(dp10687
g7
I134
sg20
VC3149841
p10688
sg10
I17
sg11
Vprotein kinase D1
p10689
sg13
I3
sa(dp10690
g7
I83
sg20
VC0334094
p10691
sg10
I13
sg11
Vproliferation
p10692
sg13
I1
sa(dp10693
g7
I153
sg20
VC3149841
p10694
sg10
I4
sg11
VPKD1
p10695
sg13
I1
sasa(dp10696
g2
VGPCR stimulation also induced the formation of a complex between PKD1 and Beta-catenin, as shown by coimmunoprecipitation that depended on PKD1 catalytic activation, as it was abrogated by cell treatment with PKD family inhibitors.
p10697
sg4
(lp10698
(dp10699
g7
I74
sg8
VP35222
p10700
sg10
I12
sg11
VBeta-catenin
p10701
sg13
I1
sa(dp10702
g7
I209
sg8
VP98161
p10703
sg10
I10
sg11
VPKD family
p10704
sg13
I2
sa(dp10705
g7
I0
sg8
g47
sg10
I4
sg11
VGPCR
p10706
sg13
I1
sa(dp10707
g7
I65
sg8
VP98161
p10708
sg10
I4
sg11
VPKD1
p10709
sg13
I1
sa(dp10710
g7
I65
sg8
VP98161
p10711
sg10
I4
sg11
VPKD1
p10712
sg13
I1
sasg17
(lp10713
(dp10714
g7
I65
sg20
VC1868682
p10715
sg10
I3
sg11
VPKD
p10716
sg13
I1
sa(dp10717
g7
I65
sg20
VC3149841
p10718
sg10
I4
sg11
VPKD1
p10719
sg13
I1
sa(dp10720
g7
I65
sg20
VC3149841
p10721
sg10
I4
sg11
VPKD1
p10722
sg13
I1
sasa(dp10723
g2
VUsing transgenic mice that express elevated PKD1 protein in the intestinal epithelium, we detected a marked increase in the localization of Beta-catenin in the nucleus of crypt epithelial cells in the ileum of PKD1 transgenic mice, compared with nontransgenic littermates.
p10724
sg4
(lp10725
(dp10726
g7
I44
sg8
VP98161
p10727
sg10
I4
sg11
VPKD1
p10728
sg13
I1
sa(dp10729
g7
I140
sg8
VP35222
p10730
sg10
I12
sg11
VBeta-catenin
p10731
sg13
I1
sa(dp10732
g7
I44
sg8
VP98161
p10733
sg10
I12
sg11
VPKD1 protein
p10734
sg13
I2
sasg17
(lp10735
(dp10736
g7
I44
sg20
VC3149841
p10737
sg10
I4
sg11
VPKD1
p10738
sg13
I1
sa(dp10739
g7
I44
sg20
VC3149841
p10740
sg10
I4
sg11
VPKD1
p10741
sg13
I1
sasa(dp10742
g2
VPachyonychia congenita subjects were sampled who exhibited a mutation in KRT6A, KRT6B, KRT6C, KRT16 or KRT17, and the proteins were digested and analyzed by tandem mass spectrometry.
p10743
sg4
(lp10744
(dp10745
g7
I73
sg8
VP02538
p10746
sg10
I5
sg11
VKRT6A
p10747
sg13
I1
sa(dp10748
g7
I94
sg8
VP08779
p10749
sg10
I5
sg11
VKRT16
p10750
sg13
I1
sa(dp10751
g7
I87
sg8
VP48668
p10752
sg10
I5
sg11
VKRT6C
p10753
sg13
I1
sa(dp10754
g7
I80
sg8
VP08779
p10755
sg10
I5
sg11
VKRT6B
p10756
sg13
I1
sasg17
(lp10757
(dp10758
g7
I0
sg20
VC0265334
p10759
sg10
I22
sg11
VPachyonychia congenita
p10760
sg13
I2
sasa(dp10761
g2
VWe thus performed extensive biomarker measures in these compartments using univariate and multivariate approaches to correlate disease biomarkers with SCORAD and with a combined hyperplasia score [thickness and keratin 16 (K16) mRNA] at baseline and after cyclosporine A treatment in 25 moderate to severe AD patients.
p10762
sg4
(lp10763
(dp10764
g7
I223
sg8
VP04264
p10765
sg10
I3
sg11
VK16
p10766
sg13
I1
sa(dp10767
g7
I211
sg8
VP04264
p10768
sg10
I10
sg11
Vkeratin 16
p10769
sg13
I2
sasg17
(lp10770
(dp10771
g7
I178
sg20
VC0020507
p10772
sg10
I11
sg11
Vhyperplasia
p10773
sg13
I1
sasa(dp10774
g2
VIn addition to increased abundance, KRT16 demonstrated autoantigenicity, since sera from both fracture mice and CRPS patients showed increased autoantibody binding to recombinant kRT16 protein.
p10775
sg4
(lp10776
(dp10777
g7
I167
sg8
VP08779
p10778
sg10
I25
sg11
Vrecombinant kRT16 protein
p10779
sg13
I3
sa(dp10780
g7
I36
sg8
VP08779
p10781
sg10
I5
sg11
VKRT16
p10782
sg13
I1
sasg17
(lp10783
(dp10784
g7
I112
sg20
VC0458219
p10785
sg10
I4
sg11
VCRPS
p10786
sg13
I1
sasa(dp10787
g2
VThe identification of autoantibodies against KRT16 as a biomarker in mice and in humans is a critical step towards these goals, and towards redefining CRPS as having an autoimmune etiology.
p10788
sg4
(lp10789
(dp10790
g7
I45
sg8
VP08779
p10791
sg10
I5
sg11
VKRT16
p10792
sg13
I1
sasg17
(lp10793
(dp10794
g7
I169
sg20
VC0443146
p10795
sg10
I10
sg11
Vautoimmune
p10796
sg13
I1
sa(dp10797
g7
I151
sg20
VC0458219
p10798
sg10
I4
sg11
VCRPS
p10799
sg13
I1
sasa(dp10800
g2
VThese findings were associated with upregulation of mitochondrial Bak and Bcl-2/Bcl-xL, proapoptotic and prosurvival members in the Bcl-2 family, respectively, as well as increased mitochondrial cytochrome c release, caspase activation, and apoptosis in pancreatitis in PKCEpsilon knockout mice.
p10801
sg4
(lp10802
(dp10803
g7
I181
sg8
VP99999
p10804
sg10
I34
sg11
Vmitochondrial cytochrome c release
p10805
sg13
I4
sa(dp10806
g7
I66
sg8
g47
sg10
I3
sg11
VBak
p10807
sg13
I1
sa(dp10808
g7
I80
sg8
g47
sg10
I6
sg11
VBcl-xL
p10809
sg13
I1
sa(dp10810
g7
I74
sg8
VP10415
p10811
sg10
I5
sg11
VBcl-2
p10812
sg13
I1
sa(dp10813
g7
I217
sg8
VP39880
p10814
sg10
I7
sg11
Vcaspase
p10815
sg13
I1
sa(dp10816
g7
I132
sg8
VP10415
p10817
sg10
I12
sg11
VBcl-2 family
p10818
sg13
I2
sasg17
(lp10819
(dp10820
g7
I254
sg20
VC0030305
p10821
sg10
I12
sg11
Vpancreatitis
p10822
sg13
I1
sasa(dp10823
g2
VWe then microinjected a GABAA receptor antagonist, an inhibitor of lactate transport (4CIN), or an inhibitor of lactate dehydrogenase, oxamate (OX), into the VMH prior to inducing hypoglycemia.
p10824
sg4
(lp10825
(dp10826
g7
I24
sg8
g47
sg10
I14
sg11
VGABAA receptor
p10827
sg13
I2
sa(dp10828
g7
I112
sg8
VP49366
p10829
sg10
I21
sg11
Vlactate dehydrogenase
p10830
sg13
I2
sasg17
(lp10831
(dp10832
g7
I180
sg20
VC0020615
p10833
sg10
I12
sg11
Vhypoglycemia
p10834
sg13
I1
sasa(dp10835
g2
VTo assess whether lactate contributes to raising GABA in RH and diabetes, we injected 4CIN or OX into the VMH of RH and diabetic rats before inducing hypoglycemia.
p10836
sg4
(lp10837
sg17
(lp10838
(dp10839
g7
I64
sg20
VC0011849
p10840
sg10
I8
sg11
Vdiabetes
p10841
sg13
I1
sa(dp10842
g7
I150
sg20
VC0020615
p10843
sg10
I12
sg11
Vhypoglycemia
p10844
sg13
I1
sasa(dp10845
g2
VMechanistically, we show that the protective effect of IL-22 on pancreatitis was mediated via the induction of Bcl-2 and Bcl-X(L), which bind to Beclin-1 and subsequently inhibit autophagosome formation to ameliorate pancreatitis.
p10846
sg4
(lp10847
(dp10848
g7
I111
sg8
VP10415
p10849
sg10
I5
sg11
VBcl-2
p10850
sg13
I1
sa(dp10851
g7
I55
sg8
g47
sg10
I5
sg11
VIL-22
p10852
sg13
I1
sa(dp10853
g7
I145
sg8
g47
sg10
I8
sg11
VBeclin-1
p10854
sg13
I1
sa(dp10855
g7
I121
sg8
g47
sg10
I8
sg11
VBcl-X(L)
p10856
sg13
I1
sasg17
(lp10857
(dp10858
g7
I64
sg20
VC0030305
p10859
sg10
I12
sg11
Vpancreatitis
p10860
sg13
I1
sa(dp10861
g7
I64
sg20
VC0030305
p10862
sg10
I12
sg11
Vpancreatitis
p10863
sg13
I1
sasa(dp10864
g2
VWe used genetically modified rat models to investigate the role of MYL4 in atrial cardiomyopathy.
p10865
sg4
(lp10866
(dp10867
g7
I67
sg8
VP12829
p10868
sg10
I4
sg11
VMYL4
p10869
sg13
I1
sasg17
(lp10870
(dp10871
g7
I82
sg20
VC0878544
p10872
sg10
I14
sg11
Vcardiomyopathy
p10873
sg13
I1
sasa(dp10874
g2
VExome sequencing and systematic bioinformatic analyses identified a rare missense variant of MYL4 (c.31G&gt;A [p.E11K]) in a large multiplex atrial cardiomyopathy family pedigree.
p10875
sg4
(lp10876
(dp10877
g7
I93
sg8
VP12829
p10878
sg10
I4
sg11
VMYL4
p10879
sg13
I1
sasg17
(lp10880
(dp10881
g7
I148
sg20
VC0878544
p10882
sg10
I14
sg11
Vcardiomyopathy
p10883
sg13
I1
sasa(dp10884
g2
VMYL4 knockout rats showed a similar atrial cardiomyopathy phenotype, whereas rats with an adjacent 4-amino-acid deletion showed no phenotype.
p10885
sg4
(lp10886
(dp10887
g7
I0
sg8
VP12829
p10888
sg10
I4
sg11
VMYL4
p10889
sg13
I1
sasg17
(lp10890
(dp10891
g7
I43
sg20
VC0878544
p10892
sg10
I14
sg11
Vcardiomyopathy
p10893
sg13
I1
sasa(dp10894
g2
VLoss-of-function MYL4 gene variants cause progressive atrial cardiomyopathy in humans and rats.
p10895
sg4
(lp10896
(dp10897
g7
I17
sg8
VP12829
p10898
sg10
I18
sg11
VMYL4 gene variants
p10899
sg13
I3
sasg17
(lp10900
(dp10901
g7
I61
sg20
VC0878544
p10902
sg10
I14
sg11
Vcardiomyopathy
p10903
sg13
I1
sasa(dp10904
g2
VGenome-wide association studies (GWAS) have yielded variants at &gt;30 loci that associate with atrial fibrillation (AF), including rare coding mutations in the sarcomere genes MYH6 and MYL4.
p10905
sg4
(lp10906
(dp10907
g7
I186
sg8
VP12829
p10908
sg10
I4
sg11
VMYL4
p10909
sg13
I1
sa(dp10910
g7
I177
sg8
VP13533
p10911
sg10
I4
sg11
VMYH6
p10912
sg13
I1
sasg17
(lp10913
(dp10914
g7
I96
sg20
VC0004238
p10915
sg10
I19
sg11
Vatrial fibrillation
p10916
sg13
I2
sa(dp10917
g7
I117
sg20
VC0004238
p10918
sg10
I2
sg11
VAF
p10919
sg13
I1
sasa(dp10920
g2
VWe imputed these variants into 104,220 individuals down to a minor allele frequency of 0.1% and found a recessive frameshift mutation in MYL4 that causes early-onset atrial fibrillation, several mutations in ABCB4 that increase risk of liver diseases and an intronic variant in GNAS associating with increased thyroid-stimulating hormone levels when maternally inherited.
p10921
sg4
(lp10922
(dp10923
g7
I137
sg8
VP12829
p10924
sg10
I4
sg11
VMYL4
p10925
sg13
I1
sa(dp10926
g7
I208
sg8
VP21439
p10927
sg10
I5
sg11
VABCB4
p10928
sg13
I1
sa(dp10929
g7
I310
sg8
VP01222
p10930
sg10
I27
sg11
Vthyroid-stimulating hormone
p10931
sg13
I2
sasg17
(lp10932
(dp10933
g7
I166
sg20
VC0004238
p10934
sg10
I19
sg11
Vatrial fibrillation
p10935
sg13
I2
sa(dp10936
g7
I236
sg20
VC0023895
p10937
sg10
I14
sg11
Vliver diseases
p10938
sg13
I2
sa(dp10939
g7
I114
sg20
VC0079380
p10940
sg10
I19
sg11
Vframeshift mutation
p10941
sg13
I2
sasa(dp10942
g2
VThe aim of this study is to examine the mitochondrial targeting of NDUFV2 and dissect the pathogenetic mechanism of one human deletion mutation present in patients with early-onset hypertrophic cardiomyopathy and encephalopathy.
p10943
sg4
(lp10944
(dp10945
g7
I67
sg8
VP19404
p10946
sg10
I6
sg11
VNDUFV2
p10947
sg13
I1
sasg17
(lp10948
(dp10949
g7
I181
sg20
VC0007194
p10950
sg10
I27
sg11
Vhypertrophic cardiomyopathy
p10951
sg13
I2
sa(dp10952
g7
I213
sg20
VC0085584
p10953
sg10
I14
sg11
Vencephalopathy
p10954
sg13
I1
sasa(dp10955
g2
VThe deletion mutant mimicking the human early-onset hypertrophic cardiomyopathy and encephalopathy lacked 19-40 residues in NDUFV2 and exhibited a significant reduction in its mitochondrial targeting ability.
p10956
sg4
(lp10957
(dp10958
g7
I124
sg8
VP19404
p10959
sg10
I6
sg11
VNDUFV2
p10960
sg13
I1
sasg17
(lp10961
(dp10962
g7
I13
sg20
VC0596988
p10963
sg10
I6
sg11
Vmutant
p10964
sg13
I1
sa(dp10965
g7
I52
sg20
VC0007194
p10966
sg10
I27
sg11
Vhypertrophic cardiomyopathy
p10967
sg13
I2
sa(dp10968
g7
I84
sg20
VC0085584
p10969
sg10
I14
sg11
Vencephalopathy
p10970
sg13
I1
sasa(dp10971
g2
VThe results of human disease cell model established that the impairment of mitochondrial localization of NDUFV2 as a mechanistic basis for early-onset hypertrophic cardiomyopathy and encephalopathy.
p10972
sg4
(lp10973
(dp10974
g7
I105
sg8
VP19404
p10975
sg10
I6
sg11
VNDUFV2
p10976
sg13
I1
sasg17
(lp10977
(dp10978
g7
I61
sg20
VC0684336
p10979
sg10
I10
sg11
Vimpairment
p10980
sg13
I1
sa(dp10981
g7
I183
sg20
VC0085584
p10982
sg10
I14
sg11
Vencephalopathy
p10983
sg13
I1
sa(dp10984
g7
I151
sg20
VC0007194
p10985
sg10
I27
sg11
Vhypertrophic cardiomyopathy
p10986
sg13
I2
sasa(dp10987
g2
VA small deletion in the second intron of human NDUFV2 (IVS2+5_+8delGTAA) has been shown to cause hypertrophic cardiomyopathy and encephalomyopathy [Benit, P., Beugnot, R., Chretien, D., Giurgea, I., de Lonlay-Debeney, P., Issartel, J.P., Kerscher, S., Rustin, P., Roetig, A.
p10988
sg4
(lp10989
(dp10990
g7
I41
sg8
VP19404
p10991
sg10
I31
sg11
Vhuman NDUFV2 (IVS2+5_+8delGTAA)
p10992
sg13
I3
sasg17
(lp10993
(dp10994
g7
I97
sg20
VC0007194
p10995
sg10
I27
sg11
Vhypertrophic cardiomyopathy
p10996
sg13
I2
sasa(dp10997
g2
VWhile mutations in the NDUFS3 gene thus result in Leigh syndrome, a dissimilar clinical phenotype is observed in mutations in the NDUFV2 and NDUFS2 genes, resulting in encephalomyopathy and cardiomyopathy.
p10998
sg4
(lp10999
(dp11000
g7
I141
sg8
g47
sg10
I12
sg11
VNDUFS2 genes
p11001
sg13
I2
sa(dp11002
g7
I130
sg8
VP19404
p11003
sg10
I6
sg11
VNDUFV2
p11004
sg13
I1
sa(dp11005
g7
I23
sg8
g47
sg10
I11
sg11
VNDUFS3 gene
p11006
sg13
I2
sasg17
(lp11007
(dp11008
g7
I50
sg20
VC0023264
p11009
sg10
I14
sg11
VLeigh syndrome
p11010
sg13
I2
sa(dp11011
g7
I190
sg20
VC0878544
p11012
sg10
I14
sg11
Vcardiomyopathy
p11013
sg13
I1
sasa(dp11014
g2
VCombination of denaturing high performance liquid chromatography and sequence analysis allowed us to show that a 4-bp deletion in intron 2 (IVS2+5_+8delGTAA) of the NDUFV2 gene (encoding NADH dehydrogenase ubiquinone flavoprotein 2) causes complex I deficiency and early onset hypertrophic cardiomyopathy with trunk hypotonia in three affected sibs of a consanguineous family.
p11015
sg4
(lp11016
(dp11017
g7
I187
sg8
VP49366
p11018
sg10
I44
sg11
VNADH dehydrogenase ubiquinone flavoprotein 2
p11019
sg13
I5
sa(dp11020
g7
I165
sg8
VP19404
p11021
sg10
I11
sg11
VNDUFV2 gene
p11022
sg13
I2
sasg17
(lp11023
(dp11024
g7
I316
sg20
VC0026827
p11025
sg10
I9
sg11
Vhypotonia
p11026
sg13
I1
sa(dp11027
g7
I277
sg20
VC0007194
p11028
sg10
I27
sg11
Vhypertrophic cardiomyopathy
p11029
sg13
I2
sa(dp11030
g7
I240
sg20
VC0342776
p11031
sg10
I20
sg11
Vcomplex I deficiency
p11032
sg13
I3
sasa(dp11033
g2
VWhile mutation in a number of genes encoding complex I subunits essentially result in neurological symptoms, this first mutation in NDUFV2 is strikingly associated with cardiomyopathy, as previously observed in the unique case of NDFUS2 mutations.
p11034
sg4
(lp11035
(dp11036
g7
I132
sg8
VP19404
p11037
sg10
I6
sg11
VNDUFV2
p11038
sg13
I1
sasg17
(lp11039
(dp11040
g7
I86
sg20
VC0235031
p11041
sg10
I21
sg11
Vneurological symptoms
p11042
sg13
I2
sa(dp11043
g7
I169
sg20
VC0878544
p11044
sg10
I14
sg11
Vcardiomyopathy
p11045
sg13
I1
sasa(dp11046
g2
VMice were fed a high fat diet to cause diet-induced obesity (DIO) and then administered GALP intranasally for 2 weeks (experimental), or vehicle (control).
p11047
sg4
(lp11048
sg17
(lp11049
(dp11050
g7
I52
sg20
VC0028754
p11051
sg10
I7
sg11
Vobesity
p11052
sg13
I1
sasa(dp11053
g2
VGAL and GALP concentrations may be taken as potential biomarkers to predict development of obesity.
p11054
sg4
(lp11055
(dp11056
g7
I0
sg8
VP16278
p11057
sg10
I3
sg11
VGAL
p11058
sg13
I1
sa(dp11059
g7
I8
sg8
g47
sg10
I4
sg11
VGALP
p11060
sg13
I1
sasg17
(lp11061
(dp11062
g7
I91
sg20
VC0028754
p11063
sg10
I7
sg11
Vobesity
p11064
sg13
I1
sasa(dp11065
g2
VGalanin-like peptide (GALP) has an anti-obesity effect in rats and mice.
p11066
sg4
(lp11067
(dp11068
g7
I0
sg8
g47
sg10
I20
sg11
VGalanin-like peptide
p11069
sg13
I2
sa(dp11070
g7
I22
sg8
g47
sg10
I4
sg11
VGALP
p11071
sg13
I1
sasg17
(lp11072
(dp11073
g7
I40
sg20
VC0028754
p11074
sg10
I7
sg11
Vobesity
p11075
sg13
I1
sasa(dp11076
g2
VThese results suggest that intranasal administration is an effective route whereby GALP can exert its effect as an anti-obesity drug.
p11077
sg4
(lp11078
sg17
(lp11079
(dp11080
g7
I120
sg20
VC0028754
p11081
sg10
I7
sg11
Vobesity
p11082
sg13
I1
sasa(dp11083
g2
VThese results show that GALP stimulates fatty acid Beta-oxidation in liver and lipolysis in adipose tissue, and suggest that the anti-obesity effect of GALP may be due to anorexigenic actions and improvement of lipid metabolism in peripheral tissues via the sympathetic nervous system.
p11084
sg4
(lp11085
(dp11086
g7
I24
sg8
g47
sg10
I4
sg11
VGALP
p11087
sg13
I1
sa(dp11088
g7
I24
sg8
g47
sg10
I4
sg11
VGALP
p11089
sg13
I1
sasg17
(lp11090
(dp11091
g7
I270
sg20
VC0027769
p11092
sg10
I7
sg11
Vnervous
p11093
sg13
I1
sa(dp11094
g7
I134
sg20
VC0028754
p11095
sg10
I7
sg11
Vobesity
p11096
sg13
I1
sasa(dp11097
g2
VWe conclude that GALP may be of therapeutic value for obesity and life-style-related diseases in the near future.
p11098
sg4
(lp11099
(dp11100
g7
I17
sg8
g47
sg10
I4
sg11
VGALP
p11101
sg13
I1
sasg17
(lp11102
(dp11103
g7
I54
sg20
VC0028754
p11104
sg10
I7
sg11
Vobesity
p11105
sg13
I1
sasa(dp11106
g2
VGalanin-like peptide (GALP) shows potential as a therapeutic in the treatment of obesity and related conditions.
p11107
sg4
(lp11108
(dp11109
g7
I0
sg8
g47
sg10
I20
sg11
VGalanin-like peptide
p11110
sg13
I2
sa(dp11111
g7
I22
sg8
g47
sg10
I4
sg11
VGALP
p11112
sg13
I1
sasg17
(lp11113
(dp11114
g7
I81
sg20
VC0028754
p11115
sg10
I7
sg11
Vobesity
p11116
sg13
I1
sasa(dp11117
g2
VVariations within the gene locus encoding SHP-2 have been associated with increased susceptibility to develop ulcerative colitis and gastric atrophy.
p11118
sg4
(lp11119
(dp11120
g7
I42
sg8
g47
sg10
I5
sg11
VSHP-2
p11121
sg13
I1
sasg17
(lp11122
(dp11123
g7
I133
sg20
VC0017154
p11124
sg10
I15
sg11
Vgastric atrophy
p11125
sg13
I2
sa(dp11126
g7
I110
sg20
VC0009324
p11127
sg10
I18
sg11
Vulcerative colitis
p11128
sg13
I2
sasa(dp11129
g2
VWhen we considered the host genetic effects alone, gene-gene interactions consistently decreased the risks of gastric cancer and/or atrophic gastritis, including three two-way interactions: PGC rs6912200-PTPN11 rs12229892, PGC rs4711690-IL1B rs1143623 and PTPN11 rs12229892-IL1B rs1143623 and a three-way interaction: PGC rs4711690-PGC rs6912200-PTPN11 rs12229892.
p11130
sg4
(lp11131
(dp11132
g7
I190
sg8
VP20142
p11133
sg10
I31
sg11
VPGC rs6912200-PTPN11 rs12229892
p11134
sg13
I3
sa(dp11135
g7
I223
sg8
VP20142
p11136
sg10
I28
sg11
VPGC rs4711690-IL1B rs1143623
p11137
sg13
I3
sa(dp11138
g7
I318
sg8
VP20142
p11139
sg10
I45
sg11
VPGC rs4711690-PGC rs6912200-PTPN11 rs12229892
p11140
sg13
I4
sa(dp11141
g7
I256
sg8
g47
sg10
I32
sg11
VPTPN11 rs12229892-IL1B rs1143623
p11142
sg13
I3
sasg17
(lp11143
(dp11144
g7
I132
sg20
VC0017154
p11145
sg10
I18
sg11
Vatrophic gastritis
p11146
sg13
I2
sa(dp11147
g7
I110
sg20
VC0024623
p11148
sg10
I14
sg11
Vgastric cancer
p11149
sg13
I2
sasa(dp11150
g2
VInconsistency of reported associations of the G/A polymorphism (rs2301756) in the PTPN11 gene and gastric atrophy prompted us to undertake a meta-analysis.
p11151
sg4
(lp11152
(dp11153
g7
I82
sg8
g47
sg10
I11
sg11
VPTPN11 gene
p11154
sg13
I2
sasg17
(lp11155
(dp11156
g7
I98
sg20
VC0017154
p11157
sg10
I15
sg11
Vgastric atrophy
p11158
sg13
I2
sasa(dp11159
g2
VAssociations of PTPN11 polymorphism with gastric atrophy in H. pylori (-) and (+) subjects are more readily interpreted in the homozygous and recessive models given that the dominant codominant effects skirted null associations.
p11160
sg4
(lp11161
(dp11162
g7
I16
sg8
g47
sg10
I6
sg11
VPTPN11
p11163
sg13
I1
sasg17
(lp11164
(dp11165
g7
I41
sg20
VC0017154
p11166
sg10
I15
sg11
Vgastric atrophy
p11167
sg13
I2
sasa(dp11168
g2
VEvidence of overall and subgroup decreased risks, strong in seropositive subjects, demonstrates protective effects of the PTPN11 G/A polymorphism from gastric atrophy.
p11169
sg4
(lp11170
(dp11171
g7
I122
sg8
g47
sg10
I10
sg11
VPTPN11 G/A
p11172
sg13
I2
sasg17
(lp11173
(dp11174
g7
I151
sg20
VC0017154
p11175
sg10
I15
sg11
Vgastric atrophy
p11176
sg13
I2
sasa(dp11177
g2
VThe interaction between Src homology 2 domain-containing protein tyrosine phosphatase (SHP-2) of gastric epithelial cells and cagA from H. pylori plays a crucial role in developments of gastric atrophy and gastric cancer.
p11178
sg4
(lp11179
(dp11180
g7
I24
sg8
VP12931
p11181
sg10
I61
sg11
VSrc homology 2 domain-containing protein tyrosine phosphatase
p11182
sg13
I7
sa(dp11183
g7
I126
sg8
VP05109
p11184
sg10
I4
sg11
VcagA
p11185
sg13
I1
sa(dp11186
g7
I87
sg8
g47
sg10
I5
sg11
VSHP-2
p11187
sg13
I1
sasg17
(lp11188
(dp11189
g7
I186
sg20
VC0017154
p11190
sg10
I15
sg11
Vgastric atrophy
p11191
sg13
I2
sa(dp11192
g7
I206
sg20
VC0024623
p11193
sg10
I14
sg11
Vgastric cancer
p11194
sg13
I2
sasa(dp11195
g2
VThis study aimed to investigate the association of haplotype tagging SNPs (htSNPs) in the PTPN11 gene encoding SHP-2 with gastric atrophy and gastric cancer in Chinese population.
p11196
sg4
(lp11197
(dp11198
g7
I111
sg8
g47
sg10
I5
sg11
VSHP-2
p11199
sg13
I1
sa(dp11200
g7
I90
sg8
g47
sg10
I11
sg11
VPTPN11 gene
p11201
sg13
I2
sasg17
(lp11202
(dp11203
g7
I122
sg20
VC0017154
p11204
sg10
I15
sg11
Vgastric atrophy
p11205
sg13
I2
sa(dp11206
g7
I142
sg20
VC0024623
p11207
sg10
I14
sg11
Vgastric cancer
p11208
sg13
I2
sasa(dp11209
g2
VOur study provides the first evidence that rs12423190 polymorphism of the PTPN11 gene is significantly associated with an increased risk of gastric atrophy in H. pylori infected Chinese Han population, suggesting that rs12423190 polymorphism could be used as a useful marker of genetic susceptibility to gastric atrophy among H. pylori infected subjects.
p11210
sg4
(lp11211
(dp11212
g7
I74
sg8
g47
sg10
I11
sg11
VPTPN11 gene
p11213
sg13
I2
sasg17
(lp11214
(dp11215
g7
I140
sg20
VC0017154
p11216
sg10
I15
sg11
Vgastric atrophy
p11217
sg13
I2
sa(dp11218
g7
I140
sg20
VC0017154
p11219
sg10
I15
sg11
Vgastric atrophy
p11220
sg13
I2
sasa(dp11221
g2
VThe present study indicated that overexpression of GRP78 in colon cancer cells could promote cell-matrix adhesion through the upregulation of fibronectin, integrin-Beta1 and phosphorylated FAK.
p11222
sg4
(lp11223
(dp11224
g7
I189
sg8
g47
sg10
I3
sg11
VFAK
p11225
sg13
I1
sa(dp11226
g7
I51
sg8
VP11021
p11227
sg10
I5
sg11
VGRP78
p11228
sg13
I1
sasg17
(lp11229
(dp11230
g7
I60
sg20
VC0699790
p11231
sg10
I12
sg11
Vcolon cancer
p11232
sg13
I2
sa(dp11233
g7
I105
sg20
VC0001511
p11234
sg10
I8
sg11
Vadhesion
p11235
sg13
I1
sasa(dp11236
g2
VCollectively, our results suggest that berberine-induced AMPK activation inhibits the metastatic potential of colon cancer cells by decreasing integrin Beta1 protein levels and downstream signaling.
p11237
sg4
(lp11238
(dp11239
g7
I57
sg8
VP54646
p11240
sg10
I4
sg11
VAMPK
p11241
sg13
I1
sasg17
(lp11242
(dp11243
g7
I110
sg20
VC0699790
p11244
sg10
I12
sg11
Vcolon cancer
p11245
sg13
I2
sasa(dp11246
g2
VOn multivariate analysis, the independent predictors of gene expression were hepatitis C (Mx1, OAS2, PKR and IFI16), donor age (IFI16) and recipient gender (IRF7A) (P &lt; .05 for all).
p11247
sg4
(lp11248
(dp11249
g7
I101
sg8
g47
sg10
I3
sg11
VPKR
p11250
sg13
I1
sa(dp11251
g7
I95
sg8
VP29728
p11252
sg10
I4
sg11
VOAS2
p11253
sg13
I1
sa(dp11254
g7
I90
sg8
VP20591
p11255
sg10
I3
sg11
VMx1
p11256
sg13
I1
sa(dp11257
g7
I157
sg8
g47
sg10
I5
sg11
VIRF7A
p11258
sg13
I1
sasg17
(lp11259
(dp11260
g7
I77
sg20
VC0019196
p11261
sg10
I11
sg11
Vhepatitis C
p11262
sg13
I2
sasa(dp11263
g2
VNo significant difference was observed in the expression of ERRbeta mRNA between endometrial carcinoma (23%, 0.21 +/- 0.16) and normal endometrium (22%, 0.27 +/- 0.15; P &gt; 0.05).
p11264
sg4
(lp11265
(dp11266
g7
I60
sg8
g47
sg10
I12
sg11
VERRbeta mRNA
p11267
sg13
I2
sasg17
(lp11268
(dp11269
g7
I81
sg20
VC0476089
p11270
sg10
I21
sg11
Vendometrial carcinoma
p11271
sg13
I2
sasa(dp11272
g2
VPatients undergoing major open vascular surgery (open abdominal aortic aneurysm [oAAA] repair, aortofemoral bypass, and lower extremity infrainguinal bypass [LEB]) were identified using the Michigan Surgical Quality Collaborative (MSQC) between July 2012 and June 2015.
p11273
sg4
(lp11274
sg17
(lp11275
(dp11276
g7
I54
sg20
VC0162871
p11277
sg10
I25
sg11
Vabdominal aortic aneurysm
p11278
sg13
I3
sasa(dp11279
g2
VBeta blocker utilization (&lt;1 month preoperative versus chronic) and POMI rates were prospectively collected for patients undergoing open abdominal aortic aneurysm (AAA) repair (n = 926) and lower extremity bypass (LEB; n = 2,123) from 2003 through 2008.
p11280
sg4
(lp11281
sg17
(lp11282
(dp11283
g7
I167
sg20
VC0162871
p11284
sg10
I3
sg11
VAAA
p11285
sg13
I1
sa(dp11286
g7
I140
sg20
VC0162871
p11287
sg10
I25
sg11
Vabdominal aortic aneurysm
p11288
sg13
I3
sasa(dp11289
g2
VWe studied 10,081 patients who underwent nonemergent carotid endarterectomy (CEA; n = 5293), lower extremity bypass (LEB; n = 2673), endovascular abdominal aortic aneurysm repair (EVAR; n = 1005), and open infrarenal abdominal aortic aneurysm repair (OAAA; n = 1,110) within the VSGNE from 2003 to 2008.
p11290
sg4
(lp11291
sg17
(lp11292
(dp11293
g7
I146
sg20
VC0162871
p11294
sg10
I25
sg11
Vabdominal aortic aneurysm
p11295
sg13
I3
sa(dp11296
g7
I146
sg20
VC0162871
p11297
sg10
I25
sg11
Vabdominal aortic aneurysm
p11298
sg13
I3
sasa(dp11299
g2
VWe mailed a survey to the directors of the 8 Canadian vascular surgery training programs, to ascertain the yearly operative volumes of their 3 most recent trainees with respect to 6 index operations: carotid endarterectomy (CEA), types I-IV thoracoabdominal aortic aneurysm (TAA) repair, elective open infrarenal aortic aneurysm (eAAA) repair, ruptured abdominal aortic aneurysm (rAAA) repair, endovascular abdominal aortic aneurysm repair (EVAR) and lower extremity arterial bypass (LEB).
p11300
sg4
(lp11301
sg17
(lp11302
(dp11303
g7
I380
sg20
VC0265012
p11304
sg10
I4
sg11
VrAAA
p11305
sg13
I1
sa(dp11306
g7
I344
sg20
VC0265012
p11307
sg10
I34
sg11
Vruptured abdominal aortic aneurysm
p11308
sg13
I4
sa(dp11309
g7
I248
sg20
VC0162871
p11310
sg10
I25
sg11
Vabdominal aortic aneurysm
p11311
sg13
I3
sa(dp11312
g7
I241
sg20
VC0340630
p11313
sg10
I32
sg11
Vthoracoabdominal aortic aneurysm
p11314
sg13
I3
sa(dp11315
g7
I258
sg20
VC0003486
p11316
sg10
I15
sg11
Vaortic aneurysm
p11317
sg13
I2
sa(dp11318
g7
I275
sg20
VC0162872
p11319
sg10
I3
sg11
VTAA
p11320
sg13
I1
sasa(dp11321
g2
VBetween 1999 and 2002, vascular surgery trainees in Canadian training programs were exposed to the following yearly clinical volumes (expressed as mean [and standard deviation]): CEA 55.4 (33.9), TAA 6.2 (3.8), eAAA 63.8 (30.0), rAAA 13.5 (9.4), EVAR 14.9 (9.6) and LEB 74.5 (34.5).
p11322
sg4
(lp11323
sg17
(lp11324
(dp11325
g7
I196
sg20
VC0162872
p11326
sg10
I3
sg11
VTAA
p11327
sg13
I1
sasa(dp11328
g2
VThe range of yearly clinical volumes were: CEA 21-124, TAA 1-18, eAAA 30-133, rAAA 3-45, EVAR 0-34 and LEB 20-143.
p11329
sg4
(lp11330
sg17
(lp11331
(dp11332
g7
I55
sg20
VC0162872
p11333
sg10
I3
sg11
VTAA
p11334
sg13
I1
sasa(dp11335
g2
VRisk-adjustment models have not been developed for elective abdominal aortic aneurysm repair (AAA), lower extremity bypass revascularization (LEB), or lower extremity amputation (AMP).
p11336
sg4
(lp11337
sg17
(lp11338
(dp11339
g7
I60
sg20
VC0162871
p11340
sg10
I25
sg11
Vabdominal aortic aneurysm
p11341
sg13
I3
sa(dp11342
g7
I94
sg20
VC0162871
p11343
sg10
I3
sg11
VAAA
p11344
sg13
I1
sa(dp11345
g7
I70
sg20
VC0162871
p11346
sg10
I22
sg11
Vaortic aneurysm repair
p11347
sg13
I3
sasa(dp11348
g2
VPostoperative ileus is accompanied by activation of CGRP, NGF-TrkA, and PAR-2 in DRGs.
p11349
sg4
(lp11350
(dp11351
g7
I72
sg8
VP55085
p11352
sg10
I5
sg11
VPAR-2
p11353
sg13
I1
sa(dp11354
g7
I58
sg8
VP01138
p11355
sg10
I3
sg11
VNGF
p11356
sg13
I1
sa(dp11357
g7
I52
sg8
VP80511
p11358
sg10
I4
sg11
VCGRP
p11359
sg13
I1
sa(dp11360
g7
I62
sg8
VP06753
p11361
sg10
I4
sg11
VTrkA
p11362
sg13
I1
sasg17
(lp11363
(dp11364
g7
I0
sg20
VC0400877
p11365
sg10
I19
sg11
VPostoperative ileus
p11366
sg13
I2
sasa(dp11367
g2
VThe present study by examining the mRNA and/or protein levels of TrkA and TrkB in the distal colon and in colonic primary afferent neurons in the dorsal root ganglia (DRG) during colitis demonstrated that colitis elicited location-specific changes in the mRNA and protein levels of TrkA and TrkB in colonic primary sensory pathways.
p11368
sg4
(lp11369
(dp11370
g7
I65
sg8
VP06753
p11371
sg10
I4
sg11
VTrkA
p11372
sg13
I1
sa(dp11373
g7
I74
sg8
g47
sg10
I4
sg11
VTrkB
p11374
sg13
I1
sa(dp11375
g7
I65
sg8
VP06753
p11376
sg10
I4
sg11
VTrkA
p11377
sg13
I1
sa(dp11378
g7
I74
sg8
g47
sg10
I4
sg11
VTrkB
p11379
sg13
I1
sasg17
(lp11380
(dp11381
g7
I179
sg20
VC0009319
p11382
sg10
I7
sg11
Vcolitis
p11383
sg13
I1
sa(dp11384
g7
I179
sg20
VC0009319
p11385
sg10
I7
sg11
Vcolitis
p11386
sg13
I1
sasa(dp11387
g2
VIn colitis both the TrkA and TrkB protein levels were increased in the L1 and S1 DRGs in a time-dependent manner; however, the level of TrkB mRNA but not TrkA mRNA was increased in these DRGs.
p11388
sg4
(lp11389
(dp11390
g7
I29
sg8
g47
sg10
I12
sg11
VTrkB protein
p11391
sg13
I2
sa(dp11392
g7
I154
sg8
VP06753
p11393
sg10
I9
sg11
VTrkA mRNA
p11394
sg13
I2
sa(dp11395
g7
I136
sg8
g47
sg10
I9
sg11
VTrkB mRNA
p11396
sg13
I2
sa(dp11397
g7
I20
sg8
VP06753
p11398
sg10
I4
sg11
VTrkA
p11399
sg13
I1
sa(dp11400
g7
I78
sg8
g47
sg10
I7
sg11
VS1 DRGs
p11401
sg13
I2
sasg17
(lp11402
(dp11403
g7
I3
sg20
VC0009319
p11404
sg10
I7
sg11
Vcolitis
p11405
sg13
I1
sasa(dp11406
g2
VFurther experiments showed that colitis facilitated a retrograde transport of TrkA protein toward and an anterograde transport of TrkA mRNA away from the DRG, which may contribute to the increased TrkA mRNA level in the distal colon during colitis.
p11407
sg4
(lp11408
(dp11409
g7
I130
sg8
VP06753
p11410
sg10
I9
sg11
VTrkA mRNA
p11411
sg13
I2
sa(dp11412
g7
I130
sg8
VP06753
p11413
sg10
I9
sg11
VTrkA mRNA
p11414
sg13
I2
sa(dp11415
g7
I78
sg8
VP06753
p11416
sg10
I12
sg11
VTrkA protein
p11417
sg13
I2
sasg17
(lp11418
(dp11419
g7
I32
sg20
VC0009319
p11420
sg10
I7
sg11
Vcolitis
p11421
sg13
I1
sa(dp11422
g7
I32
sg20
VC0009319
p11423
sg10
I7
sg11
Vcolitis
p11424
sg13
I1
sasa(dp11425
g2
VDouble staining showed that the expression of TrkA but not TrkB was increased in the specifically labeled colonic afferent neurons in the L1 and S1 DRGs during colitis; this increase in TrkA level was attenuated by pretreatment with resiniferatoxin.
p11426
sg4
(lp11427
(dp11428
g7
I46
sg8
VP06753
p11429
sg10
I4
sg11
VTrkA
p11430
sg13
I1
sa(dp11431
g7
I145
sg8
g47
sg10
I7
sg11
VS1 DRGs
p11432
sg13
I2
sa(dp11433
g7
I59
sg8
g47
sg10
I4
sg11
VTrkB
p11434
sg13
I1
sa(dp11435
g7
I46
sg8
VP06753
p11436
sg10
I4
sg11
VTrkA
p11437
sg13
I1
sasg17
(lp11438
(dp11439
g7
I160
sg20
VC0009319
p11440
sg10
I7
sg11
Vcolitis
p11441
sg13
I1
sasa(dp11442
g2
VThese results suggested that colitis-induced primary afferent activation involved retrograde transport of TrkA but not TrkB from the distal colon to primary afferent neurons in DRG.
p11443
sg4
(lp11444
(dp11445
g7
I106
sg8
VP06753
p11446
sg10
I4
sg11
VTrkA
p11447
sg13
I1
sa(dp11448
g7
I119
sg8
g47
sg10
I4
sg11
VTrkB
p11449
sg13
I1
sasg17
(lp11450
(dp11451
g7
I29
sg20
VC0009319
p11452
sg10
I7
sg11
Vcolitis
p11453
sg13
I1
sasa(dp11454
g2
VIn fact, receptor rearrangements or point mutations convert RET and NTRK1 in dominantly acting transforming genes leading to thyroid tumors, whereas inactivating mutations, associated with Hirschsprung's disease (HSCR) and congenital insensitivity to pain with anhidrosis (CIPA), impair RET and NTRK1 functions, respectively.
p11455
sg4
(lp11456
(dp11457
g7
I60
sg8
VP07949
p11458
sg10
I3
sg11
VRET
p11459
sg13
I1
sa(dp11460
g7
I60
sg8
VP07949
p11461
sg10
I3
sg11
VRET
p11462
sg13
I1
sa(dp11463
g7
I189
sg8
VP14138
p11464
sg10
I22
sg11
VHirschsprung's disease
p11465
sg13
I2
sa(dp11466
g7
I213
sg8
VP14138
p11467
sg10
I4
sg11
VHSCR
p11468
sg13
I1
sasg17
(lp11469
(dp11470
g7
I223
sg20
VC0020074
p11471
sg10
I48
sg11
Vcongenital insensitivity to pain with anhidrosis
p11472
sg13
I6
sa(dp11473
g7
I189
sg20
VC0019569
p11474
sg10
I22
sg11
VHirschsprung's disease
p11475
sg13
I2
sa(dp11476
g7
I125
sg20
VC0040136
p11477
sg10
I14
sg11
Vthyroid tumors
p11478
sg13
I2
sa(dp11479
g7
I213
sg20
VC2931876
p11480
sg10
I4
sg11
VHSCR
p11481
sg13
I1
sa(dp11482
g7
I273
sg20
VC0020074
p11483
sg10
I4
sg11
VCIPA
p11484
sg13
I1
sasa(dp11485
g2
VThus, our results corroborate that therapeutic strategies based on the modulation of CCR1/CCR5-mediated cell migration and/or effector function may contribute to cardiac tissue damage limitation during chronic Chagas disease.
p11486
sg4
(lp11487
(dp11488
g7
I85
sg8
VP32246
p11489
sg10
I4
sg11
VCCR1
p11490
sg13
I1
sa(dp11491
g7
I90
sg8
VP32302
p11492
sg10
I4
sg11
VCCR5
p11493
sg13
I1
sasg17
(lp11494
(dp11495
g7
I210
sg20
VC0041234
p11496
sg10
I14
sg11
VChagas disease
p11497
sg13
I2
sasa(dp11498
g2
VThe results of integrated analysis explored 3 OA-related pathways (rheumatoid arthritis, osteoclast differentiation and ECM-receptor interaction) and 4 candidate genes of OA (BST2, HDAC4, ITGB2 and VCAM1) that may be therapeutic targets.
p11499
sg4
(lp11500
(dp11501
g7
I188
sg8
VP05107
p11502
sg10
I5
sg11
VITGB2
p11503
sg13
I1
sa(dp11504
g7
I175
sg8
g47
sg10
I4
sg11
VBST2
p11505
sg13
I1
sa(dp11506
g7
I198
sg8
VP19320
p11507
sg10
I5
sg11
VVCAM1
p11508
sg13
I1
sa(dp11509
g7
I120
sg8
g47
sg10
I12
sg11
VECM-receptor
p11510
sg13
I1
sa(dp11511
g7
I181
sg8
VP56524
p11512
sg10
I5
sg11
VHDAC4
p11513
sg13
I1
sasg17
(lp11514
(dp11515
g7
I67
sg20
VC0003873
p11516
sg10
I20
sg11
Vrheumatoid arthritis
p11517
sg13
I2
sasa(dp11518
g2
VThe patient showed moderate expression of CD18 in neutrophils with a homozygous splice mutation with c.41_c.58+2dup20 of ITGB2 and experienced recurrent severe infections complicated with systemic lupus erythematosus.
p11519
sg4
(lp11520
(dp11521
g7
I101
sg8
VP05107
p11522
sg10
I25
sg11
Vc.41_c.58+2dup20 of ITGB2
p11523
sg13
I3
sa(dp11524
g7
I42
sg8
VP05107
p11525
sg10
I4
sg11
VCD18
p11526
sg13
I1
sasg17
(lp11527
(dp11528
g7
I188
sg20
VC0024141
p11529
sg10
I28
sg11
Vsystemic lupus erythematosus
p11530
sg13
I3
sa(dp11531
g7
I160
sg20
VC0021311
p11532
sg10
I10
sg11
Vinfections
p11533
sg13
I1
sasa(dp11534
g2
VShe received hematopoietic stem cell transplantation from a matched elder brother with heterozygous mutation of ITGB2, and has since remained free of infection and systemic lupus erythematosus symptoms without immunosuppression therapy.
p11535
sg4
(lp11536
(dp11537
g7
I100
sg8
VP05107
p11538
sg10
I17
sg11
Vmutation of ITGB2
p11539
sg13
I3
sasg17
(lp11540
(dp11541
g7
I150
sg20
VC0009450
p11542
sg10
I9
sg11
Vinfection
p11543
sg13
I1
sa(dp11544
g7
I164
sg20
VC0024141
p11545
sg10
I28
sg11
Vsystemic lupus erythematosus
p11546
sg13
I3
sasa(dp11547
g2
VUsing mice deficient in all beta2 integrins (CD18 null mice), we demonstrate that expression of these heterodimeric adhesion molecules is critical for arthritis induction in the K/B x N serum transfer model.
p11548
sg4
(lp11549
(dp11550
g7
I45
sg8
VP05107
p11551
sg10
I9
sg11
VCD18 null
p11552
sg13
I2
sa(dp11553
g7
I102
sg8
VP01185
p11554
sg10
I32
sg11
Vheterodimeric adhesion molecules
p11555
sg13
I3
sasg17
(lp11556
(dp11557
g7
I151
sg20
VC0003864
p11558
sg10
I9
sg11
Varthritis
p11559
sg13
I1
sa(dp11560
g7
I116
sg20
VC0001511
p11561
sg10
I8
sg11
Vadhesion
p11562
sg13
I1
sasa(dp11563
g2
VUsing null-allele mice and blocking mAbs, we demonstrate specifically that CD11a/CD18 (LFA-1) is absolutely required for the development of arthritis in this model.
p11564
sg4
(lp11565
(dp11566
g7
I87
sg8
VP20701
p11567
sg10
I5
sg11
VLFA-1
p11568
sg13
I1
sa(dp11569
g7
I81
sg8
VP05107
p11570
sg10
I4
sg11
VCD18
p11571
sg13
I1
sa(dp11572
g7
I75
sg8
VP20701
p11573
sg10
I5
sg11
VCD11a
p11574
sg13
I1
sasg17
(lp11575
(dp11576
g7
I27
sg20
VC0233660
p11577
sg10
I8
sg11
Vblocking
p11578
sg13
I1
sa(dp11579
g7
I140
sg20
VC0003864
p11580
sg10
I9
sg11
Varthritis
p11581
sg13
I1
sasa(dp11582
g2
VThus, key proteins in Alzheimer Disease and Amyotrophic lateral sclerosis (ALS), including amyloid-Beta precursor protein, Tau and superoxide dismutase 1 (SOD1), spread to adjacent cells in their misfolded aggregated forms and exhibit template-directed misfolding to induce further misfolding, disruptions to proteostasis and toxicity.
p11583
sg4
(lp11584
(dp11585
g7
I155
sg8
VP00441
p11586
sg10
I4
sg11
VSOD1
p11587
sg13
I1
sa(dp11588
g7
I91
sg8
VP17342
p11589
sg10
I30
sg11
Vamyloid-Beta precursor protein
p11590
sg13
I3
sa(dp11591
g7
I131
sg8
VP00441
p11592
sg10
I22
sg11
Vsuperoxide dismutase 1
p11593
sg13
I3
sa(dp11594
g7
I123
sg8
VP49768
p11595
sg10
I3
sg11
VTau
p11596
sg13
I1
sasg17
(lp11597
(dp11598
g7
I44
sg20
VC0002736
p11599
sg10
I29
sg11
VAmyotrophic lateral sclerosis
p11600
sg13
I3
sa(dp11601
g7
I75
sg20
VC0002736
p11602
sg10
I3
sg11
VALS
p11603
sg13
I1
sa(dp11604
g7
I22
sg20
VC0002395
p11605
sg10
I17
sg11
VAlzheimer Disease
p11606
sg13
I2
sa(dp11607
g7
I91
sg20
VC0011560
p11608
sg10
I7
sg11
Vamyloid
p11609
sg13
I1
sasa(dp11610
g2
VThe method is useful for identifying the defective APP-mRNA isoform in LND patients, and in neurodevelopmental and neurodegenerative disorders in which the APP gene is involved in the pathogenesis of diseases such as autism, fragile X syndrome, amyotrophic lateral sclerosis, and Alzheimer's disease, and may pave the way for new strategies applicable to rational antisense drugs design.
p11611
sg4
(lp11612
(dp11613
g7
I156
sg8
g47
sg10
I8
sg11
VAPP gene
p11614
sg13
I2
sa(dp11615
g7
I51
sg8
g47
sg10
I8
sg11
VAPP-mRNA
p11616
sg13
I1
sasg17
(lp11617
(dp11618
g7
I245
sg20
VC0002736
p11619
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p11620
sg13
I3
sa(dp11621
g7
I184
sg20
VC0699748
p11622
sg10
I12
sg11
Vpathogenesis
p11623
sg13
I1
sa(dp11624
g7
I225
sg20
VC0016667
p11625
sg10
I18
sg11
Vfragile X syndrome
p11626
sg13
I3
sa(dp11627
g7
I280
sg20
VC1521724
p11628
sg10
I19
sg11
VAlzheimer's disease
p11629
sg13
I2
sa(dp11630
g7
I217
sg20
VC0004352
p11631
sg10
I6
sg11
Vautism
p11632
sg13
I1
sa(dp11633
g7
I115
sg20
VC0524851
p11634
sg10
I27
sg11
Vneurodegenerative disorders
p11635
sg13
I2
sasa(dp11636
g2
VSeveral findings suggest that the amyloid precursor protein (APP) and the amyloid cascade may play a role in motor neuron disease (MND).
p11637
sg4
(lp11638
(dp11639
g7
I34
sg8
VP17342
p11640
sg10
I25
sg11
Vamyloid precursor protein
p11641
sg13
I3
sa(dp11642
g7
I61
sg8
g47
sg10
I3
sg11
VAPP
p11643
sg13
I1
sasg17
(lp11644
(dp11645
g7
I131
sg20
VC0085084
p11646
sg10
I3
sg11
VMND
p11647
sg13
I1
sa(dp11648
g7
I34
sg20
VC0011560
p11649
sg10
I7
sg11
Vamyloid
p11650
sg13
I1
sa(dp11651
g7
I109
sg20
VC0085084
p11652
sg10
I20
sg11
Vmotor neuron disease
p11653
sg13
I3
sa(dp11654
g7
I34
sg20
VC0011560
p11655
sg10
I7
sg11
Vamyloid
p11656
sg13
I1
sasa(dp11657
g2
VConsidering that dementia is one of the most frequent non-motor symptoms in amyotrophic lateral sclerosis (ALS) and that hippocampus is one of the brain areas with greater presence of amyloid-related changes in neurodegenerative diseases, our aim was to analyze the molecular markers of the amyloid cascade of APP in pathology studies of the hippocampus of autopsied patients with ALS and ALS-frontotemporal dementia (FTD).
p11658
sg4
(lp11659
sg17
(lp11660
(dp11661
g7
I76
sg20
VC0002736
p11662
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p11663
sg13
I3
sa(dp11664
g7
I184
sg20
VC0011560
p11665
sg10
I7
sg11
Vamyloid
p11666
sg13
I1
sa(dp11667
g7
I17
sg20
VC0497327
p11668
sg10
I8
sg11
Vdementia
p11669
sg13
I1
sa(dp11670
g7
I107
sg20
VC0002736
p11671
sg10
I3
sg11
VALS
p11672
sg13
I1
sa(dp11673
g7
I58
sg20
VC0426980
p11674
sg10
I14
sg11
Vmotor symptoms
p11675
sg13
I2
sa(dp11676
g7
I389
sg20
VC0338451
p11677
sg10
I27
sg11
VALS-frontotemporal dementia
p11678
sg13
I2
sa(dp11679
g7
I418
sg20
VC0338451
p11680
sg10
I3
sg11
VFTD
p11681
sg13
I1
sa(dp11682
g7
I184
sg20
VC0011560
p11683
sg10
I7
sg11
Vamyloid
p11684
sg13
I1
sa(dp11685
g7
I317
sg20
VC0677042
p11686
sg10
I9
sg11
Vpathology
p11687
sg13
I1
sa(dp11688
g7
I211
sg20
VC0524851
p11689
sg10
I26
sg11
Vneurodegenerative diseases
p11690
sg13
I2
sa(dp11691
g7
I107
sg20
VC0002736
p11692
sg10
I3
sg11
VALS
p11693
sg13
I1
sasa(dp11694
g2
VImmunohistochemical studies and confocal microscopy were used to analyze the expression of APP, TDP-43, pho-TDP-43, ABeta, APP intracellular cytoplasmatic domain (AICD) peptide, Fe65 protein, and pho-TAU in the hippocampus of seven patients with ALS, two patients with ALS-FTD, and four controls.
p11695
sg4
(lp11696
(dp11697
g7
I104
sg8
g47
sg10
I10
sg11
Vpho-TDP-43
p11698
sg13
I1
sa(dp11699
g7
I196
sg8
VP49768
p11700
sg10
I7
sg11
Vpho-TAU
p11701
sg13
I1
sa(dp11702
g7
I91
sg8
g47
sg10
I3
sg11
VAPP
p11703
sg13
I1
sa(dp11704
g7
I141
sg8
g47
sg10
I35
sg11
Vcytoplasmatic domain (AICD) peptide
p11705
sg13
I4
sa(dp11706
g7
I91
sg8
g47
sg10
I3
sg11
VAPP
p11707
sg13
I1
sa(dp11708
g7
I178
sg8
g47
sg10
I12
sg11
VFe65 protein
p11709
sg13
I2
sa(dp11710
g7
I96
sg8
g47
sg10
I6
sg11
VTDP-43
p11711
sg13
I1
sa(dp11712
g7
I116
sg8
g47
sg10
I5
sg11
VABeta
p11713
sg13
I1
sasg17
(lp11714
(dp11715
g7
I273
sg20
VC0338451
p11716
sg10
I3
sg11
VFTD
p11717
sg13
I1
sa(dp11718
g7
I246
sg20
VC0002736
p11719
sg10
I3
sg11
VALS
p11720
sg13
I1
sa(dp11721
g7
I246
sg20
VC0002736
p11722
sg10
I3
sg11
VALS
p11723
sg13
I1
sasa(dp11724
g2
VThese results suggest that Sidt2(-/-) mice had spontaneous nonalcoholic fatty liver disease (NAFLD) accompanied by ERS.
p11725
sg4
(lp11726
sg17
(lp11727
(dp11728
g7
I115
sg20
VC0403549
p11729
sg10
I3
sg11
VERS
p11730
sg13
I1
sa(dp11731
g7
I59
sg20
VC0400966
p11732
sg10
I32
sg11
Vnonalcoholic fatty liver disease
p11733
sg13
I4
sa(dp11734
g7
I93
sg20
VC0400966
p11735
sg10
I5
sg11
VNAFLD
p11736
sg13
I1
sasa(dp11737
g2
VIntraperitoneal and oral glucose tolerance tests in Sidt2 knockout mice indicated glucose intolerance and decreased serum insulin level.
p11738
sg4
(lp11739
(dp11740
g7
I116
sg8
VP01308
p11741
sg10
I13
sg11
Vserum insulin
p11742
sg13
I2
sasg17
(lp11743
(dp11744
g7
I33
sg20
VC0020963
p11745
sg10
I9
sg11
Vtolerance
p11746
sg13
I1
sa(dp11747
g7
I82
sg20
VC0271650
p11748
sg10
I19
sg11
Vglucose intolerance
p11749
sg13
I2
sasa(dp11750
g2
VFor example, CDH15 and PCDH19 are associated with cognitive impairment; CDH5, CDH8, CDH9, CDH10, CDH13, CDH15, PCDH10, PCDH19 and PCDHb4 with autism; CDH7, CDH12, CDH18, PCDH12 and FAT with bipolar disease and schizophrenia; and CDH11, CDH12 and CDH13 with methamphetamine and alcohol dependency.
p11751
sg4
(lp11752
(dp11753
g7
I13
sg8
VP55291
p11754
sg10
I5
sg11
VCDH15
p11755
sg13
I1
sa(dp11756
g7
I90
sg8
g47
sg10
I5
sg11
VCDH10
p11757
sg13
I1
sa(dp11758
g7
I78
sg8
VP55286
p11759
sg10
I4
sg11
VCDH8
p11760
sg13
I1
sa(dp11761
g7
I130
sg8
g47
sg10
I6
sg11
VPCDHb4
p11762
sg13
I1
sa(dp11763
g7
I229
sg8
VP55287
p11764
sg10
I5
sg11
VCDH11
p11765
sg13
I1
sa(dp11766
g7
I156
sg8
VP55289
p11767
sg10
I5
sg11
VCDH12
p11768
sg13
I1
sa(dp11769
g7
I156
sg8
VP55289
p11770
sg10
I5
sg11
VCDH12
p11771
sg13
I1
sa(dp11772
g7
I163
sg8
g47
sg10
I5
sg11
VCDH18
p11773
sg13
I1
sa(dp11774
g7
I23
sg8
g47
sg10
I6
sg11
VPCDH19
p11775
sg13
I1
sa(dp11776
g7
I170
sg8
g47
sg10
I6
sg11
VPCDH12
p11777
sg13
I1
sa(dp11778
g7
I97
sg8
VP55290
p11779
sg10
I5
sg11
VCDH13
p11780
sg13
I1
sa(dp11781
g7
I23
sg8
g47
sg10
I6
sg11
VPCDH19
p11782
sg13
I1
sa(dp11783
g7
I72
sg8
VP33151
p11784
sg10
I4
sg11
VCDH5
p11785
sg13
I1
sa(dp11786
g7
I150
sg8
g47
sg10
I4
sg11
VCDH7
p11787
sg13
I1
sa(dp11788
g7
I97
sg8
VP55290
p11789
sg10
I5
sg11
VCDH13
p11790
sg13
I1
sa(dp11791
g7
I84
sg8
g47
sg10
I4
sg11
VCDH9
p11792
sg13
I1
sa(dp11793
g7
I111
sg8
g47
sg10
I6
sg11
VPCDH10
p11794
sg13
I1
sa(dp11795
g7
I13
sg8
VP55291
p11796
sg10
I5
sg11
VCDH15
p11797
sg13
I1
sasg17
(lp11798
(dp11799
g7
I142
sg20
VC0004352
p11800
sg10
I6
sg11
Vautism
p11801
sg13
I1
sa(dp11802
g7
I277
sg20
VC0001973
p11803
sg10
I18
sg11
Valcohol dependency
p11804
sg13
I2
sa(dp11805
g7
I50
sg20
VC0338656
p11806
sg10
I20
sg11
Vcognitive impairment
p11807
sg13
I2
sa(dp11808
g7
I210
sg20
VC0036341
p11809
sg10
I13
sg11
Vschizophrenia
p11810
sg13
I1
sasa(dp11811
g2
VThe UCNs emitting UV/blue and green/red multiband light were used to activate the photoresponsive Azo and photosensitizer RB molecules; The mesoporous silica shell offered the possibilities to load anticancer drug and conjugate the light triggers; As there are strong charge interaction and hydrogen bonds between Dox and surface silanols of mesoporous silica, the azobenzene molecules worked as "gatekeeper" and "molecular stirrer" to precisely trap and propel the release of Dox under the external stimuli.
p11812
sg4
(lp11813
sg17
(lp11814
sa(dp11815
g2
VUCN1 is significantly reduced in endometrial adenocarcinoma compared to healthy controls.
p11816
sg4
(lp11817
(dp11818
g7
I0
sg8
g47
sg10
I4
sg11
VUCN1
p11819
sg13
I1
sasg17
(lp11820
(dp11821
g7
I33
sg20
VC1153706
p11822
sg10
I26
sg11
Vendometrial adenocarcinoma
p11823
sg13
I2
sasa(dp11824
g2
VUCN1 suppressed migration of endometrial cancer cells in vitro.
p11825
sg4
(lp11826
sg17
(lp11827
(dp11828
g7
I29
sg20
VC0476089
p11829
sg10
I18
sg11
Vendometrial cancer
p11830
sg13
I2
sasa(dp11831
g2
VWe demonstrate that UCN1 significantly suppresses the migration of endometrial cancer cells but has no effect on their proliferation.
p11832
sg4
(lp11833
(dp11834
g7
I20
sg8
g47
sg10
I4
sg11
VUCN1
p11835
sg13
I1
sasg17
(lp11836
(dp11837
g7
I119
sg20
VC0334094
p11838
sg10
I13
sg11
Vproliferation
p11839
sg13
I1
sa(dp11840
g7
I67
sg20
VC0476089
p11841
sg10
I18
sg11
Vendometrial cancer
p11842
sg13
I2
sasa(dp11843
g2
VThus, loss of UCN1 in endometrial cancer may promote invasion and metastatic spread.
p11844
sg4
(lp11845
(dp11846
g7
I14
sg8
g47
sg10
I4
sg11
VUCN1
p11847
sg13
I1
sasg17
(lp11848
(dp11849
g7
I53
sg20
VC2699153
p11850
sg10
I8
sg11
Vinvasion
p11851
sg13
I1
sa(dp11852
g7
I22
sg20
VC0476089
p11853
sg10
I18
sg11
Vendometrial cancer
p11854
sg13
I2
sasa(dp11855
g2
VSeven pathogenic variants leading to NSHL have so far been reported on two mitochondrial genes: MT-RNR1 encoding 12SrRNA and MT-TS1 encoding tRNA for Ser((UCN)) .
p11856
sg4
(lp11857
(dp11858
g7
I96
sg8
VP43354
p11859
sg10
I24
sg11
VMT-RNR1 encoding 12SrRNA
p11860
sg13
I3
sasg17
(lp11861
sa(dp11862
g2
VThis study examines the role of FcgammaRIIB in the initiation of allergic rhinitis in mice.
p11863
sg4
(lp11864
(dp11865
g7
I32
sg8
VP31994
p11866
sg10
I11
sg11
VFcgammaRIIB
p11867
sg13
I1
sasg17
(lp11868
(dp11869
g7
I65
sg20
VC2607914
p11870
sg10
I17
sg11
Vallergic rhinitis
p11871
sg13
I2
sasa(dp11872
g2
VThese results suggest that FcgammaRIIB plays a regulatory role in the initiation of allergic rhinitis that is independent of either mouse strain or type of sensitization.
p11873
sg4
(lp11874
(dp11875
g7
I27
sg8
VP31994
p11876
sg10
I11
sg11
VFcgammaRIIB
p11877
sg13
I1
sasg17
(lp11878
(dp11879
g7
I84
sg20
VC2607914
p11880
sg10
I17
sg11
Vallergic rhinitis
p11881
sg13
I2
sasa(dp11882
g2
VThis study evaluated the interaction of radiation therapy (RT) and radiofrequency kyphoplasty (RFK) in the treatment of myeloma associated VCF.
p11883
sg4
(lp11884
sg17
(lp11885
(dp11886
g7
I120
sg20
VC0026764
p11887
sg10
I7
sg11
Vmyeloma
p11888
sg13
I1
sasa(dp11889
g2
VEighty-six myeloma patients with VCF were treated with RFK followed by radiation therapy (RFK group) or vice versa (RT group).
p11890
sg4
(lp11891
sg17
(lp11892
(dp11893
g7
I11
sg20
VC0026764
p11894
sg10
I7
sg11
Vmyeloma
p11895
sg13
I1
sasa(dp11896
g2
VRFK is an effective method for treating VCF in myeloma patients independent of treatment order with regard to radiation therapy.
p11897
sg4
(lp11898
(dp11899
g7
I0
sg8
g47
sg10
I3
sg11
VRFK
p11900
sg13
I1
sasg17
(lp11901
(dp11902
g7
I47
sg20
VC0026764
p11903
sg10
I7
sg11
Vmyeloma
p11904
sg13
I1
sasa(dp11905
g2
VWe investigated the involvement of RFK in cisplatin resistance using human prostate cancer PC3 cells.
p11906
sg4
(lp11907
(dp11908
g7
I35
sg8
g47
sg10
I3
sg11
VRFK
p11909
sg13
I1
sasg17
(lp11910
(dp11911
g7
I75
sg20
VC0600139
p11912
sg10
I15
sg11
Vprostate cancer
p11913
sg13
I2
sasa(dp11914
g2
VThe present study suggests that RFK expression is involved not only in cellular protection from oxidative stress but also in malignant progression of prostate cancer.
p11915
sg4
(lp11916
(dp11917
g7
I32
sg8
g47
sg10
I3
sg11
VRFK
p11918
sg13
I1
sasg17
(lp11919
(dp11920
g7
I135
sg20
VC1739135
p11921
sg10
I30
sg11
Vprogression of prostate cancer
p11922
sg13
I4
sa(dp11923
g7
I96
sg20
VC0242606
p11924
sg10
I16
sg11
Voxidative stress
p11925
sg13
I2
sasa(dp11926
g2
VThe anti-cancer effect of ATF-Fc (alone and in combination with trastuzumab) on tumor cells and in a nude mouse tumor model was evaluated by detecting the expression of uPA, urokinase plasminogen activator receptor (uPAR) and HER-2.
p11927
sg4
(lp11928
(dp11929
g7
I169
sg8
VP00749
p11930
sg10
I3
sg11
VuPA
p11931
sg13
I1
sa(dp11932
g7
I226
sg8
VP04626
p11933
sg10
I5
sg11
VHER-2
p11934
sg13
I1
sa(dp11935
g7
I174
sg8
VP00747
p11936
sg10
I40
sg11
Vurokinase plasminogen activator receptor
p11937
sg13
I4
sa(dp11938
g7
I216
sg8
VP00747
p11939
sg10
I4
sg11
VuPAR
p11940
sg13
I1
sa(dp11941
g7
I26
sg8
VP00749
p11942
sg10
I3
sg11
VATF
p11943
sg13
I1
sasg17
(lp11944
(dp11945
g7
I80
sg20
VC0027651
p11946
sg10
I5
sg11
Vtumor
p11947
sg13
I1
sa(dp11948
g7
I80
sg20
VC0027651
p11949
sg10
I5
sg11
Vtumor
p11950
sg13
I1
sa(dp11951
g7
I9
sg20
VC0006826
p11952
sg10
I6
sg11
Vcancer
p11953
sg13
I1
sasa(dp11954
g2
VThe ability of HMGA1 to regulate the plasminogen activator system may constitute an important mechanism by which HMGA1 promotes cancer progression.
p11955
sg4
(lp11956
(dp11957
g7
I15
sg8
VP17096
p11958
sg10
I5
sg11
VHMGA1
p11959
sg13
I1
sa(dp11960
g7
I15
sg8
VP17096
p11961
sg10
I5
sg11
VHMGA1
p11962
sg13
I1
sa(dp11963
g7
I37
sg8
VP00747
p11964
sg10
I28
sg11
Vplasminogen activator system
p11965
sg13
I3
sasg17
(lp11966
(dp11967
g7
I128
sg20
VC0178874
p11968
sg10
I18
sg11
Vcancer progression
p11969
sg13
I2
sasa(dp11970
g2
VKCNJ1 variation is associated with multiple diseases, such as antenatal Bartter syndrome and diabetes.
p11971
sg4
(lp11972
(dp11973
g7
I0
sg8
VP48048
p11974
sg10
I5
sg11
VKCNJ1
p11975
sg13
I1
sasg17
(lp11976
(dp11977
g7
I72
sg20
VC0004775
p11978
sg10
I16
sg11
VBartter syndrome
p11979
sg13
I2
sa(dp11980
g7
I93
sg20
VC0011849
p11981
sg10
I8
sg11
Vdiabetes
p11982
sg13
I1
sasa(dp11983
g2
VNeither diabetes mellitus nor Tempol altered Kir1.1, Kir2.1, Kir6.1, or SUR2B protein levels in renal cortical microvessels.
p11984
sg4
(lp11985
(dp11986
g7
I53
sg8
VP63252
p11987
sg10
I6
sg11
VKir2.1
p11988
sg13
I1
sa(dp11989
g7
I72
sg8
g47
sg10
I13
sg11
VSUR2B protein
p11990
sg13
I2
sa(dp11991
g7
I61
sg8
g47
sg10
I6
sg11
VKir6.1
p11992
sg13
I1
sa(dp11993
g7
I45
sg8
VP48048
p11994
sg10
I6
sg11
VKir1.1
p11995
sg13
I1
sasg17
(lp11996
(dp11997
g7
I8
sg20
VC0011849
p11998
sg10
I17
sg11
Vdiabetes mellitus
p11999
sg13
I2
sasa(dp12000
g2
VTo the extent that the effects of Tempol reflect its antioxidant actions, our observations indicate that oxidative stress contributes to the exaggerated impact of Kir1.1, Kir2.1, and K(ATP) channels on afferent arteriolar tone during diabetes mellitus and that this phenomenon involves posttranslational modulation of channel function.
p12001
sg4
(lp12002
(dp12003
g7
I171
sg8
VP63252
p12004
sg10
I6
sg11
VKir2.1
p12005
sg13
I1
sa(dp12006
g7
I163
sg8
VP48048
p12007
sg10
I6
sg11
VKir1.1
p12008
sg13
I1
sasg17
(lp12009
(dp12010
g7
I234
sg20
VC0011849
p12011
sg10
I17
sg11
Vdiabetes mellitus
p12012
sg13
I2
sa(dp12013
g7
I105
sg20
VC0242606
p12014
sg10
I16
sg11
Voxidative stress
p12015
sg13
I2
sasa(dp12016
g2
VFurthermore, results suggested that co-exposure exacerbated the activation of TRPV1 signal pathways, with an enhancement in substance P and calcitonin gene-related peptide production, which contributed to inflammation in asthma by neurogenic inflammation.
p12017
sg4
(lp12018
(dp12019
g7
I140
sg8
VP06881
p12020
sg10
I15
sg11
Vcalcitonin gene
p12021
sg13
I2
sa(dp12022
g7
I78
sg8
g47
sg10
I5
sg11
VTRPV1
p12023
sg13
I1
sasg17
(lp12024
(dp12025
g7
I221
sg20
VC0004096
p12026
sg10
I6
sg11
Vasthma
p12027
sg13
I1
sa(dp12028
g7
I205
sg20
VC0021368
p12029
sg10
I12
sg11
Vinflammation
p12030
sg13
I1
sa(dp12031
g7
I205
sg20
VC0021368
p12032
sg10
I12
sg11
Vinflammation
p12033
sg13
I1
sasa(dp12034
g2
VIt is concluded that co-exposure to PM2.5 and FA exacerbated allergic asthma through oxidative stress and enhanced TRPV1 activation.
p12035
sg4
(lp12036
(dp12037
g7
I115
sg8
g47
sg10
I5
sg11
VTRPV1
p12038
sg13
I1
sasg17
(lp12039
(dp12040
g7
I85
sg20
VC0242606
p12041
sg10
I16
sg11
Voxidative stress
p12042
sg13
I2
sa(dp12043
g7
I61
sg20
VC0155877
p12044
sg10
I15
sg11
Vallergic asthma
p12045
sg13
I2
sasa(dp12046
g2
VIn this review we will summarize recent evidence for an involvement of TRP channels (TRPA1, TRPC4, TRPC6, TRPV1, TRPV4, TRPM2 and TRPM8) expressed in the lung in pathways of toxin sensing and as mediators of lung inflammation and associated diseases like asthma, COPD, lung fibrosis and edema formation.
p12047
sg4
(lp12048
(dp12049
g7
I71
sg8
VP13686
p12050
sg10
I12
sg11
VTRP channels
p12051
sg13
I2
sa(dp12052
g7
I120
sg8
VP10909
p12053
sg10
I5
sg11
VTRPM2
p12054
sg13
I1
sa(dp12055
g7
I130
sg8
g47
sg10
I5
sg11
VTRPM8
p12056
sg13
I1
sa(dp12057
g7
I99
sg8
g47
sg10
I5
sg11
VTRPC6
p12058
sg13
I1
sa(dp12059
g7
I92
sg8
g47
sg10
I5
sg11
VTRPC4
p12060
sg13
I1
sa(dp12061
g7
I106
sg8
g47
sg10
I5
sg11
VTRPV1
p12062
sg13
I1
sa(dp12063
g7
I85
sg8
g47
sg10
I5
sg11
VTRPA1
p12064
sg13
I1
sasg17
(lp12065
(dp12066
g7
I208
sg20
VC0032285
p12067
sg10
I17
sg11
Vlung inflammation
p12068
sg13
I2
sa(dp12069
g7
I255
sg20
VC0004096
p12070
sg10
I6
sg11
Vasthma
p12071
sg13
I1
sa(dp12072
g7
I263
sg20
VC0024117
p12073
sg10
I4
sg11
VCOPD
p12074
sg13
I1
sa(dp12075
g7
I287
sg20
VC0013604
p12076
sg10
I5
sg11
Vedema
p12077
sg13
I1
sa(dp12078
g7
I269
sg20
VC0034069
p12079
sg10
I13
sg11
Vlung fibrosis
p12080
sg13
I2
sasa(dp12081
g2
VOur purpose was to investigate the regulatory mechanism of TRPV1 and related cytokines on children bronchial asthma.
p12082
sg4
(lp12083
(dp12084
g7
I59
sg8
g47
sg10
I5
sg11
VTRPV1
p12085
sg13
I1
sasg17
(lp12086
(dp12087
g7
I99
sg20
VC0004096
p12088
sg10
I16
sg11
Vbronchial asthma
p12089
sg13
I2
sasa(dp12090
g2
VLogistic regression analysis further demonstrated that TRPV1 mRNA level, EOS, IL-4 and IL-5 may be risk factors for children bronchial asthma.
p12091
sg4
(lp12092
(dp12093
g7
I78
sg8
VP05112
p12094
sg10
I4
sg11
VIL-4
p12095
sg13
I1
sa(dp12096
g7
I87
sg8
VP05113
p12097
sg10
I4
sg11
VIL-5
p12098
sg13
I1
sa(dp12099
g7
I55
sg8
g47
sg10
I10
sg11
VTRPV1 mRNA
p12100
sg13
I2
sa(dp12101
g7
I73
sg8
g47
sg10
I3
sg11
VEOS
p12102
sg13
I1
sasg17
(lp12103
(dp12104
g7
I125
sg20
VC0004096
p12105
sg10
I16
sg11
Vbronchial asthma
p12106
sg13
I2
sa(dp12107
g7
I73
sg20
VC1836122
p12108
sg10
I3
sg11
VEOS
p12109
sg13
I1
sasa(dp12110
g2
VThe preliminary regulatory network of TRPV1 and related cytokines on children bronchial asthma established in this study provides certain theoretical basis for pathogenesis and treatment of children bronchial asthma.
p12111
sg4
(lp12112
(dp12113
g7
I38
sg8
g47
sg10
I5
sg11
VTRPV1
p12114
sg13
I1
sasg17
(lp12115
(dp12116
g7
I78
sg20
VC0004096
p12117
sg10
I16
sg11
Vbronchial asthma
p12118
sg13
I2
sa(dp12119
g7
I160
sg20
VC0699748
p12120
sg10
I12
sg11
Vpathogenesis
p12121
sg13
I1
sa(dp12122
g7
I78
sg20
VC0004096
p12123
sg10
I16
sg11
Vbronchial asthma
p12124
sg13
I2
sasa(dp12125
g2
Voleoylethanolamide, sphingosine-1-phosphate, N-palmitoyltaurine) were postulated to be involved in activating the transient receptor potential vanilloid type 1 (TRPV1) receptor, driving TRPV1-dependent pathogenesis in asthma.Our findings suggest that asthma is characterised by a modest systemic metabolic shift in a disease severity-dependent manner, and that steroid treatment significantly affects metabolism.
p12126
sg4
(lp12127
(dp12128
g7
I161
sg8
g47
sg10
I5
sg11
VTRPV1
p12129
sg13
I1
sa(dp12130
g7
I114
sg8
g47
sg10
I62
sg11
Vtransient receptor potential vanilloid type 1 (TRPV1) receptor
p12131
sg13
I8
sasg17
(lp12132
(dp12133
g7
I218
sg20
VC0004096
p12134
sg10
I6
sg11
Vasthma
p12135
sg13
I1
sa(dp12136
g7
I218
sg20
VC0004096
p12137
sg10
I6
sg11
Vasthma
p12138
sg13
I1
sa(dp12139
g7
I202
sg20
VC0699748
p12140
sg10
I12
sg11
Vpathogenesis
p12141
sg13
I1
sasa(dp12142
g2
VTo investigate the effects of particulate matter &lt;= 2.5 microns (PM2.5) on asthma-related phenotypes and on lung expression of TRPA1 and TRPV1 proteins in a mouse model of asthma.
p12143
sg4
(lp12144
(dp12145
g7
I140
sg8
g47
sg10
I14
sg11
VTRPV1 proteins
p12146
sg13
I2
sa(dp12147
g7
I130
sg8
g47
sg10
I5
sg11
VTRPA1
p12148
sg13
I1
sasg17
(lp12149
(dp12150
g7
I78
sg20
VC0004096
p12151
sg10
I6
sg11
Vasthma
p12152
sg13
I1
sa(dp12153
g7
I78
sg20
VC0004096
p12154
sg10
I6
sg11
Vasthma
p12155
sg13
I1
sasa(dp12156
g2
VPM2.5 exacerbates effects of asthma in this model, possibly by regulating TRPA1 and TRPV1 and the relevant neurokines.
p12157
sg4
(lp12158
(dp12159
g7
I74
sg8
g47
sg10
I5
sg11
VTRPA1
p12160
sg13
I1
sa(dp12161
g7
I84
sg8
g47
sg10
I5
sg11
VTRPV1
p12162
sg13
I1
sasg17
(lp12163
(dp12164
g7
I29
sg20
VC0004096
p12165
sg10
I6
sg11
Vasthma
p12166
sg13
I1
sasa(dp12167
g2
VOur results show that CM Tln2 is essential for proper Beta1D-integrin expression and that Tln1 can substitute for Tln2 in preserving heart function, but that loss of all Tln forms from the heart-muscle cell leads to myocyte instability and a dilated cardiomyopathy.
p12168
sg4
(lp12169
(dp12170
g7
I25
sg8
g47
sg10
I4
sg11
VTln2
p12171
sg13
I1
sa(dp12172
g7
I90
sg8
g47
sg10
I4
sg11
VTln1
p12173
sg13
I1
sa(dp12174
g7
I22
sg8
g47
sg10
I7
sg11
VCM Tln2
p12175
sg13
I2
sasg17
(lp12176
(dp12177
g7
I242
sg20
VC0007193
p12178
sg10
I22
sg11
Vdilated cardiomyopathy
p12179
sg13
I2
sasa(dp12180
g2
VThe levels of two miRNAs, hsa-miR-132-5p and hsa-miR-221-5p, were inversely correlated with the expression of CYP1A2 mRNA transcripts in normal human liver tissue samples represented in The Cancer Genome Atlas (TCGA) dataset.
p12181
sg4
(lp12182
(dp12183
g7
I26
sg8
g47
sg10
I14
sg11
Vhsa-miR-132-5p
p12184
sg13
I1
sa(dp12185
g7
I110
sg8
VP05177
p12186
sg10
I23
sg11
VCYP1A2 mRNA transcripts
p12187
sg13
I3
sa(dp12188
g7
I45
sg8
g47
sg10
I14
sg11
Vhsa-miR-221-5p
p12189
sg13
I1
sasg17
(lp12190
(dp12191
g7
I190
sg20
VC0006826
p12192
sg10
I6
sg11
VCancer
p12193
sg13
I1
sa(dp12194
g7
I26
sg20
VC0393754
p12195
sg10
I3
sg11
Vhsa
p12196
sg13
I1
sa(dp12197
g7
I26
sg20
VC0393754
p12198
sg10
I3
sg11
Vhsa
p12199
sg13
I1
sasa(dp12200
g2
VIn situ hybridization and functional experiments in a panel of colorectal cancer cell lines and xenografts further clarified the role of clinical relevant miRNAs.Results: Six miRNAs (miR-92b-3p, miR-188-3p, miR-221-5p, miR-331-3p, miR-425-3p, and miR-497-5p) were identified as strong predictors of survival in the screening cohort.
p12201
sg4
(lp12202
(dp12203
g7
I195
sg8
g47
sg10
I10
sg11
VmiR-188-3p
p12204
sg13
I1
sa(dp12205
g7
I231
sg8
g47
sg10
I10
sg11
VmiR-425-3p
p12206
sg13
I1
sa(dp12207
g7
I183
sg8
g47
sg10
I10
sg11
VmiR-92b-3p
p12208
sg13
I1
sa(dp12209
g7
I247
sg8
g47
sg10
I10
sg11
VmiR-497-5p
p12210
sg13
I1
sa(dp12211
g7
I219
sg8
g47
sg10
I10
sg11
VmiR-331-3p
p12212
sg13
I1
sa(dp12213
g7
I207
sg8
g47
sg10
I10
sg11
VmiR-221-5p
p12214
sg13
I1
sasg17
(lp12215
(dp12216
g7
I63
sg20
VC1527249
p12217
sg10
I17
sg11
Vcolorectal cancer
p12218
sg13
I2
sasa(dp12219
g2
VParticularly, CLN1, CLN2 and CLN3 were obtained by adding derivatives C1, C2 or C3 during nanoparticles preparation, while CLN2-Pt were obtained by treating preformed CLN2 with Pt(II).
p12220
sg4
(lp12221
(dp12222
g7
I20
sg8
g47
sg10
I4
sg11
VCLN2
p12223
sg13
I1
sa(dp12224
g7
I20
sg8
g47
sg10
I4
sg11
VCLN2
p12225
sg13
I1
sa(dp12226
g7
I29
sg8
g47
sg10
I4
sg11
VCLN3
p12227
sg13
I1
sa(dp12228
g7
I123
sg8
g47
sg10
I7
sg11
VCLN2-Pt
p12229
sg13
I1
sa(dp12230
g7
I14
sg8
VP50897
p12231
sg10
I4
sg11
VCLN1
p12232
sg13
I1
sasg17
(lp12233
(dp12234
g7
I20
sg20
VC1876161
p12235
sg10
I4
sg11
VCLN2
p12236
sg13
I1
sa(dp12237
g7
I20
sg20
VC1876161
p12238
sg10
I4
sg11
VCLN2
p12239
sg13
I1
sa(dp12240
g7
I29
sg20
VC2931674
p12241
sg10
I4
sg11
VCLN3
p12242
sg13
I1
sa(dp12243
g7
I14
sg20
VC1850451
p12244
sg10
I4
sg11
VCLN1
p12245
sg13
I1
sa(dp12246
g7
I20
sg20
VC1876161
p12247
sg10
I4
sg11
VCLN2
p12248
sg13
I1
sasa(dp12249
g2
VAs determined by ICP-OES, a content of P and Pt 2.2-fold and 2.5-fold higher in CLN2-Pt than in CLN3 was evidenced.
p12250
sg4
(lp12251
(dp12252
g7
I80
sg8
g47
sg10
I7
sg11
VCLN2-Pt
p12253
sg13
I1
sa(dp12254
g7
I96
sg8
g47
sg10
I4
sg11
VCLN3
p12255
sg13
I1
sa(dp12256
g7
I17
sg8
g47
sg10
I7
sg11
VICP-OES
p12257
sg13
I1
sasg17
(lp12258
(dp12259
g7
I21
sg20
VC1838329
p12260
sg10
I3
sg11
VOES
p12261
sg13
I1
sa(dp12262
g7
I80
sg20
VC1876161
p12263
sg10
I4
sg11
VCLN2
p12264
sg13
I1
sa(dp12265
g7
I96
sg20
VC2931674
p12266
sg10
I4
sg11
VCLN3
p12267
sg13
I1
sa(dp12268
g7
I17
sg20
VC0268318
p12269
sg10
I3
sg11
VICP
p12270
sg13
I1
sasa(dp12271
g2
VIn fact, the antiproliferative activity shown by CLN3, CLN2-Pt on the three model cancer cell lines was substantially similar and comparable to that of complex C3 in dmso solution.
p12272
sg4
(lp12273
(dp12274
g7
I55
sg8
g47
sg10
I7
sg11
VCLN2-Pt
p12275
sg13
I1
sa(dp12276
g7
I49
sg8
g47
sg10
I4
sg11
VCLN3
p12277
sg13
I1
sasg17
(lp12278
(dp12279
g7
I55
sg20
VC1876161
p12280
sg10
I4
sg11
VCLN2
p12281
sg13
I1
sa(dp12282
g7
I49
sg20
VC2931674
p12283
sg10
I4
sg11
VCLN3
p12284
sg13
I1
sa(dp12285
g7
I82
sg20
VC0006826
p12286
sg10
I6
sg11
Vcancer
p12287
sg13
I1
sasa(dp12288
g2
VSeparate prediction models which could predict consumption of each blood component in intra and postoperative phase of LDLT were derived from among the preoperative Hb, Hct, model for end-stage liver disease (MELD) score, body surface area (BSA), Plt, T. proteins, S. creatinine, B. urea, INR, and serum sodium and chloride.
p12289
sg4
(lp12290
(dp12291
g7
I247
sg8
g47
sg10
I3
sg11
VPlt
p12292
sg13
I1
sasg17
(lp12293
(dp12294
g7
I194
sg20
VC0023895
p12295
sg10
I13
sg11
Vliver disease
p12296
sg13
I2
sasa(dp12297
g2
VNo association with vitiligo was found for the MECL1 gene, which encodes a third immunoproteasome subunit and is unlinked to the MHC class II region.
p12298
sg4
(lp12299
(dp12300
g7
I129
sg8
VP13747
p12301
sg10
I19
sg11
VMHC class II region
p12302
sg13
I4
sa(dp12303
g7
I47
sg8
VP40313
p12304
sg10
I10
sg11
VMECL1 gene
p12305
sg13
I2
sasg17
(lp12306
(dp12307
g7
I20
sg20
VC0042900
p12308
sg10
I8
sg11
Vvitiligo
p12309
sg13
I1
sasa(dp12310
g2
VWe report a novel LHX3 mutation, which is associated with combined pituitary hormone deficiency including ACTH deficiency, short neck, and sensorineural hearing loss.
p12311
sg4
(lp12312
(dp12313
g7
I58
sg8
VP18509
p12314
sg10
I26
sg11
Vcombined pituitary hormone
p12315
sg13
I3
sa(dp12316
g7
I18
sg8
g47
sg10
I4
sg11
VLHX3
p12317
sg13
I1
sa(dp12318
g7
I106
sg8
VP01189
p12319
sg10
I4
sg11
VACTH
p12320
sg13
I1
sasg17
(lp12321
(dp12322
g7
I139
sg20
VC0018784
p12323
sg10
I26
sg11
Vsensorineural hearing loss
p12324
sg13
I3
sa(dp12325
g7
I77
sg20
VC0599750
p12326
sg10
I18
sg11
Vhormone deficiency
p12327
sg13
I2
sa(dp12328
g7
I106
sg20
VC0342388
p12329
sg10
I15
sg11
VACTH deficiency
p12330
sg13
I2
sasa(dp12331
g2
VSo-called stress hormones, like adrenocorticotropic hormone, cortisol, and antidiuretic hormone, are released concomitant with nausea and vomiting in motion sickness, but do not seem to be involved in the aetiology of motion sickness.
p12332
sg4
(lp12333
(dp12334
g7
I32
sg8
VP01189
p12335
sg10
I27
sg11
Vadrenocorticotropic hormone
p12336
sg13
I2
sasg17
(lp12337
(dp12338
g7
I150
sg20
VC0026603
p12339
sg10
I15
sg11
Vmotion sickness
p12340
sg13
I2
sa(dp12341
g7
I127
sg20
VC0027498
p12342
sg10
I19
sg11
Vnausea and vomiting
p12343
sg13
I3
sa(dp12344
g7
I150
sg20
VC0026603
p12345
sg10
I15
sg11
Vmotion sickness
p12346
sg13
I2
sasa(dp12347
g2
VMMP-1/7 serum levels were measured using Luminex xMAP technology in 139 patients- 47 IPF, 36 non-IPF Usual Interstitial Pneumonia (UIP), 14 idiopathic Nonspecific Interstitial Pneumonia (iNSIP), 29 secondary NSIP (secNSIP), 13 stage IV sarcoidosis- and 20 healthy controls, and compared using the Mann-Whitney U test.
p12348
sg4
(lp12349
(dp12350
g7
I0
sg8
VP03956
p12351
sg10
I5
sg11
VMMP-1
p12352
sg13
I1
sasg17
(lp12353
(dp12354
g7
I101
sg20
VC0085786
p12355
sg10
I28
sg11
VUsual Interstitial Pneumonia
p12356
sg13
I3
sa(dp12357
g7
I151
sg20
VC1290344
p12358
sg10
I34
sg11
VNonspecific Interstitial Pneumonia
p12359
sg13
I3
sa(dp12360
g7
I236
sg20
VC0036202
p12361
sg10
I11
sg11
Vsarcoidosis
p12362
sg13
I1
sa(dp12363
g7
I131
sg20
VC0085786
p12364
sg10
I3
sg11
VUIP
p12365
sg13
I1
sasa(dp12366
g2
VThis activity is regulated by such inhibitors as metalloprvteinase 1 tissue inhibitor and cystatin C. The comparative analysis was applied concerning matrix metalloproteinase 1 precursor; metalloproteinase I tissue inhibitor and cystatin C--indicators of conditions of the "proteolysis-antiproteolysis" system in the bronchoalveolar secretion of patients with chronic obstructive lung disease, bronchial asthma and pneumonia.
p12367
sg4
(lp12368
(dp12369
g7
I90
sg8
VP01034
p12370
sg10
I10
sg11
Vcystatin C
p12371
sg13
I2
sa(dp12372
g7
I150
sg8
VP03956
p12373
sg10
I74
sg11
Vmatrix metalloproteinase 1 precursor; metalloproteinase I tissue inhibitor
p12374
sg13
I8
sa(dp12375
g7
I90
sg8
VP01034
p12376
sg10
I10
sg11
Vcystatin C
p12377
sg13
I2
sasg17
(lp12378
(dp12379
g7
I394
sg20
VC0004096
p12380
sg10
I16
sg11
Vbronchial asthma
p12381
sg13
I2
sa(dp12382
g7
I415
sg20
VC0032285
p12383
sg10
I9
sg11
Vpneumonia
p12384
sg13
I1
sa(dp12385
g7
I360
sg20
VC0024117
p12386
sg10
I32
sg11
Vchronic obstructive lung disease
p12387
sg13
I4
sasa(dp12388
g2
VTo observe the effects of Dureping Injection on the contents of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in the lung tissue of mice with pneumonia of influenza virus infection.
p12389
sg4
(lp12390
(dp12391
g7
I64
sg8
VP14780
p12392
sg10
I26
sg11
Vmatrix metalloproteinase-9
p12393
sg13
I2
sa(dp12394
g7
I92
sg8
VP14780
p12395
sg10
I5
sg11
VMMP-9
p12396
sg13
I1
sa(dp12397
g7
I103
sg8
VP01033
p12398
sg10
I46
sg11
Vtissue inhibitor of matrix metalloproteinase-1
p12399
sg13
I5
sa(dp12400
g7
I151
sg8
VP01033
p12401
sg10
I6
sg11
VTIMP-1
p12402
sg13
I1
sasg17
(lp12403
(dp12404
g7
I204
sg20
VC0021400
p12405
sg10
I9
sg11
Vinfluenza
p12406
sg13
I1
sa(dp12407
g7
I191
sg20
VC0032285
p12408
sg10
I9
sg11
Vpneumonia
p12409
sg13
I1
sa(dp12410
g7
I214
sg20
VC0042769
p12411
sg10
I15
sg11
Vvirus infection
p12412
sg13
I2
sasa(dp12413
g2
VWe developed a Korean version of the NPI-Q (KNPI-Q) and compared subitems with those of the Korean version of the NPI (KNPI) in 63 dementia patients; 47 patients had been diagnosed with Alzheimer's disease with dementia, 8 with vascular dementia, and 8 with dementia with Lewy body disease.
p12414
sg4
(lp12415
(dp12416
g7
I44
sg8
g47
sg10
I6
sg11
VKNPI-Q
p12417
sg13
I1
sa(dp12418
g7
I15
sg8
g47
sg10
I27
sg11
VKorean version of the NPI-Q
p12419
sg13
I5
sasg17
(lp12420
(dp12421
g7
I131
sg20
VC0497327
p12422
sg10
I8
sg11
Vdementia
p12423
sg13
I1
sa(dp12424
g7
I186
sg20
VC1521724
p12425
sg10
I19
sg11
VAlzheimer's disease
p12426
sg13
I2
sa(dp12427
g7
I131
sg20
VC0497327
p12428
sg10
I8
sg11
Vdementia
p12429
sg13
I1
sa(dp12430
g7
I131
sg20
VC0497327
p12431
sg10
I8
sg11
Vdementia
p12432
sg13
I1
sa(dp12433
g7
I272
sg20
VC0752347
p12434
sg10
I17
sg11
VLewy body disease
p12435
sg13
I3
sa(dp12436
g7
I228
sg20
VC0011269
p12437
sg10
I17
sg11
Vvascular dementia
p12438
sg13
I2
sasa(dp12439
g2
VAll patients received the Korean version of the Mini-Mental State Examination and the Clinical Dementia Rating within 1 month of the KNPI-Q.
p12440
sg4
(lp12441
(dp12442
g7
I133
sg8
g47
sg10
I6
sg11
VKNPI-Q
p12443
sg13
I1
sasg17
(lp12444
(dp12445
g7
I95
sg20
VC0497327
p12446
sg10
I8
sg11
VDementia
p12447
sg13
I1
sasa(dp12448
g2
VThe KNPI-Q is a reliable and brief instrument that can be employed for screening in the evaluation of neuropsychiatric symptoms of dementia and associated caregiver distress.
p12449
sg4
(lp12450
(dp12451
g7
I4
sg8
g47
sg10
I6
sg11
VKNPI-Q
p12452
sg13
I1
sasg17
(lp12453
(dp12454
g7
I131
sg20
VC0497327
p12455
sg10
I8
sg11
Vdementia
p12456
sg13
I1
sasa(dp12457
g2
VThe cognitive function of each sub-domain, functional impairments, depressive symptoms, and caregiver burden were assessed using the dementia version of Seoul Neuropsychological Screening Battery (SNSB-D), Barthel Index for Daily Living Activities (ADL), Seoul-Instrumental Activities of Daily Living (S-IADL), the Clinical Dementia Rating Sum of Box (CDR-SB), the Global Deterioration Scale (GDS), the Korean version of the Neuropsychiatric Inventory (K-NPI), and the 15-item Geriatric Depression Scale.
p12458
sg4
(lp12459
(dp12460
g7
I352
sg8
VP51861
p12461
sg10
I6
sg11
VCDR-SB
p12462
sg13
I1
sa(dp12463
g7
I315
sg8
VP51861
p12464
sg10
I35
sg11
VClinical Dementia Rating Sum of Box
p12465
sg13
I6
sasg17
(lp12466
(dp12467
g7
I324
sg20
VC0497327
p12468
sg10
I8
sg11
VDementia
p12469
sg13
I1
sa(dp12470
g7
I133
sg20
VC0497327
p12471
sg10
I8
sg11
Vdementia
p12472
sg13
I1
sa(dp12473
g7
I487
sg20
VC0011581
p12474
sg10
I10
sg11
VDepression
p12475
sg13
I1
sa(dp12476
g7
I67
sg20
VC0086132
p12477
sg10
I19
sg11
Vdepressive symptoms
p12478
sg13
I2
sasa(dp12479
g2
VOur primary endpoints were change from baseline to weeks 12 and 24 in the Seoul Neuropsychological Screening Battery-Dementia version (SNSB-D) and the Korean version of neuropsychiatric inventory (K-NPI).
p12480
sg4
(lp12481
sg17
(lp12482
(dp12483
g7
I117
sg20
VC0497327
p12484
sg10
I8
sg11
VDementia
p12485
sg13
I1
sasa(dp12486
g2
VThe patients were also evaluated using the Korean version of the Severe Impairment Battery (SIB-Ko), Clinical Dementia Rating (CDR), Global Deterioration Scale (GDS), Barthel Activities of Daily Living (B-ADL), the Korean version of the Instrumental Activities of Daily Living (K-IADL), the Korean version of the Neuropsychiatric Inventory (K-NPI) and the Functional Assessment Staging (FAST).
p12487
sg4
(lp12488
sg17
(lp12489
(dp12490
g7
I72
sg20
VC0684336
p12491
sg10
I10
sg11
VImpairment
p12492
sg13
I1
sa(dp12493
g7
I110
sg20
VC0497327
p12494
sg10
I8
sg11
VDementia
p12495
sg13
I1
sasa(dp12496
g2
VThe aim of this study is to develop the Korean version of the NPI (K-NPI) and to test its reliability and usefulness in dementia patients.
p12497
sg4
(lp12498
sg17
(lp12499
(dp12500
g7
I120
sg20
VC0497327
p12501
sg10
I8
sg11
Vdementia
p12502
sg13
I1
sasa(dp12503
g2
VTotal K-NPI scores correlated positively with dementia severity assessed with the Korean Mini-Mental State Examination.
p12504
sg4
(lp12505
sg17
(lp12506
(dp12507
g7
I46
sg20
VC0497327
p12508
sg10
I8
sg11
Vdementia
p12509
sg13
I1
sasa(dp12510
g2
VThe K-NPI, whose reliability and competency are comparable to those of the original version, may be a reliable and useful tool for measuring neuropsychiatric disturbances in Korean dementia patients.
p12511
sg4
(lp12512
sg17
(lp12513
(dp12514
g7
I181
sg20
VC0497327
p12515
sg10
I8
sg11
Vdementia
p12516
sg13
I1
sasa(dp12517
g2
VBone and cartilage and their disorders are addressed under the following headings: functions of bone; normal and abnormal bone remodeling; osteopetrosis and osteoporosis; epithelial-mesenchymal interaction, condensation and differentiation; osteoblasts, markers of bone formation, osteoclasts, components of bone, and pathology of bone; chondroblasts, markers of cartilage formation, secondary cartilage, components of cartilage, and pathology of cartilage; intramembranous and endochondral bone formation; RUNX genes and cleidocranial dysplasia (CCD); osterix; histone deacetylase 4 and Runx2; Ligand to receptor activator of NFkappaB (RANKL), RANK, osteoprotegerin, and osteoimmunology; WNT signaling, LRP5 mutations, and beta-catenin; the role of leptin in bone remodeling; collagens, collagenopathies, and osteogenesis imperfecta; FGFs/FGFRs, FGFR3 skeletal dysplasias, craniosynostosis, and other disorders; short limb chondrodysplasias; molecular control of the growth plate in endochondral bone formation and genetic disorders of IHH and PTHR1; ANKH, craniometaphyseal dysplasia, and chondrocalcinosis; transforming growth factor beta, Camurati-Engelmann disease (CED), and Marfan syndrome, types I and II; an ACVR1 mutation and fibrodysplasia ossificans progressiva; MSX1 and MSX2: biology, mutations, and associated disorders; G protein, activation of adenylyl cyclase, GNAS1 mutations, McCune-Albright syndrome, fibrous dysplasia, and Albright hereditary osteodystrophy; FLNA and associated disorders; and morphological development of teeth and their genetic mutations.
p12518
sg4
(lp12519
(dp12520
g7
I562
sg8
VP56524
p12521
sg10
I21
sg11
Vhistone deacetylase 4
p12522
sg13
I3
sa(dp12523
g7
I704
sg8
g47
sg10
I4
sg11
VLRP5
p12524
sg13
I1
sa(dp12525
g7
I1217
sg8
g47
sg10
I5
sg11
VACVR1
p12526
sg13
I1
sa(dp12527
g7
I1284
sg8
VP35548
p12528
sg10
I4
sg11
VMSX2
p12529
sg13
I1
sa(dp12530
g7
I1045
sg8
g47
sg10
I5
sg11
VPTHR1
p12531
sg13
I1
sa(dp12532
g7
I1037
sg8
g47
sg10
I3
sg11
VIHH
p12533
sg13
I1
sa(dp12534
g7
I627
sg8
VP19838
p12535
sg10
I8
sg11
VNFkappaB
p12536
sg13
I1
sa(dp12537
g7
I1275
sg8
VP28360
p12538
sg10
I4
sg11
VMSX1
p12539
sg13
I1
sa(dp12540
g7
I1379
sg8
VP84996
p12541
sg10
I5
sg11
VGNAS1
p12542
sg13
I1
sa(dp12543
g7
I1171
sg8
VP01137
p12544
sg10
I3
sg11
VCED
p12545
sg13
I1
sa(dp12546
g7
I588
sg8
g47
sg10
I5
sg11
VRunx2
p12547
sg13
I1
sa(dp12548
g7
I847
sg8
VP22607
p12549
sg10
I5
sg11
VFGFR3
p12550
sg13
I1
sa(dp12551
g7
I1052
sg8
g47
sg10
I4
sg11
VANKH
p12552
sg13
I1
sa(dp12553
g7
I1143
sg8
VP01137
p12554
sg10
I26
sg11
VCamurati-Engelmann disease
p12555
sg13
I2
sa(dp12556
g7
I1110
sg8
VP18075
p12557
sg10
I31
sg11
Vtransforming growth factor beta
p12558
sg13
I4
sa(dp12559
g7
I750
sg8
VP41159
p12560
sg10
I6
sg11
Vleptin
p12561
sg13
I1
sa(dp12562
g7
I724
sg8
VP35222
p12563
sg10
I12
sg11
Vbeta-catenin
p12564
sg13
I1
sa(dp12565
g7
I1361
sg8
VP51828
p12566
sg10
I16
sg11
Vadenylyl cyclase
p12567
sg13
I2
sa(dp12568
g7
I651
sg8
g47
sg10
I15
sg11
Vosteoprotegerin
p12569
sg13
I1
sa(dp12570
g7
I637
sg8
g47
sg10
I5
sg11
VRANKL
p12571
sg13
I1
sasg17
(lp12572
(dp12573
g7
I1016
sg20
VC0019247
p12574
sg10
I17
sg11
Vgenetic disorders
p12575
sg13
I2
sa(dp12576
g7
I157
sg20
VC0029456
p12577
sg10
I12
sg11
Vosteoporosis
p12578
sg13
I1
sa(dp12579
g7
I862
sg20
VC0334044
p12580
sg10
I10
sg11
Vdysplasias
p12581
sg13
I1
sa(dp12582
g7
I522
sg20
VC0008928
p12583
sg10
I23
sg11
Vcleidocranial dysplasia
p12584
sg13
I2
sa(dp12585
g7
I1422
sg20
VC0259779
p12586
sg10
I17
sg11
Vfibrous dysplasia
p12587
sg13
I2
sa(dp12588
g7
I810
sg20
VC0029434
p12589
sg10
I23
sg11
Vosteogenesis imperfecta
p12590
sg13
I2
sa(dp12591
g7
I547
sg20
VC0008928
p12592
sg10
I3
sg11
VCCD
p12593
sg13
I1
sa(dp12594
g7
I1058
sg20
VC0265292
p12595
sg10
I27
sg11
Vcraniometaphyseal dysplasia
p12596
sg13
I2
sa(dp12597
g7
I1091
sg20
VC0553730
p12598
sg10
I17
sg11
Vchondrocalcinosis
p12599
sg13
I1
sa(dp12600
g7
I318
sg20
VC0677042
p12601
sg10
I9
sg11
Vpathology
p12602
sg13
I1
sa(dp12603
g7
I1445
sg20
VC2931404
p12604
sg10
I34
sg11
VAlbright hereditary osteodystrophy
p12605
sg13
I3
sa(dp12606
g7
I1037
sg20
VC0342384
p12607
sg10
I3
sg11
VIHH
p12608
sg13
I1
sa(dp12609
g7
I1143
sg20
VC0011989
p12610
sg10
I26
sg11
VCamurati-Engelmann disease
p12611
sg13
I2
sa(dp12612
g7
I139
sg20
VC0029454
p12613
sg10
I13
sg11
Vosteopetrosis
p12614
sg13
I1
sa(dp12615
g7
I1396
sg20
VC0242292
p12616
sg10
I24
sg11
VMcCune-Albright syndrome
p12617
sg13
I2
sa(dp12618
g7
I318
sg20
VC0677042
p12619
sg10
I9
sg11
Vpathology
p12620
sg13
I1
sa(dp12621
g7
I207
sg20
VC0233656
p12622
sg10
I12
sg11
Vcondensation
p12623
sg13
I1
sa(dp12624
g7
I924
sg20
VC0343284
p12625
sg10
I17
sg11
Vchondrodysplasias
p12626
sg13
I1
sa(dp12627
g7
I1236
sg20
VC0016037
p12628
sg10
I37
sg11
Vfibrodysplasia ossificans progressiva
p12629
sg13
I3
sa(dp12630
g7
I1181
sg20
VC0024796
p12631
sg10
I15
sg11
VMarfan syndrome
p12632
sg13
I2
sa(dp12633
g7
I874
sg20
VC0010278
p12634
sg10
I16
sg11
Vcraniosynostosis
p12635
sg13
I1
sa(dp12636
g7
I1171
sg20
VC0011989
p12637
sg10
I3
sg11
VCED
p12638
sg13
I1
sasa(dp12639
g2
VGenome-wide analysis showed an association of asthma in Russians with the polymorphic loci of gene MUC19 (12q12) encoding gel-forming mucin 19.
p12640
sg4
(lp12641
(dp12642
g7
I122
sg8
g47
sg10
I20
sg11
Vgel-forming mucin 19
p12643
sg13
I3
sa(dp12644
g7
I94
sg8
g47
sg10
I18
sg11
Vgene MUC19 (12q12)
p12645
sg13
I3
sasg17
(lp12646
(dp12647
g7
I46
sg20
VC0004096
p12648
sg10
I6
sg11
Vasthma
p12649
sg13
I1
sasa(dp12650
g2
VSeven polymorphic loci of gene MUC19 (rs1492313, rs2588401, rs2588402, rs2638863, rs2638864, rs1352940, and rs2933373), which are in close linkage disequilibrium among themselves and rs2933346, are associated with asthma with the same p-value (p = 4.96 x 10(-6)).
p12651
sg4
(lp12652
(dp12653
g7
I31
sg8
g47
sg10
I5
sg11
VMUC19
p12654
sg13
I1
sasg17
(lp12655
(dp12656
g7
I214
sg20
VC0004096
p12657
sg10
I6
sg11
Vasthma
p12658
sg13
I1
sa(dp12659
g7
I147
sg20
VC0394006
p12660
sg10
I14
sg11
Vdisequilibrium
p12661
sg13
I1
sasa(dp12662
g2
VAccording to our data, the association of polymorphic variants of gene MUC19 with asthma has not been previously identified in any study.
p12663
sg4
(lp12664
(dp12665
g7
I71
sg8
g47
sg10
I5
sg11
VMUC19
p12666
sg13
I1
sasg17
(lp12667
(dp12668
g7
I82
sg20
VC0004096
p12669
sg10
I6
sg11
Vasthma
p12670
sg13
I1
sasa(dp12671
g2
VOur results indicate the important role of polymorphic variants of gene MUC19 in the formation of a predisposition to the development of asthma in individuals of Russian ethnicity.
p12672
sg4
(lp12673
(dp12674
g7
I72
sg8
g47
sg10
I5
sg11
VMUC19
p12675
sg13
I1
sasg17
(lp12676
(dp12677
g7
I137
sg20
VC0004096
p12678
sg10
I6
sg11
Vasthma
p12679
sg13
I1
sasa(dp12680
g2
VTo detect the mucin gene (MUC2, MUC5AC, MUC5B, MUC18 and MUC19) expression in the nasal polyps, allergic rhinitis (AR) and the normal nasal mucosa in human.
p12681
sg4
(lp12682
(dp12683
g7
I26
sg8
g47
sg10
I4
sg11
VMUC2
p12684
sg13
I1
sa(dp12685
g7
I47
sg8
VP43121
p12686
sg10
I5
sg11
VMUC18
p12687
sg13
I1
sa(dp12688
g7
I14
sg8
g47
sg10
I10
sg11
Vmucin gene
p12689
sg13
I2
sa(dp12690
g7
I57
sg8
g47
sg10
I5
sg11
VMUC19
p12691
sg13
I1
sasg17
(lp12692
(dp12693
g7
I96
sg20
VC2607914
p12694
sg10
I17
sg11
Vallergic rhinitis
p12695
sg13
I2
sa(dp12696
g7
I115
sg20
VC2607914
p12697
sg10
I2
sg11
VAR
p12698
sg13
I1
sa(dp12699
g7
I82
sg20
VC0027430
p12700
sg10
I12
sg11
Vnasal polyps
p12701
sg13
I2
sasa(dp12702
g2
VIt indicates that the secretion of MUC19 in allergic rhinitis was on high level.
p12703
sg4
(lp12704
(dp12705
g7
I35
sg8
g47
sg10
I5
sg11
VMUC19
p12706
sg13
I1
sasg17
(lp12707
(dp12708
g7
I44
sg20
VC2607914
p12709
sg10
I17
sg11
Vallergic rhinitis
p12710
sg13
I2
sasa(dp12711
g2
VWe aimed to assess the impact of hypocretin deficiency on attentional functioning by comparing performances on the attention network test (ANT) of narcoleptic patients with hypocretin deficiency (narcolepsy type 1-NT1) versus patients without hypocretin deficiency (narcolepsy type 2-NT2) and healthy controls.
p12712
sg4
(lp12713
(dp12714
g7
I33
sg8
VP50336
p12715
sg10
I10
sg11
Vhypocretin
p12716
sg13
I1
sa(dp12717
g7
I33
sg8
VP50336
p12718
sg10
I10
sg11
Vhypocretin
p12719
sg13
I1
sa(dp12720
g7
I33
sg8
VP50336
p12721
sg10
I10
sg11
Vhypocretin
p12722
sg13
I1
sasg17
(lp12723
(dp12724
g7
I196
sg20
VC0027404
p12725
sg10
I10
sg11
Vnarcolepsy
p12726
sg13
I1
sa(dp12727
g7
I196
sg20
VC0027404
p12728
sg10
I10
sg11
Vnarcolepsy
p12729
sg13
I1
sasa(dp12730
g2
VA randomized, double-blind prospective trial among recent onset type 1 diabetes patients has been designed using Cyclosporine A and a proton-pump inhibitor, which increases gastrin levels and has been shown to work through the Reg receptor to transform pancreatic duct cells into islets.
p12731
sg4
(lp12732
(dp12733
g7
I173
sg8
VP01350
p12734
sg10
I7
sg11
Vgastrin
p12735
sg13
I1
sa(dp12736
g7
I227
sg8
g47
sg10
I12
sg11
VReg receptor
p12737
sg13
I2
sasg17
(lp12738
(dp12739
g7
I21
sg20
VC0456909
p12740
sg10
I5
sg11
Vblind
p12741
sg13
I1
sa(dp12742
g7
I64
sg20
VC0011854
p12743
sg10
I15
sg11
Vtype 1 diabetes
p12744
sg13
I3
sasa(dp12745
g2
VIn the A(1)AR agonist area, clinical candidates have been discovered for the following conditions: atrial arrhythmias (tecadenoson, selodenoson and PJ-875); Type II diabetes and insulin sensitizing agents (GR79236, ARA, RPR-749, and CVT-3619); and angina (BAY 68-4986).
p12746
sg4
(lp12747
(dp12748
g7
I178
sg8
VP01308
p12749
sg10
I7
sg11
Vinsulin
p12750
sg13
I1
sasg17
(lp12751
(dp12752
g7
I99
sg20
VC0085611
p12753
sg10
I18
sg11
Vatrial arrhythmias
p12754
sg13
I2
sa(dp12755
g7
I157
sg20
VC0011860
p12756
sg10
I16
sg11
VType II diabetes
p12757
sg13
I3
sa(dp12758
g7
I248
sg20
VC0002962
p12759
sg10
I6
sg11
Vangina
p12760
sg13
I1
sa(dp12761
g7
I233
sg20
VC0240912
p12762
sg10
I3
sg11
VCVT
p12763
sg13
I1
sasa(dp12764
g2
VThe treatment of type II diabetes using A(1)AR agonists in the clinic has met with limited success due to cardiovascular side effects and a well-defined desensitization of full agonists in human trials (GR79236, ARA, and RPR 749).
p12765
sg4
(lp12766
sg17
(lp12767
(dp12768
g7
I17
sg20
VC0011860
p12769
sg10
I16
sg11
Vtype II diabetes
p12770
sg13
I3
sasa(dp12771
g2
VReg protein acts as an autocrine/paracrine growth factor to induce beta-cell replication via the Reg receptor and ameliorates experimental diabetes.
p12772
sg4
(lp12773
(dp12774
g7
I97
sg8
g47
sg10
I12
sg11
VReg receptor
p12775
sg13
I2
sa(dp12776
g7
I0
sg8
VP05451
p12777
sg10
I11
sg11
VReg protein
p12778
sg13
I2
sasg17
(lp12779
(dp12780
g7
I139
sg20
VC0011849
p12781
sg10
I8
sg11
Vdiabetes
p12782
sg13
I1
sasa(dp12783
g2
VWe have demonstrated in vitro and in vivo that the exogenous addition of rat and human Reg gene products, Reg/REG proteins, induced beta-cell replication via the Reg receptor and thereby ameliorated experimental diabetes.
p12784
sg4
(lp12785
(dp12786
g7
I87
sg8
VP05451
p12787
sg10
I3
sg11
VReg
p12788
sg13
I1
sa(dp12789
g7
I81
sg8
VP05451
p12790
sg10
I23
sg11
Vhuman Reg gene products
p12791
sg13
I4
sa(dp12792
g7
I162
sg8
g47
sg10
I12
sg11
VReg receptor
p12793
sg13
I2
sa(dp12794
g7
I110
sg8
VP05451
p12795
sg10
I3
sg11
VREG
p12796
sg13
I1
sasg17
(lp12797
(dp12798
g7
I212
sg20
VC0011849
p12799
sg10
I8
sg11
Vdiabetes
p12800
sg13
I1
sasa(dp12801
g2
VFrom the regenerating islet-derived cDNA library we isolated Reg (Regenerating Gene) and demonstrated that Reg protein induces beta-cell replication via the Reg receptor and ameliorates experimental diabetes.
p12802
sg4
(lp12803
(dp12804
g7
I107
sg8
VP05451
p12805
sg10
I11
sg11
VReg protein
p12806
sg13
I2
sa(dp12807
g7
I61
sg8
VP05451
p12808
sg10
I3
sg11
VReg
p12809
sg13
I1
sa(dp12810
g7
I157
sg8
g47
sg10
I12
sg11
VReg receptor
p12811
sg13
I2
sasg17
(lp12812
(dp12813
g7
I199
sg20
VC0011849
p12814
sg10
I8
sg11
Vdiabetes
p12815
sg13
I1
sasa(dp12816
g2
VGenomic DNA was isolated from patients with hypopituitarism to amplify and sequence eight pituitary specific transcription factors (HESX1, LHX3, LHX4, OTX2, PITX2, POU1F1, PROP1, and SIX6).
p12817
sg4
(lp12818
(dp12819
g7
I132
sg8
g47
sg10
I5
sg11
VHESX1
p12820
sg13
I1
sa(dp12821
g7
I172
sg8
g47
sg10
I5
sg11
VPROP1
p12822
sg13
I1
sa(dp12823
g7
I145
sg8
g47
sg10
I4
sg11
VLHX4
p12824
sg13
I1
sa(dp12825
g7
I164
sg8
VP28069
p12826
sg10
I6
sg11
VPOU1F1
p12827
sg13
I1
sa(dp12828
g7
I151
sg8
VP32243
p12829
sg10
I4
sg11
VOTX2
p12830
sg13
I1
sa(dp12831
g7
I157
sg8
g47
sg10
I5
sg11
VPITX2
p12832
sg13
I1
sa(dp12833
g7
I139
sg8
g47
sg10
I4
sg11
VLHX3
p12834
sg13
I1
sa(dp12835
g7
I183
sg8
g47
sg10
I4
sg11
VSIX6
p12836
sg13
I1
sa(dp12837
g7
I90
sg8
VP19883
p12838
sg10
I40
sg11
Vpituitary specific transcription factors
p12839
sg13
I4
sasg17
(lp12840
(dp12841
g7
I44
sg20
VC0020635
p12842
sg10
I15
sg11
Vhypopituitarism
p12843
sg13
I1
sasa(dp12844
g2
VRat insulinoma INS-1E cells and mouse beta-TC3 cells stably expressing Gadd45b were generated.
p12845
sg4
(lp12846
(dp12847
g7
I0
sg8
VP01308
p12848
sg10
I21
sg11
VRat insulinoma INS-1E
p12849
sg13
I3
sa(dp12850
g7
I71
sg8
g47
sg10
I7
sg11
VGadd45b
p12851
sg13
I1
sasg17
(lp12852
(dp12853
g7
I15
sg20
VC1533172
p12854
sg10
I3
sg11
VINS
p12855
sg13
I1
sa(dp12856
g7
I4
sg20
VC0021670
p12857
sg10
I10
sg11
Vinsulinoma
p12858
sg13
I1
sasa(dp12859
g2
VTo define the genetic landscape of amyotrophic lateral sclerosis (ALS) and assess the contribution of possible oligogenic inheritance, we aimed to comprehensively sequence 17 known ALS genes in 391 ALS patients from the United States.
p12860
sg4
(lp12861
sg17
(lp12862
(dp12863
g7
I66
sg20
VC0002736
p12864
sg10
I3
sg11
VALS
p12865
sg13
I1
sa(dp12866
g7
I66
sg20
VC0002736
p12867
sg10
I3
sg11
VALS
p12868
sg13
I1
sa(dp12869
g7
I35
sg20
VC0002736
p12870
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p12871
sg13
I3
sa(dp12872
g7
I66
sg20
VC0002736
p12873
sg10
I3
sg11
VALS
p12874
sg13
I1
sasa(dp12875
g2
VHigh nuclear ATF2 expression was mainly observed in translocation-associated and/or spindle cell sarcomas including synovial sarcoma, desmoplastic small round cell tumor, endometrial stromal sarcoma, gastrointestinal stromal tumor, malignant peripheral nerve sheath tumor, and solitary fibrous tumor.
p12876
sg4
(lp12877
(dp12878
g7
I0
sg8
VP15336
p12879
sg10
I17
sg11
VHigh nuclear ATF2
p12880
sg13
I3
sasg17
(lp12881
(dp12882
g7
I134
sg20
VC0281508
p12883
sg10
I35
sg11
Vdesmoplastic small round cell tumor
p12884
sg13
I5
sa(dp12885
g7
I171
sg20
VC0206630
p12886
sg10
I27
sg11
Vendometrial stromal sarcoma
p12887
sg13
I3
sa(dp12888
g7
I84
sg20
VC0205945
p12889
sg10
I21
sg11
Vspindle cell sarcomas
p12890
sg13
I3
sa(dp12891
g7
I116
sg20
VC0039101
p12892
sg10
I16
sg11
Vsynovial sarcoma
p12893
sg13
I2
sa(dp12894
g7
I277
sg20
VC1266119
p12895
sg10
I22
sg11
Vsolitary fibrous tumor
p12896
sg13
I3
sa(dp12897
g7
I52
sg20
VC0040715
p12898
sg10
I13
sg11
Vtranslocation
p12899
sg13
I1
sa(dp12900
g7
I200
sg20
VC3179349
p12901
sg10
I41
sg11
Vgastrointestinal stromal tumor, malignant
p12902
sg13
I4
sa(dp12903
g7
I242
sg20
VC0751689
p12904
sg10
I29
sg11
Vperipheral nerve sheath tumor
p12905
sg13
I4
sasa(dp12906
g2
VSIRT1 immunoreactivity was reviewed in a series of 164 soft tissue tumors including alveolar soft part sarcoma, angiomyolipoma, clear cell sarcoma, desmoid/fibromatosis, desmoplastic small round cell tumor, Ewing sarcoma, gastrointestinal stromal tumor, glomus tumor, leiomyoma, leiomyosarcoma, lipoma, liposarcoma, malignant peripheral nerve sheath tumor, nodular fasciitis, osteosarcoma, rhabdomyosarcoma, schwannoma, solitary fibrous tumor, synovial sarcoma, undifferentiated pleomorphic sarcoma, and Wilms tumor.
p12907
sg4
(lp12908
(dp12909
g7
I0
sg8
g47
sg10
I5
sg11
VSIRT1
p12910
sg13
I1
sasg17
(lp12911
(dp12912
g7
I444
sg20
VC0039101
p12913
sg10
I16
sg11
Vsynovial sarcoma
p12914
sg13
I2
sa(dp12915
g7
I420
sg20
VC1266119
p12916
sg10
I22
sg11
Vsolitary fibrous tumor
p12917
sg13
I3
sa(dp12918
g7
I462
sg20
VC1704218
p12919
sg10
I36
sg11
Vundifferentiated pleomorphic sarcoma
p12920
sg13
I3
sa(dp12921
g7
I390
sg20
VC0035412
p12922
sg10
I16
sg11
Vrhabdomyosarcoma
p12923
sg13
I1
sa(dp12924
g7
I408
sg20
VC0027809
p12925
sg10
I10
sg11
Vschwannoma
p12926
sg13
I1
sa(dp12927
g7
I254
sg20
VC0017653
p12928
sg10
I12
sg11
Vglomus tumor
p12929
sg13
I2
sa(dp12930
g7
I268
sg20
VC0023267
p12931
sg10
I9
sg11
Vleiomyoma
p12932
sg13
I1
sa(dp12933
g7
I156
sg20
VC0016048
p12934
sg10
I12
sg11
Vfibromatosis
p12935
sg13
I1
sa(dp12936
g7
I207
sg20
VC0553580
p12937
sg10
I13
sg11
VEwing sarcoma
p12938
sg13
I2
sa(dp12939
g7
I112
sg20
VC0206633
p12940
sg10
I14
sg11
Vangiomyolipoma
p12941
sg13
I1
sa(dp12942
g7
I376
sg20
VC0029463
p12943
sg10
I12
sg11
Vosteosarcoma
p12944
sg13
I1
sa(dp12945
g7
I128
sg20
VC0206651
p12946
sg10
I18
sg11
Vclear cell sarcoma
p12947
sg13
I3
sa(dp12948
g7
I148
sg20
VC0079218
p12949
sg10
I7
sg11
Vdesmoid
p12950
sg13
I1
sa(dp12951
g7
I120
sg20
VC3489413
p12952
sg10
I6
sg11
Vlipoma
p12953
sg13
I1
sa(dp12954
g7
I303
sg20
VC0023827
p12955
sg10
I11
sg11
Vliposarcoma
p12956
sg13
I1
sa(dp12957
g7
I170
sg20
VC0281508
p12958
sg10
I35
sg11
Vdesmoplastic small round cell tumor
p12959
sg13
I5
sa(dp12960
g7
I84
sg20
VC0206657
p12961
sg10
I26
sg11
Valveolar soft part sarcoma
p12962
sg13
I4
sa(dp12963
g7
I222
sg20
VC0238198
p12964
sg10
I30
sg11
Vgastrointestinal stromal tumor
p12965
sg13
I3
sa(dp12966
g7
I55
sg20
VC0037579
p12967
sg10
I18
sg11
Vsoft tissue tumors
p12968
sg13
I3
sa(dp12969
g7
I504
sg20
VC0027708
p12970
sg10
I11
sg11
VWilms tumor
p12971
sg13
I2
sa(dp12972
g7
I279
sg20
VC0023269
p12973
sg10
I14
sg11
Vleiomyosarcoma
p12974
sg13
I1
sa(dp12975
g7
I357
sg20
VC0410005
p12976
sg10
I17
sg11
Vnodular fasciitis
p12977
sg13
I2
sa(dp12978
g7
I316
sg20
VC0751690
p12979
sg10
I39
sg11
Vmalignant peripheral nerve sheath tumor
p12980
sg13
I5
sasa(dp12981
g2
VPathologic diagnosis of CD117-negative GISTs can be facilitated with the application of a panel of immunohistochemical markers, including DOG-1 and WT-1.
p12982
sg4
(lp12983
(dp12984
g7
I138
sg8
g47
sg10
I5
sg11
VDOG-1
p12985
sg13
I1
sa(dp12986
g7
I24
sg8
VP10721
p12987
sg10
I20
sg11
VCD117-negative GISTs
p12988
sg13
I2
sasg17
(lp12989
(dp12990
g7
I39
sg20
VC0238198
p12991
sg10
I5
sg11
VGISTs
p12992
sg13
I1
sasa(dp12993
g2
VIn this study, WT-1 immunoreactivity was explored in 97 gastrointestinal stromal tumours (GISTs).
p12994
sg4
(lp12995
sg17
(lp12996
(dp12997
g7
I56
sg20
VC0238198
p12998
sg10
I32
sg11
Vgastrointestinal stromal tumours
p12999
sg13
I3
sa(dp13000
g7
I90
sg20
VC0238198
p13001
sg10
I5
sg11
VGISTs
p13002
sg13
I1
sasa(dp13003
g2
VThe expression of WT-1 was compared with other immunohistochemical markers of GIST and the association with clinicopathological features was also evaluated.
p13004
sg4
(lp13005
(dp13006
g7
I78
sg8
VP10721
p13007
sg10
I4
sg11
VGIST
p13008
sg13
I1
sasg17
(lp13009
(dp13010
g7
I78
sg20
VC1847319
p13011
sg10
I4
sg11
VGIST
p13012
sg13
I1
sasa(dp13013
g2
VAll 97 GISTs were positive for WT-1 and the staining intensity was strong in 59 (60.8%), moderate in 28 (28.9%) and weak in 10 cases (10.3%).
p13014
sg4
(lp13015
sg17
(lp13016
(dp13017
g7
I7
sg20
VC0238198
p13018
sg10
I5
sg11
VGISTs
p13019
sg13
I1
sasa(dp13020
g2
VAlthough the biological roles of WT-1 in GIST are still unknown, our findings might provide a rationale for immunotherapy targeting WT-1 and a therapeutic solution to the challenge of imatinib-resistant GISTs.
p13021
sg4
(lp13022
sg17
(lp13023
(dp13024
g7
I203
sg20
VC0238198
p13025
sg10
I5
sg11
VGISTs
p13026
sg13
I1
sa(dp13027
g7
I41
sg20
VC0238198
p13028
sg10
I4
sg11
VGIST
p13029
sg13
I1
sasa(dp13030
g2
VWT-1 immunoreactivity in gastrointestinal stromal tumor (GIST) was currently not known.
p13031
sg4
(lp13032
sg17
(lp13033
(dp13034
g7
I57
sg20
VC0238198
p13035
sg10
I4
sg11
VGIST
p13036
sg13
I1
sa(dp13037
g7
I25
sg20
VC0238198
p13038
sg10
I30
sg11
Vgastrointestinal stromal tumor
p13039
sg13
I3
sasa(dp13040
g2
VWe, therefore, investigated the expression of WT-1 in GIST in comparison to other soft tissue tumors by immunohistochemistry and Western blot analysis.
p13041
sg4
(lp13042
sg17
(lp13043
(dp13044
g7
I54
sg20
VC1847319
p13045
sg10
I4
sg11
VGIST
p13046
sg13
I1
sa(dp13047
g7
I82
sg20
VC0037579
p13048
sg10
I18
sg11
Vsoft tissue tumors
p13049
sg13
I3
sasa(dp13050
g2
VWe found that all 28 cases (100%) of GIST are positive for WT-1, diffusely (&gt;75%, 3+) in 13 (46.4%) cases, moderately (26% to 75%, 2+) in 13 (46.4%) cases, and focally (5% to 25%, 1+) in 2 (7.2%) cases.
p13051
sg4
(lp13052
(dp13053
g7
I37
sg8
VP10721
p13054
sg10
I4
sg11
VGIST
p13055
sg13
I1
sasg17
(lp13056
(dp13057
g7
I37
sg20
VC1847319
p13058
sg10
I4
sg11
VGIST
p13059
sg13
I1
sasa(dp13060
g2
VThe significance of cytoplasmic expression of WT-1 in GIST and some smooth muscle tumors is unclear and warrant further investigation.
p13061
sg4
(lp13062
sg17
(lp13063
(dp13064
g7
I68
sg20
VC0206658
p13065
sg10
I20
sg11
Vsmooth muscle tumors
p13066
sg13
I3
sa(dp13067
g7
I54
sg20
VC1847319
p13068
sg10
I4
sg11
VGIST
p13069
sg13
I1
sasa(dp13070
g2
VThe potential roles of WT-1 in the diagnosis and treatment of GIST were discussed.
p13071
sg4
(lp13072
sg17
(lp13073
(dp13074
g7
I62
sg20
VC1847319
p13075
sg10
I4
sg11
VGIST
p13076
sg13
I1
sasa(dp13077
g2
VThis review will discuss five types of sarcoma that display aberrant tyrosine kinase pathway signaling: gastrointestinal stromal tumor, inflammatory myofibroblastic tumor, congenital fibrosarcoma and mesoblastic nephroma, dermatofibrosarcoma protuberans, and desmoplastic small round cell tumor; one sarcoma predisposition syndrome with specific dysregulation of the ras pathway--neurofibromatosis--will also be discussed.
p13078
sg4
(lp13079
(dp13080
g7
I69
sg8
VP29401
p13081
sg10
I15
sg11
Vtyrosine kinase
p13082
sg13
I2
sa(dp13083
g7
I367
sg8
VP01116
p13084
sg10
I3
sg11
Vras
p13085
sg13
I1
sasg17
(lp13086
(dp13087
g7
I39
sg20
VC1261473
p13088
sg10
I7
sg11
Vsarcoma
p13089
sg13
I1
sa(dp13090
g7
I172
sg20
VC0334459
p13091
sg10
I23
sg11
Vcongenital fibrosarcoma
p13092
sg13
I2
sa(dp13093
g7
I200
sg20
VC0206628
p13094
sg10
I20
sg11
Vmesoblastic nephroma
p13095
sg13
I2
sa(dp13096
g7
I380
sg20
VC0162678
p13097
sg10
I17
sg11
Vneurofibromatosis
p13098
sg13
I1
sa(dp13099
g7
I104
sg20
VC0238198
p13100
sg10
I30
sg11
Vgastrointestinal stromal tumor
p13101
sg13
I3
sa(dp13102
g7
I39
sg20
VC1261473
p13103
sg10
I7
sg11
Vsarcoma
p13104
sg13
I1
sa(dp13105
g7
I323
sg20
VC0039082
p13106
sg10
I8
sg11
Vsyndrome
p13107
sg13
I1
sa(dp13108
g7
I259
sg20
VC0281508
p13109
sg10
I35
sg11
Vdesmoplastic small round cell tumor
p13110
sg13
I5
sa(dp13111
g7
I136
sg20
VC0334121
p13112
sg10
I34
sg11
Vinflammatory myofibroblastic tumor
p13113
sg13
I3
sa(dp13114
g7
I222
sg20
VC0392784
p13115
sg10
I31
sg11
Vdermatofibrosarcoma protuberans
p13116
sg13
I2
sasa(dp13117
g2
VAn additional 80 endometrial cancer patients were studied for RAB32 methylation and MSI status.
p13118
sg4
(lp13119
(dp13120
g7
I62
sg8
g47
sg10
I5
sg11
VRAB32
p13121
sg13
I1
sasg17
(lp13122
(dp13123
g7
I84
sg20
VC0920269
p13124
sg10
I3
sg11
VMSI
p13125
sg13
I1
sa(dp13126
g7
I17
sg20
VC0476089
p13127
sg10
I18
sg11
Vendometrial cancer
p13128
sg13
I2
sasa(dp13129
g2
VIn contrast, RAB32 methylation occurred in only 1 of 80 endometrial cancers, including 20 MSI-H, 8 MSI-L and 52 MSS tumors.
p13130
sg4
(lp13131
(dp13132
g7
I13
sg8
g47
sg10
I5
sg11
VRAB32
p13133
sg13
I1
sasg17
(lp13134
(dp13135
g7
I112
sg20
VC0024814
p13136
sg10
I3
sg11
VMSS
p13137
sg13
I1
sa(dp13138
g7
I116
sg20
VC0027651
p13139
sg10
I6
sg11
Vtumors
p13140
sg13
I1
sa(dp13141
g7
I90
sg20
VC0920269
p13142
sg10
I3
sg11
VMSI
p13143
sg13
I1
sa(dp13144
g7
I56
sg20
VC0476089
p13145
sg10
I19
sg11
Vendometrial cancers
p13146
sg13
I2
sa(dp13147
g7
I90
sg20
VC0920269
p13148
sg10
I3
sg11
VMSI
p13149
sg13
I1
sasa(dp13150
g2
VWe conclude that although RAB32 methylation is rare in endometrial cancers, it is strongly associated with hMLH1 hypermethylation and MSI in gastric adenocarcinomas.
p13151
sg4
(lp13152
(dp13153
g7
I107
sg8
VP40692
p13154
sg10
I5
sg11
VhMLH1
p13155
sg13
I1
sa(dp13156
g7
I26
sg8
g47
sg10
I5
sg11
VRAB32
p13157
sg13
I1
sasg17
(lp13158
(dp13159
g7
I134
sg20
VC0920269
p13160
sg10
I3
sg11
VMSI
p13161
sg13
I1
sa(dp13162
g7
I55
sg20
VC0476089
p13163
sg10
I19
sg11
Vendometrial cancers
p13164
sg13
I2
sa(dp13165
g7
I149
sg20
VC0001418
p13166
sg10
I15
sg11
Vadenocarcinomas
p13167
sg13
I1
sasa(dp13168
g2
VPanel, consisting of 16 new potential markers for early and differentiated diagnosis of prostatic gland cancer, was identified: BHLHE40, FOXP1, LOC285205, ITGA9, CTDSPL, FGF12, LOC440944/SETD5, VHL, CLCN2, OSBPL10/ZNF860, LMCD1, FAM19A4, CAND2, MAP4, KY and LRRC58.
p13169
sg4
(lp13170
(dp13171
g7
I177
sg8
g47
sg10
I9
sg11
VLOC440944
p13172
sg13
I1
sa(dp13173
g7
I199
sg8
VP51788
p13174
sg10
I5
sg11
VCLCN2
p13175
sg13
I1
sa(dp13176
g7
I245
sg8
VP27816
p13177
sg10
I4
sg11
VMAP4
p13178
sg13
I1
sa(dp13179
g7
I238
sg8
g47
sg10
I5
sg11
VCAND2
p13180
sg13
I1
sa(dp13181
g7
I222
sg8
g47
sg10
I5
sg11
VLMCD1
p13182
sg13
I1
sa(dp13183
g7
I229
sg8
g47
sg10
I7
sg11
VFAM19A4
p13184
sg13
I1
sa(dp13185
g7
I162
sg8
g47
sg10
I6
sg11
VCTDSPL
p13186
sg13
I1
sa(dp13187
g7
I128
sg8
g47
sg10
I7
sg11
VBHLHE40
p13188
sg13
I1
sa(dp13189
g7
I187
sg8
g47
sg10
I5
sg11
VSETD5
p13190
sg13
I1
sa(dp13191
g7
I258
sg8
g47
sg10
I6
sg11
VLRRC58
p13192
sg13
I1
sa(dp13193
g7
I137
sg8
g47
sg10
I5
sg11
VFOXP1
p13194
sg13
I1
sa(dp13195
g7
I194
sg8
VP40337
p13196
sg10
I3
sg11
VVHL
p13197
sg13
I1
sa(dp13198
g7
I206
sg8
g47
sg10
I7
sg11
VOSBPL10
p13199
sg13
I1
sa(dp13200
g7
I170
sg8
VP61328
p13201
sg10
I5
sg11
VFGF12
p13202
sg13
I1
sa(dp13203
g7
I155
sg8
g47
sg10
I5
sg11
VITGA9
p13204
sg13
I1
sa(dp13205
g7
I214
sg8
g47
sg10
I6
sg11
VZNF860
p13206
sg13
I1
sasg17
(lp13207
(dp13208
g7
I104
sg20
VC0006826
p13209
sg10
I6
sg11
Vcancer
p13210
sg13
I1
sa(dp13211
g7
I194
sg20
VC0019562
p13212
sg10
I3
sg11
VVHL
p13213
sg13
I1
sasa(dp13214
g2
VHowever, there is little information about the involvement of MAP4 in human cancer.
p13215
sg4
(lp13216
(dp13217
g7
I62
sg8
VP27816
p13218
sg10
I4
sg11
VMAP4
p13219
sg13
I1
sasg17
(lp13220
(dp13221
g7
I76
sg20
VC0006826
p13222
sg10
I6
sg11
Vcancer
p13223
sg13
I1
sasa(dp13224
g2
VHere we show that MAP4 serves as a regulator of invasion and migration in esophageal squamous cancer cells.
p13225
sg4
(lp13226
(dp13227
g7
I18
sg8
VP27816
p13228
sg10
I4
sg11
VMAP4
p13229
sg13
I1
sasg17
(lp13230
(dp13231
g7
I48
sg20
VC2699153
p13232
sg10
I8
sg11
Vinvasion
p13233
sg13
I1
sa(dp13234
g7
I94
sg20
VC0006826
p13235
sg10
I6
sg11
Vcancer
p13236
sg13
I1
sasa(dp13237
g2
VThe fusion between echinoderm microtubule-associated protein 4 (EML4) and anaplastic lymphatic tumor kinase (ALK) rearrangement is present in approximately 5% of non-small cell lung cancer (NSCLC) patients.
p13238
sg4
(lp13239
(dp13240
g7
I74
sg8
g47
sg10
I33
sg11
Vanaplastic lymphatic tumor kinase
p13241
sg13
I4
sa(dp13242
g7
I19
sg8
g47
sg10
I43
sg11
Vechinoderm microtubule-associated protein 4
p13243
sg13
I4
sa(dp13244
g7
I64
sg8
g47
sg10
I4
sg11
VEML4
p13245
sg13
I1
sa(dp13246
g7
I109
sg8
g47
sg10
I3
sg11
VALK
p13247
sg13
I1
sasg17
(lp13248
(dp13249
g7
I162
sg20
VC0007131
p13250
sg10
I26
sg11
Vnon-small cell lung cancer
p13251
sg13
I4
sa(dp13252
g7
I190
sg20
VC0007131
p13253
sg10
I5
sg11
VNSCLC
p13254
sg13
I1
sa(dp13255
g7
I95
sg20
VC0027651
p13256
sg10
I5
sg11
Vtumor
p13257
sg13
I1
sasa(dp13258
g2
V#\u80cc#\u666f#\u4e0e#\u76ee#\u7684 #\u68d8#\u76ae#\u52a8#\u7269#\u5fae#\u7ba1#\u76f8#\u5173#\u86cb#\u767d4 (echinoderm microtubule-associated protein 4, EML4) #\u4e0e#\u95f4#\u53d8#\u6027#\u6dcb#\u5df4#\u7624#\u6fc0#\u9176 (anaplastic lymphatic tumor kinase, ALK) #\u91cd#\u6392#\u5f62#\u6210#\u7684#\u878d#\u5408#\u57fa#\u56e0#\u5b58#\u5728#\u4e8e#\u5927#\u7ea65%#\u7684#\u975e#\u5c0f#\u7ec6#\u80de#\u80ba#\u764c (non-small cell lung cancer, NSCLC) #\u60a3#\u8005#\u4e2d, #\u662f#\u7ee7#\u8868#\u76ae#\u751f#\u957f#\u56e0#\u5b50#\u53d7#\u4f53 (epidermal growth factor receptor, EGFR) #\u3001K-ras#\u4e4b#\u540e#\u53c8#\u4e00#\u65b0#\u578b#\u9776#\u70b9#\u57fa#\u56e0#\u3002#\u6709#\u6570#\u636e#\u663e#\u793a#\u643a#\u5e26EML4-ALK#\u878d#\u5408#\u57fa#\u56e0#\u7684NSCLC#\u60a3#\u8005#\u63a5#\u53d7ALK#\u6291#\u5236#\u5242#\u6cbb#\u7597#\u540e, #\u5176#\u75be#\u75c5#\u63a7#\u5236#\u7684#\u6709#\u6548#\u7387#\u53ef#\u8fbe80%, #\u63a2#\u7d22#\u548c#\u5efa#\u7acb#\u80fd#\u591f#\u51c6#\u786e#\u5feb#\u901f#\u68c0#\u6d4b#\u51faNSCLC#\u60a3#\u8005EML4-ALK#\u878d#\u5408#\u7a81#\u53d8#\u7684#\u65b9#\u6cd5, #\u662f#\u7b5b#\u9009#\u51fa#\u9002#\u5408#\u6cbb#\u7597#\u7684#\u4f18#\u52bf#\u4eba#\u7fa4#\u7684#\u5173#\u952e#\u3002#\u672c#\u7814#\u7a76#\u5206#\u6790#\u514d#\u75ab#\u7ec4#\u5316#\u6cd5 (immunohistochemistry, IHC) #\u68c0#\u6d4bEML4-ALK#\u878d#\u5408#\u57fa#\u56e0#\u7a81#\u53d8#\u7684#\u654f#\u611f#\u5ea6#\u4e0e#\u7279#\u5f02#\u5ea6, #\u8bc4#\u4ef7#\u8be5#\u65b9#\u6cd5#\u51c6#\u786e#\u6027#\u53ca#\u4e34#\u5e8a#\u5e94#\u7528#\u4ef7#\u503c, #\u4ece#\u800c#\u4e3a#\u80ba#\u764c#\u60a3#\u8005"#\u4e2a#\u4f53#\u5316#\u5206#\u5b50#\u6cbb#\u7597"#\u63d0#\u4f9b#\u4f9d#\u636e#\u3002#\u65b9#\u6cd5 #\u901a#\u8fc7Pubmed#\u6570#\u636e#\u5e93#\u68c0#\u7d22#\u6240#\u6709#\u7b26#\u5408#\u68c0#\u7d22#\u6761#\u4ef6#\u7684#\u6587#\u732e, #\u672b#\u6b21#\u68c0#\u7d22#\u65e5#\u671f#\u4e3a2015#\u5e742#\u670825#\u65e5, #\u6839#\u636e#\u7eb3#\u5165#\u548c#\u6392#\u9664#\u6807#\u51c6#\u8fdb#\u884c#\u8fdb#\u4e00#\u6b65#\u7b5b#\u9009, #\u91c7#\u7528#\u8bca#\u65ad#\u8bd5#\u9a8cmeta#\u5206#\u6790#\u65b9#\u6cd5, #\u6bd4#\u8f83#\u7279#\u5f02#\u6027#\u6297#\u4f53#\u514d#\u75ab#\u7ec4#\u5316#\u6cd5#\u4e0e"#\u91d1#\u6807#\u51c6"#\u8367#\u5149#\u539f#\u4f4d#\u6742#\u4ea4 (fluorescence in situ hybridization, FISH) #\u6cd5#\u7684#\u654f#\u611f#\u5ea6#\u3001#\u7279#\u5f02#\u5ea6, #\u4ee5#\u660e#\u786e#\u7279#\u5f02#\u6027#\u6297#\u4f53IHC#\u4f5c#\u4e3a#\u7b5b#\u67e5#\u65b9#\u6cd5#\u7684#\u53ef#\u884c#\u6027#\u3002#\u7ed3#\u679c #\u672c#\u658711#\u7bc7#\u6587#\u732e#\u7eb3#\u5165meta#\u5206#\u6790, EML4-ALK#\u878d#\u5408#\u57fa#\u56e0#\u514d#\u75ab#\u7ec4#\u5316#\u7d2f#\u8ba1#\u75c5#\u4f8b3,234#\u4f8b, #\u8bca#\u65ad#\u6bd4#\u503c#\u6bd4 (diagnositic odds ratio, DOR) #\u4e3a1,135.00 (95%CI: 337.10-3,821.46) #\uff1b#\u7efc#\u5408#\u53d7#\u8bd5#\u8005#\u5de5#\u4f5c#\u7279#\u5f81#\u66f2#\u7ebf  (summary receiver operating characteristic curve, SROC) #\u4e0b#\u9762#\u79ef#\u4e3a0.992,3 (SEAUC=0.003,2) , Q*#\u7edf#\u8ba1#\u91cf#\u4e3a0.964,4 (SEQ*=0.008,7) #\u3002#\u7ed3#\u8bba #\u7279#\u5f02#\u6027#\u6297#\u4f53IHC#\u6cd5#\u68c0#\u6d4bEML4-ALK#\u878d#\u5408#\u57fa#\u56e0#\u7684#\u65b9#\u6cd5#\u53ef#\u884c, #\u5177#\u6709#\u9ad8#\u7279#\u5f02#\u5ea6#\u548c#\u654f#\u611f#\u5ea6, #\u53ef#\u4f5c#\u4e3a#\u4e00#\u79cd#\u7b80#\u5355#\u5feb#\u901f#\u7684#\u7b5b#\u67e5#\u65b9#\u6cd5, #\u5177#\u6709#\u4e34#\u5e8a#\u5e94#\u7528#\u4ef7#\u503c#\u3002.
p13259
sg4
(lp13260
(dp13261
g7
I256
sg8
VP01133
p13262
sg10
I32
sg11
Vepidermal growth factor receptor
p13263
sg13
I4
sa(dp13264
g7
I45
sg8
VP27816
p13265
sg10
I32
sg11
Vmicrotubule-associated protein 4
p13266
sg13
I3
sa(dp13267
g7
I79
sg8
g47
sg10
I4
sg11
VEML4
p13268
sg13
I1
sa(dp13269
g7
I140
sg8
g47
sg10
I3
sg11
VALK
p13270
sg13
I1
sa(dp13271
g7
I79
sg8
g47
sg10
I4
sg11
VEML4
p13272
sg13
I1
sa(dp13273
g7
I140
sg8
g47
sg10
I3
sg11
VALK
p13274
sg13
I1
sa(dp13275
g7
I140
sg8
g47
sg10
I3
sg11
VALK
p13276
sg13
I1
sa(dp13277
g7
I140
sg8
g47
sg10
I3
sg11
VALK
p13278
sg13
I1
sa(dp13279
g7
I300
sg8
VP01116
p13280
sg10
I3
sg11
Vras
p13281
sg13
I1
sa(dp13282
g7
I140
sg8
g47
sg10
I3
sg11
VALK
p13283
sg13
I1
sa(dp13284
g7
I140
sg8
g47
sg10
I3
sg11
VALK
p13285
sg13
I1
sasg17
(lp13286
(dp13287
g7
I191
sg20
VC0007131
p13288
sg10
I26
sg11
Vnon-small cell lung cancer
p13289
sg13
I4
sa(dp13290
g7
I126
sg20
VC0027651
p13291
sg10
I5
sg11
Vtumor
p13292
sg13
I1
sa(dp13293
g7
I219
sg20
VC0007131
p13294
sg10
I5
sg11
VNSCLC
p13295
sg13
I1
sasa(dp13296
g2
VBased on these data, we proposed the set of potential biomarkers for detection of prostate cancer and discrimination between prostate tumors with different malignancy and aggressiveness: BHLHE40, FOXP1, LOC285205, ITGA9, CTDSPL, FGF12, LOC440944/SETD5, VHL, CLCN2, OSBPL10/ZNF860, LMCD1, FAM19A4, CAND2, MAP4, KY, and LRRC58.
p13297
sg4
(lp13298
(dp13299
g7
I258
sg8
VP51788
p13300
sg10
I5
sg11
VCLCN2
p13301
sg13
I1
sa(dp13302
g7
I318
sg8
g47
sg10
I6
sg11
VLRRC58
p13303
sg13
I1
sa(dp13304
g7
I281
sg8
g47
sg10
I5
sg11
VLMCD1
p13305
sg13
I1
sa(dp13306
g7
I187
sg8
g47
sg10
I7
sg11
VBHLHE40
p13307
sg13
I1
sa(dp13308
g7
I196
sg8
g47
sg10
I5
sg11
VFOXP1
p13309
sg13
I1
sa(dp13310
g7
I253
sg8
VP40337
p13311
sg10
I3
sg11
VVHL
p13312
sg13
I1
sa(dp13313
g7
I246
sg8
g47
sg10
I5
sg11
VSETD5
p13314
sg13
I1
sa(dp13315
g7
I288
sg8
g47
sg10
I7
sg11
VFAM19A4
p13316
sg13
I1
sa(dp13317
g7
I229
sg8
VP61328
p13318
sg10
I5
sg11
VFGF12
p13319
sg13
I1
sa(dp13320
g7
I221
sg8
g47
sg10
I6
sg11
VCTDSPL
p13321
sg13
I1
sa(dp13322
g7
I304
sg8
VP27816
p13323
sg10
I4
sg11
VMAP4
p13324
sg13
I1
sa(dp13325
g7
I214
sg8
g47
sg10
I5
sg11
VITGA9
p13326
sg13
I1
sa(dp13327
g7
I265
sg8
g47
sg10
I7
sg11
VOSBPL10
p13328
sg13
I1
sa(dp13329
g7
I297
sg8
g47
sg10
I5
sg11
VCAND2
p13330
sg13
I1
sa(dp13331
g7
I273
sg8
g47
sg10
I6
sg11
VZNF860
p13332
sg13
I1
sa(dp13333
g7
I236
sg8
g47
sg10
I9
sg11
VLOC440944
p13334
sg13
I1
sasg17
(lp13335
(dp13336
g7
I82
sg20
VC0600139
p13337
sg10
I15
sg11
Vprostate cancer
p13338
sg13
I2
sa(dp13339
g7
I125
sg20
VC0033578
p13340
sg10
I15
sg11
Vprostate tumors
p13341
sg13
I2
sa(dp13342
g7
I171
sg20
VC0001807
p13343
sg10
I14
sg11
Vaggressiveness
p13344
sg13
I1
sa(dp13345
g7
I156
sg20
VC0006826
p13346
sg10
I10
sg11
Vmalignancy
p13347
sg13
I1
sa(dp13348
g7
I253
sg20
VC0019562
p13349
sg10
I3
sg11
VVHL
p13350
sg13
I1
sasa(dp13351
g2
VWe also analyzed gene expression of MAP4 in 34 patients with bladder cancer using immunohistochemical staining assay.
p13352
sg4
(lp13353
(dp13354
g7
I36
sg8
VP27816
p13355
sg10
I4
sg11
VMAP4
p13356
sg13
I1
sasg17
(lp13357
(dp13358
g7
I61
sg20
VC0699885
p13359
sg10
I14
sg11
Vbladder cancer
p13360
sg13
I2
sasa(dp13361
g2
VWe used cAMP elevators and small interfering RNA of MAP4 here, found that both of them can potently inhibit the invasion and the migration of bladder cancer cells by disrupting microtubule (MT) cytoskeleton.
p13362
sg4
(lp13363
(dp13364
g7
I52
sg8
VP27816
p13365
sg10
I4
sg11
VMAP4
p13366
sg13
I1
sasg17
(lp13367
(dp13368
g7
I112
sg20
VC2699153
p13369
sg10
I8
sg11
Vinvasion
p13370
sg13
I1
sa(dp13371
g7
I142
sg20
VC0699885
p13372
sg10
I14
sg11
Vbladder cancer
p13373
sg13
I2
sasa(dp13374
g2
VConsistently, the bladder cancer grade is positively correlated with the protein level of MAP4.
p13375
sg4
(lp13376
(dp13377
g7
I90
sg8
VP27816
p13378
sg10
I4
sg11
VMAP4
p13379
sg13
I1
sasg17
(lp13380
(dp13381
g7
I18
sg20
VC0699885
p13382
sg10
I14
sg11
Vbladder cancer
p13383
sg13
I2
sasa(dp13384
g2
VOur results indicated that the cAMP/PKA signaling pathway might inhibit bladder cancer cell invasion by targeting MAP4-dependent microtubule dynamics, which could be exploited for the therapy of invasive bladder cancer.
p13385
sg4
(lp13386
(dp13387
g7
I114
sg8
VP27816
p13388
sg10
I4
sg11
VMAP4
p13389
sg13
I1
sa(dp13390
g7
I36
sg8
VP17612
p13391
sg10
I3
sg11
VPKA
p13392
sg13
I1
sasg17
(lp13393
(dp13394
g7
I87
sg20
VC2699153
p13395
sg10
I13
sg11
Vcell invasion
p13396
sg13
I2
sa(dp13397
g7
I72
sg20
VC0699885
p13398
sg10
I14
sg11
Vbladder cancer
p13399
sg13
I2
sa(dp13400
g7
I195
sg20
VC0859917
p13401
sg10
I23
sg11
Vinvasive bladder cancer
p13402
sg13
I3
sasa(dp13403
g2
VIrritable bowel syndrome symptoms consistently improved after 3 weeks of LFD, and significantly more participants reported symptom relief in response to placebo (80%) than FOS (30%).
p13404
sg4
(lp13405
sg17
(lp13406
(dp13407
g7
I25
sg20
VC1457887
p13408
sg10
I7
sg11
Vsymptom
p13409
sg13
I1
sa(dp13410
g7
I0
sg20
VC0022104
p13411
sg10
I24
sg11
VIrritable bowel syndrome
p13412
sg13
I3
sasa(dp13413
g2
VChildren with congenital esophageal atresia (EA) and tracheoesophageal fistula (TEF) have chronic respiratory symptoms including recurrent pneumonia, wheezing and persistent cough.
p13414
sg4
(lp13415
sg17
(lp13416
(dp13417
g7
I25
sg20
VC0014850
p13418
sg10
I18
sg11
Vesophageal atresia
p13419
sg13
I2
sa(dp13420
g7
I163
sg20
VC0562483
p13421
sg10
I16
sg11
Vpersistent cough
p13422
sg13
I2
sa(dp13423
g7
I80
sg20
VC0040588
p13424
sg10
I3
sg11
VTEF
p13425
sg13
I1
sa(dp13426
g7
I129
sg20
VC0694550
p13427
sg10
I19
sg11
Vrecurrent pneumonia
p13428
sg13
I2
sa(dp13429
g7
I45
sg20
VC0014850
p13430
sg10
I2
sg11
VEA
p13431
sg13
I1
sa(dp13432
g7
I150
sg20
VC0043144
p13433
sg10
I8
sg11
Vwheezing
p13434
sg13
I1
sa(dp13435
g7
I53
sg20
VC0040588
p13436
sg10
I25
sg11
Vtracheoesophageal fistula
p13437
sg13
I2
sa(dp13438
g7
I98
sg20
VC0037090
p13439
sg10
I20
sg11
Vrespiratory symptoms
p13440
sg13
I2
sasa(dp13441
g2
VAdult patients experiencing symptoms of cough and recurrent aspiration pneumonia should be evaluated for congenital TEF.
p13442
sg4
(lp13443
sg17
(lp13444
(dp13445
g7
I50
sg20
VC0747651
p13446
sg10
I30
sg11
Vrecurrent aspiration pneumonia
p13447
sg13
I3
sa(dp13448
g7
I40
sg20
VC0010200
p13449
sg10
I5
sg11
Vcough
p13450
sg13
I1
sasa(dp13451
g2
VOur patient underwent primary repair of OA/TEF malformations, which was later complicated by pneumonia and a recurrent TEF.
p13452
sg4
(lp13453
sg17
(lp13454
(dp13455
g7
I93
sg20
VC0032285
p13456
sg10
I9
sg11
Vpneumonia
p13457
sg13
I1
sa(dp13458
g7
I47
sg20
VC0000768
p13459
sg10
I13
sg11
Vmalformations
p13460
sg13
I1
sasa(dp13461
g2
VThese findings suggest that a relatively small increase in plasma TNF-Alfa, and decreases in urine TNF-Alfa, GM-CSF, and IL-15 from just before to just after the diagnosis of pneumonia could be markers for an increased risk of PUs in individuals with pneumonia after traumatic SCI.
p13462
sg4
(lp13463
(dp13464
g7
I121
sg8
VP40933
p13465
sg10
I5
sg11
VIL-15
p13466
sg13
I1
sa(dp13467
g7
I93
sg8
VP01375
p13468
sg10
I14
sg11
Vurine TNF-Alfa
p13469
sg13
I2
sa(dp13470
g7
I109
sg8
VP04141
p13471
sg10
I6
sg11
VGM-CSF
p13472
sg13
I1
sa(dp13473
g7
I66
sg8
VP01375
p13474
sg10
I3
sg11
VTNF
p13475
sg13
I1
sasg17
(lp13476
(dp13477
g7
I175
sg20
VC0032285
p13478
sg10
I9
sg11
Vpneumonia
p13479
sg13
I1
sa(dp13480
g7
I175
sg20
VC0032285
p13481
sg10
I9
sg11
Vpneumonia
p13482
sg13
I1
sasa(dp13483
g2
VThe study aimed to investigate the innate cytokine interleukin-15 (IL-15) as a marker of disease severity.A prospective single-centre observational study was conducted in a university-affiliated paediatric teaching hospital, comparing children (0-18 months) hospitalised for viral bronchiolitis, those admitted to the paediatric intensive care unit with severe disease and healthy age-matched controls.
p13484
sg4
(lp13485
(dp13486
g7
I67
sg8
VP40933
p13487
sg10
I5
sg11
VIL-15
p13488
sg13
I1
sa(dp13489
g7
I42
sg8
VP13236
p13490
sg10
I23
sg11
Vcytokine interleukin-15
p13491
sg13
I2
sasg17
(lp13492
(dp13493
g7
I275
sg20
VC0006274
p13494
sg10
I19
sg11
Vviral bronchiolitis
p13495
sg13
I2
sasa(dp13496
g2
VPeripheral blood mononuclear cell (PBMC) IL-15 mRNA expression was significantly higher in those with moderate severity bronchiolitis compared with controls and those with severe disease.
p13497
sg4
(lp13498
(dp13499
g7
I11
sg8
VP40933
p13500
sg10
I40
sg11
Vblood mononuclear cell (PBMC) IL-15 mRNA
p13501
sg13
I6
sasg17
(lp13502
(dp13503
g7
I120
sg20
VC0006271
p13504
sg10
I13
sg11
Vbronchiolitis
p13505
sg13
I1
sasa(dp13506
g2
VTargets of de-regulated miRNA were differentially expressed in bronchiolitis, including JAK3, STAT5A and NFKB1 on the IL-15 signalling pathway.IL-15 is associated with disease severity in children hospitalised with viral bronchiolitis.
p13507
sg4
(lp13508
(dp13509
g7
I88
sg8
VP52333
p13510
sg10
I4
sg11
VJAK3
p13511
sg13
I1
sa(dp13512
g7
I118
sg8
VP40933
p13513
sg10
I30
sg11
VIL-15 signalling pathway.IL-15
p13514
sg13
I3
sa(dp13515
g7
I105
sg8
VP19838
p13516
sg10
I5
sg11
VNFKB1
p13517
sg13
I1
sa(dp13518
g7
I94
sg8
VP42229
p13519
sg10
I6
sg11
VSTAT5A
p13520
sg13
I1
sasg17
(lp13521
(dp13522
g7
I215
sg20
VC0006274
p13523
sg10
I19
sg11
Vviral bronchiolitis
p13524
sg13
I2
sa(dp13525
g7
I63
sg20
VC0006271
p13526
sg10
I13
sg11
Vbronchiolitis
p13527
sg13
I1
sasa(dp13528
g2
VThe present study aimed to investigate the role of Interleukin 15 (IL-15) in protein degradation in skeletal muscle mediated by the ubiquitin-proteasome pathway (UPP) in a rat model of chronic obstructive pulmonary disease (COPD).
p13529
sg4
(lp13530
(dp13531
g7
I132
sg8
VP62979
p13532
sg10
I9
sg11
Vubiquitin
p13533
sg13
I1
sa(dp13534
g7
I51
sg8
VP40933
p13535
sg10
I14
sg11
VInterleukin 15
p13536
sg13
I2
sa(dp13537
g7
I67
sg8
VP40933
p13538
sg10
I5
sg11
VIL-15
p13539
sg13
I1
sasg17
(lp13540
(dp13541
g7
I185
sg20
VC0024117
p13542
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p13543
sg13
I4
sa(dp13544
g7
I224
sg20
VC0024117
p13545
sg10
I4
sg11
VCOPD
p13546
sg13
I1
sasa(dp13547
g2
VPatients with SWA were older at seizure diagnosis than those with SA (p=0.04), were less often referred for evaluation of seizures or epilepsy (p=0.04), and were referred faster for VEM, despite SWA were significantly less likely to include motor manifestations (p=0.0004).
p13548
sg4
(lp13549
sg17
(lp13550
(dp13551
g7
I122
sg20
VC0036572
p13552
sg10
I8
sg11
Vseizures
p13553
sg13
I1
sa(dp13554
g7
I32
sg20
VC0036572
p13555
sg10
I7
sg11
Vseizure
p13556
sg13
I1
sa(dp13557
g7
I134
sg20
VC0014544
p13558
sg10
I8
sg11
Vepilepsy
p13559
sg13
I1
sa(dp13560
g7
I241
sg20
VC1334804
p13561
sg10
I20
sg11
Vmotor manifestations
p13562
sg13
I2
sasa(dp13563
g2
VWe suggest that patients with SWA have a unique epilepsy syndrome.
p13564
sg4
(lp13565
sg17
(lp13566
(dp13567
g7
I57
sg20
VC0039082
p13568
sg10
I8
sg11
Vsyndrome
p13569
sg13
I1
sa(dp13570
g7
I48
sg20
VC0014544
p13571
sg10
I8
sg11
Vepilepsy
p13572
sg13
I1
sasa(dp13573
g2
VAchilles tendon (T) and Hoffmann (H) reflexes were evoked during spike and wave activity (SWA) in 6 patients with generalized epilepsy, selected on the basis of their photosensitivity.
p13574
sg4
(lp13575
sg17
(lp13576
(dp13577
g7
I167
sg20
VC0393720
p13578
sg10
I16
sg11
Vphotosensitivity
p13579
sg13
I1
sa(dp13580
g7
I114
sg20
VC0014548
p13581
sg10
I20
sg11
Vgeneralized epilepsy
p13582
sg13
I2
sasa(dp13583
g2
VPartial epilepsy after shunting manifested itself in 15 patients, but this did not correlate with the side of the shunt or with the side of the SWA in the EEG.
p13584
sg4
(lp13585
sg17
(lp13586
(dp13587
g7
I0
sg20
VC0014547
p13588
sg10
I16
sg11
VPartial epilepsy
p13589
sg13
I2
sasa(dp13590
g2
VWe hypothesized that the NDI may be due to of severe hypokalemia induced tubular dysfunction.
p13591
sg4
(lp13592
sg17
(lp13593
(dp13594
g7
I25
sg20
VC1563705
p13595
sg10
I3
sg11
VNDI
p13596
sg13
I1
sasa(dp13597
g2
VPreviously, we reported an increase of V1aR mRNA and a decrease of V2R mRNA in the collecting ducts under chronic metabolic acidosis.
p13598
sg4
(lp13599
(dp13600
g7
I39
sg8
VP37288
p13601
sg10
I9
sg11
VV1aR mRNA
p13602
sg13
I2
sa(dp13603
g7
I67
sg8
VP30518
p13604
sg10
I8
sg11
VV2R mRNA
p13605
sg13
I2
sasg17
(lp13606
(dp13607
g7
I114
sg20
VC0220981
p13608
sg10
I18
sg11
Vmetabolic acidosis
p13609
sg13
I2
sasa(dp13610
g2
VPatients with moderate to severe nonproliferative diabetic retinopathy (NPDR) had POBF 18% higher than the control (mean OBF, 943 microL/min).
p13611
sg4
(lp13612
sg17
(lp13613
(dp13614
g7
I26
sg20
VC0730278
p13615
sg10
I44
sg11
Vsevere nonproliferative diabetic retinopathy
p13616
sg13
I4
sasa(dp13617
g2
VAmong PRP-treated subjects with PDR, ocular blood flow was 22% below the control (mean OBF, 619 microL/min), and 34% less than moderate to severe nonproliferative diabetic retinopathy.
p13618
sg4
(lp13619
(dp13620
g7
I6
sg8
g47
sg10
I3
sg11
VPRP
p13621
sg13
I1
sasg17
(lp13622
(dp13623
g7
I139
sg20
VC0730278
p13624
sg10
I44
sg11
Vsevere nonproliferative diabetic retinopathy
p13625
sg13
I4
sa(dp13626
g7
I32
sg20
VC1845050
p13627
sg10
I3
sg11
VPDR
p13628
sg13
I1
sasa(dp13629
g2
VDiabetic patients with no retinopathy or mild NPDR had OBF indistinguishable from the control (785 vs. 797 microL/min).
p13630
sg4
(lp13631
sg17
(lp13632
(dp13633
g7
I26
sg20
VC0035309
p13634
sg10
I11
sg11
Vretinopathy
p13635
sg13
I1
sasa(dp13636
g2
VPOBF is unaffected early in diabetic retinopathy, but increases significantly in eyes with moderate to severe NPDR.
p13637
sg4
(lp13638
sg17
(lp13639
(dp13640
g7
I28
sg20
VC0011884
p13641
sg10
I20
sg11
Vdiabetic retinopathy
p13642
sg13
I2
sa(dp13643
g7
I103
sg20
VC0730278
p13644
sg10
I11
sg11
Vsevere NPDR
p13645
sg13
I2
sasa(dp13646
g2
VThese experimental data represent the largest published assessment of POBF in NPDR.
p13647
sg4
(lp13648
sg17
(lp13649
sa(dp13650
g2
VPOBF in the patients with non-exudative and exudative age related macular degeneration (AMD) was investigated.
p13651
sg4
(lp13652
sg17
(lp13653
(dp13654
g7
I88
sg20
VC0242383
p13655
sg10
I3
sg11
VAMD
p13656
sg13
I1
sa(dp13657
g7
I54
sg20
VC0242383
p13658
sg10
I32
sg11
Vage related macular degeneration
p13659
sg13
I4
sasa(dp13660
g2
VThe POBF increased but was still below normal levels at the NPDR stage, and then increased to an above normal level in the PPDR/PDR stage of diabetic retinopathy.
p13661
sg4
(lp13662
sg17
(lp13663
(dp13664
g7
I141
sg20
VC0011884
p13665
sg10
I20
sg11
Vdiabetic retinopathy
p13666
sg13
I2
sa(dp13667
g7
I61
sg20
VC1845050
p13668
sg10
I3
sg11
VPDR
p13669
sg13
I1
sasa(dp13670
g2
VRight before and one month after this fourth vaccine dose, the avidity of IgG antibodies against diphtheria toxin (DT), tetanus toxin (TT), pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (Prn) was determined using 1.5 M ammonium thiocyanate as dissociating agent.
p13671
sg4
(lp13672
(dp13673
g7
I209
sg8
g47
sg10
I3
sg11
VPrn
p13674
sg13
I1
sa(dp13675
g7
I198
sg8
g47
sg10
I9
sg11
Vpertactin
p13676
sg13
I1
sa(dp13677
g7
I115
sg8
g47
sg10
I2
sg11
VDT
p13678
sg13
I1
sa(dp13679
g7
I140
sg8
g47
sg10
I15
sg11
Vpertussis toxin
p13680
sg13
I2
sa(dp13681
g7
I97
sg8
g47
sg10
I16
sg11
Vdiphtheria toxin
p13682
sg13
I2
sa(dp13683
g7
I157
sg8
g47
sg10
I2
sg11
VPT
p13684
sg13
I1
sasg17
(lp13685
(dp13686
g7
I162
sg20
VC1704429
p13687
sg10
I25
sg11
Vfilamentous hemagglutinin
p13688
sg13
I2
sa(dp13689
g7
I189
sg20
VC1704429
p13690
sg10
I3
sg11
VFHA
p13691
sg13
I1
sa(dp13692
g7
I140
sg20
VC0043167
p13693
sg10
I9
sg11
Vpertussis
p13694
sg13
I1
sa(dp13695
g7
I120
sg20
VC0039614
p13696
sg10
I7
sg11
Vtetanus
p13697
sg13
I1
sa(dp13698
g7
I97
sg20
VC0012546
p13699
sg10
I10
sg11
Vdiphtheria
p13700
sg13
I1
sasa(dp13701
g2
VImmunoglobulin G (IgG) antibodies against pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (Prn), tetanus toxoid (TT), and diphtheria toxoid (DT) were measured using commercially available enzyme-linked immunosorbent assays (ELISA).
p13702
sg4
(lp13703
(dp13704
g7
I18
sg8
g47
sg10
I3
sg11
VIgG
p13705
sg13
I1
sa(dp13706
g7
I97
sg8
g47
sg10
I9
sg11
Vpertactin
p13707
sg13
I1
sa(dp13708
g7
I108
sg8
g47
sg10
I3
sg11
VPrn
p13709
sg13
I1
sa(dp13710
g7
I0
sg8
g47
sg10
I16
sg11
VImmunoglobulin G
p13711
sg13
I2
sa(dp13712
g7
I59
sg8
g47
sg10
I2
sg11
VPT
p13713
sg13
I1
sa(dp13714
g7
I42
sg8
g47
sg10
I15
sg11
Vpertussis toxin
p13715
sg13
I2
sasg17
(lp13716
(dp13717
g7
I42
sg20
VC0043167
p13718
sg10
I9
sg11
Vpertussis
p13719
sg13
I1
sa(dp13720
g7
I64
sg20
VC1704429
p13721
sg10
I25
sg11
Vfilamentous hemagglutinin
p13722
sg13
I2
sa(dp13723
g7
I114
sg20
VC0039614
p13724
sg10
I7
sg11
Vtetanus
p13725
sg13
I1
sa(dp13726
g7
I139
sg20
VC0012546
p13727
sg10
I10
sg11
Vdiphtheria
p13728
sg13
I1
sa(dp13729
g7
I91
sg20
VC1704429
p13730
sg10
I3
sg11
VFHA
p13731
sg13
I1
sasa(dp13732
g2
VWe have developed a magnetic bead-based pentaplex immunoassay (MIA) for the simultaneous detection of IgG antibodies against diphtheria toxin (DT), tetanus toxin (TT), pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (Prn).
p13733
sg4
(lp13734
(dp13735
g7
I185
sg8
g47
sg10
I2
sg11
VPT
p13736
sg13
I1
sa(dp13737
g7
I237
sg8
g47
sg10
I3
sg11
VPrn
p13738
sg13
I1
sa(dp13739
g7
I143
sg8
g47
sg10
I2
sg11
VDT
p13740
sg13
I1
sa(dp13741
g7
I226
sg8
g47
sg10
I9
sg11
Vpertactin
p13742
sg13
I1
sa(dp13743
g7
I168
sg8
g47
sg10
I15
sg11
Vpertussis toxin
p13744
sg13
I2
sa(dp13745
g7
I125
sg8
g47
sg10
I16
sg11
Vdiphtheria toxin
p13746
sg13
I2
sasg17
(lp13747
(dp13748
g7
I148
sg20
VC0039614
p13749
sg10
I7
sg11
Vtetanus
p13750
sg13
I1
sa(dp13751
g7
I190
sg20
VC1704429
p13752
sg10
I25
sg11
Vfilamentous hemagglutinin
p13753
sg13
I2
sa(dp13754
g7
I168
sg20
VC0043167
p13755
sg10
I9
sg11
Vpertussis
p13756
sg13
I1
sa(dp13757
g7
I217
sg20
VC1704429
p13758
sg10
I3
sg11
VFHA
p13759
sg13
I1
sa(dp13760
g7
I125
sg20
VC0012546
p13761
sg10
I10
sg11
Vdiphtheria
p13762
sg13
I1
sasa(dp13763
g2
VImmunoglobulin G (IgG) antibodies against pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (Prn), tetanus toxoid (TT) and diphtheria toxoid (DT) were measured using commercially available ELISA tests.
p13764
sg4
(lp13765
(dp13766
g7
I18
sg8
g47
sg10
I3
sg11
VIgG
p13767
sg13
I1
sa(dp13768
g7
I97
sg8
g47
sg10
I9
sg11
Vpertactin
p13769
sg13
I1
sa(dp13770
g7
I108
sg8
g47
sg10
I3
sg11
VPrn
p13771
sg13
I1
sa(dp13772
g7
I0
sg8
g47
sg10
I16
sg11
VImmunoglobulin G
p13773
sg13
I2
sa(dp13774
g7
I59
sg8
g47
sg10
I2
sg11
VPT
p13775
sg13
I1
sa(dp13776
g7
I42
sg8
g47
sg10
I15
sg11
Vpertussis toxin
p13777
sg13
I2
sasg17
(lp13778
(dp13779
g7
I42
sg20
VC0043167
p13780
sg10
I9
sg11
Vpertussis
p13781
sg13
I1
sa(dp13782
g7
I64
sg20
VC1704429
p13783
sg10
I25
sg11
Vfilamentous hemagglutinin
p13784
sg13
I2
sa(dp13785
g7
I114
sg20
VC0039614
p13786
sg10
I7
sg11
Vtetanus
p13787
sg13
I1
sa(dp13788
g7
I138
sg20
VC0012546
p13789
sg10
I10
sg11
Vdiphtheria
p13790
sg13
I1
sa(dp13791
g7
I91
sg20
VC1704429
p13792
sg10
I3
sg11
VFHA
p13793
sg13
I1
sasa(dp13794
g2
VAntibody geometric mean concentrations (GMCs) against tetanus (TT), diphtheria (DT), pertussis toxin (PT), filamentous haemagglutinin (FHA) and pertactin (Prn) were measured with commercial ELISA tests in samples taken preceding maternal vaccination and one month afterwards, at delivery and from the cord blood, and in infants before and 1 month after the primary series of 3 pertussis containing hexavalent vaccines.
p13795
sg4
(lp13796
(dp13797
g7
I155
sg8
g47
sg10
I3
sg11
VPrn
p13798
sg13
I1
sa(dp13799
g7
I144
sg8
g47
sg10
I9
sg11
Vpertactin
p13800
sg13
I1
sa(dp13801
g7
I85
sg8
g47
sg10
I15
sg11
Vpertussis toxin
p13802
sg13
I2
sa(dp13803
g7
I102
sg8
g47
sg10
I2
sg11
VPT
p13804
sg13
I1
sasg17
(lp13805
(dp13806
g7
I301
sg20
VC0035334
p13807
sg10
I4
sg11
Vcord
p13808
sg13
I1
sa(dp13809
g7
I135
sg20
VC1704429
p13810
sg10
I3
sg11
VFHA
p13811
sg13
I1
sa(dp13812
g7
I85
sg20
VC0043167
p13813
sg10
I9
sg11
Vpertussis
p13814
sg13
I1
sa(dp13815
g7
I85
sg20
VC0043167
p13816
sg10
I9
sg11
Vpertussis
p13817
sg13
I1
sa(dp13818
g7
I68
sg20
VC0012546
p13819
sg10
I10
sg11
Vdiphtheria
p13820
sg13
I1
sa(dp13821
g7
I54
sg20
VC0039614
p13822
sg10
I7
sg11
Vtetanus
p13823
sg13
I1
sa(dp13824
g7
I107
sg20
VC1704429
p13825
sg10
I26
sg11
Vfilamentous haemagglutinin
p13826
sg13
I2
sa(dp13827
g7
I63
sg20
VC0039614
p13828
sg10
I2
sg11
VTT
p13829
sg13
I1
sa(dp13830
g7
I80
sg20
VC0012546
p13831
sg10
I2
sg11
VDT
p13832
sg13
I1
sasa(dp13833
g2
VImmunoglobulin G (IgG) against tetanus (TT), diphtheria (DT), pertussis toxin (PT), filamentous hemaglutinin (FHA) and pertactin (Prn) were measured using commercial ELISA tests, at baseline, 1 month after maternal vaccination, at delivery, and in infants from cord blood and before and after the primary series (EPI: month 2-3-4) of a pertussis containing vaccine.
p13834
sg4
(lp13835
(dp13836
g7
I18
sg8
g47
sg10
I3
sg11
VIgG
p13837
sg13
I1
sa(dp13838
g7
I79
sg8
g47
sg10
I2
sg11
VPT
p13839
sg13
I1
sa(dp13840
g7
I0
sg8
g47
sg10
I16
sg11
VImmunoglobulin G
p13841
sg13
I2
sa(dp13842
g7
I62
sg8
g47
sg10
I15
sg11
Vpertussis toxin
p13843
sg13
I2
sa(dp13844
g7
I119
sg8
g47
sg10
I9
sg11
Vpertactin
p13845
sg13
I1
sa(dp13846
g7
I130
sg8
g47
sg10
I3
sg11
VPrn
p13847
sg13
I1
sasg17
(lp13848
(dp13849
g7
I62
sg20
VC0043167
p13850
sg10
I9
sg11
Vpertussis
p13851
sg13
I1
sa(dp13852
g7
I45
sg20
VC0012546
p13853
sg10
I10
sg11
Vdiphtheria
p13854
sg13
I1
sa(dp13855
g7
I62
sg20
VC0043167
p13856
sg10
I9
sg11
Vpertussis
p13857
sg13
I1
sa(dp13858
g7
I57
sg20
VC0012546
p13859
sg10
I2
sg11
VDT
p13860
sg13
I1
sa(dp13861
g7
I31
sg20
VC0039614
p13862
sg10
I7
sg11
Vtetanus
p13863
sg13
I1
sa(dp13864
g7
I84
sg20
VC1704429
p13865
sg10
I24
sg11
Vfilamentous hemaglutinin
p13866
sg13
I2
sa(dp13867
g7
I110
sg20
VC1704429
p13868
sg10
I3
sg11
VFHA
p13869
sg13
I1
sa(dp13870
g7
I261
sg20
VC0035334
p13871
sg10
I4
sg11
Vcord
p13872
sg13
I1
sa(dp13873
g7
I40
sg20
VC0039614
p13874
sg10
I2
sg11
VTT
p13875
sg13
I1
sa(dp13876
g7
I313
sg20
VC0267963
p13877
sg10
I3
sg11
VEPI
p13878
sg13
I1
sasa(dp13879
g2
VAnti-Pertussis Toxin (PT), filamentous hemagglutinin (FHA), pertactin (Prn), tetanus toxin (TT) and diphtheria toxin (DT) antibodies were measured by ELISA.
p13880
sg4
(lp13881
(dp13882
g7
I100
sg8
g47
sg10
I32
sg11
Vdiphtheria toxin (DT) antibodies
p13883
sg13
I4
sa(dp13884
g7
I22
sg8
g47
sg10
I2
sg11
VPT
p13885
sg13
I1
sa(dp13886
g7
I71
sg8
g47
sg10
I3
sg11
VPrn
p13887
sg13
I1
sa(dp13888
g7
I60
sg8
g47
sg10
I9
sg11
Vpertactin
p13889
sg13
I1
sa(dp13890
g7
I0
sg8
g47
sg10
I20
sg11
VAnti-Pertussis Toxin
p13891
sg13
I2
sasg17
(lp13892
(dp13893
g7
I5
sg20
VC0043167
p13894
sg10
I9
sg11
VPertussis
p13895
sg13
I1
sa(dp13896
g7
I54
sg20
VC1704429
p13897
sg10
I3
sg11
VFHA
p13898
sg13
I1
sa(dp13899
g7
I77
sg20
VC0039614
p13900
sg10
I7
sg11
Vtetanus
p13901
sg13
I1
sa(dp13902
g7
I27
sg20
VC1704429
p13903
sg10
I25
sg11
Vfilamentous hemagglutinin
p13904
sg13
I2
sa(dp13905
g7
I100
sg20
VC0012546
p13906
sg10
I10
sg11
Vdiphtheria
p13907
sg13
I1
sasa(dp13908
g2
VGeometric mean titers were not different after prebiotic supplementation at 5 months, Ptx (37/44 EU/ml), FHA (78/96 EU/ml), Prn (78/80 EU/ml), Diphtheria (0.40/0.57 IU/ml), Tetanus (0.74/0.99 IU/ml) and Hib (0.35/0.63 myg/ml), and at 12 months Ptx (55/66 EU/ml), FHA (122/119 EU/ml), Prn (116/106 Eu/ml), Diphtheria (0.88/1.11 IU/ml), Tetanus (1.64/1.79 IU/ml) and Hib (2.91/2.55 myg/ml).
p13909
sg4
(lp13910
(dp13911
g7
I124
sg8
g47
sg10
I3
sg11
VPrn
p13912
sg13
I1
sasg17
(lp13913
(dp13914
g7
I173
sg20
VC0039614
p13915
sg10
I7
sg11
VTetanus
p13916
sg13
I1
sa(dp13917
g7
I105
sg20
VC1704429
p13918
sg10
I3
sg11
VFHA
p13919
sg13
I1
sa(dp13920
g7
I105
sg20
VC1704429
p13921
sg10
I3
sg11
VFHA
p13922
sg13
I1
sa(dp13923
g7
I173
sg20
VC0039614
p13924
sg10
I7
sg11
VTetanus
p13925
sg13
I1
sa(dp13926
g7
I143
sg20
VC0012546
p13927
sg10
I10
sg11
VDiphtheria
p13928
sg13
I1
sa(dp13929
g7
I143
sg20
VC0012546
p13930
sg10
I10
sg11
VDiphtheria
p13931
sg13
I1
sasa(dp13932
g2
VThis multiplex immunoassay (MIA) can simultaneously determine levels of specific mouse serum IgG antibodies to P antigens P.69 pertactin (P.69 Prn), filamentous hemagglutinin (FHA), pertussis toxin (Ptx), and combined fimbria type 2 and 3 antigens (Fim2/3) and to diphtheria toxin (Dtx) and tetanus toxin (TT) in a single well.
p13933
sg4
(lp13934
(dp13935
g7
I199
sg8
g47
sg10
I3
sg11
VPtx
p13936
sg13
I1
sa(dp13937
g7
I249
sg8
VP07333
p13938
sg10
I6
sg11
VFim2/3
p13939
sg13
I1
sa(dp13940
g7
I138
sg8
g47
sg10
I8
sg11
VP.69 Prn
p13941
sg13
I2
sa(dp13942
g7
I81
sg8
g47
sg10
I26
sg11
Vmouse serum IgG antibodies
p13943
sg13
I4
sa(dp13944
g7
I111
sg8
VP01893
p13945
sg10
I25
sg11
VP antigens P.69 pertactin
p13946
sg13
I4
sa(dp13947
g7
I264
sg8
g47
sg10
I16
sg11
Vdiphtheria toxin
p13948
sg13
I2
sa(dp13949
g7
I209
sg8
VP01893
p13950
sg10
I38
sg11
Vcombined fimbria type 2 and 3 antigens
p13951
sg13
I7
sa(dp13952
g7
I282
sg8
g47
sg10
I3
sg11
VDtx
p13953
sg13
I1
sa(dp13954
g7
I182
sg8
g47
sg10
I15
sg11
Vpertussis toxin
p13955
sg13
I2
sasg17
(lp13956
(dp13957
g7
I182
sg20
VC0043167
p13958
sg10
I9
sg11
Vpertussis
p13959
sg13
I1
sa(dp13960
g7
I264
sg20
VC0012546
p13961
sg10
I10
sg11
Vdiphtheria
p13962
sg13
I1
sa(dp13963
g7
I176
sg20
VC1704429
p13964
sg10
I3
sg11
VFHA
p13965
sg13
I1
sa(dp13966
g7
I149
sg20
VC1704429
p13967
sg10
I25
sg11
Vfilamentous hemagglutinin
p13968
sg13
I2
sa(dp13969
g7
I291
sg20
VC0039614
p13970
sg10
I7
sg11
Vtetanus
p13971
sg13
I1
sasa(dp13972
g2
VOur recent study showed reduced G protein Gamma2 subunit (Gng2/GNG2) expression levels in malignant melanoma cells compared with those in benign melanocytic cells in both mice and humans.
p13973
sg4
(lp13974
(dp13975
g7
I63
sg8
VP59768
p13976
sg10
I4
sg11
VGNG2
p13977
sg13
I1
sa(dp13978
g7
I58
sg8
VP59768
p13979
sg10
I4
sg11
VGng2
p13980
sg13
I1
sa(dp13981
g7
I32
sg8
VP59768
p13982
sg10
I24
sg11
VG protein Gamma2 subunit
p13983
sg13
I4
sasg17
(lp13984
(dp13985
g7
I90
sg20
VC0025202
p13986
sg10
I18
sg11
Vmalignant melanoma
p13987
sg13
I2
sasa(dp13988
g2
VOur recent study also showed that reduced GNG2 alone augmented proliferation of malignant melanoma cells.
p13989
sg4
(lp13990
(dp13991
g7
I42
sg8
VP59768
p13992
sg10
I4
sg11
VGNG2
p13993
sg13
I1
sasg17
(lp13994
(dp13995
g7
I80
sg20
VC0025202
p13996
sg10
I18
sg11
Vmalignant melanoma
p13997
sg13
I2
sa(dp13998
g7
I63
sg20
VC0334094
p13999
sg10
I13
sg11
Vproliferation
p14000
sg13
I1
sasa(dp14001
g2
VTo our knowledge, however, there is no evidence showing an effect of Gng2/GNG2 alone on metastasis of any cancers including malignant melanoma.
p14002
sg4
(lp14003
(dp14004
g7
I69
sg8
VP59768
p14005
sg10
I4
sg11
VGng2
p14006
sg13
I1
sa(dp14007
g7
I74
sg8
VP59768
p14008
sg10
I4
sg11
VGNG2
p14009
sg13
I1
sasg17
(lp14010
(dp14011
g7
I106
sg20
VC0006826
p14012
sg10
I7
sg11
Vcancers
p14013
sg13
I1
sa(dp14014
g7
I88
sg20
VC0027627
p14015
sg10
I10
sg11
Vmetastasis
p14016
sg13
I1
sa(dp14017
g7
I124
sg20
VC0025202
p14018
sg10
I18
sg11
Vmalignant melanoma
p14019
sg13
I2
sasa(dp14020
g2
VIn his study, we first prepared GNG2-overexpressed SK-Mel28 human malignant melanoma cells, in which GNG2 protein expression level was undetectably low.
p14021
sg4
(lp14022
(dp14023
g7
I32
sg8
VP59768
p14024
sg10
I4
sg11
VGNG2
p14025
sg13
I1
sa(dp14026
g7
I101
sg8
VP59768
p14027
sg10
I12
sg11
VGNG2 protein
p14028
sg13
I2
sasg17
(lp14029
(dp14030
g7
I66
sg20
VC0025202
p14031
sg10
I18
sg11
Vmalignant melanoma
p14032
sg13
I2
sasa(dp14033
g2
VMigration and invasion activities of the GNG2-overexpressed malignant melanoma cells were suppressed up to 1/10th, with decreased activity of focal adhesion kinase (FAK).
p14034
sg4
(lp14035
(dp14036
g7
I165
sg8
g47
sg10
I3
sg11
VFAK
p14037
sg13
I1
sa(dp14038
g7
I142
sg8
g47
sg10
I21
sg11
Vfocal adhesion kinase
p14039
sg13
I3
sa(dp14040
g7
I41
sg8
VP59768
p14041
sg10
I4
sg11
VGNG2
p14042
sg13
I1
sasg17
(lp14043
(dp14044
g7
I60
sg20
VC0025202
p14045
sg10
I18
sg11
Vmalignant melanoma
p14046
sg13
I2
sa(dp14047
g7
I120
sg20
VC0086439
p14048
sg10
I18
sg11
Vdecreased activity
p14049
sg13
I2
sa(dp14050
g7
I14
sg20
VC2699153
p14051
sg10
I8
sg11
Vinvasion
p14052
sg13
I1
sa(dp14053
g7
I148
sg20
VC0001511
p14054
sg10
I8
sg11
Vadhesion
p14055
sg13
I1
sasa(dp14056
g2
VTaken together, our results suggest that overexpression of GNG2 alone inhibits metastasis in human malignant melanoma cells with decreased FAK activity.
p14057
sg4
(lp14058
(dp14059
g7
I139
sg8
g47
sg10
I3
sg11
VFAK
p14060
sg13
I1
sa(dp14061
g7
I59
sg8
VP59768
p14062
sg10
I4
sg11
VGNG2
p14063
sg13
I1
sasg17
(lp14064
(dp14065
g7
I79
sg20
VC0027627
p14066
sg10
I10
sg11
Vmetastasis
p14067
sg13
I1
sa(dp14068
g7
I99
sg20
VC0025202
p14069
sg10
I18
sg11
Vmalignant melanoma
p14070
sg13
I2
sasa(dp14071
g2
VThus, GNG2 might be a candidate of molecular targets of prevention and therapy for metastasis of malignant melanoma.
p14072
sg4
(lp14073
(dp14074
g7
I6
sg8
VP59768
p14075
sg10
I4
sg11
VGNG2
p14076
sg13
I1
sasg17
(lp14077
(dp14078
g7
I83
sg20
VC0027627
p14079
sg10
I10
sg11
Vmetastasis
p14080
sg13
I1
sa(dp14081
g7
I97
sg20
VC0025202
p14082
sg10
I18
sg11
Vmalignant melanoma
p14083
sg13
I2
sasa(dp14084
g2
VOur recent study showed reduced G protein Gamma2 subunit (Gng2/GNG2) expression levels in malignant melanoma cells compared with those in benign melanocytic cells in both mice and humans.
p14085
sg4
(lp14086
(dp14087
g7
I63
sg8
VP59768
p14088
sg10
I4
sg11
VGNG2
p14089
sg13
I1
sa(dp14090
g7
I58
sg8
VP59768
p14091
sg10
I4
sg11
VGng2
p14092
sg13
I1
sa(dp14093
g7
I32
sg8
VP59768
p14094
sg10
I24
sg11
VG protein Gamma2 subunit
p14095
sg13
I4
sasg17
(lp14096
(dp14097
g7
I90
sg20
VC0025202
p14098
sg10
I18
sg11
Vmalignant melanoma
p14099
sg13
I2
sasa(dp14100
g2
VAt present, however, there is no evidence showing an effect of Gng2/GNG2 alone on cancer biology.
p14101
sg4
(lp14102
(dp14103
g7
I68
sg8
VP59768
p14104
sg10
I4
sg11
VGNG2
p14105
sg13
I1
sa(dp14106
g7
I63
sg8
VP59768
p14107
sg10
I4
sg11
VGng2
p14108
sg13
I1
sasg17
(lp14109
(dp14110
g7
I82
sg20
VC0006826
p14111
sg10
I6
sg11
Vcancer
p14112
sg13
I1
sasa(dp14113
g2
VThe purpose of this study was to examine the biological significance of GNG2 in human malignant melanoma cells.
p14114
sg4
(lp14115
(dp14116
g7
I72
sg8
VP59768
p14117
sg10
I4
sg11
VGNG2
p14118
sg13
I1
sasg17
(lp14119
(dp14120
g7
I86
sg20
VC0025202
p14121
sg10
I18
sg11
Vmalignant melanoma
p14122
sg13
I2
sasa(dp14123
g2
VLevels of proliferation and activities of signal transduction molecules were examined in both GNG2-overexpressed and -depleted human malignant melanoma cells.
p14124
sg4
(lp14125
(dp14126
g7
I94
sg8
VP59768
p14127
sg10
I4
sg11
VGNG2
p14128
sg13
I1
sasg17
(lp14129
(dp14130
g7
I10
sg20
VC0334094
p14131
sg10
I13
sg11
Vproliferation
p14132
sg13
I1
sa(dp14133
g7
I133
sg20
VC0025202
p14134
sg10
I18
sg11
Vmalignant melanoma
p14135
sg13
I2
sasa(dp14136
g2
VProliferation of GNG2-overexpressed SK-Mel28 human malignant melanoma cells was suppressed with decreased c-SRC and AKT activities and increased p21(Cip/WAF1) expression level in vitro.
p14137
sg4
(lp14138
(dp14139
g7
I153
sg8
VP38936
p14140
sg10
I4
sg11
VWAF1
p14141
sg13
I1
sa(dp14142
g7
I106
sg8
VP12931
p14143
sg10
I5
sg11
Vc-SRC
p14144
sg13
I1
sa(dp14145
g7
I17
sg8
VP59768
p14146
sg10
I4
sg11
VGNG2
p14147
sg13
I1
sa(dp14148
g7
I116
sg8
g47
sg10
I3
sg11
VAKT
p14149
sg13
I1
sa(dp14150
g7
I145
sg8
VP42857
p14151
sg10
I3
sg11
Vp21
p14152
sg13
I1
sa(dp14153
g7
I149
sg8
g47
sg10
I3
sg11
VCip
p14154
sg13
I1
sasg17
(lp14155
(dp14156
g7
I51
sg20
VC0025202
p14157
sg10
I18
sg11
Vmalignant melanoma
p14158
sg13
I2
sa(dp14159
g7
I0
sg20
VC0334094
p14160
sg10
I13
sg11
VProliferation
p14161
sg13
I1
sasa(dp14162
g2
VIn contrast, proliferation of GNG2-depleted A375P human malignant melanoma cells was enhanced with increased c-SRC and AKT activities and decreased p21(Cip/WAF1) expression level in vitro.
p14163
sg4
(lp14164
(dp14165
g7
I152
sg8
g47
sg10
I3
sg11
VCip
p14166
sg13
I1
sa(dp14167
g7
I156
sg8
VP38936
p14168
sg10
I4
sg11
VWAF1
p14169
sg13
I1
sa(dp14170
g7
I109
sg8
VP12931
p14171
sg10
I5
sg11
Vc-SRC
p14172
sg13
I1
sa(dp14173
g7
I119
sg8
g47
sg10
I3
sg11
VAKT
p14174
sg13
I1
sa(dp14175
g7
I148
sg8
VP42857
p14176
sg10
I3
sg11
Vp21
p14177
sg13
I1
sa(dp14178
g7
I30
sg8
VP59768
p14179
sg10
I4
sg11
VGNG2
p14180
sg13
I1
sasg17
(lp14181
(dp14182
g7
I13
sg20
VC0334094
p14183
sg10
I13
sg11
Vproliferation
p14184
sg13
I1
sa(dp14185
g7
I56
sg20
VC0025202
p14186
sg10
I18
sg11
Vmalignant melanoma
p14187
sg13
I2
sasa(dp14188
g2
VWe demonstrated for the first time that increased protein expression level of GNG2 alone inhibits proliferation of malignant melanoma cells in vitro and in vivo, suggesting that GNG2 could be a novel molecular target for malignant melanoma therapy.
p14189
sg4
(lp14190
(dp14191
g7
I78
sg8
VP59768
p14192
sg10
I4
sg11
VGNG2
p14193
sg13
I1
sa(dp14194
g7
I78
sg8
VP59768
p14195
sg10
I4
sg11
VGNG2
p14196
sg13
I1
sasg17
(lp14197
(dp14198
g7
I115
sg20
VC0025202
p14199
sg10
I18
sg11
Vmalignant melanoma
p14200
sg13
I2
sa(dp14201
g7
I98
sg20
VC0334094
p14202
sg10
I13
sg11
Vproliferation
p14203
sg13
I1
sa(dp14204
g7
I115
sg20
VC0025202
p14205
sg10
I18
sg11
Vmalignant melanoma
p14206
sg13
I2
sasa(dp14207
g2
VGng2 transcript expression levels in a malignant melanoma were less than 1/10 of the level in a benign tumor.
p14208
sg4
(lp14209
(dp14210
g7
I0
sg8
VP59768
p14211
sg10
I15
sg11
VGng2 transcript
p14212
sg13
I2
sasg17
(lp14213
(dp14214
g7
I96
sg20
VC0086692
p14215
sg10
I12
sg11
Vbenign tumor
p14216
sg13
I2
sa(dp14217
g7
I39
sg20
VC0025202
p14218
sg10
I18
sg11
Vmalignant melanoma
p14219
sg13
I2
sasa(dp14220
g2
VThe difference in Gng2 transcript expression levels between benign tumors and malignant melanomas was greatest among all of the G protein Gamma subunits examined in this study.
p14221
sg4
(lp14222
(dp14223
g7
I18
sg8
VP59768
p14224
sg10
I15
sg11
VGng2 transcript
p14225
sg13
I2
sa(dp14226
g7
I128
sg8
g47
sg10
I24
sg11
VG protein Gamma subunits
p14227
sg13
I4
sasg17
(lp14228
(dp14229
g7
I60
sg20
VC0086692
p14230
sg10
I13
sg11
Vbenign tumors
p14231
sg13
I2
sa(dp14232
g7
I78
sg20
VC0025202
p14233
sg10
I19
sg11
Vmalignant melanomas
p14234
sg13
I2
sasa(dp14235
g2
VMoreover, protein expression levels of Gng2 were decreased in malignant melanomas compared with those in benign melanocytic tumors in RET-mice.
p14236
sg4
(lp14237
(dp14238
g7
I39
sg8
VP59768
p14239
sg10
I4
sg11
VGng2
p14240
sg13
I1
sasg17
(lp14241
(dp14242
g7
I124
sg20
VC0027651
p14243
sg10
I6
sg11
Vtumors
p14244
sg13
I1
sa(dp14245
g7
I62
sg20
VC0025202
p14246
sg10
I19
sg11
Vmalignant melanomas
p14247
sg13
I2
sasa(dp14248
g2
VAnalysis of human malignant melanomas also showed reduced GNG2 protein expression levels in five human malignant melanoma cell lines compared with the expression levels in normal human epithelial melanocytes (NHEM).
p14249
sg4
(lp14250
(dp14251
g7
I58
sg8
VP59768
p14252
sg10
I12
sg11
VGNG2 protein
p14253
sg13
I2
sasg17
(lp14254
(dp14255
g7
I18
sg20
VC0025202
p14256
sg10
I19
sg11
Vmalignant melanomas
p14257
sg13
I2
sa(dp14258
g7
I18
sg20
VC0025202
p14259
sg10
I18
sg11
Vmalignant melanoma
p14260
sg13
I2
sasa(dp14261
g2
VThus, we demonstrated for the first time that Gng2/GNG2 expression levels are reduced in malignant melanoma, suggesting that GNG2 could be a novel biomarker for malignant melanoma.
p14262
sg4
(lp14263
(dp14264
g7
I46
sg8
VP59768
p14265
sg10
I4
sg11
VGng2
p14266
sg13
I1
sa(dp14267
g7
I51
sg8
VP59768
p14268
sg10
I4
sg11
VGNG2
p14269
sg13
I1
sa(dp14270
g7
I51
sg8
VP59768
p14271
sg10
I4
sg11
VGNG2
p14272
sg13
I1
sasg17
(lp14273
(dp14274
g7
I89
sg20
VC0025202
p14275
sg10
I18
sg11
Vmalignant melanoma
p14276
sg13
I2
sa(dp14277
g7
I89
sg20
VC0025202
p14278
sg10
I18
sg11
Vmalignant melanoma
p14279
sg13
I2
sasa(dp14280
g2
VSeveral DNA repair enzymes are essential for comprehensive neural repair mechanisms after stroke, including PolBeta and NEIL3 for neurogenesis, APE1 for white matter repair, Gadd45b for axonal regeneration, and DNA-PKs for neurovascular remodeling.
p14281
sg4
(lp14282
(dp14283
g7
I144
sg8
VP27695
p14284
sg10
I4
sg11
VAPE1
p14285
sg13
I1
sa(dp14286
g7
I120
sg8
g47
sg10
I5
sg11
VNEIL3
p14287
sg13
I1
sa(dp14288
g7
I174
sg8
g47
sg10
I7
sg11
VGadd45b
p14289
sg13
I1
sa(dp14290
g7
I8
sg8
g47
sg10
I18
sg11
VDNA repair enzymes
p14291
sg13
I3
sa(dp14292
g7
I211
sg8
g47
sg10
I7
sg11
VDNA-PKs
p14293
sg13
I1
sasg17
(lp14294
(dp14295
g7
I90
sg20
VC0038454
p14296
sg10
I6
sg11
Vstroke
p14297
sg13
I1
sa(dp14298
g7
I215
sg20
VC0265449
p14299
sg10
I3
sg11
VPKs
p14300
sg13
I1
sasa(dp14301
g2
VThe aims of this study are to determine the expression and the prognostic value of TFF3 in a large series of human endometrial cancer and its relation with ER.
p14302
sg4
(lp14303
(dp14304
g7
I83
sg8
g47
sg10
I4
sg11
VTFF3
p14305
sg13
I1
sasg17
(lp14306
(dp14307
g7
I115
sg20
VC0476089
p14308
sg10
I18
sg11
Vendometrial cancer
p14309
sg13
I2
sasa(dp14310
g2
VWe evaluated 328 endometrial carcinomas using TFF3 and ER antibody on paraffin-embedded tissue.
p14311
sg4
(lp14312
(dp14313
g7
I46
sg8
g47
sg10
I4
sg11
VTFF3
p14314
sg13
I1
sasg17
(lp14315
(dp14316
g7
I17
sg20
VC0476089
p14317
sg10
I22
sg11
Vendometrial carcinomas
p14318
sg13
I2
sasa(dp14319
g2
V1-TFF3 seems to be a novel pathway in the pathogenesis of type I endometrial carcinomas.
p14320
sg4
(lp14321
(dp14322
g7
I0
sg8
g47
sg10
I6
sg11
V1-TFF3
p14323
sg13
I1
sasg17
(lp14324
(dp14325
g7
I42
sg20
VC0699748
p14326
sg10
I12
sg11
Vpathogenesis
p14327
sg13
I1
sa(dp14328
g7
I65
sg20
VC0476089
p14329
sg10
I22
sg11
Vendometrial carcinomas
p14330
sg13
I2
sasa(dp14331
g2
V2-The strong association of TFF3 and ER in the estrogen-dependent endometrioid carcinoma could explain the reason for its frequent expression by this tumor type.
p14332
sg4
(lp14333
(dp14334
g7
I28
sg8
g47
sg10
I4
sg11
VTFF3
p14335
sg13
I1
sasg17
(lp14336
(dp14337
g7
I66
sg20
VC0206687
p14338
sg10
I22
sg11
Vendometrioid carcinoma
p14339
sg13
I2
sa(dp14340
g7
I150
sg20
VC0027651
p14341
sg10
I5
sg11
Vtumor
p14342
sg13
I1
sasa(dp14343
g2
V3-TFF3(+) seems to forecast a good prognosis in type I endometrial carcinomas.
p14344
sg4
(lp14345
(dp14346
g7
I0
sg8
g47
sg10
I6
sg11
V3-TFF3
p14347
sg13
I1
sasg17
(lp14348
(dp14349
g7
I55
sg20
VC0476089
p14350
sg10
I22
sg11
Vendometrial carcinomas
p14351
sg13
I2
sasa(dp14352
g2
VBased on our data, TFF3 expression in endometrial cancer deserves further investigation.
p14353
sg4
(lp14354
(dp14355
g7
I19
sg8
g47
sg10
I4
sg11
VTFF3
p14356
sg13
I1
sasg17
(lp14357
(dp14358
g7
I38
sg20
VC0476089
p14359
sg10
I18
sg11
Vendometrial cancer
p14360
sg13
I2
sasa(dp14361
g2
VWe evaluated 401 endometrial carcinomas cases by using four immunomarkers - oestrogen receptor (ER), progesterone receptor (PR), insulin-like growth factor II mRNA - binding protein 3 (IMP3), and intestinal trefoil factor 3 (TFF3)-on a tissue microarray.
p14362
sg4
(lp14363
(dp14364
g7
I101
sg8
VP06401
p14365
sg10
I21
sg11
Vprogesterone receptor
p14366
sg13
I2
sa(dp14367
g7
I129
sg8
VP01344
p14368
sg10
I54
sg11
Vinsulin-like growth factor II mRNA - binding protein 3
p14369
sg13
I9
sa(dp14370
g7
I225
sg8
g47
sg10
I4
sg11
VTFF3
p14371
sg13
I1
sa(dp14372
g7
I76
sg8
VP03372
p14373
sg10
I18
sg11
Voestrogen receptor
p14374
sg13
I2
sa(dp14375
g7
I196
sg8
g47
sg10
I27
sg11
Vintestinal trefoil factor 3
p14376
sg13
I4
sa(dp14377
g7
I185
sg8
g47
sg10
I4
sg11
VIMP3
p14378
sg13
I1
sa(dp14379
g7
I124
sg8
VP06401
p14380
sg10
I2
sg11
VPR
p14381
sg13
I1
sasg17
(lp14382
(dp14383
g7
I17
sg20
VC0476089
p14384
sg10
I22
sg11
Vendometrial carcinomas
p14385
sg13
I2
sasa(dp14386
g2
VWe recommend using an ER/PR/TFF3/IMP3 immunohistochemical panel in selected cases of endometrial carcinoma where the differential diagnosis is challenging.
p14387
sg4
(lp14388
(dp14389
g7
I28
sg8
g47
sg10
I4
sg11
VTFF3
p14390
sg13
I1
sa(dp14391
g7
I33
sg8
g47
sg10
I4
sg11
VIMP3
p14392
sg13
I1
sasg17
(lp14393
(dp14394
g7
I85
sg20
VC0476089
p14395
sg10
I21
sg11
Vendometrial carcinoma
p14396
sg13
I2
sasa(dp14397
g2
VBy RT-PCR we have confirmed complete FAM107A downregulation in laryngeal cancer cell lines (15/15) and primary tumors (21/21) and this finding was further supported by FAM107A protein immunohistochemistry (15/15).
p14398
sg4
(lp14399
(dp14400
g7
I37
sg8
g47
sg10
I7
sg11
VFAM107A
p14401
sg13
I1
sasg17
(lp14402
(dp14403
g7
I63
sg20
VC0595989
p14404
sg10
I16
sg11
Vlaryngeal cancer
p14405
sg13
I2
sa(dp14406
g7
I103
sg20
VC0677930
p14407
sg10
I14
sg11
Vprimary tumors
p14408
sg13
I2
sasa(dp14409
g2
VDownregulated in renal cell carcinoma 1 (DRR1) has important roles in tumor cell growth, neuron survival and spine formation, and was recently shown to bind actin.
p14410
sg4
(lp14411
(dp14412
g7
I41
sg8
g47
sg10
I4
sg11
VDRR1
p14413
sg13
I1
sa(dp14414
g7
I0
sg8
g47
sg10
I39
sg11
VDownregulated in renal cell carcinoma 1
p14415
sg13
I6
sasg17
(lp14416
(dp14417
g7
I17
sg20
VC2931882
p14418
sg10
I22
sg11
Vrenal cell carcinoma 1
p14419
sg13
I4
sa(dp14420
g7
I70
sg20
VC0027651
p14421
sg10
I5
sg11
Vtumor
p14422
sg13
I1
sasa(dp14423
g2
VIn addition, DRR1 and COMMD1 suppressed the cyclin D1 expression, G1/S transition and cell proliferation of neuroblastoma cells.
p14424
sg4
(lp14425
(dp14426
g7
I13
sg8
g47
sg10
I4
sg11
VDRR1
p14427
sg13
I1
sa(dp14428
g7
I22
sg8
g47
sg10
I6
sg11
VCOMMD1
p14429
sg13
I1
sa(dp14430
g7
I44
sg8
VP24385
p14431
sg10
I9
sg11
Vcyclin D1
p14432
sg13
I2
sasg17
(lp14433
(dp14434
g7
I91
sg20
VC0334094
p14435
sg10
I13
sg11
Vproliferation
p14436
sg13
I1
sa(dp14437
g7
I71
sg20
VC0599156
p14438
sg10
I10
sg11
Vtransition
p14439
sg13
I1
sa(dp14440
g7
I108
sg20
VC0027819
p14441
sg10
I13
sg11
Vneuroblastoma
p14442
sg13
I1
sasa(dp14443
g2
VConsistent with these facts, low expressions of DRR1 were associated with tumorigenesis of human neuroblastoma and its mouse model.
p14444
sg4
(lp14445
(dp14446
g7
I48
sg8
g47
sg10
I4
sg11
VDRR1
p14447
sg13
I1
sasg17
(lp14448
(dp14449
g7
I74
sg20
VC0007621
p14450
sg10
I13
sg11
Vtumorigenesis
p14451
sg13
I1
sa(dp14452
g7
I97
sg20
VC0027819
p14453
sg10
I13
sg11
Vneuroblastoma
p14454
sg13
I1
sasa(dp14455
g2
VThis study has thus revealed a novel nuclear complex of F-actin, DRR1 and COMMD1 that is involved in NF-KB degradation and cell cycle suppression in neuroblastoma cells.
p14456
sg4
(lp14457
(dp14458
g7
I65
sg8
g47
sg10
I4
sg11
VDRR1
p14459
sg13
I1
sa(dp14460
g7
I74
sg8
g47
sg10
I6
sg11
VCOMMD1
p14461
sg13
I1
sasg17
(lp14462
(dp14463
g7
I134
sg20
VC0221103
p14464
sg10
I11
sg11
Vsuppression
p14465
sg13
I1
sa(dp14466
g7
I149
sg20
VC0027819
p14467
sg10
I13
sg11
Vneuroblastoma
p14468
sg13
I1
sasa(dp14469
g2
VThe aim of the present study was to analyze the expression level of FAM107A gene, a TSG located in 3p21.1, in lung cancer tumors and in tumor adjacent normal lung samples.
p14470
sg4
(lp14471
(dp14472
g7
I68
sg8
g47
sg10
I12
sg11
VFAM107A gene
p14473
sg13
I2
sa(dp14474
g7
I84
sg8
g47
sg10
I21
sg11
VTSG located in 3p21.1
p14475
sg13
I4
sasg17
(lp14476
(dp14477
g7
I122
sg20
VC0027651
p14478
sg10
I6
sg11
Vtumors
p14479
sg13
I1
sa(dp14480
g7
I110
sg20
VC0684249
p14481
sg10
I11
sg11
Vlung cancer
p14482
sg13
I2
sa(dp14483
g7
I122
sg20
VC0027651
p14484
sg10
I5
sg11
Vtumor
p14485
sg13
I1
sasa(dp14486
g2
VPromoter methylation of FAM107A gene was confirmed only in the minority of NSCLCs.
p14487
sg4
(lp14488
(dp14489
g7
I24
sg8
g47
sg10
I12
sg11
VFAM107A gene
p14490
sg13
I2
sasg17
(lp14491
sa(dp14492
g2
VWe recently characterized a stress and glucocorticoid-regulated gene, down-regulated in renal cell carcinoma - DRR1 (Fam107A).
p14493
sg4
(lp14494
(dp14495
g7
I117
sg8
g47
sg10
I7
sg11
VFam107A
p14496
sg13
I1
sa(dp14497
g7
I111
sg8
g47
sg10
I4
sg11
VDRR1
p14498
sg13
I1
sa(dp14499
g7
I39
sg8
VP48506
p14500
sg10
I29
sg11
Vglucocorticoid-regulated gene
p14501
sg13
I2
sasg17
(lp14502
(dp14503
g7
I88
sg20
VC0007134
p14504
sg10
I20
sg11
Vrenal cell carcinoma
p14505
sg13
I3
sasa(dp14506
g2
VIn human, FAM107A termed TU3A/DRR1 has been reported as a candidate tumor suppressor gene which expression is downregulated in several types of cancer, however no studies have investigated the other family protein, FAM107B.
p14507
sg4
(lp14508
(dp14509
g7
I215
sg8
g47
sg10
I7
sg11
VFAM107B
p14510
sg13
I1
sa(dp14511
g7
I10
sg8
g47
sg10
I7
sg11
VFAM107A
p14512
sg13
I1
sa(dp14513
g7
I30
sg8
g47
sg10
I4
sg11
VDRR1
p14514
sg13
I1
sa(dp14515
g7
I25
sg8
g47
sg10
I4
sg11
VTU3A
p14516
sg13
I1
sasg17
(lp14517
(dp14518
g7
I68
sg20
VC0027651
p14519
sg10
I5
sg11
Vtumor
p14520
sg13
I1
sa(dp14521
g7
I144
sg20
VC0006826
p14522
sg10
I6
sg11
Vcancer
p14523
sg13
I1
sasa(dp14524
g2
VDown-regulated in renal cell carcinoma 1 (DRR1) is mapped at 3p21.1, and is a candidate tumor suppressor gene.
p14525
sg4
(lp14526
(dp14527
g7
I0
sg8
g47
sg10
I40
sg11
VDown-regulated in renal cell carcinoma 1
p14528
sg13
I6
sa(dp14529
g7
I42
sg8
g47
sg10
I4
sg11
VDRR1
p14530
sg13
I1
sasg17
(lp14531
(dp14532
g7
I88
sg20
VC0027651
p14533
sg10
I5
sg11
Vtumor
p14534
sg13
I1
sa(dp14535
g7
I18
sg20
VC2931882
p14536
sg10
I22
sg11
Vrenal cell carcinoma 1
p14537
sg13
I4
sasa(dp14538
g2
VDRR1 was poorly expressed in established cancer cell lines, including neuroblastoma cells, whereas strong expression was observed in normal cells.
p14539
sg4
(lp14540
(dp14541
g7
I0
sg8
g47
sg10
I4
sg11
VDRR1
p14542
sg13
I1
sasg17
(lp14543
(dp14544
g7
I41
sg20
VC0006826
p14545
sg10
I6
sg11
Vcancer
p14546
sg13
I1
sa(dp14547
g7
I70
sg20
VC0027819
p14548
sg10
I13
sg11
Vneuroblastoma
p14549
sg13
I1
sasa(dp14550
g2
VA neuroblastoma model, MYCN transgenic mice, revealed that DRR1 protein was expressed in the celiac ganglion 2 weeks after birth when neuroblast hyperplasia was also observed; however, there was no longer any expression of DRR1 protein in tumors originating from the ganglion 8 weeks after birth.
p14551
sg4
(lp14552
(dp14553
g7
I59
sg8
g47
sg10
I12
sg11
VDRR1 protein
p14554
sg13
I2
sa(dp14555
g7
I23
sg8
VP04198
p14556
sg10
I4
sg11
VMYCN
p14557
sg13
I1
sa(dp14558
g7
I59
sg8
g47
sg10
I12
sg11
VDRR1 protein
p14559
sg13
I2
sasg17
(lp14560
(dp14561
g7
I100
sg20
VC1258666
p14562
sg10
I8
sg11
Vganglion
p14563
sg13
I1
sa(dp14564
g7
I2
sg20
VC0027819
p14565
sg10
I13
sg11
Vneuroblastoma
p14566
sg13
I1
sa(dp14567
g7
I239
sg20
VC0027651
p14568
sg10
I6
sg11
Vtumors
p14569
sg13
I1
sa(dp14570
g7
I100
sg20
VC1258666
p14571
sg10
I8
sg11
Vganglion
p14572
sg13
I1
sa(dp14573
g7
I145
sg20
VC0020507
p14574
sg10
I11
sg11
Vhyperplasia
p14575
sg13
I1
sasa(dp14576
g2
VTogether, our data indicate that DRR1 protein is expressed in normal cells, particularly in the nervous system during embryogenesis, is involved in neuronal cell survival, and is downregulated during neuroblastoma carcinogenesis.
p14577
sg4
(lp14578
(dp14579
g7
I33
sg8
g47
sg10
I12
sg11
VDRR1 protein
p14580
sg13
I2
sasg17
(lp14581
(dp14582
g7
I214
sg20
VC0596263
p14583
sg10
I14
sg11
Vcarcinogenesis
p14584
sg13
I1
sa(dp14585
g7
I96
sg20
VC0027769
p14586
sg10
I7
sg11
Vnervous
p14587
sg13
I1
sa(dp14588
g7
I200
sg20
VC0027819
p14589
sg10
I13
sg11
Vneuroblastoma
p14590
sg13
I1
sasa(dp14591
g2
VTU3A, located on 3p21.1, was originally identified as a candidate tumor suppressor gene in renal cell carcinoma (RCC).
p14592
sg4
(lp14593
(dp14594
g7
I0
sg8
g47
sg10
I4
sg11
VTU3A
p14595
sg13
I1
sasg17
(lp14596
(dp14597
g7
I91
sg20
VC0007134
p14598
sg10
I20
sg11
Vrenal cell carcinoma
p14599
sg13
I3
sa(dp14600
g7
I66
sg20
VC0027651
p14601
sg10
I5
sg11
Vtumor
p14602
sg13
I1
sa(dp14603
g7
I113
sg20
VC0007134
p14604
sg10
I3
sg11
VRCC
p14605
sg13
I1
sasa(dp14606
g2
VRecently, down-regulation of TU3A expression has been reported not only in RCC but also in other types of cancers.
p14607
sg4
(lp14608
(dp14609
g7
I29
sg8
g47
sg10
I4
sg11
VTU3A
p14610
sg13
I1
sasg17
(lp14611
(dp14612
g7
I106
sg20
VC0006826
p14613
sg10
I7
sg11
Vcancers
p14614
sg13
I1
sa(dp14615
g7
I75
sg20
VC0007134
p14616
sg10
I3
sg11
VRCC
p14617
sg13
I1
sasa(dp14618
g2
VFurthermore, we observed promoter hyper-methylation of TU3A in several types of cancer cell lines and primary cancers of the bladder and testis.
p14619
sg4
(lp14620
(dp14621
g7
I55
sg8
g47
sg10
I4
sg11
VTU3A
p14622
sg13
I1
sasg17
(lp14623
(dp14624
g7
I110
sg20
VC0006826
p14625
sg10
I7
sg11
Vcancers
p14626
sg13
I1
sa(dp14627
g7
I80
sg20
VC0006826
p14628
sg10
I6
sg11
Vcancer
p14629
sg13
I1
sasa(dp14630
g2
VTo our knowledge, the present study is the first to demonstrate the epigenetic inactivation of TU3A in human cancers.
p14631
sg4
(lp14632
(dp14633
g7
I95
sg8
g47
sg10
I4
sg11
VTU3A
p14634
sg13
I1
sasg17
(lp14635
(dp14636
g7
I109
sg20
VC0006826
p14637
sg10
I7
sg11
Vcancers
p14638
sg13
I1
sa(dp14639
g7
I79
sg20
VC0544461
p14640
sg10
I12
sg11
Vinactivation
p14641
sg13
I1
sasa(dp14642
g2
VThe findings of this study warrant further study to investigate the role of TU3A methylation in cancer development.
p14643
sg4
(lp14644
(dp14645
g7
I76
sg8
g47
sg10
I4
sg11
VTU3A
p14646
sg13
I1
sasg17
(lp14647
(dp14648
g7
I96
sg20
VC0006826
p14649
sg10
I6
sg11
Vcancer
p14650
sg13
I1
sasa(dp14651
g2
VThe aim of this study was to examine the association between GCK, GCKR, FADS1, DGKB/TMEM195 and CDKAL1 gene polymorphisms and the development of gestational diabetes.
p14652
sg4
(lp14653
(dp14654
g7
I66
sg8
g47
sg10
I4
sg11
VGCKR
p14655
sg13
I1
sa(dp14656
g7
I84
sg8
g47
sg10
I7
sg11
VTMEM195
p14657
sg13
I1
sa(dp14658
g7
I96
sg8
g47
sg10
I11
sg11
VCDKAL1 gene
p14659
sg13
I2
sa(dp14660
g7
I61
sg8
VP35557
p14661
sg10
I3
sg11
VGCK
p14662
sg13
I1
sasg17
(lp14663
(dp14664
g7
I145
sg20
VC0085207
p14665
sg10
I20
sg11
Vgestational diabetes
p14666
sg13
I2
sasa(dp14667
g2
VBackground Familial hemiplegic migraine type 3 is a monogenic subtype of migraine caused by missense mutations in the neuronal voltage-gated sodium channel gene SCN1A, with 10 different mutations reported so far.
p14668
sg4
(lp14669
(dp14670
g7
I118
sg8
VP29475
p14671
sg10
I48
sg11
Vneuronal voltage-gated sodium channel gene SCN1A
p14672
sg13
I6
sasg17
(lp14673
(dp14674
g7
I31
sg20
VC0149931
p14675
sg10
I8
sg11
Vmigraine
p14676
sg13
I1
sa(dp14677
g7
I11
sg20
VC0338484
p14678
sg10
I28
sg11
VFamilial hemiplegic migraine
p14679
sg13
I3
sasa(dp14680
g2
VResults In both pedigrees, we identified SCN1A mutation p.F1499L, which has been previously associated with familial hemiplegic migraine type 3 and elicited repetitive daily blindness.
p14681
sg4
(lp14682
(dp14683
g7
I41
sg8
VP35498
p14684
sg10
I23
sg11
VSCN1A mutation p.F1499L
p14685
sg13
I3
sasg17
(lp14686
(dp14687
g7
I174
sg20
VC0456909
p14688
sg10
I9
sg11
Vblindness
p14689
sg13
I1
sa(dp14690
g7
I108
sg20
VC0338484
p14691
sg10
I28
sg11
Vfamilial hemiplegic migraine
p14692
sg13
I3
sasa(dp14693
g2
VConclusion Like a substantial proportion of other familial hemiplegic migraine type 3 mutations, p.F1499L affects the intracellular linker between domains III and IV of SCN1A, which seems to be a mutational hot-spot.
p14694
sg4
(lp14695
(dp14696
g7
I169
sg8
VP35498
p14697
sg10
I5
sg11
VSCN1A
p14698
sg13
I1
sasg17
(lp14699
(dp14700
g7
I50
sg20
VC0338484
p14701
sg10
I28
sg11
Vfamilial hemiplegic migraine
p14702
sg13
I3
sasa(dp14703
g2
VA genetic link between these two diseases is particularly evident in familial hemiplegic migraine: mutations of ATP1A2, SCN1A and CACNA1A genes, identified in this disease, have also been involved in different types of epilepsy and febrile seizures.
p14704
sg4
(lp14705
(dp14706
g7
I112
sg8
VP50993
p14707
sg10
I6
sg11
VATP1A2
p14708
sg13
I1
sa(dp14709
g7
I120
sg8
VP35498
p14710
sg10
I5
sg11
VSCN1A
p14711
sg13
I1
sa(dp14712
g7
I130
sg8
VP01893
p14713
sg10
I13
sg11
VCACNA1A genes
p14714
sg13
I2
sasg17
(lp14715
(dp14716
g7
I232
sg20
VC0009952
p14717
sg10
I16
sg11
Vfebrile seizures
p14718
sg13
I2
sa(dp14719
g7
I69
sg20
VC0338484
p14720
sg10
I28
sg11
Vfamilial hemiplegic migraine
p14721
sg13
I3
sa(dp14722
g7
I219
sg20
VC0014544
p14723
sg10
I8
sg11
Vepilepsy
p14724
sg13
I1
sasa(dp14725
g2
VMutations in three genes (CACNA1A, ATP1A2, and SCN1A) have been found to cause FHM.
p14726
sg4
(lp14727
(dp14728
g7
I35
sg8
VP50993
p14729
sg10
I6
sg11
VATP1A2
p14730
sg13
I1
sa(dp14731
g7
I47
sg8
VP35498
p14732
sg10
I5
sg11
VSCN1A
p14733
sg13
I1
sasg17
(lp14734
(dp14735
g7
I79
sg20
VC1832894
p14736
sg10
I3
sg11
VFHM
p14737
sg13
I1
sasa(dp14738
g2
VAmong these, nine SCN1A gene mutations were reported to cause familial hemiplegic migraine type 3 (FHM3).
p14739
sg4
(lp14740
(dp14741
g7
I62
sg8
VP35498
p14742
sg10
I35
sg11
Vfamilial hemiplegic migraine type 3
p14743
sg13
I5
sa(dp14744
g7
I99
sg8
VP35498
p14745
sg10
I4
sg11
VFHM3
p14746
sg13
I1
sa(dp14747
g7
I18
sg8
VP35498
p14748
sg10
I10
sg11
VSCN1A gene
p14749
sg13
I2
sasg17
(lp14750
(dp14751
g7
I62
sg20
VC1864987
p14752
sg10
I35
sg11
Vfamilial hemiplegic migraine type 3
p14753
sg13
I5
sa(dp14754
g7
I99
sg20
VC1864987
p14755
sg10
I4
sg11
VFHM3
p14756
sg13
I1
sasa(dp14757
g2
VMethod The clinical manifestations of a Chinese FHM family were recorded and all coding exons and flanking intronic regions of the CACNA1A, ATP1A2, and SCN1A genes were tested for mutations.
p14758
sg4
(lp14759
(dp14760
g7
I140
sg8
VP50993
p14761
sg10
I6
sg11
VATP1A2
p14762
sg13
I1
sa(dp14763
g7
I152
sg8
VP35498
p14764
sg10
I11
sg11
VSCN1A genes
p14765
sg13
I2
sasg17
(lp14766
(dp14767
g7
I48
sg20
VC1832894
p14768
sg10
I3
sg11
VFHM
p14769
sg13
I1
sasa(dp14770
g2
VConclusion The identification of a novel mutation in the SCN1A gene in the Chinese population may further aid in the understanding of FHM genetics.
p14771
sg4
(lp14772
(dp14773
g7
I57
sg8
VP35498
p14774
sg10
I10
sg11
VSCN1A gene
p14775
sg13
I2
sasg17
(lp14776
(dp14777
g7
I134
sg20
VC1832894
p14778
sg10
I3
sg11
VFHM
p14779
sg13
I1
sa(dp14780
g7
I35
sg20
VC2985438
p14781
sg10
I14
sg11
Vnovel mutation
p14782
sg13
I2
sasa(dp14783
g2
VMutations in four genes have been identified in familial hemiplegic migraine (FHM), from which CACNA1A (FHM type 1) and SCN1A (FHM type 3) code for neuronal voltage-gated calcium or sodium channels, respectively, while ATP1A2 (FHM type 2) encodes the Alfa2 isoform of the Na(+),K(+)-ATPase's catalytic subunit, thus classifying FHM primarily as an ion channel/ion transporter pathology.
p14784
sg4
(lp14785
(dp14786
g7
I219
sg8
VP50993
p14787
sg10
I6
sg11
VATP1A2
p14788
sg13
I1
sa(dp14789
g7
I120
sg8
VP35498
p14790
sg10
I5
sg11
VSCN1A
p14791
sg13
I1
sa(dp14792
g7
I283
sg8
VP38606
p14793
sg10
I6
sg11
VATPase
p14794
sg13
I1
sasg17
(lp14795
(dp14796
g7
I78
sg20
VC1832894
p14797
sg10
I3
sg11
VFHM
p14798
sg13
I1
sa(dp14799
g7
I78
sg20
VC1832894
p14800
sg10
I3
sg11
VFHM
p14801
sg13
I1
sa(dp14802
g7
I376
sg20
VC0677042
p14803
sg10
I9
sg11
Vpathology
p14804
sg13
I1
sa(dp14805
g7
I78
sg20
VC1832894
p14806
sg10
I3
sg11
VFHM
p14807
sg13
I1
sa(dp14808
g7
I48
sg20
VC0338484
p14809
sg10
I28
sg11
Vfamilial hemiplegic migraine
p14810
sg13
I3
sa(dp14811
g7
I78
sg20
VC1832894
p14812
sg10
I3
sg11
VFHM
p14813
sg13
I1
sa(dp14814
g7
I78
sg20
VC1832894
p14815
sg10
I3
sg11
VFHM
p14816
sg13
I1
sasa(dp14817
g2
VMoreover, three genes (CACNA1A, ATP1A2, and SCN1A) have come from studies performed in individuals with familial hemiplegic migraine (FHM), a monogenic form of migraine with aura.
p14818
sg4
(lp14819
(dp14820
g7
I44
sg8
VP35498
p14821
sg10
I5
sg11
VSCN1A
p14822
sg13
I1
sa(dp14823
g7
I32
sg8
VP50993
p14824
sg10
I6
sg11
VATP1A2
p14825
sg13
I1
sasg17
(lp14826
(dp14827
g7
I134
sg20
VC1832894
p14828
sg10
I3
sg11
VFHM
p14829
sg13
I1
sa(dp14830
g7
I160
sg20
VC0154723
p14831
sg10
I18
sg11
Vmigraine with aura
p14832
sg13
I3
sa(dp14833
g7
I104
sg20
VC0338484
p14834
sg10
I28
sg11
Vfamilial hemiplegic migraine
p14835
sg13
I3
sasa(dp14836
g2
VThe FHM3 subtype is caused by mutations in SCN1A, which is also the most frequent epilepsy gene encoding the voltage-gated Na+ channel NaV1.1.
p14837
sg4
(lp14838
(dp14839
g7
I123
sg8
VP37088
p14840
sg10
I18
sg11
VNa+ channel NaV1.1
p14841
sg13
I3
sa(dp14842
g7
I43
sg8
VP35498
p14843
sg10
I5
sg11
VSCN1A
p14844
sg13
I1
sa(dp14845
g7
I4
sg8
VP35498
p14846
sg10
I12
sg11
VFHM3 subtype
p14847
sg13
I2
sasg17
(lp14848
(dp14849
g7
I82
sg20
VC0014544
p14850
sg10
I8
sg11
Vepilepsy
p14851
sg13
I1
sa(dp14852
g7
I4
sg20
VC1864987
p14853
sg10
I4
sg11
VFHM3
p14854
sg13
I1
sasa(dp14855
g2
VThe aim of this study was to explore the clinical, genetic and pathogenetic features of a pure FHM3 family.
p14856
sg4
(lp14857
(dp14858
g7
I95
sg8
VP35498
p14859
sg10
I11
sg11
VFHM3 family
p14860
sg13
I2
sasg17
(lp14861
(dp14862
g7
I95
sg20
VC1864987
p14863
sg10
I4
sg11
VFHM3
p14864
sg13
I1
sasa(dp14865
g2
VResults and conclusions We identified a novel SCN1A (p.Leu1624Pro) mutation in a pure FHM family with notably early-onset attacks at mean age of 7.
p14866
sg4
(lp14867
(dp14868
g7
I46
sg8
VP35498
p14869
sg10
I5
sg11
VSCN1A
p14870
sg13
I1
sasg17
(lp14871
(dp14872
g7
I86
sg20
VC1832894
p14873
sg10
I3
sg11
VFHM
p14874
sg13
I1
sasa(dp14875
g2
VL1624P locates in S3 of domain IV, the same domain as two of four known pure FHM3 mutations.
p14876
sg4
(lp14877
(dp14878
g7
I77
sg8
VP35498
p14879
sg10
I4
sg11
VFHM3
p14880
sg13
I1
sasg17
(lp14881
(dp14882
g7
I77
sg20
VC1864987
p14883
sg10
I4
sg11
VFHM3
p14884
sg13
I1
sasa(dp14885
g2
VSimilar to the known FHM3 mutations, this novel mutation predicts hyperexcitability of GABAergic inhibitory neurons.
p14886
sg4
(lp14887
(dp14888
g7
I21
sg8
VP35498
p14889
sg10
I14
sg11
VFHM3 mutations
p14890
sg13
I2
sasg17
(lp14891
(dp14892
g7
I21
sg20
VC1864987
p14893
sg10
I4
sg11
VFHM3
p14894
sg13
I1
sa(dp14895
g7
I42
sg20
VC2985438
p14896
sg10
I14
sg11
Vnovel mutation
p14897
sg13
I2
sasa(dp14898
g2
VSixty patients with migraine without aura (MO) or with different types of migraine with aura (MA), including sporadic hemiplegic, familial hemiplegic, and probable familial hemiplegic, were screened for mutations in the four genes previously linked with different types of migraine (ATP1A2, CACNA1A, SCN1A, and KCNK18).
p14899
sg4
(lp14900
(dp14901
g7
I300
sg8
VP35498
p14902
sg10
I5
sg11
VSCN1A
p14903
sg13
I1
sa(dp14904
g7
I283
sg8
VP50993
p14905
sg10
I6
sg11
VATP1A2
p14906
sg13
I1
sa(dp14907
g7
I311
sg8
g47
sg10
I6
sg11
VKCNK18
p14908
sg13
I1
sasg17
(lp14909
(dp14910
g7
I94
sg20
VC0154723
p14911
sg10
I2
sg11
VMA
p14912
sg13
I1
sa(dp14913
g7
I20
sg20
VC0338480
p14914
sg10
I21
sg11
Vmigraine without aura
p14915
sg13
I3
sa(dp14916
g7
I20
sg20
VC0149931
p14917
sg10
I8
sg11
Vmigraine
p14918
sg13
I1
sa(dp14919
g7
I43
sg20
VC0338480
p14920
sg10
I2
sg11
VMO
p14921
sg13
I1
sa(dp14922
g7
I74
sg20
VC0154723
p14923
sg10
I18
sg11
Vmigraine with aura
p14924
sg13
I3
sasa(dp14925
g2
VOne novel mutation in SCN1A, encoding Alfa subunit of sodium channel, causing amino acid change M1500V localized to a region encoding inactivation loop between transmembrane domains III and IV of the channel, was detected in a female FHM patient.
p14926
sg4
(lp14927
(dp14928
g7
I22
sg8
VP35498
p14929
sg10
I5
sg11
VSCN1A
p14930
sg13
I1
sasg17
(lp14931
(dp14932
g7
I234
sg20
VC1832894
p14933
sg10
I3
sg11
VFHM
p14934
sg13
I1
sa(dp14935
g7
I134
sg20
VC0544461
p14936
sg10
I12
sg11
Vinactivation
p14937
sg13
I1
sa(dp14938
g7
I4
sg20
VC2985438
p14939
sg10
I14
sg11
Vnovel mutation
p14940
sg13
I2
sasa(dp14941
g2
VThe presence of SCN1A mutations and absence of mutations in ATP1A2 or CACNA1A suggest that the Polish patients represent FHM type 3.
p14942
sg4
(lp14943
(dp14944
g7
I16
sg8
VP35498
p14945
sg10
I15
sg11
VSCN1A mutations
p14946
sg13
I2
sa(dp14947
g7
I60
sg8
VP50993
p14948
sg10
I6
sg11
VATP1A2
p14949
sg13
I1
sasg17
(lp14950
(dp14951
g7
I121
sg20
VC1832894
p14952
sg10
I3
sg11
VFHM
p14953
sg13
I1
sasa(dp14954
g2
VMutations of the voltage gated Na(+) channel Na(V)1.1 (SCN1A) are important causes of different genetic epilepsies and can also cause familial hemiplegic migraine (FHM-III).
p14955
sg4
(lp14956
(dp14957
g7
I55
sg8
VP35498
p14958
sg10
I5
sg11
VSCN1A
p14959
sg13
I1
sasg17
(lp14960
(dp14961
g7
I104
sg20
VC0014544
p14962
sg10
I10
sg11
Vepilepsies
p14963
sg13
I1
sa(dp14964
g7
I164
sg20
VC0338484
p14965
sg10
I7
sg11
VFHM-III
p14966
sg13
I1
sa(dp14967
g7
I134
sg20
VC0338484
p14968
sg10
I28
sg11
Vfamilial hemiplegic migraine
p14969
sg13
I3
sasa(dp14970
g2
VA mutation causing FHM type 3 (FHM3) has been identified in SCN1A encoding the Nav1.1 Na(+) channel.
p14971
sg4
(lp14972
(dp14973
g7
I60
sg8
VP35498
p14974
sg10
I5
sg11
VSCN1A
p14975
sg13
I1
sa(dp14976
g7
I19
sg8
VP35498
p14977
sg10
I10
sg11
VFHM type 3
p14978
sg13
I3
sa(dp14979
g7
I79
sg8
VP35498
p14980
sg10
I12
sg11
VNav1.1 Na(+)
p14981
sg13
I2
sa(dp14982
g7
I31
sg8
VP35498
p14983
sg10
I4
sg11
VFHM3
p14984
sg13
I1
sasg17
(lp14985
(dp14986
g7
I19
sg20
VC1864987
p14987
sg10
I10
sg11
VFHM type 3
p14988
sg13
I3
sa(dp14989
g7
I31
sg20
VC1864987
p14990
sg10
I4
sg11
VFHM3
p14991
sg13
I1
sasa(dp14992
g2
VIn particular, we investigate the dynamical repertoire from normal spiking (milliseconds) to spreading depression and anoxic depolarization (tens of seconds) and show that FHM3 mutations render gray matter tissue more vulnerable to spreading depression despite opposing effects associated with action potential generation.
p14993
sg4
(lp14994
(dp14995
g7
I172
sg8
VP35498
p14996
sg10
I4
sg11
VFHM3
p14997
sg13
I1
sasg17
(lp14998
(dp14999
g7
I172
sg20
VC1864987
p15000
sg10
I4
sg11
VFHM3
p15001
sg13
I1
sa(dp15002
g7
I103
sg20
VC0011581
p15003
sg10
I10
sg11
Vdepression
p15004
sg13
I1
sa(dp15005
g7
I103
sg20
VC0011581
p15006
sg10
I10
sg11
Vdepression
p15007
sg13
I1
sasa(dp15008
g2
VPAR2 gene expression correlated positively with transcript levels of IL-8, IL-1Beta as well mucosal SLPI levels in H. pylori-infected patients (r: 0.47-0.84; p &lt; .0001), whereas no correlation was found with the degree of gastritis.
p15009
sg4
(lp15010
(dp15011
g7
I0
sg8
VP55085
p15012
sg10
I4
sg11
VPAR2
p15013
sg13
I1
sa(dp15014
g7
I75
sg8
VP01584
p15015
sg10
I8
sg11
VIL-1Beta
p15016
sg13
I1
sasg17
(lp15017
(dp15018
g7
I225
sg20
VC0017152
p15019
sg10
I9
sg11
Vgastritis
p15020
sg13
I1
sasa(dp15021
g2
VMucosal levels of Secretory Leukocyte Protease Inhibitor (SLPI) are specifically reduced in relation to H. pylori-induced gastritis.
p15022
sg4
(lp15023
sg17
(lp15024
(dp15025
g7
I122
sg20
VC0017152
p15026
sg10
I9
sg11
Vgastritis
p15027
sg13
I1
sasa(dp15028
g2
VIn contrast to other diseases, SLPI seems not to have a regulatory role for Progranulin in H. pylori-mediated gastritis.
p15029
sg4
(lp15030
sg17
(lp15031
(dp15032
g7
I110
sg20
VC0017152
p15033
sg10
I9
sg11
Vgastritis
p15034
sg13
I1
sasa(dp15035
g2
VSLPI expression is generally induced during inflammation; however, Helicobacter pylori-mediated gastritis is associated with significantly decreased antral SLPI levels.
p15036
sg4
(lp15037
(dp15038
g7
I0
sg8
VP03973
p15039
sg10
I4
sg11
VSLPI
p15040
sg13
I1
sasg17
(lp15041
(dp15042
g7
I44
sg20
VC0021368
p15043
sg10
I12
sg11
Vinflammation
p15044
sg13
I1
sa(dp15045
g7
I96
sg20
VC0017152
p15046
sg10
I9
sg11
Vgastritis
p15047
sg13
I1
sasa(dp15048
g2
VSLPI expression was retrospectively analysed by immunohistochemistry in 85 paraffin-embedded samples: H. pylori-induced (n=13), non-steroidal anti-inflammatory drug (NSAID)-enhanced (n=18), autoimmune (n=11), lymphocytic gastritis (n=26) and H. pylori-negative controls (n=17).
p15049
sg4
(lp15050
sg17
(lp15051
(dp15052
g7
I190
sg20
VC0443146
p15053
sg10
I10
sg11
Vautoimmune
p15054
sg13
I1
sa(dp15055
g7
I209
sg20
VC1283271
p15056
sg10
I21
sg11
Vlymphocytic gastritis
p15057
sg13
I2
sasa(dp15058
g2
VIn comparison with the control group, the SLPI expression of antral mucosa in H. pylori-mediated and lymphocytic gastritis was significantly lower (P&lt;0.001), whereas epithelial SLPI expression was not affected in NSAID-enhanced and autoimmune gastritis either in the antrum or corpus, respectively.
p15059
sg4
(lp15060
(dp15061
g7
I42
sg8
VP03973
p15062
sg10
I4
sg11
VSLPI
p15063
sg13
I1
sa(dp15064
g7
I169
sg8
VP12830
p15065
sg10
I15
sg11
Vepithelial SLPI
p15066
sg13
I2
sasg17
(lp15067
(dp15068
g7
I101
sg20
VC1283271
p15069
sg10
I21
sg11
Vlymphocytic gastritis
p15070
sg13
I2
sa(dp15071
g7
I235
sg20
VC0017154
p15072
sg10
I20
sg11
Vautoimmune gastritis
p15073
sg13
I2
sasa(dp15074
g2
VBoth the H. pylori-mediated and lymphocytic gastritis revealed a significantly lower expression of SLPI in infiltrating immune cells (P&lt;0.01), whereas immune cells infiltrating the corpus in autoimmune gastritis showed higher SLPI levels than the immune cells of other groups (P&lt;0.03).
p15075
sg4
(lp15076
(dp15077
g7
I99
sg8
VP03973
p15078
sg10
I4
sg11
VSLPI
p15079
sg13
I1
sasg17
(lp15080
(dp15081
g7
I32
sg20
VC1283271
p15082
sg10
I21
sg11
Vlymphocytic gastritis
p15083
sg13
I2
sa(dp15084
g7
I194
sg20
VC0017154
p15085
sg10
I20
sg11
Vautoimmune gastritis
p15086
sg13
I2
sa(dp15087
g7
I107
sg20
VC0332448
p15088
sg10
I12
sg11
Vinfiltrating
p15089
sg13
I1
sa(dp15090
g7
I107
sg20
VC0332448
p15091
sg10
I12
sg11
Vinfiltrating
p15092
sg13
I1
sasa(dp15093
g2
VAntral SLPI levels were inversely correlated with inflammatory scores of antrum-predominant gastritis.
p15094
sg4
(lp15095
sg17
(lp15096
(dp15097
g7
I92
sg20
VC0017152
p15098
sg10
I9
sg11
Vgastritis
p15099
sg13
I1
sasa(dp15100
g2
VPharmacological inhibition of different signaling pathways and genetic knockdown of Notch-2 further revealed JNK as an upstream effector of Notch-2 in TGF-Beta1-mediated renal fibrosis.
p15101
sg4
(lp15102
(dp15103
g7
I109
sg8
VP53779
p15104
sg10
I3
sg11
VJNK
p15105
sg13
I1
sa(dp15106
g7
I151
sg8
VP01137
p15107
sg10
I9
sg11
VTGF-Beta1
p15108
sg13
I1
sa(dp15109
g7
I84
sg8
g47
sg10
I7
sg11
VNotch-2
p15110
sg13
I1
sa(dp15111
g7
I84
sg8
g47
sg10
I7
sg11
VNotch-2
p15112
sg13
I1
sasg17
(lp15113
(dp15114
g7
I170
sg20
VC0151650
p15115
sg10
I14
sg11
Vrenal fibrosis
p15116
sg13
I2
sasa(dp15117
g2
VConsistently, we also demonstrated that administration of TSA or a Gamma-secretase inhibitor RO4929097 in the mouse model of unilateral ureteral obstruction significantly ameliorated renal fibrosis through suppression of the JNK/Notch-2 signaling activation.
p15118
sg4
(lp15119
(dp15120
g7
I229
sg8
g47
sg10
I7
sg11
VNotch-2
p15121
sg13
I1
sa(dp15122
g7
I225
sg8
VP53779
p15123
sg10
I3
sg11
VJNK
p15124
sg13
I1
sasg17
(lp15125
(dp15126
g7
I136
sg20
VC0041956
p15127
sg10
I20
sg11
Vureteral obstruction
p15128
sg13
I2
sa(dp15129
g7
I183
sg20
VC0151650
p15130
sg10
I14
sg11
Vrenal fibrosis
p15131
sg13
I2
sa(dp15132
g7
I206
sg20
VC0221103
p15133
sg10
I11
sg11
Vsuppression
p15134
sg13
I1
sasa(dp15135
g2
VAlthough, renal abnormalities are considered an integral part of the HJCYS, published reports on ESRD are scarce.
p15136
sg4
(lp15137
sg17
(lp15138
(dp15139
g7
I69
sg20
VC0917715
p15140
sg10
I5
sg11
VHJCYS
p15141
sg13
I1
sa(dp15142
g7
I97
sg20
VC0022661
p15143
sg10
I4
sg11
VESRD
p15144
sg13
I1
sasa(dp15145
g2
VHere we show that Notch2 prevents podocyte loss and nephrosis.
p15146
sg4
(lp15147
(dp15148
g7
I18
sg8
g47
sg10
I6
sg11
VNotch2
p15149
sg13
I1
sasg17
(lp15150
(dp15151
g7
I52
sg20
VC0027720
p15152
sg10
I9
sg11
Vnephrosis
p15153
sg13
I1
sasa(dp15154
g2
VAdministration of a Notch2 agonistic monoclonal antibody ameliorates proteinuria and glomerulosclerosis in a mouse model of nephrosis and focal segmental glomerulosclerosis.
p15155
sg4
(lp15156
(dp15157
g7
I20
sg8
g47
sg10
I6
sg11
VNotch2
p15158
sg13
I1
sasg17
(lp15159
(dp15160
g7
I138
sg20
VC0017668
p15161
sg10
I34
sg11
Vfocal segmental glomerulosclerosis
p15162
sg13
I3
sa(dp15163
g7
I85
sg20
VC0178664
p15164
sg10
I18
sg11
Vglomerulosclerosis
p15165
sg13
I1
sa(dp15166
g7
I124
sg20
VC0027720
p15167
sg10
I9
sg11
Vnephrosis
p15168
sg13
I1
sasa(dp15169
g2
VHence, specific activation of Notch2 rescues damaged podocytes and activating Notch2 may represent a novel clinical strategy for the amelioration of nephrosis and glomerulosclerosis.
p15170
sg4
(lp15171
(dp15172
g7
I30
sg8
g47
sg10
I6
sg11
VNotch2
p15173
sg13
I1
sa(dp15174
g7
I30
sg8
g47
sg10
I6
sg11
VNotch2
p15175
sg13
I1
sasg17
(lp15176
(dp15177
g7
I149
sg20
VC0027720
p15178
sg10
I9
sg11
Vnephrosis
p15179
sg13
I1
sa(dp15180
g7
I163
sg20
VC0178664
p15181
sg10
I18
sg11
Vglomerulosclerosis
p15182
sg13
I1
sasa(dp15183
g2
VTo investigate the effect of both fermented Cordyceps powder (CS) and prednisone on the Notch2/hes-1 signaling activation in the kidney tubules of rats with acute aristolochic acid nephropathy (AAAN).
p15184
sg4
(lp15185
(dp15186
g7
I95
sg8
g47
sg10
I5
sg11
Vhes-1
p15187
sg13
I1
sa(dp15188
g7
I88
sg8
g47
sg10
I6
sg11
VNotch2
p15189
sg13
I1
sasg17
(lp15190
(dp15191
g7
I95
sg20
VC0206141
p15192
sg10
I3
sg11
Vhes
p15193
sg13
I1
sa(dp15194
g7
I181
sg20
VC0022658
p15195
sg10
I11
sg11
Vnephropathy
p15196
sg13
I1
sasa(dp15197
g2
VThe role of NOTCH2 and JAG1 in formation of proximal nephron structures and podocytes might explain the observed phenotypes of renal dysplasia and proteinuria in patients with Alagille syndrome, and renal tubular acidosis may be the result of JAG1 expression in the collecting ducts.
p15198
sg4
(lp15199
(dp15200
g7
I12
sg8
g47
sg10
I6
sg11
VNOTCH2
p15201
sg13
I1
sa(dp15202
g7
I23
sg8
VP78504
p15203
sg10
I4
sg11
VJAG1
p15204
sg13
I1
sa(dp15205
g7
I23
sg8
VP78504
p15206
sg10
I4
sg11
VJAG1
p15207
sg13
I1
sasg17
(lp15208
(dp15209
g7
I127
sg20
VC0266313
p15210
sg10
I15
sg11
Vrenal dysplasia
p15211
sg13
I2
sa(dp15212
g7
I199
sg20
VC0001126
p15213
sg10
I22
sg11
Vrenal tubular acidosis
p15214
sg13
I3
sa(dp15215
g7
I176
sg20
VC0085280
p15216
sg10
I17
sg11
VAlagille syndrome
p15217
sg13
I2
sasa(dp15218
g2
VThe oral pathogenic bacterium involved in human dental caries formation Streptococcus mutans, encodes for two carbonic anhydrase (CA, EC 4.2.1.1) one belonging to the Alfa- and the other one to the Beta-class.
p15219
sg4
(lp15220
(dp15221
g7
I110
sg8
VP35218
p15222
sg10
I18
sg11
Vcarbonic anhydrase
p15223
sg13
I2
sa(dp15224
g7
I130
sg8
VP35218
p15225
sg10
I2
sg11
VCA
p15226
sg13
I1
sasg17
(lp15227
(dp15228
g7
I48
sg20
VC0333519
p15229
sg10
I13
sg11
Vdental caries
p15230
sg13
I2
sasa(dp15231
g2
VStreptococcus mutans, the oral pathogenic bacterium provoking dental caries formation, encodes for a Beta-class carbonic anhydrase (CA, EC 4.2.1.1), SmuCA.
p15232
sg4
(lp15233
(dp15234
g7
I101
sg8
VP35218
p15235
sg10
I29
sg11
VBeta-class carbonic anhydrase
p15236
sg13
I3
sasg17
(lp15237
(dp15238
g7
I62
sg20
VC0333519
p15239
sg10
I13
sg11
Vdental caries
p15240
sg13
I2
sasa(dp15241
g2
VA carbonic anhydrase (CA, EC 4.2.1.1) denominated PgiCA, belonging to the Gamma-class, from the oral pathogenic bacteria Porphyromonas gingivalis, the main causative agent of periodontitis, was investigated for its inhibition profile with sulfonamides and one sulfamate.
p15242
sg4
(lp15243
(dp15244
g7
I22
sg8
VP35218
p15245
sg10
I2
sg11
VCA
p15246
sg13
I1
sa(dp15247
g7
I2
sg8
VP35218
p15248
sg10
I18
sg11
Vcarbonic anhydrase
p15249
sg13
I2
sasg17
(lp15250
(dp15251
g7
I175
sg20
VC0031099
p15252
sg10
I13
sg11
Vperiodontitis
p15253
sg13
I1
sasa(dp15254
g2
VRecently, an interaction between FIR (FUSE-Binding Protein-Interacting Repressor) and TFIIH/p89/XPB helicase was found to repress c-myc transcription and so might be important for suppressing tumor formation.
p15255
sg4
(lp15256
(dp15257
g7
I130
sg8
VP12524
p15258
sg10
I5
sg11
Vc-myc
p15259
sg13
I1
sa(dp15260
g7
I96
sg8
VP19447
p15261
sg10
I12
sg11
VXPB helicase
p15262
sg13
I2
sa(dp15263
g7
I86
sg8
VP32780
p15264
sg10
I5
sg11
VTFIIH
p15265
sg13
I1
sasg17
(lp15266
(dp15267
g7
I192
sg20
VC0027651
p15268
sg10
I5
sg11
Vtumor
p15269
sg13
I1
sa(dp15270
g7
I96
sg20
VC0268136
p15271
sg10
I3
sg11
VXPB
p15272
sg13
I1
sasa(dp15273
g2
VIn XPB cells carrying mutant TFIIH, loop formation failed and the serum response was abnormal; RNAi depletion of FIR similarly disabled c-myc regulation.
p15274
sg4
(lp15275
(dp15276
g7
I113
sg8
g47
sg10
I3
sg11
VFIR
p15277
sg13
I1
sa(dp15278
g7
I136
sg8
VP12524
p15279
sg10
I5
sg11
Vc-myc
p15280
sg13
I1
sa(dp15281
g7
I29
sg8
VP32780
p15282
sg10
I5
sg11
VTFIIH
p15283
sg13
I1
sasg17
(lp15284
(dp15285
g7
I3
sg20
VC0268136
p15286
sg10
I3
sg11
VXPB
p15287
sg13
I1
sa(dp15288
g7
I22
sg20
VC0596988
p15289
sg10
I6
sg11
Vmutant
p15290
sg13
I1
sasa(dp15291
g2
VRecently, an interaction between FUSE-binding protein-interacting repressor (FIR) and TFIIH/p89/XPB helicase was found to repress c-myc transcription and might be important for suppressing tumor formation.
p15292
sg4
(lp15293
(dp15294
g7
I130
sg8
VP12524
p15295
sg10
I5
sg11
Vc-myc
p15296
sg13
I1
sa(dp15297
g7
I77
sg8
g47
sg10
I3
sg11
VFIR
p15298
sg13
I1
sa(dp15299
g7
I96
sg8
VP19447
p15300
sg10
I12
sg11
VXPB helicase
p15301
sg13
I2
sa(dp15302
g7
I86
sg8
VP32780
p15303
sg10
I5
sg11
VTFIIH
p15304
sg13
I1
sa(dp15305
g7
I33
sg8
g47
sg10
I42
sg11
VFUSE-binding protein-interacting repressor
p15306
sg13
I3
sasg17
(lp15307
(dp15308
g7
I189
sg20
VC0027651
p15309
sg10
I5
sg11
Vtumor
p15310
sg13
I1
sa(dp15311
g7
I96
sg20
VC0268136
p15312
sg10
I3
sg11
VXPB
p15313
sg13
I1
sasa(dp15314
g2
VHere, XPB and XPD mutations are shown to block transcription activation by the FUSE Binding Protein (FBP), a regulator of c-myc expression, and repression by the FBP Interacting Repressor (FIR).
p15315
sg4
(lp15316
(dp15317
g7
I189
sg8
g47
sg10
I3
sg11
VFIR
p15318
sg13
I1
sa(dp15319
g7
I101
sg8
g47
sg10
I3
sg11
VFBP
p15320
sg13
I1
sa(dp15321
g7
I122
sg8
VP12524
p15322
sg10
I5
sg11
Vc-myc
p15323
sg13
I1
sa(dp15324
g7
I6
sg8
VP19447
p15325
sg10
I3
sg11
VXPB
p15326
sg13
I1
sa(dp15327
g7
I14
sg8
VP18074
p15328
sg10
I3
sg11
VXPD
p15329
sg13
I1
sa(dp15330
g7
I79
sg8
g47
sg10
I20
sg11
VFUSE Binding Protein
p15331
sg13
I3
sa(dp15332
g7
I162
sg8
g47
sg10
I25
sg11
VFBP Interacting Repressor
p15333
sg13
I3
sasg17
(lp15334
(dp15335
g7
I14
sg20
VC0268138
p15336
sg10
I3
sg11
VXPD
p15337
sg13
I1
sa(dp15338
g7
I6
sg20
VC0268136
p15339
sg10
I3
sg11
VXPB
p15340
sg13
I1
sasa(dp15341
g2
VThe repression domain of FIR targeted only TFIIH's p89/XPB helicase, required at several stages in transcription, but not factors required for promoter selection.
p15342
sg4
(lp15343
(dp15344
g7
I55
sg8
VP19447
p15345
sg10
I12
sg11
VXPB helicase
p15346
sg13
I2
sa(dp15347
g7
I25
sg8
g47
sg10
I3
sg11
VFIR
p15348
sg13
I1
sa(dp15349
g7
I43
sg8
VP32780
p15350
sg10
I5
sg11
VTFIIH
p15351
sg13
I1
sasg17
(lp15352
(dp15353
g7
I55
sg20
VC0268136
p15354
sg10
I3
sg11
VXPB
p15355
sg13
I1
sasa(dp15356
g2
VTo investigate the tissue expression and systemic levels of IL-32, as well as its cellular sources, in patients with HS in comparison with healthy donors and patients with two other inflammatory skin diseases: psoriasis and atopic dermatitis (AD).
p15357
sg4
(lp15358
sg17
(lp15359
(dp15360
g7
I243
sg20
VC0011615
p15361
sg10
I2
sg11
VAD
p15362
sg13
I1
sa(dp15363
g7
I210
sg20
VC0033860
p15364
sg10
I9
sg11
Vpsoriasis
p15365
sg13
I1
sa(dp15366
g7
I195
sg20
VC0037274
p15367
sg10
I13
sg11
Vskin diseases
p15368
sg13
I2
sa(dp15369
g7
I224
sg20
VC0011615
p15370
sg10
I17
sg11
Vatopic dermatitis
p15371
sg13
I2
sasa(dp15372
g2
VIL-32 was upregulated in patients with HS in both lesional skin and serum when compared with healthy donors and patients with AD or psoriasis.
p15373
sg4
(lp15374
sg17
(lp15375
(dp15376
g7
I132
sg20
VC0033860
p15377
sg10
I9
sg11
Vpsoriasis
p15378
sg13
I1
sasa(dp15379
g2
VUsing skin samples from patients with mycosis fungoides (n = 21), healthy volunteers (n = 17), and individuals with atopic dermatitis (n = 17) and psoriasis (n = 9), we found IL32 mRNA expression significantly higher in mycosis fungoides samples than in samples from benign inflammatory skin diseases, and its expression increases with disease progression.
p15380
sg4
(lp15381
(dp15382
g7
I175
sg8
VP24001
p15383
sg10
I9
sg11
VIL32 mRNA
p15384
sg13
I2
sasg17
(lp15385
(dp15386
g7
I116
sg20
VC0011615
p15387
sg10
I17
sg11
Vatopic dermatitis
p15388
sg13
I2
sa(dp15389
g7
I38
sg20
VC0026948
p15390
sg10
I17
sg11
Vmycosis fungoides
p15391
sg13
I2
sa(dp15392
g7
I336
sg20
VC0242656
p15393
sg10
I19
sg11
Vdisease progression
p15394
sg13
I2
sa(dp15395
g7
I147
sg20
VC0033860
p15396
sg10
I9
sg11
Vpsoriasis
p15397
sg13
I1
sa(dp15398
g7
I38
sg20
VC0026948
p15399
sg10
I17
sg11
Vmycosis fungoides
p15400
sg13
I2
sa(dp15401
g7
I287
sg20
VC0037274
p15402
sg10
I13
sg11
Vskin diseases
p15403
sg13
I2
sasa(dp15404
g2
VImmunofluorescence staining demonstrated that IL-32 was expressed in AD lesional skin, whereas it was present in neither skin biopsy specimens from healthy donors nor in lesional skin from patients with psoriasis.
p15405
sg4
(lp15406
sg17
(lp15407
(dp15408
g7
I203
sg20
VC0033860
p15409
sg10
I9
sg11
Vpsoriasis
p15410
sg13
I1
sasa(dp15411
g2
VIn this study, the expression profile of ASPP2 in choriocarcinoma was examined in comparison with normal placentas and hydatidiform moles, the latter being a type of GTD that carries malignant potential.
p15412
sg4
(lp15413
(dp15414
g7
I41
sg8
g47
sg10
I5
sg11
VASPP2
p15415
sg13
I1
sasg17
(lp15416
(dp15417
g7
I50
sg20
VC0008497
p15418
sg10
I15
sg11
Vchoriocarcinoma
p15419
sg13
I1
sa(dp15420
g7
I119
sg20
VC0020217
p15421
sg10
I18
sg11
Vhydatidiform moles
p15422
sg13
I2
sasa(dp15423
g2
VDownregulation of ASPP2 messenger RNA and protein was demonstrated in choriocarcinoma by quantitative PCR and immunohistochemistry.
p15424
sg4
(lp15425
(dp15426
g7
I18
sg8
g47
sg10
I31
sg11
VASPP2 messenger RNA and protein
p15427
sg13
I5
sasg17
(lp15428
(dp15429
g7
I70
sg20
VC0008497
p15430
sg10
I15
sg11
Vchoriocarcinoma
p15431
sg13
I1
sasa(dp15432
g2
VASPP2-transfected choriocarcinoma cells (JEG-3 and JAR) showed an increase in apoptosis and a decrease in cell migration as detected by TdT-mediated dUTP nick end labeling and wound healing assays, respectively, illustrating the complex action of ASPP2 on cell functions other than programmed cell death.
p15433
sg4
(lp15434
(dp15435
g7
I0
sg8
g47
sg10
I5
sg11
VASPP2
p15436
sg13
I1
sa(dp15437
g7
I0
sg8
g47
sg10
I5
sg11
VASPP2
p15438
sg13
I1
sa(dp15439
g7
I136
sg8
VP04053
p15440
sg10
I3
sg11
VTdT
p15441
sg13
I1
sasg17
(lp15442
(dp15443
g7
I18
sg20
VC0008497
p15444
sg10
I15
sg11
Vchoriocarcinoma
p15445
sg13
I1
sasa(dp15446
g2
VTaken together, we demonstrated a loss of tumor-suppressive ASPP2 in choriocarcinoma with effects on cell migration and apoptosis.
p15447
sg4
(lp15448
(dp15449
g7
I60
sg8
g47
sg10
I5
sg11
VASPP2
p15450
sg13
I1
sasg17
(lp15451
(dp15452
g7
I69
sg20
VC0008497
p15453
sg10
I15
sg11
Vchoriocarcinoma
p15454
sg13
I1
sa(dp15455
g7
I42
sg20
VC0027651
p15456
sg10
I5
sg11
Vtumor
p15457
sg13
I1
sasa(dp15458
g2
VNo correlation between erythrocyte TDP concentration and transketolase activity and/or alpha-ETK was observed in ESRD patients, either before or 10 h after administration.
p15459
sg4
(lp15460
(dp15461
g7
I57
sg8
VP29401
p15462
sg10
I13
sg11
Vtransketolase
p15463
sg13
I1
sa(dp15464
g7
I87
sg8
VP51813
p15465
sg10
I9
sg11
Valpha-ETK
p15466
sg13
I1
sasg17
(lp15467
(dp15468
g7
I113
sg20
VC0022661
p15469
sg10
I4
sg11
VESRD
p15470
sg13
I1
sasa(dp15471
g2
VScores for VEGF, TIMP-1, TIMP-3, SLPI and PAI-1 were all increased in OA compared with PM, and higher scores were associated with greater chondropathy.
p15472
sg4
(lp15473
(dp15474
g7
I42
sg8
VP05121
p15475
sg10
I5
sg11
VPAI-1
p15476
sg13
I1
sa(dp15477
g7
I25
sg8
VP35625
p15478
sg10
I6
sg11
VTIMP-3
p15479
sg13
I1
sa(dp15480
g7
I17
sg8
VP01033
p15481
sg10
I6
sg11
VTIMP-1
p15482
sg13
I1
sa(dp15483
g7
I33
sg8
VP03973
p15484
sg10
I4
sg11
VSLPI
p15485
sg13
I1
sasg17
(lp15486
(dp15487
g7
I138
sg20
VC0007302
p15488
sg10
I12
sg11
Vchondropathy
p15489
sg13
I1
sasa(dp15490
g2
VConcentrations of the plasminogen activators pro-urokinase, tissue plasminogen activator, plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI-2), plasminogen, and fibrin split product D-dimer in synovial fluid (SF) and blood plasma of 29 patients with rheumatoid arthritis (RA) were compared with the concentrations of 18 patients with spondyloarthropathy (SpA).
p15491
sg4
(lp15492
(dp15493
g7
I132
sg8
VP05121
p15494
sg10
I5
sg11
VPAI-1
p15495
sg13
I1
sa(dp15496
g7
I60
sg8
VP00747
p15497
sg10
I28
sg11
Vtissue plasminogen activator
p15498
sg13
I3
sa(dp15499
g7
I22
sg8
VP00747
p15500
sg10
I11
sg11
Vplasminogen
p15501
sg13
I1
sa(dp15502
g7
I22
sg8
VP00747
p15503
sg10
I36
sg11
Vplasminogen activators pro-urokinase
p15504
sg13
I3
sa(dp15505
g7
I90
sg8
VP00747
p15506
sg10
I40
sg11
Vplasminogen activator inhibitors 1 and 2
p15507
sg13
I6
sa(dp15508
g7
I167
sg8
VP22087
p15509
sg10
I6
sg11
Vfibrin
p15510
sg13
I1
sa(dp15511
g7
I142
sg8
VP05120
p15512
sg10
I5
sg11
VPAI-2
p15513
sg13
I1
sasg17
(lp15514
(dp15515
g7
I278
sg20
VC0003873
p15516
sg10
I2
sg11
VRA
p15517
sg13
I1
sa(dp15518
g7
I361
sg20
VC0949691
p15519
sg10
I3
sg11
VSpA
p15520
sg13
I1
sa(dp15521
g7
I340
sg20
VC0949691
p15522
sg10
I19
sg11
Vspondyloarthropathy
p15523
sg13
I1
sa(dp15524
g7
I256
sg20
VC0003873
p15525
sg10
I20
sg11
Vrheumatoid arthritis
p15526
sg13
I2
sasa(dp15527
g2
VBesides myeloperoxidase (MPO), which was used as the gold standard in differentiating AML from other type of ALs, the most specific markers for AML in our study were CD14 and CD64 (99.5 and 95.6%).
p15528
sg4
(lp15529
(dp15530
g7
I8
sg8
VP05164
p15531
sg10
I15
sg11
Vmyeloperoxidase
p15532
sg13
I1
sa(dp15533
g7
I166
sg8
VP08571
p15534
sg10
I4
sg11
VCD14
p15535
sg13
I1
sa(dp15536
g7
I25
sg8
VP05164
p15537
sg10
I3
sg11
VMPO
p15538
sg13
I1
sasg17
(lp15539
(dp15540
g7
I86
sg20
VC0023467
p15541
sg10
I3
sg11
VAML
p15542
sg13
I1
sa(dp15543
g7
I109
sg20
VC0002736
p15544
sg10
I3
sg11
VALs
p15545
sg13
I1
sa(dp15546
g7
I86
sg20
VC0023467
p15547
sg10
I3
sg11
VAML
p15548
sg13
I1
sasa(dp15549
g2
VThey were characterized as follows: (1) disease onset with initial signs/symptoms due to intractable otitis media with effusion or granulation, which did not respond to ordinary treatments such as antibiotics and insertion of tympanic ventilation tubes, followed by progressive hearing loss; (2) predominantly female (73%) and older (median age: 68 years); (3) predominantly myeloperoxidase (MPO)-ANCA-positive (60%), followed by proteinase 3 (PR3)-ANCA-positive (19%) and both ANCAs-negative (16%); (4) frequently observed accompanying facial palsy (36%) and hypertrophic pachymeningitis (28%); and (5) disease often involving lung (35%) and kidney (26%) lesions.
p15550
sg4
(lp15551
(dp15552
g7
I430
sg8
VP63123
p15553
sg10
I12
sg11
Vproteinase 3
p15554
sg13
I2
sa(dp15555
g7
I444
sg8
VP63123
p15556
sg10
I3
sg11
VPR3
p15557
sg13
I1
sa(dp15558
g7
I375
sg8
VP05164
p15559
sg10
I15
sg11
Vmyeloperoxidase
p15560
sg13
I1
sa(dp15561
g7
I392
sg8
VP05164
p15562
sg10
I3
sg11
VMPO
p15563
sg13
I1
sasg17
(lp15564
(dp15565
g7
I537
sg20
VC0015469
p15566
sg10
I12
sg11
Vfacial palsy
p15567
sg13
I2
sa(dp15568
g7
I101
sg20
VC0029883
p15569
sg10
I26
sg11
Votitis media with effusion
p15570
sg13
I4
sa(dp15571
g7
I278
sg20
VC0011053
p15572
sg10
I12
sg11
Vhearing loss
p15573
sg13
I2
sa(dp15574
g7
I560
sg20
VC0948402
p15575
sg10
I28
sg11
Vhypertrophic pachymeningitis
p15576
sg13
I2
sasa(dp15577
g2
VEffects of zolpidem were wide ranging (eg, improvement on the JFK Coma Recovery Scale-Revised, the Unified Parkinson Disease Rating Scale, and the Burke-Fahn-Marsden Dystonia Rating Scale) and generally lasted 1 to 4 hours before the participant returned to baseline.
p15578
sg4
(lp15579
sg17
(lp15580
(dp15581
g7
I66
sg20
VC0009421
p15582
sg10
I4
sg11
VComa
p15583
sg13
I1
sa(dp15584
g7
I166
sg20
VC0393593
p15585
sg10
I8
sg11
VDystonia
p15586
sg13
I1
sa(dp15587
g7
I107
sg20
VC0030567
p15588
sg10
I17
sg11
VParkinson Disease
p15589
sg13
I2
sasa(dp15590
g2
VThe altered tissue steroid concentrations in endometriosis were in line with the expression of various steroidogenic enzymes in the lesions, of which HSD3B2 showed constantly high expression, whereas CYP11A1 expression was low.
p15591
sg4
(lp15592
(dp15593
g7
I200
sg8
VP05108
p15594
sg10
I7
sg11
VCYP11A1
p15595
sg13
I1
sa(dp15596
g7
I150
sg8
VP26439
p15597
sg10
I6
sg11
VHSD3B2
p15598
sg13
I1
sasg17
(lp15599
(dp15600
g7
I45
sg20
VC0014175
p15601
sg10
I13
sg11
Vendometriosis
p15602
sg13
I1
sasa(dp15603
g2
VType III groups together 10 autoimmune diseases (autoimmune thyroid disease, myasthenia and/or thymoma, Sjoegren's syndrome, pernicious anaemia, idiopathic thrombocytopaenic purpura, Addison's disease, insulin-dependent diabetes, vitiligo, autoimmune haemolytic anaemia, systemic lupus erythematosus) for which a genetic predisposition (phenotype HLA B8 and/or DR3 or DR5) seems to be an important factor.
p15604
sg4
(lp15605
(dp15606
g7
I202
sg8
VP01308
p15607
sg10
I7
sg11
Vinsulin
p15608
sg13
I1
sasg17
(lp15609
(dp15610
g7
I49
sg20
VC0178468
p15611
sg10
I26
sg11
Vautoimmune thyroid disease
p15612
sg13
I3
sa(dp15613
g7
I271
sg20
VC0024141
p15614
sg10
I28
sg11
Vsystemic lupus erythematosus
p15615
sg13
I3
sa(dp15616
g7
I183
sg20
VC0001403
p15617
sg10
I17
sg11
VAddison's disease
p15618
sg13
I2
sa(dp15619
g7
I202
sg20
VC0011854
p15620
sg10
I26
sg11
Vinsulin-dependent diabetes
p15621
sg13
I2
sa(dp15622
g7
I230
sg20
VC0042900
p15623
sg10
I8
sg11
Vvitiligo
p15624
sg13
I1
sa(dp15625
g7
I95
sg20
VC0040100
p15626
sg10
I7
sg11
Vthymoma
p15627
sg13
I1
sa(dp15628
g7
I28
sg20
VC0004364
p15629
sg10
I19
sg11
Vautoimmune diseases
p15630
sg13
I2
sa(dp15631
g7
I77
sg20
VC0947912
p15632
sg10
I10
sg11
Vmyasthenia
p15633
sg13
I1
sa(dp15634
g7
I104
sg20
VC1527336
p15635
sg10
I19
sg11
VSjoegren's syndrome
p15636
sg13
I2
sa(dp15637
g7
I156
sg20
VC0857305
p15638
sg10
I25
sg11
Vthrombocytopaenic purpura
p15639
sg13
I2
sa(dp15640
g7
I125
sg20
VC0002892
p15641
sg10
I18
sg11
Vpernicious anaemia
p15642
sg13
I2
sa(dp15643
g7
I240
sg20
VC0002880
p15644
sg10
I29
sg11
Vautoimmune haemolytic anaemia
p15645
sg13
I3
sasa(dp15646
g2
VA significant increase in the frequency of HLA DR5 antigen was observed in patients with ARC mainly in purpura thrombocytopenic patients.
p15647
sg4
(lp15648
(dp15649
g7
I43
sg8
VP30486
p15650
sg10
I15
sg11
VHLA DR5 antigen
p15651
sg13
I3
sasg17
(lp15652
(dp15653
g7
I103
sg20
VC0857305
p15654
sg10
I24
sg11
Vpurpura thrombocytopenic
p15655
sg13
I2
sa(dp15656
g7
I89
sg20
VC0001857
p15657
sg10
I3
sg11
VARC
p15658
sg13
I1
sasa(dp15659
g2
VGenome-wide pathway analysis with the dysregulated genes after overexpression of either of the two miRs in MCF-7 breast cancer cell identified the "Cancer"- and "Cell signaling"-related pathway as the top pathway for miR-204 and miR-211, respectively.
p15660
sg4
(lp15661
(dp15662
g7
I217
sg8
g47
sg10
I7
sg11
VmiR-204
p15663
sg13
I1
sa(dp15664
g7
I229
sg8
g47
sg10
I7
sg11
VmiR-211
p15665
sg13
I1
sasg17
(lp15666
(dp15667
g7
I148
sg20
VC0006826
p15668
sg10
I6
sg11
VCancer
p15669
sg13
I1
sa(dp15670
g7
I113
sg20
VC0678222
p15671
sg10
I13
sg11
Vbreast cancer
p15672
sg13
I2
sasa(dp15673
g2
VIn addition, a high association was observed between miR-204 and miR-211 expression in breast cancer tissue.
p15674
sg4
(lp15675
(dp15676
g7
I53
sg8
g47
sg10
I7
sg11
VmiR-204
p15677
sg13
I1
sa(dp15678
g7
I65
sg8
g47
sg10
I7
sg11
VmiR-211
p15679
sg13
I1
sasg17
(lp15680
(dp15681
g7
I87
sg20
VC0678222
p15682
sg10
I13
sg11
Vbreast cancer
p15683
sg13
I2
sasa(dp15684
g2
VTo shed light on their roles of miR-211 in breast cancer, the expression of miR-211 was examined by real-time RT-PCR in breast cancer and normal tissues.
p15685
sg4
(lp15686
sg17
(lp15687
(dp15688
g7
I43
sg20
VC0678222
p15689
sg10
I13
sg11
Vbreast cancer
p15690
sg13
I2
sa(dp15691
g7
I43
sg20
VC0678222
p15692
sg10
I13
sg11
Vbreast cancer
p15693
sg13
I2
sasa(dp15694
g2
VMiR-211 is significantly downregulated in breast cancer.
p15695
sg4
(lp15696
(dp15697
g7
I0
sg8
g47
sg10
I3
sg11
VMiR
p15698
sg13
I1
sasg17
(lp15699
(dp15700
g7
I42
sg20
VC0678222
p15701
sg10
I13
sg11
Vbreast cancer
p15702
sg13
I2
sasa(dp15703
g2
VMiR-211 re-expression suppressed cell growth, cell cycle, migration, and invasion in triple-negative breast cancer (TNBC) cell line MDA-MB231.
p15704
sg4
(lp15705
(dp15706
g7
I0
sg8
g47
sg10
I3
sg11
VMiR
p15707
sg13
I1
sasg17
(lp15708
(dp15709
g7
I101
sg20
VC0678222
p15710
sg10
I13
sg11
Vbreast cancer
p15711
sg13
I2
sa(dp15712
g7
I73
sg20
VC2699153
p15713
sg10
I8
sg11
Vinvasion
p15714
sg13
I1
sasa(dp15715
g2
VThe expression and the functional role of several miRNAs (miR-206, miR-31, miR-27a/b, miR-21, miR-92a, miR-205, miR-125a/b, miR-10b, miR-155, miR-146a/b, miR-335, miR-204, miR-211, miR-7, miR-22, miR-126, and miR-17) in breast cancer has been identified.
p15716
sg4
(lp15717
(dp15718
g7
I94
sg8
g47
sg10
I7
sg11
VmiR-92a
p15719
sg13
I1
sa(dp15720
g7
I124
sg8
g47
sg10
I7
sg11
VmiR-10b
p15721
sg13
I1
sa(dp15722
g7
I103
sg8
g47
sg10
I7
sg11
VmiR-205
p15723
sg13
I1
sa(dp15724
g7
I86
sg8
g47
sg10
I6
sg11
VmiR-21
p15725
sg13
I1
sa(dp15726
g7
I142
sg8
g47
sg10
I10
sg11
VmiR-146a/b
p15727
sg13
I1
sa(dp15728
g7
I58
sg8
g47
sg10
I7
sg11
VmiR-206
p15729
sg13
I1
sa(dp15730
g7
I188
sg8
g47
sg10
I6
sg11
VmiR-22
p15731
sg13
I1
sa(dp15732
g7
I75
sg8
g47
sg10
I9
sg11
VmiR-27a/b
p15733
sg13
I1
sa(dp15734
g7
I154
sg8
g47
sg10
I7
sg11
VmiR-335
p15735
sg13
I1
sa(dp15736
g7
I172
sg8
g47
sg10
I7
sg11
VmiR-211
p15737
sg13
I1
sa(dp15738
g7
I67
sg8
g47
sg10
I6
sg11
VmiR-31
p15739
sg13
I1
sa(dp15740
g7
I163
sg8
g47
sg10
I7
sg11
VmiR-204
p15741
sg13
I1
sa(dp15742
g7
I112
sg8
g47
sg10
I10
sg11
VmiR-125a/b
p15743
sg13
I1
sa(dp15744
g7
I209
sg8
g47
sg10
I6
sg11
VmiR-17
p15745
sg13
I1
sa(dp15746
g7
I133
sg8
g47
sg10
I7
sg11
VmiR-155
p15747
sg13
I1
sa(dp15748
g7
I196
sg8
g47
sg10
I7
sg11
VmiR-126
p15749
sg13
I1
sa(dp15750
g7
I181
sg8
g47
sg10
I5
sg11
VmiR-7
p15751
sg13
I1
sasg17
(lp15752
(dp15753
g7
I220
sg20
VC0678222
p15754
sg10
I13
sg11
Vbreast cancer
p15755
sg13
I2
sasa(dp15756
g2
VQuantitative RT-PCR analysis confirmed that miR-135b, miR-192, miR-194 and miR-211 were significantly up-regulated in radiation-induced mammary cancer compared with spontaneous cancer and normal mammary tissue.
p15757
sg4
(lp15758
(dp15759
g7
I54
sg8
g47
sg10
I7
sg11
VmiR-192
p15760
sg13
I1
sa(dp15761
g7
I44
sg8
g47
sg10
I8
sg11
VmiR-135b
p15762
sg13
I1
sasg17
(lp15763
(dp15764
g7
I144
sg20
VC0006826
p15765
sg10
I6
sg11
Vcancer
p15766
sg13
I1
sa(dp15767
g7
I144
sg20
VC0006826
p15768
sg10
I6
sg11
Vcancer
p15769
sg13
I1
sasa(dp15770
g2
VThe HBD/LD ratio in the measles patients two to three days after the onset of rash was significantly lower than that in control subjects (P less than 0.001).
p15771
sg4
(lp15772
sg17
(lp15773
(dp15774
g7
I78
sg20
VC0015230
p15775
sg10
I4
sg11
Vrash
p15776
sg13
I1
sa(dp15777
g7
I24
sg20
VC0025007
p15778
sg10
I7
sg11
Vmeasles
p15779
sg13
I1
sa(dp15780
g7
I4
sg20
VC1840321
p15781
sg10
I3
sg11
VHBD
p15782
sg13
I1
sasa(dp15783
g2
VUC treatment obviously reduced the expression levels of IL-2, IFN-Gamma, NF-KBp65, ICAM-1 and VEGF and increased inhibitory kappa B alpha (IKB-Alfa) expression in the grafts, where no obvious inflammatory cell infiltration or corneal neovascularization was found.
p15784
sg4
(lp15785
(dp15786
g7
I56
sg8
VP60568
p15787
sg10
I4
sg11
VIL-2
p15788
sg13
I1
sa(dp15789
g7
I83
sg8
VP05362
p15790
sg10
I6
sg11
VICAM-1
p15791
sg13
I1
sa(dp15792
g7
I139
sg8
VP25963
p15793
sg10
I8
sg11
VIKB-Alfa
p15794
sg13
I1
sa(dp15795
g7
I62
sg8
VP01579
p15796
sg10
I9
sg11
VIFN-Gamma
p15797
sg13
I1
sasg17
(lp15798
(dp15799
g7
I192
sg20
VC0302158
p15800
sg10
I30
sg11
Vinflammatory cell infiltration
p15801
sg13
I3
sa(dp15802
g7
I226
sg20
VC0085109
p15803
sg10
I26
sg11
Vcorneal neovascularization
p15804
sg13
I2
sasa(dp15805
g2
VIn contrast, none of other patients with MFM had necklace CBs except for one patient with reducing body myopathy.
p15806
sg4
(lp15807
sg17
(lp15808
(dp15809
g7
I104
sg20
VC0026848
p15810
sg10
I8
sg11
Vmyopathy
p15811
sg13
I1
sasa(dp15812
g2
VAmong the serums assessed, MMA levels showed a positive correlation to TNSr and KNPQ in the IPD patients with peripheral neuropathy (TNSr r = 0.882, p &lt; 0.001, KNPQ r = 0.710, p = 0.004), while Vitamin B12 and homocysteine showed no statistically significant correlation.
p15813
sg4
(lp15814
sg17
(lp15815
(dp15816
g7
I27
sg20
VC0276096
p15817
sg10
I3
sg11
VMMA
p15818
sg13
I1
sa(dp15819
g7
I110
sg20
VC0031117
p15820
sg10
I21
sg11
Vperipheral neuropathy
p15821
sg13
I2
sasa(dp15822
g2
VThe serum MMA positively correlated with the severity of neuropathic pain and this can be used as a useful marker in assessment of peripheral neuropathy in Parkinson's disease.
p15823
sg4
(lp15824
sg17
(lp15825
(dp15826
g7
I10
sg20
VC0276096
p15827
sg10
I3
sg11
VMMA
p15828
sg13
I1
sa(dp15829
g7
I131
sg20
VC0031117
p15830
sg10
I21
sg11
Vperipheral neuropathy
p15831
sg13
I2
sa(dp15832
g7
I57
sg20
VC0027796
p15833
sg10
I16
sg11
Vneuropathic pain
p15834
sg13
I2
sa(dp15835
g7
I156
sg20
VC0030567
p15836
sg10
I19
sg11
VParkinson's disease
p15837
sg13
I2
sasa(dp15838
g2
VFunctional vitamin B12 deficiency, defined by elevated levels of the B12-dependent metabolites, methylmalonic acid (MMA), and/or homocysteine, despite normal B12 values, may cause neuropathy and is associated with disorders linked to increased oxidative stress.
p15839
sg4
(lp15840
sg17
(lp15841
(dp15842
g7
I244
sg20
VC0242606
p15843
sg10
I16
sg11
Voxidative stress
p15844
sg13
I2
sa(dp15845
g7
I11
sg20
VC0042847
p15846
sg10
I22
sg11
Vvitamin B12 deficiency
p15847
sg13
I3
sa(dp15848
g7
I116
sg20
VC0276096
p15849
sg10
I3
sg11
VMMA
p15850
sg13
I1
sa(dp15851
g7
I180
sg20
VC0442874
p15852
sg10
I10
sg11
Vneuropathy
p15853
sg13
I1
sa(dp15854
g7
I96
sg20
VC0276096
p15855
sg10
I18
sg11
Vmethylmalonic acid
p15856
sg13
I2
sasa(dp15857
g2
VCDC6 and GDF-9 expressions in 108 gallbladder adenocarcinomas, 15 gallbladder polyps, 35 chronic cholecystitis tissues, and 46 peritumoral tissues were detected using immunohistochemistry (IHC).
p15858
sg4
(lp15859
(dp15860
g7
I0
sg8
g47
sg10
I4
sg11
VCDC6
p15861
sg13
I1
sa(dp15862
g7
I9
sg8
VP09466
p15863
sg10
I5
sg11
VGDF-9
p15864
sg13
I1
sasg17
(lp15865
(dp15866
g7
I66
sg20
VC0262493
p15867
sg10
I18
sg11
Vgallbladder polyps
p15868
sg13
I2
sa(dp15869
g7
I46
sg20
VC0001418
p15870
sg10
I15
sg11
Vadenocarcinomas
p15871
sg13
I1
sa(dp15872
g7
I89
sg20
VC0085694
p15873
sg10
I21
sg11
Vchronic cholecystitis
p15874
sg13
I2
sasa(dp15875
g2
VWe demonstrated that positive CDC6 and GDF-9 expressions were significantly higher in adenocarcinomas than that in peritumoral tissues, polyps, and chronic cholecystitis (p &lt; 0.01).
p15876
sg4
(lp15877
(dp15878
g7
I30
sg8
g47
sg10
I4
sg11
VCDC6
p15879
sg13
I1
sa(dp15880
g7
I39
sg8
VP09466
p15881
sg10
I5
sg11
VGDF-9
p15882
sg13
I1
sasg17
(lp15883
(dp15884
g7
I148
sg20
VC0085694
p15885
sg10
I21
sg11
Vchronic cholecystitis
p15886
sg13
I2
sa(dp15887
g7
I136
sg20
VC0032584
p15888
sg10
I6
sg11
Vpolyps
p15889
sg13
I1
sa(dp15890
g7
I86
sg20
VC0001418
p15891
sg10
I15
sg11
Vadenocarcinomas
p15892
sg13
I1
sasa(dp15893
g2
VPreviously, we identified MFAP4 as a serum biomarker candidate for hepatic fibrosis and cirrhosis in hepatitis C patients.
p15894
sg4
(lp15895
(dp15896
g7
I26
sg8
VP55083
p15897
sg10
I5
sg11
VMFAP4
p15898
sg13
I1
sasg17
(lp15899
(dp15900
g7
I67
sg20
VC0239946
p15901
sg10
I16
sg11
Vhepatic fibrosis
p15902
sg13
I2
sa(dp15903
g7
I88
sg20
VC0023890
p15904
sg10
I9
sg11
Vcirrhosis
p15905
sg13
I1
sa(dp15906
g7
I101
sg20
VC0019196
p15907
sg10
I11
sg11
Vhepatitis C
p15908
sg13
I2
sasa(dp15909
g2
VThe aim of the present study was to elucidate the potential of MFAP4 as biomarker for hepatic fibrosis with a focus on the differentiation of no to moderate (F0-F2) and severe fibrosis stages and cirrhosis (F3 and F4, Desmet-Scheuer scoring system).
p15910
sg4
(lp15911
(dp15912
g7
I63
sg8
VP55083
p15913
sg10
I5
sg11
VMFAP4
p15914
sg13
I1
sasg17
(lp15915
(dp15916
g7
I196
sg20
VC0023890
p15917
sg10
I9
sg11
Vcirrhosis
p15918
sg13
I1
sa(dp15919
g7
I86
sg20
VC0239946
p15920
sg10
I16
sg11
Vhepatic fibrosis
p15921
sg13
I2
sa(dp15922
g7
I94
sg20
VC0016059
p15923
sg10
I8
sg11
Vfibrosis
p15924
sg13
I1
sasa(dp15925
g2
VLinear and logistic multivariate regression analyses were performed and nonparametric receiver operating characteristic-curves for cirrhosis were used to estimate cut-off points for pMFAP4.
p15926
sg4
(lp15927
sg17
(lp15928
(dp15929
g7
I131
sg20
VC0023890
p15930
sg10
I9
sg11
Vcirrhosis
p15931
sg13
I1
sasa(dp15932
g2
VMicrofibrillar-associated protein 4 (MFAP4) is a systemic biomarker that is significantly elevated in samples from patients suffering from hepatic cirrhosis.
p15933
sg4
(lp15934
(dp15935
g7
I0
sg8
VP55083
p15936
sg10
I35
sg11
VMicrofibrillar-associated protein 4
p15937
sg13
I3
sa(dp15938
g7
I37
sg8
VP55083
p15939
sg10
I5
sg11
VMFAP4
p15940
sg13
I1
sasg17
(lp15941
(dp15942
g7
I124
sg20
VC0683278
p15943
sg10
I9
sg11
Vsuffering
p15944
sg13
I1
sa(dp15945
g7
I139
sg20
VC0023890
p15946
sg10
I17
sg11
Vhepatic cirrhosis
p15947
sg13
I2
sasa(dp15948
g2
VTropomyosin and MFAP-4 demonstrated high serum levels in patients with hepatic cirrhosis of different causes.
p15949
sg4
(lp15950
(dp15951
g7
I0
sg8
VP07951
p15952
sg10
I11
sg11
VTropomyosin
p15953
sg13
I1
sasg17
(lp15954
(dp15955
g7
I71
sg20
VC0023890
p15956
sg10
I17
sg11
Vhepatic cirrhosis
p15957
sg13
I2
sasa(dp15958
g2
VA quantitative analysis of MFAP-4 serum levels in a large number of patients showed MFAP-4 as novel candidate biomarker with high diagnostic accuracy for prediction of nondiseased liver versus cirrhosis [area under receiver operating characteristic curve (AUC) = 0.97, P &lt; 0.0001] as well as stage 0 versus stage 4 fibrosis (AUC = 0.84, P &lt; 0.0001), and stages 0 to 3 versus stage 4 fibrosis (AUC = 0.76, P &lt; 0.0001).
p15959
sg4
(lp15960
sg17
(lp15961
(dp15962
g7
I318
sg20
VC0016059
p15963
sg10
I8
sg11
Vfibrosis
p15964
sg13
I1
sa(dp15965
g7
I318
sg20
VC0016059
p15966
sg10
I8
sg11
Vfibrosis
p15967
sg13
I1
sa(dp15968
g7
I193
sg20
VC0023890
p15969
sg10
I9
sg11
Vcirrhosis
p15970
sg13
I1
sasa(dp15971
g2
VLow CRF had PARs of 9.3% and 10.5% for cancer mortality in subjects who had overweight and obesity, respectively.
p15972
sg4
(lp15973
(dp15974
g7
I4
sg8
VP06850
p15975
sg10
I3
sg11
VCRF
p15976
sg13
I1
sasg17
(lp15977
(dp15978
g7
I4
sg20
VC0022661
p15979
sg10
I3
sg11
VCRF
p15980
sg13
I1
sa(dp15981
g7
I39
sg20
VC0006826
p15982
sg10
I6
sg11
Vcancer
p15983
sg13
I1
sa(dp15984
g7
I76
sg20
VC1561826
p15985
sg10
I22
sg11
Voverweight and obesity
p15986
sg13
I3
sasa(dp15987
g2
VThe population attributable risks (PARs) were 0.41, 0.40 and 0.38 for total, CVD and cancer mortality, accordingly.
p15988
sg4
(lp15989
sg17
(lp15990
(dp15991
g7
I85
sg20
VC0006826
p15992
sg10
I6
sg11
Vcancer
p15993
sg13
I1
sa(dp15994
g7
I77
sg20
VC0007222
p15995
sg10
I3
sg11
VCVD
p15996
sg13
I1
sasa(dp15997
g2
VMean EARs for lung cancer were 17.5 cases per 10,000 persons per year (PY) and 10.1 PY.
p15998
sg4
(lp15999
sg17
(lp16000
(dp16001
g7
I14
sg20
VC0684249
p16002
sg10
I11
sg11
Vlung cancer
p16003
sg13
I2
sasa(dp16004
g2
VMean EARs for breast cancer were 8.2 PY and 2.8 PY.
p16005
sg4
(lp16006
sg17
(lp16007
(dp16008
g7
I14
sg20
VC0678222
p16009
sg10
I13
sg11
Vbreast cancer
p16010
sg13
I2
sasa(dp16011
g2
VIn addition, through activation of G-protein-coupled protease activated receptors (PARs) TF induces cell signaling that is related to cancer, angiogenesis and inflammation.
p16012
sg4
(lp16013
(dp16014
g7
I83
sg8
g47
sg10
I4
sg11
VPARs
p16015
sg13
I1
sa(dp16016
g7
I35
sg8
VP63123
p16017
sg10
I46
sg11
VG-protein-coupled protease activated receptors
p16018
sg13
I4
sasg17
(lp16019
(dp16020
g7
I134
sg20
VC0006826
p16021
sg10
I6
sg11
Vcancer
p16022
sg13
I1
sa(dp16023
g7
I159
sg20
VC0021368
p16024
sg10
I12
sg11
Vinflammation
p16025
sg13
I1
sasa(dp16026
g2
VPARs are implicated in a wide range of diseases, such as cancer and inflammation.
p16027
sg4
(lp16028
(dp16029
g7
I0
sg8
g47
sg10
I4
sg11
VPARs
p16030
sg13
I1
sasg17
(lp16031
(dp16032
g7
I57
sg20
VC0006826
p16033
sg10
I6
sg11
Vcancer
p16034
sg13
I1
sa(dp16035
g7
I68
sg20
VC0021368
p16036
sg10
I12
sg11
Vinflammation
p16037
sg13
I1
sasa(dp16038
g2
VThrombin-induced activation of protease-activated receptors (PARs) represents a link between inflammation and cancer.
p16039
sg4
(lp16040
(dp16041
g7
I61
sg8
g47
sg10
I4
sg11
VPARs
p16042
sg13
I1
sa(dp16043
g7
I31
sg8
VP63123
p16044
sg10
I28
sg11
Vprotease-activated receptors
p16045
sg13
I2
sa(dp16046
g7
I0
sg8
VP00734
p16047
sg10
I8
sg11
VThrombin
p16048
sg13
I1
sasg17
(lp16049
(dp16050
g7
I93
sg20
VC0021368
p16051
sg10
I12
sg11
Vinflammation
p16052
sg13
I1
sa(dp16053
g7
I110
sg20
VC0006826
p16054
sg10
I6
sg11
Vcancer
p16055
sg13
I1
sasa(dp16056
g2
VFrozen tunica vaginalis specimens from patients with adult-onset primary hydrocele testis and control male nonhydrocele patients were subjected to Western blot analysis for the detection of AQP1 and AQP3 proteins.
p16057
sg4
(lp16058
(dp16059
g7
I190
sg8
VP29972
p16060
sg10
I4
sg11
VAQP1
p16061
sg13
I1
sa(dp16062
g7
I199
sg8
g47
sg10
I13
sg11
VAQP3 proteins
p16063
sg13
I2
sasg17
(lp16064
(dp16065
g7
I73
sg20
VC1720771
p16066
sg10
I16
sg11
Vhydrocele testis
p16067
sg13
I2
sa(dp16068
g7
I14
sg20
VC0750103
p16069
sg10
I9
sg11
Vvaginalis
p16070
sg13
I1
sasa(dp16071
g2
VAQP1 protein expression in the tunica vaginalis was significantly higher in patients with adult-onset hydrocele testis than in the controls.
p16072
sg4
(lp16073
(dp16074
g7
I0
sg8
VP29972
p16075
sg10
I4
sg11
VAQP1
p16076
sg13
I1
sasg17
(lp16077
(dp16078
g7
I38
sg20
VC0750103
p16079
sg10
I9
sg11
Vvaginalis
p16080
sg13
I1
sa(dp16081
g7
I102
sg20
VC1720771
p16082
sg10
I16
sg11
Vhydrocele testis
p16083
sg13
I2
sasa(dp16084
g2
VThe densities of AQP1-expressing capillaries and lymphatic vessels were similar between the tunica vaginalis of the controls and those of hydrocele patients.
p16085
sg4
(lp16086
(dp16087
g7
I17
sg8
VP29972
p16088
sg10
I4
sg11
VAQP1
p16089
sg13
I1
sasg17
(lp16090
(dp16091
g7
I99
sg20
VC0750103
p16092
sg10
I9
sg11
Vvaginalis
p16093
sg13
I1
sa(dp16094
g7
I138
sg20
VC1720771
p16095
sg10
I9
sg11
Vhydrocele
p16096
sg13
I1
sasa(dp16097
g2
VIn conclusion, overexpression of the AQP1 protein in individual capillary endothelial cells of the tunica vaginalis may contribute to the development of adult-onset primary noncommunicating hydrocele testis as another aquaporin-related disease.
p16098
sg4
(lp16099
(dp16100
g7
I218
sg8
VP30301
p16101
sg10
I9
sg11
Vaquaporin
p16102
sg13
I1
sa(dp16103
g7
I37
sg8
VP29972
p16104
sg10
I12
sg11
VAQP1 protein
p16105
sg13
I2
sasg17
(lp16106
(dp16107
g7
I190
sg20
VC1720771
p16108
sg10
I16
sg11
Vhydrocele testis
p16109
sg13
I2
sa(dp16110
g7
I106
sg20
VC0750103
p16111
sg10
I9
sg11
Vvaginalis
p16112
sg13
I1
sasa(dp16113
g2
VThere are very few reports in the published literature of abdominal aortic aneurysm in patient with situs inversus totalis, all of whom underwent open aneurysm repair.
p16114
sg4
(lp16115
sg17
(lp16116
(dp16117
g7
I100
sg20
VC0037221
p16118
sg10
I14
sg11
Vsitus inversus
p16119
sg13
I2
sa(dp16120
g7
I58
sg20
VC0162871
p16121
sg10
I25
sg11
Vabdominal aortic aneurysm
p16122
sg13
I3
sa(dp16123
g7
I75
sg20
VC0002940
p16124
sg10
I8
sg11
Vaneurysm
p16125
sg13
I1
sasa(dp16126
g2
VThe authors describe a case of successfully repaired abdominal aortic aneurysm with a false aneurysm of the right external iliac artery in situs inversus totalis.
p16127
sg4
(lp16128
sg17
(lp16129
(dp16130
g7
I139
sg20
VC0037221
p16131
sg10
I14
sg11
Vsitus inversus
p16132
sg13
I2
sa(dp16133
g7
I53
sg20
VC0162871
p16134
sg10
I25
sg11
Vabdominal aortic aneurysm
p16135
sg13
I3
sa(dp16136
g7
I86
sg20
VC1510412
p16137
sg10
I14
sg11
Vfalse aneurysm
p16138
sg13
I2
sasa(dp16139
g2
VThe surgical management of patients with abdominal aortic aneurysm in situs inversus totalis is discussed.
p16140
sg4
(lp16141
sg17
(lp16142
(dp16143
g7
I41
sg20
VC0162871
p16144
sg10
I25
sg11
Vabdominal aortic aneurysm
p16145
sg13
I3
sa(dp16146
g7
I70
sg20
VC0037221
p16147
sg10
I14
sg11
Vsitus inversus
p16148
sg13
I2
sasa(dp16149
g2
VCollectively, the MLN CD11b- CD103+ PD-L1High DC subset probably takes up luminal antigens in the intestine, migrates to MLNs, and highly induces regulatory T cells through TGF-Beta activation.
p16150
sg4
(lp16151
(dp16152
g7
I121
sg8
VP12872
p16153
sg10
I4
sg11
VMLNs
p16154
sg13
I1
sa(dp16155
g7
I18
sg8
VP12872
p16156
sg10
I27
sg11
VMLN CD11b- CD103+ PD-L1High
p16157
sg13
I4
sa(dp16158
g7
I173
sg8
VP18075
p16159
sg10
I8
sg11
VTGF-Beta
p16160
sg13
I1
sasg17
(lp16161
(dp16162
g7
I121
sg20
VC0026691
p16163
sg10
I4
sg11
VMLNs
p16164
sg13
I1
sasa(dp16165
g2
VFurthermore, Ye were found exclusively associated with CD103(+) DCs in the MLNs from wild-type mice, but not from CCR7(-/-) mice, demonstrating a CCR7 dependent transport of Ye by CD103(+) DCs from LP to the MLNs.
p16166
sg4
(lp16167
(dp16168
g7
I55
sg8
VP38570
p16169
sg10
I12
sg11
VCD103(+) DCs
p16170
sg13
I2
sa(dp16171
g7
I55
sg8
VP38570
p16172
sg10
I12
sg11
VCD103(+) DCs
p16173
sg13
I2
sa(dp16174
g7
I114
sg8
VP32248
p16175
sg10
I4
sg11
VCCR7
p16176
sg13
I1
sa(dp16177
g7
I114
sg8
VP32248
p16178
sg10
I4
sg11
VCCR7
p16179
sg13
I1
sasg17
(lp16180
(dp16181
g7
I75
sg20
VC0026691
p16182
sg10
I4
sg11
VMLNs
p16183
sg13
I1
sa(dp16184
g7
I75
sg20
VC0026691
p16185
sg10
I4
sg11
VMLNs
p16186
sg13
I1
sa(dp16187
g7
I64
sg20
VC0268238
p16188
sg10
I3
sg11
VDCs
p16189
sg13
I1
sa(dp16190
g7
I64
sg20
VC0268238
p16191
sg10
I3
sg11
VDCs
p16192
sg13
I1
sasa(dp16193
g2
VAlthough extensive studies have demonstrated the importance of the mesenteric lymph nodes (MLNs) and intestinal CD103(+) dendritic cells (DCs) in driving small intestinal tolerance to protein antigen, the structural and immunological basis of colonic tolerance remain poorly understood.
p16194
sg4
(lp16195
sg17
(lp16196
(dp16197
g7
I171
sg20
VC0020963
p16198
sg10
I9
sg11
Vtolerance
p16199
sg13
I1
sa(dp16200
g7
I67
sg20
VC0026691
p16201
sg10
I22
sg11
Vmesenteric lymph nodes
p16202
sg13
I3
sa(dp16203
g7
I138
sg20
VC0268238
p16204
sg10
I3
sg11
VDCs
p16205
sg13
I1
sa(dp16206
g7
I91
sg20
VC0026691
p16207
sg10
I4
sg11
VMLNs
p16208
sg13
I1
sa(dp16209
g7
I171
sg20
VC0020963
p16210
sg10
I9
sg11
Vtolerance
p16211
sg13
I1
sa(dp16212
g7
I121
sg20
VC0268238
p16213
sg10
I15
sg11
Vdendritic cells
p16214
sg13
I2
sasa(dp16215
g2
VDespite tolerance development, CD103(+)CD11b(+) DCs, which are the major migratory DC population in the MLNs, and the tolerance-related retinoic acid-generating enzyme RALDH2 were virtually absent from the ILNs.
p16216
sg4
(lp16217
(dp16218
g7
I168
sg8
g47
sg10
I6
sg11
VRALDH2
p16219
sg13
I1
sa(dp16220
g7
I31
sg8
VP38570
p16221
sg10
I20
sg11
VCD103(+)CD11b(+) DCs
p16222
sg13
I2
sasg17
(lp16223
(dp16224
g7
I8
sg20
VC0020963
p16225
sg10
I9
sg11
Vtolerance
p16226
sg13
I1
sa(dp16227
g7
I48
sg20
VC0268238
p16228
sg10
I3
sg11
VDCs
p16229
sg13
I1
sa(dp16230
g7
I8
sg20
VC0020963
p16231
sg10
I9
sg11
Vtolerance
p16232
sg13
I1
sa(dp16233
g7
I104
sg20
VC0026691
p16234
sg10
I4
sg11
VMLNs
p16235
sg13
I1
sasa(dp16236
g2
VHere, we demonstrate that GVHD markedly enhances alloantigen presentation within the mesenteric lymph nodes (mLNs), mediated by donor CD103(+)CD11b(-) dendritic cells (DCs) that migrate from the colon under the influence of CCR7.
p16237
sg4
(lp16238
(dp16239
g7
I224
sg8
VP32248
p16240
sg10
I4
sg11
VCCR7
p16241
sg13
I1
sa(dp16242
g7
I134
sg8
VP38570
p16243
sg10
I16
sg11
VCD103(+)CD11b(-)
p16244
sg13
I1
sasg17
(lp16245
(dp16246
g7
I85
sg20
VC0026691
p16247
sg10
I22
sg11
Vmesenteric lymph nodes
p16248
sg13
I3
sa(dp16249
g7
I168
sg20
VC0268238
p16250
sg10
I3
sg11
VDCs
p16251
sg13
I1
sa(dp16252
g7
I26
sg20
VC0018133
p16253
sg10
I4
sg11
VGVHD
p16254
sg13
I1
sa(dp16255
g7
I109
sg20
VC0026691
p16256
sg10
I4
sg11
VmLNs
p16257
sg13
I1
sa(dp16258
g7
I151
sg20
VC0268238
p16259
sg10
I15
sg11
Vdendritic cells
p16260
sg13
I2
sasa(dp16261
g2
VCD103(+) dendritic cells (DCs) continuously migrate from the intestine to the mesenteric lymph nodes (MLNs) and maintain tolerance by driving the development of regulatory T cells (Treg) in the gut.
p16262
sg4
(lp16263
(dp16264
g7
I0
sg8
VP38570
p16265
sg10
I5
sg11
VCD103
p16266
sg13
I1
sasg17
(lp16267
(dp16268
g7
I26
sg20
VC0268238
p16269
sg10
I3
sg11
VDCs
p16270
sg13
I1
sa(dp16271
g7
I78
sg20
VC0026691
p16272
sg10
I22
sg11
Vmesenteric lymph nodes
p16273
sg13
I3
sa(dp16274
g7
I121
sg20
VC0020963
p16275
sg10
I9
sg11
Vtolerance
p16276
sg13
I1
sa(dp16277
g7
I102
sg20
VC0026691
p16278
sg10
I4
sg11
VMLNs
p16279
sg13
I1
sa(dp16280
g7
I9
sg20
VC0268238
p16281
sg10
I15
sg11
Vdendritic cells
p16282
sg13
I2
sasa(dp16283
g2
VTreatment with PBS followed by 1 single dose of VSL#3, 18 h before killing, was associated with a 2-fold increase in CD103(+)CD11c(+) dendritic cells in MLNs and PPs.
p16284
sg4
(lp16285
(dp16286
g7
I117
sg8
VP38570
p16287
sg10
I13
sg11
VCD103(+)CD11c
p16288
sg13
I1
sasg17
(lp16289
(dp16290
g7
I162
sg20
VC0265259
p16291
sg10
I3
sg11
VPPs
p16292
sg13
I1
sa(dp16293
g7
I15
sg20
VC1720830
p16294
sg10
I3
sg11
VPBS
p16295
sg13
I1
sa(dp16296
g7
I153
sg20
VC0026691
p16297
sg10
I4
sg11
VMLNs
p16298
sg13
I1
sasa(dp16299
g2
VReduced numbers of Th17 cells, suppressed interleukin (IL)-6 production by intestinal explants, and increased Tregs and CD103-positive regulatory dendritic cells in mesenteric lymph nodes (MLNs) were observed.
p16300
sg4
(lp16301
(dp16302
g7
I42
sg8
VP60568
p16303
sg10
I18
sg11
Vinterleukin (IL)-6
p16304
sg13
I2
sa(dp16305
g7
I120
sg8
VP38570
p16306
sg10
I5
sg11
VCD103
p16307
sg13
I1
sasg17
(lp16308
(dp16309
g7
I189
sg20
VC0026691
p16310
sg10
I4
sg11
VMLNs
p16311
sg13
I1
sa(dp16312
g7
I165
sg20
VC0026691
p16313
sg10
I22
sg11
Vmesenteric lymph nodes
p16314
sg13
I3
sasa(dp16315
g2
VThus, oral administration of C. kefyr ameliorated EAE by altering the microflora, accompanied by increased Tregs and CD103-positive regulatory dendritic cells in MLNs and decreased Th17 cells in the intestinal lamina propria.
p16316
sg4
(lp16317
(dp16318
g7
I117
sg8
VP38570
p16319
sg10
I5
sg11
VCD103
p16320
sg13
I1
sasg17
(lp16321
(dp16322
g7
I162
sg20
VC0026691
p16323
sg10
I4
sg11
VMLNs
p16324
sg13
I1
sasa(dp16325
g2
VThe proportion of CD103 DCs in PPs and MLNs and IL-10-expressing CD4 T cells of PPs and the LP increased after indomethacin treatment.
p16326
sg4
(lp16327
(dp16328
g7
I31
sg8
g47
sg10
I3
sg11
VPPs
p16329
sg13
I1
sa(dp16330
g7
I31
sg8
g47
sg10
I3
sg11
VPPs
p16331
sg13
I1
sa(dp16332
g7
I48
sg8
VP01730
p16333
sg10
I22
sg11
VIL-10-expressing CD4 T
p16334
sg13
I3
sa(dp16335
g7
I39
sg8
VP12872
p16336
sg10
I4
sg11
VMLNs
p16337
sg13
I1
sa(dp16338
g7
I18
sg8
VP38570
p16339
sg10
I9
sg11
VCD103 DCs
p16340
sg13
I2
sasg17
(lp16341
(dp16342
g7
I31
sg20
VC0265259
p16343
sg10
I3
sg11
VPPs
p16344
sg13
I1
sa(dp16345
g7
I24
sg20
VC0268238
p16346
sg10
I3
sg11
VDCs
p16347
sg13
I1
sa(dp16348
g7
I31
sg20
VC0265259
p16349
sg10
I3
sg11
VPPs
p16350
sg13
I1
sa(dp16351
g7
I39
sg20
VC0026691
p16352
sg10
I4
sg11
VMLNs
p16353
sg13
I1
sasa(dp16354
g2
VThe PP-null mice showed greater indomethacin-induced enteropathy, fewer CD103 DCs in their MLNs, and lower proportion of IL-10-expressing CD4 T cells of their LP than WT mice, regardless of commensal bacteria.
p16355
sg4
(lp16356
(dp16357
g7
I72
sg8
VP38570
p16358
sg10
I9
sg11
VCD103 DCs
p16359
sg13
I2
sa(dp16360
g7
I121
sg8
VP01730
p16361
sg10
I22
sg11
VIL-10-expressing CD4 T
p16362
sg13
I3
sasg17
(lp16363
(dp16364
g7
I53
sg20
VC0021831
p16365
sg10
I11
sg11
Venteropathy
p16366
sg13
I1
sa(dp16367
g7
I91
sg20
VC0026691
p16368
sg10
I4
sg11
VMLNs
p16369
sg13
I1
sa(dp16370
g7
I78
sg20
VC0268238
p16371
sg10
I3
sg11
VDCs
p16372
sg13
I1
sasa(dp16373
g2
VNaive splenic CD4 T cells co-cultured with CD103 DCs isolated from the MLNs of indomethacin-injected WT mice produced a higher amount of IL-10 compared with those co-cultured with CD103 DCs.
p16374
sg4
(lp16375
(dp16376
g7
I14
sg8
VP01730
p16377
sg10
I3
sg11
VCD4
p16378
sg13
I1
sa(dp16379
g7
I43
sg8
VP38570
p16380
sg10
I9
sg11
VCD103 DCs
p16381
sg13
I2
sa(dp16382
g7
I43
sg8
VP38570
p16383
sg10
I9
sg11
VCD103 DCs
p16384
sg13
I2
sasg17
(lp16385
(dp16386
g7
I71
sg20
VC0026691
p16387
sg10
I4
sg11
VMLNs
p16388
sg13
I1
sa(dp16389
g7
I49
sg20
VC0268238
p16390
sg10
I3
sg11
VDCs
p16391
sg13
I1
sa(dp16392
g7
I49
sg20
VC0268238
p16393
sg10
I3
sg11
VDCs
p16394
sg13
I1
sasa(dp16395
g2
VIn rickets, on the other hand, no PTH/PTHrP receptor gene expression was observed in the growth plate from day 8 of a vitamin D-deficient diet.
p16396
sg4
(lp16397
(dp16398
g7
I38
sg8
VP12272
p16399
sg10
I19
sg11
VPTHrP receptor gene
p16400
sg13
I3
sa(dp16401
g7
I34
sg8
VP01270
p16402
sg10
I3
sg11
VPTH
p16403
sg13
I1
sasg17
(lp16404
(dp16405
g7
I3
sg20
VC0035579
p16406
sg10
I7
sg11
Vrickets
p16407
sg13
I1
sasa(dp16408
g2
VThese results suggest that alterations in the PTH/PTHrP receptor gene expression are associated with rickets but not with TD.
p16409
sg4
(lp16410
(dp16411
g7
I50
sg8
VP12272
p16412
sg10
I19
sg11
VPTHrP receptor gene
p16413
sg13
I3
sa(dp16414
g7
I46
sg8
VP01270
p16415
sg10
I3
sg11
VPTH
p16416
sg13
I1
sasg17
(lp16417
(dp16418
g7
I101
sg20
VC0035579
p16419
sg10
I7
sg11
Vrickets
p16420
sg13
I1
sasa(dp16421
g2
VThe reduction in the PTH/PTHrP receptor gene expression in rickets may be due to the high plasma levels of PTH.
p16422
sg4
(lp16423
(dp16424
g7
I21
sg8
VP01270
p16425
sg10
I3
sg11
VPTH
p16426
sg13
I1
sa(dp16427
g7
I25
sg8
VP12272
p16428
sg10
I19
sg11
VPTHrP receptor gene
p16429
sg13
I3
sa(dp16430
g7
I21
sg8
VP01270
p16431
sg10
I3
sg11
VPTH
p16432
sg13
I1
sasg17
(lp16433
(dp16434
g7
I59
sg20
VC0035579
p16435
sg10
I7
sg11
Vrickets
p16436
sg13
I1
sasa(dp16437
g2
VWhat is more important is that the depressed-expression of Cav1.3 paralleled with enhanced-expression of Snapin was documented in atrial samples from atrial fibrillation (AF) patients.
p16438
sg4
(lp16439
(dp16440
g7
I105
sg8
g47
sg10
I6
sg11
VSnapin
p16441
sg13
I1
sa(dp16442
g7
I59
sg8
g47
sg10
I6
sg11
VCav1.3
p16443
sg13
I1
sasg17
(lp16444
(dp16445
g7
I171
sg20
VC0004238
p16446
sg10
I2
sg11
VAF
p16447
sg13
I1
sa(dp16448
g7
I150
sg20
VC0004238
p16449
sg10
I19
sg11
Vatrial fibrillation
p16450
sg13
I2
sasa(dp16451
g2
VFurthermore, inactivation of Cav1.3 channels promotes also atrial fibrillation and flutter in knockout mice suggesting that these channels can play a role in stabilizing atrial rhythm.
p16452
sg4
(lp16453
(dp16454
g7
I29
sg8
g47
sg10
I15
sg11
VCav1.3 channels
p16455
sg13
I2
sasg17
(lp16456
(dp16457
g7
I59
sg20
VC0155709
p16458
sg10
I31
sg11
Vatrial fibrillation and flutter
p16459
sg13
I4
sa(dp16460
g7
I13
sg20
VC0544461
p16461
sg10
I12
sg11
Vinactivation
p16462
sg13
I1
sasa(dp16463
g2
VThe significance of the tissue-specific expression of the channel is underpinned by our previous demonstration of atrial fibrillation in a Cav1.3 null mutant mouse model.
p16464
sg4
(lp16465
(dp16466
g7
I139
sg8
g47
sg10
I6
sg11
VCav1.3
p16467
sg13
I1
sasg17
(lp16468
(dp16469
g7
I151
sg20
VC0596988
p16470
sg10
I6
sg11
Vmutant
p16471
sg13
I1
sa(dp16472
g7
I114
sg20
VC0004238
p16473
sg10
I19
sg11
Vatrial fibrillation
p16474
sg13
I2
sasa(dp16475
g2
VMRS studies (MRI 1.5 T unit) were performed in 49 patients with schizophrenia (30 with auditory hallucinations and 19 without auditory hallucinations) and 37 controls.
p16476
sg4
(lp16477
sg17
(lp16478
(dp16479
g7
I87
sg20
VC0233762
p16480
sg10
I23
sg11
Vauditory hallucinations
p16481
sg13
I2
sa(dp16482
g7
I64
sg20
VC0036341
p16483
sg10
I13
sg11
Vschizophrenia
p16484
sg13
I1
sa(dp16485
g7
I87
sg20
VC0233762
p16486
sg10
I23
sg11
Vauditory hallucinations
p16487
sg13
I2
sa(dp16488
g7
I0
sg20
VC0025235
p16489
sg10
I3
sg11
VMRS
p16490
sg13
I1
sasa(dp16491
g2
VAs a first step towards understanding the role of OPN in retinal degeneration (RD), we examined changes in OPN expression in a mouse model of RD induced by exposure to a blue light-emitting diode (LED).
p16492
sg4
(lp16493
(dp16494
g7
I50
sg8
VP10451
p16495
sg10
I3
sg11
VOPN
p16496
sg13
I1
sasg17
(lp16497
(dp16498
g7
I57
sg20
VC0035304
p16499
sg10
I20
sg11
Vretinal degeneration
p16500
sg13
I2
sa(dp16501
g7
I79
sg20
VC0035304
p16502
sg10
I2
sg11
VRD
p16503
sg13
I1
sa(dp16504
g7
I79
sg20
VC0035304
p16505
sg10
I2
sg11
VRD
p16506
sg13
I1
sasa(dp16507
g2
VSimilarly, those who had retinal disease had higher osteopontin concentrations than those without (16.8+/-2 vs. 12.4+/-3 mg/L; p=0.005).
p16508
sg4
(lp16509
(dp16510
g7
I52
sg8
VP10451
p16511
sg10
I11
sg11
Vosteopontin
p16512
sg13
I1
sasg17
(lp16513
(dp16514
g7
I25
sg20
VC0035309
p16515
sg10
I15
sg11
Vretinal disease
p16516
sg13
I2
sasa(dp16517
g2
VWe investigated the expression of S100A4 and correlated it with clinical disease activity as well as with the levels of osteopontin (OPN), soluble syndecan-1, and vascular endothelial growth factor (VEGF) in proliferative diabetic retinopathy (PDR).
p16518
sg4
(lp16519
(dp16520
g7
I199
sg8
g47
sg10
I4
sg11
VVEGF
p16521
sg13
I1
sa(dp16522
g7
I34
sg8
VP26447
p16523
sg10
I6
sg11
VS100A4
p16524
sg13
I1
sa(dp16525
g7
I163
sg8
g47
sg10
I34
sg11
Vvascular endothelial growth factor
p16526
sg13
I4
sa(dp16527
g7
I120
sg8
VP10451
p16528
sg10
I11
sg11
Vosteopontin
p16529
sg13
I1
sa(dp16530
g7
I147
sg8
VP18827
p16531
sg10
I10
sg11
Vsyndecan-1
p16532
sg13
I1
sa(dp16533
g7
I133
sg8
VP10451
p16534
sg10
I3
sg11
VOPN
p16535
sg13
I1
sasg17
(lp16536
(dp16537
g7
I208
sg20
VC0154830
p16538
sg10
I34
sg11
Vproliferative diabetic retinopathy
p16539
sg13
I3
sa(dp16540
g7
I244
sg20
VC0154830
p16541
sg10
I3
sg11
VPDR
p16542
sg13
I1
sasa(dp16543
g2
VRecent studies show overexpressed ENAH in several cancer types, and ENAH correlates with tumor invasiveness.
p16544
sg4
(lp16545
(dp16546
g7
I34
sg8
g47
sg10
I4
sg11
VENAH
p16547
sg13
I1
sasg17
(lp16548
(dp16549
g7
I50
sg20
VC0006826
p16550
sg10
I6
sg11
Vcancer
p16551
sg13
I1
sa(dp16552
g7
I89
sg20
VC0027651
p16553
sg10
I5
sg11
Vtumor
p16554
sg13
I1
sasa(dp16555
g2
VThis study aimed to investigate the expression and function of ENAH in primary gastric adenocarcinoma, and its prognostic significance.
p16556
sg4
(lp16557
(dp16558
g7
I63
sg8
g47
sg10
I4
sg11
VENAH
p16559
sg13
I1
sasg17
(lp16560
(dp16561
g7
I79
sg20
VC0278701
p16562
sg10
I22
sg11
Vgastric adenocarcinoma
p16563
sg13
I2
sasa(dp16564
g2
VWe found significantly increased mRNA (P = 0.0283) and protein (P = 0.0301) expression of ENAH in gastric cancer tissues.
p16565
sg4
(lp16566
(dp16567
g7
I90
sg8
g47
sg10
I4
sg11
VENAH
p16568
sg13
I1
sasg17
(lp16569
(dp16570
g7
I98
sg20
VC0024623
p16571
sg10
I14
sg11
Vgastric cancer
p16572
sg13
I2
sasa.